Posting ID	Sponsor	Study Title	Medicine or Vaccine (generic name)	Sponsor Identification Number	Medical Condition	Phase	Link to Sponsor Study Registry	Link to study details on ClinicalTrials.gov (if available)	Link to study details on EudraCT (if available)	Analysis-ready dataset	Annotated case report form	Clinical study report	Dataset specifications	Protocol with any amendments	Raw dataset	Reporting and analysis plan	Additional Information about the data and documents available for this study	Date Added to this Site
1	GSK	U0289-401: An Evaluator Blinded, 8 Week, Split-Face Study to Evaluate and Compare the Efficacy and Tolerability of MAXCLARITY II and PROACTIV in Subjects with Acne	benzoyl peroxide/salicylic acid	STF114550	Acne Vulgaris	Phase 4	https://www.gsk-studyregister.com/en/trial-details/?id=114550	http://clinicaltrials.gov/show/NCT01706250		N	Y	Y	Y	N	Y	N	An analysis-ready dataset and a reporting and analysis plan are not available for this study. A protocol is not available for this study because only a draft version was located; no final version found in archives.	1-Aug-2015
3	GSK	GSK1550188, A randomised, single-blind, placebo controlled, dose ascending, single dose study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamic of GSK1550188 in Japanese subjects with Systemic Lupus Erythematosus (SLE)	belimumab	BEL114243	Systemic Lupus Erythematosus	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=114243	http://clinicaltrials.gov/show/NCT01381536		N	Y	Y	Y	N	Y	Y	An analysis-ready dataset is not available for this study. A protocol is not available for this study because an English language version was not created.	1-Jul-2015
4	GSK	A Multicenter, Randomized, Double-Blind, Phase 3 Study of the Safety and Efficacy of Emulsion Formulation U0267, versus Vehicle in Subjects with Plaque-type Psoriasis	calcipotriol, calcipotriene	STF114741	Psoriasis	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=114741	http://clinicaltrials.gov/show/NCT00688519		Y	Y	Y	Y	Y	Y	Y		1-Jul-2015
8	GSK	Two-week Study to Determine and Compare the Tolerance and Irritation Potential of Duac® Topical Gel (clindamycin 1% and benzoyl peroxide 5%) to ACANYA™ Gel (clindamycin phosphate 1.2% and benzoyl peroxide 2.5%) Topical Acne Medications	benzoyl peroxide/clindamycin phosphate	STF114546	Acne Vulgaris	Phase 4	https://www.gsk-studyregister.com/en/trial-details/?id=114546	http://clinicaltrials.gov/show/NCT01015638		N	N	Y	Y	Y	Y	N	An analysis-ready dataset and reporting and analysis plan are not available for this study. An annotated case report form is not available for this study. A blank case report form will be provided.	1-Aug-2014
9	GSK	A single-blind, randomized, comparative split-face study evaluating the tolerability of clindamycin and benzoyl peroxide gel to benzoyl peroxide/adapalene gel in the treatment of acne vulgaris.	benzoyl peroxide/clindamycin phosphate	STF114547	Acne Vulgaris	Phase 4	https://www.gsk-studyregister.com/en/trial-details/?id=114547	http://clinicaltrials.gov/show/NCT00964223		Y	Y	Y	Y	Y	N	Y	A raw dataset is not available for this study.	1-Aug-2014
10	GSK	A Phase 4, Single-Blind, Randomized, Study to Compare the Tolerability and Efficacy of Tazorac Cream when used in Combination with Either Duac Gel or Acanya Gel for the Treatment of Facial Acne Vulgaris	benzoyl peroxide/clindamycin phosphate	STF114566	Acne Vulgaris	Phase 4	https://www.gsk-studyregister.com/en/trial-details/?id=114566	http://clinicaltrials.gov/show/NCT01016977		Y	Y	Y	Y	Y	N	Y	A raw dataset is not available for this study.	1-Aug-2014
11	GSK	A Phase 3 Multicenter, Randomized, Double-Blind, Active And Vehicle-Controlled Study Of The Safety And Efficacy Of A Clindamycin / Benzoyl Peroxide Gel Versus Clindamycin Gel Versus Benzoyl Peroxide Gel Versus Vehicle Gel In Subjects With Acne Vulgaris	benzoyl peroxide/clindamycin phosphate	STF114677	Acne Vulgaris	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=114677	http://clinicaltrials.gov/show/NCT00776919		Y	Y	Y	Y	Y	N	Y	A raw dataset is not available for this study.	1-Aug-2014
12	GSK	A Multicenter, Randomized, Double-Blind Study of the Safety and Efficacy of Calcipotriene Foam, 0.005%, Versus Vehicle Foam In The Treatment Of Moderate Plaque-Type Scalp And Body Psoriasis	calcipotriol, calcipotriene	STF114743	Psoriasis	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=114743	http://clinicaltrials.gov/show/NCT01139580		N	Y	Y	Y	Y	Y	Y	An analysis-ready dataset is not available for this study.	1-May-2013
13	GSK	A study to evaluate the potential incidence of orthostatic hypotension in elderly hypertensive patients following administration of a combination of carvedilol CR and lisinopril	carvedilol	CFD109701	Hypertension	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=CFD109701	http://clinicaltrials.gov/show/NCT00508365		Y	Y	Y	Y	Y	Y	Y		1-May-2013
14	GSK	COR111096, A Randomized, Double-Blind, Active-Controlled, Parallel Group, Multicenter Study Comparing the Proportion of Subjects with Stage 1 or 2 Essential Hypertension Who Achieve Target Blood Pressure While Receiving Either carvedilol CR + lisinopril or lisinopril Monotherapy	carvedilol	COR111096	Hypertension	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=COR111096	http://clinicaltrials.gov/show/NCT00624065		Y	Y	Y	Y	Y	Y	Y		1-May-2013
16	GSK	A Phase I, Open-Label, Randomized, Two Period Crossover Study to Investigate the Effects of GW679769 on the Pharmacokinetics of Docetaxel in Subjects with Cancer	casopitant	NKV100781	Nausea and Vomiting, Chemotherapy-Induced	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=NKV100781	http://clinicaltrials.gov/show/NCT00440128		Y	Y	Y	Y	Y	Y	Y		1-Jul-2014
19	GSK	A single-blind, randomized, comparative pilot study evaluating the tolerability of two topical combination therapies in the treatment of acne vulgaris	benzoyl peroxide/clindamycin phosphate	STF114544	Acne Vulgaris	Phase 4	https://www.gsk-studyregister.com/en/trial-details/?id=114544	http://clinicaltrials.gov/show/NCT00887484		N	N	Y	Y	Y	Y	N	An analysis-ready dataset is not available for this study. An annotated case report form is not available for this study. A blank case report form will be provided.	1-Aug-2014
20	GSK	Ethanol-Free Clobetasol Propionate Foam 0.05% (Olux-E Foam) vs Vehicle Foam in the Treatment of Chronic Hand Dermatitis.	clobetasol	STF115054	Dermatitis, Chronic	Phase 4	https://www.gsk-studyregister.com/en/trial-details/?id=115054	http://clinicaltrials.gov/show/NCT01323673		N	Y	Y	Y	Y	Y	Y	An analysis-ready dataset is not available for this study.	1-May-2013
21	GSK	A randomised, double-blind, placebo-controlled, dose ascending, 2-cohort, parallel group study to examine the safety, tolerability, pharmacokinetics and pharmacodynamics of twice-daily inhaled doses of GSK233705B formulated with the excipient Magnesium Stearate in COPD subjects for 7-days.	darotropium bromide	AC2108378	Pulmonary Disease, Chronic Obstructive	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=AC2108378	http://clinicaltrials.gov/show/NCT00453479	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006083-33	Y	Y	Y	Y	Y	Y	Y		1-May-2013
22	GSK	Dose-Ranging Study for GSK233705B Delivered Once Daily in Subjects with COPD	darotropium bromide	AC2110664	Pulmonary Disease, Chronic Obstructive	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=AC2110664	http://clinicaltrials.gov/show/NCT00676052	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-006287-29	Y	Y	Y	Y	Y	Y	Y		1-May-2013
23	GSK	A multicenter, randomized, double-blind, placebo-controlled, parallel-group, 4-week study to evaluate the safety, tolerability, pharmacodynamics and pharmacokinetics of repeat inhaled doses of the combination of GSK233705 and GW642444 administered once-daily in subjects with COPD	vilanterol/darotropium bromide	DB1111581	Pulmonary Disease, Chronic Obstructive	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=DB1111581	http://clinicaltrials.gov/show/NCT00749411	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-004266-78	Y	Y	Y	Y	Y	Y	Y		1-May-2013
32	GSK	A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multi-Center Study to Evaluate the Effects of a One-Year Course of Fluticasone Furoate Nasal Spray 110mcg QD on Growth in Pre-Pubescent, Pediatric Subjects with Perennial Allergic Rhinitis	fluticasone furoate	FFR101782	Rhinitis, Allergic, Perennial	Phase 4	https://www.gsk-studyregister.com/en/trial-details/?id=FFR101782	http://clinicaltrials.gov/show/NCT00570492	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005148-26	Y	Y	Y	Y	Y	Y	Y		1-Jul-2015
33	GSK	A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multicenter, Two-Year Study to Evaluate the Ocular Safety of Once-Daily, Fluticasone Furoate Nasal Spray 110mcg in Adults and Adolescents 12 Years of Age and Older with Perennial Allergic Rhinitis	fluticasone furoate	FFR110537	Rhinitis, Allergic, Perennial	Phase 4	https://www.gsk-studyregister.com/en/trial-details/?id=FFR110537	http://clinicaltrials.gov/show/NCT00682643		Y	Y	Y	Y	Y	Y	Y	A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Sep-2013
34	GSK	A Pilot, Randomised, Double-blind, Placebo-controlled, Parallel-group, Multicentre Study to Evaluate the Efficacy and Safety of Once-daily Intranasal Administration of Fluticasone Furoate Nasal Spray 110 mcg for 4 Weeks in Adults and Adolescents with Irritant (Non-Allergic) Rhinitis	fluticasone furoate	FFR111158	Rhinitis, Allergic, Perennial	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=FFR111158	http://clinicaltrials.gov/show/NCT00730756		Y	Y	Y	Y	Y	Y	Y		1-May-2013
35	GSK	A Randomized, Double-blind, Placebo-controlled, Active Comparator, One-Week, Cross-Over, Multicenter Study to Evaluate the Efficacy and Patient Preference of Nasal Spray Characteristics of Once-Daily, Intranasal Administration of 110mcg Fluticasone Furoate Nasal Spray and 200mcg Fluticasone Propionate Nasal Spray in Adult Subjects with Seasonal Allergic Rhinitis	fluticasone furoate	FFU105924	Rhinitis, Allergic, Perennial	Phase 4	https://www.gsk-studyregister.com/en/trial-details/?id=FFU105924	http://clinicaltrials.gov/show/NCT00539006		Y	Y	Y	Y	Y	Y	Y		1-May-2013
36	GSK	A Randomized, Double-blind, Placebo-controlled, Active Comparator, One-Week, Cross-Over, Multicenter Study to Evaluate the Efficacy and Patient Preference of Nasal Spray Characteristics of Once-Daily, Intranasal Administration of 110mcg Fluticasone Furoate Nasal Spray and 200mcg Fluticasone Propionate Nasal Spray in Adult Subjects with Seasonal Allergic Rhinitis	fluticasone furoate	FFU105927	Rhinitis, Allergic, Perennial	Phase 4	https://www.gsk-studyregister.com/en/trial-details/?id=FFU105927	http://clinicaltrials.gov/show/NCT00519636		Y	Y	Y	Y	Y	Y	Y		1-May-2013
37	GSK	A Comparison of Fluticasone Furoate Nasal Spray versus Oral Fexofenadine in the treatment of seasonal allergic rhinitis	fluticasone furoate	FFU109047	Rhinitis, Allergic, Seasonal	Phase 4	https://www.gsk-studyregister.com/en/trial-details/?id=FFU109047	http://clinicaltrials.gov/show/NCT00502775		Y	Y	Y	Y	Y	Y	Y		1-May-2013
38	GSK	A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Evaluate the Efficacy and Safety of Once-Daily Intranasal Administration of Fluticasone Furoate Nasal Spray 110mcg in Adult and Adolescent Subjects 12 years of Age and Older with Perennial Allergic Rhinitis (PAR)	fluticasone furoate	FFU111439	Rhinitis, Allergic, Perennial	Phase 4	https://www.gsk-studyregister.com/en/trial-details/?id=FFU111439	http://clinicaltrials.gov/show/NCT00609674	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-006562-15	Y	Y	Y	Y	Y	Y	Y		1-May-2013
39	GSK	A randomised, double-blind, placebo-controlled, 4-period, incomplete block, crossover study to assess the dose-response curve of intranasal fluticasone propionate (25, 50, 100 and 200 g, once daily for 8 days) in the Vienna Challenge Chamber for the purpose of investigating the sensitivity of the model when evaluating glucocorticosteroids	fluticasone propionate	NSG110341	Rhinitis, Allergic, Perennial	Phase 4	https://www.gsk-studyregister.com/en/trial-details/?id=110341	http://clinicaltrials.gov/show/NCT00848965		Y	Y	Y	Y	Y	Y	Y		1-May-2013
40	GSK	A 52-week, Randomized, Double-Blind, Parallel-Group Study of Fluticasone Propionate/Salmeterol DISKUS Combination Product (FSC) 250/50 mcg BID and Fluticasone Propionate (FP) DISKUS 250 mcg BID in Treatment of Subjects with Asthma	fluticasone propionate/salmeterol	ADA109055	Asthma	Phase 4	https://www.gsk-studyregister.com/en/trial-details/?id=ADA109055	http://clinicaltrials.gov/show/NCT00452699		Y	Y	Y	Y	Y	Y	Y		1-May-2013
41	GSK	A 52-week, Randomized, Double-Blind, Parallel-Group Study of Fluticasone Propionate/Salmeterol DISKUS Combination Product (FSC) 250/50 mcg BID and Fluticasone Propionate (FP) DISKUS 250 mcg BID in Treatment of Subjects with Asthma	fluticasone propionate/salmeterol	ADA109057	Asthma	Phase 4	https://www.gsk-studyregister.com/en/trial-details/?id=ADA109057	http://clinicaltrials.gov/show/NCT00452348		Y	Y	Y	Y	Y	Y	Y		1-May-2013
42	GSK	A Randomized, Double-Blind, Parallel Group study of ADVAIR™ DISKUS™ 100/50 and FLOVENT™DISKUS™ 100, both twice daily, in a Pediatric Population during the Fall Viral Season.	fluticasone propionate/salmeterol	ADA113872	Asthma	Phase 4	https://www.gsk-studyregister.com/en/trial-details/?id=113872	http://clinicaltrials.gov/show/NCT01192178		Y	Y	Y	Y	Y	Y	Y		1-Nov-2015
43	GSK	A Randomized, Double-Blind, Parallel-Group, 24-Week Study to Evaluate the Efficacy and Safety of ADVAIR DISKUS (Fluticasone Propionate/Salmeterol Combination Product 250/50mcg Inhalation Powder) BID Plus Spiriva HandiHaler (Tiotropium Bromide Inhalation Powder 18mcg) QD Versus Spiriva QD Plus Placebo DISKUS BID in Subjects with Chronic Obstructive Pulmonary Disease (COPD)	fluticasone propionate/salmeterol	ADC111114	Pulmonary Disease, Chronic Obstructive	Phase 4	https://www.gsk-studyregister.com/en/trial-details/?id=111114	http://clinicaltrials.gov/show/NCT00784550		Y	Y	Y	Y	Y	Y	Y		1-May-2013
44	GSK	A Randomized, Double-Blind, Double-Dummy, Parallel Group 12-Week Comparison of the Efficacy and Safety of Fluticasone Propionate/Salmeterol Hydrofluoroalkane 134a Metered-Dose-Inhaler 230/42mcg twice-daily with Fluticasone Propionate/Salmeterol DISKUS 250/50mcg twice-daily in subjects with COPD	fluticasone propionate/salmeterol	ADC111117	Pulmonary Disease, Chronic Obstructive	Phase 4	https://www.gsk-studyregister.com/en/trial-details/?id=111117	http://clinicaltrials.gov/show/NCT00633217		Y	Y	Y	Y	Y	Y	Y		1-May-2013
45	GSK	A Randomized, Double-Blind, Parallel-Group, 16-Week Study to Evaluate the Effect of Fluticasone Propionate/Salmeterol DISKUS® 250/50mcg BID and Placebo on Arterial Stiffness in Subjects with Chronic Obstructive Pulmonary Disease (COPD)	fluticasone propionate/salmeterol	ADC112355	Pulmonary Disease, Chronic Obstructive	Phase 4	https://www.gsk-studyregister.com/en/trial-details/?id=112355	http://clinicaltrials.gov/show/NCT00857766		Y	Y	Y	Y	Y	Y	Y		1-May-2013
46	GSK	A study of fluticasone propionate/salmeterol DISKUS combination product 250/50 mcg twice daily plus tiotropium 18 mcg daily versus placebo DISKUS twice daily plus tiotropium 18 mcg daily on exercise time and physiological parameters in subjects with Chronic Obstructive Pulmonary Disease	fluticasone propionate/salmeterol	ADC113877	Pulmonary Disease, Chronic Obstructive	Phase 4	https://www.gsk-studyregister.com/en/trial-details/?id=113877	http://clinicaltrials.gov/show/NCT01124422		Y	Y	Y	Y	Y	Y	Y		1-Sep-2013
47	GSK	A randomized, double-blind, parallel group study evaluating the safety of fluticasone propionate/salmeterol 100/50mcg HFA (2 inhalations of 50/25mcg) twice daily compared with fluticasone propionate 100mcg HFA (2 inhalations of 50mcg) twice daily in subjects 4-11 years of age with persistent asthma	fluticasone propionate/salmeterol	SFA106484	Asthma	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=SFA106484	http://clinicaltrials.gov/show/NCT00441441	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001417-16	Y	Y	Y	Y	Y	Y	Y		1-May-2013
48	GSK	FondaparinUx Trial with Unfractionated Heparin (UFH) during Revascularization in Acute Coronary Syndromes (ACS) (FUTURA). A prospective study evaluating the safety of two regimens of adjunctive intravenous UFH during PCI in high risk patients with Unstable Angina/Non ST segment elevation myocardial infarction (UA/NSTEMI) initially treated with subcutaneous fondaparinux and referred for early coronary angiography (OASIS 8)	fondaparinux sodium	AR1108888	Acute Coronary Syndrome	Phase 4	https://www.gsk-studyregister.com/en/trial-details/?id=108888	http://clinicaltrials.gov/show/NCT00790907	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-002747-16	Y	Y	Y	Y	Y	Y	Y	The raw data are included within the analysis-ready data for this study and are not provided separately.	1-May-2013
49	GSK	Clinical Evaluation of GSK576428 (Fondaparinux Sodium) in the Treatment of Acute Pulmonary Thromboembolism (PE)	fondaparinux sodium	AR3106206	Embolism, Pulmonary	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=106206	http://clinicaltrials.gov/show/NCT00981409		N	Y	N	Y	N	Y	N	An analysis-ready dataset and reporting and analysis plan are not available for this study. A clinical study report and a protocol are not available for this study because English language versions were not created.	1-Jul-2015
50	GSK	Clinical Evaluation of GSK576428 (Fondaparinux Sodium) in the Treatment of Acute Deep Vein Thrombosis (DVT)	fondaparinux sodium	AR3111436	Thrombosis, Venous	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=111436	http://clinicaltrials.gov/show/NCT00911157		N	Y	N	Y	N	Y	N	An analysis-ready dataset and reporting and analysis plan are not available for this study. A clinical study report and a protocol are not available for this study because English language versions were not created.	1-Jul-2015
51	GSK	An 8 day, randomised, double blind, 3-way crossover trial of repeat doses of intranasal GSK256066 and fluticasone propionate in the Vienna Challenge Chamber in subjects with seasonal allergic rhinitis (SAR)	GSK256066	IPR110723	Rhinitis, Allergic, Seasonal	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=IPR110723	http://clinicaltrials.gov/show/NCT00612820	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005301-22	Y	Y	Y	Y	Y	Y	Y		1-May-2013
52	GSK	A randomised, placebo-controlled, incomplete block, three-way cross-over study to evaluate the effect of treatment with repeat inhaled doses of GW870086X on the allergen-induced early and late asthmatic response in subjects with mild asthma	GW870086	SIG110762	Asthma	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=110762	http://clinicaltrials.gov/show/NCT00857857	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005791-14	Y	Y	Y	Y	Y	Y	Y		1-Mar-2015
53	GSK	An Open-Label Trial Measuring Satisfaction and Convenience of Two Formulations of Lamotrigine in Subjects with a Mood Disorder	lamotrigine	LBI108884	Mood Disorders	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=LBI108884	http://clinicaltrials.gov/show/NCT00579982		Y	Y	Y	Y	Y	Y	Y		1-May-2013
54	GSK	Lamotrigine Extended-Release in Elderly Patients with Epilepsy	lamotrigine	LEP105972	Epilepsy	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=LEP105972	http://clinicaltrials.gov/show/NCT00516139		Y	Y	Y	Y	Y	Y	Y		1-May-2015
55	GSK	Study SCA104779, an evaluation of BW430C (lamotrigine) versus placebo in the prevention of mood episodes in bipolar I disorder patients	lamotrigine	SCA104779	Bipolar Disorder	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=SCA104779	http://clinicaltrials.gov/show/NCT00550407		Y	N	N	Y	N	Y	Y	Extension study SCA106052 was conducted. A clinical study report and a protocol are not available for this study because English language versions were not created. An annotated case report form is not available for this study. A blank case report form will be provided.	1-Jul-2015
56	GSK	Study SCA106052, a clinical evaluation of BW430C (lamotrigine) in bipolar I disorder– Long-term extension study (extension of study SCA104779 (NCT00550407))	lamotrigine	SCA106052	Bipolar Disorder	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=SCA106052	http://clinicaltrials.gov/show/NCT00566020		N	Y	N	Y	N	Y	Y	This is an extension study to SCA104779. An analysis-ready dataset is not available for this study. A clinical study report is not available for this study because an English language version was not created.	1-Jul-2015
74	GSK	A Randomized, Double-Blind, Placebo-Controlled, Forced Titration Study to Assess the Efficacy and Safety of Omacor, Co-Administered with Open-Label Atorvastatin Therapy, in Hypertriglyceridemic Subjects	omega-3-acid ethyl esters	LOV111819	Hypertriglyceridemia	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=OM9L	http://clinicaltrials.gov/show/NCT00435045		Y	Y	Y	Y	Y	Y	Y		1-May-2013
79	GSK	Durable-Response Therapy Evaluation For Early or New-Onset Type 1 Diabetes - DEFEND	otelixizumab	OTX115495	Diabetes Mellitus, Type 1	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=115495	http://clinicaltrials.gov/show/NCT00678886	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-002205-40	Y	Y	Y	Y	Y	Y	Y	A follow-on study OTX115496 was conducted.	1-Jun-2014
80	GSK	A randomised, single-blind, placebo-controlled, study to evaluate the safety, tolerability, pharmacodynamics and pharmacokinetics of single ascending administration of otelixizumab in subjects with Type 1 Diabetes Mellitus	otelixizumab	RAO112438	Diabetes Mellitus, Type 1	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=112438	http://clinicaltrials.gov/show/NCT00946257	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-008207-18	Y	Y	Y	Y	Y	Y	Y		1-Jan-2017
82	GSK	A randomised, double-blind, placebo controlled, parallel group , flexible dose study to evaluate the efficacy and safety of Paxil® Tablets in children and adolescents with Major Depressive Disorder<Post-marketing clinical study>	paroxetine	PIR112487	Depressive Disorder	Phase 4	https://www.gsk-studyregister.com/en/trial-details/?id=112487	http://clinicaltrials.gov/show/NCT00812812		N	Y	N	Y	N	Y	Y	An analysis-ready dataset is not available for this study. A clinical study report and a protocol are not available for this study because English language versions were not created.	1-Jul-2015
101	GSK	Randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability, pharmacokinetics (PK) and efficacy of Retapamulin ointment, 1% applied twice daily for 3 or 5 days to the anterior nares of healthy adult subjects nasally colonized with Staphylococcus aureus	retapamulin	ALB110247	Infections, Bacterial	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=ALB110247	http://clinicaltrials.gov/show/NCT00539994		Y	Y	Y	Y	Y	Y	Y		1-May-2013
102	GSK	An Open-Label, Non-Comparative Study to Assess the Pharmacokinetics, Safety and Efficacy of Topical Retapamulin (SB-275833) Ointment, 1%, Twice Daily for Five Days in the Treatment of Uncomplicated Skin and Skin Structure Infections in Pediatric Subjects Aged 2 to 24 Months	retapamulin	TOC106489	Skin Infections, Bacterial	Phase 4	https://www.gsk-studyregister.com/en/trial-details/?id=TOC106489	http://clinicaltrials.gov/show/NCT00555061	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003374-10	Y	Y	Y	Y	Y	Y	Y		1-Nov-2014
103	GSK	A Randomized, Double-Blind, Multicenter, Placebo-controlled, Phase III Superiority Study to Assess the Safety and Efficacy of Topical Retapamulin Ointment, 1%, versus Placebo Ointment Applied Twice Daily for 5 Days in the Treatment of Adult and Pediatric Subjects with SITL	retapamulin	TOC110977	Skin Infections, Bacterial	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=110977	http://clinicaltrials.gov/show/NCT00684177		Y	Y	Y	Y	Y	Y	Y		1-Sep-2013
104	GSK	A Randomized, Double-Blind, Double Dummy, Comparative, Multicenter Study to Assess the Safety and Efficacy of Topical Retapamulin Ointment, 1%, versus Oral Linezolid in the Treatment of Secondarily-Infected Traumatic Lesions and Impetigo Due to Methicillin-Resistant Staphylococcus aureus	retapamulin	TOC110978	Skin Infections, Bacterial	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=110978	http://clinicaltrials.gov/show/NCT00852540		Y	Y	Y	Y	Y	Y	Y		1-Sep-2013
105	GSK	An open label, single-dose, fixed sequence, two treatment period study to assess the effect of haemodialysis on the pharmacokinetics of ezogabine/retigabine and the n-acetyl metabolite of ezogabine/retigabine (NAMR).	retigabine, ezogabine	RTG115214	Epilepsy	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=115214	http://clinicaltrials.gov/show/NCT01480609		Y	Y	Y	Y	Y	Y	Y		1-Jul-2015
106	GSK	A multicenter, randomized, 12 week, double-blind, placebo-controlled, parallel-group, Phase IIa study using 18F fluorodeoxyglucose (FDG)-PET to measure the effects of rilapladib on macrophage activity in subjects with atherosclerosis	rilapladib	LP2105521	Atherosclerosis	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=LP2105521	http://clinicaltrials.gov/show/NCT00695305	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006201-91	Y	Y	Y	Y	Y	Y	Y		1-Nov-2014
107	GSK	A Proof-of-Concept Study Of SB-751689 In Men And Post-menopausal Women With A Fractured Distal Radius	ronacaleret	CR9108914	Fracture Healing	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=CR9108914	http://clinicaltrials.gov/show/NCT00548496	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001477-29	Y	Y	Y	Y	Y	Y	Y		1-May-2013
108	GSK	Study CR9108963: A 12-month, randomized, double-blind, parallel-group, placebo and active-controlled dose-range finding study of the efficacy and safety of SB-751689 in post-menopausal women with osteoporosis	ronacaleret	CR9108963	Osteoporosis	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=CR9108963	http://clinicaltrials.gov/show/NCT00471237	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006015-72	Y	Y	Y	Y	Y	Y	Y		1-May-2013
110	GSK	Clinical Evaluation of ropinirole PR/XR Tablet for Adjunctive Therapy to L-dopa in subjects with advanced Parkinson’s disease	ropinirole	ROP106066	Parkinson Disease	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=106066	http://clinicaltrials.gov/show/NCT00823836		Y	Y	Y	Y	N	Y	Y	A protocol is not available for this study because an English language version was not created.	1-Oct-2015
111	GSK	An open label, repeat dose, dose escalation study conducted in Parkinson's Disease patients to characterize the pharmacokinetics and effect of food on ropinirole prolonged release (PR/CR) 12mg tablets.	ropinirole	ROP109087	Parkinson Disease	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=ROP109087	http://clinicaltrials.gov/show/NCT00460148	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006209-94	Y	Y	Y	Y	Y	Y	Y		1-May-2013
112	GSK	Clinical evaluation of ropinirole IR (immediate release) tablets in patients who are diagnosed with symptomatic restless legs syndrome (RLS) associated with Chronic kidney disease (CKD) managed with haemodialysis (including haemofiltration and haemodiafiltration)	ropinirole	ROR113079	Restless Legs Syndrome	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=113079	http://clinicaltrials.gov/show/NCT00996944		Y	Y	N	Y	N	N	Y	A raw dataset is not available for this study. A clinical study report and a protocol are not available for this study because English language versions were not created.	1-Jul-2015
113	GSK	Clinical Evaluation of Ropinirole CR-RLS Tablets in Restless Legs Syndrome-Open-Label, Uncontrolled Study. Classification: Clinical Pharmacology, Exploratory	ropinirole	ROX107846	Restless Legs Syndrome	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=107846	http://clinicaltrials.gov/show/NCT00530790		Y	Y	N	Y	N	N	Y	A raw dataset is not available for this study. A clinical study report and a protocol are not available for this study because English language versions were not created.	1-Jul-2015
114	GSK	An open-label extension study of the long-term safety and efficacy of rosiglitazone extended-release (RSG XR) as adjunctive therapy to acetylcholinesterase inhibitors in subjects with mild-to-moderate Alzheimer's disease (REFLECT-4).	rosiglitazone	AVA102675	Alzheimer's Disease	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=AVA102675	http://clinicaltrials.gov/show/NCT00490568	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004152-20	Y	N	Y	Y	Y	Y	Y	This is a follow-up study to AVA102670 and AVA102672. An annotated case report form is not available for this study. A blank case report form will be provided.	1-May-2013
115	GSK	An open-label extension study of the long-term safety and efficacy of rosiglitazone extended-release (RSG XR) in subjects with mild-to-moderate Alzheimer's disease (REFLECT-5)	rosiglitazone	AVA102677	Alzheimer's Disease	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=AVA102677	http://clinicaltrials.gov/show/NCT00550420	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005078-28	Y	Y	Y	Y	Y	Y	Y	This is a follow-up study to AVA105640.	1-May-2013
116	GSK	A 24-week, double-blind, double-dummy, randomized, parallel-group study to investigate the effects of rosiglitazone (extended release tablets), donepezil, and placebo as monotherapy on cognition and overall clinical response in APOE ε4-stratified subjects with mild to moderate Alzheimer’s disease. (REFLECT-1)	rosiglitazone	AVA105640	Alzheimer's Disease	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=105640	http://clinicaltrials.gov/show/NCT00428090	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002038-39	Y	Y	Y	Y	Y	Y	Y	A follow-on study AVA102677 was conducted.	1-May-2013
117	GSK	An open label single oral dose study in patients with mild Alzheimer's disease to assess the pharmacokinetics of extended release formulation of Rosiglitazone (RSG XR) in this population	rosiglitazone	AVA109941	Alzheimer's Disease	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=AVA109941	http://clinicaltrials.gov/show/NCT00688207	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005924-34	Y	Y	Y	Y	Y	Y	Y		1-May-2013
118	GSK	A 52 Week Randomized, Double-Blind, Multicenter, Mechanistic Study with a 24 Week Open-Label Follow-Up to Evaluate the Effect of AVANDIA TM on Bone in Postmenopausal Women with Type 2 Diabetes Mellitus	rosiglitazone	AVD111179	Diabetes Mellitus, Type 2	Phase 4	https://www.gsk-studyregister.com/en/trial-details/?id=AVD111179	http://clinicaltrials.gov/show/NCT00679939	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-002301-38	Y	Y	Y	Y	Y	Y	Y		1-May-2013
119	GSK	Thiazolidinedione Intervention with vitamin D Evaluation (TIDE) A Multicenter Randomized Double-Blind Placebo Controlled Trial of a Thiazolidinedione or Placebo and of Vitamin D or Placebo In People With Type 2 Diabetes at Risk For Cardiovascular Disease	rosiglitazone	AVD111960	Diabetes Mellitus, Type 2	Phase 4	https://www.gsk-studyregister.com/en/trial-details/?id=111960	http://clinicaltrials.gov/show/NCT00879970	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-005030-73	N	Y	Y	Y	Y	Y	Y	An analysis-ready dataset is not available for this study.	1-May-2013
120	GSK	A randomized, double-blind, placebo controlled, incomplete block, 3 way cross over study in subjects with allergic rhinitis to assess the effect of intranasal repeat doses of SB-705498 when administered alone or in conjunction with intranasal fluticasone propionate on the symptoms of rhinitis in the Vienna allergen challenge chamber	SB705498	VR1111924	Rhinitis	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=111924	http://clinicaltrials.gov/show/NCT01424397	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000115-11	Y	Y	Y	Y	Y	Y	Y		1-May-2013
121	GSK	A Randomized, Double-blind, Double-dummy, Placebo-controlled, Crossover Study to Evaluate the Efficacy of TREXIMET® (Sumatriptan + Naproxen Sodium) vs. Butalbital-containing Combination Medications for the Acute Treatment of Migraine when administered during the Moderate-Severe Migraine Pain, 1 of 2	sumatriptan/naproxen	TRX109011	Migraine Disorders	Phase 3		http://clinicaltrials.gov/show/NCT01812408		Y	Y	Y	Y	Y	Y	Y	There is no GSK Study Register entry for this study.	1-May-2013
122	GSK	A Crossover, Randomized, Double-blind, Double-dummy, Placebo-controlled Study to Evaluate the Efficacy of TREXIMET®/Sumatriptan + Naproxen Sodium vs. Butalbital-containing Combination Medications for the Acute Treatment of Migraine when administered during Moderate-Severe Migraine Pain, 2 of 2	sumatriptan/naproxen	TRX109013	Migraine Disorders	Phase 3		http://clinicaltrials.gov/show/NCT00599157		Y	Y	Y	Y	Y	Y	Y	There is no GSK Study Register entry for this study.	1-May-2013
123	GSK	Assessment of the effect of sumatriptan and naproxen sodium combination tablet, sumatriptan tablet, and naproxen sodium tablet treatment on blood pressure when administered intermittently for six months for the acute treatment of migraine attacks, with or without aura, in adults	sumatriptan/naproxen	TXA110948	Migraine Disorders	Phase 4	https://www.gsk-studyregister.com/en/trial-details/?id=110948	http://clinicaltrials.gov/show/NCT00792636		Y	Y	Y	Y	Y	Y	Y		1-May-2013
124	GSK	A Multicenter, Randomized, Double-Blind, Vehicle-Controlled, Parallel-Group Study to Evaluate the Safety and Efficacy of Tazarotene Foam, 0.1%, in Subjects with Acne Vulgaris	tazarotene	STF114575	Acne Vulgaris	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=114575	http://clinicaltrials.gov/show/NCT01017146		N	Y	Y	Y	Y	Y	Y	An analysis-ready dataset is not available for this study.	1-May-2013
125	GSK	A Multicenter, Randomized, Double-Blind, Vehicle-Controlled, Parallel-Group Study to Evaluate the Safety and Efficacy of Tazarotene Foam, 0.1%, in Subjects with Acne Vulgaris	tazarotene	STF114576	Acne Vulgaris	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=114576	http://clinicaltrials.gov/show/NCT01017120		N	Y	Y	Y	Y	Y	Y	An analysis-ready dataset is not available for this study.	1-May-2013
127	GSK	A multi-centre, randomized, double-blind, placebo-controlled, cross-over study to evaluate the effects of GW597599 and GR205171 on sleep continuity, PSG sleep recordings, subjective sleep assessment and daytime cognitive function in subjects with primary insomnia	vestipitant	NKI110334	Sleep Initiation and Maintenance Disorders	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=NKI110334	http://clinicaltrials.gov/show/NCT00606697	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004035-35	Y	Y	Y	Y	Y	Y	Y		1-Mar-2015
128	GSK	A 28-Day, Polysomnographic and Subjective Assessment of Vestipitant (15mg/day) for the Treatment of Primary Insomnia in Adult Outpatients	vestipitant	NKI111364	Sleep Disorders	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=111364	http://clinicaltrials.gov/show/NCT00992160	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-006345-72	Y	Y	Y	Y	Y	Y	Y		1-Mar-2015
132	GSK	Evaluation of the immunogenicity and safety of GlaxoSmithKline Biologicals' HPV vaccine 580299 when administered as a 3-dose schedule in healthy Japanese pre-adolescent and adolescent female subjects.	Human Papillomavirus Types 16 and 18 Vaccine	110168	Infections, Papillomavirus	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=110168	http://clinicaltrials.gov/show/NCT00492544		Y	Y	Y	Y	Y	Y	Y		1-May-2013
134	GSK	Booster Vaccination With Pneumococcal Vaccine GSK1024850A, a DTPa-Combined and MenC or Hib-MenC Vaccines	Pneumococcal Polysaccharide Conjugate Vaccine (Adsorbed)	109507	Infections, Streptococcal	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=109507	http://clinicaltrials.gov/show/NCT00463437	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005733-38	Y	Y	Y	Y	Y	Y	Y		1-May-2013
135	GSK	Immunogenicity and reactogenicity study of a new formulation of GSK Biologicals' DTPa-HBV-IPV/Hib vaccine administered as a booster dose to 18-23 months old children	Combined Diphtheria, Tetanus, Acellular Pertussis Adsorbed, Hepatitis B (Recombinant), Inactivated Polio Vaccine	110478	Acellular pertussis; Diphtheria; Hepatitis B; Poliomyelitis; Tetanus	Phase 4	https://www.gsk-studyregister.com/en/trial-details/?id=110478	http://clinicaltrials.gov/show/NCT00611559	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002428-34	Y	Y	Y	Y	Y	Y	Y		1-May-2013
136	GSK	Immunogenicity and safety study of GlaxoSmithKline Biologicals’ GSK2202083A vaccine in healthy infants at 2, 3 and 4 months of age	Combined Diphtheria, Tetanus, Acellular Pertussis, Hepatitis B, Inactivated Polio, Haemophilus influenzae Type b Vaccine	112157	Acellular Pertussis; Diphtheria; Haemophilus influenzae type b; Hepatitis B; Poliomyelitis; Tetanus	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=112157	http://clinicaltrials.gov/show/NCT00970307	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-010431-41	Y	Y	Y	Y	Y	Y	Y		1-May-2013
137	GSK	Immunogenicity and safety study of GlaxoSmithKline Biologicals’ GSK2202083A vaccine administered as a booster dose in 12-18 months old healthy children	Combined Diphtheria, Tetanus, Acellular Pertussis, Hepatitis B, Inactivated Polio, Haemophilus influenzae Type b Vaccine	113978	Acellular Pertussis; Diphtheria; Haemophilus influenzae type b; Hepatitis B; Poliomyelitis; Tetanus	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=113978	http://clinicaltrials.gov/show/NCT01171989	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-019253-18	Y	Y	Y	Y	Y	Y	Y		1-May-2013
138	GSK	Immunogenicity and safety study of Kinrix® co-administered with Varivax®	Diphtheria, Tetanus, Acellular Pertussis Vaccine Adsorbed	111852	Acellular pertussis; Diphtheria; Tetanus	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=111852	http://clinicaltrials.gov/show/NCT00871117	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002946-11	Y	Y	Y	Y	Y	Y	Y		1-May-2013
140	GSK	Feasibility study of GlaxoSmithKline Biologicals’ GSK2202083A vaccine in healthy infants at 3, 5 and 11 months of age.	Combined Diphtheria, Tetanus, Pertussis, HepB, Polio, Hib and Neisseria meningitis serogroup C tetanus toxoid conjugate vaccine	111761	Acellular pertussis; Diphtheria; Haemophilus influenzae type b; Hepatitis B; Neisseria Meningitidis; Poliomyelitis; Tetanus	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=111761	http://clinicaltrials.gov/show/NCT00871741	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-006365-91	Y	Y	Y	Y	Y	Y	Y		1-May-2013
141	GSK	Non-inferiority of one formulation of GSK Biologicals' DTPw-HBV/Hib to 2 formulations of GSK Biologicals' DTPw-HBV/Hib with respect to the immune response to the PRP antigen, when administered to healthy infants at 6, 10, 14 weeks of age	Combined Diphtheria, Tetanus, Whole Cell Pertussis, Hepatitis B, Haemophilus influenzae Type b Vaccine (KFT)	104977	Diphtheria; Haemophilus influenzae type b; Hepatitis B; Tetanus; Whole Cell Pertussis	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=104977	http://clinicaltrials.gov/show/NCT00473668		Y	N	Y	Y	Y	Y	Y	An annotated case report form is not available for this study. A blank case report form will be provided.	1-May-2013
142	GSK	Immunogenicity and reactogenicity of a booster dose of GlaxoSmithKline Biologicals’ GSK2036874A vaccine in healthy toddlers	Combined Diphtheria, Tetanus, Whole Cell Pertussis, Hepatitis B, Haemophilus influenzae Type b Vaccine (KFT)	113264	Diphtheria; Haemophilus influenzae type b; Hepatitis B; Tetanus; Whole Cell Pertussis	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=113264	http://clinicaltrials.gov/show/NCT01106092	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000645-31	Y	Y	Y	Y	Y	Y	Y		1-May-2013
143	GSK	Immunogenicity of GlaxoSmithKline Biologicals' MMRV vaccine (208136) vs. ProQuad®, when coadministered with hepatitis A and pneumococcal conjugate vaccines to children 12-14 months of age.	Combined Measles, Mumps, Rubella, Varicella Vaccine	110058	Measles; Mumps; Rubella; Varicella	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=110058	http://clinicaltrials.gov/show/NCT00578175	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000454-18	Y	Y	Y	Y	Y	Y	Y		1-May-2013
144	GSK	Immunogenicity & safety study of GSK Biologicals’ combined measles-mumps-rubella-varicella vaccine 208136	Combined Measles, Mumps, Rubella, Varicella Vaccine	110876	Measles; Mumps; Rubella; Varicella	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=110876	http://clinicaltrials.gov/show/NCT00751348	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004485-15	Y	N	Y	Y	Y	Y	Y	An annotated case report form is not available for this study. A blank case report form will be provided.	1-Feb-2015
145	GSK	A phase IIIb, open, randomised, multicentre, primary study in healthy children, to establish the non-inferiority of GlaxoSmithKline (GSK) Biologicals’ MeMuRu-OKA vaccine (administered at 9 and 15 months of age) versus Priorix™ (9 months of age) and Priorix™ co-administered with Varilrix™ at 15 months of age (comparator) and also to evaluate the non-inferiority of Priorix™ (9 months of age) and MeMuRu-OKA vaccine (15 months of age) versus the comparator, all administered subcutaneously as two-dose primary vaccination course	Combined Measles, Mumps, Rubella, Varicella Vaccine	109995	Measles; Mumps; Rubella; Varicella	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=109995	http://clinicaltrials.gov/show/NCT00969436	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005882-19	Y	Y	Y	Y	Y	Y	Y		1-Sep-2015
146	GSK	Open, booster vaccination study to assess safety and reactogenicity of GSK Biologicals’ dTpa vaccine (Boostrix) when administered to healthy chinese children 6-8 years of age.	Combined Reduced Antigen Content Diphtheria, Tetanus, Acellular Pertussis Vaccine	107924	Acellular pertussis; Diphtheria; Tetanus	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=107924	http://clinicaltrials.gov/show/NCT00406562		Y	Y	Y	Y	Y	Y	Y		1-May-2013
147	GSK	Immunogenicity and safety study of GlaxoSmithKline (GSK) Biologicals’ Boostrix (dTpa) vaccine and the Chinese DT vaccine, when administered as booster vaccination in healthy children aged 6-8 years	Combined Reduced Antigen Content Diphtheria, Tetanus, Acellular Pertussis Vaccine	108638	Acellular pertussis; Diphtheria; Tetanus	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=108638	http://clinicaltrials.gov/show/NCT00452686	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000644-34	Y	Y	Y	Y	Y	Y	Y		1-May-2013
148	GSK	Evaluation of GSK Biologicals’ dTpa booster vaccine in adults, given 10 years after previous dTpa boosting.	Combined Reduced Antigen Content Diphtheria, Tetanus, Acellular Pertussis Vaccine	110804	Acellular pertussis; Diphtheria; Tetanus	Phase 4	https://www.gsk-studyregister.com/en/trial-details/?id=110804	http://clinicaltrials.gov/show/NCT00548171		Y	Y	Y	Y	Y	Y	Y		1-May-2013
149	GSK	Evaluation of GSK Biologicals’ dTpa booster vaccine in young adults 10 years after previous dTpa boosting.	Combined Reduced Antigen Content Diphtheria, Tetanus, Acellular Pertussis Vaccine	110806	Acellular pertussis; Diphtheria; Tetanus	Phase 4	https://www.gsk-studyregister.com/en/trial-details/?id=110806	http://clinicaltrials.gov/show/NCT00610168	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003248-31	Y	Y	Y	Y	Y	Y	Y		1-May-2013
150	GSK	Evaluation of GSK Biologicals’ Boostrix® vaccine when compared with Decavac™ in adults aged 65 years or older.	Combined Reduced Antigen Content Diphtheria, Tetanus, Acellular Pertussis Vaccine	BTX111413	Acellular pertussis; Diphtheria; Tetanus	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=111413	http://clinicaltrials.gov/show/NCT00835237		Y	Y	Y	Y	Y	Y	Y		1-May-2013
151	GSK	Evaluation of GSK Biological’s dTpa-IPV booster vaccine in children and adolescents, 5 years after previous dTpa-IPV boosting.	Combined Reduced Antigen Content Diphtheria, Tetanus, Acellular Pertussis, Inactivated Polio Vaccine	110947	Acellular pertussis; Diphtheria; Poliomyelitis; Tetanus	Phase 4	https://www.gsk-studyregister.com/en/trial-details/?id=110947	http://clinicaltrials.gov/show/NCT00635128	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003477-94	Y	Y	Y	Y	Y	Y	Y		1-Mar-2015
152	GSK	Immunogenicity and safety of GSK Biologicals’ dTpa-IPV vaccine (Boostrix Polio) as a booster dose in 5 to 6-year-old children.	Combined Reduced Antigen Content Diphtheria, Tetanus, Acellular Pertussis, Inactivated Polio Vaccine	111815	Acellular pertussis; Diphtheria; Poliomyelitis; Tetanus	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=111815	http://clinicaltrials.gov/show/NCT00871000	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-006124-64	Y	Y	Y	Y	Y	Y	Y		1-May-2013
153	GSK	Phase IIIb, multicentre study to assess safety & immunogenicity of GSK Biologicals’ combined DTPa/Hib (Infanrix/Hib) vaccine vs separate administration of DTPa (Infanrix) & Hib (Hiberix) vaccines in healthy infants 3,4,&5 months of age as compared with the separate administration of DTPa and Hib vaccines at different injection sites.	Diphtheria, Tetanus, Acellular Pertussis Vaccine Adsorbed	104567	Acellular pertussis; Diphtheria; Tetanus	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=104567	http://clinicaltrials.gov/show/NCT00412854		Y	Y	Y	Y	Y	Y	Y		1-May-2013
154	GSK	Immunogenicity and reactogenicity study of GlaxoSmithKline Biologicals' Infanrix™/Hib vaccine administered as a booster dose to 18-24 months old children	Diphtheria, Tetanus, Acellular Pertussis Vaccine Adsorbed	111535	Acellular pertussis; Diphtheria; Tetanus	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=111535	http://clinicaltrials.gov/show/NCT00696423	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-001507-31	Y	Y	Y	Y	Y	Y	Y		1-May-2013
155	GSK	Long-term persistence of hepatitis B antibodies & immune response to a hepatitis B vaccine challenge in 7-8 year old children, previously vaccinated in infancy with GlaxoSmithKline (GSK) Biologicals' HBV vaccine.	Hepatitis B Vaccine, Recombinant	110474	Hepatitis B	Phase 4	https://www.gsk-studyregister.com/en/trial-details/?id=110474	http://clinicaltrials.gov/show/NCT00519649	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002221-76	Y	Y	Y	Y	Y	Y	Y		1-Mar-2015
156	GSK	Immunogenicity and safety study of a GSK influenza vaccine candidate GSK 2115160A in adults.	Influenza Vaccine (Quadrivalent)	111295	Influenza	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=111295	http://clinicaltrials.gov/show/NCT00714285	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001303-34	Y	Y	Y	Y	Y	Y	Y		1-Mar-2014
157	GSK	Safety and immunogenicity study of GSK Biologicals’ cell culture-based influenza virus vaccine 1388442A compared with US licensed TIV in healthy adults	GSK1388442A	110127	Influenza	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=110127	http://clinicaltrials.gov/show/NCT00693706		Y	Y	Y	Y	Y	Y	Y		1-May-2013
158	GSK	A trial to evaluate the safety & immunogenicity of investigational influenza vaccine GSK1557484A in adults 18-64 yrs of age	H5N1 Pandemic Influenza Vaccine	111729	Influenza	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=111729	http://clinicaltrials.gov/show/NCT00771615		Y	Y	Y	Y	Y	Y	Y		1-May-2013
159	GSK	Immunogenicity and safety study of GSK Biologicals’ influenza vaccine GSK2186877A in elderly adults.	Influenza Vaccine	112662	Influenza	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=112662	http://clinicaltrials.gov/show/NCT00938392	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-011051-51	Y	Y	Y	Y	Y	Y	Y		1-May-2013
160	GSK	Non-inferiority study of GlaxoSmithKline Biologicals' influenza vaccine GSK576389A using different formulations.	Influenza Vaccine	111454	Influenza	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=111454	http://clinicaltrials.gov/show/NCT00633074	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-007043-27	Y	Y	Y	Y	Y	Y	Y		1-May-2013
161	GSK	Immunogenicity and safety study of GSK Biologicals’ influenza vaccine Arepanrix™ (GSK2340274A) in adults 65 years of age or older	H1N1 Pandemic Influenza Vaccine	114270	Influenza	Phase 4	https://www.gsk-studyregister.com/en/trial-details/?id=114270	http://clinicaltrials.gov/show/NCT01114620		Y	Y	Y	Y	Y	Y	Y		1-May-2013
162	GSK	A study to evaluate the safety and immunogenicity of A/California/7/2009 (H1N1)v-like vaccines GSK2340273A and GSK2340274A in adults aged 18 years and older	H1N1 Pandemic Influenza Vaccine	113440	Influenza	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=113440	http://clinicaltrials.gov/show/NCT00985088		Y	Y	Y	Y	Y	Y	Y		1-May-2013
163	GSK	Safety and immunogenicity study of GSK Biologicals’ influenza vaccine GSK2340272A in adults aged 18 to 60 years	H1N1 Pandemic Influenza Vaccine	113456	Influenza	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=113456	http://clinicaltrials.gov/show/NCT00968539	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-013710-27	Y	Y	Y	Y	Y	Y	Y		1-May-2013
164	GSK	Safety and immunogenicity study of GSK Biologicals’ influenza vaccine GSK2340272A in adults aged 18 years and above	H1N1 Pandemic Influenza Vaccine	113459	Influenza	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=113459	http://clinicaltrials.gov/show/NCT00968526	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-013837-92	Y	Y	Y	Y	Y	Y	Y		1-May-2013
165	GSK	Safety and immunogenicity study of GSK Biologicals’ pandemic influenza candidate vaccine (GSK2340272A) in children aged 6 to 35 months	H1N1 Pandemic Influenza Vaccine	113462	Influenza	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=113462	http://clinicaltrials.gov/show/NCT00971321	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-013783-39	Y	Y	Y	Y	Y	Y	Y		1-May-2013
166	GSK	A study to evaluate the safety, immunogenicity, and relative efficacy of A/California/7/2009 (H1N1)v-like vaccines GSK2340274A and GSK2340273A in adults aged 18 years and older	H1N1 Pandemic Influenza Vaccine	113480	Influenza	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=113480	http://clinicaltrials.gov/show/NCT00979602		Y	Y	Y	Y	Y	Y	Y		1-Mar-2014
167	GSK	A study to evaluate immune responses following A/California/7/2009 (H1N1)v-like virus vaccination given 4 months following seasonal influenza vaccination in adults 19 to 40 years of age	H1N1 Pandemic Influenza Vaccine	113483	Influenza	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=113483	http://clinicaltrials.gov/show/NCT01059617		Y	N	Y	Y	Y	Y	Y	An annotated case report form is not available for this study. A blank case report form will be provided.	1-Feb-2015
168	GSK	Immunogenicity and safety study of GSK Biologicals’ influenza candidate vaccine GSK2340274A	H1N1 Pandemic Influenza Vaccine	113519	Influenza	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=113519	http://clinicaltrials.gov/show/NCT00989612		Y	Y	Y	Y	Y	Y	Y		1-May-2013
169	GSK	Immunogenicity, safety and reactogenicity of GSK Biologicals’ influenza GSK2340272A and Fluarix™ 2009-2010 vaccines when co-administered in elderly subjects aged 61 years and older	H1N1 Pandemic Influenza Vaccine	113525	Influenza	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=113525	http://clinicaltrials.gov/show/NCT00968890	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-013931-39	Y	Y	Y	Y	Y	Y	Y		1-May-2013
170	GSK	Safety and immunogenicity study of GSK Biologicals’ pandemic influenza candidate vaccine (GSK2340272A) in children aged 3 to 17 years	H1N1 Pandemic Influenza Vaccine	113528	Influenza	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=113528	http://clinicaltrials.gov/show/NCT00964158	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-013785-52	Y	Y	Y	Y	Y	Y	Y		1-May-2013
171	GSK	Immunological equivalence between GSK2340272A and GSK2340274A influenza vaccines in adults aged 18 to 60 years	H1N1 Pandemic Influenza Vaccine	113535	Influenza	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=113535	http://clinicaltrials.gov/show/NCT00979407	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-014419-11	Y	N	Y	Y	Y	Y	Y	An annotated case report form is not available for this study. A blank case report form will be provided.	1-Feb-2015
172	GSK	A study to evaluate the safety and immunogenicity of an A/California/7/2009 (H1N1)v-like vaccine GSK2340274A or GSK2340273A co-administered with trivalent inactivated seasonal influenza vaccine in adults 19 to 40 years of age.	H1N1 Pandemic Influenza Vaccine	113536	Influenza	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=113536	http://clinicaltrials.gov/show/NCT00985673		Y	Y	Y	Y	Y	Y	Y		1-May-2013
173	GSK	Immunogenicity and safety of GSK Biologicals’ pandemic influenza candidate vaccine GSK2340272A	H1N1 Pandemic Influenza Vaccine	113572	Influenza	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=113572	http://clinicaltrials.gov/show/NCT00971425	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-014448-13	Y	Y	Y	Y	Y	Y	Y		1-Mar-2015
174	GSK	Safety and Immunogenicity Study of GSK Biologicals' Influenza Vaccine GSK2340272A in Adults Aged 18 to 60 Years	H1N1 Pandemic Influenza Vaccine	113574	Influenza	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=113574	http://clinicaltrials.gov/show/NCT00951041	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-014449-96	Y	Y	Y	Y	Y	Y	Y		1-Mar-2015
175	GSK	Safety and immunogenicity study of GSK Biologicals’ pandemic influenza candidate vaccine (GSK2340272A) in children aged 8 to 12 weeks	H1N1 Pandemic Influenza Vaccine	113629	Influenza	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=113629	http://clinicaltrials.gov/show/NCT01003418	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-015174-35	N	Y	Y	Y	Y	Y	N	An analysis-ready dataset and a reporting and analysis plan are not available for this study.	1-May-2013
176	GSK	Safety and immunogenicity study of GSK Biologicals’ influenza vaccine GSK2340272A in adults aged 18 years and above	H1N1 Pandemic Influenza Vaccine	113630	Influenza	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=113630	http://clinicaltrials.gov/show/NCT00975884	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-015008-25	Y	N	Y	Y	Y	Y	Y	An annotated case report form is not available for this study. A blank case report form will be provided.	1-Feb-2015
177	GSK	Safety and immunogenicity study of GSK Biologicals’ pandemic influenza candidate vaccine (GSK2340272A) in children aged 3 to 17 years	H1N1 Pandemic Influenza Vaccine	113638	Influenza	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=113638	http://clinicaltrials.gov/show/NCT00972517	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-015011-41	Y	Y	Y	Y	Y	Y	Y		1-Mar-2015
178	GSK	Immunological non-inferiority between two process-manufactured influenza vaccines in adults aged 18 to 60 years	H1N1 Pandemic Influenza Vaccine	113809	Influenza	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=113809	http://clinicaltrials.gov/show/NCT00992511	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-015997-36	Y	Y	Y	Y	Y	Y	Y		1-Mar-2015
179	GSK	Safety and immunogenicity study of GSK Biologicals’ pandemic influenza candidate vaccine (GSK2340272A) in children aged 3 to 9 years	H1N1 Pandemic Influenza Vaccine	113810	Influenza	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=113810	http://clinicaltrials.gov/show/NCT01014091	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-015960-32	Y	Y	Y	Y	Y	Y	Y		1-May-2013
180	GSK	Safety and immunogenicity study of GSK Biologicals’ pandemic influenza (H1N1) candidate vaccine (GSK2340274A) in Japanese children aged 6 months to 17 years	H1N1 Pandemic Influenza Vaccine	113847	Influenza	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=113847	http://clinicaltrials.gov/show/NCT01001169		Y	Y	Y	Y	Y	Y	Y		1-May-2013
181	GSK	Safety and immunogenicity study of GSK Biologicals’ influenza vaccine GSK2340272A in adults aged 18 to 60 years	H1N1 Pandemic Influenza Vaccine	113866	Influenza	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=113866	http://clinicaltrials.gov/show/NCT00989287	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-016078-33	Y	Y	Y	Y	Y	Y	Y		1-May-2013
183	GSK	An observer-blind safety and immunogenicity study of GSK Biologicals’ A/California/7/2009 (H1N1)v-like vaccines GSK2340274A and GSK2340272A in children 3 to less than 10 years old	H1N1 Pandemic Influenza Vaccine	114495	Influenza	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=114495	http://clinicaltrials.gov/show/NCT01161160	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-003512-23	Y	Y	Y	Y	Y	Y	Y		1-May-2013
184	GSK	A phase II, randomized, open, controlled study to evaluate the safety and immunogenicity of different formulations of a pandemic influenza vaccine candidate (split virus formulation adjuvanted with AS03) given following a two-administration schedule (21 days apart) in children between 3 and 9 years of age.	H5N1 Pandemic Influenza Vaccine	107066	Influenza	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=107066	http://clinicaltrials.gov/show/NCT00502593	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001168-22	Y	Y	Y	Y	Y	Y	Y	The results of this study are summarised with studies 108498 (second cohort study) and 108500 (third cohort study) on the GSK Study Register.	1-May-2013
185	GSK	Reactogenicity and Immunogenicity Study of GlaxoSmithKline Biologicals Pandemic Influenza Vaccine (GSK1119711A) Administered According to Different Vaccination Schedules	H5N1 Pandemic Influenza Vaccine	107495	Influenza	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=107495	http://clinicaltrials.gov/show/NCT00430521	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005477-22	Y	Y	Y	Y	Y	Y	Y		1-Mar-2015
186	GSK	Assess the consistency of the immunogenicity of a GlaxoSmithKline Biologicals' pandemic influenza vaccine (GSK1562902A) in adults aged between 18 and 60 years	H5N1 Pandemic Influenza Vaccine	109630	Influenza	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=109630	http://clinicaltrials.gov/show/NCT00449670		Y	Y	Y	Y	Y	Y	Y	The results of this study are summarised with long term immunogenicity study 109873 on the GSK Study Register.	1-May-2013
187	GSK	A trial to evaluate the safety and immunogenicity of an investigational vaccination regimen in adults aged ≥18 years	H5N1 Pandemic Influenza Vaccine	110464	Influenza	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=110464	http://clinicaltrials.gov/show/NCT00616928		Y	Y	Y	Y	Y	Y	Y		1-May-2013
188	GSK	A trial to evaluate the safety and immunogenicity of monovalent H5N1 vaccine in adults >=18 yrs of age	H5N1 Pandemic Influenza Vaccine	110624	Influenza	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=110624	http://clinicaltrials.gov/show/NCT00719043		Y	N	Y	Y	Y	Y	Y	An annotated case report form is not available for this study. A blank case report form will be provided.	1-Feb-2015
189	GSK	Immunogenicity and safety of GSK Biologicals’ (pre-) pandemic influenza candidate vaccine GSK 1557484A.	H5N1 Pandemic Influenza Vaccine	111756	Influenza	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=111756	http://clinicaltrials.gov/show/NCT00742885		Y	Y	Y	Y	Y	Y	Y		1-May-2013
190	GSK	Evaluate the reactogenicity & immunogenicity of 1 or 2 booster administrations of an influenza pandemic candidate vaccine (GSK1562902A) in primed adults aged between 19 & 61 years	H5N1 Pandemic Influenza Vaccine	109817	Influenza	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=109817	http://clinicaltrials.gov/show/NCT00506350	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000115-28	Y	Y	Y	Y	Y	Y	Y		1-May-2013
191	GSK	A Phase I/II, Observer-Blind, Randomized, Active-Controlled Trial to Evaluate the Safety and Immunogenicity of a Two-Dose Series of GSK Biologicals' Candidate Influenza Vaccine GSK 1557484A Antigens With or Without Adjuvant	H5N1 Pandemic Influenza Vaccine	110028	Influenza	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=110028	http://clinicaltrials.gov/show/NCT00510874		Y	Y	Y	Y	Y	Y	Y		1-May-2013
192	GSK	Immunogenicity of GSK Biologicals’ pandemic influenza vaccine (GSK1562902A) at different boosting vaccination schedules	H5N1 Pandemic Influenza Vaccine	111443	Influenza	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=111443	http://clinicaltrials.gov/show/NCT00652743		Y	N	Y	Y	Y	Y	Y	The results of this study 111443 are summarised with studies 111470, 111471, and 111472 on the GSK Study Register. An annotated case report form is not available for this study. A blank case report form will be provided.	1-Oct-2014
193	GSK	A trial to evaluate the immunogenicity of accelerated primary vaccination with monovalent A/Indonesia/5/05 (H5N1) vaccine antigen in association with AS03 adjuvant in adults aged 18-64.	H5N1 Pandemic Influenza Vaccine	111626	Influenza	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=111626	http://clinicaltrials.gov/show/NCT00695669		Y	Y	Y	Y	Y	Y	Y		1-May-2013
194	GSK	Non-inferiority study of GSK Biologicals’ Pandemic influenza vaccine 1562902A.	H5N1 Pandemic Influenza Vaccine	111954	Influenza	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=111954	http://clinicaltrials.gov/show/NCT00812981		Y	Y	Y	Y	Y	Y	Y		1-May-2013
195	GSK	Single-blind, randomized, controlled, multinational study for the evaluation of safety of GSK Biologicals' Hib-MenCY-TT vaccine compared to monovalent Hib control vaccine in healthy infants at 2, 4, 6, and 12 to 15 months of age.	Haemophilus influenzae Type b, Meningococcal C and Y-Tetanus Toxoid Conjugate Vaccine	105988	Haemophilus influenzae type b; Neisseria Meningitidis	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=105988	http://clinicaltrials.gov/show/NCT00345683	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-006066-34	Y	Y	Y	Y	Y	Y	Y	The results of this study 105988 are summarised with study 105987 on the GSK Study Register.	1-May-2013
196	GSK	Immunogenicity & safety study in preterm & full-term infants of GSK Biologicals' Hib-MenC vaccine, Menitorix™ co-administered with Infanrix™ penta & Prevenar™ at 2, 4, 6 months & as a booster with Infanrix™ IPV & Prevenar™ at 16-18 months	Haemophilus influenzae Type b, Meningococcal C-Tetanus Toxoid Conjugate Vaccine	110215	Haemophilus influenzae type b; Neisseria Meningitidis	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=110215	http://clinicaltrials.gov/show/NCT00586612	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001167-29	Y	Y	Y	Y	Y	Y	Y	A booster study 110217 was conducted. The results of this study are summarised with 110217 on the GSK Study Register.	1-May-2013
197	GSK	Study in healthy children of GSK Biologicals’ DTPa-IPV/Hib-MenC-TT vaccine, GSK2197870A, co-administered with Prevenar™ as a three-dose primary vaccination course in infancy followed by a booster dose of Menitorix™ at 12 months of age	Haemophilus influenzae Type b, Meningococcal C-Tetanus Toxoid Conjugate Vaccine	111709	Haemophilus influenzae type b; Neisseria Meningitidis	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=111709	http://clinicaltrials.gov/show/NCT00871338	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-003741-87	Y	Y	Y	Y	Y	Y	Y		1-May-2013
198	GSK	To Evaluate Immune Response to a Hepatitis B Vaccine (Engerix™-B ) Challenge Dose in Healthy Subjects Who Received GSK Biologicals' Hepatitis B Vaccine (Engerix™-B ) Approximately 20 Years Ago as Primary Vaccination at 0, 1, 2 and 12 Months.	Hepatitis B Vaccine, Recombinant	108984	Hepatitis B	Phase 4	https://www.gsk-studyregister.com/en/trial-details/?id=108984	http://clinicaltrials.gov/show/NCT00456625		Y	Y	Y	Y	Y	Y	Y		1-May-2013
199	GSK	Long-term persistence of hepatitis B antibodies and immune response to a hepatitis B vaccine challenge in 12-13 year old adolescents, vaccinated in infancy with GlaxoSmithKline (GSK) Biologicals’ HBV vaccine (Engerix™-B)	Hepatitis B Vaccine, Recombinant	112682	Hepatitis B	Phase 4	https://www.gsk-studyregister.com/en/trial-details/?id=112682	http://clinicaltrials.gov/show/NCT00984139	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-012117-21	Y	Y	Y	Y	Y	Y	Y		1-Mar-2015
200	GSK	Antibody persistence and immune memory against the hepatitis B antigen in 11-12 year old children, previously vaccinated with DTPa-HBV-IPV/Hib vaccine in study 217744/031	Combined Diphtheria, Tetanus, Acellular Pertussis, Hepatitis B, Inactivated Polio, Haemophilus influenzae Type b Vaccine	113954	Diphtheria; Tetanus; Acellular Pertussis; Hepatitis B; Poliomyelitis; Haemophilus influenzae type b	Phase 4	https://www.gsk-studyregister.com/en/trial-details/?id=113954	http://clinicaltrials.gov/show/NCT01138098	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-016911-39	Y	N	Y	Y	Y	Y	Y	This is a follow-up study to 217744/031. An annotated case report form is not available for this study. A blank case report form will be provided.	1-Jun-2014
201	GSK	Immunogenicity and safety study of GSK Biologicals' HPV vaccine (GSK-580299) co-administered with a commercially available vaccine in healthy female adolescents	Human Papillomavirus Types 16 and 18 Vaccine	110886	Infections, Papillomavirus	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=110886	http://clinicaltrials.gov/show/NCT00578227	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004347-30	Y	Y	Y	Y	Y	Y	Y		1-May-2013
202	GSK	Study to assess the immunogenicity and safety of GlaxoSmithKline Biologicals’ HPV vaccine GSK580299 in healthy female subjects aged 10-25 years	Human Papillomavirus Types 16 and 18 Vaccine	106069	Infections, Papillomavirus	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=106069	http://clinicaltrials.gov/show/NCT00481767	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000416-42	Y	Y	Y	Y	Y	Y	Y		1-May-2013
203	GSK	A phase IIIb, double-blind, randomized, controlled study to evaluate the immunogenicity and safety of GlaxoSmithKline Biologicals’ HPV-16/18 L1 VLP AS04 vaccine, administered intramuscularly in healthy female subjects aged 15 – 25 years	Human Papillomavirus Types 16 and 18 Vaccine	107291	Infections, Papillomavirus	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=107291	http://clinicaltrials.gov/show/NCT00485732		Y	Y	Y	Y	Y	Y	Y		1-May-2013
204	GSK	Safety and immunogenicity study of the HPV vaccine (GSK-580299) in healthy, Chinese, female subjects	Human Papillomavirus Types 16 and 18 Vaccine	107336	Infections, Papillomavirus	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=107336	http://clinicaltrials.gov/show/NCT00549900		Y	N	Y	Y	Y	Y	Y	An annotated case report form is not available for this study. A blank case report form will be provided.	1-May-2013
205	GSK	A multicentre study to evaluate the immunogenicity and safety of GSK Biologicals’ HPV vaccine (580299) Co-administered with Boostrix Polio (dTpa-IPV) in healthy female subjects aged 10–18 years	Human Papillomavirus Types 16 and 18 Vaccine	108464	Infections, Papillomavirus	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=108464	http://clinicaltrials.gov/show/NCT00426361	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003807-38	Y	Y	Y	Y	Y	Y	Y		1-May-2013
206	GSK	Phase IIIb, Observer-blind Study to Compare Immunogenicity of GSK Biologicals' HPV-16/18 L1/AS04 Vaccine Versus Gardasil® [Quadrivalent Human Papillomavirus (HPV-6,11,16,18 L1 VLP) Recombinant Vaccine Merck & Co., Inc.]	Human Papillomavirus Types 16 and 18 Vaccine	108933	Infections, Papillomavirus	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=108933	http://clinicaltrials.gov/show/NCT00423046		Y	Y	Y	Y	Y	Y	Y		1-May-2013
207	GSK	Immunogenicity and safety study of GlaxoSmithKline Biologicals' HPV vaccine GSK580299 administered according to an alternative dosing schedule as compared to the standard dosing schedule in young female subjects aged 15-25 years	Human Papillomavirus Types 16 and 18 Vaccine	109179	Infections, Papillomavirus	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=109179	http://clinicaltrials.gov/show/NCT00552279	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003256-11	Y	Y	Y	Y	Y	Y	Y		1-May-2013
208	GSK	Safety and immunogenicity study of an additional dose of HPV vaccine (580299) in young, adult women in North America.	Human Papillomavirus Types 16 and 18 Vaccine	109628	Infections, Papillomavirus	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=109628	http://clinicaltrials.gov/show/NCT00546078		Y	Y	Y	Y	Y	Y	Y		1-May-2013
209	GSK	Evaluation of the safety and immunogenicity of GSK Biologicals' HPV vaccine 580299 when administered in healthy females aged 9 - 25 years using an alternative schedule and an alternative dosing as compared to the standard schedule and dosing	Human Papillomavirus Types 16 and 18 Vaccine	110659	Infections, Papillomavirus	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=110659	http://clinicaltrials.gov/show/NCT00541970	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002777-32	Y	Y	Y	Y	Y	Y	Y		1-May-2013
210	GSK	Immunogenicity and safety study of GlaxoSmithKline Biologicals' HPV vaccine (580299) co-administrated with a commercially available vaccine in healthy female adolescents	Human Papillomavirus Types 16 and 18 Vaccine	111507	Infections, Papillomavirus	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=111507	http://clinicaltrials.gov/show/NCT00652938	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-007783-14	Y	Y	Y	Y	Y	Y	Y		1-May-2013
211	GSK	Evaluation of the immunogenicity and safety of a commercially available vaccine when co-administered with GlaxoSmithKline Biologicals' HPV vaccine (580299) in healthy female subjects.	Human Papillomavirus Types 16 and 18 Vaccine	111567	Infections, Papillomavirus	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=111567	http://clinicaltrials.gov/show/NCT00637195	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-007876-41	Y	Y	Y	Y	Y	Y	Y		1-May-2013
212	GSK	Safety study of GSK Biologicals’ human papillomavirus vaccine (GSK-580299) in healthy female subjects.	Human Papillomavirus Types 16 and 18 Vaccine	111712	Infections, Papillomavirus	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=111712	http://clinicaltrials.gov/show/NCT00811798		Y	Y	Y	Y	Y	Y	Y		1-May-2013
213	GSK	Immunogenicity and safety of GlaxoSmithKline (GSK) Biologicals’ Human Papillomavirus (HPV) 580299 vaccine in healthy Chinese female subjects	Human Papillomavirus Types 16 and 18 Vaccine	112022	Infections, Papillomavirus	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=112022	http://clinicaltrials.gov/show/NCT00996125	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003025-25	Y	N	Y	Y	Y	Y	Y	A follow-on study 207347 was conducted. An annotated case report form is not available for this study. A blank case report form will be provided.	1-Feb-2015
214	GSK	Observer-blind superior efficacy trial with GlaxoSmithKline Biologicals' influenza vaccine GSK2186877A in elderly subjects	Influenza Vaccine	106372	Influenza	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=106372	http://clinicaltrials.gov/show/NCT00753272	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000872-25	Y	Y	Y	Y	Y	Y	Y		1-May-2013
215	GSK	A Phase III study for evaluation of immunogenicity and reactogenicity of Fluarix™ (Influsplit SSW®) 2007/2008 in people aged 18 years or above	Influenza Vaccine (Split Virion, Inactivated)	110221	Influenza	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=110221	http://clinicaltrials.gov/show/NCT00476307	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001828-12	Y	Y	Y	Y	Y	Y	Y		1-Aug-2015
216	GSK	Reactogenicity and immunogenicity of GSK Biologicals' influenza vaccine GSK576389A in elderly adults (≥67 years) previously vaccinated with the same candidate vaccine. Fluarix™ will be used as reference.	Influenza Vaccine	110223	Influenza	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=110223	http://clinicaltrials.gov/show/NCT00538473	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002881-36	Y	N	Y	Y	Y	Y	Y	This is a follow-up study to 103304-001, 104540 and 107973. An annotated case report form is not available for this study. A blank case report form will be provided.	1-May-2013
217	GSK	Reactogenicity and immunogenicity of GSK Biologicals' influenza vaccine GSK576389A in elderly adults (≥66 years) previously vaccinated with the same candidate vaccine. Fluarix™ will be used as reference	Influenza Vaccine	110263	Influenza	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=110263	http://clinicaltrials.gov/show/NCT00538213	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002880-29	Y	Y	Y	Y	Y	Y	Y		1-May-2013
218	GSK	Non-Inferiority of GlaxoSmithKline Biologicals' Influenza Vaccine (GSK576389A) 1 Container Over 2 Container Presentation in Adults Aged 65 Years and Over	Influenza Vaccine	110620	Influenza	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=110620	http://clinicaltrials.gov/show/NCT00532298	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003290-29	Y	Y	Y	Y	Y	Y	Y		1-May-2013
219	GSK	Safety and Immunogenicity of a Second Vaccination With GSK Biologicals' Influenza Vaccine GSK1247446A in Subjects 18-60 Years Previously Vaccinated in Study 108656	Influenza Vaccine	110674	Influenza	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=110674	http://clinicaltrials.gov/show/NCT00545025	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002783-10	Y	Y	Y	Y	Y	Y	N	A reporting and analysis plan is not available for this study.	1-May-2013
220	GSK	Immunogenicity, safety and reactogenicity of GSK Biologicals' influenza vaccine GSK1247446A with various formulations in subjects aged 18-64 years	Influenza Vaccine	110794	Influenza	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=110794	http://clinicaltrials.gov/show/NCT00540228	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003776-18	Y	N	Y	Y	Y	Y	Y	An annotated case report form is not available for this study. A blank case report form will be provided.	1-May-2013
221	GSK	Observer blind immunogenicity and safety study of GlaxoSmithKline Biologicals' influenza vaccine GSK576389A with various formulations in adults aged 65 years and above	Influenza Vaccine	110847	Influenza	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=110847	http://clinicaltrials.gov/show/NCT00540592	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003802-86	Y	Y	Y	Y	Y	Y	Y	A follow-on study 111737 was conducted.	1-Mar-2014
222	GSK	A Phase III study for evaluation of immunogenicity and reactogenicity of Fluarix™ / Influsplit SSW® 2008/2009 in people aged 18 years or above	Influenza Vaccine (Split Virion, Inactivated)	111631	Influenza	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=111631	http://clinicaltrials.gov/show/NCT00706563	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001310-24	Y	Y	Y	Y	Y	Y	Y		1-Mar-2015
223	GSK	Observer-blind safety and immunogenicity study of GlaxoSmithKline Biologicals’ influenza vaccine GSK2186877A when administered to elderly subjects.	Influenza Vaccine	111737	Influenza	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=111737	http://clinicaltrials.gov/show/NCT00760617	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-002360-33	Y	Y	Y	Y	Y	Y	Y	This is a follow-up study to 110847.	1-May-2013
224	GSK	Safety and immunogenicity of the influenza vaccine GSK2186877A in the elderly	Influenza Vaccine	111738	Influenza	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=111738	http://clinicaltrials.gov/show/NCT00772889	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-002362-66	Y	Y	Y	Y	Y	Y	Y		1-May-2013
225	GSK	Immunogenicity and safety of GSK Biologicals’ thimerosal-free TIV flu vaccine versus a licensed comparator in children	Influenza Vaccine (Split Virion, Inactivated)	111751	Influenza	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=111751	http://clinicaltrials.gov/show/NCT00764790	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-001258-13	Y	Y	Y	Y	Y	Y	Y		1-Mar-2014
226	GSK	Observer-blind immunogenicity study of GSK Biologicals’ influenza vaccine GSK2186877A in elderly subjects	Influenza Vaccine	112147	Influenza	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=112147	http://clinicaltrials.gov/show/NCT00765076	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-004711-35	Y	N	Y	Y	Y	Y	Y	An annotated case report form is not available for this study. A blank case report form will be provided.	1-Feb-2015
227	GSK	A Phase III study for evaluation of immunogenicity and reactogenicity of FluarixTM / Influsplit SSW® 2009/2010 in people aged 18 years or above	Influenza Vaccine (Split Virion, Inactivated)	113018	Influenza	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=113018	http://clinicaltrials.gov/show/NCT00920374	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-010811-34	Y	Y	Y	Y	Y	Y	Y		1-Mar-2015
228	GSK	Observer-blind safety and immunogenicity study of GlaxoSmithKline Biologicals’ influenza vaccine GSK2186877A when administered to elderly subjects	Influenza Vaccine	113094	Influenza	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=113094	http://clinicaltrials.gov/show/NCT00992784	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-012188-32	Y	Y	Y	Y	Y	Y	Y		1-May-2013
229	GSK	Immunogenicity and safety study of a GlaxoSmithKline Biologicals’ candidate influenza vaccine GSK2321138A in healthy children	Influenza Vaccine (Quadrivalent)	113237	Influenza	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=113237	http://clinicaltrials.gov/show/NCT00985790	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002587-27	Y	N	Y	Y	Y	Y	Y	An annotated case report form is not available for this study. A blank case report form will be provided.	1-Jun-2014
230	GSK	Safety and immunogenicity of GSK2186877A candidate seasonal influenza vaccine in healthy children 6 to 35 months of age.	Influenza Vaccine	114182	Influenza	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=114182	http://clinicaltrials.gov/show/NCT01096056	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-018392-22	Y	N	Y	Y	Y	Y	Y	An annotated case report form is not available for this study. A blank case report form will be provided.	1-Feb-2015
231	GSK	A phase III study for evaluation of immunogenicity and reactogenicity of Fluarix™/Influsplit SSW® 2010/2011 in people aged 18 years or above	Influenza Vaccine (Split Virion, Inactivated)	114292	Influenza	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=114292	http://clinicaltrials.gov/show/NCT01144299	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-019600-23	Y	Y	Y	Y	Y	Y	Y		1-Mar-2015
232	GSK	Observer blind study to evaluate safety, reactogenicity and immunogenicity of GSK Biologicals influenza vaccine GSK576389A administered to adults over 65 years previously vaccinated with the same vaccine, compared to Fluarix™	Influenza Vaccine	109821	Influenza	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=109821	http://clinicaltrials.gov/show/NCT00529516	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002368-83	Y	Y	Y	Y	Y	Y	Y		1-May-2013
233	GSK	A Phase III, Open-Label, Single-Dose Study to Evaluate the Safety and Immunogenicity of Fluviral® Trivalent Split Virion Influenza Vaccine (2007 – 2008 Season) in Adults Ranging in Age from 18 to 60 Years and 61 Years and Over	Influenza Vaccine (Split Virion, Inactivated, Fluviral)	110502	Influenza	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=110502	http://clinicaltrials.gov/show/NCT00505453		Y	Y	Y	Y	Y	Y	Y		1-May-2013
234	GSK	Immunogenicity and safety study of a single injection of GSK Biologicals' Trivalent Split virion Influenza vaccine Fluviral® (2008 - 2009 Season) in adults aged 18 to 60 years and over 60 years.	Influenza Vaccine (Split Virion, Inactivated, Fluviral)	110584	Influenza	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=110584	http://clinicaltrials.gov/show/NCT00718120		Y	Y	Y	Y	Y	Y	Y		1-May-2013
235	GSK	Immunogenicity and safety study of GSK Biologicals’ (GSK1536489A) Trivalent Split Virion Influenza Vaccine Fluviral® (2010 - 2011 Season) in adults aged 18 to 60 years and over 60 years.	Influenza Vaccine (Split Virion, Inactivated, Fluviral)	110628	Influenza	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=110628	http://clinicaltrials.gov/show/NCT01153685		Y	N	Y	Y	Y	Y	Y	An annotated case report form is not available for this study. A blank case report form will be provided.	1-Feb-2015
236	GSK	Observer-blind, Post-Marketing Study to Compare the Safety and Immunogenicity of Fluviral® Trivalent Split Virion Influenza Vaccine (2007-2008 Season) Made With New vs. Aged Bulk Material, in Adults Ranging in Age from 18 to 60 Years	Influenza Vaccine (Split Virion, Inactivated, Fluviral)	111258	Influenza	Phase 4	https://www.gsk-studyregister.com/en/trial-details/?id=111258	http://clinicaltrials.gov/show/NCT00586469		Y	Y	Y	Y	Y	Y	Y		1-May-2013
237	GSK	Immunogenicity and safety study of GSK Biologicals’ Trivalent Split Virion Influenza Vaccine Fluviral® (2009 - 2010 Season) in adults aged 18 to 60 years and over 60 years.	Influenza Vaccine (Split Virion, Inactivated, Fluviral)	110586	Influenza	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=110586	http://clinicaltrials.gov/show/NCT00929331		Y	Y	Y	Y	Y	Y	Y		1-May-2013
253	GSK	Prophylactic antipyretic treatment in children receiving booster dose of pneumococcal vaccine GSK1024850A and DTPa-HBV-IPV/Hib vaccine (Infanrix hexa) and assessment of impact of pneumococcal vaccination on nasopharyngeal carriage	Pneumococcal Polysaccharide Conjugate Vaccine (Adsorbed)	107137	Infections, Streptococcal	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=107137	http://clinicaltrials.gov/show/NCT00496015	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001481-17	Y	Y	Y	Y	Y	Y	Y	This is a follow-up study to 107017.	1-May-2013
254	GSK	Booster vaccination course with the pneumococcal vaccine GSK 1024850A, DTPw-HBV/Hib and OPV or IPV in children who completed the primary vaccination course in study 107007	Pneumococcal Polysaccharide Conjugate Vaccine (Adsorbed)	109509	Infections, Streptococcal	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=109509	http://clinicaltrials.gov/show/NCT00547248	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005891-41	Y	Y	Y	Y	Y	Y	Y		1-May-2013
255	GSK	Safety, reactogenicity and immunogenicity following booster dose of GSK Biologicals´ pneumococcal conjugate vaccine when co-administered with a booster dose of Infanrix-IPV/Hib in preterm born children at 16-18 months of age	Pneumococcal Polysaccharide Conjugate Vaccine (Adsorbed)	109621	Infections, Streptococcal	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=109621	http://clinicaltrials.gov/show/NCT00609492	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000596-42	Y	Y	Y	Y	Y	Y	Y		1-May-2013
256	GSK	Primary vaccination course in children receiving the pneumococcal vaccine GSK 1024850A, Infanrix hexa and Rotarix	Pneumococcal Polysaccharide Conjugate Vaccine (Adsorbed)	109661	Infections, Streptococcal	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=109661	http://clinicaltrials.gov/show/NCT00489554	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-001510-10	Y	N	Y	Y	Y	Y	Y	A follow-on study 111393 was conducted. An annotated case report form is not available for this study. A blank case report form will be provided.	1-May-2013
257	GSK	Phase II, observer-blind follow-up study to assess reacto-and immunogenicity of GSK Biologicals' pneumococcal conjugate vaccine (GSK1024850A), when given as booster in primed children or as 2-dose catch-up in unprimed children.	Pneumococcal Polysaccharide Conjugate Vaccine (Adsorbed)	110031	Infections, Streptococcal	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=110031	http://clinicaltrials.gov/show/NCT00513409	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-014415-12	Y	N	Y	Y	Y	Y	Y	An annotated case report form is not available for this study. A blank case report form will be provided.	1-May-2013
258	GSK	Primary vaccination course in children receiving the pneumococcal vaccine GSK 1024850A co-administered with Zilbrix™ Hib and Polio Sabin™	Pneumococcal Polysaccharide Conjugate Vaccine (Adsorbed)	110521	Infections, Streptococcal	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=110521	http://clinicaltrials.gov/show/NCT00678301	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004650-25	Y	Y	Y	Y	Y	Y	Y		1-May-2013
259	GSK	Primary vaccination course in children receiving the pneumococcal vaccine GSK 1024850A or Prevenar™ co-administered with Hiberix™	Pneumococcal Polysaccharide Conjugate Vaccine (Adsorbed)	110808	Infections, Streptococcal	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=110808	http://clinicaltrials.gov/show/NCT00680914	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-001505-14	Y	Y	Y	Y	Y	Y	Y	A booster study 112933 was conducted	1-May-2013
260	GSK	Primary vaccination course in healthy children receiving the pneumococcal vaccine GSK 1024850A co-administered with Tritanrix™-HepB/Hib at 6, 10 and 14 weeks of age	Pneumococcal Polysaccharide Conjugate Vaccine (Adsorbed)	111188	Infections, Streptococcal	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=111188	http://clinicaltrials.gov/show/NCT00814710	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004644-22	Y	Y	Y	Y	Y	Y	Y	A booster study 112909 was conducted.	1-May-2013
261	GSK	Evaluation of effectiveness of GSK Biologicals’ pneumococcal conjugate vaccine 1024850A against invasive disease	Pneumococcal Polysaccharide Conjugate Vaccine (Adsorbed)	111442	Infections, Streptococcal	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=111442	http://clinicaltrials.gov/show/NCT00861380	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-005149-48	Y	Y	Y	Y	Y	Y	Y	A nested study 112595 was conducted.	1-Sep-2015
262	GSK	Vaccination course in children primed and boosted with pneumococcal vaccine GSK 1024850A and in age-matched unprimed children	Pneumococcal Polysaccharide Conjugate Vaccine (Adsorbed)	112801	Infections, Streptococcal	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=112801	http://clinicaltrials.gov/show/NCT00950833	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-008104-41	Y	Y	Y	Y	Y	Y	Y		1-May-2013
263	GSK	Booster vaccination with pneumococcal vaccine GSK1024850A or Prevenar™ co-administered with Hiberix™ in children primed with the same vaccines	Pneumococcal Polysaccharide Conjugate Vaccine (Adsorbed)	112933	Infections, Streptococcal	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=112933	http://clinicaltrials.gov/show/NCT00911144	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-001506-34	Y	Y	Y	Y	Y	Y	Y	This is a booster study of 110808.	1-May-2013
264	GSK	Safety, reactogenicity and immunogenicity study of GSK Biologicals’ pneumococcal vaccine GSK1024850A, given either as a booster dose or as a 2-dose catch-up immunization in healthy Malian children	Pneumococcal Polysaccharide Conjugate Vaccine (Adsorbed)	113166	Infections, Streptococcal	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=113166	http://clinicaltrials.gov/show/NCT00985465	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-003711-39	Y	Y	Y	Y	Y	Y	Y		1-May-2013
265	GSK	Safety, reactogenicity and immunogenicity study of GSK Biologicals’ pneumococcal vaccine GSK1024850A, given either as a booster dose or as a 2-dose catch-up immunization in healthy Nigerian children	Pneumococcal Polysaccharide Conjugate Vaccine (Adsorbed)	113199	Infections, Streptococcal	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=113199	http://clinicaltrials.gov/show/NCT01153893	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000826-23	Y	N	Y	Y	Y	Y	Y	An annotated case report form is not available for this study. A blank case report form will be provided.	1-Jun-2014
266	GSK	Evaluation of immunological persistence following 3-dose priming with GSK Biologicals’ 10-valent pneumococcal conjugate vaccine in study NCT00808444 and safety and immunogenicity following a booster dose of the same vaccine	Pneumococcal Polysaccharide Conjugate Vaccine (Adsorbed)	113266	Infections, Streptococcal	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=113266	http://clinicaltrials.gov/show/NCT01119625	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000819-82	Y	Y	Y	Y	Y	Y	Y	This is a follow-up study to 111654.	1-Jun-2015
267	GSK	An open-label primary vaccination study to assess the safety and reactogenicity of GlaxoSmithKline Biologicals’ Inactivated Poliomyelitis vaccine Poliorix administered as a three-dose primary vaccination course at 2, 3 and 4 months of age in healthy infants in China.	Poliomyelitis Vaccine (Inactivated)	112581	Poliomyelitis	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=112581	http://clinicaltrials.gov/show/NCT00937404	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001607-80	Y	N	Y	Y	Y	Y	Y	An annotated case report form is not available for this study. A blank case report form will be provided. This is primary study with booster study 112683	1-Mar-2017
268	GSK	Immunogenicity and safety of GSK Biologicals’ IPV (Poliorix™) in infants	Poliomyelitis Vaccine (Inactivated)	112679	Poliomyelitis	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=112679	http://clinicaltrials.gov/show/NCT01021293	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-003167-30	Y	N	Y	Y	Y	Y	Y	An annotated case report form is not available for this study. A blank case report form will be provided.	1-Feb-2015
269	GSK	An open-label study to assess the safety and reactogenicity of GlaxoSmithKline Biologicals’ Inactivated Poliomyelitis Vaccine Poliorix administered as a booster dose at 18-24 months of age in healthy toddlers in China.	Poliomyelitis Vaccine (Inactivated)	112683	Poliomyelitis	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=112683	http://clinicaltrials.gov/show/NCT00920439	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001608-32	Y	N	Y	Y	Y	Y	Y	An annotated case report form is not available for this study. A blank case report form will be provided. This study is a booster of study 112581	1-Mar-2017
270	GSK	A Phase IIIb, Randomized, Double-Blind, Placebo-Controlled Study to Explore the Existence of Horizontal Transmission of the RIX4414 Vaccine Strain Between Twins Within a Family.	Rotavirus Vaccine	106260	Infections, Rotavirus	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=106260	http://clinicaltrials.gov/show/NCT00396630	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-001542-29	Y	Y	Y	Y	Y	Y	Y		1-May-2013
271	GSK	Phase IIIb, Double Blind, Randomised, Placebo-Controlled, Multi-Country/Centre, Study to Assess Safety, Reactogenicity & Immunogenicity of 2 Doses of GSK Biologicals' Oral Live Attenuated Human Rotavirus (HRV) Vaccine in Pre-Term Infants	Rotavirus Vaccine	106481	Infections, Rotavirus	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=106481	http://clinicaltrials.gov/show/NCT00420745	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003762-33	Y	Y	Y	Y	Y	Y	Y		1-May-2013
272	GSK	Efficacy, safety, reactogenicity and immunogenicity study of the lyophilised formulation of Rotarix vaccine in healthy Japanese infants	Rotavirus Vaccine	107625	Infections, Rotavirus	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=107625	http://clinicaltrials.gov/show/NCT00480324	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-001543-36	Y	Y	Y	Y	Y	Y	Y		1-May-2013
273	GSK	Immunogenicity and safety of two doses of GlaxoSmithKline (GSK) Biologicals’ oral live attenuated human rotavirus (HRV) liquid vaccine (GSK 357941A) in healthy infants.	Rotavirus Vaccine	109216	Infections, Rotavirus	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=109216	http://clinicaltrials.gov/show/NCT00432380	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-001544-11	Y	Y	Y	Y	Y	Y	Y		1-May-2013
274	GSK	Primary vaccination course in children receiving the pneumococcal vaccine GSK 1024850A, Infanrix hexa and Rotarix	Pneumococcal Polysaccharide Conjugate Vaccine (Adsorbed)	109861	Infections, Streptococcal	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=109861	http://clinicaltrials.gov/show/NCT00533507	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-001511-12	Y	Y	Y	Y	Y	Y	Y	A follow-on study 111393 was conducted.	1-May-2013
275	GSK	Non-inferiority of a commercial lot of the pneumococcal vaccine GSK1024850A compared to a clinical lot.	Pneumococcal Polysaccharide Conjugate Vaccine (Adsorbed)	111654	Infections, Streptococcal	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=111654	http://clinicaltrials.gov/show/NCT00808444	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-000101-12	Y	Y	Y	Y	Y	Y	Y	A follow-on study 113266 was conducted.	1-Jun-2015
276	GSK	Immunogenicity, reactogenicity and safety study to evaluate two doses of the lyophilised formulation of the human rotavirus (HRV) vaccine when administered to healthy Korean infants previously uninfected with HRV	Rotavirus Vaccine	112269	Infections, Rotavirus	Phase 4	https://www.gsk-studyregister.com/en/trial-details/?id=112269	http://clinicaltrials.gov/show/NCT00969228	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-001545-81	Y	N	Y	Y	Y	Y	Y	An annotated case report form is not available for this study. A blank case report form will be provided.	1-May-2013
277	GSK	Reactogenicity and safety of two doses of GlaxoSmithKline (GSK) Biologicals’ oral live attenuated liquid human rotavirus (HRV) vaccine 444563, in healthy infants	Rotavirus Vaccine	113518	Infections, Rotavirus	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=113518	http://clinicaltrials.gov/show/NCT01107587	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001481-16	Y	N	Y	Y	Y	Y	Y	An annotated case report form is not available for this study. A blank case report form will be provided.	1-Jan-2014
278	GSK	Reactogenicity and safety of a single dose of GlaxoSmithKline (GSK) Biologicals’ human rotavirus (HRV) vaccine (444563) in healthy adults	Rotavirus Vaccine	113545	Infections, Rotavirus	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=113545	http://clinicaltrials.gov/show/NCT01162590		Y	N	Y	Y	Y	Y	Y	An annotated case report form is not available for this study. A blank case report form will be provided. A link to ClinicalTrials.gov and an NCTID number is not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Jan-2014
279	GSK	Reactogenicity and safety of a single dose of GlaxoSmithKline (GSK) Biologicals’ human rotavirus (HRV) vaccine (444563) in healthy children	Rotavirus Vaccine	113552	Infections, Rotavirus	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=113552	http://clinicaltrials.gov/show/NCT01086436	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-001547-37	Y	N	Y	Y	Y	Y	Y	An annotated case report form is not available for this study. A blank case report form will be provided. A link to ClinicalTrials.gov and an NCTID number is not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Jan-2014
280	GSK	Immunogenicity and reactogenicity of GSK Biologicals' DTPa-HBV-IPV/Hib vaccine when given as a booster dose.	Combined Diphtheria, Tetanus, Acellular Pertussis, Hepatitis B, Inactivated Polio, Haemophilus influenzae Type b Vaccine	111344	Acellular pertussis; Diphtheria; Haemophilus influenzae type b; Hepatitis B; Poliomyelitis; Tetanus	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=111344	http://clinicaltrials.gov/show/NCT00627458	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005343-16	Y	Y	Y	Y	Y	Y	Y		1-May-2013
281	GSK	A Double-Blind, Randomized, Placebo-Controlled, Parallel Group, Multicenter Study To Investigate The Efficacy And Safety Of Zanamivir (GG167) 10mg Administered Twice A Day For Five Days In The Treatment Of Influenza In Patients 12 Years Or Over With Asthma Or Chronic Obstructive Pulmonary Disease (COPD)	zanamivir	NAI30008	Influenza, Human	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=NAI30008			N	Y	Y	Y	Y	Y	Y	An analysis-ready dataset is not available for this study. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Sep-2013
282	GSK	A double-blind, randomized, placebo-controlled, parallel-group, multicenter study to investigate the efficacy and safety of zanamivir (GG167) 10 mg administered by inhalation twice daily for five days in the treatment of symptomatic influenza A and B viral infections in children ages 5-12.	zanamivir	NAI30009	Influenza, Human	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=NAI30009			N	Y	Y	Y	Y	Y	Y	An analysis-ready dataset is not available for this study. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Sep-2013
283	GSK	A double-blind, randomized, placebo-controlled, parallel-group, multicenter study to investigate the efficacy and safety of inhaled zanamivir (GG167) 10 mg administered once a day for 10 days in the prevention of transmission of symptomatic influenza A and B viral infections within families.	zanamivir	NAI30010	Influenza, Human	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=NAI30010			N	Y	Y	Y	Y	Y	Y	An analysis-ready dataset is not available for this study. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Sep-2013
284	GSK	A Double-Blind, Randomised, Placebo-Controlled, Parallel-Group, Multicentre Study to Investigate the Efficacy and Safety of Inhaled Zanamivir 10mg Administered Twice Daily for Five Days in the Treatment of Symptomatic Influenza A and B Viral Infections in Subjects Aged >= 65 Years.	zanamivir	NAI30012	Influenza, Human	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=NAI30012			N	Y	Y	Y	Y	Y	Y	An analysis-ready dataset is not available for this study. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Sep-2013
285	GSK	A double-blind, randomised, placebo-controlled, parallel-group, multicentre study to investigate the efficacy and safety of inhaled zanamivir 10mg administered twice daily for five days in the treatment of symptomatic influenza A and B viral infections in armed services personnel.	zanamivir	NAI30015	Influenza, Human	Phase 4	https://www.gsk-studyregister.com/en/trial-details/?id=NAI30015			N	Y	Y	Y	Y	Y	Y	An analysis-ready dataset is not available for this study. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Sep-2013
286	GSK	A Double-Blind, Randomized, Placebo-Controlled, Parallel-Group, Multicenter Study to Investigate the Efficacy and Safety of Inhaled Zanamivir 10mg Administered Twice a Day for Five Days in the Treatment of Symptomatic influenza A and B Viral Infections in High Risk Patients	zanamivir	NAI30020	Influenza, Human	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=NAI30020			N	Y	Y	Y	Y	Y	N	An analysis-ready dataset and a reporting and analysis plan are not available for this study. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Sep-2013
287	GSK	A Double-Blind,Randomized, Placebo-Controlled, Parallel-Group, Multicenter Study to Investigate the Efficacy and Safety of Inhaled Zanamivir 10 mg Administered Twice a Day for Five Days in the Treatment of Symptomatic Influenza A and B Viral Infections in Children.	zanamivir	NAI30028	Influenza, Human	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=NAI30028			N	Y	Y	Y	Y	Y	N	An analysis-ready dataset and a reporting and analysis plan are not available for this study. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Sep-2013
288	GSK	A Double-Blind, Randomised, Placebo-Controlled, Parallel-Group, Multicentre Study to Investigate the Efficacy and Safety of Inhaled Zanamivir 10mg Administered Once a Day for 10 Days in the Prevention of Transmission of Symptomatic Influenza A and B Viral Infections within Households	zanamivir	NAI30031	Influenza, Human	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=NAI30031			N	Y	Y	Y	Y	Y	Y	An analysis-ready dataset is not available for this study. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Sep-2013
289	GSK	A Double-Blind, Randomized, Placebo-Controlled, Parallel-Group, Multicentre Study to Investigate the Efficacy and Safety of Inhaled Zanamivir 10 mg Administered Once a Day for 28 Days in the Prevention of Symptomatic Influenza A and B Viral Infections in Community-Dwelling High-risk …	zanamivir	NAI30034	Influenza, Human	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=NAI30034			N	Y	Y	Y	Y	Y	Y	An analysis-ready dataset is not available for this study. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Sep-2013
290	GSK	A double-blind, randomized, placebo-controlled, parallel-group, multicenter study to investigate the efficacy and safety of inhaled zanamivir (GG167) 10 mg administered twice a day for five days in the treatment of symptomatic influenza A and B viral infections in adolescents and adults.	zanamivir	NAIA3002	Influenza, Human	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=NAIA3002			N	Y	Y	Y	Y	Y	Y	An analysis-ready dataset is not available for this study. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Sep-2013
291	GSK	A Double-Blind, Randomized, Parallel-Group, Multi-Center Study to Investigate the Efficacy and Safety of Inhaled Zanamivir 10mg Administered Once a Day Compared to the Standard of Care in Controlling Nursing Home Influenza Outbreaks	zanamivir	NAIA3003	Influenza, Human	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=NAIA3003			N	Y	Y	Y	Y	Y	Y	An analysis-ready dataset is not available for this study. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Sep-2013
292	GSK	A double-blind, randomized, placebo-controlled, parallel-group, multi-center study to investigate the efficacy and safety of inhaled zanamivir 10 mg once a day in controlling nursing home influenza outbreaks.	zanamivir	NAIA3004	Influenza, Human	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=NAIA3004			N	Y	Y	Y	Y	Y	Y	An analysis-ready dataset is not available for this study. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Sep-2013
293	GSK	A double-blind, randomized, placebo-controlled, parallel-group, multicenter study to investigate the efficacy and safety of zanamivir (GG167) 10 mg administered once a day for 28 days in the prevention of symptomatic influenza A and B viral infections in community dwelling adults.	zanamivir	NAIA3005	Influenza, Human	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=NAIA3005			N	Y	Y	Y	Y	Y	Y	An analysis-ready dataset is not available for this study. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Sep-2013
294	GSK	A double-blind, randomized, placebo-controlled, parallel-group, multicenter study to investigate the efficacy and safety of zanamivir administered twice daily in the treatment of influenza A and B viral infections in adults.	zanamivir	NAIB3001	Influenza, Human	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=NAIB3001			N	Y	Y	Y	Y	Y	Y	An analysis-ready dataset is not available for this study. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Sep-2013
295	GSK	A double-blind, randomised, placebo-controlled, parallel-group, multicentre study to investigate the efficacy and safety of inhaled zanamivir (GG167) 10mg administered twice a day for five days in the treatment of symptomatic influenza A and B viral infections in adolescents and adults.	zanamivir	NAIB3002	Influenza, Human	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=NAIB3002			N	Y	Y	Y	Y	Y	Y	An analysis-ready dataset is not available for this study. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Sep-2013
296	GSK	A Phase 1, Single Center, Randomized, Open-Label Study to Evaluate the Bioavailability of Clindamycin from Clindamycin 1%-Benzoyl Peroxide 3% Gel, Topical Gel (Clindamycin 1%- Benzoyl Peroxide 5%), and Once Daily Gel (Clindamycin 1%-Benzoyl Peroxide 5%) in Subjects with Acne Vulgaris	benzoyl peroxide/clindamycin phosphate	STF115902	Acne Vulgaris	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=115902	http://clinicaltrials.gov/show/NCT01132443		N	Y	Y	Y	Y	Y	Y	An analysis-ready dataset is not available for this study.	1-May-2013
297	GSK	Single-Dose Pharmacokinetics of Retigabine in Healthy Subjects and Patients with Various Degrees of Renal Insufficiency	retigabine, ezogabine	VRX-RET-E22-101	Seizures	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=VRX-RET-E22-101			Y	Y	Y	Y	Y	Y	Y	A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-May-2013
298	GSK	Single-Dose Pharmacokinetics Study of Retigabine in Patients with Various Degrees of Hepatic Impairment	retigabine, ezogabine	VRX-RET-E22-102	Seizures	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=VRX-RET-E22-102			Y	Y	Y	Y	Y	Y	Y	A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-May-2013
299	GSK	A Randomized, Double-Blind, Placebo-Controlled, Phase 2a Proof-of-Concept Study to Evaluate the Efficacy of Maximally Tolerated Doses of Retigabine vs. Placebo in Reducing the Pain Associated with Post-Herpetic Neuralgia	retigabine, ezogabine	VRX-RET-E22-NP201	Neuralgia, Postherpetic	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=VRX-RET-E22-NP201	http://clinicaltrials.gov/show/NCT00612105		Y	Y	Y	Y	Y	Y	Y		1-May-2013
300	GSK	A phase II, randomized, open, controlled study to evaluate the safety and immunogenicity of different formulations of a pandemic influenza vaccine candidate (split virus formulation adjuvanted with AS03) given following a two-administration schedule (21 days apart) in children between 3 and 9 years of age.	H5N1 Pandemic Influenza Vaccine	108498	Influenza	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=107066	http://clinicaltrials.gov/show/NCT00502593		Y	Y	Y	Y	Y	Y	Y	Second cohort study of study 107066. The results of this study are summarised with studies 107066 and 108500 (third cohort study) on the GSK Study Register.	1-May-2013
301	GSK	A phase II, randomized, open, controlled study to evaluate the safety and immunogenicity of different formulations of a pandemic influenza vaccine candidate (split virus formulation adjuvanted with AS03) given following a two-administration schedule (21 days apart) in children between 3 and 9 years of age.	H5N1 Pandemic Influenza Vaccine	108500	Influenza	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=107066	http://clinicaltrials.gov/show/NCT00502593		Y	Y	Y	Y	Y	Y	Y	Third cohort study of study 107066. The results of this study are summarised with studies 107066 and 108498 (second cohort study) on the GSK Study Register.	1-May-2013
303	GSK	Immunogenicity of GSK Biologicals’ pandemic influenza vaccine (GSK1562902A) at different boosting vaccination schedules	H5N1 Pandemic Influenza Vaccine	111470	Influenza	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=111443	http://clinicaltrials.gov/show/NCT00652743		Y	N	Y	Y	Y	Y	Y	The results of this study 111470 are summarised with studies 111443, 111471, and 111472 on the GSK Study Register. An annotated case report form is not available for this study. A blank case report form will be provided.	1-Oct-2014
304	GSK	Immunogenicity of GSK Biologicals’ pandemic influenza vaccine (GSK1562902A) at different boosting vaccination schedules	H5N1 Pandemic Influenza Vaccine	111471	Influenza	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=111443	http://clinicaltrials.gov/show/NCT00652743		Y	N	Y	Y	Y	Y	Y	The results of this study 111471 are summarised with studies 111443, 111470, and 111472 on the GSK Study Register. An annotated case report form is not available for this study. A blank case report form will be provided.	1-Oct-2014
305	GSK	Immunogenicity of GSK Biologicals’ pandemic influenza vaccine (GSK1562902A) at different boosting vaccination schedules	H5N1 Pandemic Influenza Vaccine	111472	Influenza	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=111443	http://clinicaltrials.gov/show/NCT00652743		Y	N	Y	Y	Y	Y	Y	The results of this study 111472 are summarised with studies 111443, 111470, and 111471 on the GSK Study Register. An annotated case report form is not available for this study. A blank case report form will be provided.	1-Oct-2014
306	GSK	Immunogenicity & safety study in preterm & full-term infants of GSK Biologicals' Hib-MenC vaccine, Menitorix™ co-administered with Infanrix™ penta & Prevenar™ at 2, 4, 6 months & as a booster with Infanrix™ IPV & Prevenar™ at 16-18 months	Haemophilus influenzae Type b, Meningococcal C-Tetanus Toxoid Conjugate Vaccine	110217	Haemophilus influenzae type b; Neisseria Meningitidis	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=110215	http://clinicaltrials.gov/show/NCT00586612		Y	Y	Y	Y	Y	Y	Y	This is a booster study of 110215. The results of this study are summarised with 110215 on the GSK Study Register.	1-May-2013
312	GSK	An Open-Label, Three-Part, Two Period, Single Sequence Study to Assess the Pharmacokinetic Interaction Between Repeat Doses of Oral Casopitant and Repeat Oral Doses of Dolasetron, Granisetron or Rosiglitazone When Co-Administered in Healthy Adult Subjects	casopitant	NKV110483	Nausea and Vomiting, Chemotherapy-Induced	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=NKV110483	http://clinicaltrials.gov/show/NCT00511823		Y	Y	Y	Y	Y	Y	Y		1-May-2013
313	GSK	A single-centre, open-label, sequential ascending cross over study to examine safety, tolerability, pharmacodynamics and pharmacokinetics of ascending single doses, nominally 10, 30, 70 and 110µg intravenous doses and a single 250µg oral dose of GSK233705 in healthy volunteers.	darotropium bromide	AC2106213	Pulmonary Disease, Chronic Obstructive	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=AC2106213	http://clinicaltrials.gov/show/NCT00500461	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006081-42	Y	Y	Y	Y	Y	Y	Y		1-May-2013
314	GSK	A single-centre, randomized, double-blind placebo-controlled, dose-ascending, cross-over study to evaluate the safety, tolerability, pharmacodynamics and pharmacokinetics of single inhaled doses of GSK233705, formulated with the excipient magnesium stearate, in healthy volunteers	darotropium bromide	AC2108380	Pulmonary Disease, Chronic Obstructive	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=AC2108380	http://clinicaltrials.gov/show/NCT00453687		Y	Y	Y	Y	Y	Y	Y		1-May-2013
319	GSK	A Single-Blind, Placebo-Controlled, Randomized First Time in Human Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single and Repeat Dose Escalation of GSK932121 in Healthy Adult Subjects	GSK932121	PFM111319	Malaria	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=111319	http://clinicaltrials.gov/show/NCT00811356		Y	Y	Y	Y	Y	Y	Y		1-May-2013
320	GSK	A pivotal single-dose randomised, parallel-group, open-label study to demonstrate bioequivalence of 300mg lamotrigine XR relative to 100mg + 200mg lamotrigine XR and to demonstrate lack of food effect on 300mg lamotrigine XR in healthy male and female volunteers	lamotrigine	LAM105379	Epilepsy	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=LAM105379	http://clinicaltrials.gov/show/NCT00412191	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003962-32	Y	Y	Y	Y	Y	Y	Y		1-Mar-2015
321	GSK	An open-label, randomised, single-dose, parallel-group study to demonstrate bioequivalence of two formulations and the effect of food and water on one formulation of lamotrigine in healthy male and female volunteers	lamotrigine	LBI108617	Mental Disorders	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=LBI108617	http://clinicaltrials.gov/show/NCT00449774	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004313-17	Y	Y	Y	Y	Y	Y	Y		1-May-2013
322	GSK	A randomised, double-blind study in healthy volunteers to compare the properties and characteristics of an investigational formulation of lamotrigine with placebo	lamotrigine	LBI111649	Mental Disorders	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=111649	http://clinicaltrials.gov/show/NCT01607086		Y	Y	Y	Y	Y	Y	Y		1-May-2013
323	GSK	An open-label, two-cohort study to assess the effect of lamotrigine and phenytoin on the pharmacokinetics of atorvastatin in healthy subjects	lamotrigine	LEP108937	Epilepsy	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=LEP108937	http://clinicaltrials.gov/show/NCT00627575		Y	Y	Y	Y	Y	Y	Y		1-May-2013
324	GSK	A pivotal single-dose, randomised, parallel-group, open-label study to demonstrate bioequivalence of 250mg lamotrigine XR relative to 200mg + 50mg lamotrigine XR and to demonstrate lack of food effect on 250mg lamotrigine XR in healthy male and female volunteers	lamotrigine	LEP111102	Epilepsy	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=LEP111102	http://clinicaltrials.gov/show/NCT00605371		Y	Y	Y	Y	Y	Y	Y		1-May-2013
325	GSK	An open-label, single-center, randomized, 2-way crossover study to evaluate the bioequivalence of retigavine given as the Market Image tablet compared to the retigavine clinical trial tablets.	retigabine, ezogabine	RTG113287	Seizures	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=113287			Y	Y	Y	Y	Y	Y	Y	A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-May-2013
326	GSK	An open label study conducted in healthy subjects to demonstrate bioequivalence between ropinirole prolonged release tablets (ropinirole XL, marketed as REQUIP-MODUTAB™, REQUIP XL™ at 2 mg) manufactured at Crawley and Aranda	ropinirole	ROP112771	Parkinson Disease	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=112771	http://clinicaltrials.gov/show/NCT01371682	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-013229-41	Y	Y	Y	Y	Y	Y	Y		1-May-2013
327	GSK	A Single-Center, Non-Randomized, Open-Label, Comparative Study to Assess the Utility of Novel Technologies and Biomarkers as Methods for Measuring Human Pharmacodynamic Response to 8 Weeks of Administration of Rosiglitazone Maleate 4mg BID in Healthy Normal or Overweight Controls, Healthy Obese Subjects and Subjects with Type 2 Diabetes Mellitus (T2DM)	rosiglitazone	DIX110434	Diabetes Mellitus, Type 2	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=DIX110434	http://clinicaltrials.gov/show/NCT00551564		Y	Y	Y	Y	Y	Y	Y		1-May-2013
328	GSK	A Phase 1, Evaluator-Blinded, Randomized, Vehicle Controlled, Study To Evaluate The Cumulative Irritation Potential Of Topically Applied Tazarotene Foam In Healthy Volunteers	tazarotene	STF114571	Acne Vulgaris	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=114571	http://clinicaltrials.gov/show/NCT01112787		N	Y	Y	Y	Y	Y	Y	An analysis-ready dataset is not available for this study.	1-May-2013
329	GSK	A Phase 1, Evaluator-Blinded, Randomized, Vehicle Controlled, Study To Evaluate The Contact Sensitization Potential Of Topically Applied Tazarotene Foam In Healthy Volunteers	tazarotene	STF114572	Acne Vulgaris	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=114572	http://clinicaltrials.gov/show/NCT01114841		N	Y	Y	Y	Y	Y	Y	An analysis-ready dataset is not available for this study.	1-May-2013
330	GSK	A Phase 1, Evaluator-Blinded, Randomized, Vehicle Controlled Study To Evaluate The Phototoxic Potential Of Topically Applied Tazarotene Foam In Healthy Volunteers	tazarotene	STF114573	Acne Vulgaris	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=114573	http://clinicaltrials.gov/show/NCT01115322		N	Y	Y	Y	Y	Y	Y	An analysis-ready dataset is not available for this study.	1-May-2013
331	GSK	A Phase 1, Evaluator-Blinded, Randomized, Vehicle Controlled, Study To Evaluate The Photoallergic Potential Of Topically Applied Tazarotene Foam In Healthy Volunteers	tazarotene	STF114574	Acne Vulgaris	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=114574	http://clinicaltrials.gov/show/NCT01119651		N	Y	Y	Y	Y	Y	Y	An analysis-ready dataset is not available for this study.	1-May-2013
332	GSK	Carvedilol Prospective Randomized Cumulative Survival Trial.	carvedilol	105517/287	Heart failure, Congestive	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=105517/287			Y	Y	Y	Y	Y	Y	N	This study is also known as 287-COPERNICUS. A reporting and analysis plan is not available for this study. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Sep-2013
333	GSK	Compare immunogenicity & reactogenicity of 2 formulations of GSK Biologicals’ DTPa-HBV-IPV/Hib vaccine (new vs current) given in healthy infants. The DTPa-HBV-IPV vaccine (new formulation) will also be assessed in a 3rd group of subjects	Combined Diphtheria, Tetanus, Acellular Pertussis Adsorbed, Hepatitis B (Recombinant), Inactivated Polio Vaccine	105910	Acellular pertussis; Diphtheria; Hepatitis B; Poliomyelitis; Tetanus	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=105910	http://clinicaltrials.gov/show/NCT00320463	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002427-15	Y	N	Y	Y	Y	Y	Y	An annotated case report form is not available for this study. A blank case report form will be provided.	1-Sep-2013
334	GSK	A phase III, double-blind, randomized, multicenter primary vaccination study to bridge the DTPa-HBV-IPV vaccine manufactured according to the large scale manufacturing process with the DTPa-HBV-IPV vaccine manufactured by the small scale manufacturing process when administered intramuscularly to infants at 2, 4 and 6 months of age, co-administered with Merck's Hib conjugate vaccine (Liquid PedvaxHIB®) in a separate injection at 2 and 4 months of age	Combined Diphtheria, Tetanus, Acellular Pertussis Adsorbed, Hepatitis B (Recombinant), Inactivated Polio Vaccine	217744/077 (DTPa-HBV-IPV-077)	Acellular pertussis; Diphtheria; Hepatitis B; Poliomyelitis; Tetanus	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=217744/077			Y	N	Y	Y	Y	Y	Y	An annotated case report form is not available for this study. A blank case report form will be provided. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Sep-2013
335	GSK	A phase III, open labeled, randomized, multicenter, clinical study of the safety of a primary series of GlaxoSmithKline Biologicals' (GSK Biologicals') DTaP-HepB-IPV combined candidate vaccine coadministered with HibTITER® and Prevnar® to healthy infants at 2, 4, and 6 months of age as compared to the separate administration of Infanrix® + Engerix-B®+ IPOL® + HibTITER + Prevnar	Combined Diphtheria, Tetanus, Acellular Pertussis Adsorbed, Hepatitis B (Recombinant), Inactivated Polio Vaccine	217744/084 (DTPa-Hep B-IPV-084)	Acellular pertussis; Diphtheria; Hepatitis B; Poliomyelitis; Tetanus	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=217744/084			Y	N	Y	Y	Y	Y	N	A reporting and analysis plan is not available for this study. An annotated case report form is not available for this study. A blank case report form will be provided. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Sep-2013
336	GSK	A phase III, open labeled, randomized, multicenter, clinical study of the safety and immunogenicity of a primary series of GlaxoSmithKline Biologicals' (GSK Biologicals') DTaP-HepBIPV candidate vaccine coadministered with HibTITER® and Prevnar® to healthy infants at 2, 4, and 6 months of age as compared to the separate administration of Infanrix® + Engerix-B® + IPOL® + HibTITER + Prevnar and to GSK Biologicals' DTaP-HepB-IPV candidate vaccine coadministered with HibTITER	Combined Diphtheria, Tetanus, Acellular Pertussis Adsorbed, Hepatitis B (Recombinant), Inactivated Polio Vaccine	217744/085 (DTPa-Hep B-IPV-085)	Acellular pertussis; Diphtheria; Hepatitis B; Poliomyelitis; Tetanus	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=217744/085			Y	N	Y	Y	Y	Y	Y	An annotated case report form is not available for this study. A blank case report form will be provided. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Sep-2013
337	GSK	Study to assess immunogenicity and reactogenicity of three doses of GSK Bio’s combined Hib-MenC vaccine co-admind with GSK Bio’s DTPa-HBV-IPV vaccine and of two doses of Baxters meningococcal C conjugate vaccine co-admind with GSK Bio’s DTPa-HBV-IPV/Hib vaccine	Combined Diphtheria, Tetanus, Acellular Pertussis Adsorbed, Hepatitis B (Recombinant), Inactivated Polio Vaccine	217744/097 (DTPa-HBV-IPV-097)	Acellular pertussis; Diphtheria; Hepatitis B; Poliomyelitis; Tetanus	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=217744/097	http://clinicaltrials.gov/show/NCT00352963		Y	N	Y	Y	Y	Y	Y	Follow-on studies 106672, 106673, 106675, 106679 and 106680 were conducted. An annotated case report form is not available for this study. A blank case report form will be provided.	1-Sep-2013
338	GSK	Open, primary vaccination study to assess safety and reactogenicity of GSK Biologicals’ DTPa/Hib vaccine when administered to healthy chinese infants at 3, 4 and 5 months of age.	Combined Diphtheria, Tetanus, Acellular Pertussis, Haemophilus influenzae Type b Conjugate Vaccine	106345	Acellular pertussis; Diphtheria; Haemophilus influenzae type b; Tetanus	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=106345	http://clinicaltrials.gov/show/NCT00379977		Y	N	Y	Y	Y	Y	Y	An annotated case report form is not available for this study. A blank case report form will be provided.	1-Sep-2013
339	GSK	A phase IV, open, multicentre study to assess the immunogenicity and reactogenicity of GSK Biologicals’ DTPa-HBV-IPV/Hib vaccine (Infanrix-hexa) given as a booster at 18-24 months of age to children who have received a three-dose primary immunisation course with the same vaccine in a previous study	Combined Diphtheria, Tetanus, Acellular Pertussis, Hepatitis B, Inactivated Polio, Haemophilus influenzae Type b Vaccine	101518 (DTPa-HBV-IPV-103)	Acellular pertussis; Diphtheria; Haemophilus influenzae type b; Hepatitis B; Poliomyelitis; Tetanus	Phase 4	https://www.gsk-studyregister.com/en/trial-details/?id=101518			Y	Y	Y	Y	Y	Y	Y	A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Sep-2013
340	GSK	Phase IIIb, open, randomized, multicenter study to assess the immunogenicity & safety of GSK Biologicals’ combined DTPa-HBV-IPV/Hib vaccine in Indian infants when given at 6-10-14 weeks of age or at 2-4-6 months of age	Combined Diphtheria, Tetanus, Acellular Pertussis, Hepatitis B, Inactivated Polio, Haemophilus influenzae Type b Vaccine	104005	Acellular pertussis; Diphtheria; Haemophilus influenzae type b; Hepatitis B; Poliomyelitis; Tetanus	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=104005	http://clinicaltrials.gov/show/NCT00316147	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002426-70	Y	N	Y	Y	Y	Y	Y	An annotated case report form is not available for this study. A blank case report form will be provided.	1-Sep-2013
341	GSK	A phase II, multicentre booster study to evaluate booster vaccination with GSK Biologicals’ 10-valent pneumococcal conjugate vaccine or to evaluate the immune memory following the administration of a single dose of 23-valent plain polysaccharide vaccine in healthy children, previously vaccinated in infancy in the primary study 11PN-PD-DIT-002 (103488)	Pneumococcal Polysaccharide Conjugate Vaccine (Adsorbed)	105555	Infections, Streptococcal	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=105555	http://clinicaltrials.gov/show/NCT00307567	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003052-36	Y	N	Y	Y	Y	Y	Y	This is a follow-up study to 103488. An annotated case report form is not available for this study. A blank case report form will be provided.	1-Mar-2015
342	GSK	A study to evaluate the immunogenicity and safety of a new formulation of GSK Biologicals' DTPa-HBV-IPV/Hib vaccine as compared to the currently licensed Infanrix hexa in healthy infants (2,3,4 M)	Combined Diphtheria, Tetanus, Acellular Pertussis, Hepatitis B, Inactivated Polio, Haemophilus influenzae Type b Vaccine	106786	Acellular pertussis; Diphtheria; Haemophilus influenzae type b; Hepatitis B; Poliomyelitis; Tetanus	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=106786	http://clinicaltrials.gov/show/NCT00376779	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000554-46	Y	N	Y	Y	Y	Y	Y	An annotated case report form is not available for this study. A blank case report form will be provided.	1-Sep-2013
343	GSK	An open, multicenter, phase IV clinical trial to assess the immunogenicity and reactogenicity of three doses of GSK Biologicals’ combined DTPa-HBV-IPV/Hib vaccine in healthy infants at 2, 4 and 6 months of age, when co-administered with Wyeth-Lederle’s meningococcal group C conjugate vaccine.	Combined Diphtheria, Tetanus, Acellular Pertussis, Hepatitis B, Inactivated Polio, Haemophilus influenzae Type b Vaccine	217744/076 (DTPa-HBV-IPV-076)	Acellular pertussis; Diphtheria; Haemophilus influenzae type b; Hepatitis B; Poliomyelitis; Tetanus	Phase 4	https://www.gsk-studyregister.com/en/trial-details/?id=217744/076			Y	N	Y	Y	Y	Y	Y	An annotated case report form is not available for this study. A blank case report form will be provided. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Sep-2013
344	GSK	An open, multicentre, phase IV clinical trial to assess the immunogenicity and reactogenicity of GSK Biologicals’ combined DTPa-HBV-IPV/Hib vaccine, when co-administered at 3-4-5 Mth of age with Wyeth-Lederle's seven-valent pneumococcal conjugate vaccine at a different injection site during the same visit	Combined Diphtheria, Tetanus, Acellular Pertussis, Hepatitis B, Inactivated Polio, Haemophilus influenzae Type b Vaccine	217744/078 (DTPa-HBV-IPV-078)	Acellular pertussis; Diphtheria; Haemophilus influenzae type b; Hepatitis B; Poliomyelitis; Tetanus	Phase 4	https://www.gsk-studyregister.com/en/trial-details/?id=217744/078			Y	N	Y	Y	Y	Y	Y	An annotated case report form is not available for this study. A blank case report form will be provided. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Sep-2013
345	GSK	An open, multicentre, phase IV booster vaccination study to assess the immunogenicity and reactogenicity of a 4th dose of GSK Biologicals’ combined DTPa-HBV-IPV/Hib vaccine, co-administered with Wyeth's seven-valent Pneumococcal conjugate vaccine at a different injection site during the same visit in healthy children	Combined Diphtheria, Tetanus, Acellular Pertussis, Hepatitis B, Inactivated Polio, Haemophilus influenzae Type b Vaccine	217744/081 (DTPa-HBV-IPV-081)	Acellular pertussis; Diphtheria; Haemophilus influenzae type b; Hepatitis B; Poliomyelitis; Tetanus	Phase 4	https://www.gsk-studyregister.com/en/trial-details/?id=217744/081			Y	N	Y	Y	Y	Y	Y	An annotated case report form is not available for this study. A blank case report form will be provided. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Sep-2013
346	GSK	Study to assess immunogenicity and reactogenicity of GSK Bio’s combined DTPa-HBV-IPV/Hib vaccine in pre-term infants in comparison with term infants, administered as a booster dose to children who previously were primed with 3 doses of GSK Biologicals combined DTPa-HBV-IPV/Hib vaccine	Combined Diphtheria, Tetanus, Acellular Pertussis, Hepatitis B, Inactivated Polio, Haemophilus influenzae Type b Vaccine	217744/083 (DTPa-HBV-IPV-083)	Acellular pertussis; Diphtheria; Haemophilus influenzae type b; Hepatitis B; Poliomyelitis; Tetanus	Phase 4	https://www.gsk-studyregister.com/en/trial-details/?id=217744/083			Y	N	Y	Y	Y	Y	Y	An annotated case report form is not available for this study. A blank case report form will be provided. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Sep-2013
347	GSK	Single-blind, multicentre, phase IV clinical trial to assess and compare the immunogenicity and reactogenicity of GSK Biologicals’ DTPa-HBV-IPV/Hib vaccine (Infanrix hexa™) and Aventis Pasteur’s DTPa-HBV-IPV-Hib vaccine (Hexavac™) given as a primary vaccination course at 2, 4 and 6 months of age.	Combined Diphtheria, Tetanus, Acellular Pertussis, Hepatitis B, Inactivated Polio, Haemophilus influenzae Type b Vaccine	217744/086 (DTPa-HBV-IPV-086)	Acellular pertussis; Diphtheria; Haemophilus influenzae type b; Hepatitis B; Poliomyelitis; Tetanus	Phase 4	https://www.gsk-studyregister.com/en/trial-details/?id=217744/086			Y	N	Y	Y	Y	Y	N	A booster study 217744/095 was conducted. An annotated case report form is not available for this study. A blank case report form will be provided. A reporting and analysis plan is not available for this study. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Sep-2013
348	GSK	A phase IV, open, multicentre study to assess the immunogenicity and reactogenicity of GlaxoSmithKline Biologicals’ DTPa-HBV-IPV/Hib vaccine (Infanrix hexa() given as a primary vaccination course at 2, 4 and 6 months of age to pre-term infants.	Combined Diphtheria, Tetanus, Acellular Pertussis, Hepatitis B, Inactivated Polio, Haemophilus influenzae Type b Vaccine	217744/090 (DTPa-HBV-IPV-090)	Acellular pertussis; Diphtheria; Haemophilus influenzae type b; Hepatitis B; Poliomyelitis; Tetanus	Phase 4	https://www.gsk-studyregister.com/en/trial-details/?id=217744/090			Y	N	Y	Y	Y	Y	Y	An annotated case report form is not available for this study. A blank case report form will be provided. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Sep-2013
349	GSK	Study to assess and compare the immunogenicity and reactogenicity of GlaxoSmithKline Biologicals’ DTPa-HBV-IPV/Hib vaccine (INFANRIX™ HEXA) and Aventis Pasteur MSD’s DTPa-HBV-IPV-Hib vaccine (HEXAVAC™) given at 3, 5 and 11-12 months of age	Combined Diphtheria, Tetanus, Acellular Pertussis, Hepatitis B, Inactivated Polio, Haemophilus influenzae Type b Vaccine	217744/094	Acellular pertussis; Diphtheria; Haemophilus influenzae type b; Hepatitis B; Poliomyelitis; Tetanus	Phase 4	https://www.gsk-studyregister.com/en/trial-details/?id=217744/094	http://clinicaltrials.gov/show/NCT01457547		Y	N	Y	Y	Y	Y	Y	An annotated case report form is not available for this study. A blank case report form will be provided.	1-Sep-2013
350	GSK	An open, multicentric, post-marketing surveillance study to assess the safety and reactogenicity of GlaxoSmithKline Biologicals' DTPa-IPV/Hib vaccine administered at 3, 4, 5 and 18 months of age, in healthy infants.	Combined Diphtheria, Tetanus, Acellular Pertussis, Inactivated Polio, Haemophilus influenzae Type b Conjugate Vaccine	100917	Acellular pertussis; Diphtheria; Haemophilus influenzae type b; Poliomyelitis; Tetanus	Phase 4	https://www.gsk-studyregister.com/en/trial-details/?id=100917	http://clinicaltrials.gov/show/NCT00325156	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-001512-35	Y	N	Y	Y	Y	Y	Y	An annotated case report form is not available for this study. A blank case report form will be provided.	1-Sep-2013
351	GSK	An open, multicentre, phase IV booster vaccination study to assess the immunogenicity and reactogenicity of GSKBiologicals combined Infanrix-IPV+Hib (DTPa-IPV/Hib) vaccine in healthy children aged 17 to 20 months whocompleted a three-dose primary vaccination course	Combined Diphtheria, Tetanus, Acellular Pertussis, Inactivated Polio, Haemophilus influenzae Type b Conjugate Vaccine	213503/049 (DTPa-IPV-049)	Acellular pertussis; Diphtheria; Haemophilus influenzae type b; Poliomyelitis; Tetanus	Phase 4	https://www.gsk-studyregister.com/en/trial-details/?id=213503/049			Y	N	Y	Y	Y	Y	Y	An annotated case report form is not available for this study. A blank case report form will be provided. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Sep-2013
352	GSK	Study to evaluate safety and immunogenicity of a booster dose of DTPa-IPV/Hib at 18 months of age with GSK Biologicals DTPa-IPV/Hib compared to Aventis Pasteurs Pentacel, after an initial primary vaccination series administered at 2, 4, and6 months of age with Aventis Pasteurs Pentacel	Combined Diphtheria, Tetanus, Acellular Pertussis, Inactivated Polio, Haemophilus influenzae Type b Conjugate Vaccine	213503/050 (DTPa-IPV-050)	Acellular pertussis; Diphtheria; Haemophilus influenzae type b; Poliomyelitis; Tetanus	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=213503/050			Y	N	Y	Y	Y	Y	Y	An annotated case report form is not available for this study. A blank case report form will be provided. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Sep-2013
353	GSK	Assess safety & reactogenicity of DTPa-IPV/Hib vaccine admnd at 3 & 4 mths & DTPa-HBV-IPV/Hib vaccine admnd at 5 mths, followed by DTPa-IPV/Hib vaccine at 18 mths in infants who received hepatitisB vaccine at birth & at one month of age	Combined Diphtheria, Tetanus, Acellular Pertussis, Inactivated Polio, Haemophilus influenzae Type b Conjugate Vaccine	217744/100	Acellular pertussis; Diphtheria; Haemophilus influenzae type b; Poliomyelitis; Tetanus	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=217744/100	http://clinicaltrials.gov/show/NCT00325143	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002439-26	Y	N	Y	Y	Y	Y	Y	An annotated case report form is not available for this study. A blank case report form will be provided.	1-Sep-2013
358	GSK	An open prospective study of immunogenicity and reactogenicity of DTPa vaccine (Infanrix) given as a booster to healthy school children 10 to 12 years of age	Diphtheria, Tetanus, Acellular Pertussis Vaccine Adsorbed	100484 (DTPa)	Acellular pertussis; Diphtheria; Tetanus	Phase 4	https://www.gsk-studyregister.com/en/trial-details/?id=100484			Y	N	Y	Y	N	Y	N	An annotated case report form is not available for this study. A blank case report form will be provided. A report and analysis plan and protocol are not available for this study. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Sep-2013
359	GSK	An open, multicentric, phase IV clinical trial to assess the immunogenicity and reactogenicity of GlaxoSmithKline Biologicals’ combined diphtheria-tetanus-acellular pertussis vaccine (Infanrix™) administered to healthy infants at 2, 4 and 6 months of age.	Diphtheria, Tetanus, Acellular Pertussis Vaccine Adsorbed	101197 (DTPa -127)	Acellular pertussis; Diphtheria; Tetanus	Phase 4	https://www.gsk-studyregister.com/en/trial-details/?id=101197			Y	N	Y	Y	Y	Y	Y	An annotated case report form is not available for this study. A blank case report form will be provided. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Sep-2013
360	GSK	Open, phase IV clinical trial to compare the immunogenicity and reactogenicity of GSK Biologicals’ Infanrix™ (DTPa) vaccine administered as a booster dose at 4 years of age in preterm vs. full-term children previously primed and boosted with Infanrix™ hexa.	Diphtheria, Tetanus, Acellular Pertussis Vaccine Adsorbed	102038 (DTPa-130)	Acellular pertussis; Diphtheria; Tetanus	Phase 4	https://www.gsk-studyregister.com/en/trial-details/?id=102038			Y	N	Y	Y	Y	Y	Y	An annotated case report form is not available for this study. A blank case report form will be provided. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Sep-2013
361	GSK	A multicentric study to compare the immunogenicity, safety & reactogenicity of GSK Biologicals' DTPa-IPV vaccine vs. co-administration of GSK's DTPa vaccine & Sanofi-Pasteurs' IPV vaccine at different injection sites, to healthy children	Diphtheria, Tetanus, Acellular Pertussis Vaccine Adsorbed	104871	Acellular pertussis; Diphtheria; Tetanus	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=104871	http://clinicaltrials.gov/show/NCT00290342	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-001508-71	Y	N	Y	Y	Y	Y	Y	An annotated case report form is not available for this study. A blank case report form will be provided.	1-Sep-2013
362	GSK	An open, 3.5 year, immunogenicity follow-up of subjects who previously received GSK Biologicals’ dTpa vaccine or GSK Biologicals’ DTPa vaccine or Chiron Behring’s Td vaccine + either Pasteur Merieux’s Pa vaccine or GSK Biologicals’ pa vaccine, administered as a booster dose at age 4-6 years in study 208355/118 (APV-118)	Diphtheria, Tetanus, Acellular Pertussis Vaccine Adsorbed	208355/124 (APV-124)	Acellular pertussis; Diphtheria; Tetanus	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=208355/124			Y	N	Y	Y	Y	Y	N	An annotated case report form is not available for this study. A blank case report form will be provided. A reporting and analysis plan is not available for this study. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Sep-2013
363	GSK	A phase III, open, multicenter study of the safety of Infanrix® when administered as a booster dose at 15 to 18 months of age following primary immunization in studies 217744/084 and 217744/085 (Subjects from DTaP-HepB-IPV-084 and DTaP-HepB-IPV-085)	Diphtheria, Tetanus, Acellular Pertussis Vaccine Adsorbed	208355/125 (APV-125)	Acellular pertussis; Diphtheria; Tetanus	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=208355/125			Y	N	Y	Y	Y	Y	Y	An annotated case report form is not available for this study. A blank case report form will be provided. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Sep-2013
364	GSK	Evaluation of safety and efficacy through Post Market Surveillance for Infanrix™, the DTaP mixed vaccine	Diphtheria, Tetanus, Acellular Pertussis Vaccine Adsorbed	208355/128	Acellular pertussis; Diphtheria; Tetanus	Phase 4	https://www.gsk-studyregister.com/en/trial-details/?id=208355/128	http://clinicaltrials.gov/show/NCT00908115		Y	N	Y	Y	Y	Y	Y	An annotated case report form is not available for this study. A blank case report form will be provided.	1-Sep-2013
365	GSK	Study to compare immunogenicity and reactogenicity of GSK Bio’s DTPa-IPV vaccine, with GSK Bio’s DTPa (Infanrix) and Aventis MSDs IPV vaccine (Imovax Polio) administered separately to healthy children 4 to 6 years of age	Diphtheria, Tetanus, Acellular Pertussis Vaccine Adsorbed	213503/045 (DTPa-IPV-045)	Acellular pertussis; Diphtheria; Tetanus	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=213503/045			Y	N	Y	Y	Y	Y	Y	An annotated case report form is not available for this study. A blank case report form will be provided. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Sep-2013
366	GSK	Open, randomised phase IIIb, clinical trial to compare the immunogenicity and reactogenicity of GSK Biologicals’ DTaP-IPV vaccine, with GSK Biologicals’ DTaP and Aventis Pasteur MSD’s IPV vaccines administered to healthy children, previously vaccinated with 4 doses of DTaP and polio vaccines, and co-administered with GSK Biologicals’ MMR vaccine	Diphtheria, Tetanus, Acellular Pertussis Vaccine Adsorbed	213503/046 (DTaP-IPV-046)	Acellular pertussis; Diphtheria; Tetanus	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=213503/046			Y	N	Y	Y	Y	Y	Y	An annotated case report form is not available for this study. A blank case report form will be provided. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Sep-2013
367	GSK	Open, randomized, phase II, clinical trial to compare the immunogenicity and safety of a booster dose of GSK Biologicals' DTaP-IPV vaccine (Infanrix®-IPV) co-administered with a booster dose of Merck and Company's M-M-R®II, to that of separate injections of GSK Biologicals' DTaP vaccine (Infanrix®), Aventis Pasteur's IPV (IPOL®) and M-M-R®II administered as booster doses to healthy children 4 to 6 years of age.	Diphtheria, Tetanus, Acellular Pertussis Vaccine Adsorbed	213503/047	Acellular pertussis; Diphtheria; Tetanus	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=213503/047	http://clinicaltrials.gov/show/NCT00263692	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-003875-13	Y	N	Y	Y	Y	Y	Y	An annotated case report form is not available for this study. A blank case report form will be provided.	1-Sep-2013
368	GSK	Safety, immunogenicity&consistency of 3 manufacturing lots of DTaP-IPV vaccine vs separate injections of GSK Biologicals' DTaP + Aventis Pasteur's IPV admd as booster doses to healthy children 4-6 yrs, each co-admd with Merck's MMR vaccine	Diphtheria, Tetanus, Acellular Pertussis Vaccine Adsorbed	213503/048	Acellular pertussis; Diphtheria; Tetanus	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=213503/048	http://clinicaltrials.gov/show/NCT00148941		Y	N	Y	Y	Y	Y	Y	An annotated case report form is not available for this study. A blank case report form will be provided.	1-Sep-2013
369	GSK	A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study of the Efficacy and Safety of Dutasteride 0.5 mg Administered Orally Once Daily for Four Years to Reduce the Risk of Biopsy-Detectable Prostate Cancer	dutasteride	ARI40006	Neoplasms, Prostate	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=ARI40006	http://clinicaltrials.gov/show/NCT00056407		Y	Y	Y	Y	Y	Y	Y	A follow-on study ARI103094 was conducted.	1-Sep-2013
370	GSK	A randomized, double-blind, parallel group study to investigate the efficacy and safety of treatment with dutasteride (0.5mg) and tamsulosin (0.4mg), administered once daily for 4 years, alone and combination, on the improvement of symptoms and clinical outcome in men with moderate to severe symptomatic benign prostatic hyperplasia	dutasteride	ARI40005	Prostatic Hyperplasia	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=ARI40005	http://clinicaltrials.gov/show/NCT00090103		Y	Y	Y	Y	Y	Y	Y		1-Sep-2013
371	GSK	A Randomized, Double-Blind, Placebo-Controlled Trial Assessing the Efficacy and Safety of Dutasteride in Extending the Time to Progression of Low-Risk, Localized Prostate Cancer in Men who are Candidates for or Undergoing Expectant Management	dutasteride	AVO105948	Neoplasms, Prostate	Phase 4	https://www.gsk-studyregister.com/en/trial-details/?id=AVO105948	http://clinicaltrials.gov/show/NCT00363311		Y	Y	Y	Y	Y	Y	Y		1-Sep-2013
372	GSK	HZC102871: A 52-week efficacy and safety study to compare the effect of three dosage strengths of Fluticasone Furoate/GW642444 Inhalation Powder with GW642444 on the Annual Rate of Exacerbations in Subjects with Chronic Obstructive Pulmonary Disease (COPD)	fluticasone furoate/vilanterol	HZC102871	Pulmonary Disease, Chronic Obstructive	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=102871	http://clinicaltrials.gov/show/NCT01009463	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-013063-19	Y	Y	Y	Y	Y	Y	Y		1-Sep-2013
373	GSK	A randomised, double blind, placebo controlled, parallel group, 14 day repeat dose study to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of inhaled GW685698X containing magnesium stearate in healthy subjects	fluticasone furoate	HZA102928	Asthma	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=HZA102928	http://clinicaltrials.gov/show/NCT00522678		Y	Y	Y	Y	Y	Y	Y		1-Sep-2013
374	GSK	An open-label, randomised, 3-way crossover single dose study to demonstrate dose proportionality of fluticasone furoate (FF) and equivalence of vilanterol (VI) when administered as FF/VI inhalation powder from the novel dry powder inhaler in healthy subjects.	fluticasone furoate	HZA102932	Asthma	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=102932	http://clinicaltrials.gov/show/NCT01213849	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-021717-22	Y	Y	Y	Y	Y	Y	Y		1-Sep-2013
375	GSK	A randomised, placebo-controlled, four-way crossover repeat dose study to evaluate the effect of the inhaled fluticasone furoate (FF)/GW642444M combination on electrocardiographic parameters, with moxifloxacin as a positive control, in healthy subjects	fluticasone furoate	HZA102936	Asthma	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=102936	http://clinicaltrials.gov/show/NCT01209026	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-015252-18	Y	Y	Y	Y	Y	Y	Y		1-Sep-2013
376	GSK	A randomised, double-blind, placebo-controlled, four-way crossover study to compare the pharmacodynamics and pharmacokinetics of GW685698X and GW642444M when administered separately and in combination as a single dose from a novel dry powder device in healthy japanese subjects	fluticasone furoate	HZA102940	Asthma	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=HZA102940	http://clinicaltrials.gov/show/NCT00625196		Y	Y	Y	Y	Y	Y	Y		1-Sep-2013
377	GSK	A randomised, double blind, two-way crossover study, to examine the safety, tolerability, pharmacokinetics and pharmacodynamics of a single inhaled administration of GW685698X (800?g) with and without magnesium stearate, in mild/moderate asthmatic patients.	fluticasone furoate	HZA108799	Asthma	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=HZA108799	http://clinicaltrials.gov/show/NCT00444509		Y	Y	Y	Y	Y	Y	Y		1-Sep-2013
378	GSK	A Randomized Double-Blind, Double Dummy, Placebo-Controlled, Parallel-Group, Multicenter Dose Ranging Study to Evaluate the Efficacy and Safety of GW685698X Inhalation Powder Once Daily and Fluticasone Propionate Inhalation Powder 500mcg Twice Daily compared with Placebo for 8 Weeks in Adolescent an	fluticasone furoate	FFA109684	Asthma	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=FFA109684	http://clinicaltrials.gov/show/NCT00603746	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004458-98	Y	Y	Y	Y	Y	Y	Y		1-Sep-2013
379	GSK	A Randomized Double-Blind, Double Dummy, Placebo-Controlled, Parallel-Group, Multicenter Dose Ranging Study to Evaluate the Efficacy and Safety of GW685698X Inhalation Powder Once Daily and Fluticasone Propionate Inhalation Powder 250mcg Twice Daily compared with Placebo for 8 Weeks in Adolescent and Adult Subjects with Persistent Asthma Symptomatic on Low-Dose ICS Therapy	fluticasone furoate	FFA109685	Asthma	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=FFA109685	http://clinicaltrials.gov/show/NCT00603278	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004459-13	Y	Y	Y	Y	Y	Y	Y	The raw data are included within the analysis-ready data for this study and are not provided separately.	1-Sep-2013
380	GSK	A Randomized Double-Blind, Double-Dummy, Placebo-Controlled, Parallel-Group, Multicenter, Dose Ranging Study to Evaluate the Efficacy and Safety of GW685698X Inhalation Powder Administered Once Daily and Fluticasone Propionate Inhalation Powder 100mcg Twice Daily compared with Placebo for 8 Weeks in Adolescent and Adult Subjects with Persistent Asthma Symptomatic on Non-Steroidal, Asthma Therapy	fluticasone furoate	FFA109687	Asthma	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=FFA109687	http://clinicaltrials.gov/show/NCT00603382	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004442-32	Y	Y	Y	Y	Y	Y	Y		1-Sep-2013
381	GSK	An open-label, non-randomized, pharmacokinetic and safety study of repeat doses of fluticasone furoate and GW642444M combination in healthy subjects and in subjects with mild, moderate or severe hepatic impairment	fluticasone furoate	HZA111789	Asthma	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=111789	http://clinicaltrials.gov/show/NCT01266941	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-020157-13	Y	Y	Y	Y	Y	Y	Y		1-Sep-2013
382	GSK	Phase I study of GW685698X-A randomized, double blind, placebo controlled, parallel-group, repeat dose study to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of inhaled dose from a novel dry powder device in healthy Japanese male subjects.	fluticasone furoate	HZA112018	Asthma	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=112018	http://clinicaltrials.gov/show/NCT00972673		N	N	Y	Y	N	Y	N	An analysis-ready dataset, a reporting and analysis plan and a protocol are not available for this study. An annotated case report form is not available for this study. A blank case report form will be provided.	1-Jul-2015
383	GSK	A Multi-Centre, Randomized, Double Blind Cross-over study to assess the non-inferiority of GW685698X 200mcg Once Daily and 100mcg Twice Daily in Adult and Adolescent Patients with Asthma	fluticasone furoate	FFA112202	Asthma	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=112202	http://clinicaltrials.gov/show/NCT00766090	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-005309-20	Y	Y	Y	Y	Y	Y	Y		1-Sep-2013
384	GSK	A 24-Week Study to Evaluate the Efficacy and Safety of Fluticasone Furoate (FF)/GW642444 Inhalation Powder and the Individual Components Delivered Once Daily (AM) Via a Novel Dry Powder Inhaler Compared with Placebo in Subjects with Chronic Obstructive Pulmonary Disease (COPD)	fluticasone furoate/vilanterol	HZC112206	Pulmonary Disease, Chronic Obstructive	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=112206	http://clinicaltrials.gov/show/NCT01053988	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-013065-25	Y	Y	Y	Y	Y	Y	Y		1-Sep-2013
385	GSK	A 24-Week Study to Evaluate the Efficacy and Safety of Fluticasone Furoate (FF)/GW642444 Inhalation Powder and the Individual Components Delivered Once Daily (AM) Via a Novel Dry Powder Inhaler Compared with Placebo in Subjects with Chronic Obstructive Pulmonary Disease (COPD)	fluticasone furoate/vilanterol	HZC112207	Pulmonary Disease, Chronic Obstructive	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=112207	http://clinicaltrials.gov/show/NCT01054885	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-013067-19	Y	Y	Y	Y	Y	Y	Y		1-Sep-2013
386	GSK	A 12-week study to evaluate the 24 hour pulmonary function of Fluticasone Furoate (FF)/Vilanterol Inhalation Powder (FF/VI Inhalation Powder) once daily compared with Salmeterol/Fluticasone Propionate (FP) Inhalation Powder twice daily in subjects with Chronic Obstructive Pulmonary Disease (COPD)	fluticasone furoate/vilanterol	HZC113107	Pulmonary Disease, Chronic Obstructive	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=113107	http://clinicaltrials.gov/show/NCT01342913	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-021059-25	Y	Y	Y	Y	Y	Y	Y		1-Sep-2013
387	GSK	An open-label, randomised, two-way crossover study, to evaluate and compare the pharmacokinetics of fluticasone furoate, administered from a novel dry powder device (repeat dose) and intravenously (single dose), in healthy Caucasian, Japanese, Korean and Chinese subjects	fluticasone furoate	HZA113477	Asthma	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=113477	http://clinicaltrials.gov/show/NCT01000597		Y	Y	Y	Y	Y	Y	Y		1-Sep-2013
388	GSK	An open-label, non-randomised, three-way crossover, single dose study to determine the absolute bioavailability of fluticasone furoate (FF)/GW642444 Inhalation Powder, in healthy subjects	fluticasone furoate/vilanterol	HZA102934	Asthma	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=102934	http://clinicaltrials.gov/show/NCT01299558		Y	Y	Y	Y	Y	Y	Y		1-Sep-2013
389	GSK	HZA106829: A randomised, double-blind, parallel group, multicentre study of Fluticasone Furoate/GW642444 Inhalation Powder, Fluticasone Furoate Inhalation Powder alone, and Fluticasone Propionate alone in the treatment of persistent asthma in adults and adolescents	fluticasone furoate/vilanterol	HZA106829	Asthma	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=106829	http://clinicaltrials.gov/show/NCT01134042	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-019594-14	Y	Y	Y	Y	Y	Y	Y	The raw data are included within the analysis-ready data for this study and are not provided separately.	1-Sep-2013
390	GSK	A Randomized, Double-Blind, Double Dummy, Active Comparator, Parallel Group, Multicenter Study to Evaluate the Safety of Once-Daily Fluticasone Furoate/GW642444 Inhalation Powder for 52 Weeks in Adolescent and Adult Subjects with Asthma	fluticasone furoate/vilanterol	HZA106839	Asthma	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=106839	http://clinicaltrials.gov/show/NCT01018186	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-01205-20	Y	Y	Y	Y	Y	Y	Y		1-Sep-2013
391	GSK	Study HZA106851: A Study of the Effects of Inhaled Fluticasone Furoate/GW642444 versus Placebo on the HPA Axis of Adolescent and Adult Asthmatics	fluticasone furoate/vilanterol	HZA106851	Asthma	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=106851	http://clinicaltrials.gov/show/NCT01086410	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-017669-44	Y	Y	Y	Y	Y	Y	Y		1-Sep-2013
392	GSK	A randomised, double-blind, double-dummy, parallel-group multicentre study to assess efficacy and safety of Fluticasone Furoate/GW642444 Inhalation Powder and Fluticasone Propionate/Salmeterol Inhalation Powder in the treatment of persistent asthma in adults and adolescents	fluticasone furoate/vilanterol	HZA113091	Asthma	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=113091	http://clinicaltrials.gov/show/NCT01147848	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-019589-10	Y	Y	Y	Y	Y	Y	Y		1-Sep-2013
394	GSK	A randomized, double-blind, parallel-group, comparative trial of inhaled fluticasone propionate 250mcg twice daily, 500mcg twice daily, and placebo twice daily via the DISKUS® inhaler in subjects with chronic obstructive pulmonary disease (COPD).	fluticasone propionate	FLTA3025	Pulmonary Disease, Chronic Obstructive	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=FLTA3025			N	Y	Y	Y	Y	Y	Y	An analysis-ready dataset is not available for this study. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Sep-2013
396	GSK	HZC102970: A 52-week efficacy and safety study to compare the effect of three dosage strengths of Fluticasone Furoate/GW642444 Inhalation Powder with GW642444 on the Annual Rate of Exacerbations in Subjects with Chronic Obstructive Pulmonary Disease (COPD)	fluticasone furoate/vilanterol	HZC102970	Pulmonary Disease, Chronic Obstructive	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=102970	http://clinicaltrials.gov/show/NCT01017952	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-013064-40	Y	Y	Y	Y	Y	Y	Y		1-Sep-2013
397	GSK	A Multicenter, Randomized, Double-Blind, Triple-Dummy, Placebo-Controlled, Parallel Group, Four-Week Study Assessing the Efficacy of Fluticasone Propionate Aqueous Nasal Spray 200mcg QD versus Montelukast 10mg QD in Adolescent and Adult Subjects with Asthma and Seasonal Allergic Rhinitis Who are Receiving ADVAIR DISKUS® 100/50mcg BID or Placebo BID	fluticasone propionate/salmeterol	ADA103575	Asthma	Phase 4	https://www.gsk-studyregister.com/en/trial-details/?id=ADA103575	http://clinicaltrials.gov/show/NCT00296491	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000548-29	Y	Y	Y	Y	Y	Y	Y		1-Sep-2013
398	GSK	A Multicenter, Randomized, Double-Blind, Triple-Dummy, Placebo-Controlled, Parallel Group, Four-Week Study Assessing the Efficacy of Fluticasone Propionate Aqueous Nasal Spray 200mcg QD versus Montelukast 10mg QD in Adolescent and Adult Subjects with Asthma and Seasonal Allergic Rhinitis Who are Receiving ADVAIR DISKUS® 100/50mcg BID or Placebo BID	fluticasone propionate/salmeterol	ADA103578	Asthma	Phase 4	https://www.gsk-studyregister.com/en/trial-details/?id=ADA103578	http://clinicaltrials.gov/show/NCT00296530	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-004867-35	Y	Y	Y	Y	Y	Y	Y		1-Sep-2013
399	GSK	A Randomized, Double-Blind, Parallel-Group, 12-Week Study to Evaluate the Anti-Inflammatory Effect of Fluticasone Propionate/Salmeterol DISKUS 250/50mcg BID Compared with Salmeterol DISKUS 50mcg Twice Daily in Subjects with Chronic Obstructive Pulmonary Disease (COPD)	fluticasone propionate/salmeterol	ADC105931	Pulmonary Disease, Chronic Obstructive	Phase 4	https://www.gsk-studyregister.com/en/trial-details/?id=ADC105931	http://clinicaltrials.gov/show/NCT00346749		Y	Y	Y	Y	Y	Y	N	A reporting and analysis plan is not available as the study was terminated early.	1-Sep-2013
400	GSK	A 13 month, randomised, double-blind, parallel-group comparison of the efficacy of Seretide and Flixotide(fluticasone propionate Accuhaler) when down-titrating the inhaled corticosteroid dose in asthmatic adults who have previously received SeretideTM 500/50 mg twice daily for at least 4 weeks.	fluticasone propionate/salmeterol	SAM40031	Asthma	Phase 4	https://www.gsk-studyregister.com/en/trial-details/?id=SAM40031			N	N	Y	Y	Y	Y	N	An annotated case report form and reporting and analysis plan are not available for this study. A blank case report form will be provided. The statistical analysis for this study did not create a separate Analysis-ready dataset and this is therefore not available. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Sep-2013
401	GSK	Randomised, double-blind, double-dummy, 52-week, parallel group study of a standard dosing regimen with salmeterol/fluticasone propionate50/250 twice daily Diskus versus a symptom-driven, variable dosing regimen with formoterol/budesonide combination 4.5/160 in adult asthmatics	fluticasone propionate/salmeterol	SAM40056	Asthma	Phase 4	https://www.gsk-studyregister.com/en/trial-details/?id=SAM40056	http://clinicaltrials.gov/show/NCT00479739		N	Y	Y	Y	Y	Y	Y	An analysis-ready dataset is not available for this study.	1-Sep-2013
402	GSK	A multicenter, randomized, double-blind, parallel group, 40-week comparison of asthma control using bronchial hyperresponsiveness as an additional guide to long-term treatment in adolescents and adults receiving either fluticasone propionate/sameterol DISKUS twice daily or fluticasone propionate DISKUS twice daily (or placebo twice daily if asymptomatic)	fluticasone propionate/salmeterol	SAM40065	Asthma	Phase 4	https://www.gsk-studyregister.com/en/trial-details/?id=SAM40065	http://clinicaltrials.gov/show/NCT01324362		N	Y	Y	Y	Y	Y	Y	An analysis-ready dataset is not available for this study.	1-Sep-2013
403	GSK	A multicenter, randomized, double-blind, parallel group, 40-week comparison of asthma control using bronchial hyperresponsiveness as an additional guide to long-term treatment in adolescents and adults receiving either fluticasone propionate/salmeterol DISKUS twice daily or fluticasone propionate DISKUS twice daily (or placebo BID if asymptomatic)	fluticasone propionate/salmeterol	SAM40086	Asthma	Phase 4	https://www.gsk-studyregister.com/en/trial-details/?id=SAM40086	http://clinicaltrials.gov/show/NCT00920543		N	Y	Y	Y	Y	Y	Y	An analysis-ready dataset is not available for this study.	1-Sep-2013
404	GSK	Randomised, double-blind parallel group study to assess the bronchodilative and bronchoprotective properties of SERETIDE DISKUS ® inhlaer 50/100mcg twice daily vs. FLIXOTIDE® inhaler 200mcg twice daily.	fluticasone propionate/salmeterol	SAM40100	Asthma	Phase 4	https://www.gsk-studyregister.com/en/trial-details/?id=SAM40100	http://clinicaltrials.gov/show/NCT00169546		N	Y	Y	Y	Y	Y	Y	An analysis-ready dataset is not available for this study.	1-Sep-2013
405	GSK	A pilot single centre, randomised, double-blind, crossover study to demonstrate the superiority of Salmeterol/fluticasone propionate combination product 50/100mcg bd versus fluticasone propionate 100mcg bd when treated for two weeks with respect to activity levels in children aged 7-15 years.	fluticasone propionate/salmeterol	SAM40101	Asthma	Phase 4	https://www.gsk-studyregister.com/en/trial-details/?id=SAM40101			N	Y	Y	Y	Y	Y	Y	The statistical analysis for this study did not create a separate analysis-ready dataset and this is therefore not available. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Sep-2013
406	GSK	Randomised, double blind, parallel group study to assess the bronchodilative and bronchoprotective properties of SERETIDE DISKUS® inhaler 50/100 mcg twice daily vs FLIXOTIDE® inhaler 200 mcg twice daily	fluticasone propionate/salmeterol	SAM40104	Asthma	Phase 4	https://www.gsk-studyregister.com/en/trial-details/?id=SAM40104	http://clinicaltrials.gov/show/NCT00370591		N	Y	Y	Y	Y	Y	Y	The statistical analysis for this study did not create a separate analysis-ready dataset and this is therefore not available.	1-Sep-2013
407	GSK	A 12-week, randomized, double-blind, placebo-controlled, 3-way crossover study in adult subjects with asthma aged 18-55 years to examine the pharmacodynamics and pharmacokinetics of fluticasone propionate (FP) administered twice daily via the Diskus (FP 100mcg) and the FP/Salmeterol (SALM) combination product (FP 100mcg/SALM 50mcg) administered twice daily via the Diskus	fluticasone propionate/salmeterol	SAS10006	Asthma	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=SAS10006			Y	Y	Y	Y	Y	Y	Y	A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Sep-2013
408	GSK	A 16-week, randomized, double-blind, double-dummy, placebo-controlled, 4-way crossover study in adult subjects with asthma aged 18-55 years to examine the pharmacodynamics and pharmacokinetics of fluticasone propionate and salmeterol administered via FP/Salmeterol (SALM) combination product Diskus (FP 250mcg/SALM 50mcg), FP/Salmeterol combination metered dose inhaler (MDI) (FP 110mcg/SALM 21mcg) containing the hydrofluoroalkane (HFA) propellant, GR106642X, and FP MDI (FP 110mcg) containing HFA propellant	fluticasone propionate/salmeterol	SAS10007	Asthma	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=SAS10007			Y	Y	Y	Y	Y	Y	Y	A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Sep-2013
409	GSK	A 4-week, randomized, double-blind, placebo run-in, parallel-group study in pediatric subjects with asthma aged 4-11 years to examine the pharmacodynamics and pharmacokinetics of the fluticasone propionate (FP) and salmeterol (SALM) combination product administered twice daily via the Diskus (FP 100mcg/SALM 50mcg) and the FP Diskus (FP 100mcg)	fluticasone propionate/salmeterol	SAS10016	Asthma	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=SAS10016			Y	Y	Y	Y	Y	Y	Y	A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Sep-2013
410	GSK	A repeat dose, randomised, double blind, 2-way crossover study to assess the safety and systemic exposure of an investigational formulation compared to concurrent administration of individual Fluticasone Propionate 50 and Salmeterol 50 DISKUS inhalers in subjects aged 18 - 55 years with mild asthma	fluticasone propionate/salmeterol	SAS10019	Asthma	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=SAS10019	http://clinicaltrials.gov/show/NCT00364442	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-003923-11	Y	Y	Y	Y	Y	Y	Y		1-Mar-2015
411	GSK	A randomised, open label, five-way crossover study to assess the systemic exposure of fluticasone propionate and salmeterol from SERETIDE/ADVAIR 250HFA MDI alone and with AeroChamber-Max spacer and VOLUMATIC both in their washed and unwashed states in adult subjects with mild or intermittent asthma	fluticasone propionate/salmeterol	SAS104449	Asthma	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=SAS104449	http://clinicaltrials.gov/show/NCT00369993		Y	Y	Y	Y	Y	Y	Y		1-Sep-2013
412	GSK	A repeat-dose, open-label, randomized, incomplete block design in pediatric subjects with asthma, ages 4 - 11 years, to compare systemic exposure and pharmacodynamics of fluticasone propionate and salmeterol following Advair HFA 45/21mcg (2 inhalations), ADVAIR® HFA 45/21mcg (2 inhalations) with Aerochamber Plus Spacer and Advair Diskus 100/50 twice daily	fluticasone propionate/salmeterol	SAS105519	Asthma	Phase 4	https://www.gsk-studyregister.com/en/trial-details/?id=SAS105519	http://clinicaltrials.gov/show/NCT00400608		Y	Y	Y	Y	Y	Y	Y		1-Sep-2013
413	GSK	A stratified, randomized, double-blind, placebo-controlled, parallel-group, 12 week trial evaluating the safety and efficacy of fluticasone propionate/salmeterol DISKUS combination product 100/50mcg once daily versus fluticasone propionate DISKUS 100mcg once daily and placebo in symptomatic pediatric subjects (4-11 years) with asthma	fluticasone propionate/salmeterol	SAS30021	Asthma	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=SAS30021	http://clinicaltrials.gov/show/NCT00920959		N	Y	Y	Y	Y	Y	Y	An analysis-ready dataset is not available for this study.	1-Sep-2013
414	GSK	A Randomized, Double-Blind, Parallel Group, 52-Week Study to Compare the Effect of Fluticasone Propionate/Salmeterol Diskus Combination Product 250/50mcg Twice Daily with Salmeterol Diskus 50mcg Twice Daily on the Annual Rate of Moderate/Severe Exacerbations in Subjects with Chronic Obstructive Pulmonary Disease	fluticasone propionate/salmeterol	SCO100250	Pulmonary Disease, Chronic Obstructive	Phase 4	https://www.gsk-studyregister.com/en/trial-details/?id=100250	http://clinicaltrials.gov/show/NCT00115492		Y	N	Y	Y	Y	Y	Y	An annotated case report form is not available for this study. A blank case report form will be provided.	1-Sep-2013
415	GSK	A randomized, double-blind placebo-controlled study of treatments with salmeterol, fluticasone propionate and their combination to evaluate novel endpoints in patients with chronic obstructive pulmonary disease	fluticasone propionate/salmeterol	SCO104925	Pulmonary Disease, Chronic Obstructive	Phase 4	https://www.gsk-studyregister.com/en/trial-details/?id=104925	http://clinicaltrials.gov/show/NCT00358358	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-005602-23	Y	N	Y	Y	Y	Y	Y	An annotated case report form is not available for this study. A blank case report form will be provided.	1-Sep-2013
416	GSK	A multicentre, randomised, double-blind, parallel group, placebo-controlled study to investigate the long-term effects of salmeterol/fluticasone propionate (SERETIDE® inhaler) 50/500mcg BD, salmeterol 50mcg BD and fluticasone propionate 500mcg BD, all delivered via the DISKUS®/ACCUHALER® inhaler, on mortality and morbidity of subjects with chronic obstructive pulmonary disease (COPD) over 3 years of treatment	fluticasone propionate/salmeterol	SCO30003	Pulmonary Disease, Chronic Obstructive	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=SCO30003	http://clinicaltrials.gov/show/NCT00268216		N	Y	Y	Y	Y	Y	Y	An analysis-ready dataset is not available for this study.	1-Sep-2013
417	GSK	A 13-week, double-blind, parallel group, multi-centre study to compare the bronchial anti-inflammatory activity of the combination of salmeterol/fluticasone propionate 50/500mcg twice daily compared with placebo twice daily in patients with Chronic Obstructive Pulmonary Disease (COPD)	fluticasone propionate/salmeterol	SCO30005	Pulmonary Disease, Chronic Obstructive	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=SCO30005	http://clinicaltrials.gov/show/NCT00268177		Y	Y	Y	Y	Y	Y	Y		1-Sep-2013
418	GSK	A Randomized, Double Blind, Placebo Controlled, Parallel Group Clinical Trial Evaluating the Effect of the Fluticasone/Salmeterol Combination Product 250/50mcg twice daily via DISKUS and Salmeterol 50 mcg twice daily via DISKUS on Lung Hyperinflation in Subjects with COPD.	fluticasone propionate/salmeterol	SCO40030	Pulmonary Disease, Chronic Obstructive	Phase 4	https://www.gsk-studyregister.com/en/trial-details/?id=SCO40030			Y	Y	Y	Y	Y	Y	Y	A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Sep-2013
419	GSK	A Randomized, Double-Blind, Parallel-Group Clinical Trial Evaluating the Effect of the fluticasone propionate/salmeterol Combination Product 250/50mcg twice daily via DISKUS® inhaler versus salmeterol 50mcg twice daily via DISKUS® inhaler on Bone Mineral Density in Subjects with Chronic Obstructive Pulmonary Disease (COPD)	fluticasone propionate/salmeterol	SCO40041	Pulmonary Disease, Chronic Obstructive	Phase 4	https://www.gsk-studyregister.com/en/trial-details/?id=SCO40041	http://clinicaltrials.gov/show/NCT00355342		Y	Y	Y	Y	Y	Y	Y		1-Sep-2013
420	GSK	A Randomized, Double-Blind, Parallel Group, 52-Week Study to Compare the Effect of Fluticasone Propionate/Salmeterol DISKUS® inhaler Combination Product 250/50mcg twice daily with Salmeterol DISKUS® inhaler 50mcg twice daily on the Annual Rate of Moderate/Severe Exacerbations in Subjects with Chronic Obstructive Pulmonary Disease (COPD)	fluticasone propionate/salmeterol	SCO40043	Pulmonary Disease, Chronic Obstructive	Phase 4	https://www.gsk-studyregister.com/en/trial-details/?id=SCO40043	http://clinicaltrials.gov/show/NCT00144911		Y	Y	Y	Y	Y	Y	Y		1-Sep-2013
421	GSK	Randomized, Double-Blind Comparison of ADVAIR® medication 100/50 Twice Daily vs Salmeterol Twice Daily vs Albuterol QID in subjects with ARG/ARG genotype 12 years of Age and Older with Presistent Asthma on Short-Acting Beta2-Agonists Alone	fluticasone propionate/salmeterol	SFA100062	Asthma	Phase 4	https://www.gsk-studyregister.com/en/trial-details/?id=100062	http://clinicaltrials.gov/show/NCT00102882	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-004865-10	Y	Y	Y	Y	Y	Y	Y		1-Sep-2013
422	GSK	A Stratified, Multicenter, Randomized, Double-Blind, Parallel Group, 4-Week Comparison of Fluticasone Propionate/Salmeterol DISKUS® inhaler Combination Product 100/50mcg Twice Daily versus Fluticasone Propionate DISKUS® inhaler 100mcg Twice Daily in Pediatric and Adolescent Subjects with Activity-Induced Bronchospasm	fluticasone propionate/salmeterol	SFA100314	Bronchospasm	Phase 4	https://www.gsk-studyregister.com/en/trial-details/?id=100314	http://clinicaltrials.gov/show/NCT00118716		Y	N	Y	Y	Y	Y	Y	An annotated case report form is not available for this study. A blank case report form will be provided.	1-Sep-2013
423	GSK	A Stratified, Multicenter, Randomized, Double-Blind, Parallel Group, 4-Week Comparison of Fluticasone Propionate/Salmeterol DISKUS® inhaler Combination Product 100/50mcg Twice Daily versus Fluticasone Propionate DISKUS® inhaler 100mcg Twice Daily in Pediatric and Adolescent Subjects with Activity-Induced Bronchospasm	fluticasone propionate/salmeterol	SFA100316	Bronchospasm	Phase 4	https://www.gsk-studyregister.com/en/trial-details/?id=100316	http://clinicaltrials.gov/show/NCT00118690		Y	N	Y	Y	Y	Y	N	An annotated case report form is not available for this study. A blank case report form will be provided. A reporting and analysis plan is not available for this study.	1-Sep-2013
424	GSK	A Multicenter, Randomized, Double-Blind, Parallel Group, 52-Week Comparison of Asthma Control and Measures of Airway Inflammation in Subjects of African Descent Receiving Fluticasone Propionate/Salmeterol 100/50mcg DISKUS® Inhaler Twice Daily or Fluticasone Propionate 100mcg DISKUS® Inhaler Twice Daily Alone.	fluticasone propionate/salmeterol	SFA103153	Asthma	Phase 4	https://www.gsk-studyregister.com/en/trial-details/?id=SFA103153	http://clinicaltrials.gov/show/NCT00102765		Y	Y	Y	Y	Y	Y	Y		1-Sep-2013
425	GSK	A multicentre, randomised, double-blind, parallel group study to compare the efficacy and safety of the Salmeterol/Fluticasone combination product (50/500mg strength) twice daily with Salmeterol 50mg twice daily alone and Fluticasone Propionate 500mg twice daily alone, all delivered via the Diskus/Accuhaler inhaler, in the treatment of patients with chronic obstructive pulmonary disease.	fluticasone propionate/salmeterol	SFCB3024	Pulmonary Disease, Chronic Obstructive	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=SFCB3024			Y	Y	Y	Y	Y	Y	Y	A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Sep-2013
426	GSK	A randomized, double-blind, placebo-controlled, parallel-group, trial evaluating the safety and efficacy of the Diskus formulation of salmeterol 50mcg twice daily and fluticasone propionate 250mcg twice daily individually and in combination as compared to placebo in COPD patients.	fluticasone propionate/salmeterol	SFCA3007	Pulmonary Disease, Chronic Obstructive	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=SFCA3007			N	Y	Y	Y	Y	Y	Y	An analysis-ready dataset is not available for this study. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Sep-2013
427	GSK	A randomized, double-blind, placebo-controlled, parallel-group, trial evaluating the safety and efficacy of the Diskus formulations of salmeterol 50mcg twice daily and fluticasone propionate 500mcg twice daily individually and in combination as compared to placebo in COPD patients.	fluticasone propionate/salmeterol	SFCA3006	Pulmonary Disease, Chronic Obstructive	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=SFCA3006			N	Y	Y	Y	Y	Y	Y	An analysis-ready dataset is not available for this study. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Sep-2013
428	GSK	A multicentre, randomised, double-blind, parallel group, 24 week study to compare the effect of salmeterol/fluticasone propionate combination product 50/250mcg, with salmeterol 50mcg both delivered twice daily via DISKUS®/ACCUHALER® inhaler on lung function and dyspnoea in subjects with Chronic Obstructive Pulmonary Disease (COPD).	fluticasone propionate/salmeterol	SCO100470	Pulmonary Disease, Chronic Obstructive	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=100470			Y	Y	Y	Y	Y	Y	Y	A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Sep-2013
429	GSK	A multicentre randomised double-blind parallel group placebo controlled study assessing the efficacy and safety of inhaled salmeterol/fluticasone 50/500mcg twice daily, inhaled fluticasone 500mcg twice daily and placebo all administered via MDI in the treatment of patients with COPD	fluticasone propionate/salmeterol	SCO30002	Pulmonary Disease, Chronic Obstructive	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=SCO30002			N	Y	Y	Y	Y	Y	Y	All or some of the data and documents for this study are in a non-English language and anonymisation may take longer. An Analysis-ready dataset is not available for this study. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Sep-2013
430	GSK	An open, parallel group, repeat dose study to determine the pharmacokinetics (PK) and pharmacodynamics (PD) of salmeterol and fluticasone propionate delivered as SERETIDE DISKUS (50/250mcg twice daily [b.i.d.]) in Japanese and Caucasian asthmatic subjects.	fluticasone propionate/salmeterol	SAS10013	Asthma	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=SAS10013			Y	Y	Y	Y	Y	Y	Y	A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Sep-2013
433	GSK	An open-label, randomised, crossover study to assess the relative bioavailability of different 2mg formulations of GSK2018682(S1P1 agonist) in healthy volunteers	GSK2018682	P1A114919	Multiple Sclerosis, Relapsing-Remitting	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=114919	http://clinicaltrials.gov/show/NCT01466322		Y	Y	Y	Y	Y	Y	Y		1-Sep-2013
436	GSK	To assess reactogenicity and immunogenicity of GSK Biologicals’ 10-valent pneumococcal conjugate vaccine, when co-administered with GSK Biologicals’ DTPa-HBV-IPV/Hib vaccine (Infanrix™ hexa) at 2, 4 and 6 months of age.	Pneumococcal Polysaccharide Conjugate Vaccine (Adsorbed)	106208	Infections, Streptococcal	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=106208	http://clinicaltrials.gov/show/NCT00338351		Y	N	Y	Y	Y	Y	Y	An annotated case report form is not available for this study. A blank case report form will be provided.	1-Sep-2013
437	GSK	Long-term study of immune response persistence of GSK Biologicals' 2-dose thiomersal-free Engerix™-B and 3-dose preservative-free Engerix™-B vaccines in subjects aged 11-15 yrs	Hepatitis B Vaccine, Recombinant	101695	Hepatitis B	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=101695 Ext. Mth30	http://clinicaltrials.gov/show/NCT00343915	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-001531-20	Y	N	Y	Y	Y	Y	N	The results of this study 101695 (Ext HBV-280 M30) are summarised with studies 103860/280 (HBV-280), 101696 (Ext HBV-280 M42), 101697 (Ext HBV-280 M54) and 101698 on the GSK Study Register. An annotated case report form is not available for this study. A blank case report form will be provided. A reporting and analysis plan is not available for this study.	1-Sep-2013
438	GSK	Long-term study of immune response persistence of GSK Biologicals' 2-dose thiomersal-free Engerix™-B and 3-dose preservative-free Engerix™-B vaccines in subjects aged 11-15 yrs	Hepatitis B Vaccine, Recombinant	101696	Hepatitis B	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=101695 Ext. Mth30	http://clinicaltrials.gov/show/NCT00343915		Y	N	Y	Y	Y	Y	N	The results of this study 101696 are summarised with studies 103860/280 (HBV-280), 101695 (Ext HBV-280 M30), 101697 (Ext HBV-280 M54) and 101698 on the GSK Study Register. An annotated case report form is not available for this study. A blank case report form will be provided. A reporting and analysis plan is not available for this study.	1-Sep-2013
439	GSK	Long-term study of immune response persistence of GSK Biologicals' 2-dose thiomersal-free Engerix™-B and 3-dose preservative-free Engerix™-B vaccines in subjects aged 11-15 yrs	Hepatitis B Vaccine, Recombinant	101697	Hepatitis B	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=101695 Ext. Mth30	http://clinicaltrials.gov/show/NCT00343915		Y	N	Y	Y	Y	Y	N	The results of this study 101697 are summarised with studies 103860/280 (HBV-280), 101695 (Ext HBV-280 M30), 101696 (Ext HBV-280 M42) and 101698 on the GSK Study Register. An annotated case report form is not available for this study. A blank case report form will be provided. A reporting and analysis plan is not available for this study.	1-Sep-2013
440	GSK	Long-term study of immune response persistence of GSK Biologicals' 2-dose thiomersal-free Engerix™-B and 3-dose preservative-free Engerix™-B vaccines in subjects aged 11-15 yrs	Hepatitis B Vaccine, Recombinant	101698	Hepatitis B	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=101695 Ext. Mth30	http://clinicaltrials.gov/show/NCT00343915		Y	N	Y	Y	Y	Y	N	The results of this study 101698 are summarised with studies 103860/280 (HBV-280), 101695 (Ext HBV-280 M30), 101696 (Ext HBV-280 M42), and 101697 on the GSK Study Register. An annotated case report form is not available for this study. A blank case report form will be provided. A reporting and analysis plan is not available for this study.	1-Sep-2013
441	GSK	Phase II study to compare immunogenicity, reactogenicity and safety of 3 different experimental formulations of GSK Biologicals’ hepatitis B vaccine compared to that of Engerix™-B administered following a 3 dose schedule (0, 1, 6 months) in healthy adults aged 18-40 years.	Hepatitis B Vaccine, Recombinant	103860/275 (HBV-275)	Hepatitis B	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=103860/275			Y	N	Y	Y	Y	Y	N	The reporting and analysis plan is not available for this study. An annotated case report form is not available for this study. A blank case report form will be provided. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Sep-2013
443	GSK	Long-term study of immune response persistence of GSK Biologicals' 2-dose thiomersal-free Engerix™-B and 3-dose preservative-free Engerix™-B vaccines in subjects aged 11-15 yrs	Hepatitis B Vaccine, Recombinant	103860/280	Hepatitis B	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=101695 Ext. Mth30	http://clinicaltrials.gov/show/NCT00343915		Y	N	Y	Y	Y	Y	N	The results of this study 103860/280 (HBV-280) are summarised with studies 101695 (Ext HBV-280 M30), and 101696 (Ext HBV-280 M42), and 101697 (Ext HBV-280 M54) on the GSK Study Register. An annotated case report form is not available for this study. A blank case report form will be provided. A reporting and analysis plan is not available for this study.	1-Sep-2013
444	GSK	Phase III study to evaluate immunogenicity, reactogenicity and safety of GSK preservative free Engerix™-B comparing aged lot and, as reference, new lot when admind intramuscularly according to a 0,1,6 month schedule in healthy volunteers	Hepatitis B Vaccine, Recombinant	103860/282 (HBV-282)	Hepatitis B	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=103860/282			Y	N	Y	Y	Y	Y	Y	An annotated case report form is not available for this study. A blank case report form will be provided. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Sep-2013
445	GSK	Phase IV study to demonstrate the non-inferiority in terms of immunogenicity of multidose ENGERIX-B with 2-phenoxyethanol as preservative to that elicited by multidose ENGERIX™-B with thiomersal as preservative, when administered according to a 0, 1, 6 month schedule in healthy adults	Hepatitis B Vaccine, Recombinant	103860/283	Hepatitis B	Phase 4	https://www.gsk-studyregister.com/en/trial-details/?id=103860/283			Y	N	Y	Y	Y	Y	N	An annotated case report form is not available for this study. A blank case report form will be provided. A separate reporting and analysis plan was not created and is therefore not available. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Sep-2013
446	GSK	Demonstrate the non-inferiority of immunogenicity elicited by GSK Biologicals’ hepatitis B vaccine, multidose Engerix™-B to that of monodose Engerix™-B when administered according to 0,1,6 mths schedule in healthy adults aged ≥ 18 yrs	Hepatitis B Vaccine, Recombinant	104387	Hepatitis B	Phase 4	https://www.gsk-studyregister.com/en/trial-details/?id=104387	http://clinicaltrials.gov/show/NCT00197158	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-005262-20	Y	N	Y	Y	Y	Y	Y	An annotated case report form is not available for this study. A blank case report form will be provided.	1-Sep-2013
447	GSK	Evaluate the anti-HBs antibody persistence, in subjects who received GSK Biologicals’ preservative-free or thiomersal-free Engerix™-B or Engerix™-B containing thiomersal, approximately 5 to 6 yrs earlier	Hepatitis B Vaccine, Recombinant	106640	Hepatitis B	Phase 4	https://www.gsk-studyregister.com/en/trial-details/?id=106640	http://clinicaltrials.gov/show/NCT00329576		Y	N	Y	Y	Y	Y	N	An annotated case report form is not available for this study. A blank case report form will be provided. A separate reporting and analysis plan was not created for this study and is therefore not available.	1-Sep-2013
448	GSK	Multicentre study to assess persistence of antibodies against hepatitis B & immune response to a hepatitis B challenge dose in healthy children 7 to 9 yrs old previously vaccinated with 4 doses of GSK Biologicals’ DTPa-HBV-IPV/Hib vaccine	Hepatitis B Vaccine, Recombinant	106744	Hepatitis B	Phase 4	https://www.gsk-studyregister.com/en/trial-details/?id=106744	http://clinicaltrials.gov/show/NCT00356564	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000549-20	Y	N	Y	Y	Y	Y	Y	An annotated case report form is not available for this study. A blank case report form will be provided.	1-Mar-2015
449	GSK	Multicentre study to assess persistence of antibodies against hepatitis B & immune response to a hepatitis B challenge dose in healthy children 4 to 6 yrs old previously vaccinated with 4 doses of GSK Biologicals’ DTPa-HBV-IPV/Hib vaccine	Hepatitis B Vaccine, Recombinant	106745	Hepatitis B	Phase 4	https://www.gsk-studyregister.com/en/trial-details/?id=106745	http://clinicaltrials.gov/show/NCT00335881	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000553-22	Y	N	Y	Y	Y	Y	Y	An annotated case report form is not available for this study. A blank case report form will be provided.	1-Mar-2015
450	GSK	Assess long-term persistence of hepatitis B antibodies & immune response to a hepatitis B vaccine (Engerix-B Kinder) challenge in children aged 4-5 yrs (previously primed & boosted in the 1st 2 yrs of life with DTPa-HBV-IPV/Hib vaccine)	Hepatitis B Vaccine, Recombinant	106789	Hepatitis B	Phase 4	https://www.gsk-studyregister.com/en/trial-details/?id=106789	http://clinicaltrials.gov/show/NCT00411697	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000556-41	Y	N	Y	Y	Y	Y	Y	An annotated case report form is not available for this study. A blank case report form will be provided.	1-Mar-2015
451	GSK	Administration of a challenge dose of hepatitis B vaccine in subjects who previously received Engerix™-B vaccine.	Hepatitis B Vaccine, Recombinant	108988	Hepatitis B	Phase 4	https://www.gsk-studyregister.com/en/trial-details/?id=108988	http://clinicaltrials.gov/show/NCT00524576	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000261-38	Y	N	Y	Y	Y	Y	N	An annotated case report form is not available for this study. A blank case report form will be provided. A separate reporting and analysis plan was not created for this study and is therefore not available.	1-Sep-2013
452	GSK	Immune response to a hepatitis B vaccine challenge dose in healthy subjects who received primary vaccination of GlaxoSmithKline Biologicals' hepatitis B vaccine, approximately 20 years ago.	Hepatitis B Vaccine, Recombinant	110071	Hepatitis B	Phase 4	https://www.gsk-studyregister.com/en/trial-details/?id=110071	http://clinicaltrials.gov/show/NCT00657657	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-003274-92	Y	N	Y	Y	Y	Y	Y	An annotated case report form is not available for this study. A blank case report form will be provided.	1-Sep-2013
453	GSK	Study to evaluate the immune response of healthy subjects who received neonatal vaccination course with GSK Biologicals’ Engerix™-B vaccine, approximately 20 years ago.	Hepatitis B Vaccine, Recombinant	110073	Hepatitis B	Phase 4	https://www.gsk-studyregister.com/en/trial-details/?id=110073	http://clinicaltrials.gov/show/NCT00774995	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-003275-10	Y	N	Y	Y	Y	Y	Y	An annotated case report form is not available for this study. A blank case report form will be provided.	1-Sep-2013
454	GSK	Immunogenicity and safety of GSK Biological’s DTPa-HBV-IPV/Hib vaccine or DTPa-IPV/Hib co-administered with HBV vaccine as primary and booster vaccination in healthy infants born to hepatitis B surface antigen negative mothers	Hepatitis B Vaccine, Recombinant	217744/069	Hepatitis B	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=217744/069	http://clinicaltrials.gov/show/NCT00880477		Y	N	Y	Y	Y	Y	N	A reporting and analysis plan is not available for this study. An annotated case report form is not available for this study. A blank case report form will be provided.	1-Sep-2013
455	GSK	Phase III, open, randomised immunogenicity and reactogenicity study to assess the interchangeability between GSK Bios' DTPa-HBV-IPV/Hib and DTPa-IPV/Hib + HBV at 3rd dose of primary vac. course in children who received HBV vac. at birth and one month of age and DTPa-IPV/Hib vac at 3-4 Mth of age	Hepatitis B Vaccine, Recombinant	217744/075 (DTPa-HBV-IPV-075)	Hepatitis B	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=217744/075	http://clinicaltrials.gov/show/NCT00366366		Y	N	Y	Y	Y	Y	Y	An annotated case report form is not available for this study. A blank case report form will be provided.	1-Sep-2013
457	GSK	A Double-blind, Double-dummy, Parallel-group Comparison of Lamotrigine and Divalproex Sodium Initial Monotherapy in Patients with Epilepsy	lamotrigine	SCAA4001	Epilepsy	Phase 4	https://www.gsk-studyregister.com/en/trial-details/?id=SCAA4001			N	Y	Y	Y	Y	Y	Y	An analysis-ready dataset is not available for this study. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Sep-2013
464	GSK	An open, randomized, phase IIIa study to evaluate the safety and immunogenicity of GSK Biologicals' 10-valent pneumococcal conjugate vaccine, when administered intramuscularly according to a 2-4-11 months vaccination schedule	Pneumococcal Polysaccharide Conjugate Vaccine (Adsorbed)	105539	Infections, Streptococcal	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=105539	http://clinicaltrials.gov/show/NCT00307034	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003437-41	Y	N	Y	Y	Y	Y	Y	A follow-on study 111736 was conducted. An annotated case report form is not available for this study. A blank case report form will be provided.	1-Sep-2013
465	GSK	Phase IIIa randomized, controlled study to assess the immunogenicity of GlaxoSmithKline (GSK) Biologicals’ 10-valent pneumococcal conjugate vaccine, when administered as a 3-dose primary immunization course before 6 months of age	Pneumococcal Polysaccharide Conjugate Vaccine (Adsorbed)	105554	Infections, Streptococcal	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=105554	http://clinicaltrials.gov/show/NCT00307541	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003299-40	Y	Y	Y	Y	Y	Y	Y	Follow-on studies 106623 and 112807 were conducted.	1-Mar-2015
466	GSK	Multicentre immune memory study in healthy children following a 3 dose primary vaccination with Prevenar or GSK Biologicals' pneumococcal conjugate vaccine via the administration of a single booster dose of Pneumovax 23	Pneumococcal Polysaccharide Conjugate Vaccine (Adsorbed)	106623	Infections, Streptococcal	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=106623	http://clinicaltrials.gov/show/NCT00333450	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000560-93	Y	Y	Y	Y	Y	Y	Y	This is a follow-up study to 105554. Follow-on study 112807 was conducted.	1-Mar-2015
467	GSK	Evaluate immunogenicity, safety & reactogenicity of GSK Biologicals' 10-valent pneumococcal conjugate vaccine given as catch-up immunization in children older than 7 mo of age or as 3-dose primary immunization in children before 6 mo of age	Pneumococcal Polysaccharide Conjugate Vaccine (Adsorbed)	107058	Infections, Streptococcal	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=107058	http://clinicaltrials.gov/show/NCT00345358	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001482-42	Y	N	Y	Y	Y	Y	Y	An annotated case report form is not available for this study. A blank case report form will be provided.	1-Sep-2013
468	GSK	To assess safety, reactogenicity & immunogenicity of a booster dose of pneumococcal conjugate vaccine, co-admin with GSK Biologicals’ MMRV vaccine in children (2nd yr of life) primed with the pneumococcal conjugate vaccine in study 105553.	Pneumococcal Polysaccharide Conjugate Vaccine (Adsorbed)	107706	Infections, Streptococcal	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=107706	http://clinicaltrials.gov/show/NCT00370227	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001934-42	Y	N	Y	Y	Y	Y	Y	An annotated case report form is not available for this study. A blank case report form will be provided.	1-Sep-2013
469	GSK	Study to assess the safety and immunogenicity of GSK Biologicals 10-valent pneumococcal conjugate vaccine when Co-administered with DTPa-HBV-IPV/Hib (Infanrix-Hexa) vaccine in preterm infants as a 3-dose primary immunization course during the first 6 months of life.	Pneumococcal Polysaccharide Conjugate Vaccine (Adsorbed)	107737	Infections, Streptococcal	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=107737	http://clinicaltrials.gov/show/NCT00390910	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002898-47	Y	Y	Y	Y	Y	Y	Y		1-Sep-2013
470	GSK	Non-inferiority of co-administration of GSK Biologicals’pneumococcal conjugate vaccine GSK1024850A with DTPa-IPV-Hib versus co-administration with DTPa-HBV-IPV/Hib.	Pneumococcal Polysaccharide Conjugate Vaccine (Adsorbed)	110142	Infections, Streptococcal	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=110142	http://clinicaltrials.gov/show/NCT00652951	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004002-26	Y	Y	Y	Y	Y	Y	Y	A follow-on study 111053 was conducted. The results of this study 110142 are summarised with 111053 on the GSK Study Register.	1-Mar-2014
471	GSK	Vaccination course in children primed and boosted with pneumococcal vaccine GSK 1024850A and in age-matched unprimed children	Pneumococcal Polysaccharide Conjugate Vaccine (Adsorbed)	111736	Infections, Streptococcal	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=111736	http://clinicaltrials.gov/show/NCT00792909	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-003950-14	Y	N	Y	Y	Y	Y	Y	This is a follow-up study to 105539. An annotated case report form is not available for this study. A blank case report form will be provided.	1-Sep-2013
472	GSK	Vaccination with the pneumococcal vaccine GSK 1024850A or Prevenar™ at approximately 4 years of age in children primed with 3 doses of GSK 1024850A vaccine or Prevenar™ and boosted with 23-valent pneumococcal plain polysaccharide vaccine	Pneumococcal Polysaccharide Conjugate Vaccine (Adsorbed)	112807	Infections, Streptococcal	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=112807	http://clinicaltrials.gov/show/NCT00907777	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-007605-37	Y	Y	Y	Y	Y	Y	Y	This is a follow-up study to 105554 and 106623.	1-Mar-2015
473	GSK	Primary vaccination course with the pneumococcal vaccine GSK 1024850A, in healthy infants in Vietnam when co-administered with GSK Biologicals’ Infanrix hexa™ (DTPa-HBV-IPV/Hib) vaccine	Pneumococcal Polysaccharide Conjugate Vaccine (Adsorbed)	113151	Infections, Streptococcal	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=113151	http://clinicaltrials.gov/show/NCT01153841	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000162-38	Y	Y	Y	Y	Y	Y	Y		1-Sep-2013
474	GSK	An open label, randomized, up-titration study to assess the effect of urine sample handling procedures on the safety results of urine obtained from healthy subjects receiving repeat doses of ezogabine/retigabine.	retigabine, ezogabine	RTG114137	Epilepsy	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=114137			Y	Y	Y	Y	Y	Y	Y	A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Sep-2013
475	GSK	A Randomized, Double-Blind Study to Compare the Durability of Glucose Lowering and Preservation of Pancreatic Beta-Cell Function of Rosiglitazone Monotherapy Compared to Metformin or Glyburide/Glibenclamide in Patients with Drug-Naive, Recently Diagnosed Type 2 Diabetes Mellitus	rosiglitazone	49653/048	Diabetes Mellitus, Type 2	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=49653/048	http://clinicaltrials.gov/show/NCT00279045		Y	Y	Y	Y	Y	Y	Y	The raw data are included within the analysis-ready data for this study and are not provided separately.	1-Sep-2013
476	GSK	A Study to Evaluate the Efficacy of Rosiglitazone (BRL-049653) on Reduction of Microalbuminuria in Subjects with Type 2 Diabetes Mellitus	rosiglitazone	49653/137	Diabetes Mellitus, Type 2	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=BRL-49653/137	http://clinicaltrials.gov/show/NCT00500955		N	N	Y	Y	Y	Y	Y	An analysis-ready dataset is not available for this study. An annotated case report form is not available for this study. A blank case report form will be provided.	1-Sep-2013
477	GSK	A 52-week double-blind study of the effect of rosiglitazone on cardiovascular structure and function in subjects with type 2 diabetes mellitus and congestive heart failure (NYHA class I/II)	rosiglitazone	49653/211	Heart failure, Congestive	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=49653/211			Y	Y	Y	Y	Y	Y	Y	A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Sep-2013
478	GSK	A long term, open label, randomised study in patients with type 2 diabetes, comparing the combination of rosiglitazone and either metformin or sulfonylurea with metformin plus sulfonylurea on cardiovascular endpoints and glycaemia	rosiglitazone	49653/231	Diabetes Mellitus, Type 2	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=BRL-049653/231	http://clinicaltrials.gov/show/NCT00379769		Y	Y	Y	Y	Y	Y	Y		1-Sep-2013
479	GSK	A Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Control, Clinical Evaluation of Rosiglitazone in Combination with Glimepiride Compared to Glimepiride Plus Placebo for 24 Weeks in Subjects with Type 2 DiabetesMellitus Who are Inadequately Controlled on Non-TZD Oral Monotherapy	rosiglitazone	49653/325	Diabetes Mellitus, Type 2	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=49653/325			N	Y	Y	Y	Y	Y	Y	An analysis-ready dataset is not available for this study. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Sep-2013
480	GSK	A Randomized, Double Blind, Placebo Controlled, Parallel Group Study to Assess the Safety and Efficacy of Three Dose Levels of Rosiglitazone Maleate in the Treatment of Chronic Plaque Psoriasis	rosiglitazone	49653/330	Psoriasis	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=49653/330			N	Y	Y	Y	Y	Y	Y	An analysis-ready dataset is not available for this study. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Sep-2013
481	GSK	A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess the Safety and Efficacy of Rosiglitazone Maleate in the Treatment of Chronic Plaque Psoriasis	rosiglitazone	49653/331	Psoriasis	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=49653/331			Y	Y	Y	Y	Y	Y	Y	A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Sep-2013
482	GSK	Effect of rosiglitazone and placebo on carotid intima media thickness in patients with insulin resistance syndrome and/or type 2 diabetes	rosiglitazone	49653/334	Diabetes Mellitus, Type 2	Phase 4	https://www.gsk-studyregister.com/en/trial-details/?id=49653/334	http://clinicaltrials.gov/show/NCT00306644		N	Y	Y	Y	Y	Y	Y	An analysis-ready dataset is not available for this study.	1-Sep-2013
483	GSK	A Study to Investigate the Mechanism of Fluid Retention with AVANDIA™ in Combination with a Euglycaemic/Hyperinsulinaemic Clamp.	rosiglitazone	49653/339	Diabetes Mellitus, Type 2	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=49653/339			N	N	Y	Y	Y	Y	Y	An analysis-ready dataset and an annotated case report form are not available for this study. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Sep-2013
484	GSK	A Randomised study Examining the Effect of Different Diuretics on Fluid Balance in Diabetics Treated with Avandia	rosiglitazone	49653/342	Diabetes Mellitus, Type 2	Phase 4	https://www.gsk-studyregister.com/en/trial-details/?id=49653/342	http://clinicaltrials.gov/show/NCT00306696		Y	Y	Y	Y	Y	Y	Y		1-Sep-2013
485	GSK	A Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Control, Clinical Evaluation of Insulin Plus Rosiglitazone (2mg and 4mg) Compared to Insulin Plus Placebo for 24 Weeks in Subjects with Type 2 Diabetes Mellitus Who are Inadequately Controlled on Insulin	rosiglitazone	49653/347	Diabetes Mellitus, Type 2	Phase 4	https://www.gsk-studyregister.com/en/trial-details/?id=49653/347	http://clinicaltrials.gov/show/NCT00329225		N	N	Y	Y	Y	Y	Y	An analysis-ready dataset is not available for this study. An annotated case report form is not available for this study. A blank case report form will be provided.	1-Sep-2013
486	GSK	A 12 month randomized, double-blind, placebo-controlled, magnetic resonance imaging study to evaulate the effect of rosiglitazone on the structure and composition of carotid atherosclerotic plaques in subjects with type 2 diabetes	rosiglitazone	49653/351	Diabetes Mellitus, Type 2	Phase 4	https://www.gsk-studyregister.com/en/trial-details/?id=BRL-049563/351			N	Y	Y	Y	Y	Y	Y	An analysis-ready dataset is not available for this study. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Sep-2013
487	GSK	A 16 Week Randomised, Double-Blind, Parallel Group, Placebo-Controlled Study to Evaluate the Effect of Rosiglitazone on Myocardial Glucose Uptake in Subjects with Type 2 Diabetes Mellitus and Stable Coronary Heart Disease	rosiglitazone	49653/352	Diabetes Mellitus, Type 2	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=49653/352			Y	Y	Y	Y	Y	Y	Y	A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Sep-2013
489	GSK	A 16-week, randomised, double-blind, placebo-controlled, single-centre study to investigate fluid retention in insulin-treated subjects with type 2 diabetes mellitus and varying degrees of autonomic neuropathy when administered rosiglitazone 4mg twice daily	rosiglitazone	49653/376	Neuropathy, Diabetic	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=49653/376	http://clinicaltrials.gov/show/NCT00422955		Y	Y	Y	Y	Y	Y	Y		1-Sep-2013
490	GSK	A Study to Evaluate the Effect of Single and Repeat Doses of Rosiglitazone on the Pharmacokinetics of Methotrexate in Patients Receiving Methotrexate for Psoriasis	rosiglitazone	49653/411	Psoriasis	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=49653/411			N	N	Y	Y	Y	Y	Y	An analysis-ready dataset is not available for this study. An annotated case report form is not available for this study. A blank case report form will be provided. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Sep-2013
491	GSK	A study to evaluate the effect of repeat doses of rosiglitazone on the pharmacokinetics of repeat doses of acitretin in patients receiving acitretin for psoriasis.	rosiglitazone	49653/413	Psoriasis	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=49653/413			N	N	Y	Y	Y	Y	Y	An analysis-ready dataset is not available for this study. An annotated case report form is not available for this study. A blank case report form will be provided. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Sep-2013
492	GSK	An open-label, non-randomized, two period study to investigate the pharmacokinetics of rosiglitazone and glibenclamide when administered alone and concomitantly in healthy male Japanese and Caucasian subjects.	rosiglitazone	49653/414	Diabetes Mellitus, Type 2	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=49653/414			N	N	Y	Y	Y	Y	N	An analysis-ready dataset is not available for this study. An annotated case report form is not available for this study. A blank case report form will be provided. A reporting and analysis plan is not available for this study. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Sep-2013
494	GSK	A randomized, double-blind, parallel group, placebo-controlled study to investigate the safety, tolerability and efficacy of six months' administration of AVANDIA (rosiglitazone maleate) in subjects with Relapsing-Remitting Multiple Sclerosis (MS)	rosiglitazone	49653/452	Multiple Sclerosis, Relapsing-Remitting	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=49653/452			Y	Y	Y	Y	Y	Y	Y	A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Sep-2013
495	GSK	A double-blind, randomized, placebo-controlled, parallel-group study to investigate the effects of rosiglitazone (extended release tablets) on cerebral glucose utilization and cognition in subjects with mild to moderate Alzheimer's Disease (AD)	rosiglitazone	49653/461	Alzheimer's Disease	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=BRL-49653/461	http://clinicaltrials.gov/show/NCT00265148	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-005089-34	N	Y	Y	Y	Y	Y	Y	A follow-on study AVA104617 was conducted. An analysis-ready dataset is not available for this study.	1-Sep-2013
496	GSK	An Open-label Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Rosiglitazone when Co-administered with Gemfibrozil in Healthy Adult Subjects	rosiglitazone	49653/902	Diabetes Mellitus, Type 2	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=49653/902			N	N	Y	Y	Y	Y	Y	An analysis-ready dataset is not available for this study. An annotated case report form is not available for this study. A blank case report form will be provided. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Sep-2013
497	GSK	A randomized, open-label, two-period crossover study to demonstrate the bioequivalence of twice-daily immediate release and once-daily extended release rosiglitazone dosing over five days in healthy volunteers.	rosiglitazone	49653/903	Diabetes Mellitus, Type 2	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=49653/903			Y	Y	Y	Y	Y	Y	Y	A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Sep-2013
498	GSK	A randomised, double-blind, placebo-controlled, parallel group study to investigate the anti-inflammatory and metabolic effects of rosiglitazone XR, 8mg once daily, in subjects with rheumatoid arthritis	rosiglitazone	ARA102198	Arthritis, Rheumatoid	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=ARA102198	http://clinicaltrials.gov/show/NCT00379600	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000482-35	Y	Y	Y	Y	Y	Y	Y		1-Sep-2013
499	GSK	A 24 week double-blind, randomised, placebo-controlled, parallel-group dose-ranging study to investigate the effects of rosiglitazone (extended release tablets) on cognition in subjects with mild to moderate Alzheimer's disease	rosiglitazone	AVA100193	Alzheimer's Disease	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=100193			Y	Y	Y	Y	Y	Y	Y	A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Sep-2013
500	GSK	An open-label extension to study AVA100193, to assess the long-term safety and efficacy of rosiglitazone (extended release tablets) in subjects with mild to moderate Alzheimer's disease	rosiglitazone	AVA100468	Alzheimer's Disease	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=100468		https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000985-12	Y	Y	Y	Y	Y	Y	Y	A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Sep-2013
501	GSK	A 54-week, study to investigate the effects of rosiglitazone (extended release tablets) as adjunctive therapy to acetylcholinesterase inhibitors on cognition and overall clinical response in APOE e4-stratified subjects with mild to moderate Alzheimer’s disease (REFLECT-3)	rosiglitazone	AVA102670	Alzheimer's Disease	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=AVA102670	http://clinicaltrials.gov/show/NCT00348140	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001402-92	Y	Y	Y	Y	Y	Y	Y	A follow-on study AVA102675 was conducted.	1-Sep-2013
502	GSK	An open-label extension to study 49653/461, to assess the long-term safety of rosiglitazone (extended release tablets) in subjects with mild to moderate Alzheimer's Disease	rosiglitazone	AVA104617	Alzheimer's Disease	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=AVA104617	http://clinicaltrials.gov/show/NCT00381238	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004924-19	Y	Y	Y	Y	Y	Y	Y	This is a follow-up study to 49653/461.	1-Sep-2013
503	GSK	A Phase III, 18 Month, Multicenter, Randomized, Double-Blind, Active-Controlled Clinical Trial to Compare Rosiglitazone versus Glipizide on the Progression of Atherosclerosis in Subjects with Type 2 Diabetes Mellitus and Cardiovascular Disease (APPROACH)	rosiglitazone	AVD100521	Atherosclerosis	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=AVD100521	http://clinicaltrials.gov/show/NCT00116831	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-004090-29	Y	Y	Y	Y	Y	Y	Y		1-Sep-2013
507	GSK	A randomised double-blind two-period crossover study to investigate the effect of treatment with repeat doses of a PPAR gamma agonist on the allergen-induced late asthmatic response in subjects with mild asthma compared with repeat doses of placebo.	rosiglitazone	RES104385	Asthma	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=104385	http://clinicaltrials.gov/show/NCT00318630		Y	Y	Y	Y	Y	Y	Y		1-Sep-2013
508	GSK	A Randomized, Single-Blind, Placebo-Controlled, Parallel Group, Exploratory Research Study to Describe the Pharmacodynamic Effects of Glyburide, Metformin, and Rosiglitazone versus Placebo for 8 Weeks in Adult Subjects with Type 2 Diabetes Mellitus	rosiglitazone	RES11098	Diabetes Mellitus, Type 2	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=RES11098			N	Y	N	Y	Y	Y	N	An analysis-ready dataset, a reporting and analysis plan, and a clinical study report are not available for this study. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Sep-2013
509	GSK	Multicentre study to assess the effect of prophylactic antipyretic treatment on the rate of febrile reactions following concomitant administration of GSK Biologicals’ 10-valent pneumococcal conjugate, Infanrix hexa and Rotarix vaccines	Pneumococcal Polysaccharide Conjugate Vaccine (Adsorbed)	107017	Infections, Streptococcal	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=107017	http://clinicaltrials.gov/show/NCT00370318	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000559-16	Y	N	Y	Y	Y	Y	Y	A follow-on study 107137 was conducted. An annotated case report form is not available for this study. A blank case report form will be provided.	1-Sep-2013
510	GSK	A placebo-controlled, multi-country & multi-center study to assess the efficacy, safety & immunogenicity of 2 doses of GSK Biologicals’ oral live attenuated human rotavirus (HRV) vaccine in healthy infants	Rotavirus Vaccine	444563/023	Infections, Rotavirus	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=444563/023	http://clinicaltrials.gov/show/NCT00140673		Y	Y	Y	Y	Y	Y	Y		1-Sep-2013
511	GSK	A Randomized, Double-Blind, Double-Dummy, Comparative Clinical Trial of 12-Week Courses of Salmeterol Xinafoate Versus Ipratropium Bromide Versus Placebo (PRN Ventolin®) in Subjects With Chronic Obstructive Pulmonary Disease	salmeterol	SLGA4005	Pulmonary Disease, Chronic Obstructive	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=SLGA4005			N	Y	Y	Y	Y	Y	Y	An analysis-ready dataset is not available for this study. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Sep-2013
512	GSK	A Randomized, Double-blind, Double-Dummy, Comparative Clinical Trial of 12-Week Courses of Salmeterol Xinafoate Versus Ipratropium Bromide Versus Placebo (PRN Ventolin) in Subjects With Chronic Obstructive Pulmonary Disease	salmeterol	SLGA4004	Pulmonary Disease, Chronic Obstructive	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=SLGA4004			N	Y	Y	Y	Y	Y	Y	An analysis-ready dataset is not available for this study. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Sep-2013
514	GSK	A Single-Center, Randomized, Open-Label Study to Evaluate the Bioavailability of Tazarotene Foam, 0.1%, and Tazorac Gel, 0.1%, in Subjects with Acne Vulgaris	tazarotene	STF114565	Acne Vulgaris	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=114565	http://clinicaltrials.gov/show/NCT01019603		N	Y	Y	Y	Y	Y	Y	An analysis-ready dataset is not available for this study.	1-Sep-2013
520	GSK	A double-blind, randomized, placebo-controlled, repeat dose, 2-way crossover drug interaction study to investigate the pharmacokinetic and pharmacodynamic effects following administration of fluticasone furoate/GW642444M Inhalation Powder with ketoconazole	fluticasone furoate/vilanterol	HZA105548	Asthma	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=105548	http://clinicaltrials.gov/show/NCT01165125	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-019976-56	Y	Y	Y	Y	Y	Y	Y		1-Sep-2013
521	GSK	A randomised, double-blind, placebo controlled, parallel group, dose ranging study evaluating the efficacy and safety of GW642444M administered once daily compared with placebo for 28 days in adolescent and adult subjects with persistent asthma	vilanterol	B2C109575	Asthma	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=B2C109575	http://clinicaltrials.gov/show/NCT00600171	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001713-42	Y	Y	Y	Y	Y	Y	Y		1-Sep-2013
522	GSK	A three-way incomplete block crossover study to investigate the 24-hour pulmonary function of three dosage strengths of Fluticasone Furoate (FF)/GW642444 Inhalation Powder vs. Placebo, in subjects with Chronic Obstructive Pulmonary Disease (COPD)	vilanterol	HZC110946	Pulmonary Disease, Chronic Obstructive	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=110946	http://clinicaltrials.gov/show/NCT01072149		Y	Y	Y	Y	Y	Y	Y		1-Sep-2013
523	GSK	Study HZC111348, a repeat-dose study of GW685698/GW642444 Inhalation Powder versus Placebo in the Treatment of Chronic Obstructive Pulmonary Disease (COPD)	fluticasone furoate/vilanterol	HZC111348	Pulmonary Disease, Chronic Obstructive	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=HZC111348	http://clinicaltrials.gov/show/NCT00731822	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000727-26	Y	Y	Y	Y	Y	Y	Y		1-Sep-2013
524	GSK	A randomised, double-blind, placebo-controlled, three-way crossover, repeat dose pilot study comparing the effect of inhaled fluticasone furoate/GW642444M combination and fluticasone furoate on the allergen-induced early asthmatic response in subjects with mild asthma	fluticasone furoate/vilanterol	HZA113090	Asthma	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=113090	http://clinicaltrials.gov/show/NCT01128569	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-016581-80	Y	Y	Y	Y	Y	Y	Y		1-Sep-2013
525	GSK	A randomised, double-blind, placebo-controlled, four-way crossover, repeat dose study comparing the effect of inhaled fluticasone furoate/GW642444M combination, GW642444M and fluticasone furoate on the allergen-induced asthmatic response in subjects with mild asthma	fluticasone furoate/vilanterol	HZA113126	Asthma	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=113126	http://clinicaltrials.gov/show/NCT01128595	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-019465-28	Y	Y	Y	Y	Y	Y	Y		1-Sep-2013
526	GSK	A multi-center, randomized, double-blind, placebo-controlled, five period cross-over study to evaluate the efficacy and safety of selected doses and dose intervals of GW642444 administered via a novel dry powder inhaler (NDPI) in subjects ≥18 years of age with persistent asthma	vilanterol	HZA113310	Asthma	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=113310	http://clinicaltrials.gov/show/NCT00980200		Y	Y	Y	Y	Y	Y	Y		1-Sep-2013
527	GSK	An open-label, non-randomized pharmacokinetic and safety study of repeat doses of fluticasone furoate and GW642444M combination in healthy subjects and in subjects with severe renal impairment.	fluticasone furoate/vilanterol	HZA113970	Pulmonary Disease, Chronic Obstructive	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=113970	http://clinicaltrials.gov/show/NCT01266980	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-020826-17	Y	Y	Y	Y	Y	Y	Y		1-Sep-2013
529	GSK	Phase III Clinical Study of GG167: An open trial of GG167 in the treatment of influenza viral infection in children (open-label study). A survey on time course of influenza-like symptoms in pediatric patients with influenza viral infection treated without an influenza antiviral.	zanamivir	167T3-11	Influenza, Human	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=167T3-11			N	Y	Y	Y	Y	Y	Y	All or some of the data and documents for this study are in a non-English language and anonymisation may take longer. An analysis-ready dataset is not available for this study. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Sep-2013
533	GSK	A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Impact of Inhaled zanamivir Treatment on Workplace Attendance Due to Influenza A and B Infections	zanamivir	NAI30011	Influenza, Human	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=NAI30011			N	Y	Y	Y	Y	Y	Y	An analysis-ready dataset is not available for this study. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Sep-2013
534	GSK	Pharmacokinetics of zanamivir (GG167) following inhaled administration in pediatric subjects with signs and symptoms of respiratory illness.	zanamivir	NAIA1009	Influenza, Human	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=NAIA1009			N	Y	Y	Y	Y	Y	N	An analysis-ready dataset and a reporting and analysis plan are not available for this study. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Sep-2013
535	GSK	A Double-Blind, Randomized Placebo-Controlled Multicenter Study to Investigate the Efficacy and Safety of GG167 in the Treatment of Influenza A and B Viral Infection	zanamivir	NAIA2005	Influenza, Human	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=NAIA2005			N	Y	Y	Y	Y	Y	Y	An analysis-ready dataset is not available for this study. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Sep-2013
536	GSK	A Double-Blind, Randomized, Placebo-Controlled Multicenter Study to Investigate the Efficacy and Safety of GG167 (zanamivir) Therapy in the Prevention of Progression of Influenza A and B Viral Infections	zanamivir	NAIA2006	Influenza, Human	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=NAIA2006			N	Y	Y	Y	Y	Y	N	An analysis-ready dataset and a reporting and analysis plan are not available for this study. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Sep-2013
537	GSK	A Double-Blind, Randomized, Placebo-Controlled, Multicenter, Parallel and Group Study to Investigate the Efficacy and Safety of GG167 Administered Twice or Four Times a Day for the Treatment of Influenza A and B Viral Infections	zanamivir	NAIA2008	Influenza, Human	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=NAIA2008			N	Y	Y	Y	Y	Y	Y	An analysis-ready dataset is not available for this study. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Sep-2013
538	GSK	A Double-Blind, Randomized, Placebo-Controlled, Multicenter, Parallel-Group Study to Investigate the Efficacy and Safety of GG167 in the Prevention and/or Progression of Influenza A and B Viral Infections	zanamivir	NAIA2009	Influenza, Human	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=NAIA2009			N	Y	Y	Y	Y	Y	Y	An analysis-ready dataset is not available for this study. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Sep-2013
539	GSK	Efficacy of zanamivir (GG167) In Controlling Nursing Home Influenza Outbreaks	zanamivir	NAIA2010	Influenza, Human	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=NAIA2010			N	Y	Y	Y	Y	Y	Y	An analysis-ready dataset is not available for this study. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Sep-2013
540	GSK	Pharmacoscintigraphic Evalutaion of Lung Deposition of GG167 Inhaled from the Diskhaler and the Free Flow Powder System (FFPS) in Healthy Volunteers.	zanamivir	NAIB1001	Influenza, Human	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=NAIB1001			N	N	Y	Y	Y	Y	N	An analysis-ready dataset and a reporting and analysis plan are not available for this study. An annotated case report form is not available for this study. A blank case report form will be provided. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Sep-2013
541	GSK	A Study to Evaluate the Effect of Repeat Doses of GG167 Dry Powder on Pulmonary Function and Bronchial Hyper-Responsiveness in Asthmatic Subjects	zanamivir	C94-085 (NAIB1002)	Hyperreactivity, Bronchial	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=NAIB1002			N	N	Y	Y	Y	Y	N	An analysis-ready dataset and a reporting and analysis plan are not available for this study. An annotated case report form is not available for this study. A blank case report form will be provided. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Sep-2013
542	GSK	A GG167 Pharmacokinetic Study to Select a Regimen for Prophylaxis.	zanamivir	NAIB1007	Influenza, Human	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=NAIB1007			N	N	Y	Y	Y	Y	N	An analysis-ready dataset and a reporting and analysis plan are not available for this study. An annotated case report form is not available for this study. A blank case report form will be provided. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Sep-2013
543	GSK	A Double-Blind, Randomised, Placebo-Controlled, Parallel-Group, Multicentre Study to Investigate the Efficacy and Safety of Inhaled and Intranasal GG167 in the Treatment of Influenza A and B Viral Infections	zanamivir	NAIB2005	Influenza, Human	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=NAIB2005			N	Y	Y	Y	Y	Y	Y	An analysis-ready dataset is not available for this study. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Sep-2013
544	GSK	Double-Blind,Randomised, Placebo-Controlled, Multicentre Study to Investigate the Efficacy and Safety of inhaled zanamivir in Preventing Progression of Influenza	zanamivir	NAIB2006	Influenza, Human	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=NAIB2006			N	Y	Y	Y	Y	Y	Y	An analysis-ready dataset is not available for this study. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Sep-2013
545	GSK	Double-Blind, Randomised, Placebo-Controlled, Multicentre Study to Investigate the Efficacy and Safety of Inhaled and Inhaled plus Intranasal GG167 in the Treatment of Influenza A and B Viral Infections	zanamivir	NAIB2007	Influenza, Human	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=NAIB2007			N	Y	Y	Y	Y	Y	Y	An analysis-ready dataset is not available for this study. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Sep-2013
546	GSK	A Double-Blind, Randomized, Placebo-Controlled, Multicenter, Parallel-Group Study to Investigate the Efficacy and Safety of GG167 Administered Twice or Four Times a Day for the Treatment of Influenza A and B Viral Infections.	zanamivir	NAIB2008	Influenza, Human	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=NAIB2008			N	Y	Y	Y	Y	Y	Y	An analysis-ready dataset is not available for this study. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Sep-2013
547	GSK	A Double-Blind, Randomized, Placebo-Controlled, Multicenter, Parallel-Group Study to Investigate the Efficacy and Safety of GG167 in the Prevention and/or Progression of Influenza A and B Viral Infections	zanamivir	NAIB2009	Influenza, Human	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=NAIB2009			N	Y	Y	Y	Y	Y	N	An analysis-ready dataset and a reporting and analysis plan are not available for this study. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Sep-2013
548	GSK	A randomized double-blind placebo-controlled study to evaluate the inhibitory effect against the onset of influenza virus-infected patients	zanamivir	PE-01	Influenza, Human	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=PE-01			N	Y	Y	Y	Y	Y	Y	All or some of the data and documents for this study are in a non-English language and anonymisation may take longer. An analysis-ready dataset is not available for this study. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Sep-2013
1276	GSK	ARI103094-Follow-Up Study for REDUCE Study Subjects	dutasteride	ARI103094	Neoplasms, Prostate	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=103094	http://clinicaltrials.gov/show/NCT00883909		Y	Y	Y	Y	Y	Y	Y	This is a follow-up study to ARI40006.	1-Jan-2014
1277	GSK	A randomised, double-blind, placebo-controlled, four-way crossover study to compare the pharmacodynamics and pharmacokinetics of GW685698X and GW642444M when administered separately and in combination as a single dose from a novel dry powder device in healthy subjects	fluticasone furoate	HZA105871	Asthma	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=105871	http://clinicaltrials.gov/show/NCT00538057		Y	Y	Y	Y	Y	Y	Y		1-Jan-2014
1278	GSK	A Randomized, Double-Blind, Double-Dummy, Parallel Group, 12-Week Comparative Trial of Salmeterol/Fluticasone Propionate Combination Product 50/100mcg Twice Daily Via the DISKUS® Inhaler Versus Oral Montelukast 10mg Once Daily in Adolescents and Adults with Persistent Asthma	fluticasone propionate/salmeterol	SAS40020	Asthma	Phase 4	https://www.gsk-studyregister.com/en/trial-details/?id=SAS40020			N	Y	Y	Y	Y	Y	Y	An analysis-ready dataset is not available for this study. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Jan-2014
1279	GSK	A Randomized, Double-Blind, Double-Dummy, Parallel Group, 12-Week Comparative Trial of Salmeterol/Fluticasone Propionate Combination Product 50/100mcg Twice Daily Via the DISKUS® Inhaler Versus Oral Montelukast 10mg Once Daily in Adolescents and Adults with Persistent Asthma	fluticasone propionate/salmeterol	SAS40021	Asthma	Phase 4	https://www.gsk-studyregister.com/en/trial-details/?id=SAS40021			N	Y	Y	Y	Y	Y	Y	An analysis-ready dataset is not available for this study. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Jan-2014
1280	GSK	A Multi-center, Double-blind, Placebo-Controlled Study of Paroxetine and Imipramine in Adolescents with Unipolar Major Depression - Acute Phase	paroxetine	BRL-029060/329: Acute Phase	Depressive Disorder	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=29060/329			N	N	Y	Y	Y	Y	Y	This study was conducted in 2 phases - an acute phase and a continuation phase. A comprehensive dataset for the complete study is available. An analysis-ready dataset is not available for this study. An annotated case report form is not available for this study. A blank case report form will be provided. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Jan-2014
1281	GSK	An interaction study to assess the effect of the ezogabine/retigabine and the main metabolite NAMR on the pharmacokinetics of digoxin in healthy volunteers	retigabine, ezogabine	RTG116216	Epilepsy	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=116216	http://clinicaltrials.gov/show/NCT01583036		Y	Y	Y	Y	Y	Y	Y		1-Jan-2014
1282	GSK	A Randomized, Double-Blind, Placebo-Controlled Trial to Assess Three Dose Levels of Rosiglitazone Maleate in the Treatment of Moderate to Severe Plaque Psoriasis.	rosiglitazone	49653/292	Psoriasis	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=49653/292			Y	N	Y	Y	Y	Y	Y	An annotated case report form is not available for this study. A blank case report form will be provided. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Jan-2014
1283	GSK	A phase II, double-blind, randomized, placebo-controlled study to compare the immunogenicity, reactogenicity and safety of 2 different formulations of GSK Biologicals’ live attenuated human rotavirus (HRV) vaccine given as a two-dose primary vaccination in healthy infants previously uninfected with HRV	Rotavirus Vaccine	101555	Infections, Rotavirus	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=101555			Y	N	N	Y	Y	Y	Y	An annotated case report form is not available for this study. A blank case report form will be provided. A clinical study report is not available for this study. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Jan-2014
1284	GSK	A phase II, randomized, double-blind, placebo-controlled study of safety, reactogenicity and immunogenicity of 2 or 3 doses of GSK Biologicals’ oral live attenuated human rotavirus vaccine at 10E6.5 CCID50 viral concentration in healthy infants (approximately 5-10 weeks old) in the Republic of South Africa	Rotavirus Vaccine	444563/013	Infections, Rotavirus	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=444563/013	http://clinicaltrials.gov/show/NCT00383903		Y	N	Y	Y	Y	Y	Y	An annotated case report form is not available for this study. A blank case report form will be provided. A link to ClinicalTrials.gov and an NCTID number is not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Jan-2014
1285	GSK	A phase II, double-blind, randomized, placebo-controlled study to assess the safety, reactogenicity and immunogenicity of three doses of GlaxoSmithKline (GSK) Biologicals’ oral live attenuated human rotavirus (HRV) vaccine	Rotavirus Vaccine	444563/022	Infections, Rotavirus	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=444563/022	http://clinicaltrials.gov/show/NCT00263666	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-001484-39	Y	N	Y	Y	Y	Y	Y	An annotated case report form is not available for this study. A blank case report form will be provided. A link to ClinicalTrials.gov and an NCTID number is not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Jan-2014
1286	GSK	A multi-country & multi-center study to assess the efficacy, immunogenicity & safety of two doses of GSK Biologicals' oral live attenuated HRV vaccine given concomitantly with routine EPI vaccinations including OPV in healthy infants	Rotavirus Vaccine	444563/024	Infections, Rotavirus	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=444563/024	http://clinicaltrials.gov/show/NCT00139347	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-001540-10	Y	Y	Y	Y	Y	Y	Y	A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Jan-2014
1287	GSK	A phase III, double-blind, randomized, placebo-controlled, multi-country and multi-center study to assess the efficacy and safety of two doses of GSK Biologicals’ oral live attenuated human rotavirus (HRV) vaccine in healthy infants	Rotavirus Vaccine	444563/028	Infections, Rotavirus	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=444563/028/029/030	http://clinicaltrials.gov/show/NCT00197210	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-001541-92	Y	N	Y	Y	Y	Y	Y	The results of this study 444563/028 are summarised with studies 444563/029, 444563/030, 107070, 107072, and 107076 on the GSK Study Register. An annotated case report form is not available for this study. A blank case report form will be provided. A link to ClinicalTrials.gov and an NCTID number is not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Jan-2014
1288	GSK	A phase III, double-blind, randomized, placebo-controlled, multi-country and multi-center study to assess the efficacy and safety of two doses of GSK Biologicals' oral live attenuated human rotavirus (HRV) vaccine in healthy infants.	Rotavirus Vaccine	107070	Infections, Rotavirus	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=107070	http://clinicaltrials.gov/show/NCT00329745	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-001541-92	Y	N	Y	Y	Y	Y	Y	The results of this study 107070 are summarised with studies 444563/028, 444563/029, 444563/030, 107072, and 107076 on the GSK Study Register. An annotated case report form is not available for this study. A blank case report form will be provided. A link to ClinicalTrials.gov and an NCTID number is not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Jan-2014
1289	GSK	A phase III, double-blind, randomized, placebo-controlled, multi-country and multi-center study to assess the efficacy and safety of two doses of GSK Biologicals’ oral live attenuated human rotavirus (HRV) vaccine in healthy infants	Rotavirus Vaccine	444563/029	Infections, Rotavirus	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=444563/028/029/030	http://clinicaltrials.gov/show/NCT00197210		Y	N	Y	Y	Y	Y	Y	The results of this study 444563/029 are summarised with studies 444563/028, 444563/030, 107070, 107072, and 107076 on the GSK Study Register. An annotated case report form is not available for this study. A blank case report form will be provided. A link to ClinicalTrials.gov and an NCTID number is not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Jan-2014
1290	GSK	A phase III, double-blind, randomized, placebo-controlled, multi-country and multi-center study to assess the efficacy and safety of two doses of GSK Biologicals' oral live attenuated human rotavirus (HRV) vaccine in healthy infants.	Rotavirus Vaccine	107072	Infections, Rotavirus	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=107070	http://clinicaltrials.gov/show/NCT00329745		Y	N	Y	Y	Y	Y	Y	The results of this study 107072 are summarised with studies 444563/028, 444563/029, 444563/030, 107070, and 107076 on the GSK Study Register. An annotated case report form is not available for this study. A blank case report form will be provided. A link to ClinicalTrials.gov and an NCTID number is not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Jan-2014
1291	GSK	A phase III, double-blind, randomized, placebo-controlled, multi-country and multi-center study to assess the efficacy and safety of two doses of GSK Biologicals’ oral live attenuated human rotavirus (HRV) vaccine in healthy infants	Rotavirus Vaccine	444563/030	Infections, Rotavirus	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=444563/028/029/030	http://clinicaltrials.gov/show/NCT00197210		Y	N	Y	Y	Y	Y	Y	The results of this study 444563/030 are summarised with studies 444563/028, 444563/029, 107070, 107072, and 107076 on the GSK Study Register. An annotated case report form is not available for this study. A blank case report form will be provided. A link to ClinicalTrials.gov and an NCTID number is not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Jan-2014
1292	GSK	A phase III, double-blind, randomized, placebo-controlled, multi-country and multi-center study to assess the efficacy and safety of two doses of GSK Biologicals' oral live attenuated human rotavirus (HRV) vaccine in healthy infants.	Rotavirus Vaccine	107076	Infections, Rotavirus	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=107070	http://clinicaltrials.gov/show/NCT00329745		Y	N	Y	Y	Y	Y	Y	The results of this study 107076 are summarised with studies 444563/028, 444563/029, 444563/030, 107070, and 107072 on the GSK Study Register. An annotated case report form is not available for this study. A blank case report form will be provided. A link to ClinicalTrials.gov and an NCTID number is not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Jan-2014
1293	GSK	Study to assess the clinical consistency of three production lots of GSK Biologicals’ HRV vaccine in terms of immunogenicity and safety when given to healthy infants at 2 and 4 months of age	Rotavirus Vaccine	444563/033	Infections, Rotavirus	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=444563/033	http://clinicaltrials.gov/show/NCT00757770		Y	N	Y	Y	Y	Y	Y	An annotated case report form is not available for this study. A blank case report form will be provided. A link to ClinicalTrials.gov and an NCTID number is not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Jan-2014
1294	GSK	A multi-country & multi-center study to assess the efficacy, safety & immunogenicity of 2 doses of GSK Biologicals’ oral live attenuated human rotavirus (HRV) vaccine in healthy infants in co-administration with specific childhood vaccines	Rotavirus Vaccine	102247	Infections, Rotavirus	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=102247/036	http://clinicaltrials.gov/show/NCT00140686	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001175-19	Y	Y	Y	Y	Y	Y	Y	A follow-on study 109810 was conducted.	1-Jan-2014
1295	GSK	To assess long-term efficacy & safety of subjects approximately 3 years after priming with 2 doses of GlaxoSmithKline (GSK) Biologicals’ oral live attenuated human rotavirus (HRV) vaccine (Rotarix) in the primary vaccination study (102247).	Rotavirus Vaccine	109810	Infections, Rotavirus	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=109810	http://clinicaltrials.gov/show/NCT00420316		Y	Y	Y	Y	Y	Y	Y	This is a follow-up study to 102247. A link to ClinicalTrials.gov and an NCTID number is not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Jan-2014
1296	GSK	Multi-Center Study to Assess the Efficacy, Safety and Immunogenicity of 2 or 3 Doses of GSK Biologicals' Oral Live Attenuated Human Rotavirus (HRV) Vaccine Given Concomitantly With Routine EPI Vaccinations in Healthy Infants	Rotavirus Vaccine	102248	Infections, Rotavirus	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=102248	http://clinicaltrials.gov/show/NCT00241644	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-001485-26	Y	Y	Y	Y	Y	Y	Y	The results of this study 102248 are summarised with study 111274 on the GSK Study Register. A link to ClinicalTrials.gov and an NCTID number is not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Jan-2014
1297	GSK	Multi-Center Study to Assess the Efficacy, Safety and Immunogenicity of 2 or 3 Doses of GSK Biologicals' Oral Live Attenuated Human Rotavirus (HRV) Vaccine Given Concomitantly With Routine EPI Vaccinations in Healthy Infants	Rotavirus Vaccine	111274	Infections, Rotavirus	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=102248	http://clinicaltrials.gov/show/NCT00241644		Y	N	Y	Y	Y	Y	Y	The results of this study 111274 are summarised with study 102248 on the GSK Study Register. An annotated case report form is not available for this study. A blank case report form will be provided. A link to ClinicalTrials.gov and an NCTID number is not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Jan-2014
1298	GSK	Study to assess the immunogenicity, reactogenicity and safety of GlaxoSmithKline Biologicals’ oral live attenuated human rotavirus (HRV) vaccine following a 0, 2 month schedule, in healthy infants previously uninfected with human rotavirus	Rotavirus Vaccine	103477	Infections, Rotavirus	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=103477	http://clinicaltrials.gov/show/NCT00169455		Y	N	Y	Y	Y	Y	Y	An annotated case report form is not available for this study. A blank case report form will be provided. A link to ClinicalTrials.gov and an NCTID number is not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Jan-2014
1299	GSK	Assess the immunogenicity, safety & reactogenicity of 2 doses of GSK Biologicals’ oral live attenuated human rotavirus (HRV) vaccine in healthy infants (6-12 weeks of age at first dose) previously uninfected with human rotavirus	Rotavirus Vaccine	103478	Infections, Rotavirus	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=103478	http://clinicaltrials.gov/show/NCT00134732	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004059-38	Y	N	Y	Y	Y	Y	Y	An annotated case report form is not available for this study. A blank case report form will be provided.	1-Jan-2014
1300	GSK	Evaluate immunogenicity, reactogenicity & safety of 2 doses of GSK Biologicals’ oral live attenuated HRV vaccine (RIX4414 at 106.5 CCID50) when given concomitantly with OPV versus given alone (HRV vaccine dose given 15 days after the OPV dose) in healthy infants in Bangladesh	Rotavirus Vaccine	103992	Infections, Rotavirus	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=103992	http://clinicaltrials.gov/show/NCT00139334	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004060-30	Y	N	Y	Y	Y	Y	Y	An annotated case report form is not available for this study. A blank case report form will be provided.	1-Jan-2014
1301	GSK	Compare the immunogenicity, reactogenicity & safety of 2 different formulations of GSK Biologicals’ live attenuated human rotavirus (HRV) vaccine given as a two-dose primary vaccination in healthy infants previously uninfected with HRV	Rotavirus Vaccine	104480	Infections, Rotavirus	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=104480	http://clinicaltrials.gov/show/NCT00137930	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000449-12	Y	N	Y	Y	Y	Y	Y	An annotated case report form is not available for this study. A blank case report form will be provided.	1-Jan-2014
1302	GSK	A placebo-controlled study to evaluate the immunogenicity, reactogenicity and safety of two doses of GSK Biologicals' oral live attenuated human rotavirus (HRV) liquid vaccine, when given to healthy infants, in Vietnam	Rotavirus Vaccine	105722	Infections, Rotavirus	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=105722	http://clinicaltrials.gov/show/NCT00345956		Y	N	Y	Y	Y	Y	Y	An annotated case report form is not available for this study. A blank case report form will be provided. A link to ClinicalTrials.gov and an NCTID number is not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Jan-2014
1303	GSK	A study to assess the immunogenicity, reactogenicity and safety of 2 different formulations of GSK Biologicals' live attenuated HRV vaccine, given as a two-dose primary vaccination, in healthy infants previously uninfected with HRV	Rotavirus Vaccine	107077	Infections, Rotavirus	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=107077	http://clinicaltrials.gov/show/NCT00363545		Y	N	Y	Y	Y	Y	Y	An annotated case report form is not available for this study. A blank case report form will be provided. A link to ClinicalTrials.gov and an NCTID number is not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Jan-2014
1304	GSK	Assess the immunogenicity of 3 doses of Pediarix®, Prevnar® & ActHIB® given to healthy infants when administered with GSK Biologicals’ 2 dose oral live attenuated human rotavirus vaccine given during the same vaccination visit or separately	Rotavirus Vaccine	107531	Infections, Rotavirus	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=107531	http://clinicaltrials.gov/show/NCT00334607	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004061-32	Y	N	Y	Y	Y	Y	Y	An annotated case report form is not available for this study. A blank case report form will be provided.	1-Jan-2014
1305	GSK	Study to evaluate clinical consistency of the liquid formulation of GSK Biologicals' HRV vaccine and to evaluate liquid formulation compared to lyophilised formulation of the HRV vaccine administered as a two-dose primary vaccination.	Rotavirus Vaccine	107876	Infections, Rotavirus	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=107876	http://clinicaltrials.gov/show/NCT00382772	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003239-61	Y	N	Y	Y	Y	Y	Y	An annotated case report form is not available for this study. A blank case report form will be provided.	1-Jan-2014
1306	GSK	A dose ranging study to assess the effect of pre-treatment with a single dose of inhaled fluticasone propionate (2 mg, 0.5 mg) on lung inflammation following challenge with inhaled ozone and intermittent exercise in healthy volunteers, relative to placebo.	fluticasone propionate	CR219039	Pulmonary Disease, Chronic Obstructive	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=CR219039			N	Y	Y	Y	Y	Y	Y	An analysis-ready dataset is not available for this study. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Jan-2014
1372	ViiV	Study of Once-Daily Abacavir/Lamivudine versus Tenofovir/Emtricitabine, Administered with Efavirenz in Antiretroviral-Naive, HIV-1 Infected Adult Subjects	abacavir	CNA109586	Infection, Human Immunodeficiency Virus I	Phase 4	https://www.viiv-studyregister.com/study/19745	http://clinicaltrials.gov/show/NCT00549198		Y	Y	Y	Y	Y	Y	Y		1-Jan-2014
1373	ViiV	A 96-Week, Phase IV, Randomized, Double-Blind, Multicenter Study of the Safety and Efficacy of EPZICOM Versus TRUVADA Administered in Combination with KALETRA in Antiretroviral-Naive HIV-1 Infected Subjects	abacavir	EPZ104057	Infection, Human Immunodeficiency Virus I	Phase 4	https://www.viiv-studyregister.com/study/19788	http://clinicaltrials.gov/show/NCT00244712		Y	Y	Y	Y	Y	Y	Y		1-Jan-2014
1374	ViiV	A phase III, randomized, open-label, parallel, multicenter study to evaluate treatment with fixed-dose combination of abacavir/lamivudine (600mg/300mg) once-daily versus abacavir (300mg) twice-daily and lamivudine (300mg) once-daily in combination with tenofovir once-daily and a new PI or NNRTI for 48 weeks in ART-experienced HIV-1 infected patients	abacavir	CAL30001	Infection, Human Immunodeficiency Virus I	Phase 3	https://www.viiv-studyregister.com/study/19740	http://clinicaltrials.gov/show/NCT00044577		Y	Y	Y	Y	Y	Y	Y		1-Jan-2014
1375	ViiV	A phase IV, randomised, multicentre, double-blind, study to evaluate the clinical utility of prospective genetic screening (HLA-B*5701) for susceptibility to abacavir hypersensitivity	abacavir	CNA106030	Infection, Human Immunodeficiency Virus	Phase 4	http://www.viiv-clinicalstudyregister.com/study/CNA106030	http://clinicaltrials.gov/show/NCT00340080		Y	Y	Y	Y	Y	Y	Y		1-Jan-2014
1376	ViiV	A Prospective, Randomized, Multicenter, Open-Label Study to Compare the Efficacy and Safety of Simplifying from a Regimen of Atazanavir (ATV) + Ritonavir (RTV) + Tenofovir/Emtricitabine to ATV + Abacavir/Lamivudine Without RTV in Virologically Suppressed, HIV-1 Infected, HLA-B*5701 Negative Subjects	abacavir/lamivudine	EPZ113734	Infection, Human Immunodeficiency Virus	Phase 4	https://www.viiv-studyregister.com/study/19538	http://clinicaltrials.gov/show/NCT01102972		Y	Y	Y	Y	Y	Y	Y		1-Jan-2014
1377	ViiV	A Phase III, 48-Week, Open-Label, Randomized, Multicenter Study of the Safety and Efficacy of the Abacavir/Lamivudine Fixed-Dose Combination Tablet Administered QD Versus Abacavir + Lamivudine Administered BID in Combination with a PI or NNRTI in Antiretroviral Experienced Patients.	abacavir/lamivudine	ESS30008	Infection, Human Immunodeficiency Virus I	Phase 3	https://www.viiv-studyregister.com/study/19791	http://clinicaltrials.gov/show/NCT00046176		Y	Y	Y	Y	Y	Y	Y		1-Jan-2014
1378	ViiV	A phase III, randomized, open-label, multicenter study of the safety and efficacy of efavirenz versus tenofovir when administered in combination with the abacavir/lamivudine fixed-dose combination tablet as a once-daily regimen in antiretroviral-naive HIV-1 infected subjects.	abacavir/lamivudine	ESS30009	Infection, Human Immunodeficiency Virus I	Phase 3	https://www.viiv-studyregister.com/study/19792	http://clinicaltrials.gov/show/NCT00053638		Y	N	Y	Y	Y	Y	Y	An annotated case report form is not available for this study.	1-Jan-2014
1379	ViiV	A Phase IIIb/IV, Randomized, Open Label, Multicenter, Pilot Trial to Explore the Safety and Tolerability of GW433908 +/- Ritonavir (1400mg twice daily or 700mg/100mg twice daily) When Used in Combination with a Zidovudine-containing Regimen (TRIZIVIR or COMBIVIR twice daily) Over a 24 Week Period in Antiretroviral Therapy Naive HIV-1 Infected Subjects.	abacavir/lamivudine/zidovudine	AZL30006	Infection, Human Immunodeficiency Virus	Phase 3	http://www.viiv-clinicalstudyregister.com/study/AZL30006	http://clinicaltrials.gov/show/NCT00043888		Y	N	Y	Y	Y	Y	Y	An annotated case report form is not available for this study.	1-Jan-2014
1380	ViiV	A phase IV, open-label, multicenter study of treatment with TRIZIVIR (abacavir 300mg/lamivudine 150mg/zidovudine 300mg) twice daily and tenofovir 300mg once-daily for 48 weeks in HIV-infected subjects experiencing early virologic failure (ZIAGEN Intensification Protocol)	abacavir/lamivudine/zidovudine	ESS 30005	Infection, Human Immunodeficiency Virus I	Phase 4	https://www.viiv-studyregister.com/study/19790	http://clinicaltrials.gov/show/NCT00038506		Y	Y	Y	Y	Y	Y	Y		1-Jan-2014
1381	ViiV	A Phase IV Randomized, Multicenter, Open-Label Study to Compare the Safety, Tolerability and Efficacy of Trizivir (abacavir 300mg, lamivudine 150mg, and zidovudine 300mg) BID vs Combivir (lamivudine 150mg and zidovudine 300mg) BID plus atazanavir 400mg QD in Antiretroviral Naive HIV-1 Infected Subjects over 48 Weeks	abacavir/lamivudine/zidovudine	100327	Infection, Human Immunodeficiency Virus	Phase 4	http://www.viiv-clinicalstudyregister.com/study/100327	http://clinicaltrials.gov/show/NCT00082394		Y	N	Y	Y	Y	Y	Y	An annotated case report form is not available for this study.	1-Jan-2014
1382	ViiV	A Randomized, Double-blind Study of the Safety and Efficacy of GSK1349572 50 mg Once Daily Versus Raltegravir 400 mg Twice Daily, Both Administered with an Investigator-selected Background Regimen Over 48 Weeks in HIV-1 Infected, Integrase Inhibitor-Naïve, Antiretroviral-Experienced Adults	dolutegravir	ING111762	Infection, Human Immunodeficiency Virus	Phase 3	https://www.viiv-studyregister.com/study/19475	http://clinicaltrials.gov/show/NCT01231516		Y	Y	Y	Y	Y	Y	Y	This study is still ongoing, however data related to the publication(s) is available.	1-Jan-2014
1383	ViiV	A Phase 2a, Multicenter, Randomized, Parallel, Double-Blind, Dose Ranging, Placebo-Controlled Study to Compare Antiviral Effect, Safety, Tolerability and Pharmacokinetics of GSK1349572 Monotherapy Versus Placebo Over 10 days in HIV-1 Infected Adults (ING111521)	dolutegravir	ING111521	Infection, Human Immunodeficiency Virus	Phase 2	https://www.viiv-studyregister.com/study/19471	http://clinicaltrials.gov/show/NCT00708110		Y	Y	Y	Y	Y	Y	Y		1-Jan-2014
1384	ViiV	A Phase IIb study to select a once daily dose of GSK1349572 administered with either abacavir/lamivudine or tenofovir/emtricitabine in HIV-1 infected antiretroviral therapy naive adult subjects	dolutegravir	ING112276	Infection, Human Immunodeficiency Virus	Phase 2	https://www.viiv-studyregister.com/study/19484	http://clinicaltrials.gov/show/NCT00951015		Y	Y	Y	Y	Y	Y	Y		1-Jan-2014
1385	ViiV	A Phase III study to demonstrate the antiviral activity and safety of dolutegravir in HIV-1 infected adult subjects with treatment failure on an integrase inhibitor containing regimen.	dolutegravir	ING112574	Infection, Human Immunodeficiency Virus	Phase 3	https://www.viiv-studyregister.com/study/19497	http://clinicaltrials.gov/show/NCT01328041		Y	Y	Y	Y	Y	Y	Y		1-Jan-2014
1386	ViiV	A pilot study to assess the antiviral activity of GSK1349572 containing regimen in antiretroviral therapy (ART)-experienced, HIV-1-infected adult subjects with raltegravir resistance	dolutegravir	ING112961	Infection, Human Immunodeficiency Virus	Phase 2	https://www.viiv-studyregister.com/study/19514	http://clinicaltrials.gov/show/NCT00950859		Y	Y	Y	Y	Y	Y	Y		1-Jan-2014
1387	ViiV	A randomized, double blind study of the safety and efficacy of GSK1349572 50mg once daily to raltegravir 400mg twice daily both administered with fixed-dose dual nucleoside reverse transcriptase inhibitor therapy over 96 weeks in HIV-1 infected antiretroviral therapy naive adult subjects	dolutegravir	ING113086	Infection, Human Immunodeficiency Virus I	Phase 3	https://www.viiv-studyregister.com/study/19519	http://clinicaltrials.gov/show/NCT01227824		Y	Y	Y	Y	Y	Y	Y		1-Jan-2014
1388	ViiV	A Randomized, Double-Blind Study of the Safety and Efficacy of GSK1349572 Plus Abacavir/Lamivudine Fixed-Dose Combination Therapy Administered Once Daily Compared to Atripla over 96 Weeks in HIV-1 Infected Antiretroviral Therapy Naive Adult Subjects	dolutegravir	ING114467	Infection, Human Immunodeficiency Virus I	Phase 3	https://www.viiv-studyregister.com/study/19545	http://clinicaltrials.gov/show/NCT01263015		Y	Y	Y	Y	Y	Y	Y		1-Jan-2014
1389	ViiV	An Open-Label Phase III Study to Assess the Long Term Safety Profile of GW433908 Containing Regimens in HIV-1 Infected Subjects	fosamprenavir	APV30005	Infection, Human Immunodeficiency Virus	Phase 3	https://www.viiv-studyregister.com/study/19721	http://clinicaltrials.gov/show/NCT00296504		N	Y	Y	Y	Y	Y	Y	The statistical analysis for this study did not create a separate analysis-ready dataset and this is therefore not available.	1-Jan-2014
1390	ViiV	A phase IIIB/IV, open-label, multi-center trial to evaluate the safety, tolerability, and efficiency of HIV-1 infected subjects switching their current protease-inhibitor therapies for a fosamprenavir therapy over 48 weeks	fosamprenavir	ESS100290	Infection, Human Immunodeficiency Virus I	Phase 3	https://www.viiv-studyregister.com/study/19453	http://clinicaltrials.gov/show/NCT00094523		Y	N	Y	Y	Y	Y	Y	An annotated case report form is not available for this study.	1-Jan-2014
1391	ViiV	A Phase IIIB, Randomized, Open-Label, Multicenter Study of the Safety and Efficacy of GW433908 (700mg BID) plus ritonavir (100mg BID) Versus Lopinavir/ritonavir (400mg/100mg BID) when Administered in Combination with the Abacavir/Lamivudine (600mg/300mg) Fixed-Dose Combination Tablet QD in Antiretroviral-Naive HIV-1 Infected Adults Over 48 Weeks	fosamprenavir	APV100732	Infection, Human Immunodeficiency Virus	Phase 3	http://www.viiv-clinicalstudyregister.com/study/100732	http://clinicaltrials.gov/show/NCT00085943		Y	Y	Y	Y	Y	Y	Y		1-Jan-2014
1392	ViiV	Study of Once-Daily Versus Twice-Daily Fosamprenavir plus Ritonavir, Administered with Abacavir/Lamivudine Once-Daily in Antiretroviral-Naive HIV-1 Infected Adult Subjects.	fosamprenavir	APV109141	Infection, Human Immunodeficiency Virus I	Phase 3	https://www.viiv-studyregister.com/study/19714	http://clinicaltrials.gov/show/NCT00450580		Y	N	Y	Y	Y	Y	Y	An annotated case report form is not available for this study.	1-Jan-2014
1393	ViiV	A Phase IIIB, randomized, open-label, parallel group, multi-center, non-inferiority, 24-week study to evaluate the safety, efficacy and tolerability of switching from a 200mg ritonavir-boosted regimen of LEXIVA (700mg/100mg BID or 1400mg/200mg QD) to a once-daily, 100mg ritonavir-boosted regimen of LEXIVA (1400mg/100mg QD)	fosamprenavir	LEX106430	Infection, Human Immunodeficiency Virus	Phase 3	https://www.viiv-studyregister.com/study/19802	http://clinicaltrials.gov/show/NCT00363142		Y	Y	Y	Y	Y	Y	Y		1-Jan-2014
1394	ViiV	A Phase III, Randomized, Controlled, Open-label, Multicentre, Three Arm Study to Compare the Efficacy and Safety of a Dual-boosted HIV-1 Protease Inhibitor regimen of Fosamprenavir/Lopinavir/Ritonavir 1400mg/533mg/133mg Twice Daily and an Increased Dosage Regimen of FPV/RTV 1400mg/100mg BID Versus the Standard Dosage Regimen of FPV/RTV 700mg/100mg BID for 24 Weeks in Multiple-PI Experienced, HIV-infected Adults Experiencing Virological Failure	fosamprenavir	APV102002	Infection, Human Immunodeficiency Virus	Phase 3	https://www.viiv-studyregister.com/study/19713	http://clinicaltrials.gov/show/NCT00144833		Y	Y	Y	Y	Y	Y	Y		1-Jan-2014
1395	ViiV	A Phase III, Randomized, Multicenter, Parallel, Open-Label Study to Compare the Efficacy, Safety and Tolerability of GW433908 (1400mg BID) and Nelfinavir (1250mg BID) Over 48 Weeks in Antiretroviral Therapy-Naïve HIV-1 Infected Adults	fosamprenavir	APV30001	Infection, Human Immunodeficiency Virus	Phase 3	https://www.viiv-studyregister.com/study/19718			Y	Y	Y	Y	Y	Y	Y	A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Jan-2014
1396	ViiV	A Randomized, Open-Label, Two Arm Trial to Compare the Safety and Antiviral Efficacy of GW433908/Ritonavir QD to Nelfinavir BID When Used in Combination with Abacavir and Lamivudine BID for 48 Weeks in Antiretroviral Therapy Naïve HIV-1 Infected Subjects	fosamprenavir	APV30002	Infection, Human Immunodeficiency Virus I	Phase 3	https://www.viiv-studyregister.com/study/19719			Y	Y	Y	Y	Y	Y	Y	A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Jan-2014
1397	ViiV	A Phase III, Randomized, Multicenter, Parallel Group, Open-label, Three Arm Study to Compare the Efficacy and Safety of Two Dosing Regimens of GW433908/ritonavir (700mg/100mg twice daily or 1400mg/200mg once daily) versus lopinavir/ritonavir (400mg/100mg twice daily) for 48 Weeks in Protease Inhibitor Experienced HIV-Infected Adults Experiencing Virological Failure	fosamprenavir	APV30003	Infection, Human Immunodeficiency Virus	Phase 3				Y	N	Y	Y	Y	Y	Y	There is no GSK Study Register entry for this study. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies. An annotated case report form is not available for this study.	1-Jan-2014
1398	ViiV	Safety and Efficacy of an Initial Regimen of Atazanavir (ATV) + Ritonavir (/r) + the Abacavir/Lamivudine Fixed-Dose Combination Tablet (ABC/3TC FDC) for 36 weeks followed by Simplification to Atazanavir with ABC/3TC FDC or Maintenance of the Initial Regimen for an Additional 48 weeks in Antiretroviral-Naive HIV-1 Infected HLA-B*5701 Negative Subjects followed by an Optional 60-Week Treatment Extension Phase	lamivudine	EPZ108859	Infection, Human Immunodeficiency Virus I	Phase 3	https://www.viiv-studyregister.com/study/19789	http://clinicaltrials.gov/show/NCT00440947		Y	Y	Y	Y	Y	Y	Y		1-Jan-2014
1399	ViiV	A Study Comparing Safety Of Abacavir And Lamivudine Administered Once-Daily As A Single Tablet Versus The Same Drugs Administered Twice-Daily As Separate Tablets (ALOHA Study)	lamivudine	ESS101822	Infection, Human Immunodeficiency Virus	Phase 3	http://www.viiv-clinicalstudyregister.com/study/101822	http://clinicaltrials.gov/show/NCT00094367		Y	N	Y	Y	Y	Y	Y	An annotated case report form is not available for this study.	1-Jan-2014
1400	ViiV	A Pilot Study Of A Novel Treatment Regimen, Maraviroc + Ritonavir Boosted Atazanavir, In Treatment Naive HIV-Infected Patients	maraviroc	A4001078	Infection, Human Immunodeficiency Virus	Phase 2	N/A	http://ClinicalTrials.gov/show/NCT00827112		Y	Y	Y	Y	Y	Y	Y	There is no GSK Study Register entry for this study.	1-Jan-2014
1401	ViiV	Effects Of Food And Dose Regimen On The Antiviral Effects Of Maraviroc (UK-427,857) In Patients With Human Immunodeficiency Virus	maraviroc	A4001015	Infection, Human Immunodeficiency Virus	Phase 2	N/A	http://ClinicalTrials.gov/show/NCT00634959		Y	Y	Y	Y	Y	Y	Y	There is no GSK Study Register entry for this study. An annotated case report form is not available for this study. A blank case report form will be provided. The clinical study report provided includes the body of the report, safety narratives and statistical tables but does not include appendices or patient data listings.	1-Jan-2014
1402	ViiV	Trial of Maraviroc (UK-427,857) in Combination With Optimized Background Therapy Versus Optimized Background Therapy Alone for the Treatment of Antiretroviral-Experienced NonCCR5-Tropic HIV-1 Infected Subjects	maraviroc	A4001029	Infection, Human Immunodeficiency Virus	Phase 2/Phase 3	N/A	http://ClinicalTrials.gov/show/NCT00098748		Y	Y	Y	Y	Y	Y	Y	There is no GSK Study Register entry for this study. An annotated case report form is not available for this study. A blank case report form will be provided. The clinical study report provided includes the body of the report, safety narratives and statistical tables but does not include appendices or patient data listings.	1-Jan-2014
1403	ViiV	Trial of Maraviroc (UK-427,857) in Combination With Optimized Background Therapy Versus Optimized Background Therapy Alone for the Treatment of HIV-1 Infected Subjects	maraviroc	A4001028	Infection, Human Immunodeficiency Virus	Phase 2/Phase 3	N/A	http://ClinicalTrials.gov/show/NCT00098722		Y	Y	Y	Y	Y	Y	Y	There is no GSK Study Register entry for this study. An annotated case report form is not available for this study. A blank case report form will be provided. The clinical study report provided includes the body of the report, safety narratives and statistical tables but does not include appendices or patient data listings.	1-Jan-2014
1404	ViiV	Trial of Maraviroc (UK-427,857) in Combination With Optimized Background Therapy Versus Optimized Background Therapy Alone for the Treatment of HIV-1 Infected Subjects	maraviroc	A4001027	Infection, Human Immunodeficiency Virus	Phase 2/Phase 3	N/A	http://ClinicalTrials.gov/show/NCT00098306		Y	Y	Y	Y	Y	Y	Y	There is no GSK Study Register entry for this study. An annotated case report form is not available for this study. A blank case report form will be provided. The clinical study report provided includes the body of the report, safety narratives and statistical tables but does not include appendices or patient data listings.	1-Jan-2014
1405	ViiV	Pharmacokinetics, Pharmacodynamics, And Safety Of Maraviroc (UK-427,857) In Patients With Human Immunodeficiency Virus	maraviroc	A4001007	Infection, Human Immunodeficiency Virus	Phase 2	N/A	http://ClinicalTrials.gov/show/NCT00643643		Y	Y	Y	Y	Y	Y	Y	There is no GSK Study Register entry for this study. An annotated case report form is not available for this study. A blank case report form will be provided. The clinical study report provided includes the body of the report, safety narratives and statistical tables but does not include appendices or patient data listings.	1-Jan-2014
1406	ViiV	Trial of Maraviroc (UK-427,857) in Combination With Zidovudine/Lamivudine Versus Efavirenz in Combination With Zidovudine/Lamivudine	maraviroc	A4001026	Infection, Human Immunodeficiency Virus	Phase 3	https://www.viiv-studyregister.com/study/19675	http://ClinicalTrials.gov/show/NCT00098293		Y	Y	Y	Y	Y	Y	Y	An annotated case report form is not available for this study. A blank case report form will be provided. The clinical study report provided includes the body of the report, safety narratives and statistical tables but does not include appendices or patient data listings.	1-Jan-2014
1415	GSK	A randomized, controlled trial to evaluate the effects of nadroparin on survival and disease progression in patients with advanced malignancies of the lung, pancreas, or prostate	nadroparin calcium	FRX106365	Thrombosis, Venous	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=FRX106365	http://clinicaltrials.gov/show/NCT00312013	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-005336-27	Y	Y	Y	Y	Y	Y	Y		1-Feb-2014
1416	GSK	A Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, 76-Week Study to Evaluate the Efficacy and Safety of Belimumab (HGS1006, LymphoStat-B™), a Fully Human Monoclonal Anti-BLyS Antibody, in Subjects with Systemic Lupus Erythematosus (SLE)	belimumab	HGS1006-C1056	Systemic Lupus Erythematosus	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=HGS1006-C1056	http://clinicaltrials.gov/show/NCT00410384		Y	Y	Y	Y	Y	Y	Y	Follow-on studies BEL112233 and BEL112234 were conducted. This study was not originally sponsored by GSK. The results summary and publications are available on ClinicalTrials.gov. GSK reference study ID: 110751.	1-Feb-2014
1417	GSK	A Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, 52-Wk Study to Evaluate the Efficacy and Safety of Belimumab (HGS1006, LymphoStat-B™), a Fully Human Monoclonal Anti-BLyS Antibody, in Subjects With Systemic Lupus Erythematosus (SLE)	belimumab	HGS1006-C1057	Systemic Lupus Erythematosus	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=HGS1006-C1057	http://clinicaltrials.gov/show/NCT00424476		Y	Y	Y	Y	Y	Y	Y	A follow-on study BEL112234 was conducted. This study was not originally sponsored by GSK. The results summary and publications are available on ClinicalTrials.gov: http://clinicaltrials.gov/show/NCT00424476. GSK reference study ID: 110752.	1-Feb-2014
1418	GSK	Phase III study of immunogenicity and safety of 3 doses of GSK Biologicals' thimerosal-free hepatitis B vaccine compared to the US-licensed GSK Biologicals' preservative-free hepatitis B vaccine when administered intramuscularly on a 0, 1, 6-month schedule to healthy infants in their first two weeks of life	Hepatitis B Vaccine, Recombinant	103860/277	Hepatitis B	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=103860/277			Y	N	Y	Y	Y	Y	Y	An annotated case report form is not available for this study. A blank case report form will be provided. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Sep-2013
1420	GSK	Safety & immunogenicity of a booster dose of dTPa vaccine (Boostrix®) co-admnd. with Aventis Pasteur’s meningococcal (serogroups A, C, Y and W-135) polysaccharide vaccine (Menactra™) vs admn. of either vaccine alone in healthy adolescents	Combined Reduced Antigen Content Diphtheria, Tetanus, Acellular Pertussis Vaccine	105753	Acellular pertussis; Diphtheria; Tetanus	Phase 4	https://www.gsk-studyregister.com/en/trial-details/?id=105753	http://clinicaltrials.gov/show/NCT00282295		Y	N	Y	Y	Y	Y	Y	An annotated case report form is not available for this study. A blank case report form will be provided.	1-Mar-2014
1421	GSK	A phase III, double-blinded, randomized, multicenter, clinical study to assess the safety and immunogenicity of GSK Biologicals' Tdap 0.3 mg candidate vaccine when given as a booster dose to healthy school children and adolescents (9-13 years of age), previously vaccinated with a 5th consecutive dose of acellular pertussis-containing vaccine, in studies APV-118 or APV-120	Combined Reduced Antigen Content Diphtheria, Tetanus, Acellular Pertussis Vaccine	100406	Acellular pertussis; Diphtheria; Tetanus	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=100406/004	http://clinicaltrials.gov/show/NCT00263679		Y	N	Y	Y	Y	Y	Y	An annotated case report form is not available for this study. A blank case report form will be provided.	1-Mar-2015
1422	GSK	Double-blind, randomized, phase III clinical trial to evaluate the immunogenicity and reactogenicity of three consecutive doses of dTpa, or of dTpa-IPV followed by two doses of Td vaccine , and compared to three consecutive doses of Td vaccine administered to healthy adults in a 0,1,6-month schedule	Combined Reduced Antigen Content Diphtheria, Tetanus, Acellular Pertussis Vaccine	263855/034	Acellular pertussis; Diphtheria; Tetanus	Phase 4	https://www.gsk-studyregister.com/en/trial-details/?id=263855/034	http://clinicaltrials.gov/show/NCT01294605		Y	N	Y	Y	Y	Y	Y	An annotated case report form is not available for this study. A blank case report form will be provided.	1-Mar-2014
1423	GSK	Phase IIIb study to evaluate immunogenicity, antibody persistency and reactogenicity of DTPa - INFANRIX and dTpa - BOOSTRIX vaccines administered to healthy children previously primed with 3 doses of DTPa vaccine compared to placebo (HAVRIX®JUNIOR)	Combined Reduced Antigen Content Diphtheria, Tetanus, Acellular Pertussis Vaccine	263855/035	Acellular pertussis; Diphtheria; Tetanus	Phase 4	https://www.gsk-studyregister.com/en/trial-details/?id=263855/035	http://clinicaltrials.gov/show/NCT00544271		Y	N	Y	Y	Y	Y	Y	An annotated case report form is not available for this study. A blank case report form will be provided.	1-Mar-2014
1424	GSK	Open, phase IIIb, multicentric, safety and reactogenicity study of GSK Biologicals’ reduced antigen content combined diphtheria-tetanus-acellular pertussis vaccine administered as a booster dose to healthy children according to the international recommended prescribing information	Combined Reduced Antigen Content Diphtheria, Tetanus, Acellular Pertussis Vaccine	263855/036	Acellular pertussis; Diphtheria; Tetanus	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=263855/036		https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-003888-30	Y	N	Y	Y	Y	Y	Y	An annotated case report form is not available for this study. A blank case report form will be provided. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Mar-2014
1426	GSK	A phase III, open study to evaluate the immunogenicity, safety and reactogenicity of GSK Bios’ dTpa-IPV vaccine when administered as a booster vaccination to healthy children (6-8 Y) and previously vaccinated with 4 doses of DTPw and at least 3 doses of OPV/ IPV vaccines	Combined Reduced Antigen Content Diphtheria, Tetanus, Acellular Pertussis, Inactivated Polio Vaccine	711866/006 (dTpa-IPV-006)	Acellular pertussis; Diphtheria; Poliomyelitis; Tetanus	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=711866/006			Y	N	Y	Y	Y	Y	Y	An annotated case report form is not available for this study. A blank case report form will be provided. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Mar-2014
1427	GSK	A double-blind, placebo-controlled, randomized, parallel group study to investigate the changes in corrected QT interval following repeat oral doses of GI198745 in healthy male subjects	dutasteride	ARI10019	Prostatic Hyperplasia	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=ARI10019			N	Y	Y	Y	Y	Y	N	An analysis-ready dataset and a reporting and analysis plan are not available for this study. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Mar-2014
1429	GSK	An Open-Label, Randomized, Single Dose Three-Period Partial Crossover Study to Determine the Bioequivalence and Food Effect of a Combination Capsule Formulation of Dutasteride and Tamsulosin Hydrochloride (0.5mg/0.4mg) Compared to Concomitant Dosing of AVODART™ 0.5mg and Flomax 0.4mg Commercial Capsules in Healthy Male Subjects	dutasteride	ARI109882	Prostatic Hyperplasia	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=ARI109882	http://clinicaltrials.gov/show/NCT00537654		Y	Y	Y	Y	Y	Y	Y		1-Mar-2014
1430	GSK	An open label, randomized, repeat dose, 3 period crossover study to determine the bioequivalence of 3 different formulations of tamsulosin at steady state in healthy male volunteers	dutasteride	ARI111402	Prostatic Hyperplasia	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=ARI111402	http://clinicaltrials.gov/show/NCT00609596		Y	Y	Y	Y	Y	Y	Y		1-Mar-2014
1433	GSK	A multicentre, randomised, double-blind, double-dummy, parallel group study to compare the efficacy of GI198745 0.5mg Once Daily versus finasteride 5mg Once Daily for 12 months in the treatment of subjects with benign prostatic hyperplasia (BPH). (EPICS)	dutasteride	ARI40001 -Open-Label	Prostatic Hyperplasia	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=ARI40001			N	N	Y	Y	Y	Y	N	This study was conducted in 2 phases - Year 1 and an Open-label Extension. A comprehensive dataset is available within the Open-label Extension. An analysis-ready dataset and a reporting and analysis plan are not available for this study. An annotated case report form is not available for this study. A blank case report form will be provided. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Mar-2014
1434	GSK	A pilot multi-centre, double-blind, parallel group, randomised study to investigate the effect on symptoms 3 months after discontinuing tamsulosin, following 6 months combination treatment with 0.5mg GI198745 and 0.4mg tamsulosin daily in patients with symptomatic Benign Prostatic Hyperplasia (BPH).	dutasteride	ARI40002	Prostatic Hyperplasia	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=ARI40002			N	Y	Y	Y	Y	Y	N	An analysis-ready dataset and a reporting and analysis plan are not available for this study. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Mar-2014
1435	GSK	An Investigation of the Pharmacokinetics of GI198745 and of the Effects of GI198745 on Semen Characteristics When Administered Daily for 12 Months to Healthy Male Subjects	dutasteride	ARIA1009	Prostatic Hyperplasia	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=ARIA1009			N	N	Y	Y	Y	Y	Y	An analysis-ready dataset is not available for this study. An annotated case report form is not available for this study. A blank case report form will be provided. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Mar-2014
1436	GSK	Investiagtion of the Metabolic Fate and Routes of Excretion of GI198745 at Steady State in Healthy Male Subjects	dutasteride	ARIA1012	Prostatic Hyperplasia	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=ARIA1012			N	N	Y	Y	Y	Y	Y	An analysis-ready dataset is not available for this study. An annotated case report form is not available for this study. A blank case report form will be provided. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Mar-2014
1437	GSK	A Randomized, double-blind, placebo-controlled, two year parallel group study of the efficacy and safety of GI198745 0.5 mg in the treatment and prevention of progression of benign prostatic hyperplasia	dutasteride	ARIA3002 (Year 1)	Prostatic Hyperplasia	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=ARIA3002			N	Y	Y	Y	Y	Y	Y	The data relating to this record represents an interim analysis of a 4-year study. A comprehensive dataset is available within ARIA3002 Year 4. An analysis-ready dataset is not available for this study. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Mar-2014
1438	GSK	A randomized, double-blind, placebo-controlled, parallel-group study of the efficacy and safety of GI198745 in the treatment and modification of progression of benign prostatic hyperplasia	dutasteride	ARIB3003 (Year 1)	Prostatic Hyperplasia	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=ARIB3003			N	N	Y	Y	Y	Y	Y	Follow-on analyses ARIB3003 (Year 2) and ARIB3003_4 (Year 4) were conducted. An analysis-ready dataset is not available for this study. An annotated case report form is not available for this study. A blank case report form will be provided. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Mar-2014
1439	GSK	A six-month, randomised, double-blind, placebo-controlled, parallel group study to evaluate the effects of repeat dose oral GI198745 on detrusor pressure and urinary flow in patients with lower urinary tract symptoms suggestive of bladder outlet obstruction, with optional six month open-label extension	dutasteride	ARIB3004 Double-blind Phase	Prostatic Hyperplasia	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=ARIB3004			N	N	Y	Y	Y	Y	Y	This study was conducted in 2 phases - a Double-blind Phase and an Open-label Extension. A comprehensive dataset is available within the Open-Label Extension. An analysis-ready dataset is not available for this study. An annotated case report form is not available for this study. A blank case report form will be provided. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Mar-2014
1440	GSK	A Randomised Double-Blind, Double-Dummy, Placebo-Controlled, Stratified, Parallel-Group, Multicentre, Dose Ranging Study to Evaluate the Efficacy and Safety of GSK2190915 Tablets Administered Once Daily, Fluticasone Propionate Inhalation Powder 100mcg Twice Daily and Montelukast 10mg Once Daily compared with Placebo for 8 Weeks in Adolescent and Adult Subjects with Persistent Asthma while Treated with Short Acting Beta2-agonist.	fiboflapon	LPA112186	Asthma	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=112186	http://clinicaltrials.gov/show/NCT01147744	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-019095-70	Y	Y	Y	Y	Y	Y	Y		1-Mar-2014
1441	GSK	A Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, Five-Treatment, Four 6-Week Period Cross-Over, Multi-Center Study to Evaluate the Effect of Adding GSK2190915 100mg, GSK2190915 300mg, Montelukast 10mg or Placebo Tablets Once Daily or Salmeterol 50mcg Inhalation Powder Twice Daily to Fluticasone Propionate 100mcg Inhalation Powder Twice Daily in Uncontrolled Asthmatic Subjects ≥ 12 Years of Age	fiboflapon	LPA114255	Asthma	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=114255	http://clinicaltrials.gov/show/NCT01156792	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-019466-81	Y	Y	Y	Y	Y	Y	Y		1-Mar-2014
1442	GSK	PD of Hydrofluoroalkane propellant of inhaled fluticasone propionate following administration in pediatric subjects 6-12 months of age with asthma	fluticasone propionate	FAS106533	Asthma	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=FAS106533	http://clinicaltrials.gov/show/NCT00370097		Y	Y	Y	Y	Y	Y	Y		1-Mar-2014
1443	GSK	Dose proportionality of fluticasone propionate from HFA inhalers and effect of propellant on FP pharmacokinetics	fluticasone propionate	FAP10001	Asthma	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=FAP10001			N	Y	Y	Y	Y	Y	N	An analysis-ready dataset and a reporting and analysis plan are not available for this study. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Mar-2014
1444	GSK	A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled 12-Week Trial of Inhaled Fluticasone Propionate 88mcg BID, 220mcg BID, and 440mcg BID versus Placebo in Propellant GR106642X in Adolescent and Adult Subjects with Asthma who are Maintained on Inhaled Corticosteroid Therapy	fluticasone propionate	FAP30007	Asthma	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=FAP30007			N	Y	Y	Y	Y	Y	Y	An analysis-ready dataset is not available for this study. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Mar-2014
1445	GSK	A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled 12-Week Trial of Inhaled Fluticasone Propionate 88mcg BID, 220mcg BID, and 440mcg BID versus Placebo in Propellant GR106642X in Adolescent and Adult Subjects with Asthma who are Maintained on Bronchodilator Therapy	fluticasone propionate	FAP30008	Asthma	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=FAP30008			N	Y	Y	Y	Y	Y	Y	An analysis-ready dataset is not available for this study. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Mar-2014
1446	GSK	A Randomized, Double-Blind, Paralled-Group, Placebo-Controlled 12 Week Trial of Inhaled Fluticasone Propionate 88mcg Twice Daily versus Placebo in Propellant GR106642X in Pediatric Subjects 4 to 11 years of age with Asthma	fluticasone propionate	FAP30010	Asthma	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=FAP30010			N	Y	Y	Y	Y	Y	Y	An analysis-ready dataset is not available for this study. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Mar-2014
1447	GSK	A multicentre, randomised, double-blind, parallel group placebo-controlled study to determine the efficacy and safety of fluticasone propionate 200mcg/day delivered via the Babyhaler in paediatric subjects aged 12 to 47 months with recurrent/persistent asthma like symptoms.	fluticasone propionate	FAS30007	Asthma	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=FAS30007			N	Y	Y	Y	Y	Y	Y	An analysis-ready dataset is not available for this study. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Mar-2014
1448	GSK	A multicentre, randomised, parallel-group open label study to assess the long term safety of fluticasone propionate 100mcg bd via the MDI and babyhaler spacer device, compared with sodium cromoglycate 5mg QDS in children aged 12-47months with documented evidence of recurrent/persistent asthma-like symptoms.	fluticasone propionate	FAS30009	Asthma	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=FAS30009			N	Y	Y	Y	Y	Y	Y	An analysis-ready dataset is not available for this study. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Mar-2014
1449	GSK	A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, 12-Week Safety and Efficacy Study of Fluticasone Propionate 88mcg BID Versus Placebo BID delivered via HFA MDI and a valved holding chamber with facemask in Pediatric Subjects with Asthma age 12 months to 47 months.	fluticasone propionate	FAS30030	Asthma	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=FAS30030			Y	Y	Y	Y	Y	Y	Y	A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Mar-2014
1450	GSK	A randomised, open label, 4-way cross-over study to assess the relative systemic pharmacokinetics and absolute bioavailability of single inhaled and intravenous doses of fluticasone propionate and mometasone furoate in healthy subjects	fluticasone propionate	FMS10026	Asthma	Phase 4	https://www.gsk-studyregister.com/en/trial-details/?id=FMS10026			N	Y	Y	Y	Y	Y	Y	An analysis-ready dataset is not available for this study. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Mar-2014
1452	GSK	A study to compare PK of a single doe of fluticasone propionate in healthy male Japanse and Caucasian subjects	fluticasone propionate	FMS10032	Asthma	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=FMS10032			N	Y	Y	Y	Y	Y	Y	An analysis-ready dataset is not available for this study. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Mar-2014
1453	GSK	A randomised, single-blind, placebo-controlled study with 5-way cross-over design to investigate the systemic pharmacokinetics and pharmacodynamics of single inhaled doses (800mcg and 1600mcg) of Fluticasone Propionate and Mometasone Furoate in healthy subjects.	fluticasone propionate	FMS10033	Asthma	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=FMS10033			Y	Y	Y	Y	Y	Y	Y	A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Mar-2014
1454	GSK	A multicenter, randomized, double-blind, parallel group, placebo-controlled, 12 week study of Fluticasone Propionate 44mcg BID and 88mcg BID delivered via CFC MDI and a valved holding chamber with facemask in subjects with asthma age 24 months to 47 months	fluticasone propionate	FMS30058	Asthma	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=FMS30058			N	Y	Y	Y	Y	Y	Y	An analysis-ready dataset is not available for this study. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Mar-2014
1455	GSK	A multicenter, randomized, double-blind, parallel group, placebo-controlled, 12 week study of Fluticasone Propionate 44mcg BID and 88mcg BID delivered via CFC MDI and a valved holding chamber with facemask in subjects with asthma age 6 months to 2 years	fluticasone propionate	FMS30059	Asthma	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=FMS30059			N	Y	Y	Y	Y	Y	Y	An analysis-ready dataset is not available for this study. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Mar-2014
1456	GSK	A randomised, double-blind, double-dummy, parallel group, multicentre study to compare the effect on growth measured by stadiometry of fluticasone propionate (100µg bd) administered via DISKUS™ with budesonide (200µg bd) administered via Turbuhaler in prepubescent children.	fluticasone propionate	FMS40001	Asthma	Phase 4	https://www.gsk-studyregister.com/en/trial-details/?id=FMS40001			N	Y	Y	Y	Y	Y	Y	An analysis-ready dataset is not available for this study. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Mar-2014
1457	GSK	An open study to investigate the nasal bioavailability of intra-nasally administered fluticasone propionate administered as a solution formulation, HFA nasal MDI formulation and as the aqueous nasal spray during charcoal block in healthy subjects.	fluticasone propionate	FNM10003	Rhinitis	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=FNM10003			N	Y	Y	Y	Y	Y	Y	An analysis-ready dataset is not available for this study. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Mar-2014
1458	GSK	An open, three-period, balanced, incomplete block crossover study in healthy subjects to investigate the effect of 7 days co-administration of fluticasone propionate aqueous nasal spray (FPANS) with ritonavir, ketoconazole, or erythromycin on serum cortisol levels	fluticasone propionate	FNM10004	Rhinitis	Phase 4	https://www.gsk-studyregister.com/en/trial-details/?id=FNM10004			N	Y	Y	Y	Y	Y	N	An Analysis-ready dataset and a reporting and analysis plan are not available for this study. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Mar-2014
1459	GSK	A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess the Efficacy of a Four-week Course of Fluticasone Propionate Aqueous Nasal Spray (200mcg QD) on Ocular Systems Commonly Associated with Allergic Rhinitis	fluticasone propionate	FNM30033	Rhinitis, Allergic, Perennial	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=FNM30033			N	Y	Y	Y	Y	Y	Y	An analysis-ready dataset is not available for this study. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Mar-2014
1460	GSK	A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess the Efficacy of a Four-Week Course of Fluticasone Propionate Aqueous Nasal Spray (200mcg QD) on Ocular Symptoms Commonly Associated with Allergic Rhinitis	fluticasone propionate	FNM30034	Rhinitis, Allergic, Perennial	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=FNM30034			N	Y	Y	Y	Y	Y	Y	An analysis-ready dataset is not available for this study. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Mar-2014
1461	GSK	A Multi-Center, Randomized, Double-Blind, Parallel Gruop Study to Assess the Potential Growth Effects of a One-year Course of Fluticasone Propionate Aqueous Nasal Spray (200mcg QD) versus Placebo in Pre-pubescent, Pediatric Subjects with Perennial Allergic Rhinitis	fluticasone propionate	FNM40017	Rhinitis, Allergic, Perennial	Phase 4	https://www.gsk-studyregister.com/en/trial-details/?id=FNM40017			N	Y	Y	Y	Y	Y	Y	An analysis-ready dataset is not available for this study. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Mar-2014
1462	GSK	A Multicenter, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Two-Week Study Assessing the Efficacy of Fluticasone Propionate Aqueous Nasal Spray 200mcg every day Versus Montelukast 10mg every day in Subjects ≥15 Years Old with Seasonal Allergic Rhinitis (SAR)	fluticasone propionate	FNM40194	Rhinitis, Allergic, Seasonal	Phase 4	https://www.gsk-studyregister.com/en/trial-details/?id=FNM40194			N	N	Y	Y	Y	Y	N	An analysis-ready dataset and a reporting and analysis plan are not available for this study. An annotated case report form is not available for this study. A blank case report form will be provided. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Mar-2014
1463	GSK	A Multicenter, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Two-Week Study Assessing the Efficacy of Fluticasone Propionate Aqueous Nasal Spray 200mcg every day Versus Montelukast 10mg every day in Subjects ≥15 Years Old with Seasonal Allergic Rhinitis (SAR)	fluticasone propionate	FNM40195	Rhinitis, Allergic, Seasonal	Phase 4	https://www.gsk-studyregister.com/en/trial-details/?id=FNM40195			N	N	Y	Y	Y	Y	Y	An analysis-ready dataset is not available for this study. An annotated case report form is not available for this study. A blank case report form will be provided. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Mar-2014
1464	GSK	A single centre, randomised, double blind, parallel group study to determine the efficacy and tolerability of Fluticasone propionate nasal drops (Nasules) 400mcg bd, 400mcg od and placebo nasal drops in adult patients with bilateral polyposis.	fluticasone propionate	FNP40010	Polyps, Nasal	Phase 4	https://www.gsk-studyregister.com/en/trial-details/?id=FNP40010			N	Y	Y	Y	N	Y	Y	An analysis-ready dataset and a protocol are not available for this study. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Mar-2014
1465	GSK	A Randomized, Double-Blind, Parallel Group Trial Assessing the Efficacy and Safety of Fluticasone Propionate Inhalation Powder (250mcg QD) and Placebo in Subjects at Least 12 Years of Age with Chronic Asthma Currently Receiving Short Acting Beta Agonist Alone	fluticasone propionate	FPD40009	Asthma	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=FPD40009			N	Y	Y	Y	Y	Y	Y	An analysis-ready dataset is not available for this study. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Mar-2014
1466	GSK	A Randomized, Double-Blind, Parallel Group Trial Assessing the Efficacy and Safety of Fluticasone Propionate Inhalation Powder (250mcg QD) and Placebo in Subjects at Least 12 Years of Age with Chronic Asthma Currently Treated with Inhaled Corticosteroids	fluticasone propionate	FPD40010	Asthma	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=FPD40010			N	Y	Y	Y	Y	Y	Y	An analysis-ready dataset is not available for this study. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Mar-2014
1467	GSK	A Randomized, Double-Blind, Double-Dummy, Parallel Group Comparison of Fluticasone Propionate Inhalation Powder (50mcg BID) with Oral Montelukast (5mg QD) in Children 6-12 Years of Age with Persistant Asthma	fluticasone propionate	FPD40012	Asthma	Phase 4	https://www.gsk-studyregister.com/en/trial-details/?id=FPD40012			N	N	Y	Y	Y	Y	Y	An analysis-ready dataset is not available for this study. An annotated case report form is not available for this study. A blank case report form will be provided. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Mar-2014
1468	GSK	A Randomized, Double-Blind, Double-Dummy, Parallel Group Comparison of Fluticasone Proprionate Inhalation Powder (50mcg BID) with Oral Montelukast (5mg QD) in Children 6-12 with Persistant Asthma	fluticasone propionate	FPD40013	Asthma	Phase 4	https://www.gsk-studyregister.com/en/trial-details/?id=FPD40013			N	N	Y	Y	Y	Y	Y	An analysis-ready dataset is not available for this study. An annotated case report form is not available for this study. A blank case report form will be provided. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Mar-2014
1469	GSK	A Randomized, Double-Blind 12-Week Comparative Trial of Fluticasone Propionate DISKUS 100mcg BID Versus Fluticasone Propionate DISKUS 100mcg BID And Oral Montelukast 10mg QD In Adults With Persistent Asthma.	fluticasone propionate	FPD40014	Asthma	Phase 4	https://www.gsk-studyregister.com/en/trial-details/?id=FPD40014			Y	Y	Y	Y	Y	Y	Y	A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Mar-2014
1470	GSK	A Randomized, Open-Label, Cross Over Trial, Assessing Ease of Use, Correctness of Use and Patient Preference of Fluticasone Propionate Inhalation Powder (100mcg BID) via the Diskus versus Fluticasone Propionate Aerosol via the Metered Dose Inhaler (88mcg BID) in Subjects at Least 12 Years of Age with Persistent Asthma Currently Receiving Short Acting Beta Agonists Alone	fluticasone propionate	FPD40015	Asthma	Phase 4	https://www.gsk-studyregister.com/en/trial-details/?id=FPD40015			N	N	Y	Y	Y	Y	N	An analysis-ready dataset and a reporting and analysis plan are not available for this study. An annotated case report form is not available for this study. A blank case report form will be provided. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Mar-2014
1471	GSK	A Randomized, Open-Label, Cross Over Trial, Assessing Ease of use, Correctness of use and Patient Preference of Fluticasone Propionate Inhalation Powder (100mcg BID) via the DISKUS™ versus Fluticasone Propionate Aerosol via the Metered Dose Inhaler (88mcg BID) in Subjects at Least 12 Years of Age with Persistent Asthma Currently Receiving Short Acting Beta Agonists Alone.	fluticasone propionate	FPD40016	Asthma	Phase 4	https://www.gsk-studyregister.com/en/trial-details/?id=FPD40016			N	Y	Y	Y	Y	Y	Y	An analysis-ready dataset is not available for this study. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Mar-2014
1472	GSK	A randomised, double-blind, placebo-controlled, incomplete block, 4-period crossover, study to investigate the effects of 5-day repeat inhaled doses of fluticasone propionate (BID, 50-2000 mcg) on airway responsiveness to adenosine 5-monophosphate (AMP) challenge when delivered after the last dose in mild asthmatic subjects.	fluticasone propionate	SIG103337	Asthma	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=SIG103337	http://clinicaltrials.gov/show/NCT00400855		Y	Y	Y	Y	Y	Y	Y		1-Mar-2014
1473	GSK	An exploratory study to evaluate the response of salmeterol plus fluticasone propionate vs fluticasone propionate alone to experimental nasal inoculation with rhinovirus	fluticasone propionate/salmeterol	HZA109895	Asthma	Phase 4	https://www.gsk-studyregister.com/en/trial-details/?id=HZA109895	http://clinicaltrials.gov/show/NCT00503009		Y	N	Y	Y	Y	Y	Y	An annotated case report form is not available for this study. A blank case report form will be provided.	1-Mar-2014
1474	GSK	A 12-week, randomised, double-blind, placebo-controlled, three-period, cross-over pilot study comparing the effect of salmeterol/fluticasone propionate, fluticasone propionate and placebo on perpheral blood eosinophils and serum IL-5 in response to allergen challenge in asthma subjects when allergen challenge is administered at 1 hour or 11-12 hours post-dose of the dosing interval	fluticasone propionate/salmeterol	HZA109912	Asthma	Phase 4	https://www.gsk-studyregister.com/en/trial-details/?id=HZA109912	http://clinicaltrials.gov/show/NCT00517634	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001345-18	Y	Y	Y	Y	Y	Y	Y		1-Mar-2014
1475	GSK	A Multicentre, stratified, randomised, double-blind, parallel-group, step-up comparison of the level of asthma control achieved with salmeterol/fluticasone propionate combination diskus (Accuhaler) dry powder inhaler compared with fluticasone propionate Diskus alone in adults and adolescents.	fluticasone propionate/salmeterol	SAM40027	Asthma	Phase 4	https://www.gsk-studyregister.com/en/trial-details/?id=SAM40027			N	Y	Y	Y	Y	Y	Y	An analysis-ready dataset is not available for this study. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Mar-2014
1476	GSK	A 12-week multicentre, randomised, double-blind, double-dummy, parallel group study to compare the efficacy and tolerability of once daily salmeterol/fluticasone propionate combination (salm/FP) 50/100mcg at night via the DISKUS/ACCUHALER with once daily budesonide (BUD) 400mcg at night via a breath-actuated dry powder inhaler (BADPI) as initial maintenance therapy in mild-to-moderate asthmatic subjects	fluticasone propionate/salmeterol	SAM40036	Asthma	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=SAM40036			N	Y	Y	Y	Y	Y	Y	An analysis-ready dataset is not available for this study. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Mar-2014
1477	GSK	A 24-week, randomsed, double dummy, double blind, parallel group study to compare the occurence of exacerbations between Seretide Diskus 50/250 bd and Symbicort BADPI (Turbuhaler) 4.5/160 two inhalations bd in subjects with moderate to severe asthma	fluticasone propionate/salmeterol	SAM40040	Asthma	Phase 4	https://www.gsk-studyregister.com/en/trial-details/?id=SAM40040			N	Y	Y	Y	Y	Y	Y	An analysis-ready dataset is not available for this study. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Mar-2014
1478	GSK	A double-blind, double-dummy, randomised, cross-over study to compare the bronchodilating action of Seretide Accuhaler 50/100mcg and Symbicort breath-actuated dry powder inhaler 6/200mcg in subjects with asthma after a single dose before and after 4 weeks of treatment	fluticasone propionate/salmeterol	SAM40042	Asthma	Phase 4	https://www.gsk-studyregister.com/en/trial-details/?id=SAM40042			N	Y	Y	Y	Y	Y	Y	An analysis-ready dataset is not available for this study. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Mar-2014
1479	GSK	A double-blind, randomised, parallel group study to evaluate the safety and tolerability of administering two inhalations twice daily of the salmeterol/fluticasone propionate combination (SERETIDE) in subjects with asthma over two weeks.	fluticasone propionate/salmeterol	SAM40058	Asthma	Phase 4	https://www.gsk-studyregister.com/en/trial-details/?id=SAM40058			N	Y	Y	Y	Y	Y	Y	An analysis-ready dataset is not available for this study. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Mar-2014
1480	GSK	A Muticenter, Randomized, Double-Blind, Double-Dummy, Placebo Controlled, Parallel Group, Four-Week Study Assessing the Efficacy of Fluticasone Propionate Aqueous Nasal Spray 200mcg every day versus Montelukast 10mg every day in Adolescent and Adult subjects with Asthma and Seasonal allergic rhinitis who are Receiving Concurrent Open-Label Advair Diskus 100/50mcg twice daily	fluticasone propionate/salmeterol	SAM40066	Asthma	Phase 4	https://www.gsk-studyregister.com/en/trial-details/?id=SAM40066			N	Y	Y	Y	Y	Y	Y	An analysis-ready dataset is not available for this study. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Mar-2014
1481	GSK	A study to compare the systemic pharmacodynamic effects and pharmacokinetics of SERETIDE DISKUS/ACCUHALER Inhaler (200/1000mcg) with salmeterol alone (200mcg) and fluticasone propionate alone (1000mcg) in healthy Japanese subjects	fluticasone propionate/salmeterol	SAS10014	Asthma	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=SAS10014			N	Y	Y	Y	Y	Y	Y	An analysis-ready dataset is not available for this study. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Mar-2014
1482	GSK	A randomised, double-blind, double-dummy, cross-over comparison of the salmeterol/fluticasone propionate combination product (50/250mg strength) twice daily via one Diskus inhaler with salmeterol 50mg twice daily via one Diskus inhaler plus fluticasone propionate 250mg twice daily via a second Diskus inhaler in Japanese and Caucasian asthmatics	fluticasone propionate/salmeterol	SAS10015	Asthma	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=SAS10015			N	Y	Y	Y	Y	Y	Y	An analysis-ready dataset is not available for this study. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Mar-2014
1483	GSK	A Randomized, Double-Blind, Active-Controlled, Parallel-Group 12-Week Trial Evaluating the Safety and Efficacy of the 50/100mcg Salmeterol/Fluticasone Propionate DISKUS Combination Product twice daily Compared with Salmeterol 50mcg via DISKUS twice daily and Fluticasone Propionate 100mcg via DISKUS twice daily in Adult and Adolescent Subjects with Asthma on Short-Acting Beta2-Agonist Therapy	fluticasone propionate/salmeterol	SAS30017	Asthma	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=SAS30017			N	Y	Y	Y	Y	Y	Y	An analysis-ready dataset is not available for this study. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Mar-2014
1484	GSK	A multicentre, randomised, double-blind, double-dummy, parallel group study to compare salmeterol/fluticasone propionate combination 50/100mcg twice daily delivered via dry powder inhaler (Diskus/Accuhaler) or non-chlorofluorocarbon metered-dose inhaler in the treatment of children with asthma aged 4-11 years.	fluticasone propionate/salmeterol	SAS30019	Asthma	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=SAS30019			N	Y	Y	Y	Y	Y	N	An Analysis-ready dataset and a reporting and analysis plan are not available for this study. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Mar-2014
1485	GSK	A randomized, double-blind, placebo-controlled, parallel-group, 12 week trial evaluating the safety and efficacy of the fluticasone propionate/salmeterol DISKUS combination product 250/50mcg once daily versus fluticasone propionate 250mcg once daily versus fluticasone propionate/salmeterol 100/50mcg twice daily versus placebo in symptomatic adolescent and adult subjects with asthma that is not controlled on short acting beta agonist therapy	fluticasone propionate/salmeterol	SAS30022	Asthma	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=SAS30022			N	Y	Y	Y	Y	Y	Y	An analysis-ready dataset is not available for this study. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Mar-2014
1486	GSK	A 12-week multicentre, randomised, double-blind, placebo-controlled parallel group study to compare the efficacy and tolerability of fluticasone propionate/salmeterol combination (SERETIDE/VIANI/ADVAIR) 88/42mcg once daily in the morning with fluticasone propionate 88mcg once daily in the morning and placebo (short-acting ß2-agonist as required only) once daily in the morning, all via the HFA MDI as initial maintenance therapy in mild asthmatic subjects	fluticasone propionate/salmeterol	SAS30023	Asthma	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=SAS30023			N	Y	Y	Y	Y	Y	Y	An analysis-ready dataset is not available for this study. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Mar-2014
1487	GSK	A Randomized, Double-Blind, 12-Week Trial Evaluating the Safety of the Fluticasone Propionate/Salmeterol DISKUS Combination Product 100/50mcg twice daily Versus Fluticasone Propionate DISKUS 100mcg twice daily in Symptomatic Pediatric Subjects (4-11 Years) With Asthma	fluticasone propionate/salmeterol	SAS30031	Asthma	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=SAS30031			N	Y	Y	Y	Y	Y	N	An analysis-ready dataset and a reporting and analysis plan are not available for this study. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Mar-2014
1488	GSK	An Open-Label, Multi-Center Study to Evaluate the Performance and Patient Satisfaction of Fluticasone Propionate/Salmeterol HFA with Counter in Asthma or COPD Subjects at Least 12 Years of Age	fluticasone propionate/salmeterol	SAS30033	Asthma	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=SAS30033			N	Y	Y	Y	Y	Y	Y	An analysis-ready dataset is not available for this study. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Mar-2014
1490	GSK	A 12-week, multi-centre, randomised, double-blind, parallel-group study to compare the efficacy and tolerability of salmeterol/fluticasone propionate combination (SERETIDE™/VIANI™/ADVAIR™) 50/250μg twice-daily with fluticasone propionate 250μg twice-daily, all via the DISKUS®/ACCUHALER® as initial maintenance therapy in moderate persistent asthma.	fluticasone propionate/salmeterol	SAS30039	Asthma	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=SAS30039			N	Y	Y	Y	Y	Y	Y	An analysis-ready dataset is not available for this study. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Mar-2014
1491	GSK	A 12-week, randomised, double-blind, parallel-group study to compare the efficacy and tolerability ofsalmeterol/fluticasone propionate combination 50/100mcg twice daily with fluticasone propionate 250mcg twice daily, all via theDISKUS™/ACCUHALER™ on maintaining asthma control in moderate persistent asthmatic subjects whose symptomshave been well-controlled following an initial maintenance therapy with salmeterol/fluticasone propionate 50/250mcgcombination twice-daily for 12 weeks	fluticasone propionate/salmeterol	SAS30040	Asthma	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=SAS30040			N	Y	Y	Y	Y	Y	Y	An analysis-ready dataset is not available for this study. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Mar-2014
1492	GSK	A Randomized, Double-Blind, Parallel Group, Comparative Trial of Salmeterol/Fluticasone Propionate Combination Product 50/100mcg twice daily Diskus Versus Fluticasone Propinate 250 mcg twice daily Diskus in Adolescents and Adults With Moderate To Persistent Asthma	fluticasone propionate/salmeterol	SAS40026	Asthma	Phase 4	https://www.gsk-studyregister.com/en/trial-details/?id=SAS40026			N	Y	Y	Y	Y	Y	Y	An analysis-ready dataset is not available for this study. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Mar-2014
1493	GSK	A Randomized, Double-Blind, Parallel Group, Comparative Trial of Salmeterol/Fluticasone Propionate Combination Product 50/100mcg twice daily Diskus Fluticasone Propinate 250 mcg twice daily Diskus In Adolescents and Adults With Moderate to Persistent Asthma	fluticasone propionate/salmeterol	SAS40027	Asthma	Phase 4	https://www.gsk-studyregister.com/en/trial-details/?id=SAS40027			N	Y	Y	Y	Y	Y	Y	An analysis-ready dataset is not available for this study. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Mar-2014
1494	GSK	An Open-Label, 12-Week Study to Evaluate the Effects of a Corticosteroid-Sparing Dose of Salmeterol/Fluticasone Propionate Combination Product 50/100mcg twice daily Via the DISKUS Inhaler on Airway Inflammation, Airway Remodeling, and Bronchial Hyperresponsiveness in Adults with Persistent Asthma	fluticasone propionate/salmeterol	SAS40028	Asthma	Phase 4	https://www.gsk-studyregister.com/en/trial-details/?id=SAS40028			N	Y	Y	Y	Y	Y	Y	An analysis-ready dataset is not available for this study. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Mar-2014
1495	GSK	A multicenter, randomized, double-blind, double-dummy, parallel group, 16-week comparison of asthma control in adolescent and adults receiving either fluticasone propionate/salmeterol Diskus combination product 100/50mcg twice daily, fluticasone propionate Diskus 100mcg twice daily, salmeterol xinafoate 50mcg twice daily, or oral montelukast 10mg every day	fluticasone propionate/salmeterol	SAS40036	Asthma	Phase 4	https://www.gsk-studyregister.com/en/trial-details/?id=SAS40036			N	N	Y	Y	Y	Y	Y	An Analysis-ready dataset is not available for this study. An annotated case report form is not available for this study. A blank case report form will be provided. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Mar-2014
1496	GSK	A multicenter, randomized, double-blind, double-dummy, parallel group, 16-week comparison of asthma control in adolescents and adults receiving either fluticasone propionate/salmeterol Diskus combination product 100/50mcg twice daily, fluticasone propionate Diskus 100mcg twice daily, salmeterol xinafoate 50mcg twice daily, or oral montelukast 10mg every day	fluticasone propionate/salmeterol	SAS40037	Asthma	Phase 4	https://www.gsk-studyregister.com/en/trial-details/?id=SAS40037			N	N	Y	Y	Y	Y	Y	An analysis-ready dataset is not available for this study. An annotated case report form is not available for this study. A blank case report form will be provided. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Mar-2014
1497	GSK	A Randomized, Open Label, Pilot Crossover Trial, Assessing Patient Preference for Efficacy of Advair Diskus 100/50 (Fluticasone Propionate 100mcg and Salmeterol 50mcg Combination Product 100/50mcg twice daily) and Singulair (Montelukast 10mg every day) in Subjects>15 years of Age with Persistent Asthma	fluticasone propionate/salmeterol	SAS40066	Asthma	Phase 4	https://www.gsk-studyregister.com/en/trial-details/?id=SAS40066			N	Y	Y	Y	Y	Y	Y	An analysis-ready dataset is not available for this study. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Mar-2014
1498	GSK	A randomised, double-blind, double dummy, 3 way crossover study evaluating the effects of a combination of Seretide 50/500mcg twice daily plus tiotropium bromide 18mcg once daily compared with the individual agents (tiotropium bromide 18mcg alone and Seretide50/500mcg alone) in the treatment of subjects with COPD	fluticasone propionate/salmeterol	SCO104962	Pulmonary Disease, Chronic Obstructive	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=104962	http://clinicaltrials.gov/show/NCT00325169	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004434-40	Y	Y	Y	Y	Y	Y	Y		1-Mar-2014
1499	GSK	A Randomized, Double-Blind, Double-Dummy, Parallel-Group, Comparative Clinical Trial Evaluating Fluticasone Propionate/Salmeterol 250/50mcg twice daily via DISKUS to Ipratropium Bromide/Albuterol Sulfate (36mcg/206mcg four times a day) Inhalation Aerosol in Subjects with Chronic Obstructive Pulmonary Disease (COPD)	fluticasone propionate/salmeterol	SCO40011	Pulmonary Disease, Chronic Obstructive	Phase 4	https://www.gsk-studyregister.com/en/trial-details/?id=SCO40011			N	Y	Y	Y	Y	Y	Y	An analysis-ready dataset is not available for this study. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Mar-2014
1500	GSK	A Randomized, Double-Blind, Double-Dummy, Parallel-Group, Comparative Clinical Trial Evaluating Fluticasone Propionate/Salmeterol Xinafoate (250/50mcg twice daily via Diskus) to Ipratropium Bromide/Albuterol Sulfate (36mcg/206mcg four times a day) Inhalation Aerosol in Subjects with Chronic Obstructive Pulmondary Disease (COPD)	fluticasone propionate/salmeterol	SCO40012	Pulmonary Disease, Chronic Obstructive	Phase 4	https://www.gsk-studyregister.com/en/trial-details/?id=SCO40012			N	Y	Y	Y	Y	Y	Y	An analysis-ready dataset is not available for this study. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Mar-2014
1501	GSK	A Randomized, Double-Blind, Parallel-Group Trial Evaluating Safety and Efficacy of Salmeterol 50mcg BID and Fluticasone Propionate 100mcg BID Individually and in Combination and Placebo in Subjects with Asthma.	fluticasone propionate/salmeterol	SFCA3002	Asthma	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=SFCA3002			N	Y	Y	Y	Y	Y	Y	An analysis-ready dataset is not available for this study. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Mar-2014
1502	GSK	A Randomized, Double-Blind, Parallel-Group Trial Evaluating Safety and Efficacy of Salmeterol 50mcg BID and Fluticasone Propionate 250mcg BID Individually and in Combination and Placebo in Subjects with Asthma.	fluticasone propionate/salmeterol	SFCA3003	Asthma	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=SFCA3003			N	Y	Y	Y	Y	Y	Y	An analysis-ready dataset is not available for this study. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Mar-2014
1503	GSK	Immunogenicity and Safety Study of GSK Biologicals' Influenza Vaccine GSK2321138A When Administered in Children	Influenza Vaccine (Quadrivalent)	113275	Influenza	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=113275	http://clinicaltrials.gov/show/NCT01196988	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-021032-34	Y	Y	Y	Y	Y	Y	Y		1-Mar-2014
1504	GSK	A dose-range study to assess the safety and immunogenicity of a novel HPV vaccine when administered intramuscularly according to a 3-dose schedule (0,1,6-month) in healthy adult females (18-25 years of age)	Human Papillomavirus Types 16 and 18 Vaccine	102115	Infections, Papillomavirus	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=102115	http://clinicaltrials.gov/show/NCT00231413	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-003766-14	Y	N	Y	Y	Y	Y	Y	Follow-on studies 107918 and 107921 were conducted. The results of this study 102115 are summarised with studies 107918, 107921, 107919 and 108052 on the GSK Study Register. An annotated case report form is not available for this study. A blank case report form will be provided.	1-Mar-2014
1505	GSK	A dose-range study to assess the safety and immunogenicity of a novel HPV vaccine when administered intramuscularly according to a 3-dose schedule (0,1,6-month) in healthy adult females (18-25 years of age)	Human Papillomavirus Types 16 and 18 Vaccine	107919	Infections, Papillomavirus	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=102115	http://clinicaltrials.gov/show/NCT00359619	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-003766-14	Y	N	Y	Y	Y	Y	N	Follow-on studies 107918 and 107921 were conducted. The results of this study are summarised under study 102115 on the GSK Study Register with studies 108052, 107918 and 107921. An annotated case report form is not available for this study. A blank case report form will be provided. A reporting and analysis plan is not available for this study.	1-Mar-2014
1506	GSK	Primary and long-term follow-up study to evaluate the safety and immunogenicity of GlaxoSmithKline Biologicals’ HPV-16/18 L1/AS04 vaccine administered intramuscularly according to a 0, 1, 6 month schedule in healthy female subjects aged 10-14 years.	Hepatitis A Vaccine, Inactivated	104902	Hepatitis A	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=580299/013	http://clinicaltrials.gov/show/NCT00316706	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000518-37	Y	N	Y	Y	Y	Y	Y	The results of studies 104896, 104902, 104904 and 104918 are summarised with study 580299/013 on the GSK Study Register. An annotated case report form is not available for this study. A blank case report form will be provided. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Mar-2014
1507	GSK	Evaluate the immunogenicity & safety of GSK Biologicals’ HPV-16/18 L1/AS04 vaccine administered intramuscularly according to a 0,1,6 mth schedule in healthy female subjects aged 10–14 yrs	Human Papillomavirus Types 16 and 18 Vaccine	104951	Infections, Papillomavirus	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=104951	http://clinicaltrials.gov/show/NCT00290277	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004058-24	Y	Y	Y	Y	Y	Y	Y		1-Mar-2014
1508	GSK	An observer-blind, randomized, controlled study to assess the immunogenicity and safety of GlaxoSmithKline Biologicals' HPV vaccine administered intramuscularly according to a 0, 1, 6 month schedule in healthy male subjects aged 10-18 years	Human Papillomavirus Types 16 and 18 Vaccine	580299/011	Infections, Papillomavirus	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=580299/011	http://clinicaltrials.gov/show/NCT00309166	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-005943-24	Y	N	Y	Y	Y	Y	Y	An annotated case report form is not available for this study. A blank case report form will be provided.	1-Mar-2014
1509	GSK	Phase 3, open, age-stratified study to assess immunogenicity and safety of GSK Biologicals' HPV-16/18 vaccine administered intramuscularly according to 3-dose schedule (0,1,6 months) in healthy female subjects aged 15 - 55 years and long term follow-up	Human Papillomavirus Types 16 and 18 Vaccine	105880	Infections, Papillomavirus	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=103514	http://clinicaltrials.gov/show/NCT00196937		Y	N	Y	Y	Y	Y	Y	This is an extension study to 103514. The results are summarised under study 103514 with studies 105879, 105881 and 105882 on the GSK Study Register. An annotated case report form is not available for this study. A blank case report form will be provided.	1-Mar-2014
1510	GSK	Phase 3, open, age-stratified study to assess immunogenicity and safety of GSK Biologicals' HPV-16/18 vaccine administered intramuscularly according to 3-dose schedule (0,1,6 months) in healthy female subjects aged 15 - 55 years and long term follow-up	Human Papillomavirus Types 16 and 18 Vaccine	105881	Infections, Papillomavirus	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=103514	http://clinicaltrials.gov/show/NCT00196937		Y	N	Y	Y	Y	Y	Y	This is an extension study to 103514. The results are summarised under study 103514 with studies 105879, 105880 and 105882 on the GSK Study Register. An annotated case report form is not available for this study. A blank case report form will be provided.	1-Mar-2014
1511	GSK	Phase 3, open, age-stratified study to assess immunogenicity and safety of GSK Biologicals' HPV-16/18 vaccine administered intramuscularly according to 3-dose schedule (0,1,6 months) in healthy female subjects aged 15 - 55 years and long term follow-up	Human Papillomavirus Types 16 and 18 Vaccine	105926	Infections, Papillomavirus	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=105926	http://clinicaltrials.gov/show/NCT00345878		Y	N	Y	Y	Y	Y	Y	An annotated case report form is not available for this study. A blank case report form will be provided.	1-Mar-2014
1512	GSK	A phase III, double-blind, randomized, controlled study to evaluate immunogenicity and safety of GSK Biologicals’ HPV-16/18 L1 VLP AS04 vaccine, administered intramuscularly (0, 1, 6 month schedule) in healthy females aged 18 – 35 years	Human Papillomavirus Types 16 and 18 Vaccine	106001	Infections, Papillomavirus	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=106001	http://clinicaltrials.gov/show/NCT00306241		Y	N	Y	Y	Y	Y	Y	An annotated case report form is not available for this study. A blank case report form will be provided.	1-Mar-2014
1513	GSK	Phase 3, open, age-stratified study to assess immunogenicity and safety of GSK Biologicals' HPV-16/18 vaccine administered intramuscularly according to 3-dose schedule (0,1,6 months) in healthy female subjects aged 15 - 55 years and long term follow-up	Human Papillomavirus Types 16 and 18 Vaccine	103514	Infections, Papillomavirus	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=103514	http://clinicaltrials.gov/show/NCT00196937	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002083-18	Y	Y	Y	Y	Y	Y	Y	Extension studies 105879, 105880, 105881 and 105882 were conducted. The results are summarised with studies 105879, 105880, 105881 and 105882 on the GSK Study Register.	1-Mar-2014
1514	GSK	Phase IIIb, double-blind, randomized, controlled study to evaluate the immunogenicity and safety of GSK Biologicals’ HPV-16/18 VLP/AS04 vaccine administered intramuscularly at 0, 1, 6 months in healthy Indian female subjects aged 18–35 yrs	Human Papillomavirus Types 16 and 18 Vaccine	104479	Infections, Papillomavirus	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=104479	http://clinicaltrials.gov/show/NCT00344032		Y	N	Y	Y	Y	Y	Y	An annotated case report form is not available for this study. A blank case report form will be provided.	1-Mar-2014
1515	GSK	Assess lot-to-lot consistency of GSK Biologicals' HPV-16/18 L1/AS04 vaccine following manufacturing adjustments administered intramuscularly according to a 0,1,6-mth schedule in healthy female subjects (18-25 y)	Human Papillomavirus Types 16 and 18 Vaccine	104772	Infections, Papillomavirus	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=104772	http://clinicaltrials.gov/show/NCT00250276	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001667-58	Y	Y	Y	Y	Y	Y	Y		1-Mar-2014
1516	GSK	A phase II study to assess the efficacy, immunogenicity and safety of GSK Biologicals' HPV-16/18 L1 VLP AS04 (Cervarix TM) vaccine administered intramuscularly according to a 0, 1, 6 month schedule in healthy Japanese female subjects aged 20 - 25 years.	Human Papillomavirus Types 16 and 18 Vaccine	104798	Infections, Papillomavirus	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=104798	http://clinicaltrials.gov/show/NCT00316693		Y	N	Y	Y	Y	Y	Y	An annotated case report form is not available for this study. A blank case report form will be provided.	1-Mar-2014
1517	GSK	A study to evaluate safety, immunogenicity and efficacy of GSK Biologicals HPV-16/18 L1/AS04 vaccine administered intramuscularly according to a three-dose schedule (0, 1, 6 month) in healthy adult female subjects aged 26 years and above	Human Papillomavirus Types 16 and 18 Vaccine	104820	Infections, Papillomavirus	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=104820	http://clinicaltrials.gov/show/NCT00294047	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002546-20	Y	N	Y	Y	Y	Y	Y	Follow-on studies 109801, 113621, 113618 and 113617 were conducted. An annotated case report form is not available for this study. A blank case report form will be provided.	1-Mar-2014
1518	GSK	Evaluate the safety and immunogenicity of GSK Biologicals’ HPV-16/18 vaccine administered intramuscularly according to a 0,1,6 month schedule in healthy female subjects (10 – 14 years)	Human Papillomavirus Types 16 and 18 Vaccine	104896	Infections, Papillomavirus	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=580299/013	http://clinicaltrials.gov/show/NCT00316706	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000518-37	Y	Y	Y	Y	Y	Y	Y	The results of studies 104896, 104902, 104904 and 104918 are summarised with study 580299/013 on the GSK Study Register.	1-Mar-2014
1519	GSK	Evaluate the safety and immunogenicity of GSK Biologicals’ HPV-16/18 vaccine administered intramuscularly according to a 0,1,6 month schedule in healthy female subjects (10 – 14 years)	Human Papillomavirus Types 16 and 18 Vaccine	104904	Infections, Papillomavirus	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=580299/013	http://clinicaltrials.gov/show/NCT00316706	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000518-37	Y	N	Y	Y	Y	Y	Y	The results of studies 104896, 104902, 104904 and 104918 are summarised with study 580299/013 on the GSK Study Register. An annotated case report form is not available for this study. A blank case report form will be provided. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Mar-2014
1520	GSK	Immunogenicity: 3 consecutive lots of GSK Biologicals’ HPV-16/18 vaccine administered intramuscularly at 0,1,6 month schedule in healthy females aged 10–25 years and demonstrate non-inferiority of candidate HPV vaccine manufactured by modified production process	Human Papillomavirus Types 16 and 18 Vaccine	107476	Infections, Papillomavirus	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=580299/012	http://clinicaltrials.gov/show/NCT00337818	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001173-26	Y	N	Y	Y	Y	Y	Y	This is an extension study of 580299/012. The results are summarised under study 580299/012 (HPV-012) on the GSK Study Register with studies 107477 (M24), 107479 (M36) and 107481 (M48). An annotated case report form is not available for this study. A blank case report form will be provided.	1-Mar-2014
1521	GSK	Immunogenicity: 3 consecutive lots of GSK Biologicals’ HPV-16/18 vaccine administered intramuscularly at 0,1,6 month schedule in healthy females aged 10–25 years and demonstrate non-inferiority of candidate HPV vaccine manufactured by modified production process	Human Papillomavirus Types 16 and 18 Vaccine	107477	Infections, Papillomavirus	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=580299/012	http://clinicaltrials.gov/show/NCT00337818		Y	N	Y	Y	Y	Y	Y	This is an extension study of 580299/012. The results are summarised under study 580299/012 (HPV-012) on the GSK Study Register with studies 107476 (M18), 107479 (M36) and 107481 (M48). An annotated case report form is not available for this study. A blank case report form will be provided.	1-Mar-2014
1522	GSK	Immunogenicity: 3 consecutive lots of GSK Biologicals’ HPV-16/18 vaccine administered intramuscularly at 0,1,6 month schedule in healthy females aged 10–25 years and demonstrate non-inferiority of candidate HPV vaccine manufactured by modified production process	Human Papillomavirus Types 16 and 18 Vaccine	107479	Infections, Papillomavirus	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=580299/012	http://clinicaltrials.gov/show/NCT00337818		Y	N	Y	Y	Y	Y	Y	This is an extension study of 580299/012. The results are summarised under study 580299/012 (HPV-012) on the GSK Study Register with studies 107476 (M18), 107477 (M24) and 107481 (M48). An annotated case report form is not available for this study. A blank case report form will be provided.	1-Mar-2014
1523	GSK	A randomized, open study to evaluate the safety and immunogenicity of GlaxoSmithKline Biologicals’ HPV vaccine Co-administered intramuscularly with Boostrix® and/or Menactra™ in healthy female subjects aged 11–18 years	Human Papillomavirus Types 16 and 18 Vaccine	107682	Infections, Papillomavirus	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=107682	http://clinicaltrials.gov/show/NCT00369824		Y	N	Y	Y	Y	Y	Y	An annotated case report form is not available for this study. A blank case report form will be provided.	1-Mar-2014
1524	GSK	A long-term, follow-up of the immunogenicity and safety of GlaxoSmithKline Biologicals’ novel HPV vaccine in healthy female subjects vaccinated in the primary study	Human Papillomavirus Types 16 and 18 Vaccine	108052	Infections, Papillomavirus	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=102115	http://clinicaltrials.gov/show/NCT00359619	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-003766-14	Y	N	Y	Y	Y	Y	N	Follow-on studies 107918 and 107921 were conducted. The results of this study are summarised under study 102115 on the GSK Study Register with studies 107918, 107919 and 107921. An annotated case report form is not available for this study. A blank case report form will be provided. A reporting and analysis plan is not available for this study.	1-Mar-2014
1525	GSK	Complementary testing to further evaluate the immunogenicity of a GSK Biologicals’ HPV vaccine (580299) in healthy female subjects aged over 26 years enrolled in study 104820.	Human Papillomavirus Types 16 and 18 Vaccine	109801	Infections, Papillomavirus	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=109801	http://clinicaltrials.gov/show/NCT00456807		Y	N	Y	Y	Y	Y	Y	This is a follow-up study to 104820. An annotated case report form is not available for this study. A blank case report form will be provided.	1-Mar-2014
1526	GSK	A multicentre study to evaluate the safety and immunogenicity of GSK Biologicals’ HPV vaccine (GSK1674330A) in healthy female subjects aged 18–25 years.	Human Papillomavirus Types 16 and 18 Vaccine	109836	Infections, Papillomavirus	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=109836	http://clinicaltrials.gov/show/NCT00478621	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000164-24	Y	N	Y	Y	Y	Y	Y	An annotated case report form is not available for this study. A blank case report form will be provided.	1-Mar-2014
1527	GSK	Study of the efficacy of candidate HPV 16/18 VLP vaccine in the prevention of HPV-16 and/or HPV-18 cervical infection in adolescent & young adult women in North America and Brazil vaccinated in primary study 580299/001	Human Papillomavirus Types 16 and 18 Vaccine	580299/007	Infections, Papillomavirus	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=580299/007	http://clinicaltrials.gov/show/NCT00120848		Y	Y	Y	Y	Y	Y	Y	This is a follow-up study to 580299/001. Follow-on studies 109616, 109624 and 109625 were conducted.	1-Mar-2014
1528	GSK	A phase III, double-blind, randomized, controlled, multi-center study to evaluate the efficacy of GlaxoSmithKline Biologicals. HPV-16/18 VLP AS04 vaccine compared to hepatitis A vaccine as control in prevention of persistent HPV-16 or HPV-18 cervical infection and cervical neoplasia, administered intramuscularly according to a 0, 1, 6 month schedule in healthy females 15-25 years of age.	Human Papillomavirus Types 16 and 18 Vaccine	580299/008	Infections, Papillomavirus	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=580299/008	http://clinicaltrials.gov/show/NCT00122681	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001325-14	Y	Y	Y	Y	Y	Y	Y	An extension study 111758 was conducted.	1-Mar-2014
1529	GSK	Immunogenicity: 3 consecutive lots of GSK Biologicals’ HPV-16/18 vaccine administered intramuscularly at 0,1,6 month schedule in healthy females aged 10–25 years and demonstrate non-inferiority of candidate HPV vaccine manufactured by modified production process	Human Papillomavirus Types 16 and 18 Vaccine	580299/012	Infections, Papillomavirus	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=580299/012	http://clinicaltrials.gov/show/NCT00169494	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001173-26	Y	Y	Y	Y	Y	Y	Y	Extension studies 107476, 107477, 107479 and 107481 were conducted. The results are summarised with studies 107476 (M18), 107477 (M24), 107479 (M36) and 107481 (M48) on the GSK Study Register.	1-Mar-2014
1530	GSK	Evaluate the safety and immunogenicity of GSK Biologicals’ HPV-16/18 vaccine administered intramuscularly according to a 0,1,6 month schedule in healthy female subjects (10 – 14 years)	Human Papillomavirus Types 16 and 18 Vaccine	580299/013	Infections, Papillomavirus	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=580299/013	http://clinicaltrials.gov/show/NCT00196924	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000518-37	Y	Y	Y	Y	Y	Y	Y	The results of this study 580299/013 are summarised with studies 104896 (M18), 104902 (M24), 104904 (M36) and 104918 (M48) on the GSK Study Register.	1-Mar-2014
1531	GSK	An open, phase IV study on the immunogenicity and tolerability of Influsplit SSW® 2005/2006 in children aged 6 – 13 years	Influenza Vaccine (Split Virion, Inactivated)	106252	Influenza	Phase 4	https://www.gsk-studyregister.com/en/trial-details/?id=106252	http://clinicaltrials.gov/show/NCT00372255	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004517-14	Y	Y	Y	Y	Y	Y	N	A reporting and analysis plan is not available for this study.	1-Mar-2015
1532	GSK	Phase III study to determine immunogenicity and reactogenicity of investigational influenza vaccine formulation I compared to the standard influenza vaccine of GSK Biologicals’ Influsplit SSW®/Fluarix™2003/2004 and compared to an investigational influenza vaccine formulation II in subjects aged over 18 years	Influenza Vaccine (Split Virion, Inactivated)	100349-054	Influenza	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=100349-054			Y	N	Y	Y	Y	Y	N	An annotated case report form is not available for this study. A blank case report form will be provided. A reporting and analysis plan is not available for this study. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Mar-2015
1533	GSK	A phase III double-blind randomized multicentric study to determine the reactogenicity of an investigational influenza vaccine compared to the standard influenza vaccine of GlaxoSmithKline Biologicals’ Influsplit SSW®/ Fluarix™ 2003/2004 in subjects aged over 18 years.	Influenza Vaccine (Split Virion, Inactivated)	100350-055	Influenza	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=100350-055			Y	N	Y	Y	Y	Y	N	An annotated case report form is not available for this study. A blank case report form will be provided. A reporting and analysis plan is not available for this study. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Mar-2015
1534	GSK	To determine the immunogenicity and reactogenicity of a thiomersal free trivalent influenza split vaccine 2003/2004 or of GSK Biologicals’ standard formulation Influsplit SSW®/Fluarix™ 2003/2004 in children aged from 6 months until 6 years	Influenza Vaccine (Split Virion, Inactivated)	100351	Influenza	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=100351	http://clinicaltrials.gov/show/NCT00731393		Y	Y	Y	Y	Y	Y	Y		1-Mar-2015
1535	GSK	Open immunization study to determine the reactogenicity and immunogenicity of Fluarix™/Influsplit SSW® 2004/2005 in persons as of 18 years of age.	Influenza Vaccine (Split Virion, Inactivated)	102151 (Flu-058)	Influenza	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=102151			Y	N	Y	Y	Y	Y	Y	An annotated case report form is not available for this study. A blank case report form will be provided. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Mar-2015
1536	GSK	A phase III, open, randomized, multicenter, comparative vaccination study to evaluate the immunogenicity and reactogenicity of various formulations of a monovalent candidate pandemic influenza A vaccine in individuals over 60 years of age	Influenza Vaccine (Split Virion, Inactivated)	102499	Influenza	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=102499	http://clinicaltrials.gov/show/NCT00306995		Y	N	Y	Y	Y	Y	N	An annotated case report form is not available for this study. A blank case report form will be provided. A reporting and analysis plan is not available for this study.	1-Aug-2015
1537	GSK	A phase III, observer-blind, randomized study to evaluate the immunogenicity and safety of Fluarix™ (GlaxoSmithKline Biologicals) compared with Fluzone® (Aventis Pasteur) administered intramuscularly in adults 18 years and older in the U.S.	Influenza Vaccine (Split Virion, Inactivated)	104437	Influenza	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=104437	http://clinicaltrials.gov/show/NCT00197288		Y	Y	Y	Y	Y	Y	Y		1-Mar-2014
1538	GSK	A randomized, double-blind, placebo-controlled, post-marketing phase III Study to evaluate the efficacy of GSK Biologicals’ influenza vaccine (Fluarix™) administered intramuscularly in adults.	Influenza Vaccine (Split Virion, Inactivated)	104438	Influenza	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=104438	http://clinicaltrials.gov/show/NCT00197223	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002044-26	Y	Y	Y	Y	Y	Y	Y		1-Mar-2014
1539	GSK	Phase III Vaccination Study for Evaluation of Immunogenicity and Reactogenicity of Influsplit SSW 2004/2005 in People age 18 or beyond	Influenza Vaccine (Split Virion, Inactivated)	104745	Influenza	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=104745	http://clinicaltrials.gov/show/NCT00306943	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001555-38	Y	N	Y	Y	Y	Y	N	An annotated case report form is not available for this study. A blank case report form will be provided. A reporting and analysis plan is not available for this study.	1-Mar-2015
1540	GSK	A phase III, single-blind, randomized study to evaluate the immunogenicity and safety of Fluarix® (GSK Biologicals) compared with Fluzone® (Aventis Pasteur/Sanofi) administered intramuscularly in children (6 months and older)	Influenza Vaccine (Split Virion, Inactivated)	104858	Influenza	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=104858	http://clinicaltrials.gov/show/NCT00383123		Y	Y	Y	Y	Y	Y	Y		1-Mar-2014
1541	GSK	A Phase III study for evaluation of immunogenicity and reactogenicity of Fluarix™ (Influsplit SSW®) 2006/2007 in people aged 18 years or above	Influenza Vaccine (Split Virion, Inactivated)	107507	Influenza	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=107507	http://clinicaltrials.gov/show/NCT00345904	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001918-33	Y	N	Y	Y	Y	Y	N	An annotated case report form is not available for this study. A blank case report form will be provided. A reporting and analysis plan is not available for this study.	1-Mar-2015
1542	GSK	A Randomized, Double-Blind Trial Evaluating the Safety and Immunogenicity of an Influenza Vaccine with reduced Preservative (FluLaval™ TR) and a Standard Influenza Vaccine (Fluarix®) in subjects between 18-60 and Over 60 Years of Age.	Influenza Vaccine (Split Virion, Inactivated, Fluviral)	109249	Influenza	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=IDB-200-001	http://clinicaltrials.gov/show/NCT00380211		Y	N	Y	Y	Y	Y	N	An annotated case report form is not available for this study. A blank case report form will be provided. A reporting and analysis plan is not available for this study.	1-Mar-2014
1545	GSK	Non-inferiority of co-administration of GSK Biologicals’pneumococcal conjugate vaccine GSK1024850A with DTPa-IPV-Hib versus co-administration with DTPa-HBV-IPV/Hib.	Pneumococcal Polysaccharide Conjugate Vaccine (Adsorbed)	111053	Infections, Streptococcal	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=110142	http://clinicaltrials.gov/show/NCT00652951	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004002-26	Y	Y	Y	Y	Y	Y	Y	This is a follow-up study to 110142. The results of this study 111053 are summarised with 110142 on the GSK Study Register.	1-Mar-2014
1546	GSK	Efficacy, immunogenicity and safety of two doses of GlaxoSmithKline (GSK) Biologicals' Oral Live Attenuated Liquid Human Rotavirus (HRV) Vaccine (444563), in healthy infants	Rotavirus Vaccine	113808	Infections, Rotavirus	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=113808	http://clinicaltrials.gov/show/NCT01171963	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-005200-18	Y	Y	Y	Y	Y	Y	Y		1-Mar-2014
1547	GSK	A Four-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel-group, Multi-Center Study of VENTOLIN™ (albuterol) HFA MDI delivered with facemask and two different holding chambers in Subjects aged 24 to <48 months with asthma symptoms (i.e. wheeze, cough, dyspnea or chest tightness) or consistent with asthma or obstructive airway disease or bronchospasm.	salbutamol	SB020001	Asthma	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=SB020001			Y	Y	Y	Y	Y	Y	Y	A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Mar-2014
1548	GSK	A Four-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel-group, Multi-Center Study of VENTOLIN™ HFA MDI delivered TID with facemask and valved holding chamber Aerochamber Plus in subjects birth to <24 months in age with symptoms of bronchospasm (i.e. wheeze, cough, dyspnea or chest tightness) consistent with obstructive airways disease.	salbutamol	SB030001	Asthma	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=SB030001			Y	Y	Y	Y	Y	Y	Y	A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Mar-2014
1549	GSK	A Randomized, Double-Blind, Parallel-group, Multi-Center Study of Albuterol Sulfate HFA Inhalation Aerosol Delivered Cumulatively with a valved holding chamber and an attached facemask in subjects between birth to 23 months of age with acute wheezing due to obstructive airways disease	salbutamol	SB030002	Asthma	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=SB030002	http://clinicaltrials.gov/show/NCT00144846		Y	Y	Y	Y	Y	Y	Y		1-Mar-2014
1550	GSK	An Open-Label, Multi-Center Study to Evaluate the Performance and Patient Satisfaction of Albuterol HFA with Counter in Asthma or COPD Subjects at Least 4 Years of Age.	salbutamol	SB030003	Asthma	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=SB030003			Y	Y	Y	Y	Y	Y	Y	A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Mar-2014
1551	GSK	Phase I study of GSK573719 -A randomized, double blind, placebo controlled, dose ascending, single and repeat dose study to investigate the safety, tolerability, and pharmacokinetics of inhaled dose of GSK573719 from a novel dry powder device in healthy Japanese male subjects	umeclidinium bromide	AC4113377	Pulmonary Disease, Chronic Obstructive	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=113377	http://clinicaltrials.gov/show/NCT01013974		Y	Y	Y	Y	Y	Y	Y		1-Mar-2014
1552	GSK	Randomized, double-blind, 5 period cross over study assessing lung function in healthy volunteers following single inhalations of GSK573719 Inhalation Powder from two configurations of the Novel Dry Powder Inhaler	umeclidinium bromide	AC4115487	Pulmonary Disease, Chronic Obstructive	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=115487	http://clinicaltrials.gov/show/NCT01521390	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002826-28	Y	Y	Y	Y	Y	Y	Y		1-Mar-2015
1553	GSK	Safety, tolerability, pharmacokinetics and pharmacodynamics of the combination of GSK573719 and GW642444 in subjects with COPD	umeclidinium bromide/vilanterol	DB2113120	Pulmonary Disease, Chronic Obstructive	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=113120	http://clinicaltrials.gov/show/NCT01039675		Y	Y	Y	Y	Y	Y	Y		1-Mar-2014
1554	GSK	A single centre, randomised, placebo-controlled, four-way cross over study to assess the safety, tolerability, pharmacodynamics and pharmacokinetics of single inhaled doses of GSK573719 and GW642444 as monotherapies and concurrently in healthy Japanese subjects	umeclidinium bromide/vilanterol	DB2113208	Pulmonary Disease, Chronic Obstructive	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=113208	http://clinicaltrials.gov/show/NCT00976144		Y	Y	Y	Y	Y	Y	Y		1-Mar-2014
1555	GSK	A 24-Week, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of GSK573719/GW642444 Inhalation Powder and the Individual Components Delivered Once-Daily via a Novel Dry Powder Inhaler in Subjects with Chronic Obstructive Pulmonary Disease	umeclidinium bromide/vilanterol	DB2113361	Pulmonary Disease, Chronic Obstructive	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=113361	http://clinicaltrials.gov/show/NCT01313637	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023348-33	Y	Y	Y	Y	Y	Y	Y		1-Mar-2014
1556	GSK	A 24-Week, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of GSK573719/GW642444 Inhalation Powder and the Individual Components Delivered Once-Daily via a Novel Dry Powder Inhaler in Subjects with Chronic Obstructive Pulmonary Disease	umeclidinium bromide/vilanterol	DB2113373	Pulmonary Disease, Chronic Obstructive	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=113373	http://clinicaltrials.gov/show/NCT01313650	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023349-32	Y	Y	Y	Y	Y	Y	Y		1-Mar-2014
1557	GSK	A Single-Centre, Randomised, Open-label Study to Evaluate the Effects of Steady-State Verapamil, a Moderate P-Glycoprotein and CYP3A4 Inhibitor, on the Pharmacokinetics of GSK573719 and GSK573719 in Combination with GW642444	umeclidinium bromide/vilanterol	DB2113950	Pulmonary Disease, Chronic Obstructive	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=113950	http://clinicaltrials.gov/show/NCT01128634	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-018255-10	Y	Y	Y	Y	Y	Y	Y		1-Mar-2014
1609	GSK	Efficacy study of GSK Biologicals’ quadrivalent influenza vaccine, GSK2282512A, (FLU Q-QIV) when administered in children	Influenza Vaccine (Quadrivalent)	114541	Influenza	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=114541	http://clinicaltrials.gov/show/NCT01218308	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-001514-97	Y	Y	Y	Y	Y	Y	Y		1-Apr-2014
1610	GSK	Immunogenicity and Safety Study of GSK Biologicals' Quadrivalent Influenza Vaccine (GSK2282512A) When Administered in Children	Influenza Vaccine (Split Virion, Inactivated)	113314	Influenza	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=113314	http://clinicaltrials.gov/show/NCT01198756	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-021073-36	Y	Y	Y	Y	Y	Y	Y		1-Apr-2014
1611	GSK	Immunogenicity & safety study of GSK Biologicals’ thimerosal-free trivalent influenza vaccine (TIV) versus a licensed comparator in children	Influenza Vaccine (Split Virion, Inactivated, Fluviral)	112999	Influenza	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=112999	http://clinicaltrials.gov/show/NCT00980005		Y	Y	Y	Y	Y	Y	Y		1-Apr-2014
1612	GSK	An adaptive design study for the assessment of the pharmacokinetics of albiglutide in subjects with normal renal function and subjects with moderate-to-severe renal impairment and hemodialysis.	albiglutide	GLP108370	Diabetes Mellitus, Type 2	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=108370	http://clinicaltrials.gov/show/NCT00938158		Y	Y	Y	Y	Y	Y	Y		1-May-2014
1613	GSK	A multicentre, double-blind, placebo-controlled, parallel group study of the efficacy and tolerability of long-term inhaled fluticasone propionate 500mg twice daily via a Volumatic Spacer device in patients with non-asthmatic chronic obstructive pulmonary disease, including…	fluticasone propionate	FLTB3054 (FLIT78) [ISOLDE]	Pulmonary Disease, Chronic Obstructive	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=FLTB3054			Y	Y	Y	Y	Y	Y	Y	A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-May-2014
1617	GSK	A double-blind, placebo-controlled, fixed-dosage study comparing the efficacy and tolerability of paroxetine CR and citalopram to placebo in the treatment of Major Depressive Disorder with anxiety	paroxetine	29060/785	Depressive Disorder, Major	Phase 4	https://www.gsk-studyregister.com/en/trial-details/?id=29060/785			N	N	Y	Y	Y	Y	Y	An analysis-ready dataset is not available for this study. An annotated case report form is not available for this study. A blank case report form will be provided. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-May-2014
1623	GSK	A multicenter, randomized, double-blind, placebo-controlled comparison of paroxetine and fluoxetine in the treatment of major depressive disorder.	paroxetine	MY-1043/BRL-029060/115	Depressive Disorder, Major	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=29060/115			N	N	Y	Y	Y	Y	N	An analysis-ready dataset is not available for this study. An annotated case report form and a reporting and analysis plan are not available for this study. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-May-2014
1632	GSK	A Double-blind, Multicentre Placebo-Controlled Study of Paroxetine in Adolescents with Unipolar Major Depression.	paroxetine	BRL-029060/377	Depressive Disorder, Major	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=29060/377			N	N	Y	Y	Y	Y	Y	An analysis-ready dataset is not available for this study. An annotated case report form is not available for this study. A blank case report form will be provided. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-May-2014
1633	GSK	A Double-Blind, Placebo Controlled Trial to Evaluate the Clinical Effects of Immediate Release Paroxetine and Modified Release Paroxetine in the Treatment of Major Depression	paroxetine	29060/448	Depressive Disorder, Major	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=29060/448			N	N	Y	Y	Y	Y	Y	An analysis-ready dataset is not available for this study. An annotated case report form is not available for this study. A blank case report form will be provided. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-May-2014
1634	GSK	A Double-Blind, Placebo Controlled Trial to Evaluate the Clinical Effects of Immediate Release Paroxetine and Modified Release Paroxetine in the Treatment of Major Depression	paroxetine	29060/449	Depressive Disorder, Major	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=29060/449			N	N	Y	Y	Y	Y	Y	An analysis-ready dataset is not available for this study. An annotated case report form is not available for this study. A blank case report form will be provided. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-May-2014
1637	GSK	A multi-center, double blind, placebo-controlled flexible dose study to evaluate the efficacy and safety of Paroxetine in children with major depression.	paroxetine	BRL-029060/701	Depressive Disorder, Major	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=29060/701			N	N	Y	Y	Y	Y	Y	An extension study BRL-029060/716 was conducted. An analysis-ready dataset is not available for this study. An annotated case report form is not available for this study. A blank case report form will be provided. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-May-2014
1638	GSK	A double-blind, placebo-controlled, 3-arm, fixed-dose study of 12.5 mg/day and 25mg/day Paroxetine CR in the treatment of Major Depression.	paroxetine	29060/810	Depressive Disorder, Major	Phase 4	https://www.gsk-studyregister.com/en/trial-details/?id=29060/810			N	N	Y	Y	Y	Y	N	An analysis-ready dataset is not available for this study. An annotated case report form and a reporting and analysis plan are not available for this study. A blank case report form will be provided. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-May-2014
1639	GSK	Assessment of Paxil CR, 12.5 and 25 mg/day in treating elderly patients with major depression	paroxetine	29060/874	Depressive Disorder, Major	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=29060/874	http://clinicaltrials.gov/show/NCT00067444		N	N	Y	Y	Y	Y	Y	An analysis-ready dataset is not available for this study. An annotated case report form is not available for this study.	1-May-2014
1641	GSK	A multi-center trial comparing the efficacy and safety of GSK573719/GW642444 with GSK573719 and with tiotropium over 24 weeks in subjects with COPD	umeclidinium bromide	DB2113374	Pulmonary Disease, Chronic Obstructive	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=113374	http://clinicaltrials.gov/show/NCT01316913	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-021802-39	Y	Y	Y	Y	Y	Y	Y		1-May-2014
1642	GSK	A multicenter trial comparing the efficacy and safety of GSK573719/GW642444 with GW642444 and with tiotropium over 24 weeks in subjects with COPD	umeclidinium bromide	DB2113360	Pulmonary Disease, Chronic Obstructive	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=113360	http://clinicaltrials.gov/show/NCT01316900	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-021800-72	Y	Y	Y	Y	Y	Y	Y		1-May-2014
1643	GSK	Medical Record Review and Data Abstraction for Pediatric, Adolescent and Pregnant Patients treated with IV zanamivir in the Relenza Compassionate Use Program	zanamivir	NAI115008	Infections, Respiratory Tract	N/A	https://www.gsk-studyregister.com/en/trial-details/?id=115008	http://clinicaltrials.gov/show/NCT01353768		N	Y	Y	Y	Y	Y	Y	The statistical analysis for this study did not create a separate analysis-ready dataset and this is therefore not available.	1-May-2014
1644	ViiV	A Phase II, Open-Label, Randomized Study to Compare the Efficacy and Safety of EPIVIR/ZIAGEN/Zerit (3TC/ABC/d4T) Versus EPIVIR/ZIAGEN/Sustiva (3TC/ABC/EFV) Versus EPIVIR/ZIAGEN/GW433908/Norvir (3TC/ABC/908/RTV) for 96 Weeks in the Treatment of HIV-1 Infected Subjects Who are Antiretroviral Thera ...	fosamprenavir	ESS40001	Infection, Human Immunodeficiency Virus I	Phase 2	https://www.viiv-studyregister.com/study/19793			N	Y	Y	Y	Y	Y	Y	A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies. Due to the age of this study the analysis-ready dataset is not available.	1-Apr-2014
1656	GSK	COPD prevalence estimation in Spanish population.	N/A	107335	Pulmonary Disease, Chronic Obstructive	N/A				N	N	N	Y	N	Y	N	This is an observational study to determine the prevalence of COPD in residents of Spain aged 40 to 80 years. An analysis-ready dataset is not available for this study. The data labels for this study are in Spanish. The supporting documents are not in English and will not be provided. There is no GSK Study Register entry for this study because the study was conducted before GSK policy requirements to register observational studies. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Jun-2014
1657	GSK	A single-blinded randomized, placebo-controlled, staggered-parallel, escalating-dose study to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of subcutaneous injections of GSK 716155 in Subjects with type 2 Diabetes Mellitus	albiglutide	GLP106073	Diabetes Mellitus, Type 2	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=GLP106073	http://clinicaltrials.gov/show/NCT00354536		Y	Y	Y	Y	Y	Y	Y		1-Jun-2014
1658	GSK	A Single-Blind, Randomized, Placebo-Controlled Study in Healthy Men and Women to Determine the Effect of Single Subcutaneous Injections of GSK716155 on Gastric Emptying Time for Solid and Liquid Components of a Meal	albiglutide	GLP107030	Diabetes Mellitus, Type 2	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=GLP107030	http://clinicaltrials.gov/show/NCT00537719		Y	Y	Y	Y	Y	Y	Y		1-Jun-2014
1659	GSK	A double-blinded, randomized, placebo-controlled, staggered-parallel, escalating dose study to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of subcutaneous injections of GSK 716155 in healthy volunteers.	albiglutide	GLP105229	Diabetes Mellitus, Type 2	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=105229			Y	Y	Y	Y	Y	Y	Y	A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Jun-2014
1660	GSK	An open-label study to evaluate the pharmacokinetics of an oral contraceptive containing Norethindrone and Ethinyl Estradiol when co-administered with GSK716155 in healthy adult female subjects	albiglutide	GLP107032	Diabetes Mellitus, Type 2	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=107032	http://clinicaltrials.gov/show/NCT01077505		Y	Y	Y	Y	Y	Y	Y		1-Jun-2014
1661	GSK	A Randomized, Double-blind, Parallel, Nested Crossover Study to Investigate the Effect of Albiglutide on Cardiac Repolarization (corrected QT Interval) Compared With Placebo in Healthy Male and Female Subjects: A Thorough ECG Study Employing Placebo, Albiglutide, and a Positive Control (Moxifloxacin)	albiglutide	GLP107085	Diabetes Mellitus, Type 2	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=107085	http://clinicaltrials.gov/show/NCT01406262		Y	Y	Y	Y	Y	Y	Y		1-Jun-2014
1662	GSK	An Open-label, Sequential Study to Evaluate the Pharmacokinetics of Digoxin When Coadministered With Albiglutide in Healthy Adult Subjects	albiglutide	GLP111680	Diabetes Mellitus, Type 2	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=111680	http://clinicaltrials.gov/show/NCT01147718		Y	Y	Y	Y	Y	Y	Y		1-Jun-2014
1663	GSK	An Open-label, Sequential Study to Evaluate the Pharmacokinetics of Warfarin When Coadministered With Albiglutide in Healthy Adult Subjects	albiglutide	GLP111681	Diabetes Mellitus, Type 2	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=111681	http://clinicaltrials.gov/show/NCT01147731		Y	Y	Y	Y	Y	Y	Y		1-Jun-2014
1664	GSK	A Randomized, Open-Label, Parallel-Group, Multicenter Study to Determine the Efficacy and Safety of Albiglutide as Compared With Liraglutide in Subjects With Type 2 Diabetes Mellitus	albiglutide	GLP114179	Diabetes Mellitus, Type 2	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=114179	http://clinicaltrials.gov/show/NCT01128894	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-019690-15	Y	Y	Y	Y	Y	Y	Y	This study is available in CDISC format	1-Jun-2014
1665	GSK	An Open-Label, Randomized, Multi-Site Study to Assess the Pharmacokinetics of Single Subcutaneous Injections of 16mg and 64mg of GSK716155 Administered at Three Different Injection Sites in Adult Male and Female Subjects with Type 2 Diabetes and of Single Subcutaneous Injections of 16mg and 64mg of GSK716155 Administered in the Abdomen of Healthy, Normal Volunteers	albiglutide	GLP107724	Diabetes Mellitus, Type 2	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=GLP107724	http://clinicaltrials.gov/show/NCT00394030		Y	Y	Y	Y	Y	Y	Y		1-Jun-2014
1666	GSK	The Effect of Antimicrobial Therapy for Otitis Media on Pneumococcal Carriage and Antibiotic Resistance	amoxicillin/clavulanic acid	25000/541	Otitis Media	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=25000/541			N	N	Y	Y	Y	Y	N	An analysis-ready dataset, an annotated case report form, and a reporting and analysis plan are not available for this study. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Jun-2014
1667	GSK	An Open, Non-Comparative Multicenter Study to Assess the Efficacy and Safety of Oral Augmentin SR 2000/125 mg Twice Daily for 7 days for the Treatment of Bacterial Community-Acquired Pneumonia in adults.	amoxicillin/clavulanic acid	25000/547	Pneumonia, Community-Acquired	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=25000/547			N	Y	Y	Y	Y	Y	Y	An analysis-ready dataset is not available for this study. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Jun-2014
1668	GSK	Evaluating the Impact of Amoxicillin/Clavulanate Potassium Therapy on Carriage of Susceptible and Resistant Streptococcus pneumoniae.	amoxicillin/clavulanic acid	25000/555	Streptococcus pneumoniae	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=25000/555			N	N	Y	Y	Y	Y	N	An analysis-ready dataset, an annotated case report form, and a reporting and analysis plan are not available for this study. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Jun-2014
1669	GSK	A Study to Determine the Bioequivalence of Reformulated Augmentin Suspension (improved stability) to Standard Marketed Suspension.	amoxicillin/clavulanic acid	25000/601	Infections, Bacterial	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=25000/601			N	N	Y	Y	Y	Y	N	An analysis-ready dataset, an annotated case report form, and reporting and analysis plan are not available for this study. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Jun-2014
1670	GSK	A Randomized, Investigator-Blind, Multicenter Study to Assess the Efficacy of Oral AUGMENTIN ES-600 Twice Daily for 10 Days Versus Oral Zithromax Once Daily for 5 Days in the Treatment of Acute Otitis Media in Infants and Children.	amoxicillin/clavulanic acid	25000/611	Otitis Media	Phase 4	https://www.gsk-studyregister.com/en/trial-details/?id=25000/611			N	N	Y	Y	Y	Y	N	An analysis-ready dataset, an annotated case report form, and a reporting and analysis plan are not available for this study. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Jun-2014
1671	GSK	A Randomised, Double-Blind, Double-Dummy, Multicentre, Parallel Group Study to Assess the Efficacy and Safety of Oral Augmentin SR 2000/125mg Twice Daily Versus Oral Augmentin 875/125mg Three Times Daily for 7 or 10 Days in the Treatment of Adults with Community Acquired Pneumonia of Suspected Pneumococcal Origin.	amoxicillin/clavulanic acid	25000/620	Pneumonia, Community-Acquired	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=25000/620			N	Y	Y	Y	Y	Y	Y	An analysis-ready dataset is not available for this study. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Jun-2014
1672	GSK	A randomised, double-blind, double-dummy, multicentre, parallel group study to assess the efficacy and safety of oral Augmentin SR 2000/125mg twice daily for 5 days versus oral Augmentin 875/125mg twice daily for 7 days in the treatment of adults with acute exacerbations of chronic bronchitis.	amoxicillin/clavulanic acid	25000/630	Bronchitis, Chronic	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=25000/630			N	N	Y	Y	Y	Y	N	An analysis-ready dataset, an annotated case report form, and a reporting and analysis plan are not available for this study. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Jun-2014
1673	GSK	A bioequivalence study to compare the currently marketed formulation of augmentin with the ES 600 Strawberry Cream Suspension (4A)	amoxicillin/clavulanic acid	25000/643	Infections, Bacterial	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=25000/643			N	N	Y	Y	Y	Y	N	An analysis-ready dataset, an annotated case report form, and reporting and analysis plan are not available for this study. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Jun-2014
1674	GSK	An open-label, randomized, period balanced, replicate, four-period crossover bioequivalence study comparing AUGMENTIN ES-600 strawberry cream formulation to the marketed suspension.	amoxicillin/clavulanic acid	25000/665	Streptococcus pneumoniae	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=25000/665			N	N	Y	Y	Y	Y	N	An analysis-ready dataset and a reporting and analysis plan are not available for this study. An annotated case report form is not available for this study. A blank case report form will be provided. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Jun-2014
1675	GSK	A study to determine PK profiles of AUGMENTIN XR in adolescents weight at least 40 kg receiving Augmentin XR BID for 10 days	amoxicillin/clavulanic acid	AUG102821	Infections, Respiratory Tract	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=AUG102821	http://clinicaltrials.gov/show/NCT00354965		N	Y	Y	Y	Y	Y	N	An analysis-ready dataset and a reporting and analysis plan are not available for this study.	1-Jun-2014
1676	GSK	A Randomised, Double-Blind, Double-Dummy, Multicentre, Parallel Group Study to Assess the Efficacy and Safety of Oral Augmentin SR 2000/125mg Twice Daily Versus Oral Augmentin 875/125mg Three Times Daily for 7 or 10 Days for the Treatment of Bacterial Community Acquired Pneumonia in Adults.	amoxicillin/clavulanic acid	25000/557	Pneumonia, Community-Acquired	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=25000/557			N	N	Y	Y	Y	Y	Y	An analysis-ready dataset and an annotated case report form are not available for this study. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Jun-2014
1677	GSK	An Open, Non-Comparative Multicenter Study to Assess the Efficacy and Safety of Oral AUGMENTIN SR 2000/125mg Twice Daily for 10 Days in the Treatment of Acute Bacterial Sinusitis in Adults.	amoxicillin/clavulanic acid	25000/592	Sinusitis	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=25000/592			N	Y	Y	Y	Y	Y	Y	An analysis-ready dataset is not available for this study. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Jun-2014
1678	GSK	A randomized open label, 4 period, crossover study to determine the bioequivalence of scored tablets of pharmacokinetically enhanced AUGMENTIN (administered as two tablets which have been broken in half) to unscored whole tablets of pharmacokinetically enhanced AUGMENTIN in healthy volunteers.	amoxicillin/clavulanic acid	25000/593	Infections, Respiratory Tract	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=25000/593			N	N	Y	Y	Y	Y	Y	An analysis-ready dataset and an annotated case report form are not available for this study. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Jun-2014
1679	GSK	A Randomised, Double-Blind, Double-Dummy, Multicentre, Parallel Group Study to Assess the Efficacy and Safety of Oral Augmentin SR 2000/125mg Twice Daily Versus Oral Augmentin 875/125mg Twice Daily for 7 days in the Treatment of Adults with Bacterial Community Acquired Pneumonia.	amoxicillin/clavulanic acid	25000/600	Pneumonia, Community-Acquired	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=25000/600			N	N	Y	Y	Y	Y	Y	An analysis-ready dataset and an annotated case report form are not available for this study. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Jun-2014
1680	GSK	A randomized, double-blind, multicentre, parallel group study to assess the efficacy and safety of oral Augmentin SR 2000/125mg twice daily for 5 days versus a 7-day regimen in the treatment of acute exacerbation of chronic bronchitis	amoxicillin/clavulanic acid	25000/627	Bronchitis, Chronic	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=25000/627			Y	N	Y	Y	Y	Y	Y	An annotated case report form is not available for this study. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Jun-2014
1681	GSK	A Randomized, Double-Blind, Multicenter Study Comparing the Effects of Administration of Modified Release COREG or Placebo on Blood Pressure in Essential Hypertension Patients	carvedilol	105517/367	Hypertension	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=105517/367			Y	Y	Y	Y	Y	Y	Y	A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Jun-2014
1682	GSK	An open, non-randomized comparison of pharmacokinetic profiles of carvedilol (SK&F-105517) MR and IR on repeat dosing in chronic CHF subjects and survivors of an acute MI and LVD	carvedilol	105517/369	Heart failure, Congestive	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=105517/369			Y	Y	Y	Y	Y	Y	Y	A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Jun-2014
1683	GSK	A Randomized, Double-Blind, Placebo-Controlled, PK/PD Modeling, Multicenter Study to Compare the B1-Blocking Effects of an investigational formulation of carvedilol to COREG Immediate Release Tablets at Steady-State in Adult Patients with Essential Hypertension, by Evaluating Heart Rate Response to Bicycle Ergometry	carvedilol	105517/902	Hypertension	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=105517/902			N	Y	Y	Y	Y	Y	Y	An analysis-ready dataset is not available for this study. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Jun-2014
1684	GSK	An Open-label, Single Dose, Three Session, Partially Randomized, Crossover Study to Assess Morning and Evening Dosing of Carvedilol Phosphate MR Capsules in Healthy Adult Subjects	carvedilol	105517/906	Hypertension	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=105517/906			Y	Y	Y	Y	Y	Y	Y	A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Jun-2014
1685	GSK	A randomized, single-blind, placebo-controlled, three-period parallel-group study to assess the pharmacokinetic and pharmacodynamic relationship of a 50 mg single oral dose of immediate release carvedilol in healthy subjects	carvedilol	105517/908	Hypertension	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=105517/908			Y	Y	Y	Y	Y	Y	Y	A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Jun-2014
1686	GSK	A randomized, open-label, single-dose, four-period cross-over study to evaluate the relative bioavailability of four formulations of GSK lisinopril compared to Zestril, and to compare over-encapsulated Zestril to Zestril	carvedilol	CFD105533	Hypertension	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=105533			Y	Y	Y	Y	Y	Y	Y	A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Jun-2014
1687	GSK	A randomized, open-label, two period, period balanced, crossover study to estimate the relative bioavailability of an investigational drug compared to Coreg IR in healthy adult volunteers	carvedilol	CRV104257	Hypertension	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=104257			Y	Y	Y	Y	Y	Y	Y	A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Jun-2014
1688	GSK	A Randomized, Open-Label, Single-Dose, Four-Period Cross-Over Study to Determine the Effects of Alcohol on the Pharmacokinetics of Carvedilol CR	carvedilol	CRV106904	Hypertension	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=106904			Y	Y	Y	Y	Y	Y	Y	A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Jun-2014
1689	GSK	A Randomized, Double-Blind, Double-Dummy, Parallel Group, Factorial Design Trial to Assess the Efficacy and Safety of up to Six Weeks Treatment with 20mg, 40mg, or 80mg QD Doses of Carvedilol Controlled Release Formulation (COREG™ CR) or 10mg, 20mg, or 40mg QD doses of Lisinopril (Zestril) or a Combination of One of the Doses of Each Medication	carvedilol; carvedilol/lisinopril; lisinopril	CFD105453	Hypertension	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=CFD105453	http://clinicaltrials.gov/show/NCT00347360		Y	Y	Y	Y	Y	Y	Y		1-Jun-2014
1690	GSK	A phase 3, open, randomized, controlled, multicentre study to evaluate the safety and reactogenicity profile of GSK Biologicals' Haemophilus influenzae type b–meningococcal serogroup C conjugate candidate vaccine given concomitantly with GSK Biologicals' diphtheria, tetanus, acellular pertussis, hepatitis B, inactivated polio (DTPa-HBV-IPV) vaccine and to compare it with MenC-CRM197 conjugate vaccine co-administered with GSK Biologicals’ DTPa-HBV-IPV/Hib vaccine, when given as a 3-dose primary vaccination (at 2, 3, 4 months of age) to healthy infants.	Combined Diphtheria, Tetanus, Acellular Pertussis Adsorbed, Hepatitis B (Recombinant), Inactivated Polio Vaccine	811936/003	Acellular pertussis; Diphtheria; Hepatitis B; Poliomyelitis; Tetanus	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=811936/003			Y	N	Y	Y	Y	Y	N	An annotated case report form is not available for this study. A blank case report form will be provided. A reporting and analysis plan is not available for this study. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Mar-2015
1691	GSK	Immunogenicity and safety of GlaxoSmithKline Biologicals’ DTPa-IPV/Hib (Infanrix™-IPV+Hib) vaccine in healthy Korean infants	Combined Diphtheria, Tetanus, Acellular Pertussis, Inactivated Polio, Haemophilus influenzae Type b Conjugate Vaccine	114260	acellular pertussis; Diphtheria; Haemophilus influenzae type b; Poliomyelitis; Tetanus	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=114260	http://clinicaltrials.gov/show/NCT01309646	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-004137-16	Y	Y	Y	Y	Y	Y	Y		1-Dec-2018
1692	GSK	Effects of Dutasteride on Intraprostatic Dihydrotestosterone (DHT) Levels	dutasteride	ARI40014	Prostatic Hyperplasia	Phase 4	https://www.gsk-studyregister.com/en/trial-details/?id=ARI40014	http://clinicaltrials.gov/show/NCT00062790		N	Y	Y	Y	Y	Y	Y	An analysis-ready dataset is not available for this study.	1-Jun-2014
1693	GSK	A Randomized Double-Blind Parallel Group Study Comparing Casodex (or generic equivalent) 50mg plus Placebo to Casodex (or generic equivalent) 50mg plus dutasteride 3.5mg Administered for 18 months to Men with Prostate Cancer Who Have Failed First-Line Androgen Deprivation Therapy (Assessed by Rising PSA) Followed by a Two-Year Extension Phase	dutasteride	AVO108943	Neoplasms, Prostate	Phase 4	https://www.gsk-studyregister.com/en/trial-details/?id=AVO108943	http://clinicaltrials.gov/show/NCT00470834		Y	Y	Y	Y	Y	Y	Y		1-Jun-2014
1707	GSK	A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter, Study to Evaluate the Efficacy and Safety of Once Daily, Intranasal Administration of GW685698X Aqueous Nasal Spray 50mcg*, 100mcg*, 200mcg*, or 400mcg* for 14 days in Adult and Adolescent Subjects with SARs.	fluticasone furoate	FFR20001	Rhinitis, Allergic, Seasonal	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=FFR20001			Y	Y	Y	Y	Y	Y	Y	A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Jun-2014
1708	GSK	A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter, Study to Evaluate the Efficacy and Safety of Once-Daily, Intranasal Administration of GW685698X Aqueous Nasal Spray 100mcg for 4 Weeks in Adult and Adolescent Subjects (12 years of age and older) with Perennial Allergic Rhinitis (PAR)	fluticasone furoate	FFR30002	Rhinitis, Allergic, Perennial	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=FFR30002	http://clinicaltrials.gov/show/NCT00103454		Y	Y	Y	Y	Y	Y	Y		1-Jun-2014
1709	GSK	"A randomized, double-blind, parallel group, placebo and active (prednisone) controlled, 6-week study of the effect of fluticasone furoate aqueous nasal spray 100mcg QD on the hypothalamic pituitary adrenocortical (HPA) axis in adolescents and adults 12 to 65 years of age with perennial allergic rhinitis (PAR)"	fluticasone furoate	FFR20002	Rhinitis, Allergic, Perennial	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=FFR20002	http://clinicaltrials.gov/show/NCT00116818		Y	Y	Y	Y	Y	Y	Y		1-Jun-2014
1710	GSK	A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multi-Center Study to Evaluate the Efficacy and Safety of Once-Daily, Intranasal Administration of GW685698X Aqueous Nasal Spray 100mcg for 14 days in Adult and Adolescent Subjects with Seasonal Allergic Rhinitis	fluticasone furoate	FFR30003	Rhinitis, Allergic, Seasonal	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=FFR30003	http://clinicaltrials.gov/show/NCT00115622		Y	Y	Y	Y	Y	Y	Y		1-Jun-2014
1711	GSK	A non-randomized, open label, two period cross-over study to determine the excretion balance and pharmacokinetics of [14C]-GW685698, administered as single doses of an oral solution and an intravenous infusion to healthy adult male subjects	fluticasone furoate	FFR10008	Rhinitis, Allergic, Perennial	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=FFR10008		https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001079-21	Y	Y	Y	Y	Y	Y	Y	A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Jun-2014
1712	GSK	A randomised, double-blind, double-dummy, placebo controlled (with rescue medication), multicenter study to evaluate the efficacy and safety of Fluticasone Furoate inhalation powder in the treatment of persistent asthma in adults and adolescents.	fluticasone furoate	FFA112059	Asthma	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=112059	http://clinicaltrials.gov/show/NCT01159912	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-020100-34	Y	Y	Y	Y	Y	Y	Y		1-Jun-2014
1713	GSK	A randomised, repeat-dose, placebo-controlled, double-blind study to evaluate and compare the efficacy of Fluticasone Furoate/Vilanterol Inhalation Powder, when administered either in the morning or in the evening, in male and female asthmatic subjects	fluticasone furoate/vilanterol	HZA114624	Asthma	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=114624	http://clinicaltrials.gov/show/NCT01287065		Y	Y	Y	Y	Y	Y	Y		1-Jun-2014
1715	GSK	A randomised, placebo-controlled, four way crossover study to evaluate the effect of double-blind 4000 mcg of orally inhaled GW685698X and of 6.25 mg cellobiose octa-acetate on electrocardiographic parameters, with single-blind 400 mg of oral moxifloxacin as a positive control, in 40 healthy male and female subjects.	fluticasone furoate	FFR101888	Rhinitis, Allergic, Perennial	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=101888		https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-004431-61	Y	Y	Y	Y	Y	Y	Y	A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Jun-2014
1716	GSK	A randomised, open label, 2-way cross-over study to assess the absolute bioavailability of GW685698X administered intranasally in healthy male and female subjects	fluticasone furoate	FFR10010	Rhinitis, Allergic, Perennial	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=FFR10010		https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-004747-21	Y	Y	Y	Y	Y	Y	Y	A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Jun-2014
1717	GSK	"A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Evaluate the Safety and Efficacy of Once-Daily, Intranasal Administration of GW685698X Aqueous Nasal Spray 50mg and 100mcg for 12 Weeks in Pediatric Subjects Ages 2 to <12 Years with Perennial Allergic Rhinitis (PAR)"	fluticasone furoate	FFR30008	Rhinitis, Allergic, Perennial	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=FFR30008	http://clinicaltrials.gov/show/NCT00108914	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-004745-18	Y	Y	Y	Y	Y	Y	Y		1-Jun-2014
1718	GSK	A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Evaluate the Efficacy and Safety of Once-Daily, Intranasal Administration of GW685698X Aqueous Nasal Spray 100mcg for 4 Weeks in Adult and Adolescent Subjects (12 years of age and older) with Vasomotor Rhinitis	fluticasone furoate	FFR30006	Rhinitis, Vasomotor	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=FFR30006	http://clinicaltrials.gov/show/NCT00117325	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-004743-22	Y	Y	Y	Y	Y	Y	Y		1-Jun-2014
1719	GSK	A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Evaluate the Efficacy and Safety of Once-Daily, Intranasal Administration of GW685698X Aqueous Nasal Spray 100mcg for 4 Weeks in Adult and Adolescent Subjects (12 years of age and older) with Vasomotor Rhinitis	fluticasone furoate	FFR30007	Rhinitis, Vasomotor	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=FFR30007	http://clinicaltrials.gov/show/NCT00118703	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-004744-43	Y	Y	Y	Y	Y	Y	Y		1-Jun-2014
1720	GSK	A Randomized, Single-Blind, Cross-Over, Multicenter Study to Validate the Preference Module of the Experience with Allergic Rhinitis Nasal Sprays Questionnaire (EARNS-Q) Administered to Adult Subjects with Seasonal Allergic Rhinitis during a Three-week Cross-over Study	fluticasone furoate	FFR105693	Rhinitis, Allergic, Perennial	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=FFR105693	http://clinicaltrials.gov/show/NCT00346775		Y	Y	Y	Y	Y	Y	Y		1-Jun-2014
1721	GSK	A Randomized, Open Label, Active Controlled (Mometasone Furoate Aqueous Nasal Spray [Nasonex®] 200mcg QD), Parallel Group, Multi-Center, 52-Week Study to Assess the Long Term Safety of GW685698X Aqueous Nasal Spray 100mcg QD via Nasal Biopsy in Subjects 18 Years of Age with Perennial Allergic Rhinitis (PAR)	fluticasone furoate	FFR104503	Rhinitis, Allergic, Perennial	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=FFR104503	http://clinicaltrials.gov/show/NCT00224523	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001771-35	Y	Y	Y	Y	Y	Y	Y		1-Jun-2014
1722	GSK	A randomised, double-blind, multi-centre study to evaluate the efficacy and safety of inhaled fluticasone furoate in the treatment of persistent asthma in adults and adolescents currently receiving mid to high strength inhaled corticosteroids.	fluticasone furoate	FFA114496	Asthma	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=114496	http://clinicaltrials.gov/show/NCT01431950	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001895-20	Y	Y	Y	Y	Y	Y	Y		1-Jun-2014
1723	GSK	A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multicenter Study to Evaluate the Efficacy and Safety of GW685698X 200 mcg Twice Daily, GW685698X 200 mcg and 400 mcg Once Daily in the Morning, and GW685698X 200 mcg and 400 mcg Once Daily in the Evening Compared with Placebo for 8 Weeks in Adolescent and Adult Subjects (12 years of age and older) with Persistent Asthma	fluticasone furoate	FFA106783	Asthma	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=FFA106783	http://clinicaltrials.gov/show/NCT00398645	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005228-18	Y	Y	Y	Y	Y	Y	Y		1-Jun-2014
1724	GSK	A randomised, double-blind, placebo-controlled, incomplete block, 3-way cross-over study to investigate the effect of repeat inhaled doses of GW685698X and FP on airway responsiveness to adenosine 5’-monophosphate (AMP) in mild asthmatic patients	fluticasone furoate	FFA10022	Asthma	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=FFA10022			Y	Y	Y	Y	Y	Y	Y	A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Jun-2014
1725	GSK	A randomised, double-blind, placebo-controlled, 6-way cross-over design study to investigate the effect of 250 µg single inhaled doses of GW685698X and FP on airway responsiveness to adenosine 5’-monophosphate (AMP) challenge in mild asthmatic patients	fluticasone furoate	FFA10027	Asthma	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=FFA10027			Y	Y	Y	Y	Y	Y	Y	A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Jun-2014
1726	GSK	A randomised, double-blind, placebo-controlled, balanced incomplete block, multiple dose crossover study to investigate the effect of 3 Days repeat dosing of GW685698X and fluticasone propionate (1000 µg) on exhaled nitric oxide in mild to moderate asthmatic patients.	fluticasone furoate	FFA10028	Asthma	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=FFA10028			Y	Y	Y	Y	Y	Y	Y	A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Mar-2015
1727	GSK	A study to investigate the pharmacokinetics of a single inhaled dose (400mcg) of GW685698X and its effect on serum cortisol in patients with impaired liver function and matched control subjects.	fluticasone furoate	FFA10013	Asthma	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=FFA10013	http://clinicaltrials.gov/show/NCT00419237	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002363-25	Y	Y	Y	Y	Y	Y	Y		1-Mar-2015
1728	GSK	A randomised double-blind placebo controlled parallel group multicentre long term study to evaluate the safety of once-daily, intranasal administration of GW685698X aqueous nasal spray 100mcg* for 52 weeks in adult and adolescent subjects with perennial allergic rhinitis.	fluticasone furoate	FFR102123	Rhinitis, Allergic, Perennial	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=102123		https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000091-14	Y	Y	Y	Y	Y	Y	Y	A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Jun-2014
1729	GSK	A randomized, double-blind, placebo-controlled, two-way crossover 14-day study to investigate the safety, tolerability, pharmacodynamics and pharmacokinetics of repeat dose inhaled fluticasone furoate 100ug (micrograms) in children aged 5-11 years with persistent asthma	fluticasone furoate	HZA102942	Asthma	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=102942	http://clinicaltrials.gov/show/NCT01332292		Y	Y	Y	Y	Y	Y	Y	The raw data are included within the analysis-ready data for this study and are not provided separately.	1-May-2016
1730	GSK	A Randomized, Double Blind, Placebo-Controlled, Single-Dose, Parallel-Group Study to Evaluate the Onset of Action of a Single Dose of Intranasal GW685698X Aqueous Nasal Spray 100mcg in Adolescent and Adult Subjects (12 years of age and older) with Seasonal Allergic Rhinitis Exposed to Ragweed Pollen in an Allergen Challenge Chamber	fluticasone furoate	FFR101816	Rhinitis, Allergic, Seasonal	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=FFR101816	http://clinicaltrials.gov/show/NCT00118729		Y	Y	Y	Y	Y	Y	Y		1-Jun-2014
1731	GSK	A Randomised, Double-Blind, Placebo-Controlled, Parallel Group, Multicentre Two Week Study to Evaluate the Efficacy and Safety of Once-Daily, Intranasal Administration of GW685698X Aqueous Nasal Spray 100mcg in Adult and Adolescent Subjects with Seasonal Allergic Rhinitis in Europe	fluticasone furoate	FFR103184	Rhinitis, Allergic, Seasonal	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=FFR103184	http://clinicaltrials.gov/show/NCT00225823	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-004434-14	Y	Y	Y	Y	Y	Y	Y		1-Jun-2014
1732	GSK	A Randomised, Double-Blind, Placebo-Controlled, Two-Week Crossover, Knemometric Assessment of the Effect of Fluticasone Furoate Nasal Spray 100mcg Once Daily on Short-Term Growth in Children Aged 6 to 11 Years with Seasonal and/or Perennial Allergic Rhinitis	fluticasone furoate	FFR101747	Rhinitis, Allergic, Perennial and Seasonal	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=FFR101747	http://clinicaltrials.gov/show/NCT00109486	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-004749-17	Y	Y	Y	Y	Y	Y	Y		1-Jun-2014
1733	GSK	A randomized, double-blind, parallel group, placebo controlled, 6-week study of the effect of GW685698X aqueous nasal spray 100mcg QD on the hypothalamic pituitary adrenocortical (HPA) axis in children 2 to 11 years of age with perennial allergic rhinitis (PAR).	fluticasone furoate	FFR100012	Rhinitis, Allergic, Perennial	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=FFR100012	http://clinicaltrials.gov/show/NCT00116883		Y	Y	Y	Y	Y	Y	Y		1-Jun-2014
1734	GSK	See Detailed Description	fluticasone furoate	FFR104861	Rhinitis, Allergic, Seasonal	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=FFR104861	http://clinicaltrials.gov/show/NCT00197262		Y	Y	Y	Y	Y	Y	Y		1-Jun-2014
1735	GSK	A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Evaluate the Efficacy and Safety of Once-Daily, Intranasal Administration of GW685698X Aqueous Nasal Spray 50mcg and 100mcg for 2 Weeks in Pediatric Subjects Ages 2 to <12 Years with Seasonal Allergic Rhinitis (SAR)	fluticasone furoate	FFR100010	Rhinitis, Allergic, Perennial	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=FFR100010	http://clinicaltrials.gov/show/NCT00107757		Y	Y	Y	Y	Y	Y	Y		1-Jun-2014
1736	GSK	A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Evaluate the Efficacy and Safety of Once-Daily Intranasal Administration of GW685698X Aqueous Nasal Spray 100mcg for 6 Weeks in Adult and Adolescent Subjects 12 years of Age and Older with Perennial Allergic Rhinitis (PAR)	fluticasone furoate	FFR106080	Rhinitis, Allergic, Perennial	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=FFR106080	http://clinicaltrials.gov/show/NCT00289198	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004493-25	Y	Y	Y	Y	Y	Y	Y		1-Jun-2014
1737	GSK	A Long-Term, Randomized, Double-Blind, Parallel Group Study of Fluticasone Furoate/GW642444 Inhalation Powder Once-Daily and Fluticasone Furoate Inhalation Powder Once-Daily in Subjects with Asthma	fluticasone furoate/vilanterol	HZA106837	Asthma	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=106837	http://clinicaltrials.gov/show/NCT01086384	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-011461-84	Y	Y	Y	Y	Y	Y	Y		1-Jun-2014
1738	GSK	HZA106827: A randomised, double-blind, placebo-controlled (with rescue medication), parallel group multicentre study of Fluticasone Furoate/GW642444 Inhalation Powder and Fluticasone Furoate Inhalation Powder alone in the treatment of persistent asthma in adults and adolescents	fluticasone furoate/vilanterol	HZA106827	Asthma	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=106827	http://clinicaltrials.gov/show/NCT01165138	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-019590-15	Y	Y	Y	Y	Y	Y	Y		1-Jun-2014
1739	GSK	A two cohort, randomised, single-blind, two-way crossover design study to assess the effects of single doses of nasally administered fluticasone propionate (400 mcg) and a new chemical entity (NCE) on nuclear translocation of the glucocorticoid receptor, using biopsy, in male healthy volunteers.	fluticasone furoate; fluticasone propionate	FFR10006	Rhinitis, Allergic, Perennial	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=FFR10006			Y	Y	Y	Y	Y	Y	Y	A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Jun-2014
1740	GSK	A randomized blinded pilot trial of fondaparinux sodium (Arixtra®) versus unfractionated heparin in addition to standard therapy in a broad range of patients undergoing percutaneous coronary intervention (ASPIRE)	fondaparinux sodium	AR1104574	Thromboembolism	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=104574			Y	Y	Y	Y	Y	Y	Y	A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Jun-2014
1741	GSK	An International Randomized Study Evaluating the Efficacy and Safety of Fondaparinux Versus Control Therapy in a Broad Range of Patients With ST Segment Elevation Acute Myocardial Infarction.	fondaparinux sodium	AR2103413	Thromboembolism	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=103413	http://clinicaltrials.gov/show/NCT00064428		Y	Y	Y	Y	Y	Y	Y		1-Jun-2014
1742	GSK	A multicenter, randomized, double-blind, parallel group trial to demonstrate the efficacy of fondaparinux sodium in association with Intermittent Pneumatic Compression (IPC) versus IPC used alone for the prevention of venous thromboembolic events in subjects at increased risk undergoing major abdomi	fondaparinux sodium	AR3103414	Thromboembolism	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=103414	http://clinicaltrials.gov/show/NCT00038961		Y	N	Y	Y	Y	N	Y	A raw dataset is not available for this study. An annotated case report form is not available for this study. A blank case report form will be provided.	1-Jun-2014
1743	GSK	An international, randomized, double-blind study evaluating the efficacy and safety of fondaparinux versus enoxaparin in the acute treatment of unstable angina/non ST-segment elevation MI acute coronary syndromes	fondaparinux sodium	AR1103420	Thromboembolism	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=103420	http://clinicaltrials.gov/show/NCT00139815		N	N	Y	Y	Y	Y	Y	An analysis-ready dataset is not available for this study. An annotated case report form is not available for this study. A blank case report form will be provided.	1-Jun-2014
1744	GSK	A multinational, randomized, double-blind comparison of once daily subcutaneous fondaparinux sodium with placebo for the prevention of venous thromboembolic events in acutely ill medical patients (ARTEMIS).	fondaparinux sodium	AR3104619	Thrombosis, Venous	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=104619			Y	Y	Y	Y	Y	Y	Y	A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Jun-2014
1745	GSK	A study to evaluate the safety and immunogenicity of A/California/7/2009 (H1N1)v-like vaccines GSK2340274A and GSK2340273A in children 6 months to less than 9 years of age	H1N1 Pandemic Influenza Vaccine	113482	Influenza	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=113482	http://clinicaltrials.gov/show/NCT00976820		Y	N	Y	Y	Y	Y	Y	An annotated case report form is not available for this study. A blank case report form will be provided.	1-Jun-2014
1746	GSK	Immunogenicity and safety study of GSK Biologicals’ monovalent pandemic H5N1 vaccine 1557484A in adults aged 18 – 64 years	H5N1 Pandemic Influenza Vaccine	112691	Influenza	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=112691	http://clinicaltrials.gov/show/NCT01416571		Y	N	Y	Y	Y	Y	Y	An annotated case report form is not available for this study. A blank case report form will be provided.	1-Jun-2014
1747	GSK	A phase II, double-blind, randomized study to compare the immunogenicity, safety and reactogenicity of GlaxoSmithKline (GSK) Biologicals’ Tritanrix™-HepB/Hib2.5 to GSK Biologicals’ Tritanrix™-HepB/Hiberix™ when administered as a three-dose primary vaccination course to healthy infants at 6, 10 and 14 weeks of age. A dose of unconjugated Hib vaccine (plain PRP booster) will be administered at the age of 10 months to 50% of the subjects	Haemophilus influenzae Type b Vaccine	208108/091	Haemophilus influenzae type b	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=208108/091	http://clinicaltrials.gov/show/NCT01061541	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004009-25	Y	N	Y	Y	Y	Y	Y	The results of study 208108/091 are summarised with study 208108/092 on the GSK Study Register. An annotated case report form is not available for this study. A blank case report form will be provided.	1-Jun-2014
1748	GSK	A phase II, double-blind, randomized study to compare the immunogenicity, safety and reactogenicity of GlaxoSmithKline (GSK) Biologicals’ Tritanrix™-HepB/Hib2.5 to GSK Biologicals’ Tritanrix™-HepB/Hiberix™ when administered as a three-dose primary vaccination course to healthy infants at 6, 10 and 14 weeks of age. A dose of unconjugated Hib vaccine (plain PRP booster) will be administered at the age of 10 months to 50% of the subjects	Haemophilus influenzae Type b Vaccine	208108/092	Haemophilus influenzae type b	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=208108/091	http://clinicaltrials.gov/show/NCT01061541		Y	N	Y	Y	Y	Y	N	The results of study 208108/092 are summarised with study 208108/091 on the GSK Study Register. An annotated case report form is not available for this study. A blank case report form will be provided. A reporting and analysis plan is not available for this study.	1-Jun-2014
1749	GSK	Study to assess safety, reactogenicity and immunogenicity of a booster dose of an investigational vaccination regimen and GSK Biologicals Hib-MenC vaccine (co-admind with Infanrix penta) compared to a booster dose of Menjugate (co-admind with Infanrix hexa)	Haemophilus influenzae Type b, Meningococcal C and Y-Tetanus Toxoid Conjugate Vaccine	100381	Haemophilus influenzae type b; Neisseria Meningitidis	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=100381			Y	N	Y	Y	Y	Y	N	An annotated case report form is not available for this study. A blank case report form will be provided. A reporting and analysis plan is not available for this study. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Mar-2015
1750	GSK	A phase II, open (partially double-blind), randomised, controlled, multicentre, primary vaccination study to evaluate the immunogenicity (including immune memory), reactogenicity and safety of three different formulations of the GSK Biologicals’ combined Haemophilus influenzae type b-meningococcal serogroups CY conjugate vaccine given concomitantly with Infanrix® penta and Prevenar®, versus ActHIB® and Meningitec® given concomitantly with Infanrix® penta and versus ActHIB® given concomitantly with Infanrix® penta and Prevenar® in infants according to a 2-4-6 month schedule.	Haemophilus influenzae Type b, Meningococcal C and Y-Tetanus Toxoid Conjugate Vaccine	792014/001	Haemophilus influenzae type b; Neisseria Meningitidis	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=792014/001	http://clinicaltrials.gov/show/NCT00127855		Y	N	Y	Y	Y	Y	N	An annotated case report form is not available for this study. A blank case report form will be provided. A reporting and analysis plan is not available for this study.	1-Jun-2014
1751	GSK	A phase II, open, randomized, controlled, multicentre, primary vaccination study to evaluate the immunogenicity, reactogenicity and safety of an investigational vaccination regimen versus ActHIB® and Menjugate® given concomitantly with Infanrix® penta and Prevenar® in infants	Haemophilus influenzae Type b, Meningococcal C and Y-Tetanus Toxoid Conjugate Vaccine	792014/002	Haemophilus influenzae type b; Neisseria Meningitidis	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=792014/002			Y	N	Y	Y	Y	Y	N	An annotated case report form is not available for this study. A blank case report form will be provided. A reporting and analysis plan is not available for ths study. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Jun-2014
1752	GSK	A phase II, open (partially double-blind), randomised, controlled, multicentre, primary vaccination study to evaluate the immunogenicity, reactogenicity and safety of three different formulations of GSK Biologicals’ combined Haemophilus influenzae type b-meningococcal serogroups C and Y- conjugate vaccine and one formulation of GSK Biologicals’ Haemophilus influenzae type b-meningococcal serogroup C conjugate vaccine each given concomitantly with InfanrixTM penta, versus MeningitecTM, given concomitantly with InfanrixTM hexa in infants according to a 2-3-4 month schedule	Haemophilus influenzae Type b, Meningococcal C and Y-Tetanus Toxoid Conjugate Vaccine	792014/003	Haemophilus influenzae type b; Neisseria Meningitidis	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=792014/003	http://clinicaltrials.gov/show/NCT00129116		Y	N	Y	Y	Y	Y	N	An annotated case report form is not available for this study. A blank case report form will be provided. A reporting and analysis plan is not available for this study.	1-Jun-2014
1753	GSK	Evaluate Immuno and Safety of GSKBiologicals' HibMenCYTT vs Licensed Hib Conjugate Vaccine, Each Coadministered With Pediarix® and Prevnar®, in Healthy Infants. An Exploratory Control Group Will Receive Licensed Menomune® at 3 to 5 years	Haemophilus influenzae Type b, Meningococcal C and Y-Tetanus Toxoid Conjugate Vaccine	101858	Haemophilus influenzae type b; Neisseria Meningitidis	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=101858	http://clinicaltrials.gov/show/NCT00129129		Y	N	Y	Y	Y	Y	N	The results of study 101858 are summarised with study 102015 on the GSK Study Register. An annotated case report form is not available for this study. A blank case report form will be provided. A reporting and analysis plan is not available for this study.	1-Jun-2014
1754	GSK	Evaluate Immuno and Safety of GSKBiologicals' HibMenCYTT vs Licensed Hib Conjugate Vaccine, Each Coadministered With Pediarix® and Prevnar®, in Healthy Infants. An Exploratory Control Group Will Receive Licensed Menomune® at 3 to 5 years	Haemophilus influenzae Type b, Meningococcal C and Y-Tetanus Toxoid Conjugate Vaccine	102015	Haemophilus influenzae type b; Neisseria Meningitidis	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=101858	http://clinicaltrials.gov/show/NCT00129129		Y	N	Y	Y	Y	Y	Y	The results of study 102015 are summarised with study 101858 on the GSK Study Register. An annotated case report form is not available for this study. A blank case report form will be provided.	1-Jun-2014
1755	GSK	A multicentre primary & booster vaccination study of GSK Biologicals' Hib-MenCY-TT conjugate vaccine vs ActHIB® & MenC conjugate licensed vaccine when given according to the 2-4-6 month schedule to healthy infants with booster dose at 12 to 15 months	Haemophilus influenzae Type b, Meningococcal C and Y-Tetanus Toxoid Conjugate Vaccine	102370	Haemophilus influenzae type b; Neisseria Meningitidis	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=102370 (primary study)	http://clinicaltrials.gov/show/NCT00134719		Y	N	Y	Y	Y	Y	N	The results of study 102370 are summarised with study 102371 on the GSK Study Register. An annotated case report form is not available for this study. A blank case report form will be provided. A reporting and analysis plan is not available for this study.	1-Jun-2014
1756	GSK	A multicentre primary & booster vaccination study of GSK Biologicals' Hib-MenCY-TT conjugate vaccine vs ActHIB® & MenC conjugate licensed vaccine when given according to the 2-4-6 month schedule to healthy infants with booster dose at 12 to 15 months	Haemophilus influenzae Type b, Meningococcal C and Y-Tetanus Toxoid Conjugate Vaccine	102371	Haemophilus influenzae type b; Neisseria Meningitidis	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=102370 (primary study)	http://clinicaltrials.gov/show/NCT00134719		Y	N	Y	Y	Y	Y	N	The results of study 102371 are summarised with study 102370 on the GSK Study Register. An annotated case report form is not available for this study. A blank case report form will be provided. A reporting and analysis plan is not available for this study.	1-Jun-2014
1757	GSK	A phase III, randomized, multinational study, double-blinded for the immunogenicity and consistency evaluation of 3 Hib-MenCY-TT vaccine lots and single-blinded and controlled for the evaluation of safety and immunogenicity of GSK Biologicals' Haemophilus influenzae type b and Neisseria meningitidis serogroups C and Y-tetanus toxoid conjugate vaccine combined (Hib-MenCY-TT) compared to monovalent Hib vaccine in healthy infants at 2, 4, 6, and 12 to 15 months of age.	Haemophilus influenzae Type b, Meningococcal C and Y-Tetanus Toxoid Conjugate Vaccine	103813	Haemophilus influenzae type b; Neisseria Meningitidis	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=103813	http://clinicaltrials.gov/show/NCT00289783	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002352-18	Y	N	Y	Y	Y	Y	N	The results of study 103813 are summarised with study 105067 on the GSK Study Register. An annotated case report form is not available for this study. A blank case report form will be provided. A reporting and analysis plan is not available for this study.	1-Jun-2014
1758	GSK	A phase III, randomized, multinational study, double-blinded for the immunogenicity and consistency evaluation of 3 Hib-MenCY-TT vaccine lots and single-blinded and controlled for the evaluation of safety and immunogenicity of GSK Biologicals' Haemophilus influenzae type b and Neisseria meningitidis serogroups C and Y-tetanus toxoid conjugate vaccine combined (Hib-MenCY-TT) compared to monovalent Hib vaccine in healthy infants at 2, 4, 6, and 12 to 15 months of age.	Haemophilus influenzae Type b, Meningococcal C and Y-Tetanus Toxoid Conjugate Vaccine	105067	Haemophilus influenzae type b; Neisseria Meningitidis	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=103813	http://clinicaltrials.gov/show/NCT00289783		Y	N	Y	Y	Y	Y	N	The results of study 105067 are summarised with study 103813 on the GSK Study Register. An annotated case report form is not available for this study. A blank case report form will be provided. A reporting and analysis plan is not available for this study.	1-Jun-2014
1759	GSK	A single-blind, randomized, controlled, multinational study for the evaluation of safety of GlaxoSmithKline (GSK) Biologicals’ investigational vaccination regimen compared to monovalent Haemophilus influenzae type b (Hib) control vaccine in healthy infants at 2, 4, 6, and 12 to 15 months of age.	Haemophilus influenzae Type b, Meningococcal C and Y-Tetanus Toxoid Conjugate Vaccine	105987	Haemophilus influenzae type b; Neisseria Meningitidis	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=105987	http://clinicaltrials.gov/show/NCT00345579	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-006066-34	Y	N	Y	Y	Y	Y	Y	An annotated case report form is not available for this study. A blank case report form will be provided.	1-Jun-2014
1760	GSK	A study to evaluate the long-term antibody persistence at 1, 3 & 5 years after the administration of a fourth dose of Hib-MenCY-TT Vaccine compared to ActHIB in subjects boosted in a previous study.	Haemophilus influenzae Type b, Meningococcal C and Y-Tetanus Toxoid Conjugate Vaccine	107824	Haemophilus influenzae type b; Neisseria Meningitidis	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=107824	http://clinicaltrials.gov/show/NCT00359983		Y	N	Y	Y	Y	Y	Y	An annotated case report form is not available for this study. A blank case report form will be provided.	1-Jun-2014
1761	GSK	Evaluate immunogenicity,safety & reactogenicity of a booster dose of Hib-MenC conjugate vaccine when given to healthy subjects aged 13-14 months who were primed with 3 doses of Hib-MenC vs a booster dose of Infanrix hexa given to subjects primed with 3 doses of Infanrix hexa and Meningitec	Haemophilus influenzae Type b, Meningococcal C-Tetanus Toxoid Conjugate Vaccine	102547	Haemophilus influenzae type b; Neisseria Meningitidis	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=102547	http://clinicaltrials.gov/show/NCT00323050	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001249-14	Y	N	Y	Y	Y	Y	Y	An annotated case report form is not available for this study. A blank case report form will be provided.	1-Jun-2014
1762	GSK	Study to evaluate the safety, reactogenicity & immunogenicity of a booster dose of GSK Biologicals’ Hib-MenC given with Priorix™, vs Hib-MenC or Priorix™ only, in toddlers (13–14 m) primed with 3 doses of Hib (as part of a DTPa –containing vaccine) & MenC-CRM197 conjugate vaccines.	Haemophilus influenzae Type b, Meningococcal C-Tetanus Toxoid Conjugate Vaccine	103954	Haemophilus influenzae type b; Neisseria Meningitidis	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=103954	http://clinicaltrials.gov/show/NCT00263653	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-003275-37	Y	N	Y	Y	Y	Y	Y	An annotated case report form is not available for this study. A blank case report form will be provided.	1-Jun-2014
1763	GSK	Demonstrate non-inferiority of Men-C immune response of Hib-MenC with Infanrix™-IPV versus a licensed Men-C vaccine with Pediacel™ when given at 2, 3, 4 months and the immunogenicity of Hib-MenC when given as a booster dose at 12-15 months	Haemophilus influenzae Type b, Meningococcal C-Tetanus Toxoid Conjugate Vaccine	103974	Haemophilus influenzae type b; Neisseria Meningitidis	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=103974 (primary study)	http://clinicaltrials.gov/show/NCT00258700	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-003769-33	Y	N	Y	Y	Y	Y	Y	An annotated case report form is not available for this study. A blank case report form will be provided.	1-Jun-2014
1764	GSK	Study to demonstrate the non-inferiority of the meningococcal serogroup C immune response of GlaxoSmithKline Biologicals’ Hib-MenC vaccine co-administered with Infanrix™-IPV versus a licensed meningococcal serogroup C vaccine co-administered with Pediacel™ vaccine	Haemophilus influenzae Type b, Meningococcal C-Tetanus Toxoid Conjugate Vaccine	104056	Haemophilus influenzae type b; Neisseria Meningitidis	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=104056		https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-003769-33	Y	N	Y	Y	Y	Y	Y	An annotated case report form is not available for this study. A blank case report form will be provided. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Jun-2014
1765	GSK	Study to demonstrate non-inferiority of GSK Biologicals’ Hib-MenC given with Infanrix™ penta versus NeisVac-C™ given with Infanrix™ hexa at 3, 5 months of age and persistence prior to a Hib-MenC booster at 11 months and immunogenicity of the booster	Haemophilus influenzae Type b, Meningococcal C-Tetanus Toxoid Conjugate Vaccine	106388	Haemophilus influenzae type b; Neisseria Meningitidis	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=106388	http://clinicaltrials.gov/show/NCT00327184	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-005421-59	Y	N	Y	Y	Y	Y	Y	The results of study 106388 are summarised with study 106390 on the GSK Study Register. An annotated case report form is not available for this study. A blank case report form will be provided.	1-Jun-2014
1766	GSK	Study to demonstrate non-inferiority of GSK Biologicals’ Hib-MenC given with Infanrix™ penta versus NeisVac-C™ given with Infanrix™ hexa at 3, 5 months of age and persistence prior to a Hib-MenC booster at 11 months and immunogenicity of the booster	Haemophilus influenzae Type b, Meningococcal C-Tetanus Toxoid Conjugate Vaccine	106390	Haemophilus influenzae type b; Neisseria Meningitidis	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=106388	http://clinicaltrials.gov/show/NCT00327184		Y	N	Y	Y	Y	Y	N	The results of study 106390 are summarised with study 106388 on the GSK Study Register. An annotated case report form is not available for this study. A blank case report form will be provided. A reporting and analysis plan is not available for this study.	1-Jun-2014
1767	GSK	Study to demonstrate non-inferiority of GSK Biologicals’ Hib-MenC with Priorix™, versus MenC-CRM197 vaccine with Hiberix™ & Priorix™ in toddlers primed with Hib but not MenC & to evaluate persistence up to 5 years after vaccination.	Haemophilus influenzae Type b, Meningococcal C-Tetanus Toxoid Conjugate Vaccine	106445	Haemophilus influenzae type b; Neisseria Meningitidis	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=106445	http://clinicaltrials.gov/show/NCT00326118	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005032-26	Y	N	Y	Y	Y	Y	Y	An annotated case report form is not available for this study. A blank case report form will be provided.	1-Jun-2014
1768	GSK	Phase III, open, multicenter Study to Assess the Long-Term Persistence of a Booster Dose of GSK Biologicals' Hib-MenC compared to a Booster Dose of Infanrix™ Hexa When Given to 14 month-old Subjects Primed in study DTPa-HBV-IPV-097 & Boosted in study Hib-MenC-TT-010 BST: DTPa-HBV-IPV-097	Haemophilus influenzae Type b, Meningococcal C-Tetanus Toxoid Conjugate Vaccine	106672	Haemophilus influenzae type b; Neisseria Meningitidis	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=106672	http://clinicaltrials.gov/show/NCT00322335	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000518-19	Y	N	Y	Y	Y	Y	Y	This is a follow-up study to 217744/097. The results of this study 106672 are summarised with studies 106673, 106675, 106679, and 106680 on the GSK Study Register.An annotated case report form is not available for this study. A blank case report form will be provided.	1-Jun-2014
1769	GSK	Assessment of long-term antibody persistence after a booster dose of GSK Biologicals’ Hib & meningococcal C vaccine (Menitorix™) 811936 given at 12-15 months of age to subjects primed with 3 doses of Menitorix™ at 2, 3, 4 months of age	Haemophilus influenzae Type b, Meningococcal C-Tetanus Toxoid Conjugate Vaccine	109664	Haemophilus influenzae type b; Neisseria Meningitidis	Phase 4	https://www.gsk-studyregister.com/en/trial-details/?id=109664	http://clinicaltrials.gov/show/NCT00454987	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006460-32	Y	N	Y	Y	Y	Y	N	An annotated case report form is not available for this study. A blank case report form will be provided. A reporting and analysis plan is not available for this study.	1-Jun-2014
1770	GSK	Evaluate the effect of risk factors that influence the immunogenicity of GSK Biologicals Twinrix compared to hepatitis A and hepatitis B vaccines given separately and to show the non-inferiority between the vaccines in adults	twinrix	111149	Hepatitis A; Hepatitis B	Phase 4	https://www.gsk-studyregister.com/en/trial-details/?id=111149	http://clinicaltrials.gov/show/NCT00603252		Y	N	Y	Y	Y	Y	N	An annotated case report form is not available for this study. A blank case report form will be provided. A reporting and analysis plan is not available for this study.	1-Mar-2015
1771	GSK	Evaluate Persistence of Immune Response of GSK Biologicals’ TWINRIX™ Vaccine Administered According to 0,6 Month Schedule Versus TWINRIX™ JUNIOR Administered According to 0,1,6 Month Schedule, in Subjects Aged 12-15 years at Time of First Vaccine Dose	twinrix	100566	Hepatitis A; Hepatitis B	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=100566	http://clinicaltrials.gov/show/NCT00197119	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-001517-27	Y	N	Y	Y	Y	Y	Y	The results of study 100566 are summarised with studies 100567, 100568, 100569, and 100570 on the GSK Study Register. An annotated case report form is not available for this study. A blank case report form will be provided.	1-Jun-2014
1772	GSK	Evaluate Persistence of Immune Response of GSK Biologicals’ TWINRIX™ Vaccine Administered According to 0,6 Month Schedule Versus TWINRIX™ JUNIOR Administered According to 0,1,6 Month Schedule, in Subjects Aged 12-15 years at Time of First Vaccine Dose	twinrix	100567	Hepatitis A; Hepatitis B	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=100566	http://clinicaltrials.gov/show/NCT00197119	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-001517-27	Y	N	Y	Y	Y	Y	Y	The results of study 100567 are summarised with studies 100566, 100568, 100569, and 100570 on the GSK Study Register. An annotated case report form is not available for this study. A blank case report form will be provided.	1-Jun-2014
1773	GSK	Evaluate Persistence of Immune Response of GSK Biologicals’ TWINRIX™ Vaccine Administered According to 0,6 Month Schedule Versus TWINRIX™ JUNIOR Administered According to 0,1,6 Month Schedule, in Subjects Aged 12-15 years at Time of First Vaccine Dose	twinrix	100568	Hepatitis A; Hepatitis B	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=100566	http://clinicaltrials.gov/show/NCT00197119	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-001517-27	Y	N	Y	Y	Y	Y	Y	The results of study 100568 are summarised with studies 100566, 100567, 100569, and 100570 on the GSK Study Register. An annotated case report form is not available for this study. A blank case report form will be provided.	1-Jun-2014
1774	GSK	Evaluate Persistence of Immune Response of GSK Biologicals’ TWINRIX™ Vaccine Administered According to 0,6 Month Schedule Versus TWINRIX™ JUNIOR Administered According to 0,1,6 Month Schedule, in Subjects Aged 12-15 years at Time of First Vaccine Dose	twinrix	100569	Hepatitis A; Hepatitis B	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=100566	http://clinicaltrials.gov/show/NCT00197119	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-001517-27	Y	N	Y	Y	Y	Y	Y	The results of study 100569 are summarised with studies 100566, 100567, 100568, and 100570 on the GSK Study Register. An annotated case report form is not available for this study. A blank case report form will be provided.	1-Jun-2014
1775	GSK	Evaluate Persistence of Immune Response of GSK Biologicals’ TWINRIX™ Vaccine Administered According to 0,6 Month Schedule Versus TWINRIX™ JUNIOR Administered According to 0,1,6 Month Schedule, in Subjects Aged 12-15 years at Time of First Vaccine Dose	twinrix	100570	Hepatitis A; Hepatitis B	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=100566	http://clinicaltrials.gov/show/NCT00197119	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-001517-27	Y	N	Y	Y	Y	Y	Y	The results of study 100570 are summarised with studies 100566, 100567, 100568, and 100569 on the GSK Study Register. An annotated case report form is not available for this study. A blank case report form will be provided.	1-Jun-2014
1776	GSK	Double-blind, randomized study to evaluate the immunogenicity and reactogenicity of three different lots of GlaxoSmithKline Biologicals' inactivated hepatitis A vaccine containing 1440 EL.U of antigen per mL and injected according to a 0, 6 month schedule in healthy adult subjects	Hepatitis A Vaccine, Inactivated	100576	Hepatitis A	Phase 4	https://www.gsk-studyregister.com/en/trial-details/?id=100576 (Y11)	http://clinicaltrials.gov/show/NCT00289757		Y	N	Y	Y	Y	Y	Y	The results of this study 100576 are summarised with studies 100577, 100578, 100579, 100580, 111028, 111029, 111030, 111031, and 111032 on the GSK Study Register. An annotated case report form is not available for this study. A blank case report form will be provided.	1-Jun-2014
1777	GSK	Double-blind, randomized study to evaluate the immunogenicity and reactogenicity of three different lots of GlaxoSmithKline Biologicals' inactivated hepatitis A vaccine containing 1440 EL.U of antigen per mL and injected according to a 0, 6 month schedule in healthy adult subjects	Hepatitis A Vaccine, Inactivated	100577	Hepatitis A	Phase 4	https://www.gsk-studyregister.com/en/trial-details/?id=100576 (Y11)	http://clinicaltrials.gov/show/NCT00289757		Y	N	Y	Y	Y	Y	Y	The results of this study 100577 are summarised with studies 100576, 100578, 100579, 100580, 111028, 111029, 111030, 111031, and 111032 on the GSK Study Register. An annotated case report form is not available for this study. A blank case report form will be provided.	1-Jun-2014
1778	GSK	Double-blind, randomized study to evaluate the immunogenicity and reactogenicity of three different lots of GlaxoSmithKline Biologicals' inactivated hepatitis A vaccine containing 1440 EL.U of antigen per mL and injected according to a 0, 6 month schedule in healthy adult subjects	Hepatitis A Vaccine, Inactivated	100578	Hepatitis A	Phase 4	https://www.gsk-studyregister.com/en/trial-details/?id=100576 (Y11)	http://clinicaltrials.gov/show/NCT00289757		Y	N	Y	Y	Y	Y	Y	The results of this study 100578 are summarised with studies 100576, 100577, 100579, 100580, 111028, 111029, 111030, 111031, and 111032 on the GSK Study Register. An annotated case report form is not available for this study. A blank case report form will be provided.	1-Jun-2014
1779	GSK	Double-blind, randomized study to evaluate the immunogenicity and reactogenicity of three different lots of GlaxoSmithKline Biologicals' inactivated hepatitis A vaccine containing 1440 EL.U of antigen per mL and injected according to a 0, 6 month schedule in healthy adult subjects	Hepatitis A Vaccine, Inactivated	100579	Hepatitis A	Phase 4	https://www.gsk-studyregister.com/en/trial-details/?id=100576 (Y11)	http://clinicaltrials.gov/show/NCT00289757		Y	N	Y	Y	Y	Y	Y	The results of this study 100579 are summarised with studies 100576, 100577, 100578, 100580, 111028, 111029, 111030, 111031, and 111032 on the GSK Study Register. An annotated case report form is not available for this study. A blank case report form will be provided.	1-Jun-2014
1780	GSK	Double-blind, randomized study to evaluate the immunogenicity and reactogenicity of three different lots of GlaxoSmithKline Biologicals' inactivated hepatitis A vaccine containing 1440 EL.U of antigen per mL and injected according to a 0, 6 month schedule in healthy adult subjects	Hepatitis A Vaccine, Inactivated	100580	Hepatitis A	Phase 4	https://www.gsk-studyregister.com/en/trial-details/?id=100576 (Y11)	http://clinicaltrials.gov/show/NCT00289757		Y	N	Y	Y	Y	Y	Y	The results of this study 100580 are summarised with studies 100576, 100577, 100578, 100579, 111028, 111029, 111030, 111031, and 111032 on the GSK Study Register. An annotated case report form is not available for this study. A blank case report form will be provided.	1-Jun-2014
1781	GSK	Double-blind, randomized study to evaluate the immunogenicity and reactogenicity of three different lots of GlaxoSmithKline Biologicals' inactivated hepatitis A vaccine containing 1440 EL.U of antigen per mL and injected according to a 0, 6 month schedule in healthy adult subjects	Hepatitis A Vaccine, Inactivated	111028	Hepatitis A	Phase 4	https://www.gsk-studyregister.com/en/trial-details/?id=100576 (Y11)	http://clinicaltrials.gov/show/NCT00289757		Y	N	Y	Y	Y	Y	Y	The results of this study 111028 are summarised with studies 100576, 100577, 100578, 100579, 100580, 111029, 111030, 111031, and 111032 on the GSK Study Register. An annotated case report form is not available for this study. A blank case report form will be provided.	1-Jun-2014
1782	GSK	Double-blind, randomized study to evaluate the immunogenicity and reactogenicity of three different lots of GlaxoSmithKline Biologicals' inactivated hepatitis A vaccine containing 1440 EL.U of antigen per mL and injected according to a 0, 6 month schedule in healthy adult subjects	Hepatitis A Vaccine, Inactivated	111029	Hepatitis A	Phase 4	https://www.gsk-studyregister.com/en/trial-details/?id=100576 (Y11)	http://clinicaltrials.gov/show/NCT00289757		Y	N	Y	Y	Y	Y	Y	The results of this study 111029 are summarised with studies 100576, 100577, 100578, 100579, 100580, 111028, 111030, 111031, and 111032 on the GSK Study Register. An annotated case report form is not available for this study. A blank case report form will be provided.	1-Jun-2014
1783	GSK	Double-blind, randomized study to evaluate the immunogenicity and reactogenicity of three different lots of GlaxoSmithKline Biologicals' inactivated hepatitis A vaccine containing 1440 EL.U of antigen per mL and injected according to a 0, 6 month schedule in healthy adult subjects	Hepatitis A Vaccine, Inactivated	111030	Hepatitis A	Phase 4	https://www.gsk-studyregister.com/en/trial-details/?id=100576 (Y11)	http://clinicaltrials.gov/show/NCT00289757		Y	N	Y	Y	Y	Y	Y	The results of this study 111030 are summarised with studies 100576, 100577, 100578, 100579, 100580, 111028, 111029, 111031, and 111032 on the GSK Study Register. An annotated case report form is not available for this study. A blank case report form will be provided.	1-Jun-2014
1784	GSK	Double-blind, randomized study to evaluate the immunogenicity and reactogenicity of three different lots of GlaxoSmithKline Biologicals' inactivated hepatitis A vaccine containing 1440 EL.U of antigen per mL and injected according to a 0, 6 month schedule in healthy adult subjects	Hepatitis A Vaccine, Inactivated	111031	Hepatitis A	Phase 4	https://www.gsk-studyregister.com/en/trial-details/?id=100576 (Y11)	http://clinicaltrials.gov/show/NCT00289757		Y	N	Y	Y	Y	Y	Y	The results of this study 111031 are summarised with studies 100576, 100577, 100578, 100579, 100580, 111028, 111029, 111030, and 111032 on the GSK Study Register. An annotated case report form is not available for this study. A blank case report form will be provided.	1-Jun-2014
1785	GSK	Double-blind randomized study to evaluate the immunogenicity and reactogenicity of two different lots of GlaxoSmithKline Biologicals' inactivated hepatitis A vaccine containing 1440 EL.U of antigen per mL and injected according to a 0, 12 month schedule in healthy adult volunteers	Hepatitis A Vaccine, Inactivated	100571	Hepatitis A	Phase 4	https://www.gsk-studyregister.com/en/trial-details/?id=100571 (M138)	http://clinicaltrials.gov/show/NCT00291876		Y	N	Y	Y	Y	Y	Y	The results of this study 100571 are summarised with studies 100572, 100573, 100574, 100575, 110677, 110678, 110679, 110680, and 110681 on the GSK Study Register. An annotated case report form is not available for this study. A blank case report form will be provided.	1-Jun-2014
1786	GSK	Double-blind randomized study to evaluate the immunogenicity and reactogenicity of two different lots of GlaxoSmithKline Biologicals' inactivated hepatitis A vaccine containing 1440 EL.U of antigen per mL and injected according to a 0, 12 month schedule in healthy adult volunteers	Hepatitis A Vaccine, Inactivated	100572	Hepatitis A	Phase 4	https://www.gsk-studyregister.com/en/trial-details/?id=100571 (M138)	http://clinicaltrials.gov/show/NCT00291876		Y	N	Y	Y	Y	Y	Y	The results of this study 100572 are summarised with studies 100571, 100573, 100574, 100575, 110677, 110678, 110679, 110680, and 110681 on the GSK Study Register. An annotated case report form is not available for this study. A blank case report form will be provided.	1-Jun-2014
1787	GSK	Double-blind randomized study to evaluate the immunogenicity and reactogenicity of two different lots of GlaxoSmithKline Biologicals' inactivated hepatitis A vaccine containing 1440 EL.U of antigen per mL and injected according to a 0, 12 month schedule in healthy adult volunteers	Hepatitis A Vaccine, Inactivated	100573	Hepatitis A	Phase 4	https://www.gsk-studyregister.com/en/trial-details/?id=100571 (M138)	http://clinicaltrials.gov/show/NCT00291876		Y	N	Y	Y	Y	Y	Y	The results of this study 100573 are summarised with studies 100571, 100572, 100574, 100575, 110677, 110678, 110679, 110680, and 110681 on the GSK Study Register. An annotated case report form is not available for this study. A blank case report form will be provided.	1-Jun-2014
1788	GSK	Double-blind randomized study to evaluate the immunogenicity and reactogenicity of two different lots of GlaxoSmithKline Biologicals' inactivated hepatitis A vaccine containing 1440 EL.U of antigen per mL and injected according to a 0, 12 month schedule in healthy adult volunteers	Hepatitis A Vaccine, Inactivated	100574	Hepatitis A	Phase 4	https://www.gsk-studyregister.com/en/trial-details/?id=100571 (M138)	http://clinicaltrials.gov/show/NCT00291876		Y	N	Y	Y	Y	Y	Y	The results of this study 100574 are summarised with studies 100571, 100572, 100573, 100575, 110677, 110678, 110679, 110680, and 110681 on the GSK Study Register. An annotated case report form is not available for this study. A blank case report form will be provided.	1-Jun-2014
1789	GSK	Double-blind randomized study to evaluate the immunogenicity and reactogenicity of two different lots of GlaxoSmithKline Biologicals' inactivated hepatitis A vaccine containing 1440 EL.U of antigen per mL and injected according to a 0, 12 month schedule in healthy adult volunteers	Hepatitis A Vaccine, Inactivated	100575	Hepatitis A	Phase 4	https://www.gsk-studyregister.com/en/trial-details/?id=100571 (M138)	http://clinicaltrials.gov/show/NCT00291876		Y	N	Y	Y	Y	Y	Y	The results of this study 100575 are summarised with studies 100571, 100572, 100573, 100574, 110677, 110678, 110679, 110680, and 110681 on the GSK Study Register. An annotated case report form is not available for this study. A blank case report form will be provided.	1-Jun-2014
1790	GSK	Double-blind randomized study to evaluate the immunogenicity and reactogenicity of two different lots of GlaxoSmithKline Biologicals' inactivated hepatitis A vaccine containing 1440 EL.U of antigen per mL and injected according to a 0, 12 month schedule in healthy adult volunteers	Hepatitis A Vaccine, Inactivated	110677	Hepatitis A	Phase 4	https://www.gsk-studyregister.com/en/trial-details/?id=100571 (M138)	http://clinicaltrials.gov/show/NCT00291876		Y	N	Y	Y	Y	Y	Y	The results of this study 110677 are summarised with studies 100571, 100572, 100573, 100574, 100575, 110678, 110679, 110680, and 110681 on the GSK Study Register. An annotated case report form is not available for this study. A blank case report form will be provided.	1-Jun-2014
1791	GSK	Double-blind randomized study to evaluate the immunogenicity and reactogenicity of two different lots of GlaxoSmithKline Biologicals' inactivated hepatitis A vaccine containing 1440 EL.U of antigen per mL and injected according to a 0, 12 month schedule in healthy adult volunteers	Hepatitis A Vaccine, Inactivated	110678	Hepatitis A	Phase 4	https://www.gsk-studyregister.com/en/trial-details/?id=100571 (M138)	http://clinicaltrials.gov/show/NCT00291876		Y	N	Y	Y	Y	Y	Y	The results of this study 110678 are summarised with studies 100571, 100572, 100573, 100574, 100575, 110677, 110679, 110680, and 110681 on the GSK Study Register. An annotated case report form is not available for this study. A blank case report form will be provided.	1-Jun-2014
1792	GSK	Double-blind randomized study to evaluate the immunogenicity and reactogenicity of two different lots of GlaxoSmithKline Biologicals' inactivated hepatitis A vaccine containing 1440 EL.U of antigen per mL and injected according to a 0, 12 month schedule in healthy adult volunteers	Hepatitis A Vaccine, Inactivated	110679	Hepatitis A	Phase 4	https://www.gsk-studyregister.com/en/trial-details/?id=100571 (M138)	http://clinicaltrials.gov/show/NCT00291876		Y	N	Y	Y	Y	Y	Y	The results of this study 110679 are summarised with studies 100571, 100572, 100573, 100574, 100575, 110677, 110678, 110680, and 110681 on the GSK Study Register. An annotated case report form is not available for this study. A blank case report form will be provided.	1-Jun-2014
1793	GSK	Double-blind randomized study to evaluate the immunogenicity and reactogenicity of two different lots of GlaxoSmithKline Biologicals' inactivated hepatitis A vaccine containing 1440 EL.U of antigen per mL and injected according to a 0, 12 month schedule in healthy adult volunteers	Hepatitis A Vaccine, Inactivated	110680	Hepatitis A	Phase 4	https://www.gsk-studyregister.com/en/trial-details/?id=100571 (M138)	http://clinicaltrials.gov/show/NCT00291876		Y	N	Y	Y	Y	Y	Y	The results of this study 110680 are summarised with studies 100571, 100572, 100573, 100574, 100575, 110677, 110678, 110679, and 110681 on the GSK Study Register. An annotated case report form is not available for this study. A blank case report form will be provided.	1-Jun-2014
1794	GSK	Long-term antibody persistence of hepatitis B antibodies and immune response to a hepatitis B vaccine (Engerix-B Kinder) challenge in children previously vaccinated with Infanrix hexa vaccine	Combined Diphtheria, Tetanus, Acellular Pertussis, Hepatitis B, Inactivated Polio, Haemophilus influenzae Type b Vaccine	112688	Diphtheria; Tetanus; Acellular Pertussis; Hepatitis B; Poliomyelitis; Haemophilus influenzae type b	Phase 4	https://www.gsk-studyregister.com/en/trial-details/?id=112688	http://clinicaltrials.gov/show/NCT01333813	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022538-10	Y	N	Y	Y	Y	Y	Y	An annotated case report form is not available for this study. A blank case report form will be provided.	1-Mar-2015
1795	GSK	Partially-blind Immunogenicity and Safety Study of GSK Biologicals' Seasonal Influenza Vaccine GSK2321138A in Adults.	Influenza Vaccine (Quadrivalent)	114269	Influenza	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=114269	http://clinicaltrials.gov/show/NCT01204671	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-021034-63	Y	Y	Y	Y	Y	Y	Y		1-Jun-2014
1797	GSK	Immunogenicity, Reactogenicity and Safety of GSK Biologicals' Quadrivalent Influenza Vaccine FLU Q-QIV (GSK2282512A) When Administered Intramuscularly to Adults 18 Years of Age and Older	Influenza Vaccine (Quadrivalent)	112963	Influenza	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=112963	http://clinicaltrials.gov/show/NCT01196975	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-021074-11	Y	Y	Y	Y	Y	Y	Y		1-Jun-2014
1798	GSK	Clinical study in children, 6 months to 3 years of age, to assess the immunogenicity and safety of two dose levels of thimerosal-free Fluviral® vaccine, using a licensed influenza virus vaccine, Vaxigrip® as the control	Influenza Vaccine (Split Virion, Inactivated, Fluviral)	111635	Influenza	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=111635	http://clinicaltrials.gov/show/NCT00778895		Y	N	Y	Y	Y	Y	Y	An annotated case report form is not available for this study. A blank case report form will be provided.	1-Jun-2014
1799	GSK	A randomised, open-label, parallel-group design study to evaluate the pharmacokinetic characteristics, safety and tolerability of single oral doses of three prototype 300mg enteric coated - modified release formulations of Lamotrigine in healthy subjects.	lamotrigine	LAM105377	Epilepsy	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=105377		https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000111-14	Y	Y	Y	Y	Y	Y	Y	A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Jun-2014
1800	GSK	A two-part, open label study in healthy, young, male and female volunteers to evaluate the pharmacokinetic characteristics of single and repeat oral doses of Lamictal SR/XR prototype formulations and to study the effects of food on pharmacokinetic parameters.	lamotrigine	LAM10005	Epilepsy	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=LAM10005			Y	Y	Y	Y	Y	Y	Y	A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Jun-2014
1801	GSK	An open-label study in healthy male and female volunteers to evaluate the repeat dose pharmacokinetics and dose strength equivalence of lamotrigine enteric coated modified release tablets over the dose range 25-200 mg.	lamotrigine	LAM10017	Epilepsy	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=LAM10017		https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001137-15	Y	Y	Y	Y	Y	Y	Y	A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Jun-2014
1802	GSK	Open label, safety study for use of lamictal in patients with diabetic neuropathy	lamotrigine	NPP30006	Neuropathy, Diabetic	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=NPP30006			Y	Y	Y	Y	Y	Y	Y	This is a follow-up study to NPP30004 and NPP30005. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Jun-2014
1803	GSK	A Multicenter, Double-blind, Randomized, Parallel-group Evaluation of LAMICTAL Extended-Release Adjunctive Therapy in Patients with Primary Generalized Tonic-Clonic Seizures	lamotrigine	LAM100036	Epilepsy, Tonic-Clonic	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=LAM100036	http://clinicaltrials.gov/show/NCT00104416	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-004343-21	Y	Y	Y	Y	Y	Y	Y		1-Jun-2014
1804	GSK	A Multicenter, Double-Blind, Randomized, Parallel-group Evaluation of LAMICTAL Extended-release Adjunctive Therapy in Subjects with Partial Seizures	lamotrigine	LAM100034	Epilepsy, Partial	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=LAM100034	http://clinicaltrials.gov/show/NCT00113165	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-004342-41	Y	Y	Y	Y	Y	Y	Y		1-Jun-2014
1805	GSK	An open-label, randomised, single-dose, parallel-group study to evaluate the pharmacokinetic characteristics, safety and tolerability of up to two formulations (with different taste masking approaches) of an orally disintegrating tablet (ODT) of lamotrigine at 25mg and 200mg versus the immediate release (IR) lamotrigine in healthy subjects	lamotrigine	LBI108614	Mental Disorders	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=LBI108614	http://clinicaltrials.gov/show/NCT00410371		Y	Y	Y	Y	Y	Y	Y		1-Jun-2014
1806	GSK	A Multicenter, Double-Blind, Placebo-Controlled, Fixed-Dose, 8-Week Evaluation of the Efficacy and Safety of Lamotrigine in the Treatment of Depression in Patients with Type II Bipolar Disorder	lamotrigine	SCA100223	Bipolar Disorder	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=SCA100223	http://clinicaltrials.gov/show/NCT00274677		N	Y	Y	Y	Y	Y	Y	An analysis-ready dataset is not available for this study.	1-Jun-2014
1807	GSK	Double blind placebo controlled study of lamictal in acute bipolar depression	lamotrigine	SCA30924	Bipolar Disorder	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=SCA30924	http://clinicaltrials.gov/show/NCT00056277		N	Y	Y	Y	Y	Y	Y	An analysis-ready dataset is not available for this study.	1-Jun-2014
1808	GSK	Lamictal in Combination with Newer and Older Antiepileptic Drugs and as Monotherapy: A Practical Clinical Assessment of Tolerability and Clinical Effectiveness (The TARGET Study: Trial to Assess and Refine Global Epilepsy Treatment)	lamotrigine	LAM40091	Epilepsy	Phase 4	https://www.gsk-studyregister.com/en/trial-details/?id=LAM40091			N	Y	Y	Y	Y	Y	Y	An analysis-ready dataset is not available for this study. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Jun-2014
1809	GSK	A Multicenter, Double-blind, Randomized Study to Evaluate the Safety and Efficacy of Lamotrigine 200mg/day, 300mg/day, and 400mg/day Compared with Placebo in Subjects with Painful Diabetic Neuropathy	lamotrigine	NPP30004	Neuropathy, Diabetic	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=NPP30004			N	Y	Y	Y	Y	Y	N	A follow-on study NPP30006 was conducted. An analysis-ready dataset is not available for this study. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Jun-2014
1810	GSK	A Multicenter, Double-blind, Randomized Study to Evaluate the Safety and Efficacy of Lamotrigine 200mg/day, 300mg/day, and 400mg/day Compared with Placebo in Subjects with Painful Diabetic Neuropathy	lamotrigine	NPP30005	Neuropathy, Diabetic	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=NPP30005			N	Y	Y	Y	Y	Y	Y	A follow-on study NPP30006 was conducted. An analysis-ready dataset is not available for this study. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Jun-2014
1811	GSK	A Multicenter, Double-blind, Placebo-controlled, Randomized, Fixed-dose Evaluation of the Safety and Efficacy of Lamotrigine in the Long-term Prevention of Relapse and Recurrence of Depression and/or Mania in Subjects with Bipolar I Disorder	lamotrigine	SCAB2003 (105-605)	Bipolar Disorder	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=SCAB2003			N	Y	Y	Y	Y	Y	Y	An analysis-ready dataset is not available for this study. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Jun-2014
1812	GSK	Open-Label, Multicenter, Randomized Trial to Evaluate the Development of Components of Polycystic Ovary Syndrome (PCOS) in Female Subjects Initiating Lamotrigine or Valproate Either as Monotherapy for Newly Diagnosed Epilepsy or as Adjunctive Therapy for Inadequately Controlled Epilepsy	lamotrigine	LAM30007	Epilepsy	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=LAM30007			N	Y	Y	Y	Y	Y	Y	An analysis-ready dataset is not available for this study. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Jun-2014
1813	GSK	A Multicenter, Double-Blind, Randomized Conversion to Monotherapy Comparison of Two Doses of Lamotrigine for the Treatment of Partial Seizures	lamotrigine	LAM30055	Epilepsy, Partial	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=LAM30055	http://clinicaltrials.gov/show/NCT00355082		Y	Y	Y	Y	Y	Y	Y		1-Jun-2014
1814	GSK	A Multi-Center, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Evaluation of Lamotrigine Adjunctive Therapy in Subjects wtih Primary Generalized Tonic-Clonic Seizures	lamotrigine	LAM40097	Epilepsy, Tonic-Clonic	Phase 4	https://www.gsk-studyregister.com/en/trial-details/?id=LAM40097	http://clinicaltrials.gov/show/NCT00043901		Y	Y	Y	Y	Y	Y	Y		1-Jun-2014
1815	GSK	An Open-label, Double Conversion Study to Characterize the Pharmacokinetics of Lamotrigine when Switching Patients with Epilepsy on LAMICTAL Immediate-release to Extended-release Formulation and Vice Versa	lamotrigine	LEP103944	Epilepsy	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=LEP103944	http://clinicaltrials.gov/show/NCT00264615		Y	Y	Y	Y	Y	Y	Y		1-Jun-2014
1816	GSK	A Double-Blind, Placebo-Controlled, Add-On Clinical Trial of the Safety, Pharmacokinetics and Efficacy of Lamictal in Pediatric Age Subjects (1-24 months)	lamotrigine	LAM20006	Epilepsy	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=LAM20006	http://clinicaltrials.gov/show/NCT00043875		N	Y	Y	Y	Y	Y	Y	An analysis-ready dataset is not available for this study.	1-Jun-2014
1817	GSK	An Open-Label, Uncontrolled, Long-Term Study to Assess the Safety of LAMICTAL in Pediatric Subjects Previously Enrolled in Protocol LAM20006 and In LAMICTAL-naive subjects (1-24 months of age)	lamotrigine	LAM20007	Epilepsy	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=LAM20007	http://clinicaltrials.gov/show/NCT00044278		N	Y	Y	Y	Y	Y	Y	An analysis-ready dataset is not available for this study.	1-Jun-2014
1818	GSK	Double-blind Randomized Trial of Cognitive Effects of LAMICTAL (lamotrigine) versus Topiramate in Epilepsy	lamotrigine	LAM40112	Epilepsy	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=LAM40112			N	Y	Y	Y	Y	Y	Y	An analysis-ready dataset is not available for this study. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Jun-2014
1819	GSK	A randomised, blinded, parallel group study to investigate the potential pharmacokinetic interaction between lamotrigine and risperidone in healthy, non-smoking, male volunteers.	lamotrigine	SCA101963	Schizophrenia	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=101963		https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-004480-29	Y	N	Y	Y	Y	Y	N	An annotated case report form and a reporting and analysis plan are not available for this study. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Jun-2014
1820	GSK	A study to evaluate the effect of repeat oral doses of lamotrigine on cardiac conduction as assessed by 12-Lead ECG as compared to placebo and single oral doses of moxifloxacin.	lamotrigine	SCA104648	Epilepsy	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=104648		https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003117-32	Y	Y	Y	Y	Y	Y	N	A reporting and analysis plan is not available for this study. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Jun-2014
1821	GSK	Lamictal for use in treatment of Bipolar Disorder In Adults. A Practical Clinical Assessment of Tolerability and Clinical Effectiveness.	lamotrigine	SCA40917	Bipolar Disorder	Phase 4	https://www.gsk-studyregister.com/en/trial-details/?id=SCA40917	http://clinicaltrials.gov/show/NCT00067938		Y	N	Y	Y	Y	Y	Y	An annotated case report form is not available for this study.	1-Jun-2014
1822	GSK	A Multicenter, Double-Blind, Randomized, Placebo-Controlled Evaluation of LAMICTAL (lamotrigine) in Adult Subjects with HIV-Associated Peripheral Neuropathy	lamotrigine	LAM40006	Peripheral Neuropathies	Phase 4	https://www.gsk-studyregister.com/en/trial-details/?id=LAM40006			N	Y	Y	Y	Y	Y	Y	An analysis-ready dataset is not available for this study. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Jun-2014
1823	GSK	A Multicenter, Open-Label Conversion of Valproate Monotherapy to Lamotrigine Monotherapy in Patients with Epilepsy	lamotrigine	LAM40013	Epilepsy	Phase 4	https://www.gsk-studyregister.com/en/trial-details/?id=LAM40013	http://clinicaltrials.gov/show/NCT00043914		N	Y	Y	Y	Y	Y	Y	An analysis-ready dataset is not available for this study.	1-Jun-2014
1824	GSK	A randomised, partially blinded, parallel group study to investigate the potential pharmacokinetic interaction between lamotrigine and olanzapine in healthy, non-smoking, male volunteers.	lamotrigine	SCA10908	Bipolar Disorder	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=SCA10908			N	Y	Y	Y	Y	Y	N	An analysis-ready dataset and a reporting and analysis plan are not available for this study. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Jun-2014
1825	GSK	A randomised, partially blinded, parallel group study to investigate the potential pharmacokinetic interaction between lamotrigine and oxcarbazepine in healthy, non-smoking, male volunteers.	lamotrigine	SCA10910	Bipolar Disorder	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=SCA10910			N	N	Y	Y	Y	Y	Y	An analysis-ready dataset and an annotated case report form are not available for this study. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Jun-2014
1826	GSK	A Multicenter, Double-Blind, Placebo-Controlled, Fixed-Dose Evaluation of the Safety, Efficacy, and Tolerability of LAMICTAL (Lamotrigine) in the Treatment of a Major Depressive Episode in Patients with Type I Bipolar Disorder	lamotrigine	SCA40910	Bipolar Disorder	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=SCA40910			N	Y	Y	Y	Y	Y	Y	An analysis-ready dataset is not available for this study. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Jun-2014
1827	GSK	Double blind, double-dummy, randomised, placebo controlled study to evaluate the effect of single doses of drug A (lamotrigine) and drug B (vofopitant) alone and in combination on resting motor threshold in healthy subjects	lamotrigine	LNK112676	Bipolar Disorder	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=112676	http://clinicaltrials.gov/show/NCT00907985	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-007451-28	Y	Y	Y	Y	Y	Y	Y		1-Mar-2015
1828	GSK	An Open-label Evaluation of LAMICTAL (lamotrigine) Monotherapy for the Treatment of Newly-diagnosed Typical Absence Seizures in Children and Adolescents	lamotrigine	LAM100118	Seizure, Absence	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=LAM100118	http://clinicaltrials.gov/show/NCT00144872		Y	Y	Y	Y	Y	Y	Y		1-Jun-2014
1829	GSK	A Multicenter, Randomized, Double-Blind, Parallel Group Study to Evaluate the Efficacy and Safety of a Flexible Dose of Lamotrigine Compared to Placebo as an Adjunctive Therapy to an Atypical Antipsychotic Agent(s) in Subjects with Schizophrenia	lamotrigine	SCA101464	Schizophrenia	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=101464	http://clinicaltrials.gov/show/NCT00086593		N	N	Y	Y	Y	Y	Y	An analysis-ready dataset and an annotated case report form are not available for this study. A blank case report form will be provided.	1-Jun-2014
1830	GSK	A Multi-Center, Double blind, Placebo-controlled, Randomized, Parallel Group Evaluation of the Efficacy of a Flexible Dose of Lamotrigine versus Placebo As Add-On Therapy In Schizophrenia	lamotrigine	SCA30926	Schizophrenia	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=SCA30926	http://clinicaltrials.gov/show/NCT00071747		N	N	Y	Y	Y	Y	Y	An analysis-ready dataset and an annotated case report form are not available for this study. A blank case report form will be provided.	1-Jun-2014
1831	GSK	An open, randomised, parallel group study in healthy, young, male and female volunteers to evaluate the pharmacokinetic characteristics of single oral does of new LAMICTAL™ formulations.	lamotrigine	LAM10004	Epilepsy	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=LAM10004			Y	Y	Y	Y	Y	Y	Y	A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Jun-2014
1832	GSK	An open-label, non-randomised, single-sequence study to investigate the effects of the combined oral contraceptive pill on the pharmacokinetics of lamotrigine and the effects of lamotrigine on the pharamcokinetics of the combined oral contraceptive pill in healthy young female subjects.	lamotrigine	LAM10016	Epilepsy	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=LAM10016			N	N	Y	Y	Y	Y	Y	An analysis-ready dataset is not available for this study. An annotated case report form is not available for this study. A blank case report form will be provided. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Jun-2014
1881	GSK	A 12-Week, Double-Blind, Placebo-Controlled, Twice-Daily Dosing Study to Assess the Efficacy and Safety of Ropinirole in Patients Suffering from Restless Legs Syndrome (RLS) Requiring Extended Treatment Coverage	ropinirole	RRL100013	Restless Legs Syndrome	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=100013			Y	Y	Y	Y	Y	Y	Y	A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Jun-2014
1882	GSK	A 12-week, double-blind, placebo-controlled, parallel group study to assess the efficacy and safety of intermittent dosing of ropinirole in patients with Restless Legs Syndrome (RLS)	ropinirole	RRL100310	Restless Legs Syndrome	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=100310	http://clinicaltrials.gov/show/NCT00225862		Y	Y	Y	Y	Y	Y	Y		1-Jun-2014
1883	GSK	An open-label, randomised, two part study to investigate the relative bioavailability of Ropinirole new and standard, marketed formulations and the effect of food on the pharmacokinetics of Ropinirole new formulation in early stage Parkinson’s disease subjects	ropinirole	101468/164	Restless Legs Syndrome	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=101468/164			N	Y	Y	Y	Y	Y	Y	A follow-on study 101468/196 was conducted. An analysis-ready dataset is not available for this study. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Jun-2014
1884	GSK	An open-label, up-titration study to assess the dose proportionality of ropinirole controlled release (CR) and to demonstrate the bioequivalence of ropinirole CR (1 x 8 mg) compared to the ropinirole CR (4 x 2 mg) in Parkinson's Disease patients not receiving other dopaminergic therapies.	ropinirole	101468/165	Parkinson Disease	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=101468/165			Y	Y	Y	Y	Y	Y	Y	Extension study 101468/248 was conducted. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Jun-2014
1885	GSK	A Phase II, randomised, double-blind, active-controlled, dose-escalation study to determine the maximum well-tolerated starting dose of a new formulation of ropinirole in Parkinson's Disease patients not receiving other dopaminergic therapies	ropinirole	SKF-101468/166	Parkinson Disease	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=101468/166			Y	Y	Y	Y	Y	Y	Y	A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Jun-2014
1886	GSK	A Randomised, Double Blind, Three Period, Cross-Over Study of Ropinirole CR and Ropinirole IR Monotherapy	ropinirole	101468/168	Parkinson Disease	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=101468/168			Y	Y	Y	Y	Y	Y	Y	Extension study 101468/248 was conducted. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Jun-2014
1887	GSK	A Phase III, Randomised, Double-blind, Placebo-controlled, Parallel Group Study of Six Months Treatment with Ropinirole CR as Adjunctive Therapy in Patients with Parkinson's Disease who are not Optimally Controlled on L-dopa	ropinirole	101468/169	Parkinson Disease	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=101468/169	http://clinicaltrials.gov/show/NCT00381472		Y	Y	Y	Y	Y	Y	Y	Extension study 101468/248 was conducted.	1-Jun-2014
1888	GSK	A Study of the Maintained Efficacy and Safety of Ropinirole Versus Placebo in the Long Term Treatment of Restless Legs Syndrome (RLS)	ropinirole	SKF-101468/188	Restless Legs Syndrome	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=101468/188			Y	Y	Y	Y	Y	Y	Y	A follow-on study 101468/192 was conducted. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Jun-2014
1889	GSK	A 12 Week, Double-Blind, Placebo-Controlled, Parallel Group Study to Assess the Efficacy and Safety of Ropinirole in Patients Suffering from Restless Legs Syndrome (RLS).	ropinirole	SKF-101468/190	Restless Legs Syndrome	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=101468/190			Y	Y	Y	Y	Y	Y	Y	A follow-on study 101468/192 was conducted. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Jun-2014
1890	GSK	A 12 Week, Double-Blind, Placebo-Controlled, Parallel Group Study to Assess the Efficacy, Safety and Tolerability of Ropinirole in Subjects with Restless Legs Syndrome (RLS) Suffering from Periodic Leg Movements of Sleep (PLMS)	ropinirole	SKF-101468/191	Restless Legs Syndrome	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=101468/191			N	Y	Y	Y	Y	Y	Y	A follow-on study 101468/243 was conducted. An analysis-ready dataset is not available for this study. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Jun-2014
1891	GSK	A 52 Week Open-Label Extension Study of the Long-Term Safety of Ropinirole in Subjects Suffering from Restless Legs Syndrome (RLS)	ropinirole	101468/192	Restless Legs Syndrome	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=101468/192			N	Y	Y	Y	Y	Y	Y	This is a follow-up study to 101468/188, 101468/190, 101468/194 and 101468/218. An analysis-ready dataset is not available for this study. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Jun-2014
1892	GSK	A 12 Week, Double-Blind, Placebo-Controlled, Parallel Group Study to Assess the Efficacy and Safety of Ropinirole in Patients Suffering from Restless Legs Syndrome (RLS).	ropinirole	101468/194	Restless Legs Syndrome	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=101468/194			N	N	Y	Y	Y	Y	Y	Follow-on studies 101468/243 and 101468/192 were conducted. An analysis-ready dataset is not available for this study. An annotated case report form is not available for this study. A blank case report form will be provided. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Jun-2014
1893	GSK	101468/196: A Long-Term, Open-Label Continuation Study of Once Daily Administration of Ropinirole CR Tablets to Patients with Parkinson's Disease who Completed the Previous Ropinirole CR Studies 167 or 164	ropinirole	101468/196	Parkinson Disease	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=101468/196	http://clinicaltrials.gov/show/NCT00650104		Y	Y	Y	Y	Y	Y	Y	This is a follow-up study to 101468/164 and 101468/167.	1-Jun-2014
1894	GSK	An open study to compare the PK and tolerability of ropinirole administered as 5 different new formulations with the standard, marketed formulation in healthy volunteers	ropinirole	SKF-101468/197	Restless Legs Syndrome	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=101468/197			Y	Y	Y	Y	Y	Y	Y	A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Jun-2014
1895	GSK	An open, randomised, crossover, healthy volunteer study to compare the PK and tolerability of ropinirole as 3 different new formulations with the standard marketed formulation and to study the effects of a high fat meal on a new formulation	ropinirole	101468/198	Restless Legs Syndrome	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=101468/198			Y	Y	Y	Y	Y	Y	Y	A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Mar-2015
1896	GSK	An open label study conducted in healthy volunteers to characterize the pharmacokinetics of a new unmarketed formulation of ropinirole	ropinirole	101468/199	Restless Legs Syndrome	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=101468/199		https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000746-37	Y	Y	Y	Y	Y	Y	Y	A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Jun-2014
1897	GSK	A Single Blind, Parallel Group, Up-titration, Phase 1 Study in Healthy Volunteers to Determine a Starting Dose and Select an Up-titration Regimen for a new Formulation of Ropinirole	ropinirole	101468/201	Restless Legs Syndrome	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=101468/201		https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000250-23	Y	Y	Y	Y	Y	Y	Y	A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Jun-2014
1898	GSK	A 12-Week, Randomized, Double-Blind, Parallel Group, Multicentre Study to Assess the Tolerability and Clinical Benefits of Ropinirole Extended Release (XR) Tablets Compared with Ropinirole Immediate Release (IR) Tablets in Subjects with Restless Legs Syndrome (RLS)	ropinirole	101468/204	Restless Legs Syndrome	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=101468/204	http://clinicaltrials.gov/show/NCT00314860	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000184-25	Y	Y	Y	Y	Y	Y	Y		1-Jun-2014
1899	GSK	A 12-Week, Double-Blind, Placebo Controlled, Parallel Group Study to Assess the Efficacy and Safety of Ropinirole XR (Extended Release) in Patients with Restless Legs Syndrome	ropinirole	101468/205	Restless Legs Syndrome	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=101468/205	http://clinicaltrials.gov/show/NCT00197080		Y	Y	Y	Y	Y	Y	Y	A follow-on study 101468/206 was conducted. The raw data are included within the analysis-ready data for this study and are not provided separately.	1-Jun-2014
1900	GSK	A 52-Week, Open-Label Study to Assess the Long-Term Safety of Ropinirole Extended Release (XR) in Patients with Restless Legs Syndrome (RLS)	ropinirole	101468/206	Restless Legs Syndrome	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=101468/206	http://clinicaltrials.gov/show/NCT00355641		Y	Y	Y	Y	Y	Y	Y	This is a follow-up study to 101468/205 and ROX104805	1-Jun-2014
1901	GSK	A double-blind, randomized, placebo-controlled, parallel-group study to investigate the tolerability of a dose-escalating regimen of ropinirole in patients suffering from Restless Legs Syndrome (RLS).	ropinirole	SKF-101468/207	Restless Legs Syndrome	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=101468/207			Y	Y	Y	Y	Y	Y	Y	A follow-on study 101468/243 was conducted. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Jun-2014
1902	GSK	A Single-Blind, Randomised, Placebo-Controlled, Parallel-Group, Multicentre, Phase IIa Study to Determine the Pharmacokinetics and Tolerability of Ropinirole in Patients Suffering from Restless Legs Syndrome (RLS)	ropinirole	SKF-101468/218	Restless Legs Syndrome	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=101468/218			Y	Y	Y	Y	Y	Y	Y	A follow-on study 101468/192 was conducted. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Jun-2014
1903	GSK	An open label, randomised, five-way crossover single-dose pharmacokinetic study to assess dosage strength equivalence of ropinirole CR in healthy male and female volunteers	ropinirole	101468/219	Parkinson Disease	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=101468/219			Y	Y	Y	Y	Y	Y	Y	A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Jun-2014
1904	GSK	A two year Phase IIIb randomised, multicenter, double-blind, SINEMET controlled, parallel group, flexible dose study, to assess the effectiveness of controlled release ropinirole add-on therapy to L-dopa at increasing the time to onset of dyskinesia in Parkinson's disease subjects.	ropinirole	101468/228	Parkinson Disease	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=101468/228	http://clinicaltrials.gov/show/NCT00363727		Y	Y	Y	Y	Y	Y	Y		1-Jun-2014
1905	GSK	A 52 Week Open-Label Extension Study of the Long-Term Safety of Ropinirole in Subjects Suffering from Restless Legs Syndrome (RLS)	ropinirole	101468/243	Restless Legs Syndrome	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=101468/243			Y	Y	Y	Y	Y	Y	Y	This is a follow-up study to 101468/191, SKF-101468/194 and SKF-101468/207. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Jun-2014
1906	GSK	A 12-Week, Double-Blind, Placebo Controlled, Parallel Group Study to Assess the Efficacy and Safety of Ropinirole in Patients Suffering from Restless Legs Syndrome (RLS)	ropinirole	101468/249	Restless Legs Syndrome	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=101468/249	http://clinicaltrials.gov/show/NCT00363857		Y	Y	Y	Y	Y	Y	Y		1-Jun-2014
1907	GSK	An open label, single dose, dose rising, multi-centre study to assess the tolerability and pharmacokinetics of Ropinirole Immediate Release in adolescent patients with RLS.	ropinirole	101468/253	Restless Legs Syndrome	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=101468/253	http://clinicaltrials.gov/show/NCT00140712		Y	Y	Y	Y	Y	Y	Y		1-Jun-2014
1908	GSK	A study to evaluate the effect of repeated oral doses of ropinirole on cardiac conduction as assessed by 12-lead electrocardiogram compared to placebo and single oral doses of moxifloxacin (Bayer) as a positive control.	ropinirole	101468/902	Restless Legs Syndrome	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=101468/902			Y	Y	Y	Y	Y	Y	Y	A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Jun-2014
1910	GSK	A randomised, double blind, placebo-controlled, parallel group study to investigate the safety and efficacy of controlled-release ropinirole (CR) (1-24 mg) administered once daily for 12 weeks in subjects with fibromyalgia	ropinirole	ROF102100	Fibromyalgia Syndrome, Primary	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=ROF102100	http://clinicaltrials.gov/show/NCT00256893	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001680-22	Y	Y	Y	Y	Y	Y	Y		1-Jun-2014
1911	GSK	A parallel group study to evaluate the efficacy and safety of ropinirole for 26 weeks and to further evaluate the incidence of augmentation and rebound for a further 40 weeks open-label extension treatment period in subjects suffering from moderate to severe Restless Legs Syndrome.	ropinirole	ROR104836	Restless Legs Syndrome	Phase 4	https://www.gsk-studyregister.com/en/trial-details/?id=ROR104836	http://clinicaltrials.gov/show/NCT00329602	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-005372-32	Y	Y	Y	Y	Y	Y	Y		1-Jun-2014
1912	GSK	An Open-Label, Parallel-Group, Repeat-Dose Study to Investigate the Effects of End Stage Renal Disease and Haemodialysis on the Pharmacokinetics of Ropinirole (Study RRL103628)	ropinirole	RRL103628	Restless Legs Syndrome	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=RRL103628	http://clinicaltrials.gov/show/NCT00422994	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-006139-55	Y	Y	Y	Y	Y	Y	Y		1-Jun-2014
1913	GSK	A 12-Week, Multi-Center, Double-Blind, Placebo-Controlled, Parallel Group, Flexible Dose Polysomnography Study of Ropinirole Controlled Release for Restless Legs Syndrome (RLS) in RLS Patients with Sleep Disturbance and Periodic Limb Movements (PLM) During Sleep	ropinirole	RRL103660	Restless Legs Syndrome	Phase 4	https://www.gsk-studyregister.com/en/trial-details/?id=RRL103660	http://clinicaltrials.gov/show/NCT00373542		Y	Y	Y	Y	Y	Y	Y		1-Jun-2014
1914	GSK	A Multicentre, Open-Label Extension Study to Assess the Long-Term Safety, Tolerability and Efficacy of Rosiglitazone When Administered to Patients With Type 2 Diabetes Mellitus.	rosiglitazone	49653/009	Diabetes Mellitus, Type 2	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=49653/009			Y	Y	Y	Y	Y	Y	N	This is an extension study to 49653/015, 49653/020, and 49653/025. Reporting and analysis plan is not available for this study. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Jun-2014
1915	GSK	A 26 Week Randomised, Double-Blind, Multicentre Study to Investigate the Effects of Rosiglitazone on Insulin Requirements in Insulin-Treated Type 2 Diabetic Patients	rosiglitazone	49653/085	Diabetes Mellitus, Type 2	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=49653/085			Y	Y	Y	Y	Y	Y	Y	A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Jun-2014
1916	GSK	A 3-Year Open-Label, Multicenter, Active (Glyburide) Comparison Study, to Evaluate the Effect of BRL49653C 8mg once daily on Cardiovascular Function in Patients with Non-Insulin Dependent Diabetes Mellitus (NIDDM)	rosiglitazone	49653/097	Diabetes Mellitus, Type 2	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=49653/097			N	N	Y	Y	Y	Y	Y	An analysis-ready dataset is not available for this study. An annotated case report form is not available for this study. A blank case report form will be provided. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Jun-2014
1917	GSK	An Open-Label Extension Study to Assess the Long-Term Safety, Tolerability and Efficacy of Rosiglitazone When Administered Once or Twice Daily in Combination with Glyburide to Patients with Non-Insulin Dependent Diabetes Mellitus (NIDDM)	rosiglitazone	49653/112	Diabetes Mellitus, Type 2	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=49653/112			Y	Y	Y	Y	Y	Y	N	This is an extension study to 49653/079 and 49653/096.  A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Jun-2014
1918	GSK	An Open-Label Extension Study to Assess the Long-Term Safety, Tolerability and Efficacy of Rosiglitazone When Administered Once or Twice Daily in Combination with Insulin to Patients with Type 2 Diabetes	rosiglitazone	49653/114	Diabetes Mellitus, Type 2	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=49653/114			N	Y	Y	Y	Y	Y	N	This is an extension study to 49653/082 and 49653/095. An analysis-ready dataset is not available for this study. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Jun-2014
1919	GSK	A Double-blind, Placebo-controlled, Parallel-group Study to Determine the Effect of BRL- 49653C Rosiglitazone, on Fat Distribution When Administered for 26 Weeks to Subjects With Impaired Glucose Tolerance (IGT)	rosiglitazone	BRL-049653/131	Diabetes Mellitus, Type 2	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=49653/131			N	N	Y	Y	Y	Y	Y	An analysis-ready dataset is not available for this study. An annotated case report form is not available for this study. A blank case report form will be provided. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Jun-2014
1920	GSK	A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Single-Attack Study to Evaluate the Onset of Efficacy of a New Formulation of Sumatriptan Tablets 50mg and 100mg in the Acute Treatment of Migraine	sumatriptan	SUM30047	Migraine Disorders	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=SUM30047			N	Y	Y	Y	Y	Y	Y	An analysis-ready dataset is not available for this study. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Jun-2014
1921	GSK	A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Single-Attack Study to Evaluate the Onset of Efficacy of a New Formulation of Sumatriptan Tablets 50mg and 100mg in the Acute Treatment of Migraine (EU study).	sumatriptan	SUM30053	Migraine Disorders	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=SUM30053			N	Y	Y	Y	Y	Y	Y	An analysis-ready dataset is not available for this study. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Jun-2014
1922	GSK	A randomized double-blind placebo-controlled crossover dose escalation study to examine the safety tolerability pharmacodynamics and pharmacokinetics of inhaled doses of GSK233719 in healthy normal volunteers (single and repeat dosing) and in healthy CYP2D6 poor metaboliser volunteers (single or repeat dosing).	umeclidinium bromide	AC4105209	Pulmonary Disease, Chronic Obstructive	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=105209		https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001420-39	Y	Y	Y	Y	Y	Y	Y	A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Mar-2015
1923	GSK	A single-centre, open-label, sequential, cross-over study to examine the safety, tolerability and pharmacokinetics of 3 ascending single intravenous doses, a single 1000μg oral dose and a single 1000μg inhaled dose of GSK573719 in healthy male volunteers.	umeclidinium bromide	AC4112008	Pulmonary Disease, Chronic Obstructive	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=112008	http://clinicaltrials.gov/show/NCT01110018	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-018429-20	Y	Y	Y	Y	Y	Y	Y		1-Jun-2014
1924	GSK	An open-label, two period study to determine the excretion balance and pharmacokinetics of 14C-GSK573719, administered as single dose of an oral solution and an intravenous infusion, to healthy male adults	umeclidinium bromide	AC4112014	Pulmonary Disease, Chronic Obstructive	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=112014	http://clinicaltrials.gov/show/NCT01362257	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-024564-17	Y	Y	Y	Y	Y	Y	Y		1-Jun-2014
1925	GSK	A randomised, double-blind, placebo-controlled, dose ascending, 2-cohort, parallel group study to examine the safety, tolerability and pharmacokinetics of once-daily inhaled doses of GSK573719 formulated with the excipient Magnesium Stearatein COPD subjects for 7 days	umeclidinium bromide	AC4105211	Pulmonary Disease, Chronic Obstructive	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=105211	http://clinicaltrials.gov/show/NCT00732472	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001095-77	Y	Y	Y	Y	Y	Y	Y		1-Jun-2014
1926	GSK	A single-centre, randomised, double-blind, placebo-controlled, dose-ascending, 3-cohort parallel-group study to evaluate the safety, tolerability, pharmacodynamics and pharmacokinetics of GSK573719 administered as singledoses (750 μg and 1000 μg) and repeat doses over 14 days (250 μg–1000 μg once-daily) of GSK573719 in healthy male and female subjects.	umeclidinium bromide	AC4106889	Pulmonary Disease, Chronic Obstructive	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=AC4106889	http://clinicaltrials.gov/show/NCT00475436	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000186-37	Y	Y	Y	Y	Y	Y	Y		1-Mar-2015
1927	GSK	A Randomized, Double-Blind, Placebo-Controlled, 3-Way Cross-Over Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of GSK573719 Administered Once- and Twice-Daily in Subjects with COPD	umeclidinium bromide	AC4113073	Pulmonary Disease, Chronic Obstructive	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=113073	http://clinicaltrials.gov/show/NCT00950807	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-014543-46	Y	Y	Y	Y	Y	Y	Y		1-Jun-2014
1928	GSK	A randomized, double-blind, parallel-group, placebo-controlled study to evaluate the efficacy and safety of GSK573719 delivered once-daily over 28 days in subjects with COPD	umeclidinium bromide	AC4113589	Pulmonary Disease, Chronic Obstructive	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=113589	http://clinicaltrials.gov/show/NCT01030965	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-016690-15	Y	Y	Y	Y	Y	Y	Y		1-Jun-2014
1929	GSK	A randomized, double blind, placebo controlled, incomplete block, crossover, dose ranging study to evaluate the dose response of GSK573719 administered once or twice daily over 7 days in patients with Chronic Obstructive Pulmonary Disease (COPD)	umeclidinium bromide	AC4115321	Pulmonary Disease, Chronic Obstructive	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=115321	http://clinicaltrials.gov/show/NCT01372410		Y	Y	Y	Y	Y	Y	Y		1-Jun-2014
1930	GSK	A12-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of GSK573719 Delivered Once-Daily via a Novel Dry Powder Inhaler in Subjects with Chronic Obstructive Pulmonary Disease	umeclidinium bromide	AC4115408	Pulmonary Disease, Chronic Obstructive	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=115408	http://clinicaltrials.gov/show/NCT01387230	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001645-33	Y	Y	Y	Y	Y	Y	Y		1-Jun-2014
1931	GSK	A randomised, double blind, placebo-controlled, double dummy, 4-way cross-over, dose ascending study to assess the safety, tolerability, pharmacodynamics and pharmacokinetics of single inhaled doses of GSK573719 (250, 500 and 1000 μg) and tiotropium bromide (18 μg) via DPI in COPD patients.	umeclidinium bromide	AC4108123	Pulmonary Disease, Chronic Obstructive	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=AC4108123	http://clinicaltrials.gov/show/NCT00515502	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000187-25	Y	Y	Y	Y	Y	Y	Y		1-Mar-2015
1932	GSK	A single centre, randomized, double-blind, dose ascending, placebo-controlled study, in two parts, to evaluate the safety, tolerability and pharmacokinetics of escalating single and repeat inhaled doses of GSK573719 and placebo formulated with the excipient magnesium stearate, in healthy subjects and in a healthy population of Cytochrome P450 Isoenzyme 2D6 poor metabolisers.	umeclidinium bromide	AC4110106	Pulmonary Disease, Chronic Obstructive	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=110106	http://clinicaltrials.gov/show/NCT00803673	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000055-97	Y	Y	Y	Y	Y	Y	Y		1-Jun-2014
1933	GSK	An open-label, multiple-dose, multicenter, pharmacokinetic, safety and tolerability study of valaciclovir oral suspension in infants and children with VZV infection	valaciclovir	HS210916	Varicella	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=HS210916			N	Y	Y	Y	Y	Y	Y	An analysis-ready dataset is not available for this study. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Jun-2014
1934	GSK	An International, Randomized, Double-Blind, Placebo-Controlled, Multicenter, 6-Month Study of the Efficacy and Safety of Valtrex 1g QD vs. Placebo for the Suppression of HSV-2 Genital Herpes in Newly Diagnosed Immunocompetent Patients	valaciclovir	HS2100275	Herpes Genitalis	Phase 4	https://www.gsk-studyregister.com/en/trial-details/?id=HS2100275	http://clinicaltrials.gov/show/NCT00158860		Y	Y	Y	Y	Y	Y	Y		1-Jun-2014
1935	GSK	An open-label, single-dose, multicenter, pharmacokinetic, safety and tolerability study of valaciclovir oral suspension in infants and children.	valaciclovir	HS210914	Herpes Simplex	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=HS210914	http://clinicaltrials.gov/show/NCT00297206		N	Y	Y	Y	Y	Y	Y	An analysis-ready dataset is not available for this study.	1-Jun-2014
1936	GSK	An open-label, multiple-dose, multicenter, pharmacokinetic, safety and tolerability study of valaciclovir oral suspension in infants and children with HSV infection	valaciclovir	HS210915	Herpes Simplex	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=HS210915			N	Y	Y	Y	Y	Y	Y	An analysis-ready dataset is not available for this study. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Jun-2014
1938	GSK	A Multicenter, Double-Blind, Placebo-Controlled Evaluation of Valaciclovir for the Reduction of the Length of Cold Sore Episodes	valaciclovir	HS230027	Herpes Labialis	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=HS230027			N	Y	Y	Y	Y	Y	Y	An analysis-ready dataset is not available for this study. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Jun-2014
1939	GSK	A Multicenter, Double-Blind, Placebo-Controlled Evaluation of Valaciclovir for the Prevention/Blockage of the Progression of Cold Sore Lesion Development	valaciclovir	HS230028	Herpes Labialis	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=HS230028			N	Y	Y	Y	Y	Y	Y	An analysis-ready dataset is not available for this study. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Jun-2014
1940	GSK	A Randomized, Double-Blind, Placebo-Controlled Evaluation of Valaciclovir for the Prevention of Herpes Simplex Virus (HSV) Transmission in Heterosexual Couples (Double-Blind Phase and Open-Label Suppression Phase)	valaciclovir	HS2AB3009	Herpes Simplex	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=HS2AB3009			N	Y	Y	Y	Y	Y	Y	An analysis-ready dataset is not available for this study. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Jun-2014
1941	GSK	An International, Randomized, Double-Blind, Placebo-Controlled Study of Valaciclovir for the Suppression of Recurrent Ano-Genital HSV Infections in HIV-Infected Subjects	valaciclovir	HS230018	Herpes Genitalis	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=HS230018			N	Y	Y	Y	Y	Y	Y	An analysis-ready dataset is not available for this study. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Jun-2014
1942	GSK	A Randomized, Double-Blind, Placebo-Controlled, Multicenter 60-Day Study Comparing the Efficacy of Valtrex 1 Gram Once Daily vs. Placebo Once Daily in Reducing Viral Shedding in Immunocompetent Subjects with Recurrent HSV-2 Genital Herpes	valaciclovir	HS2100273	Herpes Genitalis	Phase 4	https://www.gsk-studyregister.com/en/trial-details/?id=100273			Y	Y	Y	Y	Y	Y	Y	A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Jun-2014
1943	GSK	A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Two-Way Crossover Study to Investigate the Effect of VALTREX 1g Once Daily for 60 Days on Viral Shedding in HSV-2 Seropositive Subjects with No Previous History of Symptomatic Genital Herpes Infection.	valaciclovir	VLX103596	Infections, Herpesviridae	Phase 4	https://www.gsk-studyregister.com/en/trial-details/?id=VLX103596	http://clinicaltrials.gov/show/NCT00116844		Y	Y	Y	Y	Y	Y	Y		1-Jun-2014
1944	GSK	The Effect of Valacyclovir 1g Once Daily on HSV-2 Viral Shedding in Subjects Newly Diagnosed with Genital Herpes Infection	valaciclovir	VLX105832	Herpes Labialis	Phase 4	https://www.gsk-studyregister.com/en/trial-details/?id=VLX105832	http://clinicaltrials.gov/show/NCT00306293		Y	Y	Y	Y	Y	Y	Y		1-Jun-2014
1945	GSK	A Multicenter, Double-Blind, Placebo-Controlled Trial to Evaluate Daily Suppressive Therapy With VALTREX™ on the Rate of HSV Shedding in Subjects With Recurrent Genital Herpes	valaciclovir	HS240017	Herpes Genitalis	Phase 4	https://www.gsk-studyregister.com/en/trial-details/?id=HS240017			N	N	Y	Y	Y	Y	Y	An analysis-ready dataset is not available for this study. An annotated case report form is not available for this study. A blank case report form will be provided. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Jun-2014
1946	GSK	A Randomized, Double-Blind, Multicenter Study of VALTREX 500mg Suppressive Therapy in the Reduction of Anxiety Associated with Recurrent Genital Herpes	valaciclovir	HS240018	Herpes Genitalis	Phase 4	https://www.gsk-studyregister.com/en/trial-details/?id=HS240018			N	N	Y	Y	Y	Y	Y	An analysis-ready dataset is not available for this study. An annotated case report form is not available for this study. A blank case report form will be provided. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Jun-2014
1947	GSK	A Randomized, Double-Blind, Multicenter Study of VALTREX 500mg Suppressive Therapy in the Reduction of Anxiety Associated with Recurrent Genital Herpes	valaciclovir	HS240021	Herpes Genitalis	Phase 4	https://www.gsk-studyregister.com/en/trial-details/?id=HS240021			N	N	Y	Y	Y	Y	N	An analysis-ready dataset and a reporting and analysis plan are not available for this study. An annotated case report form is not available for this study. A blank case report form will be provided. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Jun-2014
1948	GSK	A Long-term Study to Evaluate the Safety and Tolerability of Fluticasone Furoate (FF)/GW642444 Inhalation Powder and FF Inhalation Powder in Japanese Subjects with asthma	vilanterol	HZA113989	Asthma	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=113989	http://clinicaltrials.gov/show/NCT01244984		Y	Y	Y	Y	Y	Y	Y		1-Jun-2014
1982	GSK	A Randomised, Double-Blind, Double-Dummy, Parallel-Group, Placebo-Controlled, Forced Dose Titration Study Evaluating the Efficacy and Safety of GW679769 and Paroxetine in Subjects with Major depressive Disorder (MDD)	casopitant	NKF100096	Depressive Disorder, Major	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=NKF100096	http://clinicaltrials.gov/show/NCT00413023	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-004984-32	Y	Y	Y	Y	Y	Y	Y	The raw data are included within the analysis-ready data for this study and are not provided separately.	1-Jul-2014
1983	GSK	A Randomized, Double-Blind, Parallel Group, Placebo-Controlled, Forced Dose Titration Study Evaluating the Efficacy and Safety of GW679769 and Paroxetine in Subjects with Social Anxiety Disorder	casopitant	NKF100110	Anxiety Disorders	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=NKF100110	http://clinicaltrials.gov/show/NCT00273039	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001336-77	Y	Y	Y	Y	Y	Y	Y		1-Jul-2014
1986	GSK	A Phase III Multicenter, Randomized, Double-blind, Parallel Group Study to Evaluate the Safety and Efficacy of the 30mg Intravenous Formulation of the Neurokinin-1 Receptor Antagonist GW679769 for Prevention of Postoperative Nausea and Vomiting in Female Subjects at High Risk for Emesis	casopitant	NKT102552	Nausea and Vomiting, Postoperative	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=NKT102552	http://clinicaltrials.gov/show/NCT00334152	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-005855-16	Y	Y	Y	Y	Y	Y	Y		1-Jul-2014
1987	GSK	A Phase III, Multicenter, Randomized, Double-blind, Parallel Group Study to Evaluate the Safety and Efficacy of 50mg Oral Dosing with the Neurokinin-1 Receptor Antagonist GW679769 for the Prevention of Postoperative Nausea and Vomiting in Female Subjects at High Risk for Emesis	casopitant	NKT102553	Nausea and Vomiting, Postoperative	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=NKT102553	http://clinicaltrials.gov/show/NCT00326248	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-005856-42	Y	Y	Y	Y	Y	Y	Y		1-Jul-2014
1988	GSK	An Open-Label, Non-Randomized, Pharmacokinetic and Safety Study of Multiple Oral Doses of GW679769 in Subjects with Renal Impairment	casopitant	NKT102783	Vomiting	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=NKT102783	http://clinicaltrials.gov/show/NCT00358813		Y	Y	Y	Y	Y	Y	Y		1-Jul-2014
1989	GSK	An Open-Label, Non-Randomized, Pharmacokinetic and Safety Study of Multiple Oral Doses of GW679769 in subjects with Hepatic Impairment	casopitant	NKT102785	Vomiting	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=NKT102785	http://clinicaltrials.gov/show/NCT00359177		Y	Y	Y	Y	Y	Y	Y		1-Jul-2014
1990	GSK	A two-part, dose-rising study to evaluate the safety, tolerability and pharmacokinetics of single intravenous doses of GW679769 when administered alone and in combination with intravenous or oral doses of dexamethasone in healthy adult subjects	casopitant	NKV100789	Nausea and Vomiting, Chemotherapy-Induced	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=100789			Y	Y	Y	Y	Y	Y	Y	A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Jul-2014
1998	GSK	A study to evaluate the safety, immunogenicity and efficacy of GlaxoSmithKline Biologicals’ candidate malaria vaccine RTS,S/AS02A, administered intramuscularly according to a 0, 1 and 2 month vaccination schedule in toddlers and children aged 1 to 4 years in a malaria-endemic region of Mozambique.	RTS,S Vaccine	257049/026	Malaria	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=257049/026	http://clinicaltrials.gov/show/NCT00197041		Y	N	Y	Y	Y	Y	Y	A follow-on study 104297 was conducted. The analysis-ready data from this study is provided in combined datasets with the analysis-ready data from 104297. An annotated case report form is not available for this study. A blank case report form will be provided	1-Jul-2014
1999	GSK	An open study for a 2-year period to confirm the safety and immunogenicity of the candidate malaria vaccine RTS,S/AS02A in Mozambican children aged 1 to 4 years at the time of first vaccine dose.	RTS,S Vaccine	104297	Malaria	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=104297	http://clinicaltrials.gov/show/NCT00323622		Y	N	Y	Y	Y	Y	Y	This is a follow-up study to 257049/026. The analysis-ready data from this study is provided in combined datasets with the analysis-ready data from 257049/026. An annotated case report form is not available for this study. A blank case report form will be provided.	1-Jul-2014
2000	ViiV	A Phase IIIb, randomized, open-label study of the safety and efficacy of GSK1349572 (dolutegravir, DTG) 50 mg once daily compared to darunavir/ritonavir (DRV/r) 800 mg/100 mg once daily each administered with fixed-dose dual nucleoside reverse transcriptase inhibitor therapy over 96 weeks in HIV-1 infected antiretroviral naïve adult subjects	dolutegravir	ING114915	Infection, Human Immunodeficiency Virus I	Phase 3	https://www.viiv-studyregister.com/study/19549	http://clinicaltrials.gov/ct2/show/NCT01449929		Y	Y	Y	Y	Y	Y	Y		1-Jul-2014
2062	GSK	An open-label, randomized, single-dose, two-way crossover study examining the bioequivalence of one newly formulated WELLBUTRIN SR† 200mg tablet versus two currently marketed WELLBUTRIN SR 100mg tablets in healthy volunteers.	bupropion	AK110022	Depressive Disorder	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=AK110022			N	N	Y	Y	Y	Y	N	An analysis-ready dataset and a reporting and analysis plan are not available for this study. An annotated case report form is not available for this study. A blank case report form will be provided. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Aug-2014
2063	GSK	A Multi-Centre, Randomised, Double-Blind, Parallel-Group, Placebo- and Active-Controlled, Flexible Dose Study Evaluating the Efficacy, Safety and Tolerability of Extended-Release Bupropion Hydrochloride (150mg - 300mg once daily), Extended-Release Venlafaxine Hydrochloride (75mg - 150mg once daily) and Placebo in Subjects with Major Depressive Disorder.	bupropion	AK130939	Depressive Disorder	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=AK130939			N	Y	Y	Y	Y	Y	Y	An analysis-ready dataset is not available for this study. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Aug-2014
2064	GSK	A Multi-Centre, Randomised, Double-Blind, Parallel-Group, Placebo- and Active-Controlled, Flexible Dose Study Evaluating the Efficacy, Safety and Tolerability of Extended-Release Bupropion Hydrochloride (150mg - 300mg once daily), Extended-Release Venlafaxine Hydrochloride (75mg - 150mg once daily) and Placebo in Subjects with Major Depressive Disorder.	bupropion	WXL101497	Depressive Disorder, Major	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=101497		https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-003803-19	N	Y	Y	Y	Y	Y	Y	An analysis-ready dataset is not available for this study. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Aug-2014
2065	GSK	An open-label, 2-period, sequential treatment, 1-way drug interaction study to evaluate the effect of ritonavir on bupropion pharmacokinetics in healthy volunteers	bupropion	WXL103106	Depressive Disorder	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=103106			Y	Y	Y	Y	Y	Y	Y	A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Aug-2014
2066	GSK	Single-Center, Randomized, Double-Blind, Placebo-Controlled, Four-Week Study to Assess the Safety of Multiple Fixed Doses of WELLBUTRIN SR (bupropion hydrochloride sustained release) Tablets in Outpatients with Untreated Stage I Hypertension	bupropion	WELL AK110021	Hypertension	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=AK110021			N	N	Y	Y	Y	Y	N	An analysis-ready dataset and a reporting and analysis plan are not available for this study. An annotated case report form is not available for this study. A blank case report form will be provided. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Aug-2014
2067	GSK	A 6 Month Multicenter, Randomized, Double-Blind, Pilot Study to Investigate the Tolerability and Efficacy of Bupropion SR Compared to Placebo for the Treatment of Mild Depressive Symptoms and Obesity, Followed by a 24-week Open-Label Extension	bupropion	WELL ZYB40021	Depressive Disorder	Phase 4	https://www.gsk-studyregister.com/en/trial-details/?id=ZYB40021			N	Y	Y	Y	Y	Y	Y	An analysis-ready dataset is not available for this study. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Aug-2014
2070	GSK	A study to evaluate the effect of casoptiant on cardiac conduction as assessed by 12-lead electrocardiogram as compared to placebo and moxifloxacin	casopitant	NKV103447	Nausea and Vomiting, Chemotherapy-Induced	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=103447			Y	N	Y	Y	Y	Y	Y	An annotated case report form is not available for this study. A blank case report form will be provided. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Aug-2014
2071	GSK	A non-randomised, open label, two period cross-over study to determine the excretion balance and metabolic disposition of [14C]-GW679769, administered as single doses of an oral solution and an intravenous infusion to healthy male subjects	casopitant	NKV103933	Nausea and Vomiting, Chemotherapy-Induced	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=103933		https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002032-96	Y	Y	Y	Y	Y	Y	Y	A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Aug-2014
2072	GSK	An open-label, two period, fixed sequence study of healthy subjects to assess the effect of repeat oral dosing of ketoconazole on the pharmacokinetics of a single oral dose of [GW679769]	casopitant	NKV105093	Nausea and Vomiting, Chemotherapy-Induced	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=NKV105093	http://clinicaltrials.gov/show/NCT00404378		Y	Y	Y	Y	Y	Y	Y		1-Aug-2014
2073	GSK	An Open-label Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Steady-State Warfarin when Co-administered with Repeat Doses of Casopitant [GW679769] in Healthy Adult Subjects.	casopitant	NKV105097	Nausea and Vomiting, Chemotherapy-Induced	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=NKV105097	http://clinicaltrials.gov/show/NCT00404274		Y	Y	Y	Y	Y	Y	Y		1-Aug-2014
2074	GSK	A Phase I, Randomized, Double-Blind Study to Assess the Effects of Repeat Oral Dosing of Ketoconazole on the Pharmacokinetics of Repeat Oral Dosing of Casopitant [GW679769] in Healthy Subjects	casopitant	NKV109990	Nausea and Vomiting, Chemotherapy-Induced	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=NKV109990	http://clinicaltrials.gov/show/NCT00460707		Y	Y	Y	Y	Y	Y	Y		1-Aug-2014
2084	GSK	A double-blind, multicentre, flexible dose, L-dopa controlled study of ropinirole to investigate A) neuroprotective effect as measured by 3D PET scanning, and B) ophthalmological safety, in patients with early Parkinson’s disease	ropinirole	SKF-101468/125	Parkinson Disease	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=101468/125			N	N	Y	Y	Y	Y	Y	An analysis-ready dataset is not available for this study. An annotated case report form is not available for this study. A blank case report form will be provided. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Aug-2014
2085	GSK	A Multicentre, Double-Blind, Parallel Group Study to Determine the Effects of Rosiglitazone on Insulin Sensitivity, Endothelial Function and Vascular Reactivity in Comparison With Metformin and Placebo When Administered to Patients With Non-insulin Dependent Diabetes Mellitus.	rosiglitazone	49653/025	Diabetes Mellitus, Type 2	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=49653/025			N	N	Y	Y	Y	Y	Y	Extension study 49653/009 was conducted. An analysis-ready dataset is not available for this study. An annotated case report form is not available for this study. A blank case report form will be provided. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Aug-2014
2112	GSK	A Randomized, Double-Blind, Placebo-Controlled, Two Year Parallel Group Study of the Efficacy and Safety of Dutasteride GI198745 0.5mg in the Treatment and Prevention of Progression of Benign Prostatic Hyperplasia, Followed by a Two-Year Open-Label Treatment Phase (Report on Year 1 Data)	dutasteride	ARIA3001_1	Prostatic Hyperplasia	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=ARIA3001			N	Y	Y	Y	Y	Y	Y	The data relating to this record represents an interim analysis of a 4-year study. A comprehensive dataset is available within ARIA3001 (Year 4). An Analysis-ready dataset is not available for this study. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Aug-2014
2113	GSK	A Randomized, Double-Blind, Placebo-Controlled, Two Year Parallel Group Study of the Efficacy and Safety of dutasteride GI198745 0.5mg in the Treatment and Prevention of Progression of Benign Prostatic Hyperplasia, Followed by a Two-Year Open-Label Treatment Phase (Report on 2 Year Data).	dutasteride	ARIA3001_2	Prostatic Hyperplasia	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=ARIA3001			N	Y	Y	Y	Y	Y	Y	The data relating to this record represents an interim analysis of a 4-year study. A comprehensive dataset is available within ARIA3001 (Year 4). An Analysis-ready dataset is not available for this study. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Aug-2014
2114	GSK	A Randomized, Double-Blind, Placebo-Controlled, Two-Year Parallel Group Study of the Efficacy and Safety of Dutasteride GI198745 0.5mg in the Treatment and Prevention of Progression of Benign Prostatic Hyperplasia, Followed by a Two-Year Open-Label Treatment Phase (Report on Open-Label Treatment Phase).	dutasteride	ARIA3001_4	Prostatic Hyperplasia	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=ARIA3001			N	Y	Y	Y	Y	Y	Y	This dataset is comprehensive of years 1 through 4 of this study. An analysis-ready dataset is not available for this study. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Aug-2014
2115	GSK	A Randomized, Double-Blind, Placebo-Controlled, Two Year Parallel Group Study of the Efficacy and Safety of GI198745 0.5mg in the Treatment and Prevention of Progression of Benign Prostatic Hyperplasia, Followed by a Two-Year Open-Label Treatment Phase (Report on 2 Year Data).	dutasteride	ARIA3002_2	Prostatic Hyperplasia	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=ARIA3002			N	Y	Y	Y	Y	Y	Y	The data relating to this record represents an interim analysis of a 4-year study. A comprehensive dataset is available within ARIA3002 (Year 4). An analysis-ready dataset is not available for this study. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Aug-2014
2116	GSK	A Randomized, Double-Blind, Placebo-Controlled, Two Year Parallel Group Study of the Efficacy and Safety of GI198745 0.5mg in the Treatment and Prevention of Progression of Benign Prostatic Hyperplasia, Followed by a Two-Year Open-Label Treatment Phase (Report on Open-Label Treatment Phase).	dutasteride	ARIA3002_4	Prostatic Hyperplasia	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=ARIA3002			N	Y	Y	Y	Y	Y	Y	This dataset is comprehensive of years 1 through 4 of this study. An analysis-ready dataset is not available for this study. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Aug-2014
2117	GSK	A Randomized, Double-Blind, Placebo-Controlled, Two-Year Parallel-Group Study of the Efficacy and Safety of GI198745 in the Treatment and Modification of Progression of Benign Prostatic Hyperplasia, Followed by a Two Year Open-Label GI198745 Treatment Phase (Report on Open-Label Treatment Phase).	dutasteride	ARIB3003_4	Prostatic Hyperplasia	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=ARIB3003			N	N	Y	Y	Y	Y	Y	This dataset is comprehensive of years 1 through 4 of this study. An analysis-ready dataset is not available for this study. An annotated case report form is not available for this study. A blank case report form will be provided. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Aug-2014
2118	GSK	A Six-Month, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Effects of Repeat Dose Oral Dutasteride GI198745 on Detrusor Pressure and Urinary Flow in Patients with Lower Urinary Tract Symptoms Suggestive of Bladder Outlet Obstruction, with Optional Six Month Open-Label Extension.	dutasteride	ARIB3004_1	Prostatic Hyperplasia	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=ARIB3004			N	N	Y	Y	Y	Y	N	This study was conducted in 2 phases - a Double-blind Phase and an Open-label Extension. A comprehensive dataset is available within the Open-label Extension. An analysis-ready dataset and a reporting and analysis plan are not available for this study. An annotated case report form is not available for this study. A blank case report form will be provided. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Aug-2014
2119	GSK	A Multicentre, Randomised, Double-Blind, Double-Dummy, Parallel-Group Study to Compare the Efficacy of Dutasteride/GI198745 0.5mg Once Daily Versus Finasteride 5mg Once Daily for 12 Months in the Treatment of Subjects with Benign Prostatic Hyperplasia (BPH), Followed by an Optional 24 Months Open Label Phase.	dutasteride	ARI40001_1	Prostatic Hyperplasia	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=ARI40001			N	N	Y	Y	Y	Y	N	This study was conducted in 2 phases - Year 1 and an Open-label Extension. A comprehensive dataset is available within the Open-label Extension. An analysis-ready dataset is not available for this study. An annotated case report form is not available for this study. A blank case report form will be provided. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Aug-2014
2121	GSK	Study in adults aged between 18 and 45 years to evaluate the reactogenicity and the immunogenicity of an experimental administration of GlaxoSmithKline Biologicals Fluarix vaccine (known as a-Rix in Belgium). Standard intramuscular and subcutaneous vaccine administration will be used as references	Influenza Vaccine (Split Virion, Inactivated)	104440-002	Influenza	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=104440-002			Y	N	Y	Y	Y	Y	Y	An annotated case report form is not available for this study. A blank case report form will be provided. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Jun-2014
2122	GSK	A Phase II, Placebo-Controlled, Double-Blind Study of Paroxetine in Depressed Outpatients	paroxetine	29060/01/001	Depressive Disorder	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=29060/01/001			N	N	Y	Y	Y	Y	N	An analysis-ready dataset is not available for this study. An annotated case report form and a reporting and analysis plan are not available for this study. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-May-2014
2123	GSK	A Double-Blind, Placebo-Controlled Study of Paroxetine in Depressed Outpatients	paroxetine	29060/02/001	Depressive Disorder	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=29060/02/001			N	N	Y	Y	Y	Y	N	This study has multiple results summaries on the GSK Study Register under the following clinical study identifiers: PAR 29060.02.001, PAR 29060.02.002, PAR 29060.02.003, and PAR 29060.02.004. This posting links only to PAR 29060.02.001. All other results summaries must be viewed directly from the GSK Study Register. An analysis-ready dataset is not available for this study. An annotated case report form and a reporting and analysis plan are not available for this study. A blank case report form will be provided. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-May-2014
2124	GSK	A Double-Blind, Imipramine- and Placebo-Controlled Study of Paroxetine in Depressed Outpatients	paroxetine	29060/03/001	Depressive Disorder	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=29060/03/001			N	N	Y	Y	Y	Y	N	This study has multiple results summaries on the GSK Study Register under the following clinical study identifiers: PAR 03 001, PAR 29060/03/002, PAR 29060.03.003, PAR 29060.03.004, PAR 29060.03.005, PAR 29060.03.006, and PAR03_001. This posting links only to PAR 03 001. All other results summaries must be viewed directly from the GSK Study Register. An analysis-ready dataset is not available for this study. An annotated case report form and a reporting and analysis plan are not available for this study. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-May-2014
2125	GSK	A Double-Blind Comparison of Paroxetine, Amitriptyline, and Placebo in Inpatients with Major Depressive Disorder with Melancholia	paroxetine	29060/07/001	Depressive Disorder, Major	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=29060/07/001			N	N	Y	Y	Y	Y	N	An analysis-ready dataset is not available for this study. An annotated case report form and a reporting and analysis plan are not available for this study. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-May-2014
2126	GSK	A Multicenter, Double-blind, Placebo-controlled Fixed-dose Evaluation of Four Doses of Paroxetine	paroxetine	29060/009	Depressive Disorder	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=29060/009			N	N	Y	Y	Y	Y	N	An analysis-ready dataset is not available for this study. An annotated case report form and a reporting and analysis plan are not available for this study. A blank case report form will be provided. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-May-2014
2127	GSK	A Double-blind comparative multicentre study of paroxetine plus supportive psychotherapy and psychotherapy alone in the prevention of recurrent suicidal behavior and episodes of intermittent brief depression	paroxetine	29060/057	Depressive Disorder	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=29060/057			N	N	Y	Y	Y	Y	N	An analysis-ready dataset is not available for this study. An annotated case report form and a reporting and analysis plan are not available for this study. A blank case report form will be provided. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-May-2014
2128	GSK	A double-blind comparative study of paroxetine and placebo in the treatment of episodes of intermittent brief depression (IBD)	paroxetine	29060/106	Depressive Disorder	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=29060/106			N	N	Y	Y	Y	Y	N	An analysis-ready dataset is not available for this study. An annotated case report form and a reporting and analysis plan are not available for this study. A blank case report form will be provided. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-May-2014
2129	GSK	A Multicenter, Randomized, Double-Blind, Placebo-Controlled Comparison of Paroxetine and Fluoxetine in the Treatment of Major Depressive Disorder	paroxetine	29060/128	Depressive Disorder, Major	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=29060/128			N	N	Y	Y	Y	Y	N	An analysis-ready dataset is not available for this study. An annotated case report form and a reporting and analysis plan are not available for this study. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-May-2014
2130	GSK	A Double-Blind, Randomized Trial of Paroxetine Versus Placebo In Patients With Depression Accompanied by Anxiety	paroxetine	29060/251	Depressive Disorder	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=29060/251			N	N	Y	Y	Y	Y	N	An analysis-ready dataset is not available for this study. An annotated case report form and a reporting and analysis plan are not available for this study. A blank case reports form will be provided. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-May-2014
2132	GSK	A Double-Blind Placebo Controlled Study to Compare Paroxetine with Maprotiline in the Treatment of Depression	paroxetine	26090/007	Depressive Disorder	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=26090/007			Y	N	Y	Y	Y	N	N	The data from this study is provided in combined datasets containing data from other paroxetine studies. A raw dataset is not available for this study. An annotated case report form and a reporting and analysis plan are not available for this study. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-May-2014
2133	GSK	A double-blind study to investigate the efficacy, safety and tolerability of Paroxetine in the treatment of depression in comparison with placebo	paroxetine	29060/276	Depressive Disorder	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=29060/276			Y	N	Y	Y	Y	N	N	The data from this study is provided in combined datasets containing data from other paroxetine studies. A raw dataset is not available for this study. An annotated case report form and a reporting and analysis plan are not available for this study. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-May-2014
2134	GSK	A Study to Assess the Effectiveness and Tolerance of Paroxetine by Double-Blind Comparison with Placebo and Mianserin	paroxetine	29060/012_3	Depressive Disorder	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=29060/012_3			Y	N	Y	Y	Y	N	N	The data from this study is provided in combined datasets containing data from other paroxetine studies. A raw dataset is not available for this study. An annotated case report form, a blank case report form and a reporting and analysis plan are not available for this study. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-May-2014
2135	GSK	A trial to assess the effectiveness and tolerance of paroxetine by double-blind comparison with placebo using a novel “shifted crossover” design	paroxetine	29060/282	Depressive Disorder	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=29060/282			Y	N	Y	Y	Y	N	Y	The data from this study is provided in combined datasets containing data from other paroxetine studies. A raw dataset is not available for this study. An annotated case report form is not available for this study. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-May-2014
2136	GSK	A double-blind, placebo-controlled, parallel group study of paroxetine in the treatment of dysthymia.	paroxetine	29060/327	Depressive Disorder	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=29060/327			N	N	Y	Y	Y	Y	Y	An analysis-ready dataset is not available for this study. An annotated case report form is not available for this study. A blank case report form will be provided. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-May-2014
2137	GSK	A Double-Blind, Placebo Controlled Trial to Evaluate the Clinical Effects of Immediate Release Paroxetine and Controlled Release Paroxetine in the Treatment of Major Depression in Elderly Patients	paroxetine	29060/487	Depressive Disorder	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=29060/487			N	N	Y	Y	Y	Y	N	An analysis-ready dataset is not available for this study. A reporting and analysis plan is not available for this study. An annotated case report form is not available for this study. A blank case report form will be provided. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-May-2014
2138	GSK	A double-blind, placebo-controlled multi-centre study to evaluate the efficacy and tolerability of Paroxetine in the treatment of post-stroke depression.	paroxetine	29060/625	Depressive Disorder, Major	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=29060/625			N	N	Y	Y	Y	Y	Y	An analysis-ready dataset is not available for this study. An annotated case report form is not available for this study. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-May-2014
2139	GSK	A Multi-center, Double-blind, Placebo-Controlled Study of Paroxetine and Imipramine in Adolescents with Unipolar Major Depression - Continuation Phase.	paroxetine	29060/329_1	Depressive Disorder	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=29060/329			N	N	Y	Y	Y	Y	Y	This study was conducted in 2 phases - an acute phase and a continuation phase. A comprehensive dataset for the complete study is available. An analysis-ready dataset is not available for this study. An annotated case report form is not available for this study. A blank case report form will be provided. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Aug-2014
2153	GSK	Assess reactogenicity & safety of a booster of either Tritanrix™-HepB/Hib-MenAC or Tritanrix™-HepB/Hiberix™ given (single-blind) at 15-18 (Philippines)/15-24 mths (Thailand) & a dose of Mencevax™ ACWY at 24-30 mths (open label)	Combined Diphtheria, Tetanus, Whole Cell Pertussis, Hepatitis B, Haemophilus influenzae Type b Vaccine	103812	Diphtheria; Haemophilus influenzae type b; Hepatitis B; Tetanus; Whole Cell Pertussis	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=104727 (Booster - 15-24 mths)	http://clinicaltrials.gov/show/NCT00228917		Y	N	Y	Y	Y	Y	Y	The safety results of this study 103812 are summarised with studies 104171 and 104727 on the GSK Study Register. An annotated case report form is not available for this study. A blank case report form will be provided.	1-Oct-2014
2154	GSK	Assess reactogenicity & safety of a booster of either Tritanrix™-HepB/Hib-MenAC or Tritanrix™-HepB/Hiberix™ given (single-blind) at 15-18 (Philippines)/15-24 mths (Thailand) & a dose of Mencevax™ ACWY at 24-30 mths (open label)	Combined Diphtheria, Tetanus, Whole Cell Pertussis, Hepatitis B, Haemophilus influenzae Type b Vaccine	104171	Diphtheria; Haemophilus influenzae type b; Hepatitis B; Tetanus; Whole Cell Pertussis	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=104727 (Booster - 15-24 mths)	http://clinicaltrials.gov/show/NCT00228917		Y	N	Y	Y	Y	Y	Y	The safety results of this study 104171 are summarised with studies 104727 and 104730 on the GSK Study Register. An annotated case report form is not available for this study. A blank case report form will be provided.	1-Oct-2014
2155	GSK	Study to evaluate immunogenicity, reactogenicity and safety of an investigational vaccination regimen as compared to extemporaneously mixed GlaxoSmithKline Biological’s Hiberix and Tritanrix-HepB vaccines, when administered intramuscularly in infants at 6, 10 and 14 weeks of age	Combined Diphtheria, Tetanus, Whole Cell Pertussis, Hepatitis B, Haemophilus influenzae Type b Vaccine	104430	Diphtheria; Haemophilus influenzae type b; Hepatitis B; Tetanus; Whole Cell Pertussis	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=104430	http://clinicaltrials.gov/show/NCT00612105		Y	N	Y	Y	Y	Y	Y	An annotated case report form is not available for this study. A blank case report form will be provided.	1-Oct-2014
2156	GSK	Assess immunogenicity, safety & reactogenicity of a 4th dose of GSK Biologicals’ Tritanrix™-HepB/Hib-MenAC at 15-24 m & of a dose of Mencevax™ ACWY at 24-30 m in subjects primed with 3 doses of Tritanrix™-HepB/Hib-MenAC	Combined Diphtheria, Tetanus, Whole Cell Pertussis, Hepatitis B, Haemophilus influenzae Type b Vaccine	104727	Diphtheria; Haemophilus influenzae type b; Hepatitis B; Tetanus; Whole Cell Pertussis	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=104727 (Booster - 15-24 mths)	http://clinicaltrials.gov/show/NCT00136604		Y	N	Y	Y	Y	Y	Y	This is a follow-up study to 100480. A follow-on study 104730 was conducted. An annotated case report form is not available for this study. A blank case report form will be provided. The results of this study 104727 are summarised with studies 104730 and 100480 on the GSK Study Register.	1-Oct-2014
2157	GSK	Demonstrate lot-to-lot consistency of final production method of GSK Biologicals' Hib-MenAC vaccine mixed extemporaneously with Tritanrix™-HepB & demonstrate its non-inferiority vs Tritanrix™-HepB/Hiberix™ in healthy infants at 2, 4 and 6 months	Combined Diphtheria, Tetanus, Whole Cell Pertussis, Hepatitis B, Haemophilus influenzae Type b Vaccine	104733	Diphtheria; Haemophilus influenzae type b; Hepatitis B; Tetanus; Whole Cell Pertussis	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=104733	http://clinicaltrials.gov/show/NCT00197275		Y	N	Y	Y	Y	Y	Y	An annotated case report form is not available for this study. A blank case report form will be provided.	1-Oct-2014
2158	GSK	Immune memory of GSK's DTPw-HBV/Hib vaccine by giving Plain PRP polysaccharide at 10 mths. Immuno & reacto of a booster dose of DTPw-HBV/Hib or DTPw-HBV or DTPw-HBV+Hib at 15-18 mths in infants previously primed with DTPw-HBV/Hib	Combined Diphtheria, Tetanus, Whole Cell Pertussis, Hepatitis B, Haemophilus influenzae Type b Vaccine (KFT)	104065	Diphtheria; Haemophilus influenzae type b; Hepatitis B; Tetanus; Whole Cell Pertussis	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=104065	http://clinicaltrials.gov/show/NCT00169442	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-003879-11	Y	N	Y	Y	Y	Y	Y	An annotated case report form is not available for this study. A blank case report form will be provided.	1-Oct-2014
2159	GSK	Study to assess immunogenicity and safety of GlaxoSmithKline Biologicals' Kft’s DTPw-HBV/Hib vs DTPwCSL-HBV/Hib Kft and vs concomitant administration of CSL’s Triple Antigen and GlaxoSmithKline Biologicals’ Hiberix, to infants at 2, 4, 6 months of age, after a birth dose of hepatitis B	Combined Diphtheria, Tetanus, Whole Cell Pertussis, Hepatitis B, Haemophilus influenzae Type b Vaccine (KFT)	104489	Diphtheria; Haemophilus influenzae type b; Hepatitis B; Tetanus; Whole Cell Pertussis	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=104489	http://clinicaltrials.gov/show/NCT00316680	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-003880-31	Y	N	Y	Y	Y	Y	Y	An annotated case report form is not available for this study. A blank case report form will be provided.	1-Oct-2014
2160	GSK	Immunogenicity, Reactogenicity & Safety of a Booster Dose of GSK Biologicals’ DTPw-HBV/Hib Kft Vaccine Vs GSK Biologicals’ DTPw-HBV/Hib Vaccine, in Infants Who Received a 3-Dose Primary Vaccination Course With the Same Vaccines.	Combined Diphtheria, Tetanus, Whole Cell Pertussis, Hepatitis B, Haemophilus influenzae Type b Vaccine (KFT)	106602	Diphtheria; Haemophilus influenzae type b; Hepatitis B; Tetanus; Whole Cell Pertussis	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=106602	http://clinicaltrials.gov/show/NCT00332566		Y	N	Y	Y	Y	Y	Y	An annotated case report form is not available for this study. A blank case report form will be provided.	1-Oct-2014
2161	GSK	Blinded, randomized study to evaluate the immunogenicity and safety of GlaxoSmithKline Biologicals’ measles-mumps-rubella-varicella candidate vaccine given to healthy children during the second year of life	Combined Measles, Mumps, Rubella, Varicella Vaccine	103388	Measles; Mumps; Rubella; Varicella	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=103388	http://clinicaltrials.gov/show/NCT00127010	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-004371-11	Y	N	Y	Y	Y	Y	Y	A follow-on study 104690 was conducted. The results of study 104690 are summarised with this study 103388 on the GSK Study Register. An annotated case report form is not available for this study. A blank case report form will be provided.	1-Oct-2014
2162	GSK	Blinded, randomised study to assess the immunogenicity and safety of GlaxoSmithKline (GSK) Biologicals’ live attenuated measles-mumps-rubella-varicella candidate vaccine when given to healthy children in their second year of life	Combined Measles, Mumps, Rubella, Varicella Vaccine	104020	Measles; Mumps; Rubella; Varicella	Phase 4	https://www.gsk-studyregister.com/en/trial-details/?id=104020	http://clinicaltrials.gov/show/NCT00126997	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-005123-18	Y	N	Y	Y	Y	Y	Y	An annotated case report form is not available for this study. A blank case report form will be provided.	1-Oct-2014
2163	GSK	Blinded, randomised, controlled study to evaluate the immunogenicity and safety of GlaxoSmithKline Biologicals’ combined measles-mumps-rubella-varicella candidate vaccine given to healthy children in their second year of life	Combined Measles, Mumps, Rubella, Varicella Vaccine	104389	Measles; Mumps; Rubella; Varicella	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=104389	http://clinicaltrials.gov/show/NCT00127023	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-005263-19	Y	N	Y	Y	Y	Y	Y	An annotated case report form is not available for this study. A blank case report form will be provided.	1-Sep-2015
2164	GSK	Comparative study evaluating the immunogenicity and safety of MeMuRu-OKA vaccine and measles-mumps-rubella vaccine (Priorix™) co-administered with varicella vaccine (Varilrix™) in children primed with measles-mumps-rubella vaccine	Combined Measles, Mumps, Rubella, Varicella Vaccine	105908	Measles; Mumps; Rubella; Varicella	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=105908	http://clinicaltrials.gov/show/NCT00353288	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-006065-14	Y	N	Y	Y	Y	Y	Y	An annotated case report form is not available for this study. A blank case report form will be provided.	1-Oct-2014
2165	GSK	Comparative study evaluating the immunogenicity & safety of MeMuRu-OKA vaccine & measles-mumps-rubella vaccine (Priorix™) co-administered with varicella vaccine (Varilrix™) in children primed with both measles-mumps-rubella & varicella vaccines	Combined Measles, Mumps, Rubella, Varicella Vaccine	105909	Measles; Mumps; Rubella; Varicella	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=105909	http://clinicaltrials.gov/show/NCT00352898	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-005825-75	Y	N	Y	Y	Y	Y	Y	An annotated case report form is not available for this study. A blank case report form will be provided.	1-Oct-2014
2166	GSK	Observer-blind monocentric study in adults aged between 18-60 years to evaluate reactogenicity and immunogenicity of 1 and 2 administrations of pandemic monovalent influenza vaccines administered at different antigen doses and adjuvanted or not	H5N1 Pandemic Influenza Vaccine	106750	Influenza	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=106750	http://clinicaltrials.gov/show/NCT00309634	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-006175-12	Y	N	Y	Y	Y	Y	Y	An annotated case report form is not available for this study. A blank case report form will be provided.	1-Oct-2014
2167	GSK	Evaluate immunogenicity & safety of a single or double-dose of the pandemic influenza candidate vaccine (GSK1562902A) given following a two-administration schedule (21 days apart) in adults over 60 yrs	H5N1 Pandemic Influenza Vaccine	108251	Influenza	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=108251	http://clinicaltrials.gov/show/NCT00397215	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004041-42	Y	N	Y	Y	Y	Y	Y	Follow-on studies 108252, 111275 and 111276 were conducted. The results of this study 108251 are summarised with studies 108252, 111275, and 111276 on the GSK Study Register. An annotated case report form is not available for this study. A blank case report form will be provided.	1-Oct-2014
2168	GSK	Evaluate immunogenicity & safety of a single or double-dose of the pandemic influenza candidate vaccine (GSK1562902A) given following a two-administration schedule (21 days apart) in adults over 60 yrs	H5N1 Pandemic Influenza Vaccine	108252	Influenza	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=108251	http://clinicaltrials.gov/show/NCT00397215		Y	N	Y	Y	Y	Y	Y	This is a follow-up study to 108251. Follow-on studies 111275 and 111276 were conducted. The results of this study 108252 are summarised with studies 108251, 111275, and 111276 on the GSK Study Register. An annotated case report form is not available for this study. A blank case report form will be provided.	1-Oct-2014
2169	GSK	Evaluate immunogenicity & safety of a single or double-dose of the pandemic influenza candidate vaccine (GSK1562902A) given following a two-administration schedule (21 days apart) in adults over 60 yrs	H5N1 Pandemic Influenza Vaccine	111275	Influenza	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=108251	http://clinicaltrials.gov/show/NCT00397215		Y	N	Y	Y	Y	Y	N	This is a follow-up study to 108251 and 108252. Follow-on study 111276 was conducted.The results of this study 111275 are summarised with studies 108251, 108252, and 111276 on the GSK Study Register. An annotated case report form is not available for this study. A blank case report form will be provided. A reporting and analysis plan is not available for this study.	1-Oct-2014
2170	GSK	Evaluate immunogenicity & safety of a single or double-dose of the pandemic influenza candidate vaccine (GSK1562902A) given following a two-administration schedule (21 days apart) in adults over 60 yrs	H5N1 Pandemic Influenza Vaccine	111276	Influenza	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=108251	http://clinicaltrials.gov/show/NCT00397215		Y	N	Y	Y	Y	Y	N	This is a follow-up study to 108251, 108252 and 111275.The results of this study 111276 are summarised with studies 108251, 108252, and 111275 on the GSK Study Register. An annotated case report form is not available for this study. A blank case report form will be provided. A reporting and analysis plan is not available for this study.	1-Oct-2014
2171	GSK	Phase III, open, multicenter Study to Assess the Long-Term Persistence of a Booster Dose of GSK Biologicals' Hib-MenC compared to a Booster Dose of Infanrix™ Hexa When Given to 14 month-old Subjects Primed in study DTPa-HBV-IPV-097 & Boosted in study Hib-MenC-TT-010 BST: DTPa-HBV-IPV-097	Haemophilus influenzae Type b, Meningococcal C-Tetanus Toxoid Conjugate Vaccine	106673	Haemophilus influenzae type b; Neisseria Meningitidis	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=106672	http://clinicaltrials.gov/show/NCT00322335		Y	N	Y	Y	Y	Y	Y	This is a follow-up study to 217744/097. The results of this study 106673 are summarised with studies 106672, 106675, 106679, and 106680 on the GSK Study Register. An annotated case report form is not available for this study. A blank case report form will be provided.	1-Oct-2014
2172	GSK	Phase III, open, multicenter Study to Assess the Long-Term Persistence of a Booster Dose of GSK Biologicals' Hib-MenC compared to a Booster Dose of Infanrix™ Hexa When Given to 14 month-old Subjects Primed in study DTPa-HBV-IPV-097 & Boosted in study Hib-MenC-TT-010 BST: DTPa-HBV-IPV-097	Haemophilus influenzae Type b, Meningococcal C-Tetanus Toxoid Conjugate Vaccine	106675	Haemophilus influenzae type b; Neisseria Meningitidis	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=106672	http://clinicaltrials.gov/show/NCT00322335		Y	N	Y	Y	Y	Y	Y	This is a follow-up study to 217744/097. The results of this study 106675 are summarised with studies 106672, 106673, 106679, and 106680 on the GSK Study Register. An annotated case report form is not available for this study. A blank case report form will be provided.	1-Oct-2014
2173	GSK	Phase III, open, multicenter Study to Assess the Long-Term Persistence of a Booster Dose of GSK Biologicals' Hib-MenC compared to a Booster Dose of Infanrix™ Hexa When Given to 14 month-old Subjects Primed in study DTPa-HBV-IPV-097 & Boosted in study Hib-MenC-TT-010 BST: DTPa-HBV-IPV-097	Haemophilus influenzae Type b, Meningococcal C-Tetanus Toxoid Conjugate Vaccine	106679	Haemophilus influenzae type b; Neisseria Meningitidis	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=106672	http://clinicaltrials.gov/show/NCT00322335		Y	N	Y	Y	Y	Y	Y	This is a follow-up study to 217744/097. The results of this study 106679 are summarised with studies 106672, 106673, 106675, and 106680 on the GSK Study Register. An annotated case report form is not available for this study. A blank case report form will be provided.	1-Oct-2014
2174	GSK	Phase III, open, multicenter Study to Assess the Long-Term Persistence of a Booster Dose of GSK Biologicals' Hib-MenC compared to a Booster Dose of Infanrix™ Hexa When Given to 14 month-old Subjects Primed in study DTPa-HBV-IPV-097 & Boosted in study Hib-MenC-TT-010 BST: DTPa-HBV-IPV-097	Haemophilus influenzae Type b, Meningococcal C-Tetanus Toxoid Conjugate Vaccine	106680	Haemophilus influenzae type b; Neisseria Meningitidis	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=106672	http://clinicaltrials.gov/show/NCT00322335		Y	N	Y	Y	Y	Y	Y	This is a follow-up study to 217744/097. The results of this study 106680 are summarised with studies 106672, 106673, 106675, and 106679 on the GSK Study Register. An annotated case report form is not available for this study. A blank case report form will be provided.	1-Oct-2014
2175	GSK	Evaluate the Effect of Several Risk Factors That Are Likely to Influence the Immunogenicity of GSK Biologicals’ Combined Hepatitis A & B Vaccine, vs Separately Administered Monovalent Hepatitis A and Hepatitis B Vaccines	twinrix	100382	Hepatitis A; Hepatitis B	Phase 4	https://www.gsk-studyregister.com/en/trial-details/?id=100382	http://clinicaltrials.gov/show/NCT00289731		Y	N	Y	Y	Y	Y	Y	The results of this study 100382 are summarised with studies 100383, 100384, and 100385 on the GSK Study Register. An annotated case report form is not available for this study. A blank case report form will be provided.	1-Oct-2014
2176	GSK	Evaluate the Effect of Several Risk Factors That Are Likely to Influence the Immunogenicity of GSK Biologicals’ Combined Hepatitis A & B Vaccine, vs Separately Administered Monovalent Hepatitis A and Hepatitis B Vaccines	twinrix	100383	Hepatitis A; Hepatitis B	Phase 4	https://www.gsk-studyregister.com/en/trial-details/?id=100382	http://clinicaltrials.gov/show/NCT00289731		Y	N	Y	Y	Y	Y	N	The results of this study 100383 are summarised with studies 100382, 100384, and 100385 on the GSK Study Register. An annotated case report form is not available for this study. A blank case report form will be provided. A reporting and analysis plan is not available for this study.	1-Oct-2014
2177	GSK	Evaluate the Effect of Several Risk Factors That Are Likely to Influence the Immunogenicity of GSK Biologicals’ Combined Hepatitis A & B Vaccine, vs Separately Administered Monovalent Hepatitis A and Hepatitis B Vaccines	twinrix	100384	Hepatitis A; Hepatitis B	Phase 4	https://www.gsk-studyregister.com/en/trial-details/?id=100382	http://clinicaltrials.gov/show/NCT00289731		Y	N	Y	Y	Y	Y	N	The results of this study 100384 are summarised with studies 100382, 100383, and 100385 on the GSK Study Register. An annotated case report form is not available for this study. A blank case report form will be provided. A reporting and analysis plan is not available for this study.	1-Oct-2014
2178	GSK	Evaluate the Effect of Several Risk Factors That Are Likely to Influence the Immunogenicity of GSK Biologicals’ Combined Hepatitis A & B Vaccine, vs Separately Administered Monovalent Hepatitis A and Hepatitis B Vaccines	twinrix	100385	Hepatitis A; Hepatitis B	Phase 4	https://www.gsk-studyregister.com/en/trial-details/?id=100382	http://clinicaltrials.gov/show/NCT00289731		Y	N	Y	Y	Y	Y	Y	The results of this study 100385 are summarised with studies 100382, 100383, and 100384 on the GSK Study Register. An annotated case report form is not available for this study. A blank case report form will be provided.	1-Oct-2014
2179	GSK	Evaluate the persistence of immune response of GSK Biologicals’ TWINRIX™ ADULT, administered according to 0,6 month schedule and 0,12 month schedule, in volunteers aged 12-15 years inclusive at the time of first vaccine dose	twinrix	100386	Hepatitis A; Hepatitis B	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=100386%20(EXT%20Y5)	http://clinicaltrials.gov/show/NCT00197171		Y	N	Y	Y	Y	Y	N	The results of this study 100386 are summarised with study 100387 on the GSK Study Register. An annotated case report form is not available for this study. A blank case report form will be provided. A reporting and analysis plan is not available for this study.	1-Oct-2014
2180	GSK	Evaluate the persistence of immune response of GSK Biologicals’ TWINRIX™ ADULT, administered according to 0,6 month schedule and 0,12 month schedule, in volunteers aged 12-15 years inclusive at the time of first vaccine dose	twinrix	100387	Hepatitis A; Hepatitis B	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=100386%20(EXT%20Y5)	http://clinicaltrials.gov/show/NCT00197171		Y	N	Y	Y	Y	Y	N	The results of this study 100387 are summarised with study 100386 on the GSK Study Register. An annotated case report form is not available for this study. A blank case report form will be provided. A reporting and analysis plan is not available for this study.	1-Oct-2014
2181	GSK	A double blind randomised, comparative study of the immunogenicity and reactogenicity of three different lots of GlaxoSmithKline Biologicals’ combined hepatitis A - hepatitis B vaccine when administered in healthy adults	twinrix	100551	Hepatitis A; Hepatitis B	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=100551 (EXT Y11)	http://clinicaltrials.gov/show/NCT00289770		Y	N	Y	Y	Y	Y	N	This is a follow-up study to 208127/021 and 208127/115 and 208127/119, a follow-on study 112267 was conducted. The results of this study 100551 are summarised with studies 100552, 100553, 100554, and 100555 on the GSK Study Register. An annotated case report form is not available for this study. A blank case report form will be provided. A reporting and analysis plan is not available for this study.	1-Oct-2014
2182	GSK	A double blind randomised, comparative study of the immunogenicity and reactogenicity of three different lots of GlaxoSmithKline Biologicals’ combined hepatitis A - hepatitis B vaccine when administered in healthy adults	twinrix	100552	Hepatitis A; Hepatitis B	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=100551 (EXT Y11)	http://clinicaltrials.gov/show/NCT00289770		Y	N	Y	Y	Y	Y	N	This is a follow-up study to 208127/021 and 208127/115 and 208127/119, a follow-on study 112267 was conducted. The results of this study 100552 are summarised with studies 100551, 100553, 100554, and 100555 on the GSK Study Register. An annotated case report form is not available for this study. A blank case report form will be provided. A reporting and analysis plan is not available for this study.	1-Oct-2014
2183	GSK	A double blind randomised, comparative study of the immunogenicity and reactogenicity of three different lots of GlaxoSmithKline Biologicals’ combined hepatitis A - hepatitis B vaccine when administered in healthy adults	twinrix	100553	Hepatitis A; Hepatitis B	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=100551 (EXT Y11)	http://clinicaltrials.gov/show/NCT00289770		Y	N	Y	Y	Y	Y	N	This is a follow-up study to 208127/021 and 208127/115 and 208127/119, a follow-on study 112267 was conducted. The results of this study 100553 are summarised with studies 100551, 100552, 100554, and 100555 on the GSK Study Register. An annotated case report form is not available for this study. A blank case report form will be provided. A reporting and analysis plan is not available for this study.	1-Oct-2014
2184	GSK	A double blind randomised, comparative study of the immunogenicity and reactogenicity of three different lots of GlaxoSmithKline Biologicals’ combined hepatitis A - hepatitis B vaccine when administered in healthy adults	twinrix	100554	Hepatitis A; Hepatitis B	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=100551 (EXT Y11)	http://clinicaltrials.gov/show/NCT00289770		Y	N	Y	Y	Y	Y	N	This is a follow-up study to 208127/021 and 208127/115 and 208127/119, a follow-on study 112267 was conducted. The results of this study 100554 are summarised with studies 100551, 100552, 100553 and 100555 on the GSK Study Register. An annotated case report form is not available for this study. A blank case report form will be provided. A reporting and analysis plan is not available for this study.	1-Oct-2014
2185	GSK	A double blind randomised, comparative study of the immunogenicity and reactogenicity of three different lots of GlaxoSmithKline Biologicals’ combined hepatitis A - hepatitis B vaccine when administered in healthy adults	twinrix	100555	Hepatitis A; Hepatitis B	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=100551 (EXT Y11)	http://clinicaltrials.gov/show/NCT00289770		Y	N	Y	Y	Y	Y	N	This is a follow-up study to 208127/021 and 208127/115 and 208127/119, a follow-on study 112267 was conducted. The results of this study 100555 are summarised with studies 100551, 100552, 100553 and 100554 on the GSK Study Register. An annotated case report form is not available for this study. A blank case report form will be provided. A reporting and analysis plan is not available for this study.	1-Oct-2014
2186	GSK	Long-Term Persistence Follow-up Study to Evaluate the Immune Persistence of GSK Biologicals' Combined Hepatitis A / Hepatitis B Vaccine in Healthy Adult Volunteers	twinrix	100556	Hepatitis A; Hepatitis B	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=100556 (Y11)	http://clinicaltrials.gov/show/NCT00289718		Y	N	Y	Y	Y	Y	N	This is a follow-up study to 208127/118. The results of this study 100556 are summarised with studies 100557, 100558, 100559, 100560, and 112266 on the GSK Study Register. An annotated case report form is not available for this study. A blank case report form will be provided. A reporting and analysis plan is not available for this study.	1-Oct-2014
2187	GSK	Long-Term Persistence Follow-up Study to Evaluate the Immune Persistence of GSK Biologicals' Combined Hepatitis A / Hepatitis B Vaccine in Healthy Adult Volunteers	twinrix	100557	Hepatitis A; Hepatitis B	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=100556 (Y11)	http://clinicaltrials.gov/show/NCT00289718		Y	N	Y	Y	Y	Y	N	This is a follow-up study to 208127/118. The results of this study 100557 are summarised with studies 100556, 100558, 100559,100560, and 112266 on the GSK Study Register. An annotated case report form is not available for this study. A blank case report form will be provided. A reporting and analysis plan is not available for this study.	1-Oct-2014
2188	GSK	Long-Term Persistence Follow-up Study to Evaluate the Immune Persistence of GSK Biologicals' Combined Hepatitis A / Hepatitis B Vaccine in Healthy Adult Volunteers	twinrix	100558	Hepatitis A; Hepatitis B	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=100556 (Y11)	http://clinicaltrials.gov/show/NCT00289718		Y	N	Y	Y	Y	Y	N	This is a follow-up study to 208127/118. The results of this study 100558 are summarised with studies 100556, 100557, 100559, 100560, and 112266 on the GSK Study Register. An annotated case report form is not available for this study. A blank case report form will be provided. A reporting and analysis plan is not available for this study.	1-Oct-2014
2190	GSK	Long-Term Persistence Follow-up Study to Evaluate the Immune Persistence of GSK Biologicals' Combined Hepatitis A / Hepatitis B Vaccine in Healthy Adult Volunteers	twinrix	100560	Hepatitis A; Hepatitis B	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=100556 (Y11)	http://clinicaltrials.gov/show/NCT00289718		Y	N	Y	Y	Y	Y	N	This is a follow-up study to 208127/118. The results of this study 100560 are summarised with studies 100556, 100557, 100558, and 100559 on the GSK Study Register. An annotated case report form is not available for this study. A blank case report form will be provided. A reporting and analysis plan is not available for this study.	1-Oct-2014
2191	GSK	Challenge dose administration of Twinrix™ or comparator 4 years after primary vaccination.	twinrix	111572	Hepatitis A; Hepatitis B	Phase 4	https://www.gsk-studyregister.com/en/trial-details/?id=111572	http://clinicaltrials.gov/show/NCT00684671	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000526-39	Y	N	Y	Y	Y	Y	Y	The results of this study 111572 are summarised with study 111149 on the GSK Study Register. An annotated case report form is not available for this study. A blank case report form will be provided.	1-Oct-2014
2192	GSK	Double-blind randomized study to evaluate the immunogenicity and reactogenicity of two different lots of GlaxoSmithKline Biologicals' inactivated hepatitis A vaccine containing 1440 EL.U of antigen per mL and injected according to a 0, 12 month schedule in healthy adult volunteers	Hepatitis A Vaccine, Inactivated	110681	Hepatitis A	Phase 4	https://www.gsk-studyregister.com/en/trial-details/?id=100571 (M138)	http://clinicaltrials.gov/show/NCT00291876		Y	N	Y	Y	Y	Y	Y	The results of this study 110681 are summarised with studies 100571, 100572, 100573, 100574, 100575, 110677, 110678, 110679, and 110680 on the GSK Study Register. An annotated case report form is not available for this study. A blank case report form will be provided.	1-Oct-2014
2193	GSK	Double-blind, randomized study to evaluate the immunogenicity and reactogenicity of three different lots of GlaxoSmithKline Biologicals' inactivated hepatitis A vaccine containing 1440 EL.U of antigen per mL and injected according to a 0, 6 month schedule in healthy adult subjects	Hepatitis A Vaccine, Inactivated	111032	Hepatitis A	Phase 4	https://www.gsk-studyregister.com/en/trial-details/?id=100576 (Y11)	http://clinicaltrials.gov/show/NCT00289757		Y	N	Y	Y	Y	Y	Y	The results of this study 111032 are summarised with studies 100576, 100577, 100578, 100579, 100580, 111028, 111029, 111030, and 111031 on the GSK Study Register. An annotated case report form is not available for this study. A blank case report form will be provided.	1-Oct-2014
2194	GSK	Long-Term Follow Up Study at Years 16-20, to Evaluate the Persistence of Immune Response of GlaxoSmithKline Biologicals' Hepatitis B Vaccine in Newborns of HBeAg+ and HBsAg+ Mothers	Hepatitis B Vaccine, Recombinant	100448	Hepatitis B	Phase 4	https://www.gsk-studyregister.com/en/trial-details/?id=100448	http://clinicaltrials.gov/show/NCT00240500		Y	N	Y	Y	Y	Y	N	An annotated case report form is not available for this study. A blank case report form will be provided. A reporting and analysis plan is not available for this study.	1-Oct-2014
2195	GSK	Long-term Follow-Up studies at Years 16-20, to evaluate the persistence of immune response of GSK Biologicals’ hepatitis B vaccine in newborns of HBeAg+ and HBsAg+ mothers in comparison with a historical control group	Hepatitis B Vaccine, Recombinant	100449	Hepatitis B	Phase 4	https://www.gsk-studyregister.com/en/trial-details/?id=100449	http://clinicaltrials.gov/show/NCT00240539	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002629-23	Y	N	Y	Y	Y	Y	N	An annotated case report form is not available for this study. A blank case report form will be provided. A reporting and analysis plan is not available for this study.	1-Oct-2014
2196	GSK	Long-Term Follow-up Study at Years 16, 17, 18, 19 and 20, to Evaluate the Persistence of Immune Response of GlaxoSmithKline Biologicals' Hepatitis B Vaccine Administered With or Without HBIG in Newborns of HBeAg+ Mothers	Hepatitis B Vaccine, Recombinant	100450	Hepatitis B	Phase 4	https://www.gsk-studyregister.com/en/trial-details/?id=100450	http://clinicaltrials.gov/show/NCT00240526	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004879-36	Y	N	Y	Y	Y	Y	Y	An annotated case report form is not available for this study. A blank case report form will be provided.	1-Oct-2014
2197	GSK	Evaluate the safety and immunogenicity of GSK Biologicals’ HPV-16/18 vaccine administered intramuscularly according to a 0,1,6 month schedule in healthy female subjects (10 – 14 years)	Human Papillomavirus Types 16 and 18 Vaccine	104918	Infections, Papillomavirus	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=580299/013	http://clinicaltrials.gov/show/NCT00316706	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000518-37	Y	N	Y	Y	Y	Y	Y	The results of studies 104896, 104902, 104904 and 104918 are summarised with study 580299/013 on the GSK Study Register. An annotated case report form is not available for this study. A blank case report form will be provided.	1-Oct-2014
2198	GSK	Evaluation of the safety and immunogenicity of GlaxoSmithKline Biologicals' HPV vaccine 580299 (Cervarix TM) in adult human immunodeficiency virus (HIV) infected female subjects	Human Papillomavirus Types 16 and 18 Vaccine	107863	Infections, Papillomavirus	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=107863	http://clinicaltrials.gov/show/NCT00586339		Y	N	Y	Y	Y	Y	Y	An annotated case report form is not available for this study. A blank case report form will be provided.	1-Oct-2014
2199	GSK	Follow-up study to evaluate the long-term efficacy of a HPV vaccine (580299) in healthy young adult women in Brazil	Human Papillomavirus Types 16 and 18 Vaccine	109624	Infections, Papillomavirus	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=109616 (Y7)	http://clinicaltrials.gov/show/NCT00518336		Y	N	Y	Y	Y	Y	Y	This is a year 8 follow-up study to 580299/001, 580299/007 and 109616. Follow-on study 109625 was conducted. The results of this study 109624 are summarised with studies 109616 and 109625 on the GSK Study Register. An annotated case report form is not available for this study. A blank case report form will be provided.	1-Oct-2014
2200	GSK	Follow-up study to evaluate the long-term efficacy of a HPV vaccine (580299) in healthy young adult women in Brazil	Human Papillomavirus Types 16 and 18 Vaccine	109625	Infections, Papillomavirus	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=109616 (Y7)	http://clinicaltrials.gov/show/NCT00518336		Y	N	Y	Y	Y	Y	Y	This is a year 9 follow-up study to 580299/001, 580299/007, 109616 and 109624. The results of this study 109625 are summarised with studies 109616 and 109624 on the GSK Study Register. An annotated case report form is not available for this study. A blank case report form will be provided.	1-Oct-2014
2201	GSK	Follow-up study to evaluate the long-term efficacy of a HPV vaccine (580299) in healthy young adult women in Brazil	Human Papillomavirus Types 16 and 18 Vaccine	109616	Infections, Papillomavirus	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=109616 (Y7)	http://clinicaltrials.gov/show/NCT00518336		Y	N	Y	Y	Y	Y	Y	This is a year 7 follow-up study to 580299/001 and 580299/007. Follow-on studies 109624 and 109625 were conducted. The results of this study 109616 are summarised with studies 109624 and 109625 on the GSK Study Register. An annotated case report form is not available for this study. A blank case report form will be provided.	1-Oct-2014
2202	GSK	A phase III, observer-blind, randomised study to evaluate the safety and immunogenicity of one and two administrations of pandemic monovalent (H5N1) influenza vaccine (adjuvanted split virus formulation) in adults aged 18 years and older	Influenza Vaccine (Split Virion, Inactivated)	107064	Influenza	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=107064	http://clinicaltrials.gov/show/NCT00319098	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001281-16	Y	N	Y	Y	Y	Y	Y	The results of this study 107064 are summarised with study 107217 on the GSK Study Register. An annotated case report form is not available for this study. A blank case report form will be provided.	1-Oct-2014
2203	GSK	A phase III, observer-blind, randomised study to evaluate the safety and immunogenicity of one and two administrations of pandemic monovalent (H5N1) influenza vaccine (adjuvanted split virus formulation) in adults aged 18 years and older	Influenza Vaccine (Split Virion, Inactivated)	107217	Influenza	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=107064	http://clinicaltrials.gov/show/NCT00319098	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001281-16	Y	N	Y	Y	Y	Y	Y	The results of this study 107217 are summarised with study 107064 on the GSK Study Register. An annotated case report form is not available for this study. A blank case report form will be provided.	1-Oct-2014
2204	GSK	A study to demonstrate the efficacy of GSK Biologicals’ influenza vaccine (Fluarix™) administered intramuscularly in adults	Influenza Vaccine (Split Virion, Inactivated)	108134	Influenza	Phase 4	https://www.gsk-studyregister.com/en/trial-details/?id=108134	http://clinicaltrials.gov/show/NCT00363870	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002839-24	Y	Y	Y	Y	Y	Y	Y		1-Oct-2014
2205	GSK	A phase III, multicentre booster vaccination study to assess the immunogenicity, safety and reactogenicity of a dose of Mencevax™ ACWY at 24 to 30 months of age in subjects primed with an investigational vaccination regimen in study 100480 and boosted at 15 to 24 months of age in study 104727.	Meningococcal Serogroups A, C, W-135 and Y Vaccine	104730	Infections, Meningococcal	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=104730	http://clinicaltrials.gov/show/NCT00136604		Y	N	Y	Y	Y	Y	Y	This is a follow-up study to 100480 and 104727. An annotated case report form is not available for this study. A blank case report form will be provided. The results of this study 104730 are summarised with studies 104727 and 100480 on the GSK Study Register.	1-Oct-2014
2206	GSK	Booster Vaccination Study to Assess Safety & Reactogenicity of a Dose of DTPw-HBV/Hib Vaccine and to Assess the Immunogenicity, Safety & Reactogenicity of a Dose of Mencevax™ ACW in Subjects Primed in Study 759346/007	Meningococcal Serogroups A, C, W-135 and Y Vaccine	104756	Infections, Meningococcal	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=104756	http://clinicaltrials.gov/show/NCT00317109		Y	N	Y	Y	Y	Y	Y	This is a follow-up study to 759346/007. An annotated case report form is not available for this study. A blank case report form will be provided.	1-Oct-2014
2207	GSK	Booster Vaccination Study to Assess Immunogenicity & Safety of a Dose of GSK Biologicals' Mencevax™ ACWY & 1/5th of a Dose of Mencevax™ ACWY in Subjects Primed in the DTPW-HBV=HIB-MENAC-TT-011 Study	Meningococcal Serogroups A, C, W-135 and Y Vaccine	105239	Infections, Meningococcal	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=105239 (mth24-30)	http://clinicaltrials.gov/show/NCT00291343		Y	Y	Y	Y	Y	Y	Y	This is a follow-up study to 100478. The results are summarised with study 105245 on the GSK Study Register.	1-Oct-2014
2208	GSK	Booster Vaccination Study to Assess Immunogenicity & Safety of a Dose of GSK Biologicals' Mencevax™ ACWY & 1/5th of a Dose of Mencevax™ ACWY in Subjects Primed in the DTPW-HBV=HIB-MENAC-TT-011 Study	Meningococcal Serogroups A, C, W-135 and Y Vaccine	105245	Infections, Meningococcal	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=105239 (mth24-30)	http://clinicaltrials.gov/show/NCT00291343		Y	N	Y	Y	Y	Y	Y	This is a follow-up study to 100478. The results are summarised with study 105239 on the GSK Study Register. An annotated case report form is not available for this study. A blank case report form will be provided	1-Oct-2014
2209	GSK	Assess lot-to-lot consistency of 3 lots (double blind design) of GlaxoSmithKline Biologicals' 10-valent pneumococcal vaccine and evaluate non-inferiority to Prevenar™ (single blind design) when administered as 3-dose primary immunization course before 6 months of age	Pneumococcal Polysaccharide Conjugate Vaccine (Adsorbed)	105553	Infections, Streptococcal	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=105553	http://clinicaltrials.gov/show/NCT00307554	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003300-11	Y	N	Y	Y	Y	Y	Y	Follow-on studies 107046, 112640, 111345,111346, and 111347 were conducted. An annotated case report form is not available for this study. A blank case report form will be provided.	1-Oct-2014
2210	GSK	To assess safety, reactogenicity and immunogenicity of GSK Biologicals’ 10-valent pneumococcal conjugate vaccine, when co-administered with DTPa-combined vaccines and MenC or Hib-MenC vaccines during the first 6 months of age.	Pneumococcal Polysaccharide Conjugate Vaccine (Adsorbed)	107005	Infections, Streptococcal	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=107005	http://clinicaltrials.gov/show/NCT00334334	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000558-30	Y	N	Y	Y	Y	Y	Y	An annotated case report form is not available for this study. A blank case report form will be provided.	1-Oct-2014
2211	GSK	To assess the safety, reactogenicity and immunogenicity of GSK Biologicals' pneumococcal conjugate vaccine compared to Prevenar™, co-administered with DTPw-HBV/Hib & OPV or IPV vaccines as a 3-dose primary immunization course during the first 6 months of age	Pneumococcal Polysaccharide Conjugate Vaccine (Adsorbed)	107007	Infections, Streptococcal	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=107007	http://clinicaltrials.gov/show/NCT00344318	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000557-21	Y	N	Y	Y	Y	Y	Y	An annotated case report form is not available for this study. A blank case report form will be provided.	1-Oct-2014
2212	GSK	To assess the safety, reactogenicity & immunogenicity of a 4th dose of GSK Biologicals’ pneumococcal vaccine or Prevenar™ in children (12-18 months) previously vaccinated in the primary study 105553 with either pneumococcal vaccine or Prevenar™	Pneumococcal Polysaccharide Conjugate Vaccine (Adsorbed)	107046	Infections, Streptococcal	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=107046	http://clinicaltrials.gov/show/NCT00370396	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001628-38	Y	N	Y	Y	Y	Y	Y	This is a booster study of 105553. Follow-on studies 112640, 111345, 111346, and 111347 were conducted. An annotated case report form is not available for this study. A blank case report form will be provided.	1-Oct-2014
2213	GSK	Long-term follow-up study to assess antibody persistence in children previously vaccinated with four doses of pneumococcal conjugate vaccine in primary vaccination study (105553) and booster vaccination study (107046)	Pneumococcal Polysaccharide Conjugate Vaccine (Adsorbed)	111345	Infections, Streptococcal	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=111345 (Mth 12)	http://clinicaltrials.gov/show/NCT00624819	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005392-34	Y	N	Y	Y	Y	Y	Y	This is a Year 1 follow-up study to 107046. An annotated case report form is not available for this study. A blank case report form will be provided.	1-Oct-2014
2214	GSK	Study of two formulations of GSK Biologicals' varicella vaccine given as a 2-dose course in the second year of life	Varicella Vaccine	109705	Varicella	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=109705	http://clinicaltrials.gov/show/NCT00568334	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000683-24	Y	Y	Y	Y	Y	Y	Y		1-Oct-2014
2225	Novartis	A Phase III, Multicenter, Randomized, Double-blind, Placebo-controlled Safety Study of Xolair (Omalizumab) in Patients With Chronic Idiopathic Urticaria (CIU) Who Remain Symptomatic Despite Treatment With H1 Antihistamines, H2 Blockers, and/or Leukotriene Receptor Antagonists	omalizumab	Q4883g	Chronic Idiopathic Urticaria (CIU)	Phase 3	http://roche-trials.com/studyResultGet.action?studyResultNumber=Q4883g	https://clinicaltrials.gov/show/NCT01264939		Y	Y	Y	Y	Y	Y	Y	Novartis & Roche co-license the Xolair studies.  Xolair information appears on both Company websites.	1-Jun-2016
2414	GSK	A 16-Week, Parallel-Group, Double-Blind, Randomized, Placebo-Controlled, Multicenter, Dose-Ranging Study to Evaluate the Efficacy, Safety, and Tolerability of Multiple Doses and Multiple Treatment Regimens of GSK716155, with Byetta as an Open Label Active Reference, in Subjects with Type 2 Diabetes Mellitus	albiglutide	GLP110125	Diabetes Mellitus, Type 2	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=GLP110125	http://clinicaltrials.gov/show/NCT00518115		Y	Y	Y	Y	Y	Y	Y		1-Nov-2014
2415	GSK	A Randomized, Double-Blind, Active-Controlled, Parallel-Group, Multicenter Study to Determine the Efficacy and Safety of Albiglutide as Compared With Sitagliptin in Subjects With Type 2 Diabetes Mellitus With Renal Impairment	albiglutide	GLP114130	Diabetes Mellitus, Type 2	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=114130	http://clinicaltrials.gov/show/NCT01098539	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-019777-15	Y	Y	Y	Y	Y	Y	Y	This study is available in CDISC format	1-Nov-2014
2416	GSK	A Randomized, Double-Blind, Placebo and Active-Controlled, Parallel-Group, Multicenter Study to Determine the Efficacy and Safety of Albiglutide When Used in Combination With Metformin Compared With Metformin Plus Sitagliptin, Metformin Plus Glimepiride, and Metformin Plus Placebo in Subjects With Type 2 Diabetes Mellitus	albiglutide/metformin	GLP112753	Diabetes Mellitus, Type 2	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=112753	http://clinicaltrials.gov/show/NCT00838903	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-007660-41	Y	Y	Y	Y	Y	Y	Y	This study is available in CDISC format	1-Nov-2014
2417	GSK	A multicenter, randomized, parallel, placebo-controlled, one-year study of the efficacy and safety of bupropion hydrochloride sustained-release tablets versus placebo as an aid to smoking cessation treatment in adult cigarette smokers previously treated with bupropion	bupropion	ZYB40003	Smoking Cessation	Phase 4	https://www.gsk-studyregister.com/en/trial-details/?id=ZYB40003			N	Y	Y	Y	Y	Y	Y	An analysis-ready dataset is not available for this study. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Nov-2014
2418	GSK	The effect of sustained-release bupropion HCl vs. placebo as an aid to smoking reduction leading to cessation among smokers unwilling and unable to quit smoking	bupropion	ZYB40005	Smoking Cessation	Phase 4	https://www.gsk-studyregister.com/en/trial-details/?id=ZYB40005			N	Y	Y	Y	Y	Y	Y	An analysis-ready dataset is not available for this study. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Nov-2014
2419	GSK	A Randomized, 24-week, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy, Safety and Tolerability of ARIFLO® (15mg BID) in Patients with Chronic Obstructive Pulmonary Disease (COPD)	cilomilast	CIL103657	Pulmonary Disease, Chronic Obstructive	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=CIL103657	http://clinicaltrials.gov/show/NCT00103922		Y	N	Y	Y	Y	Y	Y	An annotated case report form is not available for this study. A blank case report form will be provided.	1-Nov-2014
2420	GSK	An 18-week randomized, double-blind, placebo-controlled, multicenter study designed to compare treatment with cilomilast to that with placebo for changes in ventilatory mechanics and function (both at rest and during exercise), as well as related exertional dyspnea and exercise performance, in hyperinflated patients with stable COPD	cilomilast	SB207499/180	Pulmonary Disease, Chronic Obstructive	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=207499/180			N	Y	Y	Y	Y	Y	Y	An analysis-ready dataset is not available for this study. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Nov-2014
2421	GSK	A Randomized, 12-Week, Double-blind, Placebo-controlled, Parallel-group Pilot Study to Evaluate the Safety and Additional Efficacy of Adding a New Chemical Entity (NCE) to Treatment with ADVAIR 250/50 Twice Daily in Patients with Chronic Obstructive Pulmonary Disease (COPD).	cilomilast/salmeterol/fluticasone propionate	207499/125	Pulmonary Disease, Chronic Obstructive	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=207499/125			Y	Y	Y	Y	Y	Y	Y	A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Nov-2014
2422	GSK	A 12-Week, Parallel-Group, Double-Blind, Randomised, Placebo-Controlled, Multicentre, Dose Ranging Study toEvaluate the Efficacy, Safety and Tolerability of GW823093 (2.5mg, 7.5mg, 15mg, 30mg and 45mg), AdministeredOrally, Once Daily, as Monotherapy in Subjects With Type 2 Diabetes Mellitus foll ...	denagliptin	DPB100925	Diabetes Mellitus, Type 2	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=100925	http://clinicaltrials.gov/show/NCT00111800	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-004193-91	Y	Y	Y	Y	Y	Y	Y		1-Nov-2014
2423	GSK	A randomised, double-blind, placebo-controlled, 2-period cross-over study to evaluate the effect of treatment with GSK2190915 on the allergen-induced asthmatic response in subjects with mild asthma	fiboflapon	LPA111834	Asthma	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=111834	http://clinicaltrials.gov/show/NCT00748306	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-002580-13	Y	Y	Y	Y	Y	Y	Y		1-Nov-2014
2424	GSK	A multi-centre, randomized, double-blind, five-way crossover study evaluating the dose response and duration of action of GSK2190915 compared to placebo in subjects with mild asthma who experience exercise induced bronchoconstriction.	fiboflapon	LPA112025	Asthma	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=112025	http://clinicaltrials.gov/show/NCT00812929		Y	Y	Y	Y	Y	Y	Y		1-Nov-2014
2425	GSK	An open-label, randomised, single-dose, multi-cohort, crossover bioavailability study of a solution formulation and three capsule formulations of GSK2190915 in healthy adult subjects followed by a repeat-dose, randomized, parallel group, double-blinded study of one selected capsule formulation and matched placebo in elderly healthy subjects	fiboflapon	LPA112071	Asthma	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=112071	http://clinicaltrials.gov/show/NCT02224521	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-010814-31	Y	Y	Y	Y	Y	Y	Y		1-Nov-2014
2426	GSK	An open label, sequential, single cohort, repeat dose study to investigate the potential interaction of GSK2190915 on the pharmacokinetics of rosuvastatin in healthy adult subjects.	fiboflapon	LPA112362	Asthma	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=112362	http://clinicaltrials.gov/show/NCT01411111	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-020853-14	Y	Y	Y	Y	Y	Y	Y		1-Nov-2014
2427	GSK	A randomised, double-blind, placebo-controlled, cross-over study to evaluate the effect of treatment with repeat dose GSK2190915 as an add-on to current therapy on the percentage of neutrophils in induced sputum in asthmatic patients with elevated sputum neutrophils	fiboflapon	LPA115134	Asthma	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=115134	http://clinicaltrials.gov/show/NCT01471665	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-024436-41	Y	Y	Y	Y	Y	Y	Y		1-Nov-2014
2428	GSK	Randomised, open label, two period, crossover study to compare the steroid systemic exposure of Fluticasone Propionate (FP) from FP/Salmeterol (SALM) (500/50) DISKUS and Budesonide (BUD) from BUD/formoterol (FOR).(200/6) Turbuhaler in patients with severe Chronic Obstructive Pulmonary Disease.	fluticasone propionate/salmeterol	SAM100807	Pulmonary Disease, Chronic Obstructive	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=100807			N	Y	Y	Y	Y	Y	Y	An analysis-ready dataset is not available for this study. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Nov-2014
2429	GSK	A single-blind, placebo-controlled, two part study to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of single ascending doses of GSK2018682 in healthy volunteers	GSK2018682	P1A114070	Multiple Sclerosis	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=114070	http://clinicaltrials.gov/show/NCT01387217		Y	Y	Y	Y	Y	Y	Y		1-Nov-2014
2430	GSK	A single-blind, placebo-controlled study to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of repeat ascending doses of GSK2018682 (S1P1 agonist) in healthy volunteers	GSK2018682	P1A114347	Multiple Sclerosis, Relapsing-Remitting	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=114347	http://clinicaltrials.gov/show/NCT01431937		Y	Y	Y	Y	Y	Y	Y		1-Nov-2014
2431	GSK	An open-label, randomized, single centre, 4-way crossover study to evaluate the pharmacokinetics of single oral doses of ezogabine/retigabine in healthy adult Taiwanese subjects	retigabine, ezogabine	RTG115860	Epilepsy	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=115860	http://clinicaltrials.gov/show/NCT01462669		Y	Y	Y	Y	Y	Y	Y		1-Nov-2014
2432	GSK	A two part study to assess the pharmacokinetic performance of three retigabine modified release (MR) formulations after single dose and to assess the pharmacokinetics and tolerability of titration with retigabine MR	retigabine, ezogabine	RTG113215	Seizures	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=113215			Y	Y	Y	Y	Y	Y	Y	A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Nov-2014
2433	GSK	Open-Label Study to Evaluate the Pharmacokinetics,Safety and Tolerability of Retigabine Following Single and Multiple Dose Administration of Two Different Modified Release Formulations Compared to Single Dose Administration of One Immediate Release Formula	retigabine, ezogabine	VRX-RET-E22-MR103	Seizures	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=VRX-RET-E22-MR103			Y	Y	Y	Y	Y	Y	Y	This study was not originally sponsored by GSK. A link to ClinicalTrials.gov and an NCTID number are not available for this study.	1-Nov-2014
2434	GSK	A Randomized, Double-Blind, Placebo- and Active-Controlled Crossover Study to Evaluate the Abuse Potential of Retigabine in Recreational Polydrug Users	retigabine, ezogabine	VRX-RET-E22-108	Seizures	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=VRX-RET-E22-108			Y	Y	Y	Y	Y	Y	Y	This study was not originally sponsored by GSK. A link to ClinicalTrials.gov and an NCTID number are not available for this study.	1-Nov-2014
2435	GSK	A Randomized, Partially Double-Blind, Four-Way Crossover Study to Determine the Effects of a Single Dose of Retigabine Combined with a Single Dose of Alcohol	retigabine, ezogabine	VRX-RET-E22-107	Seizures	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=VRX-RET-E22-107			Y	Y	Y	Y	Y	Y	Y	This study was not originally sponsored by GSK. A link to ClinicalTrials.gov and an NCTID number are not available for this study.	1-Nov-2014
2436	GSK	A Pharmacokinetic Interaction Study Evaluating the Effect of Repeated Retigabine Dosing on the Pharmacokinetics of Oral Contraceptives in Healthy Adult Female Volunteers	retigabine, ezogabine	VRX-RET-E22-106	Seizures	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=VRX-RET-E22-106			Y	Y	Y	Y	Y	Y	Y	This study was not originally sponsored by GSK. A link to ClinicalTrials.gov and an NCTID number are not available for this study.	1-Nov-2014
2437	GSK	Comparative, Randomized, Open-Label, Single-Dose, 2-Way Crossover Bioavailability, Safety and Tolerability Study of a 400mg Dose of Retigabine Administered as the Clinical Trials Formulation and the Market Image Formulation in Healthy Adult Male Subjects	retigabine, ezogabine	VRX-RET-E22-105	Seizures	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=VRX-RET-E22-105			Y	Y	Y	Y	Y	Y	Y	This study was not originally sponsored by GSK. A link to ClinicalTrials.gov and an NCTID number are not available for this study.	1-Nov-2014
2438	GSK	Comparative, Randomized, Open-Label, Single-Dose, 2-way Crossover Food Effect, Safety and Tolerability Study of a 400-mg Dose of the Retigabine Market Image Tablet in Healthy Adult Male Subjects	retigabine, ezogabine	VRX-RET-E22-104	Seizures	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=VRX-RET-E22-104			Y	Y	Y	Y	Y	Y	Y	This study was not originally sponsored by GSK. A link to ClinicalTrials.gov and an NCTID number are not available for this study.	1-Nov-2014
2439	GSK	A Double-Blind Randomized Parallel-group Trial to Define the ECG Effects of Retigabine Using a Maximum Tolerated Dose Compared with Placebo and Moxifloxacin (a Positive Control) in Healthy Men and Women: A Thorough ECG Trial	retigabine, ezogabine	VRX-RET-E22-103	Seizures	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=VRX-RET-E22-103			Y	Y	Y	Y	Y	Y	Y	This study was not originally sponsored by GSK. A link to ClinicalTrials.gov and an NCTID number are not available for this study.	1-Nov-2014
2440	GSK	Open-Label, Single-Dose, 8-Period Study to Evaluate the Pharmacokinetics, Safety and Tolerability of a 400 mg Dose of Retigabine Sustained-Release Formulations in Seven Dosing Periods Versus a 200 mg Dose of Retigabine Immediate-Release Formulation in One Dosing Period in Healthy Adult Male Subjects	retigabine, ezogabine	VRX-RET-E22-101SR	Seizures	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=VRX-RET-E22-101SR			Y	Y	Y	Y	Y	Y	Y	This study was not originally sponsored by GSK. A link to ClinicalTrials.gov and an NCTID number are not available for this study.	1-Nov-2014
2441	GSK	A Randomized, Double-Blind, Parallel-Group, Exploratory Safety and Tolerability Study of 3 Titration Rates of Retigabine (D-23129; GKE-841) Administered as Add-on Therapy in Patients with Refractory Partial Epilepsy	retigabine, ezogabine	3065A1-214-EU/US	Seizures	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=3065A1-214			Y	Y	Y	Y	Y	N	Y	This study was not originally sponsored by GSK. A link to ClinicalTrials.gov and an NCTID number are not available for this study. A raw dataset is not available for this study.	1-Nov-2014
2442	GSK	A multicenter, open-label, long-term, safety tolerability, and efficacy study of retigabine in adult patients with epilepsy (extension of study 205)	retigabine, ezogabine	3065A1-212	Seizures	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=3065A1-212			Y	Y	Y	Y	Y	Y	Y	This study was not originally sponsored by GSK. A link to ClinicalTrials.gov and an NCTID number are not available for this study.	1-Nov-2014
2443	GSK	A multicenter, open-label, long-term, safety tolerability, and efficacy study of GKE-841 (retigabine D-23129) in adult patients with epilepsy (extension of study 202)	retigabine, ezogabine	3065A1-208	Seizures	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=3065A1-208			Y	Y	Y	Y	Y	Y	Y	This study was not originally sponsored by GSK. A link to ClinicalTrials.gov and an NCTID number are not available for this study.	1-Nov-2014
2444	GSK	A randomized, double-blind trial to evaluate the efficacy and safety of fixed dose rosiglitazone/metformin combination therapy compared to both rosiglitazone and metformin monotherapies in drug naive type 2 diabetes mellitus subjects	rosiglitazone/metformin	712753/007	Diabetes Mellitus, Type 2	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=712753/007	http://clinicaltrials.gov/show/NCT00499707		Y	Y	Y	Y	Y	Y	Y		1-Nov-2014
2445	GSK	A phase III, 24 week, multi-centre, randomised, double-blind, parallel group, dose escalation study of Avandamet (rosiglitazone/metformin) and high dose metformin monotherapy in subjects with poorly controlled type 2 diabetes mellitus	rosiglitazone/metformin	712753/002	Diabetes Mellitus, Type 2	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=712753/002			Y	Y	Y	Y	Y	Y	Y	A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Nov-2014
2446	GSK	A Phase III Multi-Centre, Double-Blind, Randomised, Parallel-Group, Dose Escalation Study Comparing the Effects of 32 Weeks Administration of Avandamet and Metformin on Hba1c Targets in Subjects With Mild Type 2 Diabetes Mellitus	rosiglitazone/metformin	712753/003	Diabetes Mellitus, Type 2	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=712753/003			Y	Y	Y	Y	Y	Y	Y	A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Nov-2014
2447	GSK	A 24 week, randomised, double blind, parallel study to compare the change in HbA1c with AVANDAMET® (8.0mg / 2.0g) plus insulin to placebo plus insulin, in subjects with type 2 diabetes starting insulin therapy	rosiglitazone/metformin	712753/009	Diabetes Mellitus, Type 2	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=712753/009	http://clinicaltrials.gov/show/NCT00069836		Y	Y	Y	Y	Y	Y	Y		1-Nov-2014
2448	GSK	A two part randomized, double-blind, placebo controlled study to investigate the effects of topical doses of SB705498 oncapsaicin, histamine, and cowhage responses in healthy volunteers.	SB705498	VRD115246	Dermatitis, Atopic	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=115246	http://clinicaltrials.gov/show/NCT01673529	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000182-20	Y	Y	Y	Y	Y	Y	Y		1-Nov-2014
2449	GSK	Two part study to investigate pharmacokinetics (PK) & pharamcodynamics (PD) of SB-705498 in cough. Part A:open label study in healthy subjects to determine exposure to SB-705498. Part B:double-blind, placebo controlled, cross over study to investigate effect of SB-705498 on capsaicin induced cough and 24 hour cough counts in cough patients	SB705498	VR1114693	Rhinitis	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=114693	http://clinicaltrials.gov/show/NCT01476098	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-021642-22	Y	Y	Y	Y	Y	Y	Y		1-Nov-2014
2450	GSK	A randomised, double blind placebo controlled, 2 way cross over study in adults with non-allergic rhinits to evaluate the effect of once daily administration of intranasal SB-705498 12mg for two weeks and the response to a chamber challenge of cold dry air	SB705498	VR1114974	Rhinitis	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=114974	http://clinicaltrials.gov/show/NCT01424514		Y	Y	Y	Y	Y	Y	Y		1-Nov-2014
2451	GSK	A Randomized, Double-Blind, Placebo-Controlled, Single-Attack, Parallel-Group Evaluation of the Efficacy of Sumatriptan 100mg Tablets versus Placebo in the Treatment of Subjects who Affirm Tension, Tension-Type or Stress Headaches and who meet International Headache Society (IHS) Criteria for Migraine.	sumatriptan	SUM40312	Migraine Disorders	Phase 4	https://www.gsk-studyregister.com/en/trial-details/?id=SUM40312			N	Y	Y	Y	Y	Y	Y	An analysis-ready dataset is not available for this study. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Nov-2014
2452	GSK	A randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and tolerability of oral sumatriptan 25mg, 50mg, and 100mg tablets for a single moderate or severe headache in adults diagnosed with migrainous disorder International Headache Society (IHS) 1.7.	sumatriptan	SUM40299	Migraine Disorders	Phase 4	https://www.gsk-studyregister.com/en/trial-details/?id=SUM40299			N	Y	Y	Y	Y	Y	Y	An analysis-ready dataset is not available for this study. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Nov-2014
2453	GSK	A randomized, double-blind, placebo-controlled, single-attack, parallel-group evaluation of the efficacy of sumatriptan 50mg tablets versus placebo in the treatment of self-described and/or physician-diagnosed sinus headaches that meet International Headache Society (IHS) criteria for migraine headache.	sumatriptan	SUM40298	Migraine Disorders	Phase 4	https://www.gsk-studyregister.com/en/trial-details/?id=SUM40298			N	Y	Y	Y	Y	Y	Y	An analysis-ready dataset is not available for this study. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Nov-2014
2454	GSK	A randomized, double-blind, placebo-controlled, parallel-group, single-attack study of sumatriptan 6 mg injection in the treatment of moderate-to-severe migraine present upon awakening.	sumatriptan	SUM40286	Migraine Disorders	Phase 4	https://www.gsk-studyregister.com/en/trial-details/?id=SUM40286			N	Y	Y	Y	Y	Y	Y	An analysis-ready dataset is not available for this study. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Nov-2014
2455	GSK	A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Evaluation of Sumatriptan 50mg and 100mg Tablets Administered During the Mild Pain Phase of a Menstrually-Associated Migraine Attack	sumatriptan	SUM40285	Migraine Disorders	Phase 4	https://www.gsk-studyregister.com/en/trial-details/?id=SUM40285			N	Y	Y	Y	Y	Y	Y	An analysis-ready dataset is not available for this study. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Nov-2014
2456	GSK	A Randomised, Double-Blind, Placebo-Controlled, Parallel-Group Evaluation of Sumatriptan 50mg and 100mg Tablets Administered During the Mild Pain Phase of a Menstrually-Associated Migraine Attack	sumatriptan	SUM40282	Migraine Disorders	Phase 4	https://www.gsk-studyregister.com/en/trial-details/?id=SUM40282			N	Y	Y	Y	Y	Y	Y	An analysis-ready dataset is not available for this study. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Nov-2014
2457	GSK	A 52 week Study to Evaluate the Safety and Tolerability of GSK573719/GW642444 125mcg once-daily alone and in combination with GW642444 25mcg once-daily via novel Dry Powder Inhaler (nDPI) in Subjects with Chronic Obstructive Pulmonary Disease	umeclidinium bromide/vilanterol	DB2113359	Pulmonary Disease, Chronic Obstructive	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=113359	http://clinicaltrials.gov/show/NCT01316887	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023417-54	Y	Y	Y	Y	Y	Y	Y		1-Nov-2014
2458	GSK	A randomised, placebo-controlled, incomplete block, four period crossover , repeat dose study to evaluate the effect of the inhaled GSK573719/Vilanterol combination and GSK573719 monotherapy on electrocardiographic parameters, with moxifloxacin as a positive control, in healthy subjects.	umeclidinium bromide/vilanterol;umeclidinium bromide	DB2114635	Pulmonary Disease, Chronic Obstructive	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=114635	http://clinicaltrials.gov/show/NCT01521377	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004543-44	Y	Y	Y	Y	Y	Y	Y		1-Nov-2014
2459	GSK	An open-label, non-randomized, pharmacokinetic and safety study of single dose GSK573719 + GW643444 (VI) combination and repeat doses of GSK573719 in healthy subjects and in subjects with moderate hepatic impairment	umeclidinium bromide/vilanterol;umeclidinium bromide	DB2114637	Pulmonary Disease, Chronic Obstructive	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=114637	http://clinicaltrials.gov/show/NCT01577680	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005454-61	Y	Y	Y	Y	Y	Y	Y		1-Nov-2014
2460	GSK	Randomised, double-blind, placebo controlled, cross-over study comparing the effects of both single dose and repeated dosing treatment for 14 days of vestipitant or vestipitant / paroxetine combination in an enriched population of subjects with tinnitus & hearing loss	vestipitant/paroxetine	NKP106254	Tinnitus	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=NKP106254	http://clinicaltrials.gov/show/NCT00394056	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003295-36	Y	N	Y	Y	Y	Y	Y	An annotated and blank case report form are not available as the electronic data capture system used for this study did not generate paper versions.	1-Nov-2014
2461	GSK	A Randomised, Double-Blind, Parallel-Group, Placebo-Controlled Fixed Dose Study Comparing the Efficacy and Safety of GW597599/paroxetine combination or paroxetine monotherapy to placebo in Patients with Social Anxiety Disorder (SAD)	vestipitant/paroxetine	NKP103401	Social Phobia	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=NKP103401	http://clinicaltrials.gov/show/NCT00403962	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001894-24	Y	Y	Y	Y	Y	Y	Y		1-Nov-2014
2462	GSK	A randomized, double-blind, double-dummy, parallel-group, placebo controlled (on inhaled corticosteroid medication), multicenter study to evaluate the efficacy and safety of vilanterol inhalation powder (GW642444) and salmeterol, compared with placebo in the treatment of persistent asthma in adults and adolescents uncontrolled on inhaled corticosteroids	vilanterol	B2C112060	Asthma	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=112060	http://clinicaltrials.gov/show/NCT01181895	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-020412-11	Y	Y	Y	Y	Y	Y	Y		1-Nov-2014
2463	ViiV	A Retrospective Case-Control Study to Estimate the Sensitivity and Specificity of a Pharmacogenetic Marker (HLA-B*5701) in Subjects With and Without Hypersensitivity to Abacavir	abacavir	ABC107442	Infection, Human Immunodeficiency Virus I	Phase 4	https://www.viiv-studyregister.com/study/19689	http://clinicaltrials.gov/show/NCT00373945		Y	Y	Y	Y	Y	Y	Y		1-Dec-2014
2523	GSK	Paroxetine versus Placebo in the Treatment of Obsessive-Compulsive Disorder	paroxetine	BRL-029060/CPMS- 116	Obsessive-Compulsive Disorder	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=29060/116			N	N	N	Y	N	Y	N	An analysis-ready dataset is not available for this study. An annotated case report form, a reporting and analysis plan, a clinical study report, and a protocol are not available for this study. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Dec-2014
2524	GSK	Paroxetine versus Clomipramine and Placebo in the Treatment of Obsessive-Compulsive Disorder	paroxetine	MY- 1028/BRL-029060/1/CPMS-118	Obsessive-Compulsive Disorder	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=29060/118			N	N	N	Y	N	Y	N	An analysis-ready dataset is not available for this study. An annotated case report form, a reporting and analysis plan, a clinical study report, and a protocol are not available for this study. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Dec-2014
2525	GSK	A double-blind, placebo-controlled, multicenter study of fixed doses of paroxetine (10, 20, and 40 mg) given as a single oral dose daily, in the treatment of panic disorder.	paroxetine	MY1047/BRL-029060/1/CPMS-120	Panic Disorder	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=29060/120			N	N	N	Y	N	Y	N	An analysis-ready dataset is not available for this study. An annotated case report form, a reporting and analysis plan, a clinical study report, and a protocol are not available for this study. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Dec-2014
2526	GSK	A Double-Blind Study to Assess the Efficacy and Tolerance of a Flexible Dose of Paroxetine Compared with a Flexible Dose of Clomipramine and Placebo in the Treatment of Obsessive Compulsive Disorder.	paroxetine	MY-1037/BRL-029060/1/CPMS-136	Obsessive-Compulsive Disorder	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=29060/136			N	N	N	Y	N	Y	N	An analysis-ready dataset is not available for this study. An annotated case report form, a reporting and analysis plan, a clinical study report, and a protocol are not available for this study. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Dec-2014
2527	GSK	A Double-Blind Placebo Controlled Comparative Study of Paroxetine and Clomipramine in the Treatment of Panic Disorder.	paroxetine	MY-1036/BRL-029060/1/CPMS-187 (PAR187)	Panic Disorder	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=29060/187			N	N	N	Y	N	Y	N	An analysis-ready dataset is not available for this study. An annotated case report form, a reporting and analysis plan, a clinical study report, and a protocol are not available for this study. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Dec-2014
2528	GSK	A Double-Blind, Multicentered, Flexible-Dose Study of Paroxetine, Alprazolam and Placebo in the Treatment of Panic Disorder	paroxetine	MY-1048/BRL-029060/1/CPMS-223 (PAR 223)	Panic Disorder	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=29060/223			N	N	N	Y	N	Y	N	An analysis-ready dataset is not available for this study. An annotated case report form, a reporting and analysis plan, a clinical study report, and a protocol are not available for this study. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Dec-2014
2529	GSK	A Randomized, Double-Blind, Comparison of Paroxetine and Placebo in the Treatment of Generalized Social Phobia	paroxetine	PAR 029060-382	Social Phobia	Phase 4	https://www.gsk-studyregister.com/en/trial-details/?id=29060/382			N	N	N	Y	N	Y	N	An analysis-ready dataset is not available for this study. An annotated case report form, a reporting and analysis plan, a clinical study report, and a protocol are not available for this study. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Dec-2014
2530	GSK	A Randomized, Double-Blind, Fixed Dose Comparison of 20, 40, and 60mg Daily of Paroxetine and Placebo in the Treatment of Generalized Social Phobia.	paroxetine	PAR 454	Social Phobia	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=29060/454			N	N	N	Y	N	Y	N	An analysis-ready dataset is not available for this study. An annotated case report form, a reporting and analysis plan, a clinical study report, and a protocol are not available for this study. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Dec-2014
2531	GSK	A Double-Blind, Placebo-Controlled, Flexible-Dosing Trial to Evaluate the Efficacy of Modified-Release Paroxetine in the Treatment of Panic Disorder	paroxetine	29060-494	Panic Disorder	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=29060/494			N	N	N	Y	N	Y	N	An analysis-ready dataset is not available for this study. An annotated case report form, a reporting and analysis plan, a clinical study report, and a protocol are not available for this study. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Dec-2014
2532	GSK	A Double-Blind, Placebo-Controlled, Flexible-Dosing Trial to Evaluate the Efficacy of Controlled-Release Paroxetine in the Treatment of Panic Disorder	paroxetine	29060/495	Panic Disorder	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=29060/495			N	N	N	Y	N	Y	N	An analysis-ready dataset is not available for this study. An annotated case report form, a reporting and analysis plan, a clinical study report, and a protocol are not available for this study. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Dec-2014
2533	GSK	A Double-Blind, Placebo-Controlled, Flexible-Dosing Trial to Evaluate the Efficacy of Controlled-Release Paroxetine in the Treatment of Panic Disorder	paroxetine	29060/497	Panic Disorder	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=29060/497			N	N	N	Y	N	Y	N	An analysis-ready dataset is not available for this study. An annotated case report form, a reporting and analysis plan, a clinical study report, and a protocol are not available for this study. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Dec-2014
2534	GSK	A Randomised, Double-blind Study of Paroxetine and Placebo in the Treatment of Social Phobia	paroxetine	PAR 029060-502	Social Phobia	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=29060/502			N	N	N	Y	N	Y	N	An analysis-ready dataset is not available for this study. An annotated case report form, a reporting and analysis plan, a clinical study report, and a protocol are not available for this study. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Dec-2014
2535	GSK	A 12-Week, Double-Blind, Placebo-Controlled, Parallel Group Study to Assess the Efficacy and Tolerability of Paroxetine in Patients Suffering from Post-traumatic Stress Disorder (PTSD)	paroxetine	PAR 29060/627	Post-Traumatic Stress Disorder	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=29060/627			N	Y	Y	Y	Y	Y	Y	An analysis-ready dataset is not available for this study. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Dec-2014
2536	GSK	A double-blind, placebo controlled study to evaluate the efficacy and tolerability of paroxetine in patients with Generalised Anxiety Disorder (GAD)	paroxetine	PAR 29060 637	Anxiety Disorders	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=29060/637			N	N	N	Y	N	Y	N	An analysis-ready dataset is not available for this study. An annotated case report form, a reporting and analysis plan, a clinical study report, and a protocol are not available for this study. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Dec-2014
2537	GSK	A Randomized, Double-Blind, Placebo Controlled, Fixed Dosage Trial to Evaluate the Efficacy and Tolerability of 20 and 40mg/day Paroxetine in Patients with Generalized Anxiety Disorder	paroxetine	BRL-029060/RSD-101336/1/CPMS-641	Anxiety Disorders	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=29060/641			N	N	N	Y	N	Y	N	An analysis-ready dataset is not available for this study. An annotated case report form, a reporting and analysis plan, a clinical study report, and a protocol are not available for this study. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Dec-2014
2538	GSK	A Randomized, Double-Blind, Placebo Controlled, Flexible Dosage Trial to Evaluate the Efficacy and Tolerability of Paroxetine in Patients with Generalized Anxiety Disorder	paroxetine	PAR 29060/642	Anxiety Disorders	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=29060/642			N	N	N	Y	N	Y	N	An analysis-ready dataset is not available for this study. An annotated case report form, a reporting and analysis plan, a clinical study report, and a protocol are not available for this study. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Dec-2014
2539	GSK	A 12 Week, Double-blind, Placebo-controlled, parallel group study to assess the efficacy and tolerability of Paroxetine in Patients suffering from Post-traumatic Stress Disorder (PTSD)	paroxetine	PAR 648	Post-Traumatic Stress Disorder	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=29060/648			N	N	Y	Y	Y	Y	N	An analysis-ready dataset is not available for this study. An annotated case report form and a reporting and analysis plan are not available for this study. A blank case report form will be provided. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Dec-2014
2540	GSK	A 12 week, double-blind, fixed dose comparison of 20 and 40 mg daily of paroxetine and placebo in Patients suffering from Post-traumatic Stress Disorder (PTSD).	paroxetine	PAR 29060 651 (BRL – 02960)	Post-Traumatic Stress Disorder	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=29060/651			N	N	N	Y	N	Y	N	An analysis-ready dataset is not available for this study. An annotated case report form, a reporting and analysis plan, a clinical study report, and a protocol are not available for this study. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Dec-2014
2541	GSK	A Double-blind, Placebo-controlled, Flexible-dose Study of Paroxetine CR in the Treatment of Patients with Social Anxiety Disorder	paroxetine	BRL-029060/CPMS-790	Social Phobia	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=29060/790			N	N	N	Y	N	Y	N	An analysis-ready dataset is not available for this study. An annotated case report form, a reporting and analysis plan, a clinical study report, and a protocol are not available for this study. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Dec-2014
2542	GSK	A Randomized, Double-Blind, Placebo-Controlled, Flexible Dosage Trial to Evaluate the Efficacy and Tolerability of Paroxetine CR in Patients with Generalized Anxiety Disorder (GAD)	paroxetine	29060/791	Anxiety Disorders	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=29060/791			N	N	N	Y	N	Y	N	An analysis-ready dataset is not available for this study. An annotated case report form, a reporting and analysis plan, a clinical study report, and a protocol are not available for this study. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Dec-2014
2543	GSK	An exercise endurance study to evaluate the effects of treatment of Chronic Obstructive Pulmonary Disease (COPD) patients with a dual bronchodilator: GSK573719/GW642444. Study A	umeclidinium bromide/vilanterol	DB2114417	Pulmonary Disease, Chronic Obstructive	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=114417	http://clinicaltrials.gov/show/NCT01328444	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023442-75	Y	Y	Y	Y	Y	Y	Y		1-Dec-2014
2544	GSK	An exercise endurance study to evaluate the effects of treatment of Chronic Obstructive Pulmonary Disease (COPD) patients with a dual bronchodilator: GSK573719/GW642444. Study B	umeclidinium bromide/vilanterol	DB2114418	Pulmonary Disease, Chronic Obstructive	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=114418	http://clinicaltrials.gov/show/NCT01323660	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023444-32	Y	Y	Y	Y	Y	Y	Y		1-Dec-2014
2629	GSK	A double-blind, placebo-controlled, randomised study of the efficacy of an HPV-16/18 VLP vaccine in the prevention of HPV-16 and/or HPV-18 cervical infection in healthy adolescent and young adult women in North America and Brazil.	Human Papillomavirus Types 16 and 18 Vaccine	580299/001	Infections, Papillomavirus	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=580299/001	http://clinicaltrials.gov/show/NCT00689741		Y	N	Y	Y	Y	Y	Y	Follow-on studies 580299/007, 109616, 109624, and 109625 were conducted. An annotated case report form is not available for this study. A blank case report form will be provided.	1-Jan-2015
2630	GSK	A 54-week, double-blind, randomized, placebo-controlled, parallel-group study to investigate the effects of rosiglitazone (extended release tablets) as adjunctive therapy to donepezil on cognition and overall clinical response in APOE ε4-stratified subjects with mild to moderate Alzheimer’s disease.	rosiglitazone	AVA102672	Alzheimer's Disease	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=AVA102672	http://clinicaltrials.gov/show/NCT00348309	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001403-11	Y	Y	Y	Y	Y	Y	Y	A follow-on study AVA102675 was conducted.	1-Jan-2015
2745	Astellas	A Randomized, Double-Blind, Parallel Group, Active Controlled, Multi-center Long-term Study to Assess the Safety and Efficacy of the Beta-3 Agonist Mirabegron (YM178) 50 mg qd and 100 mg qd in Subjects with Symptoms of Overactive Bladder.	mirabegron	178-CL-049	Urinary Bladder, Overactive	Phase 3	https://www.clinicaltrials.astellas.com/study/?pid=178-CL-049	https://clinicaltrials.gov/ct2/show/NCT00688688	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001452-39	Y	Y	Y	Y	Y	Y	Y	Extension study of 178-cl-046 and 178-cl-047.	1-Feb-2015
2746	Astellas	A Phase III, Randomized, Double-Blind, Parallel Group, Placebo Controlled, Multicenter Study to Assess the Efficacy and Safety of the Beta-3 Agonist Mirabegron (25 mg qd and 50 mg qd) in Subjects with Symptoms of Overactive bladder.	mirabegron	178-CL-074	Urinary Bladder, Overactive	Phase 3	https://www.clinicaltrials.astellas.com/study/?pid=178-CL-074	https://clinicaltrials.gov/ct2/show/NCT00912964	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-007087-42	Y	Y	Y	Y	Y	Y	Y		1-Feb-2015
2747	Astellas	A Double-Blind, Randomized, Parallel Group, Multi-Centre Study to Evaluate the Efficacy and Safety of Mirabegron Compared to Solifenacin in Subjects with Overactive Bladder (OAB) Treated with Antimuscarinics and Dissatisfied due to Lack of Efficacy.	mirabegron	178-EC-001	Urinary Bladder, Overactive	Phase 3	https://www.clinicaltrials.astellas.com/study/?pid=178-EC-001	https://clinicaltrials.gov/ct2/show/NCT01638000	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005713-37	Y	Y	Y	Y	Y	Y	Y		1-Feb-2015
2748	Astellas	A Randomized, Double-blind, Parallel Group, Placebo and Active Controlled, Multicenter Study to Assess the Efficacy and Safety of Mirabegron in Subjects with Symptoms of Overactive Bladder.	mirabegron	178-CL-046	Urinary Bladder, Overactive	Phase 3	https://www.clinicaltrials.astellas.com/study/?pid=178-CL-046	https://clinicaltrials.gov/ct2/show/NCT00689104	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001451-19	Y	Y	Y	Y	Y	Y	Y		1-Feb-2015
2749	Astellas	A Phase III, Randomized, Double-Blind, Parallel Group, Placebo Controlled, Multicenter Study to Assess the Efficacy and Safety of Mirabegron in Subjects with Symptoms of Overactive Bladder.	mirabegron	178-CL-047	Urinary Bladder, Overactive	Phase 3	https://www.clinicaltrials.astellas.com/study/?pid=178-CL-047	https://clinicaltrials.gov/ct2/show/NCT00662909		Y	Y	Y	Y	Y	Y	Y		1-Feb-2015
2750	Astellas	A randomized, double-blind, parallel group, placebo controlled, multi-center study of fixed dose combinations of solifenacin succinate (6 mg and 9 mg) with tamsulosin hydrochloride OCAS 0.4 mg and tamsulosin hydrochloride OCAS 0.4 mg monotherapy, in male subjects with lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH) with a substantial storage component.	solifenacin succinate + tamsulosin	905-CL-055	Lower Urinary Tract Symptoms / Benign Prostatic Hyperplasia	Phase 3	https://www.clinicaltrials.astellas.com/study/?pid=905-CL-055	https://clinicaltrials.gov/ct2/show/NCT01018511	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001211-37	Y	Y	Y	Y	Y	Y	Y		1-Feb-2015
2751	Astellas	An open-label, long term, multi-center study to assess the safety and efficacy of fixed dose combinations of solifenacin succinate (6 mg and 9 mg) with tamsulosin hydrochloride OCAS 0.4 mg, in male subjects with lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH) with a substantial storage component.	solifenacin succinate + tamsulosin	905-CL-057	Lower Urinary Tract Symptoms / Benign Prostatic Hyperplasia	Phase 3	https://www.clinicaltrials.astellas.com/study/?pid=905-CL-057	https://clinicaltrials.gov/ct2/show/NCT01021332	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001212-20	Y	Y	Y	Y	Y	Y	Y		1-Feb-2015
2753	GSK	A phase II, randomized, partially blinded clinical trial to evaluate the immunogenicity and reactogenicity of an investigational vaccine regimen of GSK Biologicals as compared to GSK Biologicals’ DTPa-HBV-IPV/Hib vaccine (Infanrix™ hexa) and to the concomitant administration of GSK Biologicals’ DTPa-HBV-IPV (Infanrix™ penta) and Hib (Hiberix™) vaccines, when given as a primary vaccination to healthy infants at 2, 3 and 4 months of age	Combined Diphtheria, Tetanus, Acellular Pertussis Adsorbed, Hepatitis B (Recombinant), Inactivated Polio Vaccine	217744/099	Acellular pertussis; Diphtheria; Hepatitis B; Poliomyelitis; Tetanus	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=217744/099			Y	N	Y	Y	Y	Y	Y	An annotated case report form is not available for this study. A blank case report form will be provided. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Feb-2015
2754	GSK	Assess immune persistence & memory by giving plain PRP,PSA & PSC (10 mths age), & immunogenicity & safety of a Tritanrix™-HBV/Hib-MenAC/ Tritanrix™-HBV/Hib2.5 booster (15-18 mths age) in previously primed subjects	Combined Diphtheria, Tetanus, Whole Cell Pertussis, Hepatitis B, Haemophilus influenzae Type b Vaccine	759346/002	Diphtheria; Haemophilus influenzae type b; Hepatitis B; Tetanus; Whole Cell Pertussis	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=759346/002	http://clinicaltrials.gov/show/NCT00317174		Y	N	Y	Y	Y	Y	Y	An annotated case report form is not available for this study. A blank case report form will be provided.	1-Feb-2015
2755	GSK	Study to show lot-to-lot consistency of Hib-MenAC mixed with Tritanrix™-HBV, its non-inferiority to Tritanrix™-HBV/Hiberix™ with or without Meningitec™, and MenA response in 2, 4, 6 month infants with hepatitis B birth dose	Combined Diphtheria, Tetanus, Whole Cell Pertussis, Hepatitis B, Haemophilus influenzae Type b Vaccine	100480	Diphtheria; Haemophilus influenzae type b; Hepatitis B; Tetanus; Whole Cell Pertussis	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=100480	http://clinicaltrials.gov/show/NCT00317161		Y	N	Y	Y	Y	Y	Y	Follow-on studies 104727 and 104730 were conducted. An annotated case report form is not available for this study. A blank case report form will be provided. The results of this study 100480 are summarised with studies 104727 and 104730 on the GSK Study Register.	1-Feb-2015
2756	GSK	Study to assess immunogenicity and non-inferiority of investigational vaccination regimen as compared to Tritanrix-HepB/Hiberix and as compared to Meningitec when administered to healthy infants	Combined Diphtheria, Tetanus, Whole Cell Pertussis, Hepatitis B, Haemophilus influenzae Type b Vaccine	100791	Diphtheria; Haemophilus influenzae type b; Hepatitis B; Tetanus; Whole Cell Pertussis	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=100480	http://clinicaltrials.gov/show/NCT00317187		Y	N	Y	Y	Y	Y	Y	The results of this study 100791 are summarised with 100480 and 759346/004 on the GSK Study Register. An annotated case report form is not available for this study. A blank case report form will be provided. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Feb-2015
2757	GSK	Study to demonstrate the non-inferiority of GSK Biologicals' DTPw-HBV/Hib Kft. vaccine compared to GSK Biologicals' Tritanrix™-HepB/Hiberix™ vaccine and to separate administration of DTPw-HBV Kft. and Hiberix™ vaccines with respect to the immunogenicity of all antigens, when administered to healthy infants.	Combined Diphtheria, Tetanus, Whole Cell Pertussis, Hepatitis B, Haemophilus influenzae Type b Vaccine (KFT)	101222	Diphtheria; Haemophilus influenzae type b; Hepatitis B; Tetanus; Whole Cell Pertussis	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=101222			Y	N	Y	Y	Y	Y	Y	An annotated case report form is not available for this study. A blank case report form will be provided. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Feb-2015
2758	GSK	Study to assess the lot-to-lot consistency of the production method of GSK Biologicals' DTPw-HBV/ Hib Kft. vaccine and to compare to GSK Biologicals' Tritanrix™-HepB/Hiberix™ vaccine, when administered as a primary vaccination course.	Combined Diphtheria, Tetanus, Whole Cell Pertussis, Hepatitis B, Haemophilus influenzae Type b Vaccine (KFT)	101223	Diphtheria; Haemophilus influenzae type b; Hepatitis B; Tetanus; Whole Cell Pertussis	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=101223			Y	N	Y	Y	Y	Y	Y	An annotated case report form is not available for this study. A blank case report form will be provided. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Feb-2015
2759	GSK	Follow-up to evaluate the the immunogenicity & safety of GSK Biologicals’ MMRV vaccine given as a two-dose schedule in the second year of life, as compared to separate administration of GSK Biologicals’ Priorix® & Varilrix®.	Combined Measles, Mumps, Rubella, Varicella Vaccine	208136/039	Measles; Mumps; Rubella; Varicella	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=208136/039	http://clinicaltrials.gov/show/NCT00406211		Y	N	Y	Y	Y	Y	Y	This is a Year 1 follow-up study to 208136/038. An annotated case report form is not available for this study. A blank case report form will be provided.	1-Feb-2015
2760	GSK	Study to evaluate immunogenicity and safety of three production lots of GSK Biologicals' combined MeMuRu-OKA candidate vaccine given on a two-dose schedule to healthy children, as compared to separate administration of GSK Biologicals' Priorix® and Varilrix® vaccines	Combined Measles, Mumps, Rubella, Varicella Vaccine	208136/040	Measles; Mumps; Rubella; Varicella	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=208136/040			Y	N	Y	Y	Y	Y	Y	This is a Year 2 follow-up study to 208136/038. An annotated case report form is not available for this study. A blank case report form will be provided. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Feb-2015
2761	GSK	Study to evaluate immunogenicity and safety of three production lots of GSK Biologicals' combined MeMuRu-OKA candidate vaccine given on a two-dose schedule to healthy children, as compared to separate administration of GSK Biologicals' Priorix® and Varilrix® vaccines	Combined Measles, Mumps, Rubella, Varicella Vaccine	208136/041	Measles; Mumps; Rubella; Varicella	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=208136/041			Y	N	Y	Y	Y	Y	Y	This is a Year 3 follow-up study to 208136/038. An annotated case report form is not available for this study. A blank case report form will be provided. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Feb-2015
2762	GSK	Immunogenicity & safety study of GSK Biologicals’ 208136 vaccine formulated with new measles and rubella working seeds	Combined Measles, Mumps, Rubella, Varicella Vaccine	108760	Measles; Mumps; Rubella; Varicella	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=108760	http://clinicaltrials.gov/show/NCT00892775	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005881-38	Y	N	Y	Y	Y	Y	Y	An annotated case report form is not available for this study. A blank case report form will be provided.	1-Feb-2015
2763	GSK	Study to evaluate immunogenicity and safety of three production lots of GSK Biologicals' combined MeMuRu-OKA candidate vaccine given on a two-dose schedule to healthy children in their second year of life, as compared to separate administration of GSK Biologicals' Priorix™ and Varilrix™ vaccines	Combined Measles, Mumps, Rubella, Varicella Vaccine	208136/038	Measles; Mumps; Rubella; Varicella	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=208136/038			Y	N	Y	Y	Y	Y	Y	Follow-on studies 208136/039, 208136/040, and 208136/041 were conducted. An annotated case report form is not available for this study. A blank case report form will be provided. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Feb-2015
2764	GSK	Evaluation of GSK Biologicals’ Boostrix™ in healthy adults, 10 years after previous booster vaccination	Combined Reduced Antigen Content Diphtheria, Tetanus, Acellular Pertussis Vaccine	113055	Acellular pertussis; Diphtheria; Tetanus	Phase 4	https://www.gsk-studyregister.com/en/trial-details/?id=113055	http://clinicaltrials.gov/show/NCT01147900	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-016012-21	Y	N	Y	Y	Y	Y	Y	An annotated case report form is not available for this study. A blank case report form will be provided.	1-Feb-2015
2765	GSK	Immunogenicity and safety study of GSK Biologicals’ Boostrix™ vaccine using a new syringe presentation in healthy adolescents aged 10–15 years	Combined Reduced Antigen Content Diphtheria, Tetanus, Acellular Pertussis Vaccine	114778	Acellular pertussis; Diphtheria; Tetanus	Phase 4	https://www.gsk-studyregister.com/en/trial-details/?id=114778	http://clinicaltrials.gov/show/NCT01362322	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003768-30	Y	N	Y	Y	Y	Y	Y	An annotated case report form is not available for this study. A blank case report form will be provided.	1-Feb-2015
2766	GSK	A phase III, observer-blinded randomised, multi-centre clinical study of the safety, immunogenicity and consistency of three manufacturing lots of GSK Biologicals' candidate Tdap vaccine as compared to a US-licensed Td vaccine when given as a booster dose to healthy adolescents (10-18 years of age)	Combined Reduced Antigen Content Diphtheria, Tetanus, Acellular Pertussis Vaccine	776423/001	Acellular pertussis; Diphtheria; Tetanus	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=776423/001	http://clinicaltrials.gov/show/NCT00109330		Y	N	Y	Y	Y	Y	Y	An annotated case report form is not available for this study. A blank case report form will be provided.	1-Feb-2015
2767	GSK	Evaluation of GSK Biologicals’ Boostrix™ Polio in healthy adults, 10 years after a booster vaccination	Combined Reduced Antigen Content Diphtheria, Tetanus, Acellular Pertussis, Inactivated Polio Vaccine	113060	Acellular pertussis; Diphtheria; Poliomyelitis; Tetanus	Phase 4	https://www.gsk-studyregister.com/en/trial-details/?id=113060	http://clinicaltrials.gov/show/NCT01323959	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-012219-16	Y	N	Y	Y	Y	Y	Y	An annotated case report form is not available for this study. A blank case report form will be provided.	1-Feb-2015
2768	GSK	Feasibility study of GlaxoSmithKline Biologicals’ GSK2202083A vaccine in healthy infants at 2, 4 and 12 months of age	Combined Diphtheria, Tetanus, Acellular Pertussis, Hepatitis B, Inactivated Polio, Haemophilus influenzae Type b Vaccine	113615	Acellular pertussis; Diphtheria; Haemophilus influenzae type b; Hepatitis B; Neisseria Meningitidis; Poliomyelitis; Tetanus	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=113615	http://clinicaltrials.gov/show/NCT01090453	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-016635-36	Y	N	Y	Y	Y	Y	Y	An annotated case report form is not available for this study. A blank case report form will be provided.	1-Feb-2015
2769	GSK	Immunogenicity and safety study of GSK Biologicals’ quadrivalent influenza vaccine (GSK2282512A) when administered in children	Influenza Vaccine (Quadrivalent)	116926	Influenza	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=116926	http://clinicaltrials.gov/show/NCT01711736	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003155-38	Y	N	Y	Y	Y	Y	Y	An annotated case report form is not available for this study. A blank case report form will be provided.	1-Feb-2015
2770	GSK	Immunogenicity and safety study of GSK Biologicals’ cell culture derived pandemic influenza vaccines GSK2590066A and GSK2592984A administered to healthy adults 18 - 49 years old	GSK2590066A	114371	Influenza	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=114371	http://clinicaltrials.gov/show/NCT01236040		Y	N	Y	Y	Y	Y	Y	An annotated case report form is not available for this study. A blank case report form will be provided.	1-Feb-2015
2771	GSK	Safety and immunogenicity study of a prime-boost schedule of GSK Biologicals' influenza vaccine GSK1562902A in children aged 3 to 17 years	Influenza Vaccine	115115	Influenza	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=115115	http://clinicaltrials.gov/show/NCT01379937	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004751-39	Y	N	Y	Y	Y	Y	Y	An annotated case report form is not available for this study. A blank case report form will be provided.	1-Feb-2015
2772	GSK	A Phase IIIA study of immunogenicity and safety of GSK Biologicals’ quadrivalent split virion influenza vaccine FLU-Q-QIV in adults aged 18 years and older	Influenza Vaccine	115418	Influenza	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=115418	http://clinicaltrials.gov/show/NCT01440387		Y	N	Y	Y	Y	Y	Y	An annotated case report form is not available for this study. A blank case report form will be provided.	1-Feb-2015
2773	GSK	Immunogenicity and Safety Study of GSK Biologicals' Seasonal (2010-2011) Influenza Vaccine Fluarix™ in Children Previously Vaccinated With GSK Biologicals' H1N1 Vaccine Pandemrix™	H1N1 Pandemic Influenza Vaccine	114451	Influenza	Phase 4	https://www.gsk-studyregister.com/en/trial-details/?id=114451	http://clinicaltrials.gov/show/NCT01196026	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-020330-26	Y	N	Y	Y	Y	Y	Y	An annotated case report form is not available for this study. A blank case report form will be provided.	1-Feb-2015
2774	GSK	Immunogenicity and Safety Study of GSK Biologicals' Seasonal (2010-2011) Influenza Vaccine FluarixTM in Adolescents Previously Vaccinated With GSK Biologicals' H1N1 Vaccine PandemrixTM	H1N1 Pandemic Influenza Vaccine	114452	Influenza	Phase 4	https://www.gsk-studyregister.com/en/trial-details/?id=114452	http://clinicaltrials.gov/show/NCT01190215	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-020331-39	Y	N	Y	Y	Y	Y	Y	An annotated case report form is not available for this study. A blank case report form will be provided.	1-Feb-2015
2775	GSK	Safety and immunogenicity study of GSK Biologicals’ pandemic influenza (H1N1) candidate vaccine (GSK2340274A) in children aged 10 to less than 18 years	H1N1 Pandemic Influenza Vaccine	113883	Influenza	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=113883	http://clinicaltrials.gov/show/NCT01035749	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-016268-35	Y	N	Y	Y	Y	Y	Y	An annotated case report form is not available for this study. A blank case report form will be provided.	1-Feb-2015
2776	GSK	A study to evaluate the safety and efficacy of A/California/7/2009 (H1N1)v-like vaccines GSK2340274A and GSK2340273A in children aged 6 months to less than 10 years of age	H1N1 Pandemic Influenza Vaccine	114000	Influenza	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=114000	http://clinicaltrials.gov/show/NCT01051661		Y	N	Y	Y	Y	Y	Y	An annotated case report form is not available for this study. A blank case report form will be provided.	1-Feb-2015
2777	GSK	Safety and immunogenicity of monovalent H5N1 vaccine GSK1557484A in children 6 months to < 18 years of age	H5N1 Pandemic Influenza Vaccine	114464	Influenza	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=114464	http://clinicaltrials.gov/show/NCT01310413	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001683-29	Y	N	Y	Y	Y	Y	Y	An annotated case report form is not available for this study. A blank case report form will be provided.	1-Feb-2015
2778	GSK	Study to evaluate immunogenicity, reactogenicity and safety of investigational vaccination regimen as compared to GSK Biological’s Hiberix vaccine, extemporaneously mixed with GSK Biological’s Tritanrix-HepB, when administered intramuscularly in infants at 6, 10 and 14 weeks of age	Haemophilus influenzae Type b Vaccine	759346/009	Haemophilus influenzae type b	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=759346/009			Y	N	Y	Y	Y	Y	Y	An annotated case report form is not available for this study. A blank case report form will be provided. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Feb-2015
2779	GSK	Persistence of antibodies after full vaccination course with GSK Biologicals’ Menitorix or MenC conjugate vaccine, co-administered with DTPa or DTPa/Hib containing vaccine and pneumococcal conjugate vaccine, in children up to 6 years of age	Haemophilus influenzae Type b, Meningococcal C-Tetanus Toxoid Conjugate Vaccine	112830	Haemophilus influenzae type b; Neisseria Meningitidis	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=112830	http://clinicaltrials.gov/show/NCT00891176	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-007846-69	Y	N	Y	Y	Y	Y	Y	An annotated case report form is not available for this study. A blank case report form will be provided.	1-Feb-2015
2780	GSK	A double-blind, randomized study to evaluate the immunogenicity and reactogenicity of three different lots of GlaxoSmithKline (GSK) Biologicals' combined hepatitis A / hepatitis B vaccine in healthy adult volunteers.	Hepatitis A (Inactivated), Hepatitis B (Recombinant) Vaccine	208127/118 (Ext-HAB-032 Month 120)	Hepatitis A; Hepatitis B	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=208127/118			Y	N	Y	Y	Y	Y	Y	This is a follow-up study of 208127/022. follow-on studies 100556, 100557, 100558, 100560, and 112266 were conducted. An annotated case report form is not available for this study. A blank case report form will be provided. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Feb-2015
2781	GSK	Evaluate the Persistence of Immune Response of GSK Biologicals' Twinrix™ Vaccine, Administered According to a 0,6 month Schedule and a 0,1,6 month Schedule, in Healthy Children Aged Between 1-11 years at the Time of First Vaccine Dose	twinrix	208127/132	Hepatitis A; Hepatitis B	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=208127/132 (EXT Y2)	http://clinicaltrials.gov/show/NCT00197184	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-001515-12	Y	N	Y	Y	Y	Y	Y	This is a long-term follow-up study to 208127/120. The results of this study 208127/132 are summarised with studies 208127/133, 208127/134 and 208127/137 on the GSK Study Register. An annotated case report form is not available for this study. A blank case report form will be provided.	1-Feb-2015
2782	GSK	Evaluate the Persistence of Immune Response of GSK Biologicals' Twinrix™ Vaccine, Administered According to a 0,6 month Schedule and a 0,1,6 month Schedule, in Healthy Children Aged Between 1-11 years at the Time of First Vaccine Dose	twinrix	208127/134	Hepatitis A; Hepatitis B	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=208127/132 (EXT Y2)	http://clinicaltrials.gov/show/NCT00197184	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-001515-12	Y	N	Y	Y	Y	Y	Y	This is a long-term follow-up study to 208127/120. The results of this study 208127/134 are summarised with studies 208127/132, 208127/133 and 208127/137 on the GSK Study Register. An annotated case report form is not available for this study. A blank case report form will be provided.	1-Feb-2015
2783	GSK	Evaluate the Persistence of Immune Response of GSK Biologicals' Twinrix™ Vaccine, Administered According to a 0,6 month Schedule and a 0,1,6 month Schedule, in Healthy Children Aged Between 1-11 years at the Time of First Vaccine Dose	twinrix	208127/137	Hepatitis A; Hepatitis B	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=208127/132 (EXT Y2)	http://clinicaltrials.gov/show/NCT00197184	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-001515-12	Y	N	Y	Y	Y	Y	Y	This is a long-term follow-up study to 208127/120. The results of this study 208127/137 are summarised with studies 208127/132, 208127/133 and 208127/134 on the GSK Study Register. An annotated case report form is not available for this study. A blank case report form will be provided.	1-Feb-2015
2784	GSK	An open, multicentric, post-marketing surveillance study of GlaxoSmithKline Biologicals’ combined hepatitis A-hepatitis B vaccine (Twinrix™), injected as a three dose primary vaccination course according to the prescribing information, in healthy children and adults.	twinrix	208127/127 (HAB-127)	Hepatitis A; Hepatitis B	Phase 4	https://www.gsk-studyregister.com/en/trial-details/?id=208127/127			Y	N	Y	Y	Y	Y	Y	An annotated case report form is not available for this study. A blank case report form will be provided. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Feb-2015
2785	GSK	A double-blind, randomized study to evaluate the immunogenicity and reactogenicity of two different lots of GlaxoSmithKline Biologicals' combined hepatitis A/hepatitis B vaccine in healthy children between 6 and 15 years of age.	Hepatitis A (Inactivated), Hepatitis B (Recombinant) Vaccine	101040 (HAB-164 Ext-038 Y10)	Hepatitis A; Hepatitis B	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=101040			Y	N	Y	Y	Y	Y	Y	This is a 10-year follow-up study to HAB-038. A 90-month follow-on study 208127/125 was also conducted. An annotated case report form is not available for this study. A blank case report form will be provided. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Feb-2015
2786	GSK	A phase III, open, randomized, multicentre study to demonstrate the non-inferiority of GSK Biologicals' combined hepatitis A and hepatitis B vaccine according to a 0-1-6 month schedule, to the monovalent hepatitis A vaccine Havrix and hepatitis B vaccine Engerix separately administered, in healthy adults	Hepatitis A (Inactivated), Hepatitis B (Recombinant) Vaccine	101377	Hepatitis A; Hepatitis B	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=101377			Y	N	Y	Y	Y	Y	Y	An annotated case report form is not available for this study. A blank case report form will be provided. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Feb-2015
2787	GSK	A Phase IIIb, open, randomized, controlled, multicenter study of the immunogenicity and safety of GSK Biologicals' inactivated hepatitis A vaccine administered on a 0-6 mth schedule concomitantly with Wyeth Lederle's pneumococcal conjugate vaccine in healthy children 15 months of age	Hepatitis A Vaccine, Inactivated	208109/220	Hepatitis A	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=208109/220	http://clinicaltrials.gov/show/NCT00197002	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-003920-10	Y	N	Y	Y	Y	Y	Y	An annotated case report form is not available for this study. A blank case report form will be provided.	1-Feb-2015
2788	GSK	Immunogenicity & Safety of GSK Biologicals' Inactivated Hepatitis A Vaccine (Havrix™) Co-administered With Merck & Company, Inc. Measles-Mumps-Rubella Vaccine (M-M-RII) & Merck & Co Varicella Vaccine (VARIVAX™) to Children 15 Months of Age	Hepatitis A Vaccine, Inactivated	208109/231	Hepatitis A	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=208109/231	http://clinicaltrials.gov/show/NCT00197015	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-001509-15	Y	N	Y	Y	Y	Y	Y	An annotated case report form is not available for this study. A blank case report form will be provided.	1-Feb-2015
2789	GSK	Immunogenicity and Safety of GSK Biologicals' Inactivated Hepatitis A Vaccine (Havrix™) co-administered With GSK Biologicals' DTaP Vaccine (Infanrix™) and Aventis Pasteur's Haemophilus b Conjugate Vaccine (ActHIB) in Healthy Children 15 months of Age	Hepatitis A Vaccine, Inactivated	208109/232	Hepatitis A	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=208109/232	http://clinicaltrials.gov/show/NCT00197236	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-001530-25	Y	N	Y	Y	Y	Y	Y	An annotated case report form is not available for this study. A blank case report form will be provided.	1-Feb-2015
2790	GSK	Study to assess immunogenicity and reactogenicity of a booster dose of GSK Biologicals Kft’s combined DTPwCSL-HB vaccine as compared to concomitant administration of CSL’s DTPw vaccine and GSK Biologicals' hepatitis B vaccine at separate injection sites and to GSK Biologicals' DTPw-HB vaccine	Hepatitis B Vaccine, Recombinant	102144	Hepatitis B	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=102144			Y	N	Y	Y	Y	Y	Y	An annotated case report form is not available for this study. A blank case report form will be provided. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Feb-2015
2791	GSK	A phase III, partially double blind, randomized, multicentric study to evaluate the immunogenicity, safety and reactogenicity of GlaxoSmithKline (GSK) Biologicals Kft’s combined DTPwCSL-HB vaccine as compared to Commonwealth Serum Laboratory’s (CSL’s) DTPwCSL (Triple Antigen™) and GSK Biologicals’ HBV (Engerix™-B) administered concomitantly at separate injection sites and to GSK Biologicals’ DTPw-HB vaccine (Tritanrix™-HepB) when administered to healthy infants at 3, 4 and 5 months of age	Hepatitis B Vaccine, Recombinant	196131/001	Hepatitis B	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=196131/001			Y	N	Y	Y	Y	Y	Y	An annotated case report form is not available for this study. A blank case report form will be provided. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Feb-2015
2792	GSK	A phase III, partially blind, randomized study to evaluate the immunogenicity, safety and reactogenicity of GlaxoSmithKline (GSK) Biologicals’ Tritanrix™-HepB and GSK Biologicals Kft’s DTPw-HBV vaccines as compared to concomitant administration of Commonwealth Serum Laboratory’s (CSL’s) DTPw (Triple Antigen™) and GSK Biologicals’ HBV (Engerix™-B), when co-administered with GSK Biologicals’ oral live attenuated human rotavirus (HRV) vaccine, to healthy infants at 3, 4½ and 6 months of age, after a birth dose of hepatitis B vaccine.	Hepatitis B Vaccine, Recombinant	104021	Hepatitis B	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=104021	http://clinicaltrials.gov/show/NCT00158756	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-003878-86	Y	N	Y	Y	Y	Y	Y	An annotated case report form is not available for this study. A blank case report form will be provided.	1-Feb-2015
2793	GSK	A phase III, clinical trial comparing the immunogenicity and safety of SmithKline Beecham Biologicals new adjuvanted hepatitis B vaccine to a double dose of Engerix™-B, in pre-haemodialysis/haemodialysis patients (>=15 years of age)	Hepatitis B Vaccine, Recombinant	208129/047	Hepatitis B	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=208129/047	http://clinicaltrials.gov/show/NCT00383591		Y	N	Y	Y	Y	Y	Y	The results of this study 208129/047 are summarised with 208129/032 and 208129/042 on the GSK Study Register. An annotated case report form is not available for this study. A blank case report form will be provided.	1-Feb-2015
2794	GSK	Efficacy, immunogenicity and safety of GlaxoSmithKline Biologicals’ HPV GSK 580299 vaccine in healthy Chinese female subjects	Human Papillomavirus Types 16 and 18 Vaccine	107638	Infections, Papillomavirus	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=107638	http://clinicaltrials.gov/show/NCT00779766		Y	Y	Y	Y	Y	Y	Y	A follow-on study 114590 was conducted.	1-Feb-2015
2795	GSK	Long-term extension study of the efficacy of the 580299 vaccine in the prevention of HPV-16 and/or HPV-18 associated cervical intraepithelial neoplasia (CIN) in Japanese women vaccinated in the primary vaccination study NCT00316693	Human Papillomavirus Types 16 and 18 Vaccine	112949	Infections, Papillomavirus	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=112949	http://clinicaltrials.gov/show/NCT00929526		Y	N	Y	Y	Y	Y	Y	This is a long-term follow-up study to 104798. An annotated case report form is not available for this study. A blank case report form will be provided.	1-Feb-2015
2796	GSK	A phase I/II, open, controlled study in order to evaluate the reactogenicity and the immunogenicity of GlaxoSmithKline Biologicals influenza candidate adjuvanted vaccine in an elderly population aged over 65 years previously vaccinated in 2004 with the same candidate vaccine	Influenza Vaccine	104540	Influenza	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=104540	http://clinicaltrials.gov/show/NCT00318058	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001928-37	Y	Y	Y	Y	Y	Y	N	This is a follow-up study to 103304-001. Follow-on studies 107973 and 110223 were conducted. A reporting and analysis plan is not available for this study.	1-Feb-2015
2797	GSK	Demonstrate the non-inferiority in term of cellular mediated immune response of GSK Biologicals' influenza candidate vaccines containing various adjuvants administered in elderly population (aged 65 years & older) vs Fluarix™ (known as alpha-Rix™ in Belgium) administered in adults (18-40 years)	Influenza Vaccine	104886	Influenza	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=104886	http://clinicaltrials.gov/show/NCT00318149	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002360-28	Y	N	Y	Y	Y	Y	Y	An annotated case report form is not available for this study. A blank case report form will be provided.	1-Feb-2015
2798	GSK	Evaluate reactogenicity & immunogenicity of adjuvanted influenza vaccine in elderly adults previously vaccinated with the same candidate vaccine. Fluarix™ administered in young & elderly adults will be used as reference	Influenza Vaccine	104887	Influenza	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=104887	http://clinicaltrials.gov/show/NCT00386698	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003236-30	Y	N	Y	Y	Y	Y	Y	An annotated case report form is not available for this study. A blank case report form will be provided.	1-Feb-2015
2799	GSK	A phase II/III, observer-blind, Multi-Country, Multi-Centre, randomized study to demonstrate the superiority in terms of immunogenicity of adjuvanted influenza vaccine administered in adults aged 50 years and older compared to Fluarix™	Influenza Vaccine	104888	Influenza	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=104888	http://clinicaltrials.gov/show/NCT00377585	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003238-14	Y	N	Y	Y	Y	Y	Y	A follow-on study 107509 was conducted. The results of study 107509 are summarised with this study 104888 on the GSK Study Register. An annotated case report form is not available for this study. A blank case report form will be provided.	1-Feb-2015
2800	GSK	A phase II/III, observer-blind, Multi-Country, Multi-Centre, randomized study to demonstrate the superiority in terms of immunogenicity of adjuvanted influenza vaccine administered in adults aged 50 years and older compared to Fluarix™	Influenza Vaccine	107509	Influenza	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=104888	http://clinicaltrials.gov/show/NCT00377585		Y	N	Y	Y	Y	Y	Y	This is a follow-up study to 104888. The results of this study 107509 are summarised with study 104888 on the GSK Study Register. An annotated case report form is not available for this study. A blank case report form will be provided.	1-Feb-2015
2802	GSK	Study to monitor the safety and reactogenicity of GlaxoSmithKline Biologicals’ influenza split vaccine FLUARIX™ administered according to the Prescribing Information in Korean subjects aged more than 6 months of age at the time of vaccination	Influenza Vaccine (Split Virion, Inactivated)	218352/054	Influenza	Phase 4	https://www.gsk-studyregister.com/en/trial-details/?id=218352/054	http://clinicaltrials.gov/show/NCT00750360		Y	N	Y	Y	Y	Y	Y	An annotated case report form is not available for this study. A blank case report form will be provided.	1-Feb-2015
2809	GSK	COMPAS: A phase III study to demonstrate efficacy of GSK Biologicals' 10-valent pneumococcal vaccine (GSK1024850A) against Community Acquired Pneumonia and Acute Otitis Media	Pneumococcal Polysaccharide Conjugate Vaccine (Adsorbed)	109563	Infections, Streptococcal	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=109563	http://clinicaltrials.gov/show/NCT00466947	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002076-16	Y	N	Y	Y	Y	Y	Y	An annotated case report form is not available for this study. A blank case report form will be provided.	1-Feb-2015
2810	GSK	Assessment of long-term antibody persistence and immunological memory in children previously vaccinated with four pneumococcal conjugate vaccine doses and assessment of pneumococcal catch-up vaccination with GSK1024850A at 5 years of age	Pneumococcal Polysaccharide Conjugate Vaccine (Adsorbed)	111346	Infections, Streptococcal	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=111346	http://clinicaltrials.gov/show/NCT00624819	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005392-34	Y	N	Y	Y	Y	Y	Y	This is a Year 2 follow-up study to 107046. An annotated case report form is not available for this study. A blank case report form will be provided.	1-Feb-2015
2811	GSK	Assessment of long-term antibody persistence and immunological memory in children previously vaccinated with four pneumococcal conjugate vaccine doses and assessment of pneumococcal catch-up vaccination with GSK1024850A at 5 years of age.	Pneumococcal Polysaccharide Conjugate Vaccine (Adsorbed)	111347	Infections, Streptococcal	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=111347	http://clinicaltrials.gov/show/NCT00624819	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005392-34	Y	N	Y	Y	Y	Y	Y	This is a Year 4 follow-up study to 107046. An annotated case report form is not available for this study. A blank case report form will be provided.	1-Feb-2015
2812	GSK	Immunogenicity, safety and reactogenicity of GlaxoSmithKline Biologicals’ pneumococcal vaccine GSK1024850A following primary and booster vaccination of healthy Japanese children	Pneumococcal Polysaccharide Conjugate Vaccine (Adsorbed)	112640	Infections, Streptococcal	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=112640	http://clinicaltrials.gov/show/NCT01027845	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-003710-16	Y	N	Y	Y	Y	Y	Y	This is a follow-up study to 105553. An annotated case report form is not available for this study. A blank case report form will be provided.	1-Feb-2015
2813	GSK	Booster vaccination with pneumococcal vaccine GSK1024850A in primed children and catch-up vaccination in unprimed children	Pneumococcal Polysaccharide Conjugate Vaccine (Adsorbed)	112909	Infections, Streptococcal	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=112909	http://clinicaltrials.gov/show/NCT01030822	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002140-27	Y	Y	Y	Y	Y	Y	Y	This is a booster study of 111188.	1-Feb-2015
2814	GSK	A study to compare the safety, reactogenicity & immunogenicity of GSK Biologicals pneumococcal vaccines vs the licensed 23-valent pneumococcal polysaccharide vaccine, in healthy elderly subjects	Pneumococcal Polysaccharide Conjugate Vaccine (Adsorbed)	106068	Infections, Streptococcal	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=106068	http://clinicaltrials.gov/show/NCT00327665	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-005682-11	Y	N	Y	Y	Y	Y	Y	An annotated case report form is not available for this study. A blank case report form will be provided.	1-Feb-2015
2815	GSK	A 24 Week Randomized, Double-blind, Double-dummy, Multicenter Study to Evaluate the Safety, Efficacy, and Tolerability of Avandia™ XR and AVANDIA™ (4mg BD) in Patients with Type 2 Diabetes	rosiglitazone	49653/183	Diabetes Mellitus, Type 2	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=49653/183			Y	Y	Y	Y	Y	Y	Y	A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Feb-2015
2816	GSK	A 24 Week Randomized, Double-blind, Double-dummy, Multicenter Study to Compare the Efficacy of Formulation X and AVANDIA™ (8mg OD) in Subjects with Type 2 Diabetes Mellitus	rosiglitazone	AXR100723	Diabetes Mellitus, Type 2	Phase 4	https://www.gsk-studyregister.com/en/trial-details/?id=100723			Y	Y	Y	Y	Y	Y	Y	A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Feb-2015
2817	GSK	2-year, Randomized, Double-blind, Parallel Group Study to Compare the Efficacy, Safety and Tolerability of Rosiglitazone Versus Placebo in Combination with Glipizide in Elderly Patients with Type 2 Diabetes Mellitus who are Inadequately Controlled on Glipizide Therapy	rosiglitazone	49653/135	Diabetes Mellitus, Type 2	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=49653/135			Y	Y	Y	Y	Y	Y	Y	A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Feb-2015
2818	GSK	A 26-week Randomised, Double-Blind, Multicentre, Placebo-Controlled Study to Evaluate the Efficacy, Safety and Tolerability of Rosiglitazone with Concurrent Insulin Therapy and/or a Sulphonylurea in Type 2 Diabetic Patients with Chronic Renal Failure (Not on Dialysis).	rosiglitazone	49653/136	Diabetes Mellitus, Type 2	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=49653/136			Y	Y	Y	Y	Y	Y	Y	A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Feb-2015
2819	GSK	A Randomised, Double-Blind, Placebo-Controlled Study to Investigate the Effects of Rosiglitazone on Post Prandial Glycaemia in Type 2 Diabetic Patients.	rosiglitazone	49653/140	Diabetes Mellitus, Type 2	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=49653/140			N	N	Y	Y	Y	Y	N	An analysis-ready dataset and a reporting and analysis plan are not available for this study. An annotated case report form is not available for this study. A blank case report form will be provided. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Feb-2015
2820	GSK	A 24-Week Randomized, Double-blind Study to Evaluate the Efficacy, Safety and Tolerability of AVANDIA (8mg once daily) in Combination with Glyburide in African American and Hispanic Patients with Type 2 Diabetes Mellitus who are Inadequately Controlled on Glyburide Monotherapy	rosiglitazone	49653/143	Diabetes Mellitus, Type 2	Phase 4	https://www.gsk-studyregister.com/en/trial-details/?id=49653/143	http://clinicaltrials.gov/show/NCT00333723		Y	Y	Y	Y	Y	Y	Y		1-Feb-2015
2821	GSK	A 24-Week Randomized, Double-blind, Double-Dummy, Multicenter Study to Compare the Efficacy of AVANDIA when added to Submaximal Doses of Metformin and to Compare the Tolerability of the Combination to Metformin Monotherapy when Administered to Subjects with Type 2 Diabetes Mellitus	rosiglitazone	49653/284	Diabetes Mellitus, Type 2	Phase 4	https://www.gsk-studyregister.com/en/trial-details/?id=49653/284	http://clinicaltrials.gov/show/NCT00501020		Y	Y	Y	Y	Y	N	Y	A raw dataset is not available for this study.	1-Feb-2015
2822	GSK	A 24-week Randomized, Double-Blind, Parallel-Group, Multicenter Study to Demonstrate the Efficacy and Safety of Two Different Rosiglitazone Dosing Regimens, 4mg OD and 8mg OD, in Poorly-Controlled Drug Naive Patients with Type 2 Diabetes Mellitus	rosiglitazone	49653/326	Diabetes Mellitus, Type 2	Phase 4	https://www.gsk-studyregister.com/en/trial-details/?id=49653/326	http://clinicaltrials.gov/show/NCT00044460		Y	Y	Y	Y	Y	Y	Y		1-Feb-2015
2823	GSK	A Double-Blind Feasibility Study to Estimate and Compare the Effect of Rosiglitazone in Parallel with Glyburide on Cognition in Patients with Type 2 Diabetes Mellitus	rosiglitazone	BRL-049653/282	Diabetes Mellitus, Type 2	Phase 4	https://www.gsk-studyregister.com/en/trial-details/?id=49653/282			N	N	Y	Y	Y	Y	Y	An analysis-ready dataset is not available for this study. An annotated case report form is not available for this study. A blank case report form will be provided. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Feb-2015
2824	GSK	A single-centre, randomised, double-blind, placebo controlled, two 12 week period, cross-over phase III study to investigate the effect of rosiglitazone 4mg bd on the vasodilator response to hyperinsulinaemia in obese insulin resistant subjects.	rosiglitazone	BRL-049653/375	Diabetes Mellitus, Type 2	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=49653/375	http://clinicaltrials.gov/show/NCT00197132		N	Y	Y	Y	Y	Y	Y	An analysis-ready dataset is not available for this study.	1-Feb-2015
2825	GSK	A dose proportionality study with a combination tablet formulation of rosiglitazone and glimepiride (4mg/1mg; or 4mg/2mg; or 4mg/4mg) in healthy subjects.	rosiglitazone/glimepiride	797620/001	Diabetes Mellitus, Type 2	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=797620/001			Y	N	Y	Y	Y	Y	Y	An annotated and blank case report form are not available as the electronic data capture system used for this study did not generate paper versions. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Feb-2015
2826	GSK	A study to assess effect of food on pharmacokinetics of an investigational formulation, and to compare the pharmacokinetics of an investigational formulation to concomitant dosing of rosiglitazone 4mg and glimepiride 4mg commercial tablets in the fed state in healthy subjects	rosiglitazone/glimepiride	797620/003	Diabetes Mellitus, Type 2	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=797620/003			Y	N	Y	Y	Y	Y	Y	An annotated and blank case report form are not available as the electronic data capture system used for this study did not generate paper versions. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Feb-2015
2827	GSK	A multi-center, randomized, double-blind, parallel group trial to compare the efficacy and safety of fixed-dose rosiglitazone/glimepiride combination therapy to glimepiride monotherapy and rosiglitazone monotherapy in drug naïve subjects with type 2 diabetes mellitus	rosiglitazone/glimepiride	797620/004	Diabetes Mellitus, Type 2	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=797620/004			Y	Y	Y	Y	Y	Y	Y	A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Feb-2015
2828	GSK	A Bioequivalence Study with a Combination Tablet Formulation of Rosiglitazone and Metformin (4mg/1000mg) Compared to the Commercial Tablet Formulation of AVANDAMET (2mg rosiglitazone/500mg metformin) and a Dose Proportionality Study Comparing the Combination Tablet Formulations of Rosiglitazone and Metformin (4mg/1000mg & 2mg/1000mg).	rosiglitazone/metformin	SB-712753/001	Diabetes Mellitus, Type 2	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=712753/001			Y	N	Y	Y	Y	N	Y	A raw dataset is not available for this study. An annotated case report form is not available for this study. A blank case report form will be provided. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Feb-2015
2829	GSK	A study to estimate the pharmacokinetics of six extended release formulations of AVANDAMET (rosiglitazone maleate 4mg / metformin HCl 1000mg), compared to the commercial formulation of AVANDAMET (rosiglitazone maleate 2mg / metformin HCl 500mg, q12h), and concomitant dosing of Glucophage XR (metformin HCl 2 × 500mg) with AVANDIA (rosiglitazone maleate 4mg)	rosiglitazone/metformin	SB-712753/012	Diabetes Mellitus, Type 2	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=712753/012			Y	Y	Y	Y	Y	N	Y	A raw dataset is not available for this study. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Feb-2015
2830	GSK	Study in Healthy Children (<2 Years) to Evaluate the Safety and Efficacy of GSK Biologicals' Live Attenuated Varicella Vaccine (VarilrixTM) and of GSK Biologicals' Combined Measles-Mumps-Rubella-Varicella Vaccine	Varicella Vaccine	100388	Varicella	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=100388	http://clinicaltrials.gov/show/NCT00226499	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002676-41	Y	N	Y	Y	Y	Y	Y	Follow-on studies 103494,104105, and 104106 were conducted. The results are summarised with studies 103494, 104105 and 104106 on the GSK Study Register. An annotated case report form is not available for this study. An annotated case report form is not available for this study. A blank case report form will be provided.	1-Feb-2015
2937	GSK	An Open-label, Sequential Study to Evaluate the Pharmacokinetics of Simvastatin When Coadministered With Albiglutide in Healthy Adult Subjects	albiglutide	GLP108366	Diabetes Mellitus, Type 2	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=108366	http://clinicaltrials.gov/show/NCT01147692		Y	Y	Y	Y	Y	Y	Y		1-Mar-2015
2938	GSK	A multidose study in subjects with type 2 diabetes mellitus to assess the pharmacokinetics and pharmacodynamics of albiglutide	albiglutide	GLP114856	Diabetes Mellitus, Type 2	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=114856	http://clinicaltrials.gov/show/NCT01357889		Y	Y	Y	Y	Y	Y	Y		1-Mar-2015
2939	GSK	A multi-center, randomised, parallel-group, double-blind, placebo-controlled one year study (with a 7 week Treatment Phase) to evaluate the efficacy and tolerability of bupropion hydrochloride (SR) versus placebo as an aid to smoking cessation in a population of smokers with established, stable cardiovascular disease	bupropion	ZYB40014	Smoking Cessation	Phase 4	https://www.gsk-studyregister.com/en/trial-details/?id=ZYB40014			N	Y	Y	Y	Y	Y	N	An analysis-ready dataset and a reporting and analysis plan are not available for this study. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Mar-2015
2940	GSK	A Randomized, Double-Blind, Multicenter Study Comparing the Glycemic Control Characteristics of Carvedilol and Metoprolol in Hypertensive Patients with Type II Diabetes Mellitus (Protocol 346) and A Randomized, Double-Blind, Multicenter Study Comparing the Effects of Carvedilol and Metoprolol on Glycemic Control in Hypertensive Patients with Type II Diabetes Mellitus (Protocol 347)	carvedilol	346/347 (GEMINI)	Hypertension	Phase 4	https://www.gsk-studyregister.com/en/trial-details/?id=105517/346; https://www.gsk-studyregister.com/en/trial-details/?id=105517/347			Y	Y	Y	Y	Y	Y	Y	A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Mar-2015
2941	GSK	A 13-week randomised, double-blind, parallel group, mulitcentre study to compare the bronchial anti-inflammatory activity of oral cilomilast (15 mg bd) with placebo twice daily in subjects with Chronic Obstructive Pulmonary Disease (COPD)	cilomilast	207499/181	Pulmonary Disease, Chronic Obstructive	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=207499/181			N	N	Y	Y	Y	Y	Y	An analysis-ready dataset is not available for this study. An annotated case report form is not available for this study. A blank case report form will be provided. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Mar-2015
2942	GSK	A Randomized, 12-week, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Safety and Tolerability of Cilomilast 15mg Twice Daily in Patients with Chronic Obstructive Pulmonary Disease (COPD)	cilomilast	207499/168	Pulmonary Disease, Chronic Obstructive	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=207499/168			N	Y	Y	Y	Y	Y	Y	An analysis-ready dataset is not available for this study. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Mar-2015
2943	GSK	A Randomised, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy, Safety and Tolerability of Oral Cilomilast (15 mg bd) When Given as Maintenance Treatment for 12 Months to Subjects with Chronic Obstructive Pulmonary Disease (COPD)	cilomilast	207499/157	Pulmonary Disease, Chronic Obstructive	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=207499/157			N	Y	Y	Y	Y	Y	Y	An analysis-ready dataset is not available for this study. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Mar-2015
2944	GSK	A Randomized, 24-week, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy, Safety and Tolerability of Cilomilast (15mg BID) in Patients with Chronic Obstructive Pulmonary Disease (COPD).	cilomilast	207499/156	Pulmonary Disease, Chronic Obstructive	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=207499/156			N	N	Y	Y	Y	Y	Y	An analysis-ready dataset is not available for this study. An annotated case report form is not available for this study. A blank case report form will be provided. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Mar-2015
2945	GSK	A Multicenter Open-label Extension Study to Evaluate the Safety, Tolerability and Efficacy of Oral Cilomilast (15 mg twice daily) in Patients with Chronic Obstructive Pulmonary Disease (COPD)	cilomilast	207499/041	Pulmonary Disease, Chronic Obstructive	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=207499/041			N	N	Y	Y	Y	Y	N	An analysis-ready dataset and a reporting and analysis plan are not available for this study. An annotated case report form is not available for this study. A blank case report form will be provided. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Mar-2015
2946	GSK	A Multicentre, Open-label Extension Study to Evaluate the Safety, Tolerability and Efficacy of Oral SB-207499 (15 mg twice daily) in Patients with Chronic Obstructive Pulmonary Disease (COPD).	cilomilast	207499/040	Pulmonary Disease, Chronic Obstructive	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=207499/040			N	N	Y	Y	Y	Y	Y	An analysis-ready dataset is not available for this study. An annotated case report form is not available for this study. A blank case report form will be provided. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Mar-2015
2947	GSK	A Randomised, Double-Blind, Placebo-Controlled, Dose Ascending, 3 Period Crossover Study To Examine The Safety, Tolerability, Pharmacodynamics And Pharmacokinetics Of Repeat Inhaled Doses Of GSK233705B In COPD Subjects.	darotropium bromide	AC2105333	Pulmonary Disease, Chronic Obstructive	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=AC2105333	http://clinicaltrials.gov/show/NCT00376714	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001419-30	Y	Y	Y	Y	Y	Y	Y		1-Mar-2015
2948	GSK	A multicentre, randomised, partially blinded, placebo-controlled, three-way crossover, incomplete block design study to investigate the safety, tolerability, pharmacodynamics/ efficacy and pharmacokinetics of dual bronchodilator therapy with salmeterol 50µg twice-daily plus two different doses of GSK233705B (20 and 50µg twice-daily), compared with placebo, salmeterol 50µg twice-daily alone, and Tiotropium 18µg once-daily alone, in subjects with chronic obstructive pulmonary disease	darotropium bromide	AC2106956	Pulmonary Disease, Chronic Obstructive	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=AC2106956	http://clinicaltrials.gov/show/NCT00422604	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003500-19	Y	Y	Y	Y	Y	Y	Y		1-Mar-2015
2949	GSK	A single centre, randomised, placebo-controlled, four-way cross over study to assess the safety, tolerability, pharmacodynamics and pharmacokinetics of single inhaled doses of GSK233705 and GW642444 as monotherapies and in combination in healthy subjects.	darotropium bromide	AC2111509	Pulmonary Disease, Chronic Obstructive	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=DB1111509	http://clinicaltrials.gov/show/NCT00671216		Y	Y	Y	Y	Y	Y	Y		1-Mar-2015
2950	GSK	A single-centre, randomised, double-blind placebo-controlled, dose-ascending, parallel-group study to evaluate the safety, tolerability, extra-pulmonary pharmacodynamics and systemic and urinary pharmacokinetics of GSK233705 administered twice daily for 14 days in healthy male subjects	darotropium bromide	AC2105331	Pulmonary Disease, Chronic Obstructive	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=105331		https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001418-34	Y	Y	Y	Y	Y	Y	Y	A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Mar-2015
2951	GSK	A single centre, randomised, placebo-controlled, four-way cross over study to assess the safety, tolerability, pharmacodynamics and pharmacokinetics of single inhaled doses of GSK233705 and GW642444 as monotherapies and in combination in healthy Japanese subjects	darotropium bromide; vilanterol; darotropium bromide/vilanterol	DB1112146	Pulmonary Disease, Chronic Obstructive	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=112146	http://clinicaltrials.gov/show/NCT00783003	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-004267-19	Y	Y	Y	Y	Y	Y	Y		1-Mar-2015
2952	GSK	An Open-Label Randomized Study with 3 Cohorts of 3-Way Crossovers to Investigate the Safety Tolerability and Pharmacokinetics of 45mg Oral Doses of GW823093C and 500mg BID Oral Doses of Metformin (Cohort 1) 8mg Oral Doses of Rosiglitazone (Cohort 2) and 45mg Oral Doses of Pioglitazone (Cohort 3)	denagliptin	DPB102761	Diabetes Mellitus, Type 2	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=102761			Y	N	Y	Y	Y	Y	Y	An annotated case report form is not available for this study. A blank case report form will be provided. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Mar-2015
2953	GSK	A Randomized, Double-Blind, Placebo-Controlled Pilot Study to Evaluate the Safety And Preliminary Efficacy of Neoadjuvant Therapy With GI198745 in Subjects With Localized Prostate Cancer Undergoing Radical Prostatectomy.	dutasteride	ARIA2003	Neoplasms, Prostate	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=ARIA2003			Y	N	Y	Y	Y	Y	N	An annotated case report form is not available for this study. A blank case report form will be provided. A reporting and analysis plan is not available for this study. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Mar-2015
2954	GSK	A double blind, placebo controlled, single dose, crossover study to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of inhaled reformulated FP (TIBAC) in comparison with the standard formulation FP.	fluticasone propionate	FPR10001	Asthma	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=FPR10001			Y	Y	Y	Y	Y	Y	Y	A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Mar-2015
2955	GSK	A randomised, double blind, placebo controlled, cross over study to investigate the duration of action of inhaled doses of Fluticasone Propionate (1000mg) on airway responsiveness to adenosine-5'-monophosphate (AMP) in mild asthmatic patients	fluticasone propionate	FPR10006	Asthma	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=FPR10006			N	Y	Y	Y	Y	Y	Y	An analysis-ready dataset is not available for this study. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Mar-2015
2956	GSK	Early Intervention with Inhaled Corticosteroids in Wheezing Pre-school Children: A Single-Centre, Double-Blind, Randomised 5 Years Parallel-Group Study Comparing Adjusted Dosing of Inhaled Fluticasone Propionate With Inhaled Placebo Both Administered by Metered Dose Inhaler via a Babyhaler.	fluticasone propionate	FLIQ51 / DENB3002 / (FAS40012)	Asthma	Phase 4	https://www.gsk-studyregister.com/en/trial-details/?id=FAS40012			Y	Y	Y	Y	Y	Y	Y	A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Mar-2015
2957	GSK	A Randomized, Open-Label, 2-Way Crossover, Repeat-Dose Study in Pediatric Subjects with Asthma, Age 4-11 Years, to Compare Systemic Exposure of Fluticasone Propionate 2x44mcg Following Administration by Metered-Dose Inhalers Containing Hydrofluoroalkane or Chlorofluorocarbon Propellants	fluticasone propionate	FAP10006	Asthma	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=FAP10006			Y	Y	Y	Y	Y	Y	Y	A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Mar-2015
2958	GSK	Pharmacodynamics of the 88mcg BID dose of the Hydrofluoroalkane propellant formulation of inhaled Fluticasone Propionate following Administration via the Metered-dose Inhaler in Pediatric Subjects 4 to 11 years of age with Asthma	fluticasone propionate	FAP19052	Asthma	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=FAP19052			Y	Y	Y	Y	Y	Y	N	A reporting and analysis plan is not available for this study. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Mar-2015
2959	GSK	Systemic exposure of the fluticasone propionate from the hydrofluoroalkane propellant formulation via the metered-dose inhaler with and without a spacer in pediatric subjects 4 to 11 years of age with asthma.	fluticasone propionate	FAP19058	Asthma	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=FAP19058			Y	Y	Y	Y	Y	Y	Y	A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Mar-2015
2960	GSK	A multiple-dose, open-label, 2-way crossover study in pediatric subjects with asthma aged 1 to < 4 years to compare the systemic exposure of fluticasone propionate 88mcg administered via the hydrofluoroalkane metered-dose inhaler using the valved holding chambers, Aerochamber Plus™ and Babyhaler™, with face-masks	fluticasone propionate	FAS10002	Asthma	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=FAS10002			Y	Y	Y	Y	Y	Y	N	A reporting and analysis plan is not available for this study. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Mar-2015
2961	GSK	A randomised, open label, 5-way crossover study to assess the systemic exposure of FP and salmeterol from SERETIDE/ADVAIR 250 without spacer, with Aerochamber -Plus and with -Max spacer, with VOLUMATIC spacer and SERETIDE/ADVAIR 500 DISKUS/ACCUHALER in adult subjects with mild or intermittent asthma	fluticasone propionate/salmeterol	SAS101877	Asthma	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=101877			Y	N	Y	Y	Y	Y	Y	An annotated case report form is not available for this study. A blank case report form will be provided. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Mar-2015
2962	GSK	Randomized, Open-Label, Single-Dose, 4-Way Crossover Study to Compare the Relative Bioavailability and Pharmacodymanics of Fluticasone Propionate from Two Batches of Seretide MDI with Different in vitro Characteristics	fluticasone propionate/salmeterol	SAS10017	Asthma	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=SAS10017			N	Y	Y	Y	Y	Y	Y	An analysis-ready dataset is not available for this study. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Mar-2015
2963	GSK	An interventional three year study for asthma control - In what way and in what kind of population is it possible to get asthmatic patients free from symptoms, keep the patients in work, restore a normal lung function, diminish hyperreactivity and normalise quality of life?	fluticasone propionate/salmeterol	FAS40008 double blind period (1 year)	Asthma	Phase 4	https://www.gsk-studyregister.com/en/trial-details/?id=FAS40008			Y	N	Y	Y	Y	Y	N	An annotated case report form is not available for this study. A blank case report form will be provided. A reporting and analysis plan is not available for this study. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Mar-2015
2964	GSK	A Multicentre, Randomised, Double-Blind, Parallel Group Comparison of the Efficacy of SERETIDE* bd and Fluticasone Propionate bd (Both Via DISKUS*/ACCUHALER*, Inhaler) when Tapering the Inhaled Corticosteroid Dose in Asthmatic Adults	fluticasone propionate/salmeterol	SAM40008	Asthma	Phase 4	https://www.gsk-studyregister.com/en/trial-details/?id=SAM40008			N	Y	Y	Y	Y	Y	N	An analysis-ready dataset and a reporting and analysis plan are not available for this study. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Mar-2015
2965	GSK	A multicentre, randomised, double-blind, double-dummy, parallel group comparison of three treatments : 1) salmeterol/fluticasone propionate (SFC) 50/100mcg strength) bd via DISKUS/ACCUHALER inhaler, 2) fluticasone propionate 200mcg bd via DISKUS/ACCUHALER inhaler, 3) fluticasone propionate 100mcg bd via DISKUS/ACCUHALER inhaler in children aged 4- 11 years with asthma	fluticasone propionate/salmeterol	SAM40012	Asthma	Phase 4	https://www.gsk-studyregister.com/en/trial-details/?id=SAM40012			N	Y	Y	Y	Y	Y	N	An analysis-ready dataset and a reporting and analysis plan are not available for this study. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Mar-2015
2966	GSK	A single-centre, single-dose, double-blind, double-dummy, placebo-controlled, randomised, three-way crossoverstudy to compare the duration of action of SERETIDE* DISKUS* 50/100mcg versus formoterol/budesonidecombination 4.5/160mcg Breath-Actuated Dry Powder Inhaler (BADPI) in subjects with asthma	fluticasone propionate/salmeterol	SAM40062	Asthma	Phase 4	https://www.gsk-studyregister.com/en/trial-details/?id=SAM40062			N	Y	Y	Y	Y	Y	Y	An analysis-ready dataset is not available for this study. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Mar-2015
2967	GSK	A Randomized, Double-Blind, Parallel-Group Study Evaluating the Protective Effects of the Fluticasone Propionate/Salmeterol Combination Product (FSC, 100/50mcg BID via DISKUS) Against Bronchospasms Induced by Activity as Measured by Exercise Challenge Testing in Adolescent and Adult Subjects who Require Chronic Inhaled Corticosteroid Therapy for the Treatment of Persistent Asthma	fluticasone propionate/salmeterol	SAS40024	Asthma	Phase 4	https://www.gsk-studyregister.com/en/trial-details/?id=SAS40024			N	Y	Y	Y	Y	Y	Y	An analysis-ready dataset is not available for this study. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Mar-2015
2968	GSK	A Randomized, Double-Blind, Parallel-Group Study Evaluating the Protective Effects of the Fluticasone Propionate/Salmeterol Combination Product (FSC 250/50mcg BID via DISKUS) Against Bronchospasms Induced by Activity as Measured by Exercise Challenge Testing in Adolescent and Adult Subjects who Require Chronic Inhaled Corticosteroid Therapy for the Treatment of Persistent Asthma	fluticasone propionate/salmeterol	SAS40025	Bronchospasm	Phase 4	https://www.gsk-studyregister.com/en/trial-details/?id=SAS40025			N	Y	Y	Y	Y	Y	Y	An analysis-ready dataset is not available for this study. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Mar-2015
2969	GSK	A randomised, double-blind, placebo-controlled crossover study investigating the efficacy and safety of intermittent prophylactic treatment with oral naratriptan 1mg b.i.d. in women with pre-menstrual dysphoria.	naratriptan	S2W20006	Migraine Disorders and Premenstrual Syndrome	Phase 4	https://www.gsk-studyregister.com/en/trial-details/?id=S2W20006			N	Y	N	Y	Y	Y	Y	An analysis-ready dataset is not available for this study. A Clinical Study Report is not available for this study because only a draft version was located, no final version found in archives. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Mar-2015
2970	GSK	A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Parallel-Group Phase 3 Study to Determine the Efficacy and Safety of Retigabine (1200 mg/day) Used as Adjunctive Therapy in Refractory Epilepsy Patients with Partial-Onset Seizures	retigabine, ezogabine	VRX-RET-E22-301	Seizures	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=VRX-RET-E22-301	http://clinicaltrials.gov/show/NCT00232596		Y	Y	Y	Y	Y	Y	Y	A follow-on study VRX-RET-E22-303 was conducted.	1-Mar-2015
2971	GSK	Randomized, Double-Blind, Placebo-Controlled, Multicenter, Parallel-Group Phase 3 Study - Determine Efficacy and Safety of Two Doses of Retigabine (900 Mg/Day and 600 Mg/Day) Used as Adjunctive Therapy in Refractory Epilepsy Patients with Partial-Onset Seizures	retigabine, ezogabine	VRX-RET-E22-302	Seizures	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=VRX-RET-E22-302	http://clinicaltrials.gov/show/NCT00235755		Y	Y	Y	Y	Y	Y	Y	A follow-on study VRX-RET-E22-304 was conducted.	1-Mar-2015
2972	GSK	A Multicenter, Open-Label, Long-Term Extension, Safety and Tolerability Study of Retigabine (GKE-841) in Adult Patients with Epilepsy	retigabine, ezogabine	3065A1-216-EU/US	Seizures	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=3065A1-216			Y	Y	Y	Y	Y	Y	Y	A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Mar-2015
2973	GSK	A Randomized, Double-blind, Placebo-controlled, Parallel group, Multicenter, Dose-ranging, Efficacy and Safety Study of Retigabine (D-23129; GKE-841) Administered as Add-on Therapy in Patients With Partial Epilepsy	retigabine, ezogabine	3065A1-205	Seizures	Phase 2/3	https://www.gsk-studyregister.com/en/trial-details/?id=3065A1-205			Y	Y	Y	Y	Y	Y	Y	A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Mar-2015
2974	GSK	Absolute and Relative Bioavailability of Retigabine IR capsules in Healthy Male Subjects	retigabine, ezogabine	3065a1-123	Seizures	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=3065A1-123			Y	Y	Y	Y	Y	Y	Y	A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Mar-2015
2975	GSK	Tolerability of intravenous dose titration of retigabine administered as short time infusion in healthy male volunteers	retigabine, ezogabine	3065A1-117	Seizures	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=3065A1-117			Y	Y	Y	Y	Y	Y	Y	A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Mar-2015
2976	GSK	Pharmacokinetics of Retigabine and its N-Acetylated Metabolite (NAMR) and the Impact on Serum Bilirubin in Subjects with Different Genotypes for UDP-glucuronyl transferase 1A1 (UGT1A1) and N-acetyl transferase (NAT2)	retigabine, ezogabine	3065A1-115	Seizures	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=3065A1-115			Y	Y	Y	Y	Y	Y	Y	A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Mar-2015
2977	GSK	An Open-label, Positive-controlled, Parallel-group Study to Determine the Effect of BRL 49653C, Rosiglitazone, on Body Fat Distribution When Administered for 26 Weeks to Patients with Type 2 Diabetes	rosiglitazone	049653/109	Diabetes Mellitus, Type 2	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=49653/109			Y	N	Y	Y	Y	Y	N	An annotated case report form is not available for this study. A blank case report form will be provided. A reporting and analysis plan is not available for this study. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Mar-2015
2979	GSK	A Double-Blind Study to Assess the Effect of Rosiglitazone (RSG) on the Pharmacodynamics and Pharmacokinetics of Acenocoumerol in Healthy Male Volunteers	rosiglitazone	49653/225	Diabetes Mellitus, Type 2	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=49653/225			N	N	Y	Y	Y	Y	Y	An analysis-ready dataset is not available for this study. An annotated case report form is not available for this study. A blank case report form will be provided. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Mar-2015
2980	GSK	A Study to Estimate the Effect of Repeat Oral Doses of Rosiglitazone (8 mg) on the Pharmacokinetics of Glimepiride (4 mg) and the Effect of a Single Oral Dose of Glimepiride (4 mg) on the Pharmacokinetics of Rosiglitazone (8 mg) in Healthy Subjects.	rosiglitazone	49653/340	Diabetes Mellitus, Type 2	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=49653/340			Y	N	Y	Y	Y	Y	N	An annotated and blank case report form are not available as the electronic data capture system used for this study did not generate paper versions. A reporting and analysis plan is not available for this study. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Mar-2015
2981	GSK	A 24-week Randomized, Double-blind, Active-Controlled, Multicenter Study to Evaluate the Safety and Efficacy of Rosiglitazone When Administered to Pediatric Patients with Type 2 Diabetes Mellitus	rosiglitazone	49653/207	Diabetes Mellitus, Type 2	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=49653/207			Y	Y	Y	Y	Y	Y	Y	A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Mar-2015
2982	GSK	A single dose study to assess the tolerability and food effect of an enterically-coated formulation of the commercial immediate release tablet of rosiglitazone and an enterically-coated modified release tablet formulation of rosiglitazone in healthy volunteers.	rosiglitazone	BRL-049653/299	Diabetes Mellitus, Type 2	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=49653/299			N	N	Y	Y	Y	Y	Y	An analysis-ready dataset is not available for this study. An annotated and blank case report form are not available as the electronic data capture system used for this study did not generate paper versions. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Mar-2015
2983	GSK	A study to evaluate the pharmacokinetics of eight prototype formulations of rosiglitazone 8 mg in healthy volunteers.	rosiglitazone	BRL-049653/309	Diabetes Mellitus, Type 2	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=49653/309			N	N	Y	Y	Y	Y	Y	An analysis-ready dataset is not available for this study. An annotated and blank case report form are not available as the electronic data capture system used for this study did not generate paper versions. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Mar-2015
2984	GSK	A six-month double-blind, randomised, parallel-group study to compare the effect of oral rosiglitazone (less than or equal to 4mg bd) versus oral glibenclamide therapy (less than or equal to 15mg daily) on body fat distribution when administered to subjects with type 2 diabetes mellitus	rosiglitazone	BRL-049653/369	Diabetes Mellitus, Type 2	Phase 4	https://www.gsk-studyregister.com/en/trial-details/?id=49653/369			N	Y	Y	Y	Y	Y	Y	An analysis-ready dataset is not available for this study. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Mar-2015
2985	GSK	A Study to Evaluate the Effect of Food on the Pharmacokinetics of a Modified Release Formulation of Rosiglitazone 8 mg in Healthy Volunteers After Repeat Dosing.	rosiglitazone	BRL49653/301	Diabetes Mellitus, Type 2	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=49653/301			N	N	Y	Y	Y	Y	Y	An analysis-ready dataset and an annotated case report form are not available for this study. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Mar-2015
2986	GSK	A Bioequivalence Study Comparing Tablets Manufactured with the 8 mg Anhydrate Form IV (ANF4) to the Commercial Anhydrate Form I (ANF1) of Rosiglitazone Maleate.	rosiglitazone	BRL49653C/300	Diabetes Mellitus, Type 2	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=49653/300			N	N	Y	Y	Y	Y	Y	An analysis-ready dataset and an annotated case report form are not available for this study. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Mar-2015
2987	GSK	A Bioequivalence Study With a Combination Tablet Formulation of Rosiglitazone and Metformin (4 mg/500 mg) Compared to Concomitant Dosing of Rosiglitazone 4 mg and Metformin 500 mg Commercial Tablets-and a Dose Proportionality Study Comparing the 4 mg/500 mg and 1 mg/500 mg Combination Formulations.	rosiglitazone; rosiglitazone/metformin	49653/270	Diabetes Mellitus, Type 2	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=49653/270			Y	N	Y	Y	Y	Y	Y	An annotated case report form is not available for this study. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Mar-2015
2988	GSK	A Study to Assess the Effect of Food on the Pharmacokinetics of a Rosiglitazone 4mg and Metformin 500mg Combination Tablet Formulation and a Study Comparing the Pharmacokinetics of Rosiglitazone 4mg and Metformin 500mg Combination Tablet to Concomitant Dosing of Rosiglitazone 4mg and Metformin 500mg Commercial Tablets in the Fed State in Healthy Volunteers	rosiglitazone; rosiglitazone/metformin	49653/271	Diabetes Mellitus, Type 2	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=49653/271			Y	N	Y	Y	Y	Y	Y	An annotated case report form is not available for this study. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Mar-2015
2989	GSK	A Randomised, Double-Blind, Placebo-Controlled, Cross-Over Study to Investigate the Cardiovascular Pharmacodynamic Effects and Pharmacokinetics of Salmeterol vs Placebo Following 15 Days BD Regimen In COPD Subjects	salmeterol	SCO20001	Pulmonary Disease, Chronic Obstructive	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=SCO20001			Y	Y	Y	Y	Y	Y	N	A reporting and analysis plan is not available for this study. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Mar-2015
2990	GSK	A Multi-Center, Randomized, Double-Blind, Double-Dummy, Parallel-Group Comparison of Salmeterol Xinafoate Inhalation Aerosol Versus Ipratropium Bromide and Albuterol Sulfate Inhalation Aerosol in Subjects With Chronic Obstructive Pulmonary Disease	salmeterol	SMS40320	Pulmonary Disease, Chronic Obstructive	Phase 4	https://www.gsk-studyregister.com/en/trial-details/?id=SMS40320			N	Y	Y	Y	Y	Y	Y	An analysis-ready dataset is not available for this study. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Mar-2015
2991	GSK	A randomised, open-label, parallel group 28-day pilot study to compare the addition of inhaled salmeterol 50mcg b.i.d. (via the DISKHALER inhaler) or tulobuterol patch 2mg once daily nocte in adult asthmatic subjects symptomatic on treatment with inhaled corticosteroids.	salmeterol	SMS40332	Asthma	Phase 4	https://www.gsk-studyregister.com/en/trial-details/?id=SMS40332			N	N	Y	Y	Y	Y	N	An analysis-ready dataset and a reporting and analysis plan are not available for this study. An annotated case report form is not available for this study. A blank case report form will be provided. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Mar-2015
2992	GSK	A Randomised, Single-Blind, Parallel-Group, 28-Day, Pilot Study to Compare the Addition of Inhaled Salmeterol 50µg bid (via the DISKHALER™ Inhaler) or Tulobuterol-Patch 2mg qd Nocte in Adult Asthmatic Subjects who are Symptomatic on Inhaled Corticosteroids Alone	salmeterol	SMS40329	Asthma	Phase 4	https://www.gsk-studyregister.com/en/trial-details/?id=SMS40329			Y	N	Y	Y	Y	Y	N	An annotated case report form is not available for this study. A blank case report form will be provided. A reporting and analysis plan is not available for this study. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Mar-2015
2993	GSK	A Randomised, Double-Blind, Placebo-Controlled, Cross-Over Study to Compare the Systemic Pharmacodynamic Effects and Pharmacokinetics of Salmeterol Delivered by the Non-CFC Propellant (HFA-134a; GR106642X) and the CFCPropellant (Propellant 11/12) Metered Dose Inhalers in Healthy Subjects	salmeterol	SLGB10006	Asthma	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=SLGB1006			N	N	Y	Y	Y	Y	Y	An analysis-ready dataset is not available for this study. An annotated case report form is not available for this study. A blank case report form will be provided. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Mar-2015
2994	GSK	A double-blind, randomised, two-period, crossover drug interaction study to investigate the pharmacokinetic and pharmacodynamic effects of 7 days co-administration of salmeterol (50 mcg bid) with ketoconazole (400 mg od).	salmeterol	SMS106128	Asthma	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=106128			Y	Y	Y	Y	Y	Y	Y	A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Mar-2015
2995	GSK	Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, Parallel Group, Multi-Center Clinical Trial of Four Weeks Treatment with SEREVENT™ Inhalation Aerosol, 25mcg BID, 50mcg BID and Placebo Administered Via a Valved-Holding Chamber with Facemask in Subjects with Symptoms of Asthma or Reactive Airways Disease Age 6 to 23 months	salmeterol	SMS30077	Asthma	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=SMS30077			Y	Y	Y	Y	N	N	Y	A raw dataset is not available for this study. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies. A protocol is not available for this study.	1-Mar-2015
2996	GSK	SMART: A Double-Blind, Randomized, Placebo-Controlled Surveillance Study of Asthma Event Outcomes in Subjects Receiving Either Usual Pharmacotherapy of Asthma or Usual Pharmacotherapy Plus Salmeterol 42mcg Twice Daily	salmeterol	SLGA5011 SMART	Asthma	Phase 4	https://www.gsk-studyregister.com/en/trial-details/?id=SLGA5011			Y	N	Y	Y	Y	Y	N	An annotated case report form is not available for this study. A blank case report form will be provided. A reporting and analysis plan is not available for this study. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Mar-2015
2997	GSK	A Multi-Centre, Randomised, Double-Blind, 12-Week, Parallel-Group Study to Compare Salmeterol Xinafoate 50mcg BD Delivered Either via a HFA Metered-Dose Inhaler or via a CFC Metered-Dose Inhaler, in the Treatment of Adults, Aged 12 years and Over, With Asthma	salmeterol	SMO30006	Asthma	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=SMO30006			N	Y	Y	Y	Y	Y	Y	An analysis-ready dataset is not available for this study. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Mar-2015
2998	GSK	A Multi-Centre, Randomised, Double-Blind, 12-Week, Parallel-Group Study to Compare Salmeterol Xinafoate 50mcg bd Delivered Either via a HFA Metered-Dose Inhaler or via a CFC Metered-Dose Inhaler, in the Treatment of Children Aged 4-11 Years With Asthma	salmeterol	SMO30007	Asthma	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=SMO30007			N	Y	Y	Y	Y	Y	Y	An analysis-ready dataset is not available for this study. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Mar-2015
2999	GSK	A Five-Week, Randomized, Double-Blind, Double-Dummy, Two-Period, Four-Treatment Crossover, Placebo-Controlled, Balanced, Incomplete Block Design, Multi-Center Study of Salmeterol Inhalation Aerosol 25mcg BID, 25mcg TID, 50mcg BID and Placebo Administered via a Holding Chamber with Facemask in Subjects with Asthma Aged 6 to 23 Months	salmeterol	SMS20011	Asthma	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=SMS20011			Y	Y	Y	Y	Y	Y	Y	The raw data are included within the analysis-ready data for this study and are not provided separately. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Mar-2015
3000	GSK	A Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, Parallel-Group Clinical Trial of 4 Weeks Treatment With SEREVENT Inhalation Aerosol, 25mcg BID, 50mcg BID, and Placebo Administered via a Valved Holding Chamber With Facemask in Subjects With Asthma Aged 24 to 47 Months	salmeterol	SMS30076	Asthma	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=SMS30076			Y	Y	Y	Y	Y	Y	Y	A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Mar-2015
3001	GSK	A Randomized, Multi-Center, Cross Over Comparison of Salmeterol Xinafoate Inhalation Powder (50mcg BID) via the DISKUS ™ and Salmeterol Xinafoate Inhalation Aerosol (42mcg BID) via the Metered Dose Inhaler on Measures of Device Preference in Subjects with COPD	salmeterol	SMS40330	Pulmonary Disease, Chronic Obstructive	Phase 4	https://www.gsk-studyregister.com/en/trial-details/?id=SMS40330			N	Y	Y	Y	Y	Y	Y	An analysis-ready dataset is not available for this study. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Mar-2015
3002	GSK	An open, randomised, two-period crossover study to demonstrate the bioequivalence of fast disintegrating sumatriptan 100 mg tablet dissolved in water compared to the currently marketed sumatriptan 100 mg tablet administered in the fasted state to healthy male and female subjects	sumatriptan	SUM10961	Migraine Disorders	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=SUM10961			N	N	Y	Y	Y	Y	N	An analysis-ready dataset and a reporting and analysis plan are not available for this study. An annotated case report form is not available for this study. A blank case report form will be provided. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Mar-2015
3003	GSK	An open, randomised, four-period crossover study to investigate the bioavailability of a new orally disintegrating (melt) formulation (ODT) of sumatriptan, with and without water compared to the currently marketed sumatriptan 100mg tablet and also to investigate the effect of food on the ODT formulation, in healthy male and female subjects	sumatriptan	SUM10955	Migraine Disorders	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=SUM10955			N	N	N	Y	N	Y	N	An analysis-ready dataset, a reporting and analysis plan, an annotated case report form, and a protocol are not available for this study. A Clinical Study Report is not available for this study because only a draft version was located; no final version found in archives. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Mar-2015
3004	GSK	An open, randomised, three-period crossover study to demonstrate the bioequivalence of fast disintegrating sumatriptan 100mg tablet compared to the currently marketed sumatriptan 100mg tablet administered immediately after food and the fast disintegrating tablet administered in the fasted state to healthy male and female subjects	sumatriptan	SUM10954	Migraine Disorders	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=SUM10954			Y	N	Y	Y	Y	Y	N	An annotated case report form is not available for this study. A blank case report form will be provided. A reporting and analysis plan is not available for this study. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Mar-2015
3005	GSK	An open, randomised, four-period crossover study to demonstrate the bioequivalence of fast disintegrating sumatriptan tablets (50 and 100 mg tablets) compared with the currently marketed sumatriptan tablets (50 and 100 mg IMITREX† /IMIGRAN† tablets), in healthy male and female volunteers	sumatriptan	SUM10950	Migraine Disorders	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=SUM10950			N	Y	Y	Y	Y	Y	N	An analysis-ready dataset and a reporting and analysis plan are not available for this study. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Mar-2015
3006	GSK	An open, randomised, single-dose, three-way crossover, pilot study investigating the relative bioavailability of two newly formulated fast disintegrating sumatriptan 50mg tablets versus the currently marketed sumatriptan 50mg tablets in healthy volunteers	sumatriptan	SUM10948	Migraine Disorders	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=SUM10948			N	Y	Y	Y	Y	Y	N	An analysis-ready dataset and a reporting and analysis plan are not available for this study. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Mar-2015
3007	GSK	An open-label evaluation of patient satisfaction with IMITREX (sumatriptan succinate) tablets, 100mg, administered at the first sign of pain for up to three migraines in patients who are not satisfied with their current triptan therapy.	sumatriptan	SUM40301	Migraine Disorders	Phase 4	https://www.gsk-studyregister.com/en/trial-details/?id=SUM40301			Y	N	Y	Y	Y	Y	Y	An annotated case report form is not available for this study. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Mar-2015
3008	GSK	Identification of Migraine Headache Among Self-Described and/or Physician Diagnosed Sinus Headache Sufferers and Treatment with IMITREX† 50mg Tablets	sumatriptan	SUM40294	Migraine Disorders	Phase 4	https://www.gsk-studyregister.com/en/trial-details/?id=SUM40294			N	N	Y	Y	Y	Y	Y	An analysis-ready dataset is not available for this study. An annotated case report form is not available for this study. A blank case report form will be provided. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Mar-2015
3009	GSK	A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Single-Attack Study of Sumatriptan 6 mg Injection In the Treatment of Moderate-to-Severe Migraine Present Upon Awakening.	sumatriptan	SUM40287	Migraine Disorders	Phase 4	https://www.gsk-studyregister.com/en/trial-details/?id=SUM40287			N	N	Y	Y	Y	Y	N	An analysis-ready dataset, an annotated case report form, and a reporting and analysis plan are not available for this study. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Mar-2015
3010	GSK	A randomised, double-blind, single-attack, placebo-controlled, parallel group evaluation of the efficacy and tolerability of sumatriptan Fast Disintegrating Tablets (FDT) 50 mg and 100 mg versus placebo during the mild pain phase of a migraine attack.	sumatriptan	SUM30046	Migraine Disorders	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=SUM30046			N	Y	Y	Y	Y	Y	Y	An analysis-ready dataset is not available for this study. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Mar-2015
3011	GSK	A Double-Blind, Placebo-Controlled, Parallel Group Study To Evaluate Two Dose Levels (5mg And 20mg) Of Sumatriptan Nasal Spray In The Acute Treatment Of A Single Migraine Attack In Adolescent Migraineurs (12-17 Years Of Age)	sumatriptan	SUM30045	Migraine Disorders	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=SUM30045			N	Y	Y	Y	Y	Y	Y	An analysis-ready dataset is not available for this study. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Mar-2015
3012	GSK	A Randomised, Double-Blind, Placebo-Controlled, In-Clinic Pilot Study To Investigate The Efficacy And Tolerability Of 100mg Sumatriptan Administered As A Film-Coated, Fast Disintegrating Tablet	sumatriptan	SUM20033	Migraine Disorders	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=SUM20033			N	Y	Y	Y	Y	Y	Y	An analysis-ready dataset is not available for this study. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Mar-2015
3013	GSK	A Randomized, Placebo Controlled, 3-Way Crossover Study to Investigate the Safety, Tolerability, and Pharmacokinetics of Repeat Dose Zanamivir/Placebo 10mg Administered Twice Daily for 5 Days by a Rotahaler Compared to the Diskhaler in Healthy Subjects	zanamivir	NAI113625	Influenza A Virus, H1N1 Subtype	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=113625	http://clinicaltrials.gov/show/NCT00989404		Y	Y	Y	Y	Y	Y	Y		1-Mar-2015
3084	GSK	Long-Term Persistence Follow-up Study to Evaluate the Immune Persistence of GSK Biologicals' Combined Hepatitis A / Hepatitis B Vaccine in Healthy Adult Volunteers	twinrix	100559x	Hepatitis A; Hepatitis B	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=100556 (Y11)	http://clinicaltrials.gov/show/NCT00289718		Y	N	Y	Y	Y	Y	N	This is a follow-up study to 208127/118. The results of this study 100559 are summarised with studies 100556, 100557, 100558, 100560, and 112266 on the GSK Study Register. An annotated case report form is not available for this study. A blank case report form will be provided. A reporting and analysis plan is not available for this study.	1-Oct-2014
3085	ViiV	A 48 Week, Phase II, Open-label, Multi-Cohort, Multicenter Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Antiviral Activity of GW433908/Ritonavir once daily and GW433908/Ritonavir BID when Administered to HIV-1 Infected, Antiretroviral Naïve and Experienced, Pediatric Subjects 2 to 18 Years Old.	fosamprenavir	APV20003	Infection, Human Immunodeficiency Virus	Phase 2	https://www.viiv-studyregister.com/study/19690	http://clinicaltrials.gov/show/NCT00040664		Y	Y	Y	Y	Y	Y	Y	Information on the country of a participant is not provided in order to protect their anonymity. Instead, countries have been aggregated into larger regions. If your research question requires information on countries of study participants, please submit an enquiry about the availability of such data.	1-May-2015
3086	ViiV	A 48 week, Phase II, open-label, 2-cohort, multicenter study to evaluate the pharmacokinetics, safety, tolerability and antiviral activity of GW433908 and GW433908/RTV when administered to HIV-1 infected protease inhibitor (PI) naive and PI-experienced pediatric subjects aged 4 weeks to &lt;2 years.	fosamprenavir	APV20002	Infection, Human Immunodeficiency Virus	Phase 2	https://www.viiv-studyregister.com/study/19716	http://clinicaltrials.gov/show/NCT00071760		Y	Y	Y	Y	Y	Y	Y	This study is still ongoing, however data related to the publication(s) is available. Information on the country of a participant is not provided in order to protect their anonymity. Instead, countries have been aggregated into larger regions. If your research question requires information on countries of study participants, please submit an enquiry about the availability of such data.	1-May-2015
3087	ViiV	A 48 Week, Phase II, non-comparative, open-label, multi-cohort, multicenter study to evaluate the safety, tolerability, pharmacokinetics and antiviral activity of GW433908/Ritonavir BID when administered to HIV-1 infected PI-Naive and experienced, Pediatric Subjects 2 to 18 years old and of GW433908 BID Administered to PI-Naive Pediatric subjects 2 to &lt;6 years old.	fosamprenavir	APV29005	Infection, Human Immunodeficiency Virus I	Phase 2	https://www.viiv-studyregister.com/study/19717	http://clinicaltrials.gov/show/NCT00089583		Y	Y	Y	Y	Y	Y	Y	Information on the country of a participant is not provided in order to protect their anonymity. Instead, countries have been aggregated into larger regions. If your research question requires information on countries of study participants, please submit an enquiry about the availability of such data.	1-May-2015
3123	GSK	A randomized, open-label, parallel-group, multicenter study to determine the efficacy and long-term safety of albiglutide compared with insulin in subjects with type 2 diabetes mellitus.	albiglutide	GLP112754	Diabetes Mellitus, Type 2	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=112754	http://clinicaltrials.gov/show/NCT00838916	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-007661-24	Y	Y	Y	Y	Y	Y	Y	This study is available in CDISC format	1-May-2015
3124	GSK	A Randomized, Double-blind, Placebo and Active-Controlled, Parallel-group, Multicenter Study to Determine the Efficacy and Safety of Albiglutide Administered in Combination With Metformin and Glimepiride Compared With Metformin Plus Glimepiride and Placebo and with Metformin plus Glimepiride and Pioglitazone in Subjects With Type 2 Diabetes Mellitus	albiglutide	GLP112757	Diabetes Mellitus, Type 2	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=112757	http://clinicaltrials.gov/show/NCT00839527	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-007664-42	Y	Y	Y	Y	Y	Y	Y	This study is available in CDISC format	1-May-2015
3125	GSK	A Randomized, Open-Label, Active-Controlled, Parallel-Group, Multicenter Study to Determine the Safety and Efficacy of Albiglutide Administered in Combination With Insulin Glargine as Compared with the Combination of Insulin Glargine and Preprandial Lispro Insulin in Subjects With Type 2 Diabetes Mellitus	albiglutide	GLP108486	Diabetes Mellitus, Type 2	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=108486	http://clinicaltrials.gov/show/NCT00976391	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-015386-30	Y	Y	Y	Y	Y	Y	Y		1-May-2015
3126	GSK	A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Determine the Efficacy and Safety of Albiglutide When Used in Combination With Pioglitazone With or Without Metformin in Subjects with Type 2 Diabetes Mellitus	albiglutide	GLP112755	Diabetes Mellitus, Type 2	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=112755	http://clinicaltrials.gov/show/NCT00849056	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-007662-37	Y	Y	Y	Y	Y	Y	Y	This study is available in CDISC format	1-May-2015
3127	GSK	A single-site, randomized, double-blind, placebo-controlled, parallel-group, stepped glucose clamp study to assess the effects of albiglutide on counter-regulatory hormone responses and recovery from hypoglycemia in subjects with Type 2 diabetes mellitus.	albiglutide	GLP108372	Diabetes Mellitus, Type 2	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=108372	http://clinicaltrials.gov/show/NCT01475734		Y	Y	Y	Y	Y	Y	Y		1-May-2015
3128	GSK	A multi-centre, randomised, double-blind, double dummy study comparing the efficacy and safety of chlorproguanil-dapsone-artesunate versus artemether-lumefantrine in the treatment of acute uncomplicated Plasmodium falciparum malaria in children and adolescents in Africa.	artesunate/chlorproguanil/dapsone	714703/005	Malaria, Falciparum	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=CDA 714703/005	http://clinicaltrials.gov/show/NCT00344006		Y	Y	Y	Y	Y	Y	Y		1-May-2015
3129	GSK	A multi-centre, randomised, double-blind study to compare the efficacy and safety of chlorproguanil-dapsone-artesunate versus chlorproguanil-dapsone in the treatment of acute uncomplicated Plasmodium falciparum malaria in children, adolescents and adults in Africa.	artesunate/chlorproguanil/dapsone	714703/006	Malaria, Falciparum	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=CDA 714703/006	http://clinicaltrials.gov/show/NCT00371735		Y	Y	Y	Y	Y	Y	Y		1-May-2015
3130	GSK	An open, randomised, crossover study to assess the pharmacokinetics and tolerability of single doses of LAPDAP™, artesunate, and LAPDAP plus artesunate	artesunate/chlorproguanil/dapsone	CDA103078	Malaria	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=103078		https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000978-41	Y	Y	Y	Y	Y	Y	N	A reporting and analysis plan is not available for this study. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-May-2015
3131	GSK	An Open-Label, Two Period, Fixed Sequence Study of Healthy Subjects to Assess the Effect of Repeat Oral Dosing of [Rifampin] on the Pharmacokinetics of a Single Oral Dose of [GW679769]	casopitant	NKV105091	Nausea and Vomiting, Chemotherapy-Induced	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=NKV105091	http://clinicaltrials.gov/show/NCT00405080		Y	N	Y	Y	Y	Y	Y	An annotated or blank case report form is not available as the data electronic data capture system for this study did not generate a paper version.	1-May-2015
3132	GSK	An open-label, randomized (with respect to different doses of casopitant), two-period parallel group study to evaluate the potential pharmacokinetic interaction of co-administered casopitant and digoxin in healthy subjects	casopitant	NKV105095	Nausea and Vomiting, Chemotherapy-Induced	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=105095			Y	Y	Y	Y	Y	Y	Y	A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-May-2015
3133	GSK	A randomised, double blind, placebo-controlled, double dummy, 4-way cross-over, dose ascending study to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of single inhaled doses of GSK233705 and tiotropium bromide (18µg) via DPI in COPD patients	darotropium bromide	AC2103473	Pulmonary Disease, Chronic Obstructive	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=AC2103473	http://clinicaltrials.gov/show/NCT00279019	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002093-30	Y	Y	Y	Y	Y	Y	Y		1-May-2015
3134	GSK	A randomised, double blind, placebo-controlled, double dummy, five-way cross over dose-escalation study to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of single inhaled doses of GSK233705 (20-500ug via DPI), and , tiotropium bromide (18ug via DPI) in healthy male subjects	darotropium bromide	AC2103471	Pulmonary Disease, Chronic Obstructive	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=103471		https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002092-32	Y	Y	Y	Y	Y	Y	Y	A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-May-2015
3135	GSK	Multicenter, double-blind, randomized, parallel-group study, comparing 0.5 mg and 3.5 mg dutasteride daily for 4 months prior to radical prostatectomy versus radical prostatectomy alone in men with biopsy-proven and clinically localized prostate cancer	dutasteride	ARI40010	Neoplasms, Prostate	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=ARI40010			N	Y	Y	Y	Y	Y	Y	An analysis-ready dataset is not available for this study. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-May-2015
3136	GSK	A single centre, randomised, double-blind, placebo-controlled,four-way cross over study to assess the safety, tolerability,pharmacokinetics and pharmacodynamics of single doses ofGSK2190915 in healthy Japanese subjects.	fiboflapon	LPA112359	Asthma	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=112359	http://clinicaltrials.gov/show/NCT00955383	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-012416-40	Y	Y	Y	Y	Y	Y	Y		1-May-2015
3138	GSK	A single dose, crossover study in healthy female subjects to assess the regional absorption and bioavailability of 100 mg GSK2190915A	fiboflapon	LPA114604	Asthma	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=114604	http://clinicaltrials.gov/show/NCT01318980	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-021573-36	Y	Y	Y	Y	Y	Y	Y		1-May-2015
3139	GSK	A 12 week study to evaluate the effect of fluticasone furoate (FF, GW685698)/vilanterol (VI, GW642444) 100/25 mcg Inhalation Powder delivered once daily via a Novel Dry Powder Inhaler (NDPI) on arterial stiffness compared with Tiotropium bromide 18 mcg delivered once daily via a HandiHaler in subjects with chronic obstructive pulmonary disease (COPD).	fluticasone furoate/vilanterol	HZC115247	Pulmonary Disease, Chronic Obstructive	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=115247	http://clinicaltrials.gov/show/NCT01395888	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-024435-16	Y	Y	Y	Y	Y	Y	Y		1-May-2015
3140	GSK	A randomized, double blind, placebo-controlled three-way crossover study in mild asthmatics to evaluate the effect of smoking status on the attenuation by inhaled corticosteroids of the allergen-induced asthmatic response.	fluticasone propionate	RES114748	Asthma	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=114748	http://clinicaltrials.gov/show/NCT01400906	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001541-32	Y	Y	Y	Y	Y	Y	Y		1-May-2015
3141	GSK	Validation of a New Shortness of Breath with Daily Activities Questionnaire in patients with Chronic Obstructive Pulmonary Disease	fluticasone propionate/salmeterol	ASQ112989	Pulmonary Disease, Chronic Obstructive	Phase 4	https://www.gsk-studyregister.com/en/trial-details/?id=112989	http://clinicaltrials.gov/show/NCT00984659		Y	Y	Y	Y	Y	Y	Y		1-May-2015
3142	GSK	A Randomized, Double-Blind, Parallel Group, Multicenter Study of the Effects of Fluticasone Propionate/Salmeterol Combination Product 250/50mcg BID (ADVAIR DISKUS™) in Comparison to Salmeterol 50mcg BID (SEREVENT DISKUS™) on the Rate of Exacerbations of COPD Following Hospitalization	fluticasone propionate/salmeterol	ADC113874	Pulmonary Disease, Chronic Obstructive	Phase 4	https://www.gsk-studyregister.com/en/trial-details/?id=113874	http://clinicaltrials.gov/show/NCT01110200	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022342-24	Y	Y	Y	Y	Y	Y	Y		1-May-2015
3143	GSK	A Phase I, Randomized, Placebo-Controlled, Crossover Clinical Trial to Assess the Safety of Oral SRT2104 and its Effects on Vascular Dysfunction in Otherwise Healthy Cigarette Smokers and Subjects with Type 2 Diabetes Mellitus	GSK2245840	SIR114089	Diabetes Mellitus, Type 2	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=114089	http://clinicaltrials.gov/show/NCT01031108		Y	Y	Y	Y	Y	Y	Y		1-May-2015
3144	GSK	A randomised, double-blind, placebo-controlled, dose-escalating study to evaluate the safety, tolerability, systemic pharmacokinetic profile and pharmacodynamics of single inhaled doses of a new chemical entity in healthy male subjects.	GW678007	B2B10001	Asthma	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=B2B10001			Y	Y	Y	Y	Y	Y	Y	A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-May-2015
3145	GSK	A multi-enter, randomized, double-blind, placebo-controlled, four-way incomplete block crossover study to examine efficacy, safety, tolerability, pharmacodynamics and pharmacokinetics of single and repeat administration of three inhaled doses (10, 15, and 20 mcg) of GSK159797	milveterol	B2E106359	Pulmonary Disease, Chronic Obstructive	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=B2E106359	http://clinicaltrials.gov/show/NCT00358488	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-005329-68	Y	Y	Y	Y	Y	Y	Y		1-May-2015
3146	GSK	A 16 Week Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Tolerability of Paroxetine in the Treatment of Children and Adolescents with Social Anxiety Disorder/Social Phobia.	paroxetine	BRL-029060/676	Social Phobia	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=29060/676			N	N	Y	Y	Y	Y	Y	An analysis-ready dataset is not available for this study. An annotated case report form is not available for this study. A blank case report form will be provided. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-May-2015
3147	GSK	A Double-Blind, Placebo-Controlled, 3-Arm, Fixed-Dose Study of Paroxetine CR Continuous Treatment (12.5 mg/day and 25 mg/day) for Premenstrual Dysphoric Disorder	paroxetine	29060/689	Premenstrual Syndrome	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=29060/689			N	Y	Y	Y	Y	Y	Y	An analysis-ready dataset is not available for this study. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-May-2015
3148	GSK	A Randomized, Multi-center, 10-week, Double-blind, Placebo-Controlled, Flexible-Dose Study to Evaluate the Efficacy and Safety of Paroxetine in Children and Adolescents with Obsessive Compulsive Disorder	paroxetine	BRL-029060/704	Obsessive-Compulsive Disorder	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=29060/704			N	Y	Y	Y	Y	Y	Y	An extension study BRL-029060/716 was conducted. An analysis-ready dataset is not available for this study. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-May-2015
3149	GSK	A Multi-center Study to Assess the Pharmacokinetics of Paroxetine Following Repeat-Dose Administration in Children and Adolescents with Obsessive Compulsive Disorder (OCD) and/or Depression	paroxetine	BRL-029060/715	Obsessive-Compulsive Disorder and Depressive Disorder	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=29060/715			N	N	Y	Y	Y	Y	N	An extension study BRL-029060/716 was conducted. An analysis-ready dataset is not available for this study. An annotated case report form is not available for this study. A blank case report form will be provided. A reporting and analysis plan is not available for this study. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-May-2015
3150	GSK	A Double-Blind, Randomized, Placebo-Controlled, Parallel Group, fMRI and PET Study Comparing Emotional Challenge-induced Regional Cerebral Blood Flow Changes Before and After 8 Weeks of Treatment With Placebo and Paroxetine in Subjects with Social Anxiety Disorder	paroxetine	TMT106386	Social Phobia	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=TMT106386	http://clinicaltrials.gov/show/NCT00470483	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000233-36	Y	N	Y	Y	Y	Y	Y	An annotated case report form is not available for this study. A blank case report form will be provided.	1-May-2015
3151	GSK	A Multi-center, Open-label, Six-Month Extension Study to Assess the Long-term Safety of Paroxetine in Children and Adolescents with Major Depressive Disorder (MDD) or Obsessive Compulsive Disorder (OCD)	paroxetine	BRL-029060/716	Obsessive-Compulsive Disorder and Depressive Disorder	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=29060/716			N	Y	Y	Y	N	Y	Y	This is an extension study to BRL-029060/715, BRL-029060/704 and BRL-029060/701 . An analysis-ready dataset is not available for this study. A protocol is not available for this study. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-May-2015
3152	GSK	A Double-Blind, Placebo-Controlled, Three-Arm Fixed-Dose Study of Paroxetine CR Continuous Treatment (12.5 mg/day and 25 mg/day) for Premenstrual Dysphoric Disorder	paroxetine	29060/677	Premenstrual Syndrome	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=29060/677			N	N	Y	Y	Y	Y	Y	An analysis-ready dataset is not available for this study. An annotated case report form is not available for this study. A blank case report form will be provided. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-May-2015
3153	GSK	A double-blind, placebo-controlled, 3-arm fixed dose study of paroxetine CR continuous treatment (12.5mg and 25mg) for Premenstrual Dysphoric Disorder.	paroxetine	29060/688	Premenstrual Syndrome	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=29060/688			N	Y	Y	Y	Y	Y	Y	An analysis-ready dataset is not available for this study. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-May-2015
3154	GSK	A 3-Month, Double-blind, Placebo-controlled, Fixed-dose, Extension Study of Paroxetine CR (12.5 mg and 25 mg/day) Continuous Treatment for PMDD Patients Completing Studies 29060/677, 688 or 689	paroxetine	29060/711	Premenstrual Syndrome	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=29060/711			N	N	Y	Y	Y	Y	Y	An analysis-ready dataset is not available for this study. An annotated case report form is not available for this study. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-May-2015
3155	GSK	A Double-Blind, Placebo-Controlled, 3-Arm, Fixed-Dose Study of Paroxetine CR Intermittent Dosing (12.5 mg and 25 mg) for Premenstrual Dysphoric Disorder	paroxetine	29060/717	Premenstrual Syndrome	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=29060/717			Y	Y	Y	Y	Y	Y	Y	A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-May-2015
3156	GSK	An open-label, randomized, single dose, two-period crossover study to demonstrate bioequivalence between the controlled release paroxetine tablet (37.5 mg) manufactured at Cidra and Mississauga	paroxetine	PCR111656	Depressive Disorder	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=PCR111656	http://clinicaltrials.gov/show/NCT00749359		Y	Y	Y	Y	Y	Y	Y		1-May-2015
3157	GSK	An open label, randomised, repeat dose study to assess the pharmacokinetic performance of five ezogabine/retigabine modified release (MR) formulations at steady state compared to the immediate release (IR) formulation.	retigabine, ezogabine	RTG114552	Epilepsy	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=114552	http://clinicaltrials.gov/show/NCT01332513		Y	Y	Y	Y	Y	Y	Y		1-May-2015
3158	GSK	A 12-Week, Randomized, Double-blind Study to Evaluate the Effects of Rosiglitazone 4 mg BD and Rosiglitazone 4 mg QD on Lipids in Type 2 Diabetes Mellitus Subjects Taking Statins	rosiglitazone	BRL-049653/311	Diabetes Mellitus, Type 2	Phase 4	https://www.gsk-studyregister.com/en/trial-details/?id=49653/311			N	Y	Y	Y	Y	Y	Y	An analysis-ready dataset is not available for this study. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-May-2015
3159	GSK	A bioequivalence study with a combination tablet formulation of rosiglitazone and glimepiride (4mg/4mg) compared to concomitant dosing of rosiglitazone 4mg and glimepiride 4mg (4mg + 4mg) commercial tablets in healthy subjects	rosiglitazone/glimepiride	SB-797620/002	Diabetes Mellitus, Type 2	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=797620/002			N	N	Y	Y	Y	Y	N	An analysis-ready dataset is not available for this study. An annotated or blank case report form is not available as the data electronic data capture system for this study did not generate a paper version. A reporting and analysis plan is not available for this study. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-May-2015
3160	GSK	A double-blind, double dummy, randomised, parallel group positron emission tomography study to investigate the effects of chronic administration of an oral dose of a GSK New Chemical Entity (NCE), paroxetine 20mg or placebo on regional cerebral blood flow, using the tracer [15O]-water, in subj ...	vestipitant	NKD10020	Social Phobia	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=NKD10020			N	N	Y	Y	Y	Y	Y	An analysis-ready dataset is not available for this study. An annotated case report form is not available for this study. A blank case report form will be provided. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-May-2015
3161	GSK	An 8-Week, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Fixed-Dose Study Comparing the Efficacy and Safety of GW597599B or Paroxetine to Placebo in Moderately to Severely Depressed Patients with Major Depressive Disorder	vestipitant	NKD20006	Depressive Disorder, Major	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=NKD20006	http://clinicaltrials.gov/show/NCT00048204		N	Y	Y	Y	Y	Y	Y	An analysis-ready dataset is not available for this study.	1-May-2015
3162	GSK	A double-blind, triple dummy, placebo-controlled, randomised, parallel group positron emission tomography study to investigate the effects of a 8 week administration of GW597599 and paroxetine either alone or in combination on regional cerebral blood flow during a public speaking test in subjects affected by social phobia.	vestipitant/paroxetine	NKP102280	Depressive Disorder and Anxiety Disorders	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=NKP102280	http://clinicaltrials.gov/show/NCT00343707	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001481-40	Y	N	Y	Y	Y	Y	Y	An annotated case report form is not available for this study. A blank case report form will be provided.	1-May-2015
3163	GSK	An open label repeat dose study to investigate the effect of New Compound (X mg) and paroxetine (10 mg) given in combination for 15 days on the pharmacokinetics of Midazolam and Dextromethorphan in healthy male and female volunteers	vestipitant/paroxetine	NKP100716	Depressive Disorder and Anxiety Disorders	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=100716			N	N	Y	Y	Y	Y	Y	An analysis-ready dataset is not available for this study. An annotated case report form is not available for this study. A blank case report form will be provided. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-May-2015
3164	GSK	A randomised, double blind triple dummy, placebo controlled balanced incomplete block crossover study to evaluate the change in response to a 7% CO2 challenge and pharmacokinetics of single oral doses of GW597599 (5, 7.5, 15 or 25 mg) and paroxetine (5 or 7.5 mg) either alone or in combination, or alprazolam (0.75 mg) in healthy volunteers.	vestipitant/paroxetine	NKP100690	Depressive Disorder and Anxiety Disorders	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=100690			N	N	Y	Y	Y	Y	Y	An analysis-ready dataset and an annotated case report form are not available for this study. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-May-2015
3165	GSK	A Study to Investigate the Effect of Intranasal GR121167X on Infection Rates in Healthy Male Volunteers when Experimentally Inoculated with Influenza A/Texas/91 (H1N1) virus	zanamivir	NAIA1001	Influenza, Human	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=NAIA1001			N	N	Y	Y	Y	Y	N	An analysis-ready dataset, an annotated case report form, and a reporting and analysis plan are not available for this study. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-May-2015
3166	GSK	A Study to Investigate the Effect of Intranasal GG167 Initiated at Various Intervals Post Inoculation on Infection in Healthy Volunteers when Experimentally Inoculated with Influenza A/Texas/91 (H1N1) Virus	zanamivir	NAIA1002	Influenza, Human	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=NAIA1002			N	N	Y	Y	Y	Y	N	An analysis-ready dataset, an annotated case report form, and a reporting and analysis plan are not available for this study. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-May-2015
3167	GSK	A Study to Investigate the Effect of Intranasal GG167 at Various Dosing Frequencies on Infection in Healthy Volunteers when Experimentally Inoculated with Influenza A/Texas/91 (H1N1) Virus	zanamivir	NAIA1003	Influenza, Human	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=NAIA1003			N	N	Y	Y	Y	Y	N	An analysis-ready dataset, an annotated case report form, and a reporting and analysis plan are not available for this study. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-May-2015
3168	GSK	A Study to Investigate the Effect of Intranasal GG167 as Nasal Drops and Nasal Spray on Infection in Healthy Volunteers Experimentally Inoculated with Influenza A/Texas/91 (H1N1) Virus	zanamivir	NAIA1004	Influenza, Human	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=NAIA1004			N	N	Y	Y	Y	Y	N	An analysis-ready dataset, an annotated case report form, and a reporting and analysis plan are not available for this study. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-May-2015
3169	GSK	A Study to Investigate the Effect of Intranasal GG167 on Infection in Healthy Volunteers Experimentally Inoculated with Influenza B/YAMAGATA/16/88 Virus	zanamivir	NAIA1005	Influenza, Human	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=NAIA1005			N	N	Y	Y	Y	Y	N	An analysis-ready dataset, an annotated case report form, and a reporting and analysis plan are not available for this study. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-May-2015
3215	Astellas	A Phase 2, Double-Blind, Randomized, Placebo and Active-Controlled Dose-Finding Study to Assess the Efficacy, Safety and Tolerability of Multiple Oral Doses of ASP1941 in Subjects with Type 2 Diabetes Mellitus	ipragliflozin	1941-CL-0004	Diabetes Mellitus, Type 2	Phase 2	https://www.clinicaltrials.astellas.com/study/?pid=1941-CL-0004	https://clinicaltrials.gov/ct2/show/NCT01071850		Y	Y	Y	Y	Y	Y	Y		1-Aug-2015
3216	Astellas	Phase 2b, Double-Blind, Randomized, Multicenter, Parallel Group, Placebo-Controlled, Dose-Finding Study to Evaluate the Efficacy, Safety and Tolerability of a 12- Week Treatment with ASP1941 in Combination with Metformin in Patients with Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Metformin Alone	ipragliflozin	1941-CL-0005	Diabetes Mellitus, Type 2	Phase 2	https://www.clinicaltrials.astellas.com/study/?pid=1941-CL-0005	https://clinicaltrials.gov/ct2/show/NCT01117584	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-013881-25	Y	Y	Y	Y	Y	Y	Y		1-Aug-2015
3217	Astellas	Randomized, Open-label, Non-inferiority Study of Micafungin versus Standard Care for the Prevention of Invasive Fungal Infections in High Risk Liver Transplant Recipients.	micafungin	9463-EC-0001	Invasive Fungal Infections	Phase 3	https://www.clinicaltrials.astellas.com/study/?pid=9463-EC-0001	https://clinicaltrials.gov/ct2/show/NCT01058174	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-005214-49	Y	Y	Y	Y	Y	Y	Y		1-Jun-2015
3218	Astellas	A Phase 3b, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of Caffeine Intake on Single Photon Emission Computed Tomography (SPECT) Myocardial Perfusion Imaging (MPI) in Subjects Administered Regadenoson	regadenoson	3606-CL-3002	Myocardial Perfusion Imaging	Phase 3	https://www.clinicaltrials.astellas.com/study/?pid=3606-CL-3002	https://clinicaltrials.gov/ct2/show/NCT00826280		Y	Y	Y	Y	Y	Y	Y		1-Jun-2015
3219	Astellas	A Multicenter, Four Arm, Randomized, Open Label Clinical Study Investigating Optimized Dosing in a Prograf®-/Advagraf®-Based Immunosuppressive Regimen in Kidney Transplant Subjects	tacrolimus extended-release	PMR-EC-1210	Transplantation, Kidney	Phase 3	https://www.clinicaltrials.astellas.com/study/?pid=PMR-EC-1210	https://clinicaltrials.gov/ct2/show/NCT00717470	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005376-13	Y	Y	Y	Y	Y	Y	Y		1-Jun-2015
3220	Astellas	A multicenter, three arm, randomized, open label clinical study to compare renal function in liver transplant recipients receiving an immunosuppressive regimen of Advagraf (immediately or delayed post-transplant) and MMF with or without a Monoclonal Anti-IL2R antibody (Basiliximab)	tacrolimus extended-release	PMR-EC-1106	Transplantation, Liver	Phase 3	https://www.clinicaltrials.astellas.com/study/?pid=PMR-EC-1106	https://clinicaltrials.gov/ct2/show/NCT01011205	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-002231-32	Y	Y	Y	Y	Y	Y	Y		1-Jun-2015
3222	GSK	An open, randomised, multi-centre dose-ranging phase II study to evaluate LAPDAP in combination with three different doses of artesunate.	artesunate/chlorproguanil/dapsone	714703/003	Malaria	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=714703/003	https://clinicaltrials.gov/ct/show/NCT00519467		N	Y	Y	Y	Y	Y	Y	An analysis-ready dataset is not available for this study.	1-Jun-2015
3223	GSK	Immunogenicity and reactogenicity of GSK Biologicals’ DTPa-HBV-IPV and Hib vaccines when administered concomitantly to healthy infants administered as a three-dose primary vaccination course at the age of 1.5, 3.5 and 6 months	Combined Diphtheria, Tetanus, Acellular Pertussis Adsorbed, Hepatitis B (Recombinant), Inactivated Polio Vaccine	217744/049 (DTPa-HBV-IPV-049)	Acellular pertussis; Diphtheria; Hepatitis B; Poliomyelitis; Tetanus	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=217744/049	http://clinicaltrials.gov/show/NCT00879827		Y	N	Y	Y	Y	Y	N	An annotated case report form is not available for this study. A blank case report form will be provided. A reporting and analysis plan is not available for this study.	1-Jun-2015
3224	GSK	Phase II, single-blinded, randomized comparative study of the safety and immunogenicity of a booster dose of SB Bios' DTPa-HBV-IPV vaccine compared with Infanrix when both vaccines are co-administered with OmniHIB between 15 and 18 months of age after primary immunization at the age of 2, 4 and 6	Combined Diphtheria, Tetanus, Acellular Pertussis Adsorbed, Hepatitis B (Recombinant), Inactivated Polio Vaccine	217744/061 (DTPa-HBV-IPV-061)	Acellular pertussis; Diphtheria; Hepatitis B; Poliomyelitis; Tetanus	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=217744/061			N	N	Y	Y	Y	Y	Y	This is a follow-up study to 217744/044. An analysis-ready dataset is not available for this study. An annotated case report form is not available for this study. A blank case report form will be provided. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Jun-2015
3225	GSK	A phase II, single-blind, randomised, controlled, multicentre study to evaluate the safety, reactogenicity and immunogenicity of two experimental formulations versus a licensed Haemophilus influenzae type b (Hib) conjugate vaccine (Hiberix™ or HibTiter™) administered as primary vaccination to infants in their thirth, fourth and fifth months of life, with concomitant administration of SmithKline Beecham Biologicals' DTPa-HBV-IPV vaccine	Combined Diphtheria, Tetanus, Acellular Pertussis Adsorbed, Hepatitis B (Recombinant), Inactivated Polio Vaccine	347414/016	Acellular pertussis; Diphtheria; Hepatitis B; Poliomyelitis; Tetanus	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=347414/016			Y	N	Y	Y	Y	Y	Y	A booster study 347414/028 was conducted. An annotated case report form is not available for this study. A blank case report form will be provided. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Jun-2015
3226	GSK	A randomized, controlled, open, phase-II clinical study to evaluate the safety and immunogenicity of an experimental formulation extemporaneously mixed with SmithKline Beecham Biologicals' Haemophilus influenzae type b (Hib) vaccine, administered as a booster dose with DTPa-HBV-IPV to healthy children 12 to 18 months old	Combined Diphtheria, Tetanus, Acellular Pertussis Adsorbed, Hepatitis B (Recombinant), Inactivated Polio Vaccine	347414/028	Acellular pertussis; Diphtheria; Hepatitis B; Poliomyelitis; Tetanus	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=347414/028			Y	N	Y	Y	Y	Y	N	This is a booster of primary study 347414/016. An annotated case report form is not available for this study. A blank case report form will be provided. A reporting and analysis plan is not available for this study. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Jun-2015
3227	GSK	An open clinical study to assess the immunogenicity and safety of GSK Bio’s DTPa-HBV-IPV vaccine mixed in one syringe with Hib vaccine, as a primary vaccination course to pre-term infants(<37 weeks) at 2, 4 and 6 months of age in comparison with infants born after normal gestation period	Combined Diphtheria, Tetanus, Acellular Pertussis Adsorbed, Hepatitis B (Recombinant), Inactivated Polio Vaccine	217744/070 (DTPa-HBV-IPV-070)	Acellular pertussis; Diphtheria; Hepatitis B; Poliomyelitis; Tetanus	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=217744/070	http://clinicaltrials.gov/show/NCT00366366		Y	N	Y	Y	Y	Y	Y	An annotated case report form is not available for this study. A blank case report form will be provided.	1-Jun-2015
3228	GSK	Study to assess the immunogenicity and reactogenicity of DTPa-HBV-IPV mixed with Hib vaccine in healthy infants, followed by a dose of the same vaccine administered simultaneously with one dose of oral polio vaccine (OPV)	Combined Diphtheria, Tetanus, Acellular Pertussis, Hepatitis B, Inactivated Polio, Haemophilus influenzae Type b Vaccine	217744/060	Acellular pertussis; Diphtheria; Haemophilus influenzae type b; Hepatitis B; Poliomyelitis; Tetanus	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=217744/060	http://clinicaltrials.gov/show/NCT01457560		Y	N	Y	Y	Y	Y	N	An annotated case report form is not available for this study. A blank case report form will be provided. A reporting and analysis plan is not available for this study.	1-Jun-2015
3229	GSK	Open, clinical study to assess the safety and reactogenicity of GSK Bios’ combined diphtheria, tetanus, acellular pertussis, hepatitis B, inactivated poliovirus vac. admin. with GSK Bios’ Haemophilus influenzae type b, tetanus conjugate vac. in healthy infants, before a dose of the same vac and OPV	Combined Diphtheria, Tetanus, Acellular Pertussis, Hepatitis B, Inactivated Polio, Haemophilus influenzae Type b Vaccine	217744/063 (DTPa-HBV-IPV-063)	Acellular pertussis; Diphtheria; Haemophilus influenzae type b; Hepatitis B; Poliomyelitis; Tetanus	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=217744/063			Y	N	Y	Y	Y	Y	Y	An annotated case report form is not available for this study. A blank case report form will be provided. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Jun-2015
3230	GSK	Open, randomized, multicentre, phase III clinical trial to assess the reactogenicity and immunogenicity of a booster dose of GlaxoSmithKline (GSK) Biologicals’ DTPa-HBV-IPV/Hib vaccine, co-administered during the same visit with GSK Biologicals’ HAV vaccine (Havrix(), in children in their second ...	Combined Diphtheria, Tetanus, Acellular Pertussis, Hepatitis B, Inactivated Polio, Haemophilus influenzae Type b Vaccine	217744/066 (DTPa-HBV-IPV-066)	Acellular pertussis; Diphtheria; Haemophilus influenzae type b; Hepatitis B; Poliomyelitis; Tetanus	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=217744/066			Y	N	Y	Y	Y	Y	Y	An annotated case report form is not available for this study. A blank case report form will be provided. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Jun-2015
3231	GSK	Study to assess immunogenicity, safety and reactogenicity of GSK Bio’s DTPa-IPV/Hib and HBV vaccines compared to an investigational vaccination regimen in healthy infants born to hepatitis B surface antigen negative mothers and previously primed at birth with a dose of GSK Bio’s hepatitis B vaccine	Combined Diphtheria, Tetanus, Acellular Pertussis, Hepatitis B, Inactivated Polio, Haemophilus influenzae Type b Vaccine	217744/068	Acellular pertussis; Diphtheria; Haemophilus influenzae type b; Hepatitis B; Poliomyelitis; Tetanus	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=217744/068			Y	N	Y	Y	Y	Y	N	An annotated case report form is not available for this study. A blank case report form will be provided. A reporting and analysis plan is not available for this study. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Jun-2015
3232	GSK	Open, randomized, multicenter, phase IIIb clinical trial to assess the incidence of high grade fever ((40.0°C) within 4 days following a booster dose in the second year of life of GSK Bios’ combined DTPa-HBV-IPV/Hib vaccine as compared to GSK Bios’ combined DTPa-IPV/Hib and HBV	Combined Diphtheria, Tetanus, Acellular Pertussis, Hepatitis B, Inactivated Polio, Haemophilus influenzae Type b Vaccine	217744/074  (DTPa-HBV-IPV-074)	Acellular pertussis; Diphtheria; Haemophilus influenzae type b; Hepatitis B; Poliomyelitis; Tetanus	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=217744/074			Y	N	Y	Y	Y	Y	Y	An annotated case report form is not available for this study. A blank case report form will be provided. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Jun-2015
3233	GSK	Study to assess immunogenicity and reactogenicity of GSK Bio’s DTPa-HBV-IPV/Hib vaccine when given as a booster dose to children previously primed at 2-4-6 months of age either with Aventis Pasteurs DTPa-HBV-IPV-Hib vaccine or GSK Bio’s DTPa-HBV-IPV/Hib vaccine in study DTPa-HBV-IPV-086	Combined Diphtheria, Tetanus, Acellular Pertussis, Hepatitis B, Inactivated Polio, Haemophilus influenzae Type b Vaccine	217744/095 (DTPa-HBV-IPV-095)	Acellular pertussis; Diphtheria; Haemophilus influenzae type b; Hepatitis B; Poliomyelitis; Tetanus	Phase 4	https://www.gsk-studyregister.com/en/trial-details/?id=217744/095			Y	N	Y	Y	Y	Y	N	This is a booster to primary study 217744/086. An annotated case report form is not available for this study. A blank case report form will be provided. A reporting and analysis plan is not available for this study. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Jun-2015
3234	GSK	A Phase III, randomized, single blind study to assess the immune response induced by Prevenar™(Wyeth Lederle) when administered to healthy infants with DTPa-HBV-IPV/Hib, compared to an investigational vaccination regimen as a 3-dose primary vaccination course at a monthly interval starting at 8–16 Weeks of age	Combined Diphtheria, Tetanus, Acellular Pertussis, Hepatitis B, Inactivated Polio, Haemophilus influenzae Type b Vaccine	347414/020	Acellular pertussis; Diphtheria; Haemophilus influenzae type b; Hepatitis B; Poliomyelitis; Tetanus	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=347414/020			Y	N	Y	Y	Y	Y	Y	A follow-on study 347414/035 was conducted. An annotated case report form is not available for this study. A blank case report form will be provided. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Jun-2015
3235	GSK	A Phase III, randomized single-blind clinical trial to assess the immune memory induced by an investigational vaccination regimen in comparison with Prevnar and the immune response to a fourth dose of the pneumococcal vaccine and the investigational vaccination regimen, when admininistered to healthy children (12-15 Months)	Combined Diphtheria, Tetanus, Acellular Pertussis, Hepatitis B, Inactivated Polio, Haemophilus influenzae Type b Vaccine	347414/026	Acellular pertussis; Diphtheria; Haemophilus influenzae type b; Hepatitis B; Poliomyelitis; Tetanus	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=347414/026			Y	N	Y	Y	Y	Y	N	An annotated case report form is not available for this study. A blank case report form will be provided. A reporting and analysis plan is not available for this study. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Jun-2015
3236	GSK	A randomised, controlled phase II study to evaluate the safety and immunogenicity of 7 different formulations of GSK Biologicals’ investigational vaccination regimen, when administered as a 3-dose primary immunisation schedule before 6 months of age, followed by a fourth dose during the second year of life	Combined Diphtheria, Tetanus, Acellular Pertussis, Hepatitis B, Inactivated Polio, Haemophilus influenzae Type b Vaccine	759348/001	Acellular pertussis; Diphtheria; Haemophilus influenzae type b; Hepatitis B; Poliomyelitis; Tetanus	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=759348/001			Y	N	Y	Y	Y	Y	N	An annotated case report form is not available for this study. A blank case report form will be provided. A reporting and analysis plan is not available for this study. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Jun-2015
3237	GSK	A randomized, controlled, phase II study to evaluate the safety and immunogenicity of four different formulations of GlaxoSmithKline (GSK) Biologicals’ investigational vaccination regimen, when administered as a 3-dose primary immunization schedule beginning before 6 months of age.	Combined Diphtheria, Tetanus, Acellular Pertussis, Hepatitis B, Inactivated Polio, Haemophilus influenzae Type b Vaccine	759348/003	Acellular pertussis; Diphtheria; Haemophilus influenzae type b; Hepatitis B; Poliomyelitis; Tetanus	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=759348/003			Y	N	Y	Y	Y	Y	N	An annotated case report form is not available for this study. A blank case report form will be provided. A reporting and analysis plan is not available for this study. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Jun-2015
3238	GSK	Open study to assess the immunogenicity after two and three doses of GSK Bios’ Hib vaccine combined with GSK Bios’ DTPa-IPV vaccine given to Swedish infants in a 3, 5, 12 month schedule	Combined Diphtheria, Tetanus, Acellular Pertussis, Inactivated Polio, Haemophilus influenzae Type b Conjugate Vaccine	213503/044 (DTPa-IPV-044)	Acellular pertussis; Diphtheria; Haemophilus influenzae type b; Poliomyelitis; Tetanus	Phase 4	https://www.gsk-studyregister.com/en/trial-details/?id=213503/044			Y	N	Y	Y	Y	Y	Y	An annotated case report form is not available for this study. A blank case report form will be provided. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Jun-2015
3239	GSK	A phase II, single-blind, randomized, controlled study to evaluate the immunogenicity and safety of four different formulations of an investigational vaccination regimen when given intramuscularly as primary vaccination in infants at 3, 4 ½ and 6 months of age.	Combined Diphtheria, Tetanus, Acellular Pertussis, Inactivated Polio, Haemophilus influenzae Type b Conjugate Vaccine	347414/023	Acellular pertussis; Diphtheria; Haemophilus influenzae type b; Poliomyelitis; Tetanus	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=347414/023			Y	N	Y	Y	Y	Y	Y	A booster study 347414/036 was conducted. An annotated case report form is not available for this study. A blank case report form will be provided. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Jun-2015
3240	GSK	Open, multicentric, post-marketing surveillance study of GlaxoSmithKline (GSK) Biologicals combined diphtheria-tetanus-whole cell Bordetella pertussis-hepatitis B vaccine (TRITANRIX-HB) injected in healthy infants according to theprescribing information	Combined Diphtheria, Tetanus, Whole Cell Pertussis, Hepatitis B Vaccine	208139/053 (DTPw-HBV-053)	Diphtheria; Hepatitis B; Tetanus; Whole Cell Pertussis	Phase 4	https://www.gsk-studyregister.com/en/trial-details/?id=208139/053			N	N	Y	Y	N	Y	N	An analysis-ready dataset, reporting and analysis plan and a protocol are not available for this study. An annotated case report form is not available for this study. A blank case report form will be provided. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Jun-2015
3241	GSK	A multinational, randomised, controlled, single-blind, phase-II study to evaluate the safety and immunogenicity of two investigational vaccination regimens versus a licensed Haemophilus influenzae type b (Hib) conjugate vaccine (Hiberix) given concomitantly with DTPw-HBV vaccine in a separate injection of DTPw-HBV to infants at 2, 4, and 6 months of age	Combined Diphtheria, Tetanus, Whole Cell Pertussis, Hepatitis B Vaccine	347414/017	Diphtheria; Hepatitis B; Tetanus; Whole Cell Pertussis	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=347414/017			Y	N	Y	Y	Y	Y	Y	A booster study 347414/029 was conducted. An annotated case report form is not available for this study. A blank case report form will be provided. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Jun-2015
3242	GSK	A phase II open, randomized, controlled study to evaluate an investigational vaccination regimen administered as athree dose primary vaccination course at 2, 3 and 4 months of age.	Combined Diphtheria, Tetanus, Whole Cell Pertussis, Hepatitis B Vaccine	763674/002	Diphtheria; Hepatitis B; Tetanus; Whole Cell Pertussis	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=763674/002			Y	N	Y	Y	Y	Y	Y	An annotated case report form is not available for this study. A blank case report form will be provided. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Jun-2015
3243	GSK	Study to show non-inferiority of Tritanrix™-HepB/Hib-MenAC (+/- hepatitis B vaccine at birth) versus Tritanrix™-HepB/Hiberix™ without hepatitis B vacc. at birth for antibody response to all vaccine antigens given in healthy infants	Combined Diphtheria, Tetanus, Whole Cell Pertussis, Hepatitis B, Haemophilus influenzae Type b Vaccine	100478	Diphtheria; Haemophilus influenzae type b; Hepatitis B; Tetanus; Whole Cell Pertussis	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=105239 (mth24-30)	http://clinicaltrials.gov/show/NCT00290303		Y	Y	Y	Y	Y	Y	Y	Follow-on studies 105239 and 105245 were conducted.	1-Jun-2015
3244	GSK	A post-marketing surveillance study of GlaxoSmithKline (GSK) Biologicals Diphtheria-Tetanus-whole-cell Pertussis-Hepatitis B vaccine (TRITANRIX-HB) and Haemophilus influenzae type-b tetanus-conjugate (Hib) vaccine (HIBERIX)co-administered in the same syringe in 1,000 Filipino subjects.	Combined Diphtheria, Tetanus, Whole Cell Pertussis, Hepatitis B, Haemophilus influenzae Type b Vaccine	213501/016 (DTPw-HBV-Hib/016)	Diphtheria; Haemophilus influenzae type b; Hepatitis B; Tetanus; Whole Cell Pertussis	Phase 4	https://www.gsk-studyregister.com/en/trial-details/?id=213501/016			Y	N	Y	Y	Y	Y	Y	An annotated case report form is not available for this study. A blank case report form will be provided. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Jun-2015
3245	GSK	A phase III, open, randomized study to evaluate the immunogenicity and reactogenicity of investigational vaccination regimens	Combined Diphtheria, Tetanus, Whole Cell Pertussis, Hepatitis B, Haemophilus influenzae Type b Vaccine	402764/004	Diphtheria; Haemophilus influenzae type b; Hepatitis B; Tetanus; Whole Cell Pertussis	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=402764/004			Y	N	Y	Y	Y	Y	Y	An annotated case report form is not available for this study. A blank case report form will be provided. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Jun-2015
3246	GSK	A phase II, open, randomized, controlled study to evaluate the immunogenicity of investigational vaccinationregimens administered as a three dose primary vaccination course at 6, 10 and 14 weeks of age.	Combined Diphtheria, Tetanus, Whole Cell Pertussis, Hepatitis B, Haemophilus influenzae Type b Vaccine	759346/001	Diphtheria; Haemophilus influenzae type b; Hepatitis B; Tetanus; Whole Cell Pertussis	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=759346/001			Y	N	Y	Y	Y	Y	Y	An annotated case report form is not available for this study. A blank case report form will be provided. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Jun-2015
3247	GSK	Demonstrate non-inferiority of GSK Biologicals’ Tritanrix™-HepB/Hib-MenAC vs Tritanrix™-HepB/Hiberix™ with respect to anti-HBs immune response, when given to healthy infants at 6,10 & 14 weeks age, after a birth dose of hepatitis B vaccine	Combined Diphtheria, Tetanus, Whole Cell Pertussis, Hepatitis B, Haemophilus influenzae Type b Vaccine	759346/007	Diphtheria; Haemophilus influenzae type b; Hepatitis B; Tetanus; Whole Cell Pertussis	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=759346/007	http://clinicaltrials.gov/show/NCT00317122		Y	N	Y	Y	Y	Y	Y	A follow-on study 104756 was conducted. An annotated case report form is not available for this study. A blank case report form will be provided.	1-Jun-2015
3248	GSK	A phase II, open, randomized, controlled study to evaluate an investigational vaccination regimen administered as athree dose primary vaccination course at 2, 3 and 4 months of age.	Combined Diphtheria, Tetanus, Whole Cell Pertussis, Hepatitis B, Haemophilus influenzae Type b Vaccine	763674/001	Diphtheria; Haemophilus influenzae type b; Hepatitis B; Tetanus; Whole Cell Pertussis	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=763674/001			Y	N	Y	Y	Y	Y	Y	An annotated case report form is not available for this study. A blank case report form will be provided. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Jun-2015
3249	GSK	Study to evaluate immunogenicity, safety and reactogenicity of two different immunization regimens against hepatitis B, diphtheria, tetanus, pertussis and Haemophilus influenzae type b (Hib)diseases in healthy infants primed with a birth dose of GSK Biologicals hepatitis B	Combined Diphtheria, Tetanus, Whole Cell Pertussis, Hepatitis B, Haemophilus influenzae Type b Vaccine (KFT)	213501/018 (DTPw-HBV-Hib-018)	Diphtheria; Tetanus; Whole Cell Pertussis; Hepatitis B; Haemophilus influenzae type b	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=213501/018			Y	N	Y	Y	Y	Y	Y	An annotated case report form is not available for this study. A blank case report form will be provided. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Jun-2015
3250	GSK	Study to assess immunogenicity and reactogenicity of GSK Bio’s quadrivalent diphtheria, tetanus, whole cell Bordetella pertussis, hepatitis B and Haemophilus influenzae type b conjugate vaccines when mixed extemporaneously and given in a single injection to healthy infants	Combined Diphtheria, Tetanus, Whole Cell Pertussis, Hepatitis B, Haemophilus influenzae Type b Vaccine (KFT)	213501/019 (DTPw-HBV-Hib-019)	Diphtheria; Tetanus; Whole Cell Pertussis; Hepatitis B; Haemophilus influenzae type b	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=213501/019			Y	N	Y	Y	Y	Y	N	An annotated case report form is not available for this study. A blank case report form will be provided. A reporting and analysis plan is not available for this study. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Jun-2015
3251	GSK	Open, five-year immunogenicity follow-up of subjects who previously received GSK Biologicals dTpa vaccine or GSKBiologicals pa vaccine and Lederles Td vaccine at 10 to 14 years of age in study 263855/004 (EXT: dTpa-004)	Combined Reduced Antigen Content Diphtheria, Tetanus, Acellular Pertussis Vaccine	263855/017, 263855/030	Diphtheria; Tetanus; Acellular pertussis	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=263855/017			N	N	Y	Y	Y	Y	N	This is a follow-up study to 263855/004 (dTpa-004). An analysis-ready dataset and a reporting and analysis plan are not available for this study. An annotated case report form is not available for this study. A blank case report form will be provided. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Jun-2015
3252	GSK	Open, non-randomized, phase IV study to evaluate immunogenicity and safety of GSK Biologicals’ dTpa vaccine when administered as single dose to healthy adolescents in their 11th to 18th year of life who were not previously vaccinated against pertussis and have anti-PT antibody titers < 20 EL.U/ml	Combined Reduced Antigen Content Diphtheria, Tetanus, Acellular Pertussis Vaccine	263855/019 (dTpa-019)	Acellular pertussis; Diphtheria; Tetanus	Phase 4	https://www.gsk-studyregister.com/en/trial-details/?id=263855/019			Y	N	Y	Y	Y	Y	N	An annotated case report form is not available for this study. A blank case report form will be provided. A reporting and analysis plan is not available for this study. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Jun-2015
3253	GSK	An open, phase III, single center study to assess the immunogenicity, safety and reactogenicity of GlaxoSmithKline Biologicals’ dTpa vaccine administered as a single-dose booster in healthy adults aged ≥ 18 years.	Combined Reduced Antigen Content Diphtheria, Tetanus, Acellular Pertussis Vaccine	263855/020 (dTpa-020)	Acellular pertussis; Diphtheria; Tetanus	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=263855/020			Y	N	Y	Y	Y	Y	N	An annotated case report form is not available for this study. A blank case report form will be provided. A reporting and analysis plan is not available for this study. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Jun-2015
3254	GSK	Single-blind, randomized, phase IV clinical trial to compare the immunogenicity of GSK Biologicals’ dTpa vaccine (Boostrix™) and Aventis Pasteur MSD’s tetanus toxoid vaccine (Tetavax®), ten days after vaccination of healthy adults 18 years of age and older	Combined Reduced Antigen Content Diphtheria, Tetanus, Acellular Pertussis Vaccine	263855/028 (dTpa-028)	Diphtheria; Tetanus; Acellular pertussis	Phase 4	https://www.gsk-studyregister.com/en/trial-details/?id=263855/028			Y	N	Y	Y	Y	Y	Y	An annotated case report form is not available for this study. A blank case report form will be provided. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Jun-2015
3255	GSK	Observer-blind, randomized, phase II clinical trial to assess the immunogenicity and safety of one dose of three formulations of GSK Biologicals’ dTpa vaccine containing 0.5 mg, 0.3 mg and 0.133 mg of aluminum, respectively in healthy adolescents aged 10 to 18 years	Combined Reduced Antigen Content Diphtheria, Tetanus, Acellular Pertussis Vaccine	263855/029 (dTpa-029)	Acellular pertussis; Diphtheria; Tetanus	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=263855/029			Y	N	Y	Y	Y	Y	N	An annotated case report form is not available for this study. A blank case report form will be provided. A reporting and analysis plan is not available for this study. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Jun-2015
3256	GSK	Double-blind, randomised phase IIIb, study to compare the immunogenicity and reactogenicity of GSK Biologicals DTPa vaccine (Infanrix™) with GSK Biologicals dTpa (Boostrix™) administered to healthy children 4-6 years of age, having experienced an injection site reaction following the 4th dose of Infanrix™ vaccine	Combined Reduced Antigen Content Diphtheria, Tetanus, Acellular Pertussis Vaccine	263855/033 (dTpa-033)	Diphtheria; Tetanus; Acellular pertussis	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=263855/033			Y	N	Y	Y	Y	Y	N	An annotated case report form is not available for this study. A blank case report form will be provided. A reporting and analysis plan is not available for this study. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Jun-2015
3257	GSK	A study to assess the lot-to-lot consistency of GSK Biologicals dTpa-IPV vaccine administered to healthy children 4 to 8 years of age, previously vaccinated with four doses of DTPa or DTPa-based combination vaccines and at least 3 doses of OPV or IPV	Combined Reduced Antigen Content Diphtheria, Tetanus, Acellular Pertussis Vaccine	711866/001 (dTpa-IPV-001)	Acellular pertussis; Diphtheria; Tetanus	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=711866/001			Y	N	Y	Y	Y	Y	Y	An annotated case report form is not available for this study. A blank case report form will be provided. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Jun-2015
3258	GSK	Phase II study to assess immunogenicity and reactogenicity of GSK Biologicals dTpa-IPV vaccine compared to GSK Biologicals dTpa and Aventis Pasteur Merck Sharp Dohme’s IPV vaccines admind separately,and to assess immunogenicity and reactogenicity of GSK Biologicals DTPa-IPV vaccine, when administered to healthy adolescents	Combined Reduced Antigen Content Diphtheria, Tetanus, Acellular Pertussis Vaccine	711866/002 (dTpa-IPV-002)	Acellular pertussis; Diphtheria; Tetanus	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=711866/002			Y	N	Y	Y	Y	Y	Y	An annotated case report form is not available for this study. A blank case report form will be provided. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Jun-2015
3259	GSK	Assess immunogenicity, reactogenicity of GSK Biologicals’-dTpa-IPV vaccine versus dTpa & IPV vaccines administered separately & compared with Aventis Pasteur MSD’s Td-IPV vaccine when administered to healthy adolescents & adults	Combined Reduced Antigen Content Diphtheria, Tetanus, Acellular Pertussis Vaccine	711866/003 (dTpa-IPV-003)	Acellular pertussis; Diphtheria; Tetanus	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=711866/003	http://clinicaltrials.gov/show/NCT01277705		Y	N	Y	Y	Y	Y	Y	An annotated case report form is not available for this study. A blank case report form will be provided.	1-Jun-2015
3260	GSK	A phase 3, open, multicenter study of the safety and immunogenicity of a booster dose of SB Bios’ Diphtheria and Tetanus toxoids and acellular Pertussis vaccine and Pasteur Mérieux’s Haemophilus influenzae type b conjugate vaccine when admin intramuscularly as separate injections(12-18 mths of age)	Diphtheria, Tetanus, Acellular Pertussis Vaccine Adsorbed	208355/123 (APV-123)	Acellular pertussis; Diphtheria; Tetanus	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=208355/123			Y	N	Y	Y	Y	Y	Y	This is a follow-up study to 217744/027. An annotated case report form is not available for this study. A blank case report form will be provided. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Jun-2015
3261	GSK	A randomised, double-blind, placebo-controlled, 3-period cross-over study to evaluate the effect of two doses of GSK2190915 on the allergen-induced early asthmatic response in subjects with mild asthma	fiboflapon	LPA112356	Asthma	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=112356	http://clinicaltrials.gov/show/NCT00812773	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-005205-19	Y	Y	Y	Y	Y	Y	Y		1-Jun-2015
3262	GSK	A Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, Three-Treatment, Three 6-Week Period Cross-Over, Multi-Center Study to Evaluate the Effect of Adding GSK2190915 300mg as Compared to Adding Montelukast 10mg or Placebo Tablets QD to Fluticasone Propionate/Salmeterol 250/50mcg Diskus BID	fiboflapon	LPA114387	Asthma	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=114387	http://clinicaltrials.gov/show/NCT01248975	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-019989-91	Y	Y	Y	Y	Y	Y	Y		1-Jun-2015
3263	GSK	Absolute Bioavailability of FP, BDP, and Budesonide following single inhaled 400mcg dose and assay limits of 50pg/mL.	fluticasone propionate	FMS10031	Asthma	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=FMS10031			N	N	N	Y	N	Y	N	An analysis-ready dataset and a reporting and analysis plan are not available for this study. A clinical study report and a protocol are not available for this study because only draft versions were located; no final version found in archives. An annotated and blank case report form are not available as the electronic data capture system used for this study did not generate paper versions. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Jun-2015
3264	GSK	A 52-week multicentre, randomised, double-blind, double dummy, placebo-controlled parallel group study to compare the efficacy and tolerability of salmeterol/fluticasone propionate combination (SERETIDE/VIANI/ADVAIR) 50/100mcg once daily in the morning with fluticasone propionate (FLIXOTIDE/FLOV ...	fluticasone propionate/salmeterol	SAS30024	Asthma	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=SAS30024			N	Y	Y	Y	Y	Y	Y	An analysis-ready dataset is not available for this study. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Jun-2015
3265	GSK	A randomised, double blind, placebo controlled, three-way cross-over study in asymptomatic patients with seasonal allergic rhinitis to compare the effect of 7 days treatment with intranasal salmeterol/fluticasone propionate combination ( 100mcg/200mcg) with 7 days treatment of fluticasone propionate (200mcg) or placebo, on nasal clinical symptoms and nasal blockage following intranasal allergen challenge.	fluticasone propionate/salmeterol	SNA10001	Rhinitis	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=SNA10001			N	Y	N	Y	N	Y	Y	An analysis-ready dataset is not available for this study. A clinical study report and a protocol are not available for this study because only draft versions were located; no final version found in archives. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Jun-2015
3266	GSK	A single dose, randomized, double-blind, 2-way crossover study to assess the safety, tolerability, pharmacodynamics and pharmacokinetic profile of SERETIDE™ 50/50 compared to concurrent administration of individual FP 50 and SALM 50 inhalers in healthy subjects aged 18 – 55 years.	fluticasone propionate/salmeterol	SAS10020	Asthma	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=SAS10020		https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-003924-36	N	N	N	Y	Y	Y	Y	An analysis-ready dataset is not available for this study. An annotated and blank case report form are not available as the electronic data capture system used for this study did not generate paper versions. A clinical study report is not available for this study because only a draft version was located; no final version found in archives. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Jun-2015
3267	GSK	An Open-label, Randomized, Two-way Balanced Crossover Study to Investigate the Bioavailability of two forms ofGSK1363089 in Subjects with Solid Tumors	foretinib	MET111516	Solid Tumours	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=MET111516	http://clinicaltrials.gov/show/NCT00742261		Y	Y	Y	Y	Y	Y	Y		1-Jun-2015
3268	GSK	A Phase 2 Study of the c-Met RTK Inhibitor GSK1363089 (Formerly XL880) in Subjects with Papillary Renal-Cell Carcinoma	foretinib	MET111644	Carcinoma, Renal Cell	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=MET111644	http://clinicaltrials.gov/show/NCT00726323		Y	N	Y	Y	Y	Y	Y	An annotated case report form is not available for this study. A blank case report form will be provided.	1-Jun-2015
3269	GSK	A randomised, double-blind, three-way crossover study to investigate the effects of nebulised sterile water for injection on beta-agonist induced bronchodilation in healthy male and female volunteers.	GSK159802	B2F100819	Pulmonary Disease, Chronic Obstructive	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=100819			Y	N	N	Y	Y	Y	Y	An annotated and blank case report form are not available as the electronic data capture system used for this study did not generate paper versions. A clinical study report is not available for this study because there is no evidence in the archives that a document was authored. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Jun-2015
3270	GSK	A randomised, double-blind, placebo controlled study to examine the safety, tolerability, pharmacodynamics and pharmacokinetics of single inhaled dry powder doses of GSK159802 in healthy male subjects and asthmatics	GSK159802	B2F104300	Pulmonary Disease, Chronic Obstructive	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=B2F104300	http://clinicaltrials.gov/show/NCT00364273	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002173-72	Y	Y	Y	Y	Y	Y	Y		1-Jun-2015
3272	GSK	A Phase IIa, Randomized, Placebo-Controlled, Double-Blind Clinical Study to Assess the Safety, Tolerability, and Activity of Oral SRT2104 Capsules Administered for 28 Days to Subjects with Type 2 Diabetes Mellitus	GSK2245840	SIR114010	Diabetes Mellitus, Type 2	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=114010	http://clinicaltrials.gov/show/NCT01018017		Y	Y	Y	Y	Y	Y	Y		1-Jun-2015
3273	GSK	A Randomized, Double-Blind, Placebo-Controlled, Phase I Clinical Study to Assess the Pharmacokinetics, Safety and Tolerability of SRT2104 Administered as Single and Multiple Doses in the Fed State to Normal Healthy Male Volunteers	GSK2245840	SIR113140	Diabetes Mellitus, Type 2	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=113140	http://clinicaltrials.gov/show/NCT00933062		Y	Y	Y	Y	Y	N	Y	A raw dataset is not available for this study.	1-Jun-2015
3274	GSK	A Phase II, Randomized, Placebo-Controlled, Double-Blind, Multiple-Dose Clinical Study to Assess the Safety and Pharmacokinetics of SRT2104 in Type 2 Diabetic Human Subjects	GSK2245840	SIR113160	Diabetes Mellitus, Type 2	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=113160	http://clinicaltrials.gov/show/NCT00937326		Y	Y	Y	Y	Y	N	Y	A raw dataset is not available for this study.	1-Jun-2015
3275	GSK	A phase I randomized, open-label, clinical study to assess the effect of food and gender on the pharmacokinetics of SRT2104 administered as an oral suspension or capsule formulation to normal healthy volunteers	GSK2245840	SIR113261	Diabetes Mellitus, Type 2	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=113261	http://clinicaltrials.gov/show/NCT00938275		Y	Y	Y	Y	Y	N	Y	A raw dataset is not available for this study.	1-Jun-2015
3276	GSK	A Phase I study to evaluate single and multiple (seven) oral doses of SRT2104 on the endotoxin induced inflammatory response in healthy male subjects	GSK2245840	SIR114009	Sepsis	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=114009	http://clinicaltrials.gov/show/NCT01014117		Y	N	Y	Y	Y	N	Y	A raw dataset is not available for this study. An annotated case report form is not available for this study. A blank case report form will be provided.	1-Jun-2015
3277	GSK	A Randomized, Placebo-Controlled, Double-Blind, Clinical Study to Assess the Safety, Tolerability and Pharmacokinetics of Oral SRT2104 Capsules Administered to Healthy Elderly Subjects for 28 Days	GSK2245840	SIR113312	Atrophy, Muscular	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=113312	http://clinicaltrials.gov/show/NCT00964340		Y	N	Y	Y	Y	Y	Y	An annotated case report form is not available for this study. A blank case report form will be provided.	1-Jun-2015
3278	GSK	A randomised, double-blind, placebo-controlled, multi-way crossover study to assess the effects of single oral doses of SRT2104 and prednisolone on biomarkers in blood in healthy volunteers	GSK2245840	SIR113161	Pulmonary Disease, Chronic Obstructive	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=113161	http://clinicaltrials.gov/show/NCT00920660		Y	Y	Y	Y	Y	N	Y	A raw dataset is not available for this study.	1-Jun-2015
3279	GSK	A Phase 1, Open-Label, Randomized, Controlled, Four-Period Crossover Study to Assess the Relative Bioavailability of New Oral Formulations of SRT2104 in Healthy Male Volunteers	GSK2245841	SIR117041	Psoriasis	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=117041	http://clinicaltrials.gov/show/NCT01702493		Y	Y	Y	Y	Y	Y	Y		1-Jun-2015
3280	GSK	A randomised, double blind, placebo-controlled, dose-escalating study to evaluate the safety, tolerability, pharmacodynamics and pharmacokinetic profile of single inhaled doses of a new chemical entity in healthy male subjects.	GW597901	B2A10001	Asthma	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=B2A10001			Y	Y	N	Y	Y	Y	N	A reporting and analysis plan is not available for this study. A clinical study report is not available for this study because only a draft version was located; no final version found in archives. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Jun-2015
3281	GSK	A multi-centre, randomised, double-blind, placebo controlled, crossover study to examine the efficacy, safety, tolerability and systemic pharmacokinetics of single inhaled dose of a new chemical entity in asthmatic subjects.	GW597901	B2A10002	Asthma	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=B2A10002			Y	Y	N	Y	Y	Y	N	A reporting and analysis plan is not available for this study. A clinical study report is not available for this study because only a draft version was located; no final version found in archives. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Jun-2015
3282	GSK	A multi-centre, randomized, double-blind, double dummy, placebo-controlled, 5-period crossover study to examine the safety, tolerability, systemic pharmacodynamics, and systemic pharmacokinetics of single inhaled doses of a new chemical entity in asthmatic subjects.	GW678007	B2B10002	Asthma	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=B2B10002			Y	Y	N	Y	Y	Y	N	A reporting and analysis plan is not available for this study. A clinical study report is not available for this study because only a draft version was located; no final version found in archives. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Jun-2015
3283	GSK	Safety and immunogenicity of GSK Biologicals’ (pre-) pandemic influenza candidate vaccine (GSK1562902A) in children aged 6 to 35 months	H5N1 Pre-pandemic Influenza Vaccine	109825	Influenza	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=109825	http://clinicaltrials.gov/show/NCT01323946	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004734-33	Y	Y	Y	Y	Y	Y	Y		1-Jun-2015
3284	GSK	A post-marketing surveillance study of GlaxoSmithKline Biologicals’ Haemophilus influenzae type b (Hib) tetanus conjugate vaccine in 3,000 Filipino subjects.	Haemophilus influenzae Type b Vaccine	208108/059 (Hib-059)	Haemophilus influenzae type b	Phase 4	https://www.gsk-studyregister.com/en/trial-details/?id=208108/059			Y	N	Y	Y	N	Y	Y	An annotated case report form is not available for this study. A blank case report form will be provided. A protocol is not available for this study. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Jun-2015
3285	GSK	Phase 2 open randomized primary vaccination study to assess the immunogenicity and reactogenicity of GSK Biologicals' Haemophilus influenzae type b conjugate vaccine administered with commercially available DTPw vaccine as compared to GSK Biologicals' Hib administered mixed with GSK Biologicals' DTPw vaccine in healthy infants	Haemophilus influenzae Type b Vaccine	208108/087 (Hib-087)	Haemophilus influenzae type b	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=208108/087			Y	N	Y	Y	Y	Y	Y	An annotated case report form is not available for this study. A blank case report form will be provided. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Jun-2015
3286	GSK	Multinational, randomised, controlled, open, phase 2 clinical study to evaluate the safety and immunogenicity of GSK Biologicals’ investigational vaccination regimen administered as a booster dose to healthy children, previously vaccinated in infancy with the investigational vaccination regimen in a primary study 347414/017	Haemophilus influenzae Type b Vaccine	347414/029	Haemophilus influenzae type b	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=347414/029			Y	N	Y	Y	Y	Y	N	This is a booster of primary study 347414/017. An annotated case report form is not available for this study. A blank case report form will be provided. A reporting and analysis plan is not available for this study. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Jun-2015
3287	GSK	A phase-3, open, controlled study to assess the safety and immunogenicity of four different formulations of GSK Biologicals’ investigational vaccination regimen when administered as a booster to healthy infants, 12 to 16 months old, previously vaccinated in infancy in a primary study 347414/023	Haemophilus influenzae Type b Vaccine	347414/036	Haemophilus influenzae type b	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=347414/036			Y	N	Y	Y	Y	Y	N	This is a booster of primary study 347414/023. An annotated case report form is not available for this study. A blank case report form will be provided. A reporting and analysis plan is not available for this study. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Jun-2015
3288	GSK	A phase II, open, randomized study to assess the immune memory induced by a primary vaccination course of an investigational vaccination regimen and the immunogenicity and reactogenicity of a fourth dose of an investigational vaccination regimen, to healthy toddlers primed in study 371594/004.	Haemophilus influenzae Type b Vaccine	371594/006	Hepatitis B	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=371594/006			Y	N	Y	Y	Y	Y	N	This is a follow-up study to 371594/004. An annotated case report form is not available for this study. A blank case report form will be provided. A reporting and analysis plan is not available for this study. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Jun-2015
3289	GSK	A phase IV, open, randomized, controlled, comparative, multicenter U.S. study of the safety of GSK Bios' combination hepatitis A and hepatitis B vaccine administered on a 0-1-6 mth schedule by intramuscular injection compared with concurrently administered monovalent vaccines in healthy adults	Hepatitis A (Inactivated), Hepatitis B (Recombinant) Vaccine	208127/091 (HAB-091)	Hepatitis A; Hepatitis B	Phase 4	https://www.gsk-studyregister.com/en/trial-details/?id=208127/091			N	N	Y	Y	Y	Y	N	An analysis-ready dataset and a reporting and analysis plan are not available for this study. An annotated case report form is not available for this study. A blank case report form will be provided. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Jun-2015
3290	GSK	An open, randomized, monocentric study to evaluate the immunogenicity, reactogenicity and safety of GSK Bios' combined hepatitis A/hepatitis B vaccine compared to separate vaccinations with hepatitis A and hepatitis B vaccines of Chiron Behring/Aventis Pasteur in healthy adult volunteers.	Hepatitis A (Inactivated), Hepatitis B (Recombinant) Vaccine	208127/097 (HAB-097)	Hepatitis A; Hepatitis B	Phase 4	https://www.gsk-studyregister.com/en/trial-details/?id=208127/097			N	N	Y	Y	Y	Y	N	An analysis-ready dataset and a reporting and analysis plan are not available for this study. An annotated case report form is not available for this study. A blank case report form will be provided. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Jun-2015
3291	GSK	Comparison of the immunogenicity and safety in healthy monozygotic and dizygotic twins, which have been grown up in the same environment, after having receipt three vaccinations (Mths 0-1-6) with the hepatitis A and B combination vaccine TWINRIX™ ADULT	twinrix	208127/098 (HAB-098)	Hepatitis A; Hepatitis B	Phase 4	https://www.gsk-studyregister.com/en/trial-details/?id=208127/098			N	N	Y	Y	Y	Y	N	An analysis-ready dataset and a reporting and analysis plan are not available for this study. An annotated case report form is not available for this study. A blank case report form will be provided. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Jun-2015
3292	GSK	A phase III, open, randomized, multicenter, multicountry study to compare the reactogenicity and evaluate the safety and immunogenicity of GSK Bios’ combined hepatitis A/hepatitis B vac admin according to a 0-6 mth schedule by intramuscular injection versus TWINRIX™ JUNIOR admin in healthy children	twinrix	208127/120 (HAB-120)	Hepatitis A; Hepatitis B	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=208127/120	http://clinicaltrials.gov/show/NCT00197184	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-001515-12	N	N	Y	Y	Y	Y	N	Long-term follow-on studies 208127/132, 208127/133, 208127/134 and 208127/137 were conducted. An analysis-ready dataset and a reporting and analysis plan are not available for this study. An annotated case report form is not available for this study. A blank case report form will be provided. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Jun-2015
3293	GSK	An open study to evaluate the immunogenicity and reactogenicity of GlaxoSmithKline Biologicals’ combined hepatitis A / hepatitis B vaccine (schedule 0, 1, 6 months) in healthy children aged 1 to 6 years.	Hepatitis A (Inactivated), Hepatitis B (Recombinant) Vaccine	208127/122 (Ext-HAB-039 Month 90)	Hepatitis A; Hepatitis B	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=208127/122			Y	N	Y	Y	Y	Y	N	This is a follow-up study to 208127/042. An annotated case report form is not available for this study. A blank case report form will be provided. A reporting and analysis plan is not available for this study. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Jun-2015
3294	GSK	A phase III open study to assess the anamnestic response to a single injection of Twinrix vaccine, given approximately 44 months after primary vaccination with combined hepatitis A/ hepatitis B vac, in healthy subjects who have a previously documented seroprotective anti-HBs antibody response	twinrix	208127/123 (HAB-123)	Hepatitis A; Hepatitis B	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=208127/123			Y	N	Y	Y	Y	Y	N	An annotated case report form is not available for this study. A blank case report form will be provided. A reporting and analysis plan is not available for this study. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Jun-2015
3295	GSK	A double-blind, randomized study to evaluate the immunogenicity and reactogenicity of two different lots of GlaxoSmithKline Biologicals' combined hepatitis A / hepatitis B vaccine in healthy children between 6 and 15 years of age.	Hepatitis A (Inactivated), Hepatitis B (Recombinant) Vaccine	208127/125 (Ext-HAB-038 Month 90)	Hepatitis A; Hepatitis B	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=208127/125			Y	N	Y	Y	Y	Y	N	This is a 90-month follow-up study to HAB-038. A 10-year follow-on study 101040 was also conducted. An annotated case report form is not available for this study. A blank case report form will be provided. A reporting and analysis plan is not available for this study. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Jun-2015
3296	GSK	A phase II, open, randomized, multicentric study to evaluate the immunogenicity, reactogenicity and safety of an experimental vaccine to that of Twinrix™ Adult admin following an accelerated schedule (0-7-21 days + 12 mths) in healthy adults aged more than 16 years.	twinrix	208127/126 (HAB-126)	Hepatitis A; Hepatitis B	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=208127/126			Y	N	Y	Y	Y	Y	N	An annotated case report form is not available for this study. A blank case report form will be provided. A reporting and analysis plan is not available for this study. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Jun-2015
3297	GSK	A phase III, double-blind, controlled, multicentric randomized study, to evaluate the immunogenicity and reactogenicity of the combined hepatitis A/hepatitis B preservative-free thimerosal-free vac as compared to the combined hepatitis A/hepatitis B vac with preservative, admin at 0-1-6 Mth	Hepatitis A (Inactivated), Hepatitis B (Recombinant) Vaccine	208127/129 (HAB-129)	Hepatitis A; Hepatitis B	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=208127/129			Y	N	Y	Y	Y	Y	N	An annotated case report form is not available for this study. A blank case report form will be provided. A reporting and analysis plan is not available for this study. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Jun-2015
3298	GSK	A phase IV open study to assess the persistence of anti-HBs and anti-HAV antibodies in older adults approximately 2 years after a primary 3-dose vaccination course with GlaxoSmithKline Biologicals’ combined hepatitis A/hepatitis B vaccine Twinrix( (720/20).	twinrix	208127/130 (EXT:HAB-098)	Hepatitis A; Hepatitis B	Phase 4	https://www.gsk-studyregister.com/en/trial-details/?id=208127/130			Y	N	Y	Y	Y	Y	N	This is a follow-up study to 208127/098. An annotated case report form is not available for this study. A blank case report form will be provided. A reporting and analysis plan is not available for this study. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Jun-2015
3299	GSK	A Phase 4, open, comparative, multicenter study of the immunogenicity and safety of SB Bios' inactivated hepatitis A vaccine 720 EL.U/ 0.5 ml on a 0-6-month schedule, admin by intramuscular injection, either to children aged 15-18 mths old or 11-13 mths old, when compared to 23-25 mth-old children	Hepatitis A vaccine, Inactivated	208109/210 (HAV-210)	Hepatitis A	Phase 4	https://www.gsk-studyregister.com/en/trial-details/?id=208109/210			N	N	Y	Y	Y	Y	Y	An analysis-ready dataset is not available for this study. An annotated case report form is not available for this study. A blank case report form will be provided. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Jun-2015
3300	GSK	A phase IV open study to assess the anamnestic response to a single intramuscular injection of GSK Bios’ hepatitis A vac, Havrix™ Junior in healthy adult subjects who have had a previously documented seropositive status following a full course of primary vaccination with GSK Bios’ hepatitis A vac	Hepatitis A vaccine, Inactivated	208109/228 (HAV-228)	Hepatitis A	Phase 4	https://www.gsk-studyregister.com/en/trial-details/?id=208109/228			Y	N	Y	Y	Y	Y	N	An annotated case report form is not available for this study. A blank case report form will be provided. A reporting and analysis plan is not available for this study. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Jun-2015
3301	GSK	A Phase IIIb, open, multicenter study of the immunogenicity and safety of one dose of GSK Bios' inactivated hepatitis A vaccine administered to healthy children who were seropositive for anti-HAV	Hepatitis A vaccine, Inactivated	208109/229 (HAV-229)	Hepatitis A	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=208109/229			Y	N	Y	Y	Y	Y	N	An annotated case report form is not available for this study. A blank case report form will be provided. A reporting and analysis plan is not available for this study. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Jun-2015
3302	GSK	A phase III, open, randomized, multicentric study to compare the reactogenicity and immunogenicity of GSK Bios’ combined Vi polysaccharide typhoid vac and inactivated hepatitis A vac, to that elicited by GSK Bios’ hepatitis A vac, admin singly or concomitantly with GSK Bios’ Vi polysaccharide vac	Hepatitis A Vaccine, Inactivated	270362/006, 270362/007, 270362/008, 270362/009	Hepatitis A	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=270362/006	http://clinicaltrials.gov/show/NCT00197249		N	N	Y	Y	Y	Y	N	The results are summarised with studies 270362/007 (M12), 270362/008 (M24), 270362/009 (M36) on the GSK Study Register. An analysis-ready dataset and a reporting and analysis plan are not available for this study. An annotated case report form is not available for this study. A blank case report form will be provided.	1-Jun-2015
3303	GSK	Assess, in young children, the efficacy in preventing acute otitis media (AOM) of GSK Biologicals undecavalent pneumococcal-protein D conjugate vaccine, when administered as a three dose primary vaccination course during the first year of life with a booster dose in the second year of life.	Pneumococcal Polysaccharide Conjugate Vaccine (Adsorbed)	347414/010	Otitis Media	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=347414/010	http://clinicaltrials.gov/show/NCT00119743		Y	N	Y	Y	Y	Y	Y	An annotated case report form is not available for this study. A blank case report form will be provided.	1-Jun-2015
3304	GSK	Phase II study to evaluate the immunogenicity of GSK Biologicals' preservative-free Engerix-B and thiomersal-free Engerix-B vaccines compared to Engerix™-B and evaluate safety and reactogenicity of each vaccine when administered intramuscularly according to a 0, 1, 6 month schedule in healthy volunteers	Hepatitis B Vaccine, Recombinant	103860/269 (HBV-269)	Hepatitis B	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=103860/269			N	N	Y	Y	Y	Y	N	An analysis-ready dataset and a reporting and analysis plan are not available for this study. An annotated case report form is not available for this study. A blank case report form will be provided. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Jun-2015
3305	GSK	Immunogenicity and protective efficacy of GlaxoSmithKline (GSK) recombinant-DNA hepatitis B vaccine (10 (g) in newborns of HBeAg+ and HBsAg+ mothers in comparison with a historical control group.	Hepatitis B Vaccine, Recombinant	103860/271 (Ext-HBV-064 Y14-Y15)	Hepatitis B	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=103860/271			N	N	Y	Y	N	Y	N	This is a follow-up study to 103860/064. An analysis-ready dataset, reporting and analysis plan and a protocol are not available for this study. An annotated case report form is not available for this study. A blank case report form will be provided. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Jun-2015
3306	GSK	Study in infants vaccinated with Engerix-B to evaluate immunogenicity and reactogenicity of following GSK Bio’s vaccines: combined DTP-HB vaccine(10g HBsAg)combined DTP-HB vaccine(5g HBsAg) simultaneous administration of Engerix-B vaccine in right thigh and whole-cell DTP vaccine in left thigh	Hepatitis B Vaccine, Recombinant	208139/054 (DTPw-HBV-028 Ext. Y7)	Hepatitis B	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=208139/054			N	N	Y	Y	N	Y	N	This is a follow-up study to 208139/054. An analysis-ready dataset, reporting and analysis plan and a protocol are not available for this study. An annotated case report form is not available for this study. A blank case report form will be provided. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Jun-2015
3307	GSK	Study to assess immunogenicity and safety of GSK Biologicals’ investigational vaccination regimen administered concomitantly in separate injections with GSK Biologicals’ DTPa-IPV/Hib vaccine as a primary vaccination course to healthy infants at 2-4-6 months of age and as a booster dose at 12 to 18 months of age	Hepatitis B Vaccine, Recombinant	347414/008	Hepatitis B	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=347414/008			Y	N	Y	Y	Y	Y	N	An annotated case report form is not available for this study. A blank case report form will be provided. A reporting and analysis plan is not available for this study. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Jun-2015
3308	GSK	Study to assess efficacy, immunogenicity, reactogenicity and safety of two doses of GSK Bio’s oral live attenuated human rotavirus vaccine at different viral concentrations in healthy infants previously uninfected with human rotavirus and approximately 3 months of age	Rotavirus Vaccine	444563/007 (rota-007)	Infections, Rotavirus	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=444563/007	http://clinicaltrials.gov/show/NCT00429481		Y	N	Y	Y	Y	Y	Y	An annotated case report form is not available for this study. A blank case report form will be provided.	1-Jun-2015
3309	GSK	Safety of SmithKline Beecham Biologicals' Herpes Simplex candidate vaccine (gD2t) with MPL & its efficacy to prevent genital herpes disease in HSV positive or negative consorts of subjects with genital herpes disease	Herpes Simplex Vaccine	208141/017	Herpes Simplex	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=208141/017	http://clinicaltrials.gov/show/NCT00699764		Y	N	Y	Y	Y	Y	Y	A follow-on study 208141/037 was conducted. An annotated case report form is not available for this study. A blank case report form will be provided.	1-Jun-2015
3310	GSK	Safety and reactogenicity of GSK Bio’s prophylactic herpes simplex candidate vaccine with gD-alum-MPL in HSV 1-/2- women who received either alum-MPL or alum as placebo during one of GSK Bio’s phase III studies 208141/005, 208141/016 or 208141/017.	Herpes Simplex Vaccine	208141/037	Herpes Simplex	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=208141/037			Y	N	Y	Y	Y	Y	N	This is a follow-up study to 208141/005, 208141/016 and 208141/017. An annotated case report form is not available for this study. A blank case report form will be provided. A reporting and analysis plan is not available for this study. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Jun-2015
3311	GSK	Safety, reactogenicity, and immunogenicity of GSK Bio’s prophylactic herpes simplex candidate vaccine with gD-alum-MPL in HSV 1-/2- women who received alum-MPL or alum placebo during one of GSK Bio’s Phase III studies 208141/005, 208141/016 or 208141/017.	Herpes Simplex Vaccine	208141/038	Herpes Simplex	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=208141/038			Y	N	Y	Y	Y	Y	N	This is a follow-up study to 208141/005, 208141/016 and 208141/017. An annotated case report form is not available for this study. A blank case report form will be provided. A reporting and analysis plan is not available for this study. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Jun-2015
3312	GSK	A study to evaluate the immunogenicity and safety of GlaxoSmithKline Biologicals' herpes simplex candidate vaccine (gD2‑AS04) in healthy HSV seronegative and seropositive female subjects aged 10-17 years.	Herpes Simplex Vaccine	208141/040	Herpes Simplex	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=208141/040	http://clinicaltrials.gov/show/NCT00224484		Y	N	Y	Y	Y	Y	Y	An annotated case report form is not available for this study. A blank case report form will be provided.	1-Jun-2015
3313	GSK	Extension to study comparing doses and schedules of GSK's candidate prophylactic herpes simplex virus vaccine (gD-AS04) in healthy HSV- subjects aged 10-15 and 16-18 yrs to healthy HSV- adults (aged 19-45 yrs) receiving the vaccine on a 0-1-6 mth schedule.	Herpes Simplex Vaccine	208141/041	Herpes Simplex	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=208141/041			Y	N	Y	Y	Y	Y	Y	This is a follow-up study to 208141/026. An annotated case report form is not available for this study. A blank case report form will be provided. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Jun-2015
3314	GSK	Study to Compare Immunogenicity & Safety of 3 comercial Lots of GlaxoSmithKline (GSK) Biologicals’ herpes simplex candidate Vaccine in Healthy HSV-1 & -2 Seronegative (HSV 1-/2-) Females of 10–17 y & Vaccine Immunogenicity in Healthy HSV 1-/2- Females of 10–17 y With Healthy HSV 1-/2- Adult Females	Herpes Simplex Vaccine	208141/042	Herpes Simplex	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=208141/042	http://clinicaltrials.gov/show/NCT00224471		Y	N	Y	Y	Y	Y	Y	An annotated case report form is not available for this study. A blank case report form will be provided.	1-Jun-2015
3315	GSK	Follow-up study to evaluate the long-term immunogenicity and safety of a HPV vaccine (580299) in healthy female subjects	Human Papillomavirus Types 16 and 18 Vaccine	111375	Infections, Papillomavirus	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=111375	http://clinicaltrials.gov/show/NCT00877877	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000369-44	Y	Y	Y	Y	Y	Y	Y	This is a follow-up study to 580299/013. The results of 580299/013 are summarised with studies 104896 (M18), 104902 (M24), 104904 (M36) and 104918 (M48) on the GSK Study Register	1-Jun-2015
3316	GSK	Immunogenicity and safety study of GSK Biologicals’ HPV vaccine (GSK 580299) in healthy adult Chinese female subjects	Human Papillomavirus Types 16 and 18 Vaccine	114590	Infections, Papillomavirus	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=114590	http://clinicaltrials.gov/show/NCT01277042		Y	N	Y	Y	Y	Y	Y	This is a follow-up study to 107638. An annotated case report form is not available for this study. A blank case report form will be provided.	1-Jun-2015
3317	GSK	A Phase I Study of the Safety and Immunogenicity of MEDI-517, a Vaccine Against Human Papillomavirus Types 16 and 18, in Healthy Adult Female Volunteers.	Human Papillomavirus Types 16 and 18 Vaccine	580299/002	Infections, Papillomavirus	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=580299/002			N	N	Y	Y	Y	Y	N	An analysis-ready dataset and a reporting and analysis plan are not available for this study. An annotated case report form is not available for this study. A blank case report form will be provided. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Jun-2015
3318	GSK	A Phase I/II Study to evaluate the safety and immunogenicity of MEDI-517, a virus-like particle vaccine against human papillomavirus (HPV) types 16 and 18, in healthy adult female volunteers who are HPV-16 or HPV-18 DNA positive	Human Papillomavirus Types 16 and 18 Vaccine	580299/003	Infections, Papillomavirus	Phase 1/2	https://www.gsk-studyregister.com/en/trial-details/?id=580299/003			N	N	Y	Y	Y	Y	N	An analysis-ready dataset and a reporting and analysis plan are not available for this study. An annotated case report form is not available for this study. A blank case report form will be provided. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Jun-2015
3319	GSK	Study to Evaluate the Safety and Immunogenicity of MEDI-517, a Virus-Like Particle Vaccine against Human Papillomavirus Types 16 and 18, when Formulated with Aluminum Hydroxide, AS04, or without Adjuvant, in Healthy Adult Female Volunteers	Human Papillomavirus Types 16 and 18 Vaccine	580299/004	Infections, Papillomavirus	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=580299/004	http://clinicaltrials.gov/show/NCT00693615		N	Y	Y	Y	Y	Y	Y	An analysis-ready dataset is not available for this study.	1-Jun-2015
3320	GSK	A Phase II Double-Blind, Randomized, Dose-Comparison Study to Evaluate the Safety and Immunogenicity of MEDI-517, a Virus-Like Particle Vaccine Against Human Papillomavirus Types 16 and 18, in Healthy Adult Female Volunteers	Human Papillomavirus Types 16 and 18 Vaccine	580299/005	Infections, Papillomavirus	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=580299/005	http://clinicaltrials.gov/show/NCT00693966		N	N	Y	Y	Y	Y	Y	An analysis-ready dataset is not available for this study. An annotated case report form is not available for this study. A blank case report form will be provided.	1-Jun-2015
3321	GSK	Phase I study in elderly population aged over 65 years in order to evaluate reactogenicity and immunogenicity of GlaxoSmithKline Biologicals' experimental Influenza vaccine or a Whole virus vaccine. For both immunogenicity and safety evaluations, the commercial inactivated split vaccine Fluarix will be used as reference	Influenza Vaccine	227855/001	Influenza	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=227855/001			Y	N	Y	Y	Y	Y	N	An annotated case report form is not available for this study. A blank case report form will be provided. A reporting and analysis plan is not available for this study. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Jun-2015
3322	GSK	A phase IV, open, randomised study in adults aged 18-60 and over 60 years to evaluate the immunogenicity and the reactogenicity of GlaxoSmithKline Biologicals' Fluarix™ vaccine administered using two different routes	Influenza Vaccine (Split Virion, Inactivated)	684289/001	Influenza	Phase 4	https://www.gsk-studyregister.com/en/trial-details/?id=684289/001			Y	N	Y	Y	Y	Y	N	An annotated case report form is not available for this study. A blank case report form will be provided. A reporting and analysis plan is not available for this study. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Jun-2015
3323	GSK	A phase III, open, controlled, randomised study in adults aged 18-60 and elderly aged over 60 years to confirm the immunogenicity and the reactogenicity of GlaxoSmithKline Biologicals' investigational influenza vaccine	Influenza Vaccine (Split Virion, Inactivated)	701464/005	Influenza	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=701464/005			Y	N	Y	Y	N	Y	Y	An annotated case report form is not available for this study. A blank case report form will be provided. A protocol is not available for this study. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Jun-2015
3324	GSK	A phase II study to evaluate the persistence of measles, mumps and rubella antibodies two years after the single dose primary vaccination in study 209762/151.	Measles, Mumps, Rubella Vaccine	104420	Measles; Mumps; Rubella	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=104420			Y	N	Y	Y	Y	Y	Y	This is a follow-up study to 209762/151. An annotated case report form is not available for this study. A blank case report form will be provided. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Jun-2015
3325	GSK	A phase III, blinded, randomized, multicenter U.S. study evaluating the clinical consistency of three production lots of SmithKline Beecham Biologicals' MMR vaccine (PRIORIX) and comparability of PRIORIX with Merck's M-M-R IIvaccine, administered to healthy children 12 to 18 months of age	Measles, Mumps, Rubella Vaccine	209762/136 (MeMuRu-136)	Measles; Mumps; Rubella	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=209762/136			Y	N	Y	Y	Y	Y	Y	An annotated case report form is not available for this study. A blank case report form will be provided. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Jun-2015
3326	GSK	Phase IV open study to assess the safety, reactogenicity and immunogenicity of GlaxoSmithKline (GSK)Biologicals live attenuated Measles-Mumps-Rubella (MMR) vaccine when given to healthy children at the age of 12 to 18months in Singapore.	Measles, Mumps, Rubella Vaccine	209762/147 (MeMuRu-147)	Measles; Mumps; Rubella	Phase 4	https://www.gsk-studyregister.com/en/trial-details/?id=209762/147	http://clinicaltrials.gov/show/NCT00388440		Y	N	Y	Y	Y	Y	N	An annotated case report form is not available for this study. A blank case report form will be provided. A reporting and analysis plan is not available for this study.	1-Jun-2015
3327	GSK	Phase II, double blind, randomized sequential study to compare immunogenicity and reactogenicity of the current formulations of GSK Bios’ measles-mumps-rubella vaccine and GSK Bios’ varicella vaccine containing human serum albumin with the modified formulations which do not contain HSA	Measles, Mumps, Rubella Vaccine	209762/148	Measles; Mumps; Rubella	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=209762/148			Y	N	Y	Y	Y	Y	N	An annotated case report form is not available for this study. A blank case report form will be provided. A reporting and analysis plan is not available for this study. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Jun-2015
3328	GSK	Phase IV, single-blind, randomised, multicenter study to evaluate immediate post-vaccination pain, reactogenicity and tolerance of GSK Bio’s Measles-Mumps-Rubella vaccine (Priorix) administered as a second dose compared to Aventis-Pasteur-MSDs Measles-Mumps-Rubella vaccine (ROR Vax)	Measles, Mumps, Rubella Vaccine	209762/149 (MeMuRu-149)	Measles; Mumps; Rubella	Phase 4	https://www.gsk-studyregister.com/en/trial-details/?id=209762/149			Y	N	N	Y	N	Y	N	An annotated case report form is not available for this study. A blank case report form will be provided. A reporting and analysis plan is not available for this study. A clinical study report and a protocol are not available for this study because English language versions were not created. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Jun-2015
3329	GSK	Double blind, randomized sequential study to compare immunogenicity and reactogenicity of current formulations of GSK Bios’ measles-mumps-rubella vaccine and GSK Bios’ varicella vaccine to investigational vaccination regimens	Measles, Mumps, Rubella Vaccine	209762/150	Measles; Mumps; Rubella	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=209762/150			Y	N	Y	Y	Y	Y	Y	An annotated case report form is not available for this study. A blank case report form will be provided. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Jun-2015
3330	GSK	Phase II study to evaluate immunogenicity, reactogenicity and safety of GSK Bios’ investigational vaccination regimen compared to the currently licensed GSK Bios’ Priorix™ and Merck and Co.’s M-M-R®II vaccines when administered as a primary vaccination to healthy children aged 12-24 months	Measles, Mumps, Rubella Vaccine	209762/151	Measles; Mumps; Rubella	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=209762/151			Y	N	Y	Y	Y	Y	Y	A follow-on study 104420 was conducted. An annotated case report form is not available for this study. A blank case report form will be provided. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Jun-2015
3335	GSK	A primary vaccination study to evaluate immunogenicity, safety & reactogenicity of 3 doses of GSK Biologicals/Finlay’s meningococcal B candidate vaccine given intramuscularly using either 0-2-4 mth or 0-1-6 mth schedule to healthy subjects aged 12-18 yrs	Meningococcal Vaccine	710158/002	Infections, Meningococcal	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=710158/002	http://clinicaltrials.gov/show/NCT00137917		Y	N	Y	Y	Y	Y	N	An annotated case report form is not available for this study. A blank case report form will be provided. A reporting and analysis plan is not available for this study.	1-Jun-2015
3336	GSK	Evaluate immunogenicity, reactogenicity, safety of GSK Biologicals’ MenC-TT vaccine (2 formulations) given with Infanrix hexa® + GSK Biologicals’ Hib MenC-TT vaccine (2 formulations) given with Infanrix penta® to infants in mths 3,4,5 of life	Meningococcal Vaccine	711202/001	Infections, Meningococcal	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=711202/001	http://clinicaltrials.gov/show/NCT00135486		Y	N	Y	Y	Y	Y	Y	A persistence study 711202/008 was conducted. An annotated case report form is not available for this study. A blank case report form will be provided.	1-Jun-2015
3337	GSK	Evaluate the persistence and immune memory induced by a primary vaccination course with GSK Biologicals’ MenC-TT (1 formulation) & GSK Biologicals’ Hib-MenC-TT (2 formulations) or Meningitec™ in healthy toddlers aged 12-15 mths primed in study 711202/001	Meningococcal Vaccine	711202/008	Infections, Meningococcal	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=711202/008	http://clinicaltrials.gov/show/NCT00135564		Y	N	Y	Y	Y	Y	Y	This is a persistence study of 711202/001. An annotated case report form is not available for this study. A blank case report form will be provided.	1-Jun-2015
3338	GSK	Phase 2, open, randomized, controlled study to demonstrate the non-inferiority of the meningococcal serogroup C immune response and the superiority of the Hib immune response of GSK Biologicals’ Haemophilus influenzae type b-meningococcal C-TT conjugate vaccine administered with Infanrix™ penta versus Meningitec™ administered with Infanrix™	Meningococcal Vaccine	811936/001 (Hib-MenC-TT-001)	Infections, Meningococcal	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=811936/001			Y	N	Y	Y	Y	Y	Y	An annotated case report form is not available for this study. A blank case report form will be provided. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Jun-2015
3339	GSK	A randomised, double-blind, placebo-controlled, dose ascending crossover study to assess the safety, tolerability, pharmacodynamics and pharmacokinetics of inhaled GSK159797 delivered by dry powder inhaler in mild to moderate asthmatic subjects	milveterol	B2E101312	Pulmonary Disease, Chronic Obstructive	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=B2E101312	http://clinicaltrials.gov/show/NCT00354666	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001078-16	Y	Y	N	Y	Y	Y	Y	A clinical study report is not available for this study because only a draft version was located; no final version found in archives.	1-Jun-2015
3340	GSK	A randomised, double blind, placebo controlled, parallel group study to examine the safety, tolerability, and systemic pharmacokinetic profile of repeated inhaled doses of GSK159797 and COA	milveterol	B2E100529	Pulmonary Disease, Chronic Obstructive	Phase 1				Y	Y	N	Y	Y	Y	Y	A clinical study report is not available for this study because only a draft version was located; no final version found in archives. There is no GSK Study Register entry for this study. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Jun-2015
3341	GSK	A randomised, double blind, placebo controlled, parallel group study to examine the efficacy, safety, tolerability and systemic pharmacokinetic profile of repeated inhaled doses of GSK159797	milveterol	B2E100527	Pulmonary Disease, Chronic Obstructive	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=100527			Y	Y	Y	Y	Y	Y	Y	A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Jun-2015
3342	GSK	An open labeled, single sequence study to investigate the safety and pharmacokinetics of oral pimozide when co-administered with repeat dosing oral paroxetine 60 mg od in healthy volunteers.	paroxetine	29060/877	Depressive Disorder	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=29060/877			N	N	Y	Y	Y	Y	N	An analysis-ready dataset and a reporting and analysis plan are not available for this study. An annotated case report form is not available for this study. A blank case report form will be provided. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Jun-2015
3343	GSK	A Study of the Maintained Efficacy and Safety of Paroxetine Versus Placebo in the Long-Term Treatment of Posttraumatic Stress Disorder	paroxetine	29060/650	Post-Traumatic Stress Disorder	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=29060/650			N	N	Y	Y	Y	Y	Y	An analysis-ready dataset is not available for this study. An annotated case report form is not available for this study. A blank case report form will be provided. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Jun-2015
3344	GSK	A single dose four-period crossover study to investigate the relative bioavailability of the new paroxetine dispersible tablet (20 mg) compared with a standard paroxetine 20 mg tablet	paroxetine	29060/653 (BRL-029060/653)	Depressive Disorder	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=29060/653			N	N	N	Y	N	Y	N	An analysis-ready dataset, an annotated case report form and a reporting and analysis plan are not available for this study. A clinical study report and a protocol are not available for this study because only draft versions were located; no final version found in archives. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Jun-2015
3345	GSK	A phase I, double-blind, randomized, placebo-controlled study of the safety and reactogenicity of GSK Biologicals’ live attenuated human rotavirus vaccine at 2 different virus concentrations in healthy seropositive children between 1 and 3 years of age, when given as a single oral administration	Rotavirus Vaccine	444563/002 (rota-002)	Infections, Rotavirus	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=444563/002			Y	N	Y	Y	Y	Y	N	An annotated case report form is not available for this study. A blank case report form will be provided. A reporting and analysis plan is not available for this study. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Jun-2015
3346	GSK	A phase II, double-blind, randomized, placebo-controlled, dose-escalating, stepwise study to assess safety, reactogenicity and immunogenicity of GlaxoSmithKline Biologicals’ live attenuated human rotavirus (HRV) vaccine in healthy infants previously uninfected with human rotavirus.	Rotavirus Vaccine	444563/003 (rota-003)	Infections, Rotavirus	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=444563/003			Y	N	Y	Y	Y	Y	N	An annotated case report form is not available for this study. A blank case report form will be provided. A reporting and analysis plan is not available for this study. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Jun-2015
3347	GSK	A study to assess the efficacy, immunogenicity and safety of two doses of oral live attenuated human rotavirus (HRV) vaccine (Rotarix) in healthy infants.	Rotavirus Vaccine	444563/004	Infections, Rotavirus	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=444563/004	http://clinicaltrials.gov/show/NCT00425737		Y	N	Y	Y	Y	Y	Y	An annotated case report form is not available for this study. A blank case report form will be provided.	1-Jun-2015
3348	GSK	Phase II, double-blind, randomized, placebo-controlled study of 2 doses of GSK Bios’ live attenuated human rotavirus vaccine at different virus concentrations (10 5.2 and 10 6.4 ffu) in healthy infants following a 0, 2 month schedule and previously uninfected with human rotavirus	Rotavirus Vaccine	444563/005 (rota-005)	Infections, Rotavirus	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=444563/005	http://clinicaltrials.gov/show/NCT00729001		Y	N	Y	Y	Y	Y	Y	An annotated case report form is not available for this study. A blank case report form will be provided.	1-Jun-2015
3349	GSK	To assess the efficacy, immuno & safety of 2 doses of GSK HRV vaccine at different virus concentrations in healthy infants aged 2 months & previously uninfected with HRV, concurrently given with DTPw-HBV, Hib.	Rotavirus Vaccine	444563/006	Infections, Rotavirus	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=444563/006	http://clinicaltrials.gov/show/NCT00385320		Y	N	Y	Y	Y	Y	Y	An annotated case report form is not available for this study. A blank case report form will be provided.	1-Jun-2015
3350	GSK	Study of safety, reactogenicity and immunogenicity of two doses of GSK Bio’s oral live attenuated human rotavirus vaccine co-administered with either oral polio vaccine (OPV) or inactivated polio vaccine (IPV) in healthy infants in South Africa	Rotavirus Vaccine	444563/014 (Rota-014)	Infections, Rotavirus	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=444563/014	http://clinicaltrials.gov/show/NCT00346892		Y	N	Y	Y	Y	Y	Y	An annotated case report form is not available for this study. A blank case report form will be provided.	1-Jun-2015
3351	GSK	Phase II, double-blind randomised, placebo controlled clinical dose-range study to assess immunogenicity and reactogenicity of an investigational vaccination regimen, and to assess immunogenicity of OPV orally co-administered to healthy infants at 2, 4 and 6 months of age	Rotavirus Vaccine	444563/020	Infections, Rotavirus	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=444563/020			Y	N	Y	Y	Y	Y	Y	An annotated case report form is not available for this study. A blank case report form will be provided. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Jun-2015
3352	GSK	Phase II, double-blind, randomized, placebo-controlled clinical study to assess immunogenicity and reactogenicity of doses of a modified vaccine formulation versus GSK Biologicals’ live attenuated human rotavirus vaccine when orally administered to healthy infants at 2, 4 and 6 months of age	Rotavirus Vaccine	444563/021	Infections, Rotavirus	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=444563/021			Y	N	Y	Y	Y	Y	Y	An annotated case report form is not available for this study. A blank case report form will be provided. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Jun-2015
3353	GSK	A Phase 1, Double-Blind, Randomized Clinical Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of SRT501 in Subjects with Colorectal Cancer and Hepatic Metastases	SRT501	SIR113221	Neoplasms, Colorectal	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=113221	http://clinicaltrials.gov/show/NCT00920803		N	N	Y	Y	Y	Y	Y	An analysis-ready dataset is not available for this study. An annotated case report form is not available for this study. A blank case report form will be provided.	1-Jun-2015
3355	GSK	An open-label, randomised, two-period, crossover study to assess the safety, tolerability and pharmacokinetics of the 3 mg STATdose administered two hours after a single IMITREX 100 mg tablet relative to two 6 mg STATdose injections administered one hour apart in healthy volunteers.	sumatriptan	SUM20040	Migraine Disorders	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=SUM20040			N	N	N	Y	Y	Y	N	An analysis-ready dataset, an annotated case report form, and a reporting and analysis plan are not available for this study. A clinical study report is not available for this study because only a draft version was located; no final version found in archives. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Jun-2015
3356	GSK	A Randomized, Double-Blind, Placebo-Controlled, Three Armed fMRI study Comparing Emotion-Induced Brain Activation Patterns Before and After 8 Weeks of Treatment With Placebo, Active Comparator (PAXIL, 20 mg), and a GSK New Chemical Entity (NCE)	vestipitant	NKG10006	Sleep Initiation and Maintenance Disorders	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=NKG10006			N	N	Y	Y	Y	Y	Y	An analysis-ready dataset is not available for this study. An annotated and blank case report form are not available as the electronic data capture system used for this study did not generate paper versions. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Jun-2015
3357	GSK	An Open Label, Single-Dose, Five-Way Crossover Study Examining Relative Oral Bioavailabilty of Zanamivir With Bioenhancing Excipients Following Direct Release Into Mid-Small Intestine Using Gamma Scintigraphy and the InteliSite Companion Capsule in Healthy Subjects.	zanamivir	NAI107485	Influenza, Human	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=107485			Y	Y	N	Y	Y	Y	N	A reporting and analysis plan is not available for this study. A clinical study report is not available for this study because only a draft version was located; no final version found in archives. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Jun-2015
3384	GSK	U0289-402: An Open Label, 8 Week Study to Evaluate the Efficacy and Tolerability of MAXCLARITY II in Subjects with Acne	benzoyl peroxide/salicylic acid	STF114551	Acne Vulgaris	Phase 4	https://www.gsk-studyregister.com/en/trial-details/?id=114551	http://clinicaltrials.gov/show/NCT01706263		N	Y	Y	Y	Y	Y	N	An analysis-ready dataset and reporting and analysis plan are not available for this study.	1-Jul-2015
3385	GSK	Phase 1 study of skin irritation	calcipotriol, calcipotriene	STF114731	Psoriasis	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=114731			Y	N	Y	Y	Y	Y	Y	An annotated case report form is not available for this study. A blank case report form will be provided. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Jul-2015
3386	GSK	A Randomized, Double-Blind, Multi-Center Study Comparing the Effects of Carvedilol Modified Release Formulation (COREG MR) and Atenolol in Combination with and Compared to an Angiotensin Converting Enzyme Inhibitor (Lisinopril) on Left Ventricular Mass Regression in Hypertensive Patients with Left Ventricular Hypertrophy (LVH).	carvedilol	COR100216	Hypertrophy, Left Ventricular	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=COR100216	http://clinicaltrials.gov/show/NCT00108082		Y	Y	Y	Y	Y	Y	Y		1-Jul-2015
3387	GSK	A Randomized, Double-Blind, Multi-Center Study Comparing the Effects of Carvedilol Phosphate Modified Release Formulation (COREG- MR) with Metoprolol Succinate (TOPROL XL) on the Lipid Profile in Normolipidemic, or Mildly Dyslipidemic Hypertensive Patients	carvedilol	COR103561	Hypertension	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=COR103561	http://clinicaltrials.gov/show/NCT00273052		Y	Y	Y	Y	Y	Y	Y		1-Jul-2015
3388	GSK	A Randomized, Double-blind, Positive-Controlled, Multicenter Study Comparing the Efficacy of Carvedilol Phosphate Modified Release Formulation (COREG MR) and Metoprolol Succinate Extended Release (TOPROL-XL) on the Reduction of Microalbuminuria in Patients with Hypertension and Microalbuminuria	carvedilol	COR103560	Heart failure, Congestive and Microalbuminuria	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=COR103560	http://clinicaltrials.gov/show/NCT00123903	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000034-12	Y	Y	Y	Y	Y	Y	Y		1-Jul-2015
3389	GSK	Open, 1-year, phase III, immunogenicity follow-up of subjects who previously received GSK Biologicals’ dTpa-IPV vaccine or GSK Biologicals’ dTpa (BoostrixTM) and Pasteur Mérieux’s IPV vaccine (IPV Mérieux() administered separately, at 4 to 8 years of age in study 711866/001 (dTpa-IPV-001)	Combined Reduced Antigen Content Diphtheria, Tetanus, Acellular Pertussis Vaccine	711866/005 (dTpa-IPV-005, one year follow-up of dTpa-IPV-001)	Acellular pertussis; Diphtheria; Tetanus	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=711866/005			Y	N	Y	Y	Y	Y	N	An annotated case report form is not available for this study. A blank case report form will be provided. A reporting and analysis plan is not available for this study. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Mar-2015
3390	GSK	A Two-Part, Open-label, Sequential, Double Cohort, Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Rosuvastatin when Co administered with Darapladib in Healthy Adult Subjects	darapladib	LPL115677	Atherosclerosis	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=115677	http://clinicaltrials.gov/show/NCT01751074		Y	Y	Y	Y	Y	Y	Y		1-Jul-2015
3391	GSK	A multi-centre, randomised, double-blind, placebo-controlled, parallel-group study to investigate the effect of the Lp-PLA2 inhibitor SB-480848 (40, 80mg od) on carotid plaque composition in patients with carotid artery disease and planned carotid endarterectomy, stratified for statin use and gender, after 14+/-4 days treatment	darapladib	LPL480848/010	Atherosclerosis	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=480848/010	http://clinicaltrials.gov/show/NCT01916720		Y	Y	Y	Y	Y	Y	Y		1-Jul-2015
3392	GSK	A Study to Evaluate the Effect of Steady-State New Chemical Entity (NCE) on the Single-Dose Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Warfarin in Healthy Subjects	darapladib	480848/013	Atherosclerosis	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=480848/013			Y	N	Y	Y	Y	Y	Y	An annotated and blank case report form are not available as the electronic data capture system used for this study did not generate paper versions. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Jul-2015
3393	GSK	A multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose-ranging study of SB-480848, an oral lipoprotein-associated phospholipase A2 (Lp-PLA2) inhibitor, in subjects with stable coronary heart disease (CHD) or CHD-risk equivalent to examine chronic inhibition of Lp-PLA2, eff	darapladib	LPL104884	Atherosclerosis	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=LPL104884	http://clinicaltrials.gov/show/NCT00269048	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003590-24	Y	Y	Y	Y	Y	Y	Y		1-Jul-2015
3394	GSK	An Open-Label, Non-Randomized, Pharmacokinetic and Safety Study of Multiple Oral Doses of SB-480848 in Healthy Subjects and Subjects with Moderate Hepatic Impairment	darapladib	480848/028	Atherosclerosis	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=480848/028	http://clinicaltrials.gov/show/NCT01154114		Y	Y	Y	Y	Y	Y	Y		1-Jul-2015
3395	GSK	A phase 2, multi-national, multi-centre, double masked, randomised, placebo controlled, parallel-group study to investigate the safety, tolerability, pharmacokinetics, pharmacodynamics and efficacy of darapladib administered for 3 months to adult subjects with diabetic macular edema with centre involvement	darapladib	DM2115403	Retinopathy, Diabetic	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=115403	http://clinicaltrials.gov/show/NCT01506895	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002944-28	Y	Y	Y	Y	Y	Y	Y		1-Jul-2015
3396	GSK	A Study to Evaluate the Effect of Repeat Oral Doses of SB-480848 on Platelet Function as Compared to Placebo	darapladib	LPL101597	Atherosclerosis	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=101597			Y	Y	Y	Y	Y	Y	Y	A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Jul-2015
3397	GSK	A Study to Assess the Effect of Repeat Oral Dosing of Ketoconazole on the Pharmacokinetics of Repeat Oral Dosing of SB-480848	darapladib	LPL105550	Atherosclerosis	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=105550			Y	Y	Y	Y	Y	Y	Y	A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Jul-2015
3398	GSK	Study to Estimate the Dose Proportionality of the Enteric-Coated Freebase Formulation of SB-480848	darapladib	LPL107038	Atherosclerosis	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=107038			Y	Y	Y	Y	Y	Y	Y	A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Jul-2015
3399	GSK	A Dose Rising Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Repeat Oral Doses of the Enteric-Coated Free Base Formulation of SB-480848 in Healthy Adult Subjects	darapladib	LPL107988	Atherosclerosis	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=107988			Y	Y	Y	Y	Y	Y	Y	A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Jul-2015
3400	GSK	A Study to Assess the ADMEand Absolute Bioavailability of SB-480848 in healthy subjects (3C)	darapladib	480848/015	Atherosclerosis	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=480848/015			Y	Y	Y	Y	Y	Y	Y	A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Jul-2015
3401	GSK	A Study to Evaluate the Effect of Repeat Oral Doses of Darapladib on Cardiac Conduction as Compared to Placebo and a Single Oral Dose of Moxifloxacin	darapladib	480848/035	Atherosclerosis	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=SB 480848/035	http://clinicaltrials.gov/show/NCT00411073		Y	Y	Y	Y	Y	Y	Y		1-Jul-2015
3402	GSK	A study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of single oral doses of darapladib (SB480848) in healthy Japanese male subjects	darapladib	LPL110077	Atherosclerosis	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=LPL110077	http://clinicaltrials.gov/show/NCT00551317		Y	Y	Y	Y	Y	Y	Y		1-Jul-2015
3403	GSK	A randomised, double-blind, placebo-controlled, parallel group, repeat dose study to assess the effect of SB-480848 on overall asthma control in adult subjects with persistent asthma controlled on stable, low-dose, inhaled corticosteroids	darapladib	LPL107629	Atherosclerosis	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=LPL107629	http://clinicaltrials.gov/show/NCT00368576	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002627-17	Y	Y	Y	Y	Y	Y	Y		1-Jul-2015
3404	GSK	A Study to Evaluate the Pharmacokinetics of the Enteric-Coated Micronized Free Base Formulation of Darapladib [SB-480848] and its Metabolites in Healthy Volunteers.	darapladib	LPL112498	Atherosclerosis	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=LPL112498	http://clinicaltrials.gov/show/NCT00743860		Y	Y	Y	Y	Y	Y	Y		1-Jul-2015
3405	GSK	An international, multicenter, randomized, placebo controlled, parallel-group, 1 year treatment, integrated biomarkers and imaging study in subjects with angiographically documented coronary artery disease (CHD) to examine the effects of the novel lipoprotein-associated phospholipase A2 (Lp-PLA2) inhibitor SB-480848 on intermediate cardiovascular endpoints, patient safety and tolerability	darapladib	480848/026	Atherosclerosis	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=SB-480848/026	http://clinicaltrials.gov/show/NCT00268996	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001556-20	Y	Y	Y	Y	Y	Y	Y		1-Jul-2015
3406	GSK	Study On Bioavailability And Pharmacokinetics Of Various Doses Of Testosterone Administered With And Without Dutasteride	dutasteride	TDC106218	Hypogonadism, Male	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=106218			Y	Y	Y	Y	Y	Y	Y	A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Jul-2015
3407	GSK	An open label, single dose, randomized, three period crossover study to investigate the relative bioavailability of 0.5 mg of dutasteride from soft gelatin capsules (reference) vs. soft gelatin capsules containing two investigational formulations in healthy male volunteers.	dutasteride	ARI103880	Prostatic Hyperplasia	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=103880			Y	Y	Y	Y	Y	Y	Y	A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Jul-2015
3408	GSK	An open label, single dose, randomised, three period crossover study to investigate the relative bioavailability of dutasteride softgel vs. dutasteride tablet and dutasteride softgel vs. dutasteride capsule in healthy male volunteers	dutasteride	ARI19033	Prostatic Hyperplasia	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=ARI19033			Y	Y	Y	Y	Y	Y	Y	A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Jul-2015
3409	GSK	A Randomised, Double-Blind, Placebo-Controlled, Parallel Group Study Investigating the Effects of Either 4 or 6 Weeks Dutasteride 0.5mg Daily on Peri-Operative Bleeding Following Transurethral Resection of the Prostate (TURP) in Subjects with Benign Prostatic Hyperplasia (BPH).	dutasteride	ARI40007	Prostatic Hyperplasia	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=ARI40007			N	Y	Y	Y	Y	Y	Y	An analysis-ready dataset is not available for this study. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Jul-2015
3410	GSK	A randomised, double-blind, placebo-controlled, 5-way cross incomplete block design study to investigate the relative potency of single inhaled doses of a NCE and FP on airway responsiveness to adenosine 5’-monophosphate (AMP) challenge in mild asthmatic patients	fluticasone furoate	FFA10007	Asthma	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=FFA10007			Y	Y	Y	Y	Y	Y	N	A reporting and analysis plan is not available for this study. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Jul-2015
3411	GSK	A randomised, double-blind, placebo-controlled (with rescue medication), multi-centre study to evaluate the efficacy and safety of inhaled fluticasone furoate in the treatment of persistent asthma in adults and adolescents not currently receiving inhaled corticosteroids	fluticasone furoate	FFA115283	Asthma	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=115283	http://clinicaltrials.gov/show/NCT01436071	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001901-29	Y	Y	Y	Y	Y	Y	Y		1-Jul-2015
3412	GSK	A randomised, double-blind, double-dummy, placebo controlled multi-centre study to evaluate the efficacy and safety of fluticasone furoate inhalation powder and fluticasone propionate inhalation powder in the treatment of asthma in adults and adolescents not currently treated with inhaled corticosteroids	fluticasone furoate	FFA115285	Asthma	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=115285	http://clinicaltrials.gov/show/NCT01436110	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001900-36	Y	Y	Y	Y	Y	Y	Y		1-Jul-2015
3413	GSK	A randomised, double-blind, placebo-controlled, parallel group, 14 day repeat dose study to investigate the safety, tolerability and PK of once daily inhaled GW685698 with the excipient COA administered via DISKUS in healthy subjects	fluticasone furoate	FFA10009	Asthma	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=FFA10009			Y	Y	Y	Y	Y	Y	Y	A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Jul-2015
3414	GSK	A randomised, double blind, placebo controlled, incomplete block, five-way cross-over study to investigate the effect of one week repeat dosing of a new chemical entity (NCE) and inhaled fluticasone propionate (FP) on twenty-four hour serum cortisol in healthy subjects.	fluticasone furoate	FFA103096	Asthma	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=103096		https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002364-16	Y	Y	Y	Y	Y	Y	Y	A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Jul-2015
3415	GSK	"A Comparison of Fluticasone Furoate Nasal Spray versus Oral Fexofenadine in the Treatment of Seasonal Allergic Rhinitis"	fluticasone furoate	FFU109045	Rhinitis, Allergic, Seasonal	Phase 4	https://www.gsk-studyregister.com/en/trial-details/?id=FFU109045	http://clinicaltrials.gov/show/NCT00435461	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-004885-27	Y	N	Y	Y	Y	Y	Y	An annotated case report form is not available for this study. A blank case report form will be provided.	1-Jul-2015
3416	GSK	A part-randomised, single dose, open label, 6-way cross-over study to assess the relative systemic pharmacokinetics and absolute bioavailability of GW685698X and FP (1000mg) administered via Diskhaler® in healthy male subjects	fluticasone furoate	FFA10003	Asthma	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=FFA10003			Y	Y	Y	Y	Y	Y	Y	A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Jul-2015
3417	GSK	A randomised, double-blind, placebo-controlled, six-way cross design study to investigate the effect of single inhaled doses of NCE and fluticasone propionate on airway responsiveness to adenosine 5’-monophosphate challenge in mild asthmatic patients.	fluticasone furoate	FFA10026	Asthma	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=FFA10026			Y	Y	Y	Y	Y	Y	Y	A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Jul-2015
3418	GSK	A randomised, double-blind, double dummy, placebo-controlled, parallel-group study to evaluate the efficacy and safety of GW685698X 100mcg administered once daily either in the morning or the evening and GW685698X 250mcg administered once daily in the evening all administered by inhalation via DISKHALER for 28 days in subjects with persistent bronchial asthma.	fluticasone furoate	FFA20001	Asthma	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=FFA20001	http://clinicaltrials.gov/show/NCT01499446		Y	Y	Y	Y	Y	Y	Y		1-Jul-2015
3419	GSK	An open label, part-randomised, four-way crossover, single and repeat dose study to determine the dose proportionality and absolute bioavailability of fluticasone furoate (FF) when administered as FF inhalation powder from the novel dry powder inhaler in healthy subjects	fluticasone furoate	FFA115441	Asthma	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=115441	http://clinicaltrials.gov/show/NCT01669070	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000614-11	Y	Y	Y	Y	Y	Y	Y		1-Jul-2015
3420	GSK	A randomised, double-blind, placebo-controlled, dose escalation study to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of single inhaled doses of GW685698X in healthy male subjects	fluticasone furoate	FFA10001	Asthma	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=FFA10001			Y	Y	Y	Y	Y	Y	Y	A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Jul-2015
3421	GSK	A randomised, double-blind, placebo-controlled, parallel group study to investigate the safety and tolerability and systemic pharmacokinetics and pharmacodynamics of repeat doses (500, 1000 and 2000mg) of GW685698X administered once daily for fourteen da	fluticasone furoate	FFA10002	Asthma	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=FFA10002			Y	Y	Y	Y	Y	Y	Y	A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Jul-2015
3422	GSK	A randomised, single dose, open label, 3-way cross-over study to assess the systemic pharmacokinetics of GW685698X (1000mg) administered via Diskhaler with or without charcoal and an intravenous dose (250mg) in healthy male subjects	fluticasone furoate	FFA10008	Asthma	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=FFA10008			Y	Y	Y	Y	Y	Y	Y	A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Jul-2015
3423	GSK	Study FFU108556, A Patient Preference Evaluation Study of Fluticasone Furoate Nasal Spray and FluticasonePropionate Aqueous Nasal Spray in Subjects with Allergic Rhinitis	Fluticasone furoate	FFU108556	Rhinitis, Allergic, Perennial	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=FFU108556	http://clinicaltrials.gov/show/NCT00398476		Y	Y	Y	Y	Y	Y	Y	A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Jul-2015
3424	GSK	A randomised, double-blind, double-dummy, parallel group study to evaluate the efficacy and safety of fluticasone furoate/vilanterol trifenatate (FF/VI) inhalation powder delivered once daily compared to fluticasone propionate delivered twice daily in the treatment of asthma in adolescent and adult subjects of Asian ancestry currently treated with high-strength inhaled corticosteroids or mid-strength ICS/LABA combination therapy.	fluticasone furoate/vilanterol	HZA113714	Asthma	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=113714	http://clinicaltrials.gov/show/NCT01498653		Y	Y	Y	Y	Y	Y	Y		1-Jul-2015
3425	GSK	A 12-week Study to Evaluate the 24-hour Pulmonary Function Profile of Fluticasone Furoate/Vilanterol (FF/VI) Inhalation Powder 100/25 mcg once daily Compared with Fluticasone Propionate/Salmeterol Inhalation Powder 250/50 mcg twice daily in Subjects with Chronic Obstructive Pulmonary Disease (COPD)	fluticasone furoate/vilanterol	HZC112352	Pulmonary Disease, Chronic Obstructive	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=112352	http://clinicaltrials.gov/show/NCT01323621	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023419-33	Y	Y	Y	Y	Y	Y	Y		1-Jul-2015
3426	GSK	A 12-week Study to Evaluate the 24-hour Pulmonary Function Profile of Fluticasone Furoate/Vilanterol (FF/VI) Inhalation Powder 100/25 mcg once daily Compared with Fluticasone Propionate/Salmeterol Inhalation Powder 250/50 mcg twice daily in Subjects with Chronic Obstructive Pulmonary Disease (COPD)	fluticasone furoate/vilanterol	HZC113109	Pulmonary Disease, Chronic Obstructive	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=113109	http://clinicaltrials.gov/show/NCT01323634	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023418-29	Y	Y	Y	Y	Y	Y	Y	The raw data are included within the analysis-ready data for this study and are not provided separately	1-Jul-2015
3427	GSK	A 24-week Study to Evaluate the Efficacy and Safety of Fluticasone Furoate/Vilanterol Inhalation Powder Delivered Once Daily via a Dry Powder Inhaler Compared with Placebo in Subjects of Asian Ancestry with Chronic Obstructive Pulmonary Disease	fluticasone furoate/vilanterol	HZC113684	Pulmonary Disease, Chronic Obstructive	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=113684	http://clinicaltrials.gov/show/NCT01376245		Y	Y	Y	Y	Y	Y	Y		1-Jul-2015
3428	GSK	A 12-Week Study to Evaluate the 24-Hour Pulmonary Function Profile of Fluticasone Furoate/Vilanterol (FF/VI) Inhalation Powder 100/25 mcg Once Daily Compared with Fluticasone Propionate/Salmeterol Inhalation Powder 250/50 mcg Twice Daily in Subjects with Chronic Obstructive Pulmonary Disease (COPD)	fluticasone furoate/vilanterol	RLV116974	Pulmonary Disease, Chronic Obstructive	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=116974	http://clinicaltrials.gov/show/NCT01706328	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003106-27	Y	Y	Y	Y	Y	Y	Y		1-Jul-2015
3429	GSK	An open-label, randomised, replicate, six-way crossover, single dose study to determine the bioequivalence of fluticasone furoate (FF) inhalation powder (single strip configuration) compared with FF inhalation powder (two strip configuration) and compared with FF / vilanterol (VI) inhalation powder administered via the novel dry powder inhaler.	fluticasone furoate; fluticasone furoate/vilanterol	FFA115440	Asthma	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=115440	http://clinicaltrials.gov/show/NCT01485445	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004799-12	Y	Y	Y	Y	Y	Y	Y		1-Jul-2015
3430	GSK	A multicenter, multinational, randomized, double-blind study to compare the efficacy and safety of fondaparinux sodium (Org31540/SR90107A) with dalteparin (Fragmin) in the prevention of venous thromboembolic events in high-risk abdominal surgery (PEGASUS)	fondaparinux sodium	EFC3557	Secondary prevention of Thromboembolic events; Thrombosis, Venous	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=EFC3557			Y	Y	Y	Y	Y	Y	Y	A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Jul-2015
3431	GSK	A multicenter, multinational, randomized, double-blind study of fondaparinux sodium (Org31540/SR90107A) versus placebo for the prolonged prevention of VTE in hip fracture surgery. (PENTIHFRA PLUS)	fondaparinux sodium	EFC4582	Thrombosis, Venous	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=EFC4582			Y	Y	Y	Y	Y	Y	Y	A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Jul-2015
3432	GSK	A Phase 2 Study of GSK1363089 (XL880) Administered Orally to Subjects with Metastatic Gastric Cancer	foretinib	MET111643	Neoplasms, Gastrointestinal Tract	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=MET111643	http://clinicaltrials.gov/show/NCT00725712		Y	Y	Y	Y	Y	Y	Y		1-Jul-2015
3433	GSK	A Phase 1 Dose Escalation Study of the Safety and Pharmacokinetics of GSK1363089 (Formerly XL880) Administered Orally to Subjects With Solid Tumors	foretinib	MET111647	Solid Tumours	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=MET111647	http://clinicaltrials.gov/show/NCT00742131		Y	Y	Y	Y	Y	Y	Y		1-Jul-2015
3434	GSK	A Phase 2 Study of the MET RTK Inhibitor GSK1363089 (formerly XL880) in Subjects With Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck	foretinib	MET111646	Neoplasms, Head and Neck	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=MET111646	http://clinicaltrials.gov/show/NCT00725764		Y	Y	Y	Y	Y	Y	Y		1-Jul-2015
3435	GSK	A Microdose Study to Describe the Intravenous Pharmacokinetics of [14C]-GSK2239633 in Healthy Male Subjects	GSK2239633	CC4114041	Asthma	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=114041	http://clinicaltrials.gov/show/NCT01086462	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-017584-41	Y	Y	Y	Y	Y	Y	Y		1-Jul-2015
3436	GSK	A randomised, double-blind, placebo-controlled, cross-over study to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of single ascending oral doses of GSK2239633 in healthy male subjects.	GSK2239633	CC4114660	Asthma	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=114660	http://clinicaltrials.gov/show/NCT01371812	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-024085-22	Y	Y	Y	Y	Y	Y	Y		1-Jul-2015
3437	GSK	A randomized, double-blind, placebo-controlled, parallel group study to compare GW766944 (an oral CCR3 receptor antagonist) versus placebo in patients with asthma and sputum eosinophilia.	GW766994	CRA114312	Asthma	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=114312	http://clinicaltrials.gov/show/NCT01160224		Y	Y	Y	Y	Y	Y	Y		1-Jul-2015
3438	GSK	A randomised, placebo-controlled, four-period, crossover study of 8 days repeat dosing of a new chemical entity (NCE), fluticasone propionate (200 µg od) and placebo (blinded for NCE vs placebo) to evaluate the efficacy and safety using the Vienna Challenge Chamber in subjects with allergic rhinitis.	GW799943	ODN1003	Rhinitis, Allergic, Perennial	Phase 2				N	N	N	Y	Y	Y	Y	An analysis-ready dataset is not available for this study. An annotated case report form is not available for this study. A blank case report form will be provided. A clinical study report is not available for this study because only a draft version was located; no final version found in archives. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies. There is no GSK Study Register entry for this study.	1-Jul-2015
3439	GSK	A randomised, double-blind, placebo-controlled study of topical GW870086X formulation in subjects with moderate or severe atopic dermatitis	GW870086	SSD113434	Dermatitis, Atopic	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=113434	http://clinicaltrials.gov/show/NCT01299610	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022280-35	Y	Y	Y	Y	Y	Y	Y		1-Jul-2015
3440	GSK	A randomised, double-blind (for GW870086X), placebo-controlled study of topical GW870086X formulation to explore the potential for skin thinning in healthy adult volunteers	GW870086	SSD113435	Dermatitis, Atopic	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=113435	http://clinicaltrials.gov/show/NCT01381445	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-024086-47	Y	Y	Y	Y	Y	Y	Y		1-Jul-2015
3441	GSK	A one year, parallel, placebo-controlled, double-blind, randomized study to assess the effect of monthly 150mg oral ibandronate dosing versus placebo on bone quality and strength at the proximal femur in women with osteoporosis	ibandronic acid	BON103593	Osteoporosis	Phase 4	https://www.gsk-studyregister.com/en/trial-details/?id=BON103593	http://clinicaltrials.gov/show/NCT02948881		Y	Y	Y	Y	Y	Y	Y		1-Jul-2015
3442	GSK	A PHASE 4, OPEN-LABEL STUDY TO ASSESS THE LONG-TERM SAFETY OF EXTINA (KETOCONAZOLE) FOAM, 2% IN THE TREATMENT OF SEBORRHEIC DERMATITIS	ketoconazole	STF114568	Dermatitis, Seborrheic	Phase 4	https://www.gsk-studyregister.com/en/trial-details/?id=114568	http://clinicaltrials.gov/show/NCT00703846		Y	Y	Y	Y	Y	Y	Y		1-Jul-2015
3443	GSK	A Multicenter, Open-Label, Pilot Study of Lamotrigine as Adjunctive Therapy and Monotherapy in Patients with Epilepsy and Comorbid Depressive Symptoms	lamotrigine	LAM40117	Epilepsy	Phase 4	https://www.gsk-studyregister.com/en/trial-details/?id=LAM40117			N	Y	Y	Y	Y	Y	Y	An analysis-ready dataset is not available for this study. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Jul-2015
3444	GSK	An Assessment of Behavioral Changes Associated with Lamotrigine and Levetiracetam in Patients with Epilepsy	lamotrigine	LAM40124	Epilepsy	Phase 4	https://www.gsk-studyregister.com/en/trial-details/?id=LAM40124			N	Y	Y	Y	Y	Y	N	An analysis-ready dataset and reporting and analysis plan are not available for this study. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Jul-2015
3445	GSK	Protocol SB-275833/030 – Studies 030A and 030B: Two Identical Double-blind, Double-dummy, Multicenter, Comparative Phase III Studies of the Safety and Efficacy of Topical 1% SB-275833, Applied Twice Daily, versus Oral Cephalexin, 500mg in Adults, or 12.5mg/kg (250mg/5ml) in Children, Twice Daily…	retapamulin	275833/030	Skin Infections, Bacterial	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=275833/030			Y	Y	Y	Y	Y	Y	Y	A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Jul-2015
3446	GSK	A Randomized, Double-blind, Double-Dummy, Multicenter, Non-inferiority Phase III Study to Assess the Safety and Efficacy of Topical SB-275833 Ointment, 1%, Applied Twice Daily	retapamulin	275833/032	Skin Infections, Bacterial	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=275833/032		https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000784-97	Y	Y	Y	Y	Y	Y	Y	A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Jul-2015
3447	GSK	"A Randomised, Double-blind, Multicentre, Superiority Placebo-controlled, Phase III Study to Assess the Efficacy and Safety of Topical 1% SB-275833 Ointment versus Placebo Ointment Applied Twice Daily for 5 days in the Treatment of Adults and Paediatric Subjects with Impetigo."	retapamulin	TOC103469	Impetigo	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=TOC103469	http://clinicaltrials.gov/show/NCT00133848	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-004406-24	Y	Y	Y	Y	Y	Y	Y		1-Jul-2015
3448	GSK	See Detailed Description	retapamulin	TOC100224	Skin Infections, Bacterial	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=TOC100224	http://clinicaltrials.gov/show/NCT00133874	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-004439-70	Y	Y	Y	Y	Y	Y	Y		1-Jul-2015
3450	GSK	A 4-Week, Randomized, Double-Blind, Cohort Study to Evaluate the Safety and Tolerability of Converting from Ropinirole Immediate Release (IR) to Ropinirole Extended Release (XR) Formulation in Patients with Restless Legs Syndrome (RLS)	ropinirole	ROX104805	Restless Legs Syndrome	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=ROX104805	http://clinicaltrials.gov/show/NCT00256854		Y	Y	Y	Y	Y	Y	Y	A follow-on study 101468/206 was conducted.	1-Jul-2015
3451	GSK	An Open-Label Extension Study with REQUIP (ropinirole) CR for Subjects from Studies 101468/165, 101468/168 and 101468/169	ropinirole	101468/248	Parkinson Disease	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=101468/248	http://clinicaltrials.gov/show/NCT00632736		Y	Y	Y	Y	Y	Y	Y	This is an extension study to studies 101468/165, 101468/168 and 101468/169	1-Jul-2015
3452	GSK	A Multicentre, Double-Blind, Placebo Controlled, Parallel Group Comparative Study to Evaluate the Efficacy, Safety and Tolerability of Rosiglitazone with Concurrent Sulphonylurea therapy, When Administered to Patients with Type 2 Diabetes Mellitus.	rosiglitazone	49653/015	Diabetes Mellitus, Type 2	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=49653/015			Y	Y	Y	Y	Y	Y	N	Extension study 49653/009 was conducted. A reporting and analysis plan is not available for this study. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Jul-2015
3453	GSK	A Multicentre, Double-Blind, Parallel Group Comparative Study to Evaluate the Efficacy, Safety and Tolerability of Rosiglitazone vs. Glibenclamide Therapy, When Administered to Patients with Type 2 Diabetes Mellitus.	rosiglitazone	49653/020	Diabetes Mellitus, Type 2	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=49653/020			N	N	Y	Y	Y	Y	N	Extension study 49653/009 was conducted. An analysis-ready dataset and reporting and analysis plan are not available for this study. An annotated case report form is not available for this study. A blank case report form will be provided. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Jul-2015
3454	GSK	A 26-week Randomized, Double-Blind, Double-Dummy, Multicentered Study to Evaluate the Efficacy, Safety and Tolerability of Rosiglitazone when Administered to Patients with Non-Insulin Dependent Diabetes Mellitus (NIDDM) who are Inadequately Controlled on a Maximal Dose (20 mg/day) of Glyburide.	rosiglitazone	49653/079	Diabetes Mellitus, Type 2	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=49653/079			Y	Y	Y	Y	Y	Y	N	Extension study 49653/112 was conducted. A reporting and analysis plan is not available for this study. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Jul-2015
3455	GSK	A 26-week Randomized, Double-Blind, Multicenter, Placebo-Controlled Study to Evaluate the Efficacy, Safety and Tolerability of Rosiglitazone when Administered Once Daily to Patients with Non-Insulin Dependent Diabetes Mellitus (NIDDM) who are Inadequately Controlled on…	rosiglitazone	49653/096	Diabetes Mellitus, Type 2	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=49653/096			Y	Y	Y	Y	Y	Y	N	Extension study 49653/112 was conducted. A reporting and analysis plan is not available for this study. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Jul-2015
3456	GSK	A 26-Week Randomized, Double-Blind, Multicenter Study to Evaluate the Safety, Efficacy, and Tolerability of BRL 49653C when Administered Twice Daily to Patients with Non-Insulin Dependent Diabetes Mellitus (NIDDM) who are Inadequately Controlled on Insulin Monotherapy	rosiglitazone	49653/082	Diabetes Mellitus, Type 2	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=49653/082			N	N	Y	Y	Y	Y	N	Extension study 49653/114 was conducted. An analysis-ready dataset and reporting and analysis plan are not available for this study. An annotated case report form is not available for this study. A blank case report form will be provided. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Jul-2015
3457	GSK	A 26-week Randomised, Double-Blind, Multicenter Study to Evaluate the Safety, Efficacy, and Tolerability of Rosiglitazone when Administered Once Daily to Patients with Type 2 Diabetes who are Inadequately Controlled on Insulin Monotherapy	rosiglitazone	49653/095	Diabetes Mellitus, Type 2	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=49653/095			N	N	Y	Y	Y	Y	N	Extension study 49653/114 was conducted. An analysis-ready dataset and reporting and analysis plan are not available for this study. An annotated case report form is not available for this study. A blank case report form will be provided. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Jul-2015
3458	GSK	A study to assess the effect of food and time of dosing on the pharmacokinetics of Avandamet™ (rosiglitazone maleate 8 mg/metformin HCl 1000 mg administered as 2 ' 4/500) Glucophage XR 1000 mg (given as metformin HCl 2 ' 500 mg) and Avandia™ (rosiglitazone maleate 8 mg) in healthy adult subjects.	rosiglitazone/metformin	712753/011	Diabetes Mellitus, Type 2	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=712753/011			N	N	Y	Y	Y	Y	Y	An analysis-ready dataset is not available for this study. An annotated case report form is not available for this study. A blank case report form will be provided. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Jul-2015
3459	GSK	A 28-Week, Randomized, Double-Blind, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Oral Formulation X in Subjects with Type 2 Diabetes Mellitus	rosiglitazone/metformin	AVM100344	Diabetes Mellitus, Type 2	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=100344			Y	N	Y	Y	Y	Y	N	An analysis-ready dataset and reporting and analysis plan are not available for this study. An annotated case report form is not available for this study. A blank case report form will be provided. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Jul-2015
3460	GSK	A randomized, parallel group, double-blind, multi-center study comparing the efficacy and safety of AVANDAMET and metformin after 80 weeks of treatment.	rosiglitazone/metformin	AVT105913	Diabetes Mellitus, Type 2	Phase 4	https://www.gsk-studyregister.com/en/trial-details/?id=AVT105913	http://clinicaltrials.gov/show/NCT00386100		Y	Y	Y	Y	Y	Y	Y		1-Jul-2015
3461	GSK	An open-label trial to evaluate the safety and efficacy of fixed dose rosiglitazone/metformin combination therapy in poorly-controlled subjects with type 2 diabetes mellitus	rosiglitazone/metformin	712753/004	Diabetes Mellitus, Type 2	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=712753/004	http://clinicaltrials.gov/show/NCT00067951		Y	Y	Y	Y	Y	Y	Y		1-Jul-2015
3462	GSK	A study to assess the steady state pharmacokinetics of repeat oral doses of AVANDAMET XR (combination formulation of rosiglitazone 8mg/metformin 1000mg) and AVANDAMET IR (rosiglitazone 4mg/metformin 500mg) in healthy subjects	rosiglitazone/metformin	712753/014	Diabetes Mellitus, Type 2	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=712753/014			N	Y	Y	Y	Y	Y	Y	An analysis-ready dataset is not available for this study. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Jul-2015
3463	GSK	A single centre, randomised, double-blind, placebo-controlled, crossover, pilot study to determine the efficacy and safety of 400 µg and 200 µg doses of Ventolin ™ salbutamol inhaler versus placebo for the treatment of smoking related cough.	salbutamol	SBM20002	Asthma	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=SBM20002			N	N	Y	Y	Y	Y	Y	An analysis-ready dataset, an annotated case report form, and a blank case report form are not available for this study. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Jul-2015
3464	GSK	A single centre, randomised, double blind, double dummy, cross-over study to measure the topical and systemic effects of Salbutamol delivered by the Turbuhaler inhaler compared with the Diskus dry powder inhaler at high and low flow rates in adult patients with reversible obstructive airways disease.	salbutamol	SBM40003	Asthma	Phase 4	https://www.gsk-studyregister.com/en/trial-details/?id=SBM40003			N	N	Y	Y	Y	Y	N	An analysis-ready dataset, an annotated case report form, and a blank case report form, and a reporting and analysis plan are not available for this study. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Jul-2015
3465	GSK	A 4-Week Randomized Cross-Over Study to Evaluate Daily Lung Function Following the Administration of Albuterol/Salbutamol and Ipratropium in Subjects with Chronic Obstructive Pulmonary Disease	salbutamol	DB2114956	Pulmonary Disease, Chronic Obstructive	Phase 4	https://www.gsk-studyregister.com/en/trial-details/?id=114956	http://clinicaltrials.gov/show/NCT01691482	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000384-24	Y	Y	Y	Y	Y	Y	Y		1-Jul-2015
3466	GSK	A Multicenter, Randomized, Double-Blind, Double-Dummy, Parallel-Group, 8-Week Comparison of Salmeterol Xinafoate Versus Ipratropium Bromide Versus Salmeterol Xinafoate Plus Ipratropium Bromide Versus Placebo in Subjects With Chronic Obstructive Pulmonary Disease	salmeterol	SMS40314	Pulmonary Disease, Chronic Obstructive	Phase 4	https://www.gsk-studyregister.com/en/trial-details/?id=SMS40314			N	Y	Y	Y	Y	Y	Y	An analysis-ready dataset is not available for this study. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Jul-2015
3467	GSK	A Multicenter, Randomized, Double-Blind, Double-Dummy, Parallel Group, 8-Week Comparison of Salmeterol Xinafoate Versus Ipratropium Bromide Versus Salmeterol Xinafoate Plus Ipratropium Bromide Versus Placebo in Subjects With Chronic Obstructive Pulmonary Disease	salmeterol	SMS40315	Pulmonary Disease, Chronic Obstructive	Phase 4	https://www.gsk-studyregister.com/en/trial-details/?id=SMS40315			N	N	Y	Y	Y	Y	Y	An analysis-ready dataset is not available for this study. An annotated case report form is not available for this study. A blank case report form will be provided. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Jul-2015
3468	GSK	A Multi-Center, Randomized, Double-Blind, Double-Dummy, Parallel-Group Comparison of Salmeterol Xinafoate Inhalation Aerosol Versus Ipratropium Bromide and Albuterol Sulfate Inhalation Aerosol in Subjects With Chronic Obstructive Pulmonary Disease	salmeterol	SMS40321	Pulmonary Disease, Chronic Obstructive	Phase 4	https://www.gsk-studyregister.com/en/trial-details/?id=SMS40321			Y	Y	Y	Y	Y	Y	Y	A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Jul-2015
3469	GSK	A randomized, double-blind, placebo-controlled study in healthy volunteers to examine the safety, tolerability and pharmacokinetics of a) single, ascending and b) twice-daily repeat doses of intranasal SB-705498	SB705498	VR1111610	Rhinitis	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=111610	http://clinicaltrials.gov/show/NCT00907933	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-005174-12	Y	Y	Y	Y	Y	Y	Y		1-Jul-2015
3470	GSK	A randomised, double-blind, placebo-controlled study to assess the effect of oral, single dose SB-705498 in a validated intranasal capsaicin challenge model in healthy volunteers	SB705498	VR1111611	Rhinitis	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=111611	http://clinicaltrials.gov/show/NCT00731250	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000726-39	Y	Y	Y	Y	Y	Y	Y		1-Jul-2015
3471	GSK	A randomized, double blind, placebo controlled study to assessthe effect of intranasal single dose SB-705498 on the response tointranasal capsaicin challenge in non-allergic rhinitis patients	SB705498	VR1111925	Rhinitis	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=111925	http://clinicaltrials.gov/show/NCT01439308	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-012637-30	Y	Y	Y	Y	Y	Y	Y		1-Jul-2015
3472	GSK	An open-label, randomized, three-period crossover study to demonstrate the bioequivalence of sumatriptan 4 mg STATdose to IMITREX™ 6 mg STATdose after dose-normalization, and to assess the relative bioavailability of 4 mg sumatriptan injected using the STATdose device compared to 4 mg sumatripta ...	sumatriptan	SUM102146	Migraine Disorders	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=102146			Y	Y	Y	Y	Y	Y	Y	A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Jul-2015
3473	GSK	An open label, single dose, randomised, parallel group pharmacokinetic study to evaluate a combination product containing naproxen sodium and sumatriptan in adolescent subjects with migraine and healthy adult subjects administered at three doses.	sumatriptan	TXA108504	Migraine Disorders	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=108504	http://clinicaltrials.gov/show/NCT00989625		Y	Y	Y	Y	Y	Y	Y		1-Jul-2015
3474	GSK	A randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and tolerability of TREXIMA* (sumatriptan succinate/naproxen sodium) for a single moderate or severe headache in adults diagnosed with probable migraine without aura (ICHD-II 1.6.1) (*TREXIMET)	sumatriptan/naproxen	TXA107563	Migraine, Without Aura	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=TXA107563	http://clinicaltrials.gov/show/NCT00387881		Y	Y	Y	Y	Y	Y	Y		1-Jul-2015
3475	GSK	Open-Label, Placebo-Controlled, Parallel Group Study in Healthy Volunteers to Evaluate the Effects of MT 400 Tablets or Naproxen Sodium Tablets on Chromosomal Aberrations (CA) in Peripheral Blood Lymphocytes	sumatriptan/naproxen	TXA113014	Migraine Disorders	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=MT400-108	http://clinicaltrials.gov/show/NCT00596245		Y	Y	Y	Y	Y	Y	Y		1-Jul-2015
3476	GSK	A study to evaluate the bioavailability of combo formulation, each of its components and currently marketed versions of the components in healthy volunteers.	sumatriptan/naproxen	MT400-101 (112490)	Migraine Disorders	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=MT400-101 (112490)			Y	Y	Y	Y	Y	N	Y	A raw dataset is not available for this study. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Jul-2015
3477	GSK	A study to evaluate the effect of food on the bioavailability of a sumatriptan succinate and naproxen sodium combination tablet in healthy volunteers.	sumatriptan/naproxen	MT400-102 (112491)	Migraine Disorders	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=MT400-102 (112491)			Y	Y	Y	Y	Y	N	Y	A raw dataset is not available for this study. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Jul-2015
3478	GSK	A study to evaluate the bioavailability of different dose combinations of sumatriptan succinate and naproxen sodium 500 mg in healthy volunteers.	sumatriptan/naproxen	MT400-103 (112492)	Migraine Disorders	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=MT400-103 (112492)			Y	Y	Y	Y	Y	N	Y	A raw dataset is not available for this study. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Jul-2015
3479	GSK	An open-label study to investigate the effect of migraine attacks on the pharmacokinetics of a single dose of Treximet™ (formerly known as Trexima™) administered both during and outside of a migraine attack	sumatriptan/naproxen	MT400-104 (112493)	Migraine Disorders	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=MT400-104 (112493)			Y	Y	Y	Y	Y	N	Y	A raw dataset is not available for this study. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Jul-2015
3480	GSK	A study to evaluate the pharmacokinetics and tolerability of two single Treximet™ (formerly known as Trexima™) tablets (administered two hours apart) in healthy volunteers.	sumatriptan/naproxen	MT400-105 (112494)	Migraine Disorders	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=MT400-105 (112494)			Y	Y	Y	Y	Y	N	Y	A raw dataset is not available for this study. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Jul-2015
3481	GSK	TXA107979: A Randomized, Multicenter, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of a Combination Product Containing Sumatriptan and Naproxen Sodium for the Acute Treatment of Migraine in Adolescents	sumatriptan/naproxen	TXA107979	Migraine Disorders	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=107979	http://clinicaltrials.gov/show/NCT00843024		Y	Y	Y	Y	Y	Y	Y		1-Jul-2015
3482	GSK	Study TXA107977, a Long-Term Safety Study of a Combination Product Containing Sumatriptan Succinate and Naproxen Sodium for the Treatment of Migraine in Adolescents	sumatriptan/naproxen	TXA107977	Migraine Disorders	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=TXA107977	http://clinicaltrials.gov/show/NCT00488514		Y	Y	Y	Y	Y	Y	Y		1-Jul-2015
3483	GSK	An open-label, randomized, 3-period crossover study to evaluate sumatriptan pharmacokinetics for a TREXIMA™ (sumatriptan succinate / naproxen sodium) Tablet followed by IMITREX® (sumatriptan succinate) Injection 4mg administered using the IMITREX STATdose System® and a TREXIMA tablet followed by IMI	sumatriptan/naproxen	TRX103629	Migraine Disorders	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=103629	http://clinicaltrials.gov/show/NCT00875784		Y	Y	Y	Y	Y	Y	Y		1-Jul-2015
3484	GSK	A Study of Combination Product (sumatriptan succinate and naproxen sodium) in Migraine Subjects Who Report Poor Response or Intolerance to Short Acting Triptans (Study 1 of 2)	sumatriptan/naproxen	TRX106571	Migraine Disorders	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=TRX106571	http://clinicaltrials.gov/show/NCT00383162		Y	Y	Y	Y	Y	Y	Y		1-Jul-2015
3485	GSK	A Study of Combination Product (sumatriptan succinate and naproxen sodium) in Migraine Subjects Who Report Poor Response or Intolerance to Short Acting Triptans (Study 2 of 2)	sumatriptan/naproxen	TRX106573	Migraine Disorders	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=TRX106573	http://clinicaltrials.gov/show/NCT00382993		Y	Y	Y	Y	Y	Y	Y		1-Jul-2015
3486	GSK	A Randomized, Double-Blind, Multi-Center, Placebo-Controlled, Cross-Over Study to Determine the Consistency of Response for TREXIMA™ (sumatriptan 85mg/naproxen sodium 500mg)*, Administered During the Mild Pain Phase for the Acute Treatment of Multiple Migraine Attacks	sumatriptan/naproxen	TRX103632	Migraine Disorders	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=TRX103632	http://clinicaltrials.gov/show/NCT00240630		Y	Y	Y	Y	Y	Y	Y	A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Jul-2015
3487	GSK	A randomized, double-blind, multi-center, placebo-controlled, cross-over study to determine the consistency of response for Trexima* (sumatriptan 85mg/naproxen sodium 500mg) administered during the mild pain phase for the acute treatment of multiple migraine attacks (*Treximet)	sumatriptan/naproxen	TRX103635	Migraine Disorders	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=TRX103635	http://clinicaltrials.gov/show/NCT00240617		Y	Y	Y	Y	Y	Y	Y		1-Jul-2015
3488	GSK	An Open Label, Single Dose, Parallel Group Study to Evaluate Absorption and Transit Characteristics of TREXIMA and RELPAX in Patients Inside and Outside of an Acute Migraine Attack.	sumatriptan/naproxen	TRX105848	Migraine Disorders	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=TRX105848	http://clinicaltrials.gov/show/NCT00385008		Y	Y	Y	Y	Y	Y	Y		1-Jul-2015
3489	GSK	A randomized, double-blind, single migraine attack, placebo -controlled, patallel-group multicenter study to evaluate the efficacy and tolerability or Trexima (sumatriptan succinate/naproxen sodium) tablets vs placebo when administered during the mild pain phase of menstrual migraine in women with dysmenorrhea	sumatriptan/naproxen	TRX105850	Migraine Disorders	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=TRX105850	http://clinicaltrials.gov/show/NCT00329459		Y	Y	Y	Y	Y	Y	Y		1-Jul-2015
3490	GSK	See Detailed Description	sumatriptan/naproxen	TRX105852	Migraine Disorders	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=TRX105852	http://clinicaltrials.gov/show/NCT00329355		Y	Y	Y	Y	Y	Y	Y		1-Jul-2015
3491	GSK	A randomized, double-blind, parallel group, placebo-controlled, single-attack evaluation of the efficacy and tolerability of TREXIMA™ (sumatriptan 85mg/naproxen sodium 500mg)* tablets vs placebo when administered during the mild pain phase of a migraine	sumatriptan/naproxen	TRX101998	Migraine Disorders	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=101998			Y	Y	Y	Y	Y	Y	N	A reporting and analysis plan is not available for this study. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Jul-2015
3492	GSK	A randomized, double-blind, parallel group, placebo-controlled, single-attack evaluation of the efficacy and tolerability of TREXIMA™ (sumatriptan 85mg/naproxen sodium 500mg)* tablets vs placebo when administered during the mild pain phase of a migraine	sumatriptan/naproxen	TRX101999	Migraine Disorders	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=101999			Y	Y	Y	Y	Y	Y	N	A reporting and analysis plan is not available for this study. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Jul-2015
3493	GSK	A Double-Blind, Multicenter, Randomized, Placebo-Controlled Single Dose Study to Evaluate the Safety and Efficacy of TREXIMA™* in the Acute Treatment of Migraine Headaches	sumatriptan/naproxen	TXA112495	Migraine Disorders	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=112495			Y	Y	Y	Y	Y	Y	Y	A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Jul-2015
3494	GSK	A Double-Blind, Multicenter, Randomized, Placebo-Controlled Single Dose Study to Evaluate the Safety and Efficacy of TREXIMA™*in the Acute Treatment of Migraine Headaches	sumatriptan/naproxen	TXA112496	Migraine Disorders	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=112496			Y	Y	Y	Y	Y	Y	Y	A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Jul-2015
3495	GSK	An Open-Label, Repeat Dose Study of the Safety of Combo Formulation in the Treatment of Multiple Episodes of Acute Migraine Over 12 Months.	sumatriptan/naproxen	TXA112497	Migraine Disorders	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=112497			Y	Y	Y	Y	Y	Y	Y	A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Jul-2015
3496	GSK	An open-label, randomized, single-dose, 2-period crossover study to evaluate sumatriptan pharmacokinetics for a TREXIMA™(sumatriptan 85mg and naproxen sodium 500mg)*, Tablet compared with an IMITREX® (sumatriptan) 100mg Tablet	sumatriptan/naproxen	TRX106396	Migraine Disorders	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=106396			Y	Y	Y	Y	Y	Y	Y	A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Jul-2015
3497	GSK	Phase II Multicenter Study of CVP Followed by Iodine-131 Anti-B1 Antibody for subjects with Untreated Low-Grade Non Hodgkin's Lymphoma.	tositumomab	BEX104514	Lymphoma, Non-Hodgkin	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=104514	http://clinicaltrials.gov/show/NCT01663714		Y	Y	Y	Y	Y	Y	Y		1-Jul-2015
3498	GSK	A phase I, dose-escalation, open label, multicenter study of Iodine-131 anti-B1 antibody for intermediate- and high-risk B-cell chronic lymphocytic leukemiaNote: Extensive searching has revealed that no clinical study report is available for this study.	tositumomab	BEX104510	Leukaemia, Lymphocytic, Chronic	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=CP-98-018			Y	Y	Y	Y	Y	Y	Y	A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Jul-2015
3499	GSK	Phase I, Dose-Escalation Study of Iodine-131 Anti-B1 Antibody for Patients with Previously Treated Non Hodgkin’s Lymphoma With More Than 25% Bone Marrow Involvement	tositumomab	BEX104512	Lymphoma, Non-Hodgkin	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=104512	http://clinicaltrials.gov/show/NCT00992758		Y	Y	Y	Y	Y	Y	Y		1-Jul-2015
3500	GSK	Multicenter, Phase II Dosimetry/Validation Study of 131Iodine–Anti B1 (Murine) Radioimmunotherapy for Chemotherapy Refractory Low Grade B Cell Lymphomas and Low Grade Lymphomas that Have Transformed to Higher Grade Histologies	tositumomab	BEX104731	Lymphoma, Non-Hodgkin	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=104731	http://clinicaltrials.gov/show/NCT01224821		Y	Y	Y	Y	Y	Y	Y		1-Jul-2015
3501	GSK	Fludarabine monophosphate followed by Iodine I 131 Tositumomab for untreated low-grade and follicular non-Hodgkin's lymphoma	tositumomab	393229/023	Lymphoma, Non-Hodgkin	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=393229/023	http://clinicaltrials.gov/show/NCT00933335		N	Y	Y	Y	Y	Y	Y	An analysis-ready dataset is not available for this study.	1-Jul-2015
3502	GSK	Retreatment Study of Patients with Non-Hodgkin's Lymphoma Who Have Previously Responded to Iodine-131 Anti B1 Antibody	tositumomab	393229/010	Lymphoma, Non-Hodgkin	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=393229/010	http://clinicaltrials.gov/show/NCT00938041		Y	Y	Y	Y	Y	Y	Y		1-Jul-2015
3503	GSK	A single-blind, non-randomized pharmacokinetic and safety study of single dose of GSK573719 and GSK573719 + GW642444 combination in healthy subjects and in subjects with severe renal impairment	umeclidinium bromide/vilanterol	DB2114636	Pulmonary Disease, Chronic Obstructive	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=114636	http://clinicaltrials.gov/show/NCT01571999	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005453-31	Y	Y	Y	Y	Y	Y	Y		1-Jul-2015
3510	Astellas	A Randomized, Double-blind, Parallel, Placebo-controlled, Phase 4, Multicenter Study to Assess Efficacy and Safety of VESIcare® (Solifenacin Succinate) to Improve Urinary Continence of Subjects After Robotic Assisted Radical Prostatectomy	solifenacin succinate	905-UC-050	Urinary Incontinence	Phase 4	https://www.clinicaltrials.astellas.com/study/?pid=905-UC-050	https://clinicaltrials.gov/ct2/show/NCT01371994		Y	Y	Y	Y	Y	Y	Y	Population: subjects who are incontinent after Robotic Assisted Radical Prostatectomy	1-Aug-2015
3516	GSK	An open-label, randomized, single dose, three-way crossover study to determine the comparative bioavailability of two fixed dose combination tablet formulations of amlodipine (5mg) and losartan (100mg) in healthy adult male and female Subjects under fasting conditions	amlodipine/losartan	AML116797	Hypertension	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=116797	http://clinicaltrials.gov/show/NCT01648231		Y	Y	Y	Y	Y	Y	Y		1-Aug-2015
3517	GSK	An Open-Label, 12-Week Study to Evaluate the Efficacy and Safety of the Acne System (Benzoyl Peroxide 2.5%, Salicylic Acid 0.5%) in Subjects with Acne	benzoyl peroxide/salicylic acid	STF115576	Acne Vulgaris	Phase 4	https://www.gsk-studyregister.com/en/trial-details/?id=115576	http://clinicaltrials.gov/show/NCT01446237		N	Y	Y	Y	Y	Y	Y	An analysis-ready dataset is not available for this study.	1-Aug-2015
3518	GSK	A Single-Center, Evaluator-Blinded, Randomized, Placebo-Controlled, Phase 1 Clinical Trial Evaluating the Photoallergic Potential of Topically Applied EF Calcipotriene Foam, 0.005% in Healthy Volunteers	calcipotriol, calcipotriene	STF114739	Psoriasis	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=114739			Y	N	Y	Y	Y	Y	Y	An annotated case report form is not available for this study. A blank case report form will be provided. This study was not originally sponsored by GSK. A link to ClinicalTrials.gov and an NCTID number are not available for this study.	1-Aug-2015
3519	GSK	A Single-Center, Evaluator-Blinded, Randomized, Placebo-Controlled, Phase 1 Clinical Trial Evaluating the Phototoxic Potential of Topically Applied EF Calcipotriene Foam, 0.005% in Healthy Volunteers	calcipotriol, calcipotriene	STF114740	Psoriasis	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=114740			Y	N	Y	Y	Y	Y	Y	An annotated case report form is not available for this study. A blank case report form will be provided. This study was not originally sponsored by GSK. A link to ClinicalTrials.gov and an NCTID number are not available for this study.	1-Aug-2015
3520	GSK	A Multicenter, Randomized, Double-Blind, Phase 3 Study of the Safety and Efficacy of Emulsion Formulation U0267 , versus Vehicle Foam in Subjects with Plaque-type Psoriasis	calcipotriol, calcipotriene	STF114742	Psoriasis	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=114742	http://clinicaltrials.gov/show/NCT00689481		Y	N	Y	Y	Y	Y	Y	An annotated case report form and a blank case report form are not available for this study.	1-Aug-2015
3521	GSK	A study to determine the bioequivalence of reformulated 125mg/5mL cefuroxime axetil oral suspension (CAOS) to standard marketed 125mg/5mL suspension at a dose of 250mg.	cefuroxime axetil	CAE10004	Infections, Bacterial	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=CAE10004			N	N	Y	Y	Y	Y	Y	An analysis-ready dataset is not available for this study. An annotated case report form is not available for this study. A blank case report form will be provided. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Aug-2015
3522	GSK	A study to determine the bioequivalence of reformulated 250mg/5mL cefuroxime axetil oral suspension (CAOS) to standard marketed 250mg/5mL suspension.	cefuroxime axetil	CAE10005	Infections, Bacterial	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=CAE10005			N	N	Y	Y	Y	Y	Y	An analysis-ready dataset is not available for this study. An annotated case report form is not available for this study. A blank case report form will be provided. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Aug-2015
3523	GSK	A Phase II Clinical Study of SB-480848 in Dyslipidemic Patients- A multicenter, randomized, double-blind, placebo-controlled study of SB-480848 to evaluate the Efficacy and Safety -	darapladib	LPL110118	Atherosclerosis	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=LPL110118	http://clinicaltrials.gov/show/NCT00734032		Y	Y	Y	Y	N	Y	Y	A protocol is not available for this study because an English language version was not created.	1-Aug-2015
3524	GSK	A 28 day, double blind, placebo-controlled, parallel-group dose-ranging phase IIA to examine the safety, tolerability and effects of SB-480848 on LP-PLA2 activity in dyslipidemic patients	darapladib	480848/005	Atherosclerosis	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=480848/005			Y	Y	Y	Y	Y	Y	Y	A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Aug-2015
3525	GSK	The Effect of SB-480848 on the Pharmacokinietics of Digoxin in healthy subjects	darapladib	480848/014	Atherosclerosis	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=480848/014			N	N	Y	Y	Y	Y	Y	An analysis-ready dataset is not available for this study. An annotated case report form is not available for this study. A blank case report form will be provided. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Aug-2015
3526	GSK	A Dose Ranging Study to Evaluate the Pharmacokinetics of an SB480848 Freebase Enteric Coated Formulation	darapladib	LPL101582	Atherosclerosis	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=101582			N	N	Y	Y	Y	Y	Y	An analysis-ready dataset is not available for this study. An annotated case report form is not available for this study. A blank case report form will be provided. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Aug-2015
3527	GSK	A Study to Assess the Effects of Food and Repeat Dosing of Esomeprazole on the Pharmacokinetics of a Single Dose of Freebase Enteric Coated SB480848	darapladib	LPL101560	Atherosclerosis	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=101560			N	N	Y	Y	Y	Y	Y	An analysis-ready dataset is not available for this study. An annotated case report form is not available for this study. A blank case report form will be provided. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Aug-2015
3528	GSK	A Study to Assess the Effect of Steady-state Omeprazole on the Pharmacokinetics of single dose SB480848 in Healthy Adult Subjects	darapladib	480848/019	Atherosclerosis	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=480848/019			N	N	Y	Y	Y	Y	Y	An analysis-ready dataset is not available for this study. An annotated and blank case report form are not available for this study as the electronic data capture system used for this study did not generate paper versions. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Aug-2015
3529	GSK	A Study to Evaluate the Single Dose Pharmacokinetics of Enteric Coated Freebase Formulations of SB480848 in Healthy Adults	darapladib	480848/904	Atherosclerosis	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=480848/904			N	N	Y	Y	Y	Y	Y	An analysis-ready dataset is not available for this study. An annotated and blank case report form are not available for this study as the electronic data capture system used for this study did not generate paper versions. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Aug-2015
3530	GSK	A Repeat Dose, Dose Ranging Study to Evaluate the Safety and Pharmacokinetics of a Freebase Enteric Coated Formulation of SB480848	darapladib	480848/903	Atherosclerosis	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=480848/903			N	N	Y	Y	Y	Y	Y	An analysis-ready dataset is not available for this study. An annotated and blank case report form are not available for this study as the electronic data capture system used for this study did not generate paper versions. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Aug-2015
3531	GSK	A randomized, repeat-dose, dose ranging study to evaluate the safety and pharmacokinetics of the SB480848 Enteric Coated Formulation	darapladib	480848/012	Atherosclerosis	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=480848/012			N	N	Y	Y	Y	Y	Y	An analysis-ready dataset is not available for this study. An annotated and blank case report form are not available for this study as the electronic data capture system used for this study did not generate paper versions. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Aug-2015
3532	GSK	An Open Label, Single Session Study to Collect Tolerability Information Following Repeat Dosing of Darapladib in Healthy Adult Subjects	darapladib	LPL111814	Atherosclerosis	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=LPL111814	http://clinicaltrials.gov/show/NCT00704431		Y	N	Y	Y	Y	Y	Y	An annotated case report form is not available for this study. A blank case report form will be provided.	1-Aug-2015
3533	GSK	Phase I study of SB-480848 (darapladib) -A double blind, randomised, placebo-controlled, parallel-group, repeat dose study to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of SB-480848 in healthy Japanese male subjects-	darapladib	LPL110736	Atherosclerosis	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=LPL110736	http://clinicaltrials.gov/show/NCT00622830		Y	Y	Y	Y	Y	Y	Y		1-Aug-2015
3534	GSK	Assessment of the Anti-Inflammatory activity, efficacy and safety of Intravenous SB-681323 in subjects at risk for development of Acute Lung Injury (ALI) or Acute Respiratory Distress Syndrome (ARDS).	dilmapimod	AL1111592	Lung Injury, Acute	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=111592	http://clinicaltrials.gov/show/NCT00996840		Y	Y	Y	Y	Y	Y	Y		1-Aug-2015
3535	GSK	See Detailed Description	fluticasone propionate/salmeterol	SCO40036	Pulmonary Disease, Chronic Obstructive	Phase 4	https://www.gsk-studyregister.com/en/trial-details/?id=SCO40036	http://clinicaltrials.gov/show/NCT00361959		Y	Y	Y	Y	Y	Y	Y		1-Aug-2015
3536	GSK	A single dose bioequivalence study comparing a new formulation of fondaparinux sodium at 12.5 mg/mL and the reference formulation at 10 mg/mL, in healthy male subjects. Open, randomized, crossover and single center study	fondaparinux sodium	BDR4979	Healthy Subjects	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=BDR4979			Y	N	Y	Y	Y	N	Y	A raw dataset is not available for this study. An annotated case report form is not available for this study. A blank case report form will be provided. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Aug-2015
3537	GSK	An Open-Label, Randomized, Single Dose, Four-way Crossover, Multi-stage Study to determine the Comparative Bioavailability of two fixed dose combination tablet formulations, 500 mg or 1000 mg extended release metformin and 1 mg or 2 mg extended release glimepiride, in healthy adult male and female subjects in the fed state	glimepiride/metformin	MFG116806	Diabetes Mellitus, Type 2	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=116806	http://clinicaltrials.gov/show/NCT01725672		Y	Y	Y	Y	Y	Y	Y		1-Aug-2015
3538	GSK	A randomised, double-blind, placebo-controlled, 3-period crossover study to assess the efficacy and safety of single dose intranasal GSK1004723 compared with placebo in an allergen challenge chamber in male subjects with seasonal allergic rhinitis	GSK1004723	HHI110159	Rhinitis, Allergic, Seasonal	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=110159	http://clinicaltrials.gov/show/NCT00824356	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001567-10	Y	Y	Y	Y	Y	Y	Y		1-Aug-2015
3539	GSK	See Detailed Description	GSK1004723	HHI110157	Rhinitis, Allergic, Seasonal	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=HHI110157	http://clinicaltrials.gov/show/NCT00694993	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005053-31	Y	Y	Y	Y	Y	Y	Y		1-Aug-2015
3540	GSK	A randomised, double-blind, placebo-controlled 4-period cross-over study to assess the efficacy and safety of repeat dose intranasal GSK1004723 (1000µg), oral GSK835726 (10mg) and cetirizine (10mg) in the environmental challenge chamber in subjects with seasonal allergic rhinitis	GSK1004723; GSK835726	HHI112864	Rhinitis, Allergic, Seasonal	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=112864	http://clinicaltrials.gov/show/NCT00972504	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-011459-39	Y	Y	Y	Y	Y	Y	Y		1-Aug-2015
3541	GSK	An adaptive PET study in healthy volunteers using [11C]GSK931145 to establish the relationship of Glycine Transporter 1 occupancy by GSK1018921 to plasma concentrations over time.	GSK1018921; GSK931145	GT1109731	Schizophrenia	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=109731	http://clinicaltrials.gov/show/NCT00945503	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-007163-24	Y	Y	Y	Y	Y	Y	Y		1-Aug-2015
3542	GSK	A Phase I Open-Label, Dose-Escalation Study of the Phosphoinositide 3-Kinase Inhibitor GSK1059615 in Patients with Solid Tumors or Lymphoma	GSK1059615	PIK111051	Solid Tumours	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=PIK111051	http://clinicaltrials.gov/show/NCT00695448		Y	Y	Y	Y	Y	Y	Y		1-Aug-2015
3543	GSK	A single-blind, randomised, placebo-controlled study to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of single doses of intravenously infused GSK1070806 in healthy and obese subjects.	GSK1070806	A18110040	Inflammatory Bowel Diseases	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=110040	http://clinicaltrials.gov/show/NCT01035645	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-013102-13	Y	N	Y	Y	Y	Y	Y	An annotated case report form is not available for this study. A blank case report form will be provided.	1-Aug-2015
3544	GSK	A study in healthy volunteers of single doses of orally administered GSK1292263 to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of the compound alone and when co-administered with sitagliptin	GSK1292263	GPR111596	Dyslipidaemias	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=111596	http://clinicaltrials.gov/show/NCT00783549		Y	Y	Y	Y	Y	Y	Y		1-Aug-2015
3545	GSK	A study in type 2 diabetic subjects of single and multiple doses of orally administered GSK1292263 to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of the compound	GSK1292263	GPR111598	Diabetes Mellitus, Type 2	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=111598	http://clinicaltrials.gov/show/NCT01119846		Y	Y	Y	Y	Y	Y	Y		1-Aug-2015
3546	GSK	A study in type 2 diabetic subjects on stable metformin therapy to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of co-administering single and multiple oral doses of GSK1292263	GSK1292263	GPR113132	Diabetes Mellitus, Type 2	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=113132	http://clinicaltrials.gov/show/NCT01128621		Y	Y	Y	Y	Y	Y	Y		1-Aug-2015
3547	GSK	A study to investigate the interaction of GSK1292263 with rosuvastatin and simvastatin in healthy subjects	GSK1292263	GPR113506	Diabetes Mellitus, Type 2	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=113506	http://clinicaltrials.gov/show/NCT01101568		Y	Y	Y	Y	Y	Y	Y		1-Aug-2015
3548	GSK	A Double-Blind, Parallel, Randomized, Placebo-Controlled, Single Dose Escalation First Time in Human Study to Investigate the Safety, Tolerability and Pharmacokinetics of Investigational Study Drug in Healthy Subjects	GSK1322322	PDF111341	Infections, Bacterial	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=111341	http://clinicaltrials.gov/show/NCT00828867		Y	Y	Y	Y	Y	Y	Y		1-Aug-2015
3549	GSK	A Two Part Single Dose, Randomized, Balanced, Crossover Study to Assess the Relative Bioavailability of Three Formulations, Drug Interaction and Food Effect on an GSK1322322 in Healthy Subjects	GSK1322322	PDF112034	Infections, Bacterial	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=112034	http://clinicaltrials.gov/show/NCT00924911		Y	Y	Y	Y	Y	Y	Y		1-Aug-2015
3550	GSK	A Double-Blind, Parallel, Randomized, Placebo-Controlled, Repeat Dose Escalation Study to Investigate the Safety, Tolerability and Pharmacokinetics of GSK1322322 in Healthy Subjects	GSK1322322	PDF112668	Infections, Bacterial	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=112668	http://clinicaltrials.gov/show/NCT00896558		Y	Y	Y	Y	Y	Y	Y		1-Aug-2015
3551	GSK	A Randomized, Double-Blind, Placebo-Controlled Repeat Dose Escalation, First Time in Human Study to Investigate the Safety, Tolerability and Pharmacokinetics of Oral and Intravenous GSK1322322 in Healthy Subjects	GSK1322322	PDF113376	Infections, Bacterial	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=113376	http://clinicaltrials.gov/show/NCT01610388		Y	Y	Y	Y	Y	Y	Y		1-Aug-2015
3552	GSK	An Open Label, Non-Randomized, Single dose, Two Period, Cross-Over, Mass Balance Study to Investigate the Recovery, Excretion, and Pharmacokinetics of 14C -GSK1322322 Administered as a Single Intravenous and Single Oral Dose to Healthy Adult Male Subjects	GSK1322322	PDF112167	Infections, Bacterial	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=112167	http://clinicaltrials.gov/show/NCT01663389		Y	Y	Y	Y	Y	Y	Y		1-Aug-2015
3553	GSK	A Randomized, Double Blind, Double Dummy Multicenter Phase IIa Study to Assess Safety, Tolerability and Efficacy of GSK1322322 Versus Linezolid in the Treatment of Acute Bacterial Skin and Skin Structure Infection	GSK1322322	PDF113414	Skin Infections, Bacterial	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=113414	http://clinicaltrials.gov/show/NCT01209078		Y	Y	Y	Y	Y	Y	Y		1-Aug-2015
3554	GSK	A Single Dose, Open Label, Randomized, Balanced, Crossover Study to Assess the Relative Bioavailability of ThreeFormulations and Food Effect on GSK1322322 in Healthy Subjects	GSK1322322	PDF116595	Infections, Bacterial	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=116595	http://clinicaltrials.gov/show/NCT01648179		Y	Y	Y	Y	Y	Y	Y		1-Aug-2015
3555	GSK	A Randomized, Placebo Controlled Dose Escalation Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Single Oral Doses of GSK1322888 in Healthy Caucasian and Japanese Asian Adult Subjects	GSK1322888	MTL114422	Gastroparesis	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=114422	http://clinicaltrials.gov/show/NCT01294566		Y	Y	Y	Y	Y	Y	Y		1-Aug-2015
3556	GSK	An open label positron emission tomography study in healthy male subjects to investigate brain DAT and SERT occupancy, pharmacokinetics and safety of single oral doses ofGSK1360707, using 11C- PE2I and 11C-DASB as PET ligands	GSK1360707	SNV112773	Depressive Disorder	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=112773	http://clinicaltrials.gov/show/NCT01153802	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-007327-79	Y	Y	Y	Y	Y	Y	Y		1-Aug-2015
3557	GSK	A First-Time-in-Human Randomised, Single Blind Placebo-Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics, of Single Escalating Doses of GSK1482160, in Male and Female Healthy Subjects, and to make a preliminary assessment of the effect of food.	GSK1482160	X71111383	Pain, Inflammatory	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=111383	http://clinicaltrials.gov/show/NCT00849134	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000776-24	Y	Y	Y	Y	Y	Y	Y		1-Aug-2015
3558	GSK	A First-Time-In-Human, Three-Part, Placebo-Controlled, Dose Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GSK1521498 in Healthy Subjects	GSK1521498	ORA111314	Obesity	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=111314	http://clinicaltrials.gov/show/NCT00857883	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-003790-40	Y	Y	Y	Y	Y	Y	Y		1-Aug-2015
3559	GSK	An open-label, non-randomized [11C]carfentanil PET study in healthy male subjects to investigate brain mu-opioid receptor occupancy, pharmacokinetics, and pharmacodynamics of single oral doses of GSK1521498 and naltrexone.	GSK1521498	ORA111848	Obesity	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=111848	http://clinicaltrials.gov/show/NCT00976066	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-010358-37	Y	Y	Y	Y	Y	Y	Y		1-Aug-2015
3560	GSK	A randomised, double-blind, placebo-controlled study to investigate the safety, tolerability, pharmacokinetics and pharmacodynamic effects of 10 days of repeat dosing of GSK1521498 in overweight or obese but otherwise healthy subjects.	GSK1521498	ORA111849	Obesity	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=111849	http://clinicaltrials.gov/show/NCT00976105	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-010552-97	Y	N	Y	Y	Y	Y	Y	An annotated and blank case report form are not available for this study as the electronic data capture system used for this study did not generate paper versions.	1-Aug-2015
3561	GSK	A 35-Day, Multi-Centre, Randomised, Parallel-Group, Double-Blind, Placebo-Controlled Proof of Concept Study to Investigate the Effects of GSK1521498 on Body Weight and Composition, Eating Behaviour and Related Brain Function, in Obese Subjects with Over-Eating Behaviours.	GSK1521498	ORA111850	Obesity	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=111850	http://clinicaltrials.gov/show/NCT01195792	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-016663-11	Y	Y	Y	Y	Y	Y	Y		1-Aug-2015
3562	GSK	A Randomised, Double-Blind, Single-Dose, Four-Period Cross-Over Study to Determine the Effects of Alcohol on the Pharmacokinetics and Pharmacodynamics of GSK1521498 in Healthy Subjects	GSK1521498	OAA115256	Alcoholism	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=115256	http://clinicaltrials.gov/show/NCT01366573		Y	Y	Y	Y	Y	Y	Y		1-Aug-2015
3563	GSK	A Randomised, Double-Blind, Parallel-Group, Placebo-Controlled Study Evaluating the Efficacy and Safety of GSK163090 in Subjects with Major Depressive Disorder	GSK163090	HTP109035	Depressive Disorder, Major	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=109035	http://clinicaltrials.gov/show/NCT00896363		Y	Y	Y	Y	Y	Y	Y		1-Aug-2015
3564	GSK	A single-centre, randomized, double blind, placebo-controlled, double-dummy, dose escalating cross-over study to examine the safety, tolerability, systemic pharmacokinetic profile and pharmacodynamics of single inhaled doses of a new chemical entity and salmeterol (50 µg via DPI) in COPD patients.	GSK202405	ACH101824	Pulmonary Disease, Chronic Obstructive	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=101824		https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000386-35	N	Y	N	Y	Y	Y	N	An analysis-ready dataset and a reporting and analysis plan are not available for this study. A clinical study report is not available for this study because only a draft version was located; no final version found in archives. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Aug-2015
3565	GSK	A Phase I Randomized, Placebo-Controlled, Single-Blind, Multiple-Dose, Dose-Escalation Clinical Study to Assess the Safety and Pharmacokinetics of SRT2379 in Normal Healthy Male Volunteers	GSK2245841	SIR114011	Diabetes Mellitus, Type 2	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=114011	http://clinicaltrials.gov/show/NCT01018628		N	Y	Y	Y	Y	Y	Y	An analysis-ready dataset is not available for this study.	1-Aug-2015
3566	GSK	A Phase I Study to Evaluate a Single Oral Dose of SRT2379 on the Endotoxin Induced Inflammatory Response in Healthy Male Subjects	GSK2245841	SIR115083	Sepsis	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=115083	http://clinicaltrials.gov/show/NCT01262911		Y	Y	Y	Y	Y	Y	Y		1-Aug-2015
3567	GSK	A Double blind, Placebo controlled, Phase I Dose-ranging Study to Evaluate the Activity of SRT2379 on Endotoxin induced Inflammatory Response in Healthy Male Subjects	GSK2245841	SIR115830	Sepsis	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=115830	http://clinicaltrials.gov/show/NCT01416376		Y	N	Y	Y	Y	Y	Y	An annotated case report form is not available for this study. A blank case report form will be provided.	1-Aug-2015
3568	GSK	A two part study to investigate the safety and tolerability, pharmacokinetics and pharmacodynamics of GSK2339345 in healthy subjects. Part A: an open label, dose escalating, rinse, gargle and spit study. Part B: a randomised, double-blind, placebo controlled, inhaled dose escalating study using nebulised lidocaine for blinding purposes.	GSK2339345	PNV115419	Cough	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=115419	http://clinicaltrials.gov/show/NCT01494636	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002582-38	Y	Y	Y	Y	Y	Y	Y		1-Aug-2015
3569	GSK	A randomised, double-blind, placebo controlled, inhaled single escalating and repeat dose study using an aqueous droplet inhaler to investigate the safety, tolerability and pharmacokinetics of GSK2339345.	GSK2339345	PNV115658	Cough	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=115658	http://clinicaltrials.gov/show/NCT01587716	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000127-40	Y	Y	Y	Y	Y	Y	Y		1-Aug-2015
3570	GSK	A single-blinded, randomized, placebo-controlled, staggered-parallel, escalating dose study to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of GSK2374697 in healthy volunteers	GSK2374697	EXE114403	Diabetes Mellitus, Type 2	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=114403	http://clinicaltrials.gov/show/NCT01545570		Y	Y	Y	Y	Y	Y	Y		1-Aug-2015
3571	GSK	A randomised, double-blind, placebo-controlled study to evaluate the efficacy and safety of the H3 receptor antagonist, GSK239512 in subjects with mild to moderate Alzheimer’s disease.	GSK239512	H3B110651	Alzheimer's Disease	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=110651	http://clinicaltrials.gov/show/NCT01009255	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-012614-48	Y	Y	Y	Y	Y	Y	Y		1-Aug-2015
3572	GSK	A single blind, placebo-controlled, randomised study in mild to moderate Alzheimer’s disease patients to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of GSK239512, a selective histamine H3 receptor antagonist	GSK239512	H3B109689	Alzheimer's Disease	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=H3B109689	http://clinicaltrials.gov/show/NCT00675090	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004117-33	Y	Y	Y	Y	Y	Y	Y		1-Aug-2015
3573	GSK	A randomised double-blind, placebo controlled, parallel group study to evaluate the cognitive enhancing effect of GSK239512 in stable patients with schizophrenia	GSK239512	H3B113147	Schizophrenia	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=113147	http://clinicaltrials.gov/show/NCT01009060		Y	Y	Y	Y	Y	Y	Y		1-Aug-2015
3574	GSK	An exploratory First Time in Human (FTIH) study investigating the pharmacokinetics (PK), immunogenicity, safety and tolerability of GSK2434735 administered as a single low dose in healthy male subjects	GSK2434735	RES114594	Asthma	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=114594	http://clinicaltrials.gov/show/NCT01563042	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004541-41	Y	Y	Y	Y	Y	Y	Y		1-Aug-2015
3575	GSK	A Randomized, Double Blind, Dose Escalation, Fusion, First Time in Human Study to Assess the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of Single and Repeat Doses of GSK2485852 in Chronically Infected Hepatitis C Subjects	GSK2485852	HBI115040	Hepatitis C	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=115040	http://clinicaltrials.gov/show/NCT01332552		Y	Y	Y	Y	Y	Y	Y		1-Aug-2015
3576	GSK	A Single-Blind Study of the Safety, Pharmacokinetics and Pharmacodynamics of Escalating Repeat Doses of GSK249320 in Patients With Stroke	refanezumab	MAG111539	Ischaemic Attack, Transient	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=111539	http://clinicaltrials.gov/show/NCT00833989	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-005041-33	Y	Y	Y	Y	Y	Y	Y		1-Aug-2015
3577	GSK	A single-blind, single dose, placebo controlled, parallel group, first time in human study to assess the safety, tolerability, pharmacokinetics and immunogenicity of ascending IV doses of GSK249320 in healthy volunteers	refanezumab	MAG103114	Cerebrovascular Accident	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=MAG103114	http://clinicaltrials.gov/show/NCT00622609	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003892-19	Y	N	Y	Y	Y	Y	Y	An annotated case report form is not available for this study. A blank case report form will be provided.	1-Aug-2015
3578	GSK	A randomized, single blind, placebo-controlled, three period crossover, dose selection study to evaluate the effect of GSK256073, an HM74A receptor agonist, on glucose and NEFA 24 hour profile in type 2 diabetic patients.	GSK256073	HMD114187	Diabetes Mellitus, Type 2	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=114187	http://clinicaltrials.gov/show/NCT01147861		Y	Y	Y	Y	Y	Y	Y		1-Aug-2015
3579	GSK	A single-center, randomized, blinded, placebo-controlled two-part study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of the Selective Androgen Receptor Modulator (SARM), GSK2849466, in single and repeat doses, with and without food, in healthy male subjects	GSK2849466	ARM116715	Cachexia	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=116715	http://clinicaltrials.gov/show/NCT01696604		Y	Y	Y	Y	Y	Y	Y		1-Aug-2015
3580	GSK	A randomized, double-blind, placebo-controlled, Bayesian adaptive dose finding study to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of single and repeat intravenous infusions GSK315234A in patients with active rheumatoid arthritis (RA)	GSK315234	OSM104972	Arthritis, Rheumatoid	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=104972	http://clinicaltrials.gov/show/NCT00674635	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000923-32	Y	Y	Y	Y	Y	N	Y	A raw dataset is not available for this study.	1-Aug-2015
3581	GSK	A Phase I Study to Determine the Safety, Pharmacokinetics, and Pharmacodynamics of [GSK461364], a Polo-like Kinase 1 (PLK1) Inhibitor, in Adult Subjects with Advanced Solid Tumor or Non-Hodgkins Lymphoma	GSK461364	PLK107427	Lymphoma, Non-Hodgkin	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=PLK107427	http://clinicaltrials.gov/show/NCT00536835	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005706-31	Y	Y	Y	Y	Y	Y	Y		1-Aug-2015
3582	GSK	A single-blind, randomized, placebo controlled, two-period crossover fMRI study to investigate the effects of the D3 antagonist GSK598809 on neural and behavioural responses to food reward and reinforcement after a single oral dose of GSK598809 in overweight and obese subjects.	GSK598809	DAN109710	Substance Dependence	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=109710	http://clinicaltrials.gov/show/NCT01039454	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-004918-26	Y	N	Y	Y	Y	Y	Y	An annotated case report form is not available for this study. A blank case report form will be provided.	1-Aug-2015
3583	GSK	A randomized, double-bind, placebo controlled, two-way cross-over study to assess the effects of a single dose of GSK598809, a Selective DRD3 Antagonist, in Modulating Nicotine Reward	GSK598809	DAN106593	Substance Dependence	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=DAN106593	http://clinicaltrials.gov/show/NCT00605241		Y	Y	Y	Y	Y	Y	Y		1-Aug-2015
3584	GSK	A placebo-controlled, single blind, randomized two part study toinvestigate the tolerability, pharmacokinetics, and brainDopamine D3 receptor occupancy of increasing repeat doses ofGSK618334 for up to 21 days in healthy volunteers.	GSK618334	DBU108414	Substance Dependence	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=108414	http://clinicaltrials.gov/show/NCT01036061	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-013918-27	Y	N	Y	Y	Y	Y	Y	An annotated case report form is not available for this study. A blank case report form will be provided.	1-Aug-2015
3585	GSK	An open label positron emission tomography study in healthy male subjects to investigate brain Dopamine D3 receptor occupancy, pharmacokinetics and safety of single oral doses of GSK618334, using 11C-PHNO as PET ligand.	GSK618334	DBU110269	Substance Dependence	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=110269	http://clinicaltrials.gov/show/NCT00814957	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001005-42	Y	Y	Y	Y	Y	Y	Y		1-Aug-2015
3586	GSK	A Multi-Centre, Randomized, Double-Blind, Placebo-Controlled, Repeat-Dose study to evaluate the Efficacy and Safety of Intravenous GSK679586 in Patients with Severe Asthma	GSK679586	I13106870	Asthma	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=106870	http://clinicaltrials.gov/show/NCT00843193	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-004149-27	Y	Y	Y	Y	Y	Y	Y		1-Aug-2015
3587	GSK	"A randomized double-blind, placebo-controlled, crossover, dose escalation study to examine the safety, tolerability, pharmacodynamics and pharmacokinetics of single inhaled doses of GSK704838 and tiotropium bromide"	GSK704838	AC6108697	Pulmonary Disease, Chronic Obstructive	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=AC6108697	http://clinicaltrials.gov/show/NCT00539825	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003202-10	Y	Y	Y	Y	Y	Y	Y		1-Aug-2015
3588	GSK	A randomised, double-blind, placebo-controlled, 4-period incomplete block crossover study of single oral dose GSK835726 (100mg, 50mg, 10mg), Cetirizine (10mg) and placebo to evaluate the efficacy and safety using an Environmental challenge chamber in male subjects with seasonal allergic rhinitis	GSK835726	HH3110163	Rhinitis, Allergic, Seasonal	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=110163	http://clinicaltrials.gov/show/NCT00851344	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-004092-22	Y	Y	Y	Y	Y	Y	Y		1-Aug-2015
3589	GSK	See Detailed Description	GSK835726	HH3110161	Rhinitis, Allergic, Seasonal	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=HH3110161	http://clinicaltrials.gov/show/NCT00605852	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004961-16	Y	Y	Y	Y	Y	Y	Y		1-Aug-2015
3590	GSK	A double blind, parallel group, placebo controlled study to evaluate the effect of a single oral dose of GSK958108 on ejaculatory latency time (ELT) in male patient suffering from premature ejaculation	GSK958108	SPE111155	Premature Ejaculation	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=111155	http://clinicaltrials.gov/show/NCT00861484	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-005319-16	Y	Y	Y	Y	Y	Y	Y		1-Aug-2015
3591	GSK	A randomised, double-blind, double-dummy, placebo controlled, three-way cross-over study to investigate the effect of single oral doses of 100 mg GW273225 (4030W92) and 325 mg LAMICTAL on resting motor threshold in healthy subjects	GW273225; lamotrigine	NAP107434	Bipolar Disorder	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=107434		https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002641-36	Y	Y	Y	Y	Y	Y	Y	A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Aug-2015
3592	GSK	A randomised, double-blind, placebo-controlled, parallel group study to investigate the safety, tolerability, pharmacokinetics and effect on synovial thickness and vascularity of 28 days repeat dosing of GW274150 or 7.5mg prednisolone in RA subjects.	GW274150	RA4104917	Arthritis, Rheumatoid	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=RA4104917	http://clinicaltrials.gov/show/NCT00379990	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001977-82	Y	N	Y	Y	Y	Y	Y	An annotated case report form is not available for this study. A blank case report form will be provided.	1-Aug-2015
3593	GSK	A randomised, double-blind, double dummy, placebo-controlled, three-way, balanced incomplete block, crossover study in patients with allergic rhinitis to compare the effect versus placebo of 7 days treatment with a new chemical entity (NCE) and 7 days treatment with intranasal fluticasone propionate 200 μg BID upon nasal clinical response after intranasal allergen challenge.	GW328267	AA210012	Rhinitis, Allergic, Perennial	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=AA210012			N	Y	Y	Y	Y	Y	Y	An analysis-ready dataset is not available for this study. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Aug-2015
3594	GSK	A single-centre, escalating dose study to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of a slow intravenous infusion of GW328267X in healthy volunteers	GW328267	A2L115387	Lung Injury, Acute	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=115387	http://clinicaltrials.gov/show/NCT01640990	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001896-37	Y	Y	Y	Y	Y	Y	Y		1-Aug-2015
3595	GSK	A randomised, double-blind, placebo-controlled, cross-over study to investigate the effects of pre-treatment with repeat inhaled doses of a new chemical entity on the allergen-induced late phase asthmatic response in mild asthmatic subjects.	GW328267	AA210005	Asthma	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=AA210005			N	Y	Y	Y	Y	Y	Y	An analysis-ready dataset is not available for this study. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Aug-2015
3596	GSK	A randomised, double-blind, placebo-controlled, crossover study to investigate the effects of pre-treatment with inhaled repeat doses of a new chemical entity (NCE) on the allergen induced late phase asthmatic response in mild asthmatic subjects.	GW328267	AA210013	Asthma	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=AA210013			N	Y	Y	Y	Y	Y	Y	An analysis-ready dataset is not available for this study. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Aug-2015
3597	GSK	A randomised, double-blind, placebo-controlled, 3-way cross-over study to investigate the effects of pre-treatment with single inhaled doses of an NCE and fluticasone propionate on the allergen induced late phase asthmatic response in mild asthmatic subjects.	GW559090	A4A10003	Asthma	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=A4A10003			N	Y	Y	Y	Y	Y	N	An analysis-ready dataset and a reporting and analysis plan are not available for this study. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Aug-2015
3598	GSK	An 8-day, randomised, placebo-controlled, three-way crossover trial of repeat doses of a new chemical entity (NCE), fluticasone propionate and placebo administered intranasally, blinded for fluticasone propionate versus placebo, in an environmental exposition unit, the Vienna Challenge Chamber (VCC) in subjects with seasonal allergic rhinitis (SAR)	GW559090	A4A10008	Rhinitis	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=A4A10008			N	Y	Y	Y	Y	Y	Y	An analysis-ready dataset is not available for this study. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Aug-2015
3599	GSK	A randomised,double-blind, parallel group, placebo-controlled, multicentre study to evaluate the safety, tolerability and efficacy of oral GW677954 capsules 2.5mg, 5mg, 10mg and 20mg a day for 24 weeks in overweight dyslipidaemic subjects	GW677954	ADG103440	Metabolic Syndrome X	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=ADG103440	http://clinicaltrials.gov/show/NCT00264667	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001558-26	Y	Y	Y	Y	Y	Y	Y		1-Aug-2015
3600	GSK	See Detailed Description	GW677954	ADG20001	Diabetes Mellitus, Type 2	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=ADG20001	http://clinicaltrials.gov/show/NCT00196989	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001275-38	Y	Y	Y	Y	Y	Y	Y		1-Aug-2015
3601	GSK	A randomised, placebo-controlled, 4-period, incomplete block, crossover study of 7 days dosing of intranasal GW784568X (100 mg, 200 mg and 400 mg once daily), fluticasone propionate (200 mg once daily) and placebo (blinded for GW784568X vs placebo) to evaluate the efficacy and safety	GW784568	BGS105049	Rhinitis, Allergic, Perennial	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=BGS105049	http://clinicaltrials.gov/show/NCT00404586	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002925-21	Y	Y	Y	Y	Y	Y	Y	A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Aug-2015
3602	GSK	A randomised, double-blind, placebo-controlled, dose escalating, 4-period design study to investigate the effects of 7-day repeat inhaled doses of GW799943X (250, 1000, 3000mcg once daily) on airway responsiveness to adenosine 5’-monophosphate (AMP) challenge when delivered 26 hours after the last dose, in mild asthmatic patients.	GW799943	ODS10005	Asthma	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=ODS10005			Y	Y	N	Y	Y	Y	Y	A clinical study report is not available for this study because only a draft version was located; no final version found in archives. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Aug-2015
3603	GSK	A randomised, double-blind, placebo-controlled, 2-way crossover study to determine the efficacy of repeat inhaled doses of GW870086X on FEV1 in mild to moderate asthmatics	GW870086	SIG112851	Asthma	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=112851	http://clinicaltrials.gov/show/NCT00945932	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-008254-23	Y	Y	Y	Y	Y	Y	Y		1-Aug-2015
3604	GSK	A randomised, double-blind, placebo-controlled, dose ascending,3-way crossover study to assess the pharmacokinetics, safety andtolerability of repeat inhaled doses of nebulised GW870086X inhealthy adult male volunteers.	GW870086	SIG113209	Asthma	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=113209	http://clinicaltrials.gov/show/NCT01160003	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-018106-21	Y	Y	Y	Y	Y	Y	Y		1-Aug-2015
3605	GSK	A Phase II Randomised, Double-Blind, Placebo-Controlled, Parallel Group, Multicentre Study to determine the efficacy and dose response of repeat inhaled doses of GW870086X on FEV1 in adults with Persistent Asthma	GW870086	SIG114749	Asthma	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=114749	http://clinicaltrials.gov/show/NCT01245426	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022279-77	Y	Y	Y	Y	Y	Y	Y		1-Aug-2015
3606	GSK	An Open-label, Randomized, Replicate, Four-Period Crossover Study in Healthy Post-Menopausal Women to Assess the Bioequivalence of a Single Unit Dose Tablet of 150 mg Ibandronate to 3 x 50 mg Tablets of Ibandronate	ibandronic acid	743830/002	Osteoporosis	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=743830/002			N	N	N	Y	Y	Y	N	An analysis-ready dataset and a reporting and analysis plan are not available for this study. An annotated and a blank case report form are not available for this study. A clinical study report is not available for this study because only a draft version was located; no final version found in archives. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Aug-2015
3607	GSK	An Open-label, Randomized, Replicate, Four-Period Crossover Study in Healthy Post-Menopausal Women to Assess the Bioequivalence of a Single Unit Dose Tablet of 100mg Ibandronate to 2 x 50 mg Tablets of Ibandronate	ibandronic acid	743830/003	Osteoporosis, Postmenopausal	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=743830/003			N	N	N	Y	Y	Y	N	An analysis-ready dataset and a reporting and analysis plan are not available for this study. An annotated and a blank case report form are not available for this study. A clinical study report is not available for this study because only a draft version was located; no final version found in archives. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Aug-2015
3608	GSK	A multi-center, uncontrolled, open-label, evaluation of Lamotrigine monotherapy in newly diagnosed epilepsy or recurrent epilepsy (currently untreated)	lamotrigine	LAM115376	Epilepsy	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=115376	http://clinicaltrials.gov/show/NCT01431963		N	Y	N	Y	Y	Y	Y	An analysis-ready dataset is not available for this study. A clinical study report is not available for this study because an English language version was not created.	1-Aug-2015
3609	GSK	A randomised, double-blind, placebo-controlled parallel group study to examine the safety, tolerability, and pharmacokinetics of repeat inhaled doses of GSK159797 in healthy subjects	milveterol	B2E101682	Pulmonary Disease, Chronic Obstructive	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=101682			N	Y	Y	Y	Y	Y	Y	An analysis-ready dataset is not available for this study. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Aug-2015
3610	GSK	A Single Dose Study to Evaluate the Dose Proportionality of the Tablet Formulation of Nabumetone Q and the Relative Bioavailability of Nabumetone Q Compared to RELAFEN in Healthy Subjects	nabumetone	14777/268	Osteoarthritis	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=14777/268			N	N	N	Y	N	Y	N	An analysis-ready dataset and a reporting and analysis plan are not available for this study. An annotated case report form is not available for this study. A blank case report form will be provided. A clinical study report and a protocol are not available for this study because only draft versions were located; no final versions found in archives. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Aug-2015
3611	GSK	An open-label evaluation of the long-term safety of oral naratriptan 1mg twice daily as short-term prophylactic treatment for menstrually-associated migraine.	naratriptan	S2W40027	Migraine Disorders	Phase 4	https://www.gsk-studyregister.com/en/trial-details/?id=S2W40027			N	N	Y	Y	Y	Y	N	An analysis-ready dataset and a reporting and analysis plan are not available for this study. An annotated case report form is not available for this study. A blank case report form will be provided. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Aug-2015
3612	GSK	A Randomised, Double-Blind, Placebo-Controlled, Parallel Group Evaluation of Oral Naratriptan 1mg TwiceDaily as Prophylactic Treatment for Menstrually-Associated Migraine.	naratriptan	S2W40024	Migraine Disorders	Phase 4	https://www.gsk-studyregister.com/en/trial-details/?id=S2W40024			N	N	Y	Y	Y	Y	N	An analysis-ready dataset and a reporting and analysis plan are not available for this study. An annotated case report form is not available for this study. A blank case report form will be provided. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Aug-2015
3613	GSK	An Open-Label Extension of a Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Combined Lovaza® and Simvastatin Therapy in Hypertriglyceridemic Subjects	omega-3-acid ethyl esters	LOV111818	Hypertriglyceridemia	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=111818	http://clinicaltrials.gov/show/NCT00903409		Y	N	Y	Y	Y	N	Y	This is an extension study to LOV111858. A raw dataset is not available for this study. An annotated case report form is not available for this study. A blank case report form will be provided.	1-Aug-2015
3614	GSK	A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Trial to Assess the Efficacy and Safety of Lovaza for the Prevention of Recurrent, Symptomatic Atrial Fibrillation	omega-3-acid ethyl esters	LOV111820	Fibrillation, Atrial	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=OM8 Afib	http://clinicaltrials.gov/show/NCT00402363		Y	Y	Y	Y	Y	Y	Y		1-Aug-2015
3615	GSK	An open-label single dose randomized, parallel group study followed by single-blind repeat dosing, to compare the relative bioavailability of GSK2212836	omega-3-acid ethyl esters	LEM113412	Cardiovascular Disease	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=113412	http://clinicaltrials.gov/show/NCT00996268		Y	Y	Y	Y	Y	Y	Y		1-Aug-2015
3616	GSK	A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Combined Lovaza® and Simvastatin Therapy in Hypertriglyceridemic Subjects	omega-3-acid ethyl esters	LOV111858	Hypertriglyceridemia	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=OM6%20program%20(Reliant)	http://clinicaltrials.gov/show/NCT00246701		Y	Y	Y	Y	Y	Y	Y	Extension study LOV111818 was conducted. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Aug-2015
3617	GSK	A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 4 Study to Assess the Efficacy and Safety of Adjunctive Lovaza® Therapy in Hypertriglyceridemic Subjects Treated with Antara®	omega-3-acid ethyl esters	LOV111859	Hypertriglyceridemia	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=OM5%20program%20(Reliant)	http://clinicaltrials.gov/show/NCT00246636		Y	N	Y	Y	Y	Y	Y	An annotated case report form is not available for this study. A blank case report form will be provided. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Aug-2015
3618	GSK	A Pharmacokinetic Interaction Study Evaluating the Effect of Lovaza® on Plasma Pharmacokinetics of Zocor® in Healthy Adult Volunteers Under Fasting Conditions	omega-3-acid ethyl esters	LOV111862	Dyslipidaemias	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=111862			Y	N	N	Y	Y	Y	Y	An annotated case report form is not available for this study. A blank case report form will be provided. A clinical study report is not available for this study because only a draft version was located; no final version found in archives. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Aug-2015
3619	GSK	A Pharmacokinetic Interaction Study Evaluating the Effect of Reliant Pharmaceuticals Inc. (Lovaza®) Omega-3-Acid Ethyl Esters Capsules on the Plasma Pharmacokinetics of Parke Davis (Lipitor®) Atorvastatin Tablets in Healthy Adult Volunteers Under Fasting Conditions	omega-3-acid ethyl esters	LOV111863	Dyslipidaemias	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=111863			Y	Y	Y	Y	Y	Y	Y	A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Aug-2015
3620	GSK	A Pharmacokinetic Interaction Study Evaluating the Effect of Omega-3-Acid Ethyl Esters Capsules (Omacor®; Reliant Pharmaceuticals Inc.) on the Plasma Pharmacokinetics of Rosuvastatin Tablets (Crestor®; AstraZeneca) in Healthy Adult Volunteers under Fasting Conditions.	omega-3-acid ethyl esters	LOV111864	Dyslipidaemias	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=111864			Y	Y	Y	Y	Y	Y	Y	A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Aug-2015
3621	GSK	A Phase 1, Open-Label, Crossover Study to Demonstrate the Bioequivalence of RYTHMOL SR® (propafenone hydrochloride) Manufactured at Two Different Sites	propafenone	RYT116371	Arrhythmia, Cardiac	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=116371	http://clinicaltrials.gov/show/NCT01956487		Y	Y	Y	Y	Y	Y	Y		1-Aug-2015
3622	GSK	An open-label, five-way, partially randomized crossover study to evaluate the regional gastrointestinal absorption of retigabine in healthy volunteers	retigabine, ezogabine	RTG113214	Seizures	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=113214			Y	Y	Y	Y	Y	Y	Y	This study was not originally sponsored by GSK. A link to ClinicalTrials.gov and an NCTID number are not available for this study.	1-Aug-2015
3623	GSK	A single-centre open label study to investigate the effect of repeat doses of SB-649868 on the pharmacokinetics of Simvastatin and Atorvastatin in healthy male volunteers.	SB649868	OXS109652	Sleep Disorders	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=109652	http://clinicaltrials.gov/show/NCT01299597	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-016018-26	Y	Y	Y	Y	Y	Y	Y		1-Aug-2015
3624	GSK	A single-blinded randomized, placebo-controlled, staggered-parallel, escalating-dose study to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of oral SB756050 administered for 6 days to Subjects with Type 2 Diabetes Mellitus	SB756050	AXO111829	Diabetes Mellitus, Type 2	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=111829	http://clinicaltrials.gov/show/NCT00733577		Y	Y	Y	Y	Y	Y	Y		1-Aug-2015
3625	GSK	A single-blinded, randomized, placebo-controlled, staggered-parallel, escalating single dose study to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of orally administered SB756050 in healthy volunteers and in subjects with Type 2 Diabetes Mellitus	SB756050	AXO110461	Diabetes Mellitus, Type 2	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=AXO110461	http://clinicaltrials.gov/show/NCT00607906		Y	Y	Y	Y	Y	Y	Y		1-Aug-2015
3626	GSK	RIT-I-000/RIT-I-000A: Phase I Study of Radiolabeled Monoclonal Antibody Anti B1 for the Treatment of B Cell Lymphomas & RIT-I-000B: Extended Phase I/II study to determine the safety and efficacy of Coulter Clone® 131Iodine-B1 radioimmunotherapy of advanced non-Hodgkin’s Lymphoma	tositumomab	BEX104728	Lymphoma, Non-Hodgkin	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=104728	http://clinicaltrials.gov/show/NCT01536561		N	Y	Y	Y	Y	Y	Y	An analysis-ready dataset is not available for this study.	1-Aug-2015
3627	GSK	Phase II Study of Iodine 131 Anti B1 Antibody for 1st or 2nd Relapsed Indolent B-Cell Lymphomas or B-Cell Lymphomas That Have Transformed to a More Aggressive Histology	tositumomab	BEX104505	Lymphoma, Non-Hodgkin	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=104505	http://clinicaltrials.gov/show/NCT00950755		N	Y	Y	Y	Y	Y	Y	An analysis-ready dataset is not available for this study.	1-Aug-2015
3628	GSK	Multicenter, Pivotal Phase III Study of Iodine-131 Anti-B1 Antibody (Murine) Radioimmunotherapy for Chemotherapy Refractory Low Grade B Cell Lymphomas and Low Grade Lymphomas that have Transformed to Higher Grade Histologies	tositumomab	BEX104504	Lymphoma, Non-Hodgkin	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=104504	http://clinicaltrials.gov/show/NCT00989664		N	N	Y	Y	Y	Y	Y	A follow-on study BEX104526 was conducted. An analysis-ready dataset is not available for this study. An annotated and a blank case report form are not available for this study.	1-Aug-2015
3629	GSK	Phase II Study of Iodine-131 Anti-B1 Antibody for Non Hodgkin’s Lymphoma Patients who have Previously Received Rituximab	tositumomab	BEX104507	Lymphoma, Non-Hodgkin	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=104507	http://clinicaltrials.gov/show/NCT00996593		Y	Y	Y	Y	Y	Y	Y	A follow-on study BEX104526 was conducted.	1-Aug-2015
3630	GSK	Phase II a randomized study of iodine-131 Anti-b1 Antibody versus anti-b1 Antibody in chemotherapy-relapsed/refractory low-grade or transformed low-grade non-Hodgkin’s lymphoma (NHL)	tositumomab	BEX104515	Lymphoma, Non-Hodgkin	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=104515	http://clinicaltrials.gov/show/NCT01573000		N	Y	Y	Y	Y	Y	Y	An analysis-ready dataset is not available for this study.	1-Aug-2015
3631	GSK	Expanded Access Study of Iodine I 131 Tositumomab for Relapsed/Refractory Low-Grade and Transformed Low-Grade Non-Hodgkin's Lymphoma	tositumomab	BEX104545	Lymphoma, Non-Hodgkin	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=BEX104545	http://clinicaltrials.gov/show/NCT00268203		Y	Y	Y	Y	Y	Y	N	A reporting and analysis plan is not available for this study.	1-Aug-2015
3634	Eisai	Phase II, Multicenter, Open-label, Single Arm Trial to Evaluate the Safety and Efficacy of Oral E7080 in Medullary and Iodine-131 Refractory, Unresectable Differentiated Thyroid Cancers, Stratified by Histology	lenvatinib	E7080-G000-201	Thyroid Cancer	Phase 2		https://clinicaltrials.gov/ct2/show/NCT00784303	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005933-12	Y	Y	Y	Y	Y	Y	N	No restrictions.	1-Aug-2015
3635	Eisai	A Phase 2 Study of E7080 in Subjects With Advanced Thyroid Cancer	lenvatinib	E7080-J081-208	Thyroid Cancer	Phase 2		https://clinicaltrials.gov/ct2/show/NCT01728623		Y	Y	Y	Y	Y	Y	Y	No restrictions. Note: Japan is the only country participating in this study.	1-Aug-2015
3636	Eisai	A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial of Lenvatinib (E7080) in 131I-Refractory Differentiated Thyroid Cancer	lenvatinib	E7080-G000-303	Thyroid Cancer	Phase 3		https://clinicaltrials.gov/ct2/show/NCT01321554	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023783-41	Y	Y	Y	Y	Y	Y	Y	Sharing of clinical data is restricted for the following countries; Germany, France, Sweden, Poland.	1-Aug-2015
3637	GSK	An open-label, randomised, single dose, three-way crossover, parallel groups study to determine the bioequivalence of two fixed dose combination (FDC) tablet formulations of amlodipine and losartan FDC5/50 and FDC5/100 to respective reference dosages in healthy adult male and female subjects under fasting conditions	amlodipine/losartan	AML116799	Hypertension	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=116799	http://clinicaltrials.gov/show/NCT01797926		Y	Y	Y	Y	Y	Y	Y		1-Sep-2015
3638	GSK	U0289-404: An Evaluator Blinded, 8 Week, Split Face Study to Evaluate and Compare the Efficacy and Tolerability of MAXCLARITYII and MURAD in Subjects with Acne	benzoyl peroxide/salicylic acid	STF114553	Acne Vulgaris	Phase 4	https://www.gsk-studyregister.com/en/trial-details/?id=114553	http://clinicaltrials.gov/show/NCT02524665		N	Y	Y	Y	Y	Y	N	An analysis-ready dataset and a reporting and analysis plan are not available for this study.	1-Sep-2015
3640	GSK	Antibody persistence in children previously vaccinated with three doses of Infanrix hexa™ or Infanrix-IPV/Hib™	Combined Diphtheria, Tetanus, Acellular Pertussis, Hepatitis B, Inactivated Polio, Haemophilus influenzae Type b Vaccine	115375	acellular pertussis; Diphtheria; Haemophilus influenzae type b; Hepatitis B; Poliomyelitis; Tetanus	Phase 4	https://www.gsk-studyregister.com/en/trial-details/?id=115375	http://clinicaltrials.gov/show/NCT01358825	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000943-26	Y	Y	Y	Y	Y	Y	Y	This is a long-term antibody persistence follow-up study of 105539.	1-Sep-2015
3641	GSK	Blinded, randomized study to evaluate the immunogenicity and safety of GlaxoSmithKline Biologicals’ measles-mumps-rubella-varicella candidate vaccine given to healthy children during the second year of life	Combined Measles, Mumps, Rubella, Varicella Vaccine	104690	Measles; Mumps; Rubella; Varicella	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=103388	http://clinicaltrials.gov/show/NCT00127010		Y	N	Y	Y	Y	Y	Y	This is a follow-up study to 103388. The results of this study 104690 are summarised with study 103388 on the GSK Study Register. An annotated case report form is not available for this study. A blank case report form will be provided.	1-Sep-2015
3642	GSK	Study evaluating in healthy children safety and immunogenicity of GSK Bios' combined Measles-Mumps-Rubella-Varicella vaccine, compared to GSK Bios' Varicella and Measles-Mumps-Rubella vaccines admind as separate injections	Combined Measles, Mumps, Rubella, Varicella Vaccine	208136/006 (MeMuRu-OKA-006)	Measles; Mumps; Rubella; Varicella	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=208136/006			Y	N	Y	Y	Y	Y	Y	An annotated case report form is not available for this study. A blank case report form will be provided. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Sep-2015
3643	GSK	Study to assess immunogenicity and safety of one dose of GSK Bios’ live attenuated MMRV vaccine, co-admind with a booster dose of the GSK Bios’ combined diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated polio-Haemophilus influenzae type b conjugate vaccine	Combined Measles, Mumps, Rubella, Varicella Vaccine	208136/013 (MeMuRu-OKA-013)	Measles; Mumps; Rubella; Varicella	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=208136/013			Y	N	Y	Y	Y	Y	Y	An annotated case report form is not available for this study. A blank case report form will be provided. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Sep-2015
3644	GSK	Study to assess immunogenicity, reactogenicity and safety of a 2nd dose of GlaxoSmithKline Biologicals’ measles-mumps-rubella-varicella (MeMuRu-OKA) vaccine given in healthy children of 5 to 6 years of age	Combined Measles, Mumps, Rubella, Varicella Vaccine	208136/017 (MeMuRu-OKA-017)	Measles; Mumps; Rubella; Varicella	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=208136/017			Y	N	Y	Y	Y	Y	Y	An annotated case report form is not available for this study. A blank case report form will be provided. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Sep-2015
3645	GSK	Study to evaluate immunogenicity and safety of GSK Bios’ MeMuRu-OKA vaccine compared to concomitant administrations of GSK Bios’ Priorix™ and Varilrix™ vaccines	Combined Measles, Mumps, Rubella, Varicella Vaccine	208136/018 (MeMuRu-OKA-018)	Measles; Mumps; Rubella; Varicella	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=208136/018			Y	N	Y	Y	Y	Y	Y	An annotated case report form is not available for this study. A blank case report form will be provided. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Sep-2015
3646	GSK	Study to evaluate immunogenicity and safety of one dose of GSK Bios’ measles-mumps-rubella-varicella vaccine given to healthy children previously primed with one dose of measles-mumps-rubella vaccine	Combined Measles, Mumps, Rubella, Varicella Vaccine	208136/019 (MeMuRu-OKA-019)	Measles; Mumps; Rubella; Varicella	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=208136/019			Y	N	Y	Y	Y	Y	Y	An annotated case report form is not available for this study. A blank case report form will be provided. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Sep-2015
3647	GSK	A study to evaluate immunogenicity and safety of Boostrix compared to Adacel when administered as a booster vaccination in adults aged 19 to 64 years of age	Combined Reduced Antigen Content Diphtheria, Tetanus, Acellular Pertussis Vaccine	BTX106316	Diphtheria; Tetanus; Acellular pertussis	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=106316	http://clinicaltrials.gov/show/NCT00346073		Y	N	Y	Y	Y	Y	Y	An annotated case report form is not available for this study. A blank case report form will be provided.	1-Sep-2015
3648	GSK	A study to evaluate immunogenicity and safety of Boostrix when co-administered with Fluarix in subjects 19 years of age and older	Combined Reduced Antigen Content Diphtheria, Tetanus, Acellular Pertussis Vaccine	BTX106323	Diphtheria; Tetanus; Acellular pertussis	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=106323	http://clinicaltrials.gov/show/NCT00385255		Y	N	Y	Y	Y	Y	Y	An annotated case report form is not available for this study. A blank case report form will be provided.	1-Sep-2015
3649	GSK	LPL100601, A Clinical Outcomes Study of Darapladib versus Placebo in Subjects with Chronic Coronary Heart Disease to Compare the Incidence of Major Adverse Cardiovascular Events (MACE)	darapladib	LPL100601	Atherosclerosis	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=100601	http://clinicaltrials.gov/show/NCT00799903	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-005575-96	Y	Y	Y	Y	Y	Y	Y	There is a Publication Steering Committee for this study.	1-Sep-2015
3650	GSK	A Clinical Outcomes Study of Darapladib versus Placebo in Subjects Following Acute Coronary Syndrome to Compare the Incidence of Major Adverse Cardiovascular Events (MACE).	darapladib	480848/033	acute coronary syndrome	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=480848/033	http://clinicaltrials.gov/show/NCT01000727	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-012581-32	Y	N	Y	Y	Y	Y	Y	An annotated case report form is not available for this study. A blank case report form will be provided. There is a Publication Steering Committee for this study.	1-Sep-2015
3651	GSK	An open-label, single-sequence study to evaluate the potential CYP 3A4 pharmacokinetic interaction of Darapladib (SB-480848) in healthy subjects	darapladib	LPL115678	Atherosclerosis	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=115678	http://clinicaltrials.gov/show/NCT01873339		Y	Y	Y	Y	Y	Y	Y		1-Sep-2015
3652	GSK	A Study to Evaluate the Effect of a High Fiber and a High Fat Meal on the Pharmacokinetics of LANOXIN† (digoxin) Elixir Pediatric in Healthy Adults	digoxin	120008/901	Heart failure, Congestive	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=120008/901			N	N	Y	Y	Y	Y	N	An analysis-ready dataset and a reporting and analysis plan are not available for this study. An annotated and blank case report form are not available for this study as the electronic data capture system used for this study did not generate paper versions. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Sep-2015
3653	GSK	An Open Label Study in Healthy Volunteers to Investigate the Effect of Ketoconazole on the Pharmacokinetics of GSK239512	GSK239512	H3M117016	Multiple Sclerosis	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=117016	http://clinicaltrials.gov/show/NCT01802931		Y	Y	Y	Y	Y	Y	Y		1-Sep-2015
3654	GSK	An open, controlled, randomized, comparative, phase IIIb study to evaluate the immunogenicity, safety and reactogenicity of GSK Biologicals' combined hepatitis A and hepatitis B vaccine given on an accelerated schedule compared to separate vaccine with GSK Biologicals' monovalent hepatitis A vaccine in healthy adults	Hepatitis A (Inactivated), Hepatitis B (Recombinant) Vaccine	208127/121	Hepatitis A; Hepatitis B	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=208127/121			Y	N	Y	Y	Y	Y	Y	An annotated case report form is not available for this study. A blank case report form will be provided.  The results are summarised under study 208127/021 with studies 280127/115 and 208128/119 on the GSK Study Register. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Sep-2015
3655	GSK	An open study to evaluate the immunogenicity, safety and reactogenicity of GlaxoSmithKline Biologicals' commercially available combined hepatitis A / hepatitis B vaccine (TWINRIX ADULT) containing 720 ELISA units of hepatitis A antigen and 20 µg of hepatitis B surface antigen, administered following a two-dose (0, 6 months) schedule in healthy children between the ages of 1 and 11 years	twinrix	100565	Hepatitis A; Hepatitis B	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=100565		https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-001516-35	Y	Y	Y	Y	Y	Y	Y	This is a Year 10 follow-up study to 208127/076. Other follow-up studies 208127/111 (Year 3), 208127/112 (Year 4), 208127/113 (Year 5), 100561 (Year 6), 100562 (Year 7), 100563 (Year 8), 100564 (Year 9) to 208127/076 were conducted. The results of this study 100565 are summarised with studies 208127/111, 208127/112, 208127/113, 100561, 100562, 100563 and 100564 on the GSK Study Register. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Sep-2015
3656	GSK	Assess the feasibility of an investigational vaccination regimen, compared to a 3-dose primary vaccination with GSK Bio's Infanrix hexa™ (DTPa-HBV-IPV/Hib vaccine) following hepatitis B vaccination at birth. Primary vaccination is followed in the 2nd year of life by a booster dose of Infanrix-hexa	Hepatitis B Vaccine, Recombinant	105752	Hepatitis B	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=210602-002	http://clinicaltrials.gov/show/NCT00289796		Y	N	Y	Y	Y	Y	Y	This is a booster study of 210602/002. The results of this study 105752 are summarised with primary study 210602/002 on the GSK Study Register. An annotated case report form is not available for this study. A blank case report form will be provided.	1-Sep-2015
3657	GSK	Immunogenicity and protective efficacy of GlaxoSmithKline (previously SmithKlineBeecham) Biologicals’ hepatitis B vaccine (10(g) in newborn of HBeAg and HBsAg positive mothers compared with a historical control group.	Hepatitis B Vaccine, Recombinant	103860-115 (HBV-115)	Hepatitis B	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=103860-115			Y	N	Y	Y	Y	Y	N	An annotated case report form is not available for this study. A blank case report form will be provided. A reporting and analysis plan is not available for this study. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Sep-2015
3658	GSK	Comparative study of the immunogenicity and protective efficacy of GlaxoSmithKline (previously SmithKline Beecham and SmithKline-Rit) Biologicals’ recombinant DNA hepatitis B vaccine with or without hepatitis B immune globulins (HBIg) in newborns of HBeAg-positive mothers.	Hepatitis B Vaccine, Recombinant	103860-143 (HBV-143)	Hepatitis B	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=103860-143			Y	N	N	Y	N	Y	N	An annotated case report form is not available for this study. A blank case report form will be provided. A reporting and analysis plan is not available for this study. A clinical study report and a protocol are not available for this study because there is no evidence in the archives that the documents were authored. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Sep-2015
3659	GSK	An observational study to investigate the incidence of influenza, downstream complications of influenza and hospitalizations, in elderly subjects vaccinated with GSK Biologicals’ influenza vaccine (Fluarix™) administered intramuscularly.	Influenza Vaccine	106622	Influenza	Phase 4	https://www.gsk-studyregister.com/en/trial-details/?id=106622	http://clinicaltrials.gov/show/NCT00306982		Y	N	Y	Y	Y	Y	Y	An annotated case report form is not available for this study. A blank case report form will be provided.	1-Sep-2015
3660	GSK	An observational study to investigate the incidence of influenza and influenza-related complications, in adults between 50-64 years and elderly adults 65 years and over vaccinated with Fluarix™	Influenza Vaccine	107564	Influenza	Phase 4	https://www.gsk-studyregister.com/en/trial-details/?id=107564	http://clinicaltrials.gov/show/NCT00377611	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002897-23	Y	N	Y	Y	Y	Y	Y	An annotated case report form is not available for this study. A blank case report form will be provided.	1-Sep-2015
3661	GSK	Immunogenicity, safety and reactogenicity study of GSK Biologicals’ quadrivalent seasonal influenza candidate vaccine GSK2321138A, administered to children who previously participated in study 115345	Influenza Vaccine (Quadrivalent)	116023	Influenza	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=116023	http://clinicaltrials.gov/show/NCT01702454	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001230-34	Y	Y	Y	Y	Y	Y	Y	This is a follow-up study to 115345.	1-Sep-2015
3662	GSK	Immunogenicity and safety study of GSK Biologicals’ Trivalent Split Virion Influenza Vaccine (GSK1536489A) Fluviral® (2012/2013 Season) in adults aged 18 years and older	Influenza Vaccine (Split Virion, Inactivated, Fluviral)	116664	Influenza	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=116664	http://clinicaltrials.gov/show/NCT01626820		Y	Y	Y	Y	Y	Y	Y		1-Sep-2015
3663	GSK	An Open Label Study of the Pharmacokinetics of Lamivudine (GR109714X) in Subjects Receiving Peritoneal Dialysis in Endstage Renal Failure	lamivudine	NUC10901	Hepatitis B	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=NUC10901			N	N	Y	Y	Y	Y	Y	An analysis-ready dataset is not available for this study. An annotated case report form is not available for this study. A blank case report form will be provided. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Sep-2015
3664	GSK	A Multicentre, Double-blind, Randomised, Placebo-controlled Pilot Study to Evaluate the Effect of Lamivudine on Serum HDV RNA in Subjects Co-infected with Hepatitis B and Delta Virus	lamivudine	NUC20905	Hepatitis B	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=NUC20905			N	Y	Y	Y	Y	Y	Y	An analysis-ready dataset is not available for this study. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Sep-2015
3665	GSK	A multicentre, randomised, double-blind, placebo-controlled study to evaluate the efficacy and tolerability of recombinant HBV vaccine and hepatitis B immunoglobulin (HBIg) plus lamivudine versus recombinant HBV vaccine and HBlg plus placebo for the prevention of mother-to-child transmission of HBV.	lamivudine	NUC30914	Hepatitis B	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=NUC30914			N	Y	Y	Y	Y	Y	Y	An analysis-ready dataset is not available for this study. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Sep-2015
3666	GSK	A Double-Blind, Placebo-Controlled Study Of Lamivudine In Subjects In China With Chronic Hepatitis B Infection Followed By Long-Term (5 Years) Lamivudine Treatment	lamivudine	NUCB3026	Hepatitis B, Chronic	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=NUCB3026			N	Y	Y	Y	Y	Y	Y	An analysis-ready dataset is not available for this study. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Sep-2015
3667	GSK	A Follow-On Study to Determine the Safety and Efficacy of Long-Term Lamivudine Treatment in Patients with Chronic Hepatitis B Infection (5 Year Treatment Plus 6 Months Off-treatment Follow-Up)	lamivudine	NUCB3018	Hepatitis B, Chronic	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=NUCB3018			N	Y	Y	Y	Y	Y	N	This is a follow-up study to NUCB3009. An analysis-ready dataset and a reporting and analysis plan are not available for this study. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Sep-2015
3668	GSK	An Extended, Stratified Follow-on Study In Paediatric Subjects With Chronic Hepatitis B Who Have Completed Previous Lamivudine Studies	lamivudine	NUC30926	Hepatitis B, Chronic	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=NUC30926			N	Y	Y	Y	Y	Y	Y	A follow-on study NUC40040 was conducted. An analysis-ready dataset is not available for this study. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Sep-2015
3669	GSK	A phase II, randomized, observer blind, controlled, multicenter study to assess immunogenicity and antibody persistence following vaccination with GSK's candidate combined measles, mumps, and rubella vaccine (MMR) versus M-M-R® II as a first dose, both administered subcutaneously at 12-15 months of age, concomitantly with hepatitis A vaccine (HAV), varicella vaccine (VV) and pneumococcal conjugate vaccine (PCV) but at separate sites.	Measles, Mumps, Rubella Vaccine	111870	Measles; Mumps; Rubella	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=111870	http://clinicaltrials.gov/show/NCT00861744	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005860-31	Y	Y	Y	Y	Y	Y	Y		1-Sep-2015
3670	GSK	Immunogenicity, reactogenicity and safety study of GlaxoSmithKline (GSK) Biologicals’ oral live attenuated human rotavirus (HRV) vaccine in healthy Taiwanese infants who received hepatitis B immunoglobulin after birth.	Rotavirus Vaccine	RTX114351	Infections, Rotavirus	Phase 4	https://www.gsk-studyregister.com/en/trial-details/?id=114351	http://clinicaltrials.gov/show/NCT01198769	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-003731-63	Y	Y	Y	Y	Y	Y	Y		1-Sep-2015
3671	GSK	A multicenter, trial comparing the efficacy and safety of Umeclidinium/Vilanterol 62.5/25 mcg once daily with Tiotropium 18 mcg once daily over 24 weeks in subjects with Chronic Obstructive Pulmonary Disease (COPD).	umeclidinium bromide/vilanterol	ZEP117115	Pulmonary Disease, Chronic Obstructive	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=117115	http://clinicaltrials.gov/show/NCT01777334	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003973-24	Y	Y	Y	Y	Y	Y	Y		1-Sep-2015
3672	GSK	A Randomized, Open Label, 3 Crossover, Balanced Incomplete Block Study To Evaluate The Pharmacokinetics Of Umeclidinium Bromide and Vilanterol Trifenatate as Monotherapies and Concurrently in Healthy Chinese Subjects.	umeclidinium bromide; vilanterol; umeclidinium bromide/vilanterol	DB2115380	Pulmonary Disease, Chronic Obstructive	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=115380	http://clinicaltrials.gov/show/NCT01899638		Y	Y	Y	Y	Y	Y	Y		1-Sep-2015
3673	GSK	A phase III, open-label, multi-centre study to assess the immunogenicity and safety of GlaxoSmithKline Biologicals’ live attenuated varicella vaccine (VarilrixTM), given as a primary vaccination at 4.5 months and 6.5 months post-transplantation, in autologous stem cell/ bone marrow transplant recipients aged 18 years and older.	Varicella Vaccine	208133/178	Varicella	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=208133/178	http://clinicaltrials.gov/show/NCT00792623		Y	N	Y	Y	Y	Y	Y	An annotated case report form is not available for this study. A blank case report form will be provided.	1-Sep-2015
3674	GSK	A controlled clinical study to assess the immunogenicity and reactogenicity of SmithKline Beecham Biologicals varicella vaccine in children aged between 1 and 12 years with a known history of neurodermatitis. SmithKline Beecham Biologicals is currently GlaxoSmithKline Biologicals.	Varicella Vaccine	208133/161 (OKAH-161)	Varicella	Phase 4	https://www.gsk-studyregister.com/en/trial-details/?id=208133/161			Y	N	Y	Y	Y	Y	Y	An annotated case report form is not available for this study. A blank case report form will be provided. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Sep-2015
3675	GSK	Single and Repeat Dose Pharmacokinetic Study of GSK1605786 in Healthy Chinese Subjects	vercirnon	CCX116416	Crohn's Disease	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=116416	http://clinicaltrials.gov/show/NCT01827631		Y	Y	Y	Y	Y	Y	Y		1-Sep-2015
3690	Eisai	An Open Label Phase I Dose Escalation Study of E7080 Administered to Patients With Solid Tumors	lenvatinib	E7080-J081-103	Solid Tumors	Phase 1		https://clinicaltrials.gov/ct2/show/NCT00280397		N	Y	Y	Y	Y	Y	Y	Analysis and reporting datasets are not CDISC compliant and contain labelling in English and Japanese. Note: Japan is the only country participating in this study.	1-Sep-2015
3691	Eisai	A Phase 1 Study of E7080 in Subjects With Solid Tumor	lenvatinib	E7080-J081-105	Cancer	Phase 1		https://clinicaltrials.gov/ct2/show/NCT01268293		Y	Y	Y	Y	Y	Y	Y	Can only share aggregated data due to risk of re-identification. Note: Japan is the only country participating in this study.	1-Sep-2015
3701	GSK	"Clinical assessment of GSK716155 for Type 2 Diabetes Mellitus-A Phase I/II study to investigate the safety, pharmacokinetics and pharmacodynamics of GSK716155 in Japanese subjects with type 2 diabetes mellitus"	albiglutide	GLP107865	Diabetes Mellitus, Type 2	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=GLP107865	http://clinicaltrials.gov/show/NCT00530309		Y	Y	Y	Y	Y	Y	Y		1-Oct-2015
3702	GSK	A Dose Finding Study of GSK716155 versus Placebo in the Treatment of Type 2 Diabetes Mellitus	albiglutide	GLP110932	Diabetes Mellitus, Type 2	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=110932	http://clinicaltrials.gov/show/NCT01098461		Y	Y	Y	Y	Y	Y	Y		1-Oct-2015
3703	GSK	A Study to Evaluate the Pharmacokinetics of Benzoic Acid and Hippuric Acid after Topical Administration of GSK2585823 in Japanese Subjects with Acne Vulgaris	benzoyl peroxide/clindamycin	STF115959	Acne Vulgaris	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=115959	http://clinicaltrials.gov/show/NCT01527123		Y	Y	Y	Y	N	Y	Y	A protocol is not available for this study because an English language version was not created.	1-Oct-2015
3704	GSK	Dermal Safety Study of GSK2585823 (Clindamycin 1%-Benzoyl peroxide 3% gel) with Healthy Japanese Male and Female Subjects	benzoyl peroxide/clindamycin phosphate	STF114849	Acne Vulgaris	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=114849	http://clinicaltrials.gov/show/NCT01428466		Y	Y	N	Y	N	Y	Y	A protocol is not available for this study because an English language version was not created.	1-Oct-2015
3705	GSK	Study AK1113351, a fixed dose study of 323U66 SR in the treatment of Major Depressive Disorder (MDD) - a multi-center, placebo-controlled, randomized, double-blind, parallel-comparison study	bupropion	AK1113351	Depressive Disorder	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=113351	http://clinicaltrials.gov/show/NCT01138007		Y	Y	Y	Y	Y	Y	N	A reporting and analysis plan is not available for this study.	1-Oct-2015
3706	GSK	A study to evaluate the safety and tolerability of SK&F-105517-D in patients with chronic heart failure  - An open-label study to evaluate the safety and tolerability, pharmacokinetics and pharmacodynamics of SK&F-105517-D in patients with chronic heart failure (Phase I/II study)	carvedilol	CRV110734	Heart failure, Congestive	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=CRV110734	http://clinicaltrials.gov/show/NCT00742508		Y	Y	N	Y	Y	Y	Y	A clinical study report is not available for this study because an English language version was not created.	1-Oct-2015
3707	GSK	Study to assess consistency of 3 production lots of GSK Bios’ combined measles-mumps-rubella-varicella vaccine in terms of immunogenicity and safety, compared to administration of GSK Bios’ measles-mumps-rubella vaccine and varicella vaccine in healthy children in their second year of life	Combined Measles, Mumps, Rubella, Varicella Vaccine	208136/007 (MeMuRu-OKA-007)	Measles; Mumps; Rubella; Varicella	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=208136/007			Y	N	Y	Y	Y	Y	Y	An annotated case report form is not available. A blank case report form will be provided. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Oct-2015
3708	GSK	Study to evaluate immunogenicity and safety of one dose of GSK Bios’ combined measles-mumps-rubella-varicella vaccine given to healthy children previously primed with one dose of measles-mumps-rubella vaccine in their second year of life and presumed seronegative for varicella	Combined Measles, Mumps, Rubella, Varicella Vaccine	208136/014 (MeMuRu-OKA-014)	Measles; Mumps; Rubella; Varicella	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=208136/014			Y	N	Y	Y	Y	Y	Y	An annotated case report form is not available. A blank case report form will be provided. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Oct-2015
3709	GSK	Study to assess immunogenicity and safety of two lots of GSK Bios’ live attenuated measles-mumps-rubella-varicella vaccine, at two different titres, given as a single injection to healthy children with GSK Bios’ measles-mumps-rubella vaccine as control group	Combined Measles, Mumps, Rubella, Varicella Vaccine	208136/016 (MeMuRu-OKA-016)	Measles; Mumps; Rubella; Varicella	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=208136/016			Y	N	Y	Y	Y	Y	Y	An annotated case report form is not available. A blank case report form will be provided. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Oct-2015
3710	GSK	Study to evaluate immunogenicity and safety of one dose of GSK Bios’ combined measles-mumps-rubella-varicella vaccine compared to concomitant administrations of GSK Bios’ measles-mumps-rubella vaccine and varicella vaccine	Combined Measles, Mumps, Rubella, Varicella Vaccine	208136/022 (MeMuRu-OKA-022)	Measles; Mumps; Rubella; Varicella	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=208136/022			Y	N	Y	Y	Y	Y	Y	An annotated case report form is not available. A blank case report form will be provided. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Oct-2015
3711	GSK	Study FFR116364, a double-blind, placebo-controlled study of GW685698X in paediatric subjects with perennial allergic rhinitis	fluticasone furoate	FFR116364	Rhinitis, Allergic, Perennial	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=116364	http://clinicaltrials.gov/show/NCT01630135		Y	Y	N	Y	Y	Y	Y	A clinical study report is not available for this study because English language versions were not created.	1-Oct-2015
3712	GSK	Study FFR116365, an open-label study of GW685698X in paediatric subjects with perennial allergic rhinitis	fluticasone furoate	FFR116365	Rhinitis, Allergic, Perennial	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=116365	http://clinicaltrials.gov/show/NCT01622231		Y	Y	N	Y	N	Y	Y	A clinical study report and a protocol are not available for this study because English language versions were not created.	1-Oct-2015
3713	GSK	A 24 Week Study to Evaluate the Predictive Ability of the COPD Assessment Test (CAT) for Acute Exacerbations (PACE) in Patients with Chronic Obstructive Pulmonary Disease	fluticasone propionate/salmeterol	SAM114169	Pulmonary Disease, Chronic Obstructive	N/A	https://www.gsk-studyregister.com/en/trial-details/?id=114169	http://clinicaltrials.gov/show/NCT01254032		N	N	Y	Y	Y	Y	N	An analysis-ready dataset and a reporting and analysis plan are not available for this study. An annotated and a blank case report form are not available for this study.	1-Oct-2015
3714	GSK	CAT LOC Meta-analysis Study	fluticasone propionate/salmeterol	SAM115264	Pulmonary Disease, Chronic Obstructive	N/A	https://www.gsk-studyregister.com/en/trial-details/?id=115264			N	N	N	Y	Y	Y	N	An analysis-ready dataset and a reporting and analysis plan is not available for this study. An annotated and a blank case report form are not available for this study. A clinical study report is not available as only a draft version was located; no final version found in archives. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Oct-2015
3715	GSK	A placebo-controlled, single-blind, randomised study to investigate the safety, tolerability, pharmacokinetics and drug interaction of GSK1034702 after repeat doses in healthy subjects	GSK1034702	MAA110792	Cognitive Disorders	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=110792	http://clinicaltrials.gov/show/NCT00950586	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-007759-28	Y	Y	Y	Y	Y	Y	Y		1-Oct-2015
3716	GSK	A double blind, randomized, placebo controlled, cross-over study to Examine the pharmacodynamic Effects of GSK1034702 on Neurophysiological Biomarkers of Cognition in nicotine abstained otherwise healthy smokers	GSK1034702	MAA113746	Mental Disorders	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=113746	http://clinicaltrials.gov/show/NCT01371799	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-015786-32	Y	N	Y	Y	Y	Y	Y	An annotated or blank case report form are not available as the electronic data capture system used for this study did not generate paper versions.	1-Oct-2015
3717	GSK	An open label positron emission tomography (PET) study to investigate brain penetration by [11C] GSK1034702 in healthy subjects	GSK1034702	MAA110771	Cognitive Disorders	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=110771	http://clinicaltrials.gov/show/NCT00937846	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-007450-35	Y	Y	Y	Y	Y	Y	Y		1-Oct-2015
3718	GSK	Emotional processing in healthy male volunteers treated with GSK424887. A single centre, randomised, double-blind, placebo-controlled parallel group study	GSK424887	NSS105012	Depressive Disorder and Anxiety Disorders	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=105012	http://clinicaltrials.gov/show/NCT01424384	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-007807-34	Y	Y	Y	Y	Y	Y	Y		1-Oct-2015
3719	GSK	A randomised, double-blind, placebo-controlled, rising dose, 6-way crossover study to investigate the effect on heart rate of single doses of NCE (25 μg and 50 μg) and escalating cumulative doses of salbutamol (up to 1200 μg) administered alone and in combination to healthy male smokers.	GW328267	AA210010	Pulmonary Disease, Chronic Obstructive	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=AA210010			N	N	N	Y	N	Y	Y	An analysis-ready dataset is not available for this study. An annotated case report form is not available. A blank case report form will be provided. A clinical study report and a protocol are not available for this study because only draft versions were located; no final versions found in archives. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Oct-2015
3720	GSK	A phase IV, open, multicentric, post-marketing surveillance study to monitor the safety and reactogenicity of GlaxoSmithKline Biologicals’ Haemophilus influenzae type b vaccine (Hiberix™) in Korean subjects administered according to the Prescribing Information.	Haemophilus influenzae Type b Vaccine	208108-083 (Hib-083)	Haemophilus influenzae type b	Phase 4	https://www.gsk-studyregister.com/en/trial-details/?id=208108-083			Y	N	Y	Y	N	Y	Y	An annotated case report form is not available. A blank case report form will be provided. A protocol is not available for this study because only a draft version was located; no final version found in archives. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Oct-2015
3721	GSK	A phase II, open, randomised, multicentric study to compare the immunogenicity, reactogenicity and safety of experimental vaccines to that of Twinrix (administered following a 3 dose schedule (0, 1, 6 months) in healthy adults aged 18-40 years.	twinrix	208127/ 114 (HAB-114)	Hepatitis A; Hepatitis B	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=208127/ 114			Y	N	Y	Y	Y	Y	Y	An annotated case report form is not available. A blank case report form will be provided. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Oct-2015
3722	GSK	A double-blind study to compare the immunogenicity, safety and reactogenicity of GSK Biologicals’ high-dose combined hepatitis A/B vaccine containing 1440 EL.U of hepatitis A antigen/40 mcg of hepatitis B surface antigen to that of Twinrix™, both administered following a 0-6 month schedule in healthy adolescents	twinrix	208127/100 and 208127/101 (Ext-HAB-075)	Hepatitis A; Hepatitis B	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=208127/100 and 208127/101 (Ext-HAB-075)			Y	N	Y	Y	Y	Y	N	This is a follow-up study to 208127/075. An annotated case report form is not available for this study. A blank case report form will be provided. A reporting and analysis plan is not available for this study. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Oct-2015
3723	GSK	A double-blind randomised, comparative study of the immunogenicity and reactogenicity of three different lots of GlaxoSmithKline Biologicals’ combined hepatitis A – hepatitis B vaccine when administered in healthy adults.	Hepatitis A (Inactivated), Hepatitis B (Recombinant) Vaccine	208127/115 and 208127/119 (Ext-HAB-028 Month 108 and Month 120)	Hepatitis A; Hepatitis B	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=208127/115%20and%20208127/119			Y	N	Y	Y	Y	Y	N	This is a follow-up study to 208127/021. Follow-on studies 100551,100552, 100554, 100555, and 112267 were conducted. An annotated case report form is not available for this study. A blank case report form will be provided. A reporting and analysis plan is not available for this study. The results are summarised under study 208127/021 with study 280127/121 on the GSK Study Register. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Oct-2015
3724	GSK	Phase III study to evaluate the safety and consistency of 3 consecutive lots of GSK Biologicals’ thiomersal-free Engerix-B™ vaccine containing 20 µg of hepatitis B surface antigen (HbsAg) per 1 ml dose, when administered intramuscularly according to a 0, 1, 6 month schedule in healthy volunteers	Hepatitis B Vaccine, Recombinant	103860-270 (HBV-270)	Hepatitis B	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=103860-270			Y	N	Y	Y	Y	Y	N	An annotated case report form is not available. A blank case report form will be provided. A reporting and analysis plan is not available for this study. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Oct-2015
3725	GSK	Phase IV, open, multicentric, post-marketing surveillance study to monitor safety and reactogenicity of GSK Bios’ live attenuated Measles-Mumps-Rubella vaccine in Korean subjects admind according to the Prescribing Information	Measles, Mumps, Rubella Vaccine	209762/145 (MeMuRu-145)	Measles; Mumps; Rubella	Phase 4	https://www.gsk-studyregister.com/en/trial-details/?id=209762/145			Y	N	Y	Y	Y	Y	Y	An annotated case report form is not available. A blank case report form will be provided. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Oct-2015
3726	GSK	A Phase 3, Partially Blinded, Randomized, Multi-Center, Controlled Study to Evaluate Immunogenicity, Safety and Lot to Lot Consistency of Novartis Meningococcal B Recombinant Vaccine When Administered With Routine Infant Vaccinations to Healthy Infants	Meningococcal Serogroup B Vaccine	V72P13	Infections, Meningococcal	Phase 3		http://clinicaltrials.gov/show/NCT00657709	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-007781-38	N	Y	Y	Y	Y	Y	Y	Extension study V12P13E1 was conducted. An analysis-ready dataset is not available for this study. There is no GSK Study Register entry for this study.	1-Oct-2015
3727	GSK	A Phase 3, Open Label, Multi-Center, Extension Study to Evaluate the Safety, Tolerability and Immunogenicity of Novartis Meningococcal B Recombinant Vaccine When Administered as a Booster at 12 Months of Age or as a Two-dose Catch-up to Healthy Toddlers Who Participated in Study V72P13	Meningococcal Serogroup B Vaccine	V72P13E1	Infections, Meningococcal	Phase 3		http://clinicaltrials.gov/show/NCT01139021	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-006301-17	N	Y	Y	Y	Y	Y	Y	This is an extension study to V72P13. An analysis-ready dataset is not available for this study. There is no GSK Study Register entry for this study.	1-Oct-2015
3728	GSK	A Phase 2b, Open Label, Randomized, Parallel-Group, Multi-Center Study to Evaluate the Safety, Tolerability and Immunogenicity of Novartis Meningococcal B Recombinant Vaccine When Administered With or Without Routine Infant Vaccinations to Healthy Infants According to Different Immunization Schedules.	Meningococcal Serogroup B Vaccine	V72P12	Infections, Meningococcal	Phase 2		http://clinicaltrials.gov/show/NCT00721396		N	Y	Y	Y	Y	Y	Y	An analysis-ready dataset is not available for this study. There is no GSK Study Register entry for this study.	1-Oct-2015
3729	GSK	A phase-III, open, controlled, follow-up clinical trial, with Prevenar as control, to assess the safety of GSK Biologicals’ investigational vaccination regimen administered with DTPa-HBV-IPV/Hib to healthy children, previously vaccinated in infancy with the investigational vaccination regimen in a primary study in the Netherlands	Pneumococcal Polysaccharide Conjugate Vaccine (Adsorbed)	347414/035	Infections, Streptococcal	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=347414/035			Y	N	N	Y	N	Y	N	This is a follow-up study to 347414/020. An annotated case report form is not available. A blank case report form will be provided. A reporting and analysis plan is not available for this study. A clinical study report and a protocol are not available for this study because only draft versions were located; no final version found in archives. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Oct-2015
3730	GSK	A placebo-controlled pharmacokinetic and safety study of twice daily SRT501 in type 2 diabetic human male subjects	resveratrol	SRT-501-006	Diabetes Mellitus, Type 2	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=SRT-501-006			Y	Y	Y	Y	Y	N	Y	A raw dataset is not available for this study. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Oct-2015
3731	GSK	A randomised, double-blind, triple-dummy, placebo-controlled, five-way crossover study to investigate the bronchoprotective effects against methacholine challenge and the bronchodilatory effects of single doses of salmeterol (25, 50 and 200 µg) and salbutamol (200 µg) over a 24-hour period in at ...	salmeterol	RES11070	Constriction, Bronchial	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=RES11070			N	N	Y	Y	Y	Y	N	An analysis-ready dataset and a reporting and analysis plan are not available for this study. An annotated case report form is not available. A blank case report form will be provided. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Oct-2015
3732	GSK	A randomised, double-blind, triple-dummy, placebo-controlled, five-way cross-over study to investigate the bronchodilatory effects of single doses of salmeterol (25, 50 and 200 mg) and salbutamol (200 mg) over a 24-h period in healthy subjects.	salmeterol	RES10988	Constriction, Bronchial	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=RES10988			N	Y	N	Y	N	Y	N	An analysis-ready dataset and a reporting and analysis plan are not available for this study. A clinical study report and a protocol are not available for this study because only draft versions were located; no final versions found in archives. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Oct-2015
3733	GSK	A Randomized, Multicenter, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Oral Sumatriptan for the Acute Treatment of Migraine in Children and Adolescents	sumatriptan	SUM111035	Migraine Disorders	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=111035	http://clinicaltrials.gov/show/NCT00963937	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-004880-35	Y	Y	N	Y	N	Y	Y	A clinical study report and a protocol are not available for this study because English language versions were not created.	1-Oct-2015
3734	GSK	A 52-week, Multi-centre, Open-label Study to Evaluate the Safety and Tolerability of GSK573719 125 mcg once-daily in combination with GW642444 25 mcg once-daily via novel Dry Powder Inhaler (nDPI) in Japanese Subjects with Chronic Obstructive Pulmonary Disease.	umeclidinium bromide/vilanterol	DB2115362	Pulmonary Disease, Chronic Obstructive	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=115362	http://clinicaltrials.gov/show/NCT01376388		Y	Y	N	Y	N	Y	Y	A clinical study report and a protocol are not available for this study because English language versions were not created.	1-Oct-2015
3735	GSK	A multicenter, open-label study to evaluate preventive efficacy for herpes simplex virus infection and safety of 256U87 (valaciclovir hydrochloride) in adult and pediatric hematopoietic stem cell transplantation patients	valaciclovir	HS2116100	Herpes Simplex	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=116100	http://clinicaltrials.gov/show/NCT01602562		Y	Y	N	Y	N	Y	Y	A clinical study report and a protocol are not available for this study because English language versions were not created.	1-Oct-2015
3767	Astellas	A multicenter, randomized, double-blind, placebo-controlled, phase 3 study of single-agent Tarceva® (erlotinib) following complete tumor resection with or without adjuvant chemotherapy in patients with stage IB-IIIA non-small cell lung carcinoma who have EGFR-positive tumors	erlotinib	OSI-774-302	Non-small cell lung cancer	Phase 3	https://www.clinicaltrials.astellas.com/study/?pid=OSI-774-302	https://clinicaltrials.gov/ct2/show/NCT00373425	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001747-29	Y	Y	Y	Y	Y	Y	Y		1-Nov-2015
3776	GSK	Study ATG115317, a comparison of atorvastatin and glimepiride fixed dose combination and atorvastatin and glimepiride loose combination in the treatment of patients with Type 2 diabetes mellitus	atorvastatin/glimepiride	ATG115317	Diabetes Mellitus, Type 2	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=115317	http://clinicaltrials.gov/show/NCT01495013		Y	N	Y	Y	Y	Y	Y	An annotated case report form is not available for this study. A blank case report form will be provided.	1-Nov-2015
3777	GSK	A Single-Center, Evaluator-Blinded, Randomized, Placebo-Controlled, Phase 1 Clinical Trial Evaluating the Potential of Topically Applied EF Calcipotriene Foam, 0.005% to Induce Contact Sensitization in Healthy Volunteers Upon Exposure to Repeated Skin Patch Applications	calcipotriol, calcipotriene	STF114738	Psoriasis	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=114738			Y	N	Y	Y	Y	Y	Y	An annotated case report form is not available for this study. A blank case report form will be provided. This study was not originally sponsored by GSK. A link to ClinicalTrials.gov and an NCTID number are not available for this study.	1-Nov-2015
3778	GSK	An Open-Label, Non-Randomized, Pharmacokinetic and Safety Study of Multiple Oral Doses of SB-480848 in Healthy Subjects and in Subjects with Severe Renal Impairment	darapladib	LPL115676	Atherosclerosis	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=115676	http://clinicaltrials.gov/show/NCT01711723		Y	Y	Y	Y	Y	Y	Y		1-Nov-2015
3779	GSK	A Study of the Efficacy and Safety of Multiple Doses of Dutasteride versus Placebo and Finasteride in the Treatment of Male Subjects with Androgenetic Alopecia	dutasteride	ARI114263	Alopecia	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=114263	http://clinicaltrials.gov/show/NCT01231607		Y	Y	Y	Y	Y	Y	Y		1-Nov-2015
3780	GSK	A Randomized, Double-Blind, Parallel Group, Multicenter Study of Fluticasone Furoate/Vilanterol 200/25 mcg Inhalation Powder, Fluticasone Furoate/Vilanterol 100/25 mcg Inhalation Powder, and Fluticasone Furoate 100 mcg Inhalation Powder in the Treatment of Persistent Asthma in Adults and Adolescents	fluticasone furoate/vilanterol	HZA116863	Asthma	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=116863	http://clinicaltrials.gov/show/NCT01686633	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002797-32	Y	Y	Y	Y	Y	Y	Y		1-Nov-2015
3781	GSK	A 12-Week Study to Evaluate the 24-Hour Pulmonary Function Profile of Fluticasone Furoate /Vilanterol (FF/VI) Inhalation Powder 100/25mcg Once-Daily via a Novel Dry Powder Inhaler Compared with Tiotropium Bromide Inhalation Powder 18mcg Delivered Once-Daily via the HandiHaler in Subjects with Chronic Obstructive Pulmonary Disease (COPD) Who Have or Are at Risk for Co-morbid Cardiovascular Disease	fluticasone furoate/vilanterol	HZC115805	Pulmonary Disease, Chronic Obstructive	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=115805	http://clinicaltrials.gov/show/NCT01627327	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002451-33	Y	Y	Y	Y	Y	Y	Y		1-Nov-2015
3782	GSK	A randomized, double-blind, placebo-controlled, four-way crossover study to evaluate and compare the pharmacodynamics and pharmacokinetics of fluticasone furoate /vilanterol in different dose combination (50/25mcg, 100/25mcg and 200/25mcg) after single and repeat dose administration from a novel dry powder device in healthy Chinese subjects	fluticasone furoate/vilanterol	HZA115199	Asthma	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=115199	http://clinicaltrials.gov/show/NCT01711463		Y	Y	Y	Y	Y	Y	Y		1-Nov-2015
3783	GSK	A Long-term Study to Evaluate the Safety and Tolerability of Fluticasone Furoate (FF)/GW642444 Inhalation Powder in Japanese Subjects with Chronic Obstructive Pulmonary Disease (COPD)	Fluticasone Furoate/vilanterol	HZC114156	Pulmonary Disease, Chronic Obstructive	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=114156	http://clinicaltrials.gov/show/NCT01192191		Y	Y	Y	Y	Y	Y	Y		1-Nov-2015
3784	GSK	A single centre, randomised, double-blind, double dummy, parallel group 3-week study to compare the effect of the salmeterol/fluticasone propionate combination 50/500mcg bd via the DISKUS™/ACCUHALER™ inhaler with tiotropium bromide 18 mcg od via the Handihaler inhaler on mucociliary clearance ra ...	fluticasone propionate/salmeterol	SCO30008	Pulmonary Disease, Chronic Obstructive	Phase 4	https://www.gsk-studyregister.com/en/trial-details/?id=SCO30008			N	Y	Y	Y	Y	Y	Y	An analysis-ready dataset is not available for this study. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Nov-2015
3785	GSK	A Phase 1 Dose Escalation Study of the Safety and Pharmacokinetics of GSK1363089 (Formerly XL880) Administered Orally Daily to Subjects with Solid Tumors	foretinib	MET111648	Solid Tumours	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=MET111648	http://clinicaltrials.gov/show/NCT00743067		Y	Y	Y	Y	Y	Y	Y		1-Nov-2015
3786	GSK	A Single-Blind, Randomised, Placebo-Controlled Study to Evaluate Safety, Tolerability and Pharmacokinetics of Single Oral Escalating Doses of GSK1360707	GSK1360707	SNV111914	Depressive Disorder	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=111914		https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-004203-58	Y	Y	Y	Y	Y	Y	Y	A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Nov-2015
3787	GSK	A Randomized, Double-Blind, Placebo-Controlled, Phase IIa Study of the Clinical Activity, Safety, and Tolerability of SRT2104 in Subjects with Moderate to Severe Plaque-Type Psoriasis	GSK2245840	SIR114296	Psoriasis	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=114296	http://clinicaltrials.gov/show/NCT01154101		Y	N	Y	Y	Y	Y	Y	An annotated case report form is not available for this study. A blank case report form will be provided.	1-Nov-2015
3788	GSK	A Phase 1b, Exploratory Study to Assess the Safety, Tolerability, Colonic Tissue Exposure, and Anti-Inflammatory Effects of Two Different Doses of SRT2104 in Subjects with Mild to Moderate Ulcerative Colitis	GSK2245840	SIR115951	Colitis, Ulcerative	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=115951	http://clinicaltrials.gov/show/NCT01453491		Y	Y	Y	Y	Y	Y	Y		1-Nov-2015
3789	GSK	A multicenter, two part, randomized, parallel group, placebo and sitagliptin controlled study to evaluate the safety and efficacy of GSK256073 administered once or twice daily for 12 weeks in subjects with type 2 diabetes mellitus who are being treated with metformin	GSK256073	HMD114728	Diabetes Mellitus, Type 2	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=114728	http://clinicaltrials.gov/show/NCT01376323	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000483-94	Y	N	Y	Y	Y	Y	Y	An annotated case report form is not available for this study. A blank case report form will be provided.	1-Nov-2015
3790	GSK	The Evaluation of Lamictal as an Add-on Treatment for Bipolar I Disorder in Children and Adolescents, 10 to 17 Years of Age	lamotrigine	SCA102833	Bipolar Disorder	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=SCA102833	http://clinicaltrials.gov/show/NCT00723450		Y	Y	Y	Y	Y	Y	Y		1-Nov-2015
3791	GSK	A single blind, placebo controlled, parallel group, single ascending intravenous dose study to assess safety, tolerability, pharmacokinetics and pharmacodynamics of SB-240563 (mepolizumab) in healthy Japanese male subjects.	mepolizumab	MEA115705	Asthma	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=115705	http://clinicaltrials.gov/show/NCT01471327		Y	Y	Y	Y	Y	Y	Y		1-Nov-2015
3792	GSK	A multicenter, randomized, double-blind, placebo-controlled, parallel group, dose ranging study to determine the effect of mepolizumab on exacerbation rates in subjects with severe uncontrolled refractory asthma	mepolizumab	MEA112997	Asthma	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=112997	http://clinicaltrials.gov/show/NCT01000506	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-014415-12	Y	Y	Y	Y	Y	Y	Y	A follow-on study MEA115666 was conducted.	1-Nov-2015
3793	GSK	MEA115588 A randomised, double-blind, double-dummy, placebo-controlled, parallel-group, multi-centre study of the efficacy and safety of mepolizumab adjunctive therapy in subjects with severe uncontrolled refractory asthma	mepolizumab	MEA115588	Asthma	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=115588	http://clinicaltrials.gov/show/NCT01691521	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001251-40	Y	Y	Y	Y	Y	Y	Y	A follow-on study MEA115661 was conducted. This study is available in CDISC format.	1-Nov-2015
3794	GSK	MEA115575: A Randomised, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study of Mepolizumab Adjunctive Therapy to Reduce Steroid Use in Subjects with Severe Refractory Asthma	mepolizumab	MEA115575	Asthma	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=115575	http://clinicaltrials.gov/show/NCT01691508	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001497-29	Y	Y	Y	Y	Y	Y	Y	A follow-on study MEA115661 was conducted. This study is available in CDISC format.	1-Nov-2015
3795	GSK	A multicenter, open-label, dose ranging study to determine the pharmacokinetics and pharmacodynamics of mepolizumab administered intravenously or subcutaneously to adult asthmatic subjects with elevated blood eosinophil levels	mepolizumab	MEA114092	Asthma	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=114092	http://clinicaltrials.gov/show/NCT01366521	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022510-11	Y	Y	Y	Y	Y	Y	Y		1-Nov-2015
3796	GSK	A 16 week randomized, double-blind, parallel group study to evaluate the efficacy and safety of a new medication (GSK523338) to lower LDL-c and HbA1c in subjects with type 2 diabetes mellitus	rosiglitazone/simvastatin	AVS101946	Diabetes Mellitus, Type 2	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=AVS101946	http://clinicaltrials.gov/show/NCT00256867		Y	Y	Y	Y	Y	Y	Y		1-Nov-2015
3797	GSK	An Open-Label, Randomized, Four-Period Crossover Study in Healthy Subjects to Demonstrate the Bioequivalence of a Fixed Dose Combination Tablet Formulation of Rosiglitazone and Simvastatin (8mg/80mg) to Concomitant Dosing of Rosiglitazone 8mg and Simvastatin 80mg Commercial Tablets and to Assess ...	rosiglitazone/simvastatin	AVS102130	Diabetes Mellitus, Type 2	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=102130			Y	N	Y	Y	Y	Y	Y	An annotated and a blank case report form are not available for this study, as the data electronic data capture system for this study did not generate a paper version. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Nov-2015
3798	GSK	Phase II Trial of Iodine-131 Anti-B1 Antibody for Previously Untreated, Advanced Stage, Low Grade Non-Hodgkin’s Lymphoma	tositumomab	BEX104517	Lymphoma, Non-Hodgkin	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=104517	http://clinicaltrials.gov/show/NCT00996996		N	Y	Y	Y	Y	Y	Y	An analysis-ready dataset is not available for this study.	1-Nov-2015
3799	GSK	A Multi-Center, Randomized, Phase 3 Study of Rituximab versus Iodine I 131 Tositumomab Therapeutic Regimen For Patients With Relapsed Follicular Non-Hodgkins Lymphoma	tositumomab	393229/028	Lymphoma, Non-Hodgkin	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=393229/028	http://clinicaltrials.gov/show/NCT00268983		N	Y	Y	Y	Y	Y	Y	An analysis-ready dataset is not available for this study.	1-Nov-2015
3800	GSK	A 24-week randomised, double-blind and placebo-controlled study to evaluate the efficacy and safety of GSK573719/GW642444 125/25 mcg and 62.5/25mcg Inhalation Powder compared with placebo Inhalation Powder delivered once-daily via a Novel Dry Powder Inhaler in subjects with Chronic Obstructive Pulmonary Disease (COPD)	umeclidinium bromide/vilanterol	DB2114634	Pulmonary Disease, Chronic Obstructive	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=114634	http://clinicaltrials.gov/show/NCT01636713		Y	Y	Y	Y	Y	Y	Y		1-Nov-2015
3801	GSK	DB2114930: A randomized, multi-center, double-blind, double-dummy, parallel group study to evaluate the efficacy and safety of umeclidinium/vilanterol compared with fluticasone propionate/salmeterol over 12 weeks in subjects with COPD	umeclidinium bromide/vilanterol	DB2114930	Pulmonary Disease, Chronic Obstructive	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=114930	http://clinicaltrials.gov/show/NCT01817764	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000525-45	Y	Y	Y	Y	Y	Y	Y		1-Nov-2015
3802	GSK	DB2114951: A randomized, multi-center, double-blind, double-dummy, parallel group study to evaluate the efficacy umeclidinium/vilanterol compared with fluticasone propionate/salmeterol over 12 weeks in subjects with COPD	umeclidinium bromide/vilanterol	DB2114951	Pulmonary Disease, Chronic Obstructive	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=114951	http://clinicaltrials.gov/show/NCT01879410	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002156-16	Y	Y	Y	Y	Y	Y	Y		1-Nov-2015
3884	GSK	Cultural adaptation and validation of "COPD Assessment Test" (CAT) into Spanish	fluticasone propionate/salmeterol	113047	Pulmonary Disease, Chronic Obstructive	N/A				N	N	N	Y	N	Y	N	This is an observational study. An analysis-ready dataset is not available for this study. The data labels for this study are in Spanish. The supporting documents are not in English and will not be provided. There is no GSK Study Register entry for this study because the study was conducted before GSK policy requirements to register observational studies. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Jan-2016
3885	GSK	A Phase II Multicenter, Parallel-Group, Randomized, Dose-Ranging Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics Following 12 Weeks of Oral Administration of GSK2336805 With Pegylated Interferon and Ribavirin in Treatment-Naïve Subjects With Chronic Genotype 1 or 4 Hepatitis C Infection	GSK2336805	HAI115879	Hepatitis C, Chronic	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=115879	http://clinicaltrials.gov/show/NCT01648140	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000523-40	Y	N	Y	Y	Y	Y	Y	An annotated case report form is not available for this study. A blank case report form will be provided.	1-Jan-2016
3886	GSK	An Open-label Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the AKT Inhibitor GSK690693 given on Various Schedules in Subjects with Solid Tumors or Lymphoma	GSK690693	AKT106757	Cancer	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=AKT106757	http://clinicaltrials.gov/show/NCT00493818		Y	Y	Y	Y	Y	Y	Y		1-Jan-2016
3887	GSK	Evaluation of the Quality of Life in COPD patients in Europe	N/A	111749	Pulmonary Disease, Chronic Obstructive	Phase 4	https://www.gsk-studyregister.com/en/trial-details/?id=111749			Y	Y	Y	Y	Y	Y	Y	A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Jan-2016
3888	GSK	A single-blind, randomised, placebo-controlled, parallel group study to investigate safety, tolerability, pharmacokinetics and the effects on cardiac function of repeat oral doses of SB-649868 in adult and elderly healthy volunteers	SB649868	OXS112861	Sleep Disorders	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=112861	http://clinicaltrials.gov/show/NCT01030939	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-011201-16	Y	Y	Y	Y	Y	Y	Y		1-Jan-2016
3889	GSK	A Multi-Center Study to Examine the Pharmacokinetics, Whole Body and Organ Dosimetry, and Biodistribution of Fission-Derived Iodine I 131 Tositumomab for Patients With Previously Untreated or Relapsed Follicular or Transformed Follicular Non-Hodgkin's Lymphoma	tositumomab	393229/027	Lymphoma, Follicular	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=393229/027	http://clinicaltrials.gov/show/NCT00315731		N	Y	Y	Y	Y	Y	Y	An analysis-ready dataset is not available for this study.	1-Jan-2016
3896	Astellas	Long-term Study of YM178: Long-term study of YM178 in subjects with overactive bladder.	mirabegron	178-CL-051	Urinary Bladder, Overactive	Phase 3	https://www.clinicaltrials.astellas.com/study/?pid=178-CL-051	https://clinicaltrials.gov/ct2/show/NCT00840645		Y	Y	Y	Y	Y	Y	Y		1-Jan-2016
3920	GSK	An Evaluation of the Bioequivalence of five 0.1 mg GI198745/dutasteride Soft Gelatin Capsules Compared to one 0.5 mg GI198745/dutasteride Gelatin Capsules in Healthy Male Volunteers	dutasteride	ARI117342	Alopecia	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=117342	http://clinicaltrials.gov/show/NCT01929330		Y	Y	Y	Y	Y	Y	Y		1-Feb-2016
3921	GSK	Proof of Mechanism Study to Assess the Potential of GSK239512 to Remyelinate Lesions in Subjects with Relapsing Remitting Multiple Sclerosis.	GSK239512	H3M116477	Multiple Sclerosis, Relapsing-Remitting	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=116477	http://clinicaltrials.gov/show/NCT01772199	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003627-38	Y	Y	Y	Y	Y	Y	Y		1-Feb-2016
3923	GSK	A pharmacy based open study to evaluate whether pack size affects compliance for subjects diagnosed with diabetes type II who are established on metformin treatment.	metformin	MTF116086	Diabetes Mellitus, Type 2	Phase 4	https://www.gsk-studyregister.com/en/trial-details/?id=116086	http://clinicaltrials.gov/show/NCT01817777		Y	Y	Y	Y	Y	N	Y	This study was terminated early and only limited analysis-ready data are available. A raw dataset is not available for this study.	1-Feb-2016
3936	GSK	A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Determine the Efficacy and Safety of Two Dose Levels of Albiglutide Compared With Placebo in Subjects With Type 2 Diabetes Mellitus	albiglutide	GLP112756	Diabetes Mellitus, Type 2	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=112756	http://clinicaltrials.gov/show/NCT00849017		Y	Y	Y	Y	Y	Y	Y	This study is available in CDISC format	1-Mar-2016
3937	GSK	A multicenter evaluation of the effects of Zyban™ (bupropion hydrochloride sustained release tablets) versus placebo in a population of smokers with COPD: Follow-up phase.	bupropion	AK1A4013: Follow-up phase	Smoking Cessation	Phase 4	https://www.gsk-studyregister.com/en/trial-details/?id=AK1A4013			Y	Y	Y	Y	Y	Y	Y	A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Mar-2016
3938	GSK	A multicenter evaluation of the effects of Zyban (bupropion hydrochloride sustained release tablets) versus placebo in a population of smokers with COPD: treatment phase.ZYBAN is a registered trademark of the GlaxoSmithKline group of companies.	bupropion	AK1A4013: Treatment phase	Smoking Cessation	Phase 4	https://www.gsk-studyregister.com/en/trial-details/?id=AK1A4013			N	Y	Y	Y	Y	Y	Y	An analysis-ready dataset is not available for this study. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Mar-2016
3939	GSK	A multi-centre, randomised, double-blind, placebo-controlled, dose ranging study to evaluate the safety and efficacy of GSK2586184 in patients with chronic plaque psoriasis	solcitinib	JAK116679	Psoriasis	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=116679	http://clinicaltrials.gov/show/NCT01782664	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002917-20	Y	Y	Y	Y	Y	Y	Y	This study is available in CDISC format	1-Mar-2016
3940	GSK	A Phase I, Dose-Escalation Study to Assess the Safety and Biological Activity of Recombinant Human Interleukin-18 (SB-485232) Administered by Intravenous Infusion in Combinationwith Rituximab in Adult Patients with B Cell Non-Hodgkin's Lymphoma	iboctadekin	ILI105618	Lymphoma, Non-Hodgkin	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=ILI105618	http://clinicaltrials.gov/show/NCT00500058		Y	Y	Y	Y	Y	Y	Y		1-Mar-2016
3941	GSK	A phase I, dose escalation study to assess the safety & biological activity of Interleukin 18 (SB-485232) administered by IV infusion in combination with pegylated liposomal doxorubicin (Doxil) in advanced stage epithelial ovarian cancer	iboctadekin	ILI108621	Neoplasms, Ovarian	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=ILI108621	http://clinicaltrials.gov/show/NCT00659178		Y	Y	Y	Y	Y	Y	Y		1-Mar-2016
3942	GSK	Lamotrigine as add-on therapy in patients with a clinical diagnosis of a Lennox-Gastaut syndrome (severe generalised epilepsy of childhood onset). A multicentre, double-blind, placebo-controlled, parallel group study.	lamotrigine	105-123	Lennox-Gastaut Syndrome	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=105-123			N	Y	Y	Y	Y	Y	Y	An analysis-ready dataset is not available for this study. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Mar-2016
3943	GSK	A Multicenter, Double-Blind, Placebo-Controlled, Parallel-Design Evaluation of LAMICTAL for Add-on Treatment of Partial Seizures in Pediatric Patients	lamotrigine	105-040	Epilepsy, Partial	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=105-040			N	Y	Y	Y	Y	Y	Y	An analysis-ready dataset is not available for this study. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Mar-2016
3944	GSK	Oral bioavailability study comparing OXEMET™ 1000 mg coated tablets containing metformin hydrochloride with 1000 mg of the reference product (GLAFORNIL™) administered as two 500 mg tablets, through a randomized, single-dose, open label, balanced, 2-way crossover study in healthy volunteers under fasting conditions.OXEMET (TM) is a trademark of the GlaxoSmithKline group of companies. GLAFORNIL(TM) is a trademark of Merck.	metformin	LOC117219	Diabetes Mellitus, Type 2	Phase 4	https://www.gsk-studyregister.com/en/trial-details/?id=117219	http://clinicaltrials.gov/show/NCT01842620		Y	Y	Y	Y	Y	Y	Y		1-Mar-2016
3945	GSK	A randomised, open-label, multicentre, parallel group study comparing the safety and efficacy of an Ultiva (remifentanil hydrochloride) based analgesia/sedation regimen with a conventional sedative-based regimen in long-term ICU subjects requiring analgesia and sedation for up to 10 days.	remifentanil	USA30226	Analgesia	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=USA30226			Y	Y	Y	Y	Y	Y	N	A reporting and analysis plan is not available for this study. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Mar-2016
3947	GSK	PHASE II MULTICENTER STUDY OF IODINE-131 ANTI-B1 ANTIBODY CONSOLIDATION FOR PATIENTS WITH DIFFUSE LARGE B-CELL NON-HODGKIN'S LYMPHOMA FOLLOWING FIRST-LINE CHOP	tositumomab	393229/007	Lymphoma, Non-Hodgkin	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=393229/007	http://clinicaltrials.gov/show/NCT01868035		Y	Y	Y	Y	Y	Y	Y		1-Mar-2016
3948	GSK	A Randomized, Double-Blind, 3-Way, Cross-Over Study to Evaluate Lung Function Response after Treatment with Umeclidinium 62.5mcg, Vilanterol 25mcg, and Umeclidinium/Vilanterol 62.5/25mcg Once-Daily in Subjects with Chronic Obstructive Pulmonary Disease (COPD).	umeclidinium bromide	DB2116133	Pulmonary Disease, Chronic Obstructive	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=116133	http://clinicaltrials.gov/show/NCT01716520	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005914-12	Y	Y	Y	Y	Y	Y	Y		1-Apr-2016
3949	GSK	A 52-week, Multi-centre, Open-label Study to Evaluate the Safety and Tolerability of GSK573719 125 mcg once-daily via novel Dry Powder Inhaler (nDPI) in Japanese Subjects with Chronic Obstructive Pulmonary Disease.	umeclidinium bromide	AC4115361	Pulmonary Disease, Chronic Obstructive	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=115361	http://clinicaltrials.gov/show/NCT01702363		Y	Y	Y	Y	Y	Y	Y		1-Mar-2016
3950	GSK	A Randomized, Double-Blind, 3-Way, Cross-Over Study to Evaluate Lung Function Response after Treatment with Umeclidinium 62.5 mcg, Vilanterol 25 mcg, and Umeclidinium/Vilanterol 62.5/25 mcg Once-Daily in Subjects with Chronic Obstructive Pulmonary Disease (COPD)	umeclidinium bromide	DB2116132	Pulmonary Disease, Chronic Obstructive	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=116132	http://clinicaltrials.gov/show/NCT02014480	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005913-35	Y	Y	Y	Y	Y	Y	Y		1-Mar-2016
3951	GSK	A study to compare the addition of umeclidinium bromide (UMEC) to fluticasone furoate (FF)/vilanterol (VI), with placebo plus FF/VI in subjects with Chronic Obstructive Pulmonary Disease (COPD) -Study 1	umeclidinium bromide	200109	Pulmonary Disease, Chronic Obstructive	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=200109	http://clinicaltrials.gov/show/NCT01957163	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002238-19	Y	Y	Y	Y	Y	Y	Y		1-Mar-2016
3952	GSK	A study to compare the addition of umeclidinium bromide (UMEC) to fluticasone furoate (FF)/vilanterol (VI), with placebo plus FF/VI in subjects with Chronic Obstructive Pulmonary Disease (COPD) -Study 2	umeclidinium bromide	200110	Pulmonary Disease, Chronic Obstructive	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=200110	http://clinicaltrials.gov/show/NCT02119286	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002239-44	Y	Y	Y	Y	Y	Y	Y		1-Mar-2016
3953	Novartis	A Randomized, Double-blind, Placebo Controlled, Multicenter Regimen Finding Study of Subcutaneously Administered AIN457, Assessing Psoriasis Area and Severity Index (PASI) Response in Patients With Moderate to Severe Chronic Plaque-type Psoriasis	secukinumab	CAIN457A2211	Psoriasis	Phase 2	https://www.novctrd.com/ctrdweb/trialresult/trialresults/pdf?trialResultId=4823	https://clinicaltrials.gov/show/NCT00941031		Y	Y	Y	Y	Y	Y	Y		1-Apr-2016
3955	Novartis	A Randomized, Double-blind, Placebo Controlled, Multicenter Dose Ranging Study of Subcutaneously Administered AIN457, Assessing Psoriasis Area and Severity Index (PASI) Response in Patients With Moderate to Severe Chronic Plaque-type Psoriasis	secukinumab	CAIN457A2220	Psoriasis	Phase 2	https://www.novctrd.com/ctrdweb/trialresult/trialresults/pdf?trialResultId=5383	https://clinicaltrials.gov/show/NCT01071252		Y	Y	Y	Y	Y	Y	Y		1-Apr-2016
3956	Novartis	A Randomized, Double-blind, Placebo Controlled, Multicenter Study of Subcutaneous Secukinumab to Demonstrate Efficacy After Twelve Weeks of Treatment, and to Assess the Safety, Tolerability and Long-term Efficacy up to One Year in Subjects With Moderate to Severe Chronic Plaque-type Psoriasis	secukinumab	CAIN457A2302	Psoriasis	Phase 3	https://www.novctrd.com/ctrdweb/trialresult/trialresults/pdf?trialResultId=11643	https://clinicaltrials.gov/show/NCT01365455		Y	Y	Y	Y	Y	Y	Y		1-Apr-2016
3957	Novartis	A Randomized, Double-blind, Double-dummy, Placebo Controlled, Multicenter Study of Subcutaneous Secukinumab to Demonstrate Efficacy After Twelve Weeks of Treatment, Compared to Placebo and Etanercept, and to Assess the Safety, Tolerability and Long-term Efficacy up to One Year in Subjects With Moderate to Severe Chronic Plaque-type Psoriasis	secukinumab	CAIN457A2303	Psoriasis	Phase 3	https://www.novctrd.com/ctrdweb/trialresult/trialresults/pdf?trialResultId=13605	https://clinicaltrials.gov/show/NCT01358578		Y	Y	Y	Y	Y	Y	Y		1-Apr-2016
3962	GSK	A study to evaluate the safety, tolerability, systemic pharmacokinetic profile and pharmacodynamics of single and repeat inhaled doses of GSK961081 in healthy subjects.	batefenterol	MAB104865	Pulmonary Disease, Chronic Obstructive	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=104865	http://clinicaltrials.gov/show/NCT00887406	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003419-60	Y	N	Y	Y	Y	Y	Y	An annotated case report form is not available for this study. A blank case report form will be provided.	1-Apr-2016
3963	GSK	A 2 Part Study Examining Doses Of GSK961081 In Healthy Volunteers And Then In COPD Patients.	batefenterol	MAB104958	Pulmonary Disease, Chronic Obstructive	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=MAB104958	http://clinicaltrials.gov/show/NCT00478738	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006240-63	Y	Y	Y	Y	Y	Y	Y		1-Apr-2016
3964	GSK	A randomised, double-blind, dose escalating study in healthy volunteers to assess the safety, tolerability, extra pulmonary pharmacodynamics and pharmacokinetics of single doses of GSK961081 (succinate salt).	batefenterol	MAB108115	Pulmonary Disease, Chronic Obstructive	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=MAB108115	http://clinicaltrials.gov/show/NCT00550225	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004441-15	Y	Y	Y	Y	Y	Y	Y		1-Apr-2016
3965	GSK	A randomized, double-blind, crossover study to investigate the bronchodilatation post-inhalation of GSK961081 alone and with the addition of cumulative doses of short acting bronchodilators (salbutamol and ipratropium bromide) in patients with COPD.	batefenterol	MAB110123	Pulmonary Disease, Chronic Obstructive	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=MAB110123	http://clinicaltrials.gov/show/NCT00674817	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000725-18	Y	Y	Y	Y	Y	Y	Y		1-Apr-2016
3966	GSK	A study to investigate the relative pharmacological activity of an inhaled B2-agonist/anticholinergic dual pharmacophore in healthy volunteers.	batefenterol	MAB110553	Pulmonary Disease, Chronic Obstructive	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=MAB110553	http://clinicaltrials.gov/show/NCT00687700	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-007005-74	Y	Y	Y	Y	Y	Y	Y		1-Apr-2016
3967	GSK	A 4-week Dose-Ranging, Dose-Interval, Efficacy, Safety and Tolerability Study of GSK961081 in Subjects with Chronic Obstructive Pulmonary Disease (COPD).	batefenterol	MAB115032	Pulmonary Disease, Chronic Obstructive	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=115032	http://clinicaltrials.gov/show/NCT01319019	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022796-62	Y	Y	Y	Y	Y	Y	Y		1-Apr-2016
3968	GSK	A randomised, double-blind, double-dummy, single dose, four way cross-over study to compare the pharmacokinetics and pharmacodynamics of GSK961081 and fluticasone propionate when administered alone, concurrently and as a combination blend in healthy subjects.	batefenterol	MFP113423	Pulmonary Disease, Chronic Obstructive	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=113423	http://clinicaltrials.gov/show/NCT01449799	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001828-38	Y	Y	Y	Y	Y	Y	Y		1-Apr-2016
3969	GSK	An Open-label, Randomized, Single Dose, Two-Period Crossover study to Determine the Bioavailability of a Fixed Dose Combination Capsule Formulation of Dutasteride and Tamsulosin Hydrochloride (0.5mg/0.2mg) Relative to Co-administration of Dutasteride 0.5mg capsules and Tamsulosin Hydrochloride 0.2mg.	dutasteride	ARI114694	Prostatic Hyperplasia	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=114694	http://clinicaltrials.gov/show/NCT01254071		Y	Y	Y	Y	Y	Y	Y		1-Apr-2016
3970	GSK	An Open-label, Randomized, Single Dose, Multi-stage, Cross-over study to determine the Relative bioavailability of Fixed Dose Combination Products containing a 3-oblong dutasteride soft gel capsule and tamsulosin (0.5 mg dutasteride/0.2 mg tamsulosin HCl) pellets having a range of tamsulosin release rates produced by different mixtures of enteric coated and uncoated pellets relative to Harnal-D Tablets, in Healthy Male Subjects of North East Asian ancestry.	dutasteride	ARI115708	Prostatic Hyperplasia	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=115708	http://clinicaltrials.gov/show/NCT01495026		Y	Y	Y	Y	Y	Y	Y		1-Apr-2016
3971	GSK	A randomized, double-blind, repeat dose, two period crossover study to evaluate the safety and tolerability, pharmacokinetics, and pharmacodynamics of inhaled fluticasone furoate/vilanterol 100/25 micrograms in children aged 5 to 11 years with persistent asthma.	fluticasone furoate	HZA112777	Asthma	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=112777	http://clinicaltrials.gov/show/NCT01453023		Y	Y	Y	Y	Y	Y	Y		1-Apr-2016
3972	GSK	A randomized, double-blind, placebo controlled, 3 way cross over study in subjects with allergic rhinitis to assess the effect of intranasal repeat doses of levocabastine when administered once daily or twice daily on the symptoms of rhinitis in an allergen challenge chamber.	fluticasone furoate/levocabastine	200285	Rhinitis, Allergic, Perennial and Seasonal	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=200285	http://clinicaltrials.gov/show/NCT01949051		Y	Y	Y	Y	Y	Y	Y		1-Apr-2016
3973	GSK	A randomised, double-blind, placebo-controlled, 3 way, incomplete block cross over study in subjects with allergic rhinitis to assess the effect of once daily single and repeat doses of intranasal Fluticasone furoate/Levocabastine fixed dose combination (FDC) relative to Levocabastine and Fluticasone furoate alone on the onset and magnitude of symptoms of rhinitis in an allergen challenge chamber.	fluticasone furoate/levocabastine	200286	Rhinitis, Allergic, Perennial and Seasonal	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=200286	http://clinicaltrials.gov/show/NCT01957202	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002940-94	Y	Y	Y	Y	Y	Y	Y		1-Apr-2016
3974	GSK	A Single Blind (Sponsor-unblinded), Placebo-controlled, Parallel-group Study to Investigate the Efficacy and Safety of GSK1070806 in the Treatment of Obese Subjects with T2DM.	GSK1070806	A18116378	Diabetes Mellitus	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=116378	http://clinicaltrials.gov/show/NCT01648153	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000126-22	Y	Y	Y	Y	Y	Y	Y		1-Apr-2016
3975	GSK	A single-blind, randomized, placebo controlled, ascending single dose study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of GSK1362885 in healthy normal subjects.	GSK1362885	GPA111497	Diabetes Mellitus, Type 2	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=111497	http://clinicaltrials.gov/show/NCT00823940		Y	Y	Y	Y	Y	Y	Y		1-Apr-2016
3976	GSK	A Randomized, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GSK1362885 in Subjects with Type 2 Diabetes Mellitus.	GSK1362885	GPA111823	Diabetes Mellitus, Type 2	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=111823	http://clinicaltrials.gov/show/NCT01013766		Y	Y	Y	Y	Y	Y	Y		1-Apr-2016
3977	GSK	A randomized, double-blind, parallel group clinical trial to assess safety, tolerability, pharmacokinetics, and pharmacodynamics of intravenous mepolizumab (SB240563)(0.55mg/kg, 2.5mg/kg or 10mg/kg) in pediatric subjects with eosinophilic esophagitis, aged 2 to 17 years (Study MEE103219).	mepolizumab	MEE103219	Oesophagitis, Eosinophilic	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=MEE103219	http://clinicaltrials.gov/show/NCT00358449	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-006074-10	Y	Y	Y	Y	Y	Y	Y		1-Apr-2016
3978	GSK	DEFEND 2: Durable-Response Therapy Evaluation For Early- or New-Onset Type 1 Diabetes.	otelixizumab	OTX115494	Diabetes Mellitus, Type 1	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=115494	http://clinicaltrials.gov/show/NCT01123083	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-018775-17	Y	Y	Y	Y	Y	Y	Y		1-Apr-2016
3979	GSK	A randomized, single-blind, placebo-controlled study to evaluate the safety and tolerability of raxibacumab (human monoclonal antibody to B. anthracis protective antigen) in healthy subjects.	raxibacumab	HGS1021-C1063	Therapeutic treatment of inhalation anthrax	Phase 3		http://clinicaltrials.gov/show/NCT00639678		Y	Y	Y	Y	Y	Y	Y	There is no GSK Study Register entry for this study.	1-Apr-2016
3980	GSK	A randomised, double blind, placebo controlled study to examine the safety, tolerability, pharmacodynamics and systemic pharmacokinetic profile of single inhaled doses of GW642444 in healthy male subjects.	vilanterol	B2C10001	Pulmonary Disease, Chronic Obstructive	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=B2C10001			Y	Y	Y	Y	Y	Y	Y	The raw data are included within the analysis-ready data for this study and are not provided separately. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Apr-2016
3981	GSK	A multi-centre, randomised, double-blind, placebo controlled, dose ascending, four way crossover study to examine efficacy (FEV1), safety, tolerability, pharmacodynamics and pharmacokinetics of single and repeat doses of GW642444.	vilanterol	B2C101762	Asthma	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=B2C101762	http://clinicaltrials.gov/show/NCT00354874	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002362-37	Y	Y	Y	Y	Y	Y	Y		1-Apr-2016
3982	GSK	A randomised, double-blind, placebo-controlled, dose ascending, five-way crossover study, to examine efficacy, safety, tolerability, pharmacodynamics and pharmacokinetics of a single administration of three inhaled doses (25, 100 and 400 µg) of GW642444M.	vilanterol	B2C104604	Pulmonary Disease, Chronic Obstructive	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=B2C104604	http://clinicaltrials.gov/show/NCT00381667		Y	Y	Y	Y	Y	Y	Y		1-Apr-2016
3983	GSK	Multi-centre, randomised, double-blind, placebo-controlled, four-way incomplete block crossover study, to examine efficacy, safety, tolerability, pharmacodynamics and pharmacokinetics of single and repeat administration of three inhaled doses (25, 100 and 400 mcg once daily) of GW642444.	vilanterol	B2C106093	Pulmonary Disease, Chronic Obstructive	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=B2C106093	http://clinicaltrials.gov/show/NCT00347139	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004419-31	Y	Y	Y	Y	Y	Y	Y		1-Apr-2016
3984	GSK	A single-centre, open-label, sequential, dose-ascending study to examine safety, tolerability, pharmacodynamics and pharmacokinetics of single intravenous, inhaled and oral doses of GW642444 in healthy male subjects.	vilanterol	B2C106180	Pulmonary Disease, Chronic Obstructive	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=B2C106180	http://clinicaltrials.gov/show/NCT00711126	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004188-80	Y	Y	Y	Y	Y	Y	Y		1-Apr-2016
3985	GSK	An open-label, single-arm study to determine the excretion balance and metabolic disposition of [14C]GW642444 administered as a single dose of an oral solution to healthy male volunteers.	vilanterol	B2C106181	Pulmonary Disease, Chronic Obstructive	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=106181	http://clinicaltrials.gov/show/NCT01286831	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-017948-14	Y	Y	Y	Y	Y	Y	Y		1-Apr-2016
3986	GSK	A randomized, single-dose, dose-ascending, double blind, placebo-controlled, 5-way crossover study to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of inhaled doses of GW642444M with magnesium stearate in asthmatic patients.	vilanterol	B2C106996	Pulmonary Disease, Chronic Obstructive	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=B2C106996	http://clinicaltrials.gov/show/NCT00463697	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005813-37	Y	Y	Y	Y	Y	Y	Y		1-Apr-2016
3987	GSK	A 2-wk study to evaluate the safety, tolerability, pharmacodynamics and pharmacokinetics of GW642444H(100 administered once daily in the morning via DISKUS™ dry-powder inhaler)compared with SEREVENT(salmeterol)(50mcg administered twice daily via DISKUS dry-powder inhaler)and placebo in subject w/COPD.	vilanterol	B2C108562	Pulmonary Disease, Chronic Obstructive	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=B2C108562	http://clinicaltrials.gov/show/NCT00372112	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004033-15	Y	Y	Y	Y	Y	Y	Y		1-Apr-2016
3988	GSK	A randomised, double-blind, placebo-controlled, parallel-group, 14 day repeat dose study to investigate the safety, tolerability, pharmacokinetics and extra-pulmonary pharmacodynamics of inhaled doses of GW642444M formulated with magnesium stearate in healthy subjects.	vilanterol	B2C108784	Pulmonary Disease, Chronic Obstructive	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=B2C108784	http://clinicaltrials.gov/show/NCT00469040	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005814-10	Y	Y	Y	Y	Y	Y	Y		1-Apr-2016
3989	GSK	A randomised, single-dose, dose ascending, double-blind, placebo controlled, four-way, incomplete block crossover study to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of inhaled doses of GW642444M with magnesium stearate in COPD patients.	vilanterol	B2C110165	Pulmonary Disease, Chronic Obstructive	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=B2C110165	http://clinicaltrials.gov/show/NCT00519376	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001391-37	Y	Y	Y	Y	Y	Y	Y		1-Apr-2016
3990	GSK	Study B2C111045, A Dose-Finding Study of GW642444 versus Placebo in Patients with COPD.	vilanterol	B2C111045	Pulmonary Disease, Chronic Obstructive	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=B2C111045	http://clinicaltrials.gov/show/NCT00606684	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004807-37	Y	Y	Y	Y	Y	Y	Y		1-Apr-2016
3991	GSK	A randomised, single-dose, dose-ascending, double-blind, placebo-controlled, 5-way crossover study to investigate the efficacy, pharmacokinetics and pharmacodynamics of inhaled doses of GW642444M in asthmatic patients.	vilanterol	B2C111401	Pulmonary Disease, Chronic Obstructive	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=B2C111401	http://clinicaltrials.gov/show/NCT00702910		Y	Y	Y	Y	Y	Y	Y		1-Apr-2016
3992	GSK	A double-blind, placebo-controlled, randomised, 2-way crossover drug interaction study to investigate the pharmacokinetic and pharmacodynamic effects following co-administration of GW642444M with ketoconazole.	vilanterol	B2C112205	Pulmonary Disease, Chronic Obstructive	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=112205	http://clinicaltrials.gov/show/NCT00866515		Y	Y	Y	Y	Y	Y	Y		1-Apr-2016
3993	GSK	A randomized, double-blind, placebo-controlled, two-way crossover 7-day study to investigate the safety, tolerability, pharmacodynamics and pharmacokinetics of repeat dose inhaled GW642444 25μg (micrograms) in children aged 5-11 years with persistent asthma.	vilanterol	HZA112776	Asthma	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=112776	http://clinicaltrials.gov/show/NCT01453296		Y	Y	Y	Y	Y	Y	Y		1-Apr-2016
3994	GSK	Phase I, Open-label Study To Evaluate Steady-State Serum and Pulmonary Pharmacokinetics following Intravenous Administration of Zanamivir in Healthy Adult Subjects.	zanamivir	NAI106784	Influenza, Human	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=106784			Y	Y	Y	Y	Y	Y	Y	A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Apr-2016
3995	GSK	An Open-Label, Non-Randomized, Single-Dose Study To Evaluate Serum Zanamivir Pharmacokinetics Following Intravenous Administration to Human Subjects With Renal Impairment Compared to Subjects Without Renal Impairment.	zanamivir	NAI108127	Influenza, Human	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=108127			Y	Y	Y	Y	Y	Y	N	A reporting and analysis plan is not available for this study. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study was conducted before regulatory requirements o register studies.	1-Apr-2016
3996	GSK	An open-label, multi-center, single arm study to evaluate the safety and tolerability of intravenous zanamivir in the treatment of hospitalized adult, adolescent and pediatric subjects with confirmed influenza infection.	zanamivir	NAI113678	Influenza, Human	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=113678	http://clinicaltrials.gov/show/NCT01014988	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-016035-35	Y	Y	Y	Y	Y	Y	Y		1-Apr-2016
3997	GSK	A Phase I, Randomized, Placebo-Controlled, Four-Way Crossover Study to Evaluate the Effect of Intravenous (IV) Zanamivir on Cardiac Conduction as Assessed by 12-lead Electrocardiogram (ECG) with Moxifloxacin as a Positive Control in Healthy Volunteers.	zanamivir	NAI114346	Influenza, Human	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=114346	http://clinicaltrials.gov/show/NCT01353729		Y	Y	Y	Y	Y	Y	Y		1-Apr-2016
3998	GSK	A Randomized, Open-label, Single-Dose, Two-Period, Crossover Study to Evaluate the Bioequivalence of Over-encapsulated Oseltamivir Capsules to Marketed Oseltamivir Capsules in Healthy Volunteers.	zanamivir	NAI115096	Influenza, Human	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=115096	http://clinicaltrials.gov/show/NCT01258530		Y	Y	Y	Y	Y	Y	Y		1-Apr-2016
4005	GSK	An Open-Label, Randomized, Single Dose, Two-Way Crossover Pilot Study to Evaluate the Relative Bioavailability of One Amlodipine 5 mg Tablet and One Enalapril Maleate 20mg Tablet to a Fixed Dose Combination Tablet Formulation of Amlodipine (5 mg) and Enalapril Maleate (20 mg), in Healthy Adult Male and Female Subjects under Fasting Conditions	amlodipine/enalapril	ANE116798	Hypertension	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=116798	http://clinicaltrials.gov/show/NCT01822639		Y	Y	Y	Y	Y	Y	Y		1-May-2016
4006	GSK	An open-label, randomized, single dose, three-way crossover, six sequence pilot study to evaluate the relative bioavailability of one amlodipine 10mg tablet and rosuvastatin 20mg tablet to two fixed dose combination tablet formulations of amlodipine (10mg) and rosuvastatin (20mg) in healthy adult male and female subjects under fasting conditions	amlodipine/rosuvastatin	200561	Hypertension	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=200561	http://clinicaltrials.gov/show/NCT02075619		Y	Y	Y	Y	Y	Y	Y		1-May-2016
4007	GSK	An open label, randomized, parallel, single dose study to investigate safety and pharmacokinetics following intravenous administration and subcutaneous administration of GSK1550188 in healthy Japanese males	belimumab	BEL116119	Systemic Lupus Erythematosus	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=116119	http://clinicaltrials.gov/show/NCT01516450		Y	Y	Y	Y	Y	Y	Y		1-May-2016
4008	GSK	A Study to Evaluate the Pharmacokinetics, Pharmacodynamics and Safety of 160 mg Enteric-coated Micronised Free Base Darapladib in Healthy Chinese Subjects.	darapladib	LPL117326	Atherosclerosis	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=117326	http://clinicaltrials.gov/show/NCT02000804		Y	Y	Y	Y	Y	Y	Y		1-May-2016
4009	GSK	An Open-label, Randomized, Single Dose, Four-Period Crossover study to compare the Bioavailability of Fixed Dose Combination Capsule Formulations of Dutasteride and Tamsulosin Hydrochloride (0.5 mg/0.2 mg) with 10% and 15% of enteric coated pellets with Harnal-D tablets and Harnal capsules co-administered with dutasteride (0.5 mg) Soft Gel Capsules in Healthy Male Subjects of North East Asian ancestry	dutasteride	ARI115707	Prostatic Hyperplasia	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=115707	http://clinicaltrials.gov/show/NCT01471678		Y	Y	Y	Y	Y	Y	Y		1-May-2016
4010	GSK	A Phase I, Randomized, Single-Blind, Placebo-Controlled Dose-Escalation Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Food Effect Following Single Oral Doses of the Focal Adhesion Kinase Inhibitor, GSK2256098, in Healthy Subjects	GSK2256098	FAK113581	Cancer	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=113581	http://clinicaltrials.gov/show/NCT00996671		Y	Y	Y	Y	Y	Y	Y		1-May-2016
4011	GSK	A Randomised, Double-Blind (Sponsor-Unblind), Placebo Controlled, Cross-Over Study to Investigate the Efficacy, Effect on Cough Reflex Sensitivity, Safety, Tolerability and Pharmacokinetics of Inhaled GSK2339345 in Patients with Chronic Idiopathic Cough Using an Aqueous Droplet Inhaler	GSK2339345	PNV117270	Cough	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=117270	http://clinicaltrials.gov/show/NCT01899768	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-004891-20	Y	Y	Y	Y	Y	Y	Y		1-May-2016
4012	GSK	A study to evaluate the immunogenicity, safety and reactogenicity of adjuvinated influenza vaccine candidate compared to Fluarix™ (GlaxoSmithKline Biologicals) administered intramuscularly in elderly aged 60 years and older.	Influenza Vaccine	107975	Influenza	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=107975	http://clinicaltrials.gov/show/NCT00363077	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002680-18	N	N	Y	Y	Y	Y	N	An annotated case report form is not available for this study. A blank case report form will be provided. An analysis-ready dataset and reporting and analysis plan are not available for this study.	1-May-2016
4013	GSK	A study to evaluate the immunogenicity, safety and reactogenicity of adjuvinated influenza vaccine candidates compared to Fluarix™ administered intramuscularly in subjects aged 18-59 years.	Influenza Vaccine	108656	Influenza	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=108656	http://clinicaltrials.gov/show/NCT00374842	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003769-15	N	N	Y	Y	Y	Y	N	An annotated case report form is not available for this study. A blank case report form will be provided. An analysis-ready dataset and reporting and analysis plan are not available for this study.	1-May-2016
4014	GSK	A study to evaluate the immunogenicity, safety and reactogenicity of a second vaccination with the adjuvanted influenza vaccine candidate compared to Fluarix™ administered intramuscularly in elderly aged 60 years and above.	Influenza Vaccine	108708	Influenza	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=108708	http://clinicaltrials.gov/show/NCT00385840	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003815-31	Y	N	Y	Y	Y	Y	Y	This is a follow-up study to 107192 was conducted. An annotated case report form is not available for this study. A blank case report form will be provided.	1-May-2016
4015	GSK	An Open-Label Study to Evaluate the Immunogenicity and Safety of Raxibacumab (Human Monoclonal Antibody to B. anthracis Protective Antigen) Administered in Healthy Subjects	raxibacumab	HGS1021-C1069	Therapeutic treatment of inhalation anthrax	Phase 2/3	https://www.gsk-studyregister.com/en/trial-details/?id=HGS1021-C1069	http://clinicaltrials.gov/show/NCT02016963		Y	Y	Y	Y	Y	Y	Y	The raw data are included within the analysis-ready data for this study and are not provided separately.	1-May-2016
4016	GSK	A Study to Evaluate the Feasibility of Microdialysis to Determine Skin Concentrations of Retapamulin in Healthy Volunteers	retapamulin	RNG117151	Skin Infections, Bacterial	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=117151	http://clinicaltrials.gov/show/NCT01812382		N	Y	Y	Y	Y	Y	Y	An analysis-ready dataset is not available for this study.	1-May-2016
4017	GSK	A study to optimise the propranolol block model for assessment of the pharmacological activity of bronchodilators in healthy volunteers.	salbutamol	MAB104954	Pulmonary Disease, Chronic Obstructive	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=MAB104954	http://clinicaltrials.gov/show/NCT00549120		Y	Y	Y	Y	Y	Y	Y		1-May-2016
4018	GSK	A dose-ranging study of vilanterol (VI) inhalation powder in children aged 5-11 years with asthma on a background of inhaled corticosteroid therapy	vilanterol	HZA106853	Asthma	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=106853	http://clinicaltrials.gov/show/NCT01573767	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-003337-34	Y	Y	Y	Y	Y	Y	Y		1-May-2016
4033	Astellas	A phase III, double-blind, randomized study to evaluate safety and efficacy of BAL8557 versus voriconazole for primary treatment of invasive fungal disease caused by Aspergillus species or other filamentous fungi.	isavuconazonium sulfate	9766-CL-0104	Invasive aspergillosis / Invasive mucormycosis	Phase 3	https://www.clinicaltrials.astellas.com/study/?pid=9766-CL-0104	https://clinicaltrials.gov/ct2/show/NCT00412893	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003868-59	Y	Y	Y	Y	Y	Y	Y		1-May-2016
4034	Astellas	Open-Label Study of Isavuconazole in the Treatment of Patients with Aspergillosis and Renal Impairment or of Patients with Invasive Fungal Disease Caused by Rare Moulds, Yeasts or Dimorphic Fungi	isavuconazonium sulfate	9766-CL-0103	Invasive aspergillosis / Invasive mucormycosis	Phase 3	https://www.clinicaltrials.astellas.com/study/?pid=9766-CL-0103	https://clinicaltrials.gov/ct2/show/NCT00634049	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005003-33	Y	Y	Y	Y	Y	Y	Y		1-May-2016
4035	Astellas	A Study to Evaluate the Overall Effect of Solifenacin 5 mg and 10 mg on Bladder Wall Thickness and Urinary Nerve Growth Factor in Female Subjects with Overactive Bladder and a Diagnosis of Detrusor Overactivity – A Double-blind, Randomized, Placebo-controlled, Parallel-group, Multi-center Study	solifenacin succinate	905-EC-007	Urinary Bladder, Overactive	Phase 4	https://www.clinicaltrials.astellas.com/study/?pid=905-EC-007	https://clinicaltrials.gov/ct2/show/NCT01093534	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-005215-17	Y	Y	Y	Y	Y	Y	Y		1-May-2016
4040	Novartis	Three Month Efficacy and Safety Study of a Fixed Combination of Brinzolamide 1 %/Brimonidine 0.2 % Compared to Brinzolamide 1 % and Brimonidine 0.2 % All Dosed Three Times Daily in Patients With Open-Angle Glaucoma and/or Ocular Hypertension	brinzolamide	C-10-033	Open-Angle Glaucoma; Ocular Hypertension	Phase 3	https://www.novctrd.com/ctrdweb/trialresult/trialresults/pdf?trialResultId=12971	https://clinicaltrials.gov/show/NCT01297517		Y	Y	Y	Y	Y	Y	Y	Alcon is a division of Novartis	1-Jun-2016
4041	Novartis	A Three-Month, Randomized, Double-Masked, Parallel-Group Study with a Planned Three-Month Safety Extension of the Efficacy and Safety of a Fixed Combination of Brinzolamide 1 %/Brimonidine 0.2 % Compared to Brinzolamide 1 % and Brimonidine 0.2 % All Dosed Three Times Daily in Patients with Open-Angle Glaucoma and/or Ocular Hypertension	brinzolamide	C-10-039	Open-Angle Glaucoma; Ocular Hypertension	Phase 3	https://www.novctrd.com/ctrdweb/trialresult/trialresults/pdf?trialResultId=12972	https://clinicaltrials.gov/show/NCT01297920		Y	Y	Y	Y	Y	Y	Y	Alcon is a division of Novartis	1-Jun-2016
4042	Novartis	Safety and IOP-Lowering Efficacy of Brinzolamide 10 mg/mL/Brimonidine 2 mg/mL Fixed Combination Eye Drops, Suspension Compared to Brinzolamide 10 mg/mL Eye Drops, Suspension and Brimonidine 2 mg/mL Eye Drops, Solution in Patients With Open-Angle Glaucoma or Ocular Hypertension	brinzolamide	C-10-040	Open-Angle Glaucoma; Ocular Hypertension	Phase 3	https://www.novctrd.com/ctrdweb/trialresult/trialresults/pdf?trialResultId=12973	https://clinicaltrials.gov/show/NCT01310777	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-024512-34	Y	Y	Y	Y	Y	Y	Y	Alcon is a division of Novartis	1-Jun-2016
4044	Novartis	A Randomized, Double-blind, Multi-center Phase III Study Comparing Everolimus (RAD001) Plus Best Supportive Care Versus Placebo Plus Best Supportive Care in Patients With Advanced Gastric Cancer After Progression on 1 or 2 Prior Systemic Chemotherapy	everolimus	CRAD001R2301	Cancer, Advanced Gastric	Phase 3	https://www.novctrd.com/ctrdweb/trialresult/trialresults/pdf?trialResultId=13505	https://clinicaltrials.gov/show/NCT00879333	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-006544-20	Y	Y	Y	Y	Y	Y	Y		1-Jun-2016
4045	Novartis	A Phase III Randomized, Double-blind, Placebo-controlled, 2-period Crossover, Multicenter Study to Assess the Effect of Indacaterol (300 μg o.d.) on Exercise Endurance in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)	indacaterol	CQAB149B2311	Chronic Obstructive Pulmonary Disease (COPD)	Phase 3	https://www.novctrd.com/ctrdweb/trialresult/trialresults/pdf?trialResultId=2822	https://clinicaltrials.gov/show/NCT00620022	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004143-30	Y	Y	Y	Y	Y	Y	Y		1-Jun-2016
4046	Novartis	A Randomized, Blinded, Double Dummy, Multi-center, Placebo Controlled, 3 Period, Crossover Study to Assess the Effect of QVA149 (110/50 µg o.d.) on Exercise Endurance in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD), Using Tiotropium as an Active Control.	indacaterol, glycopyrrolate	CQVA149A2305	Chronic Obstructive Pulmonary Disease (COPD)	Phase 3	https://www.novctrd.com/ctrdweb/trialresult/trialresults/pdf?trialResultId=7505	https://clinicaltrials.gov/show/NCT01294787	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022721-14	Y	Y	Y	Y	Y	Y	Y		1-Jun-2016
4047	Novartis	An Open Label, Randomized Study of Nilotinib vs. Standard Imatinib (400/600 mg QD) Comparing the Kinetics of Complete Molecular Response for CML-CP Patients With Evidence of Persistent Leukemia by RQ-PCR.	nilotinib	CAMN107A2405	Chronic Myelogenous Leukemia	Phase 3	https://www.novctrd.com/ctrdweb/trialresult/trialresults/pdf?trialResultId=15067	https://www.clinicaltrials.gov/ct2/show/NCT00760877?term=CAMN107A2405&rank=1	https://www.clinicaltrialsregister.eu/ctr-search/search?query=CAMN107A2405	Y	Y	Y	Y	Y	Y	Y		1-May-2019
4048	Novartis	A Multi-center, Randomized, Double-blind, Placebo-controlled, Two-period Cross-over Study to Assess the Effect of 50µg Inhaled NVA237 on Exercise Endurance in Patients With Moderate to Severe COPD	glycopyrronium	CNVA237A2310	Chronic Obstructive Pulmonary Disease (COPD)	Phase 3	https://www.novctrd.com/ctrdweb/trialresult/trialresults/pdf?trialResultId=5183	https://clinicaltrials.gov/show/NCT01154127	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-018597-20	Y	Y	Y	Y	Y	Y	Y		1-Jun-2016
4050	Novartis	A Phase III, Multicenter, Randomized, Double-blind, Placebo-controlled, Dose-ranging Study to Evaluate the Efficacy and Safety of Xolair® (Omalizumab) in Patients With Chronic Idiopathic Urticaria (CIU)/Chronic Spontaneous Urticaria (CSU) Who Remain Symptomatic Despite Antihistamine Treatment (H1)	omalizumab	Q4881g	Chronic Idiopathic Urticaria (CIU)	Phase 3	http://roche-trials.com/studyResultGet.action?studyResultNumber=Q4881g	https://clinicaltrials.gov/show/NCT01287117		Y	Y	Y	Y	Y	Y	Y	Novartis & Roche co-license the Xolair studies.  Xolair information appears on both Company websites.	1-Jun-2016
4051	Novartis	A Phase III, Multicenter, Randomized, Double-blind, Dose-ranging, Placebo-controlled Study to Evaluate the Efficacy, Response Duration and Safety of Xolair (Omalizumab) in Patients With Chronic Idiopathic Urticaria (CIU)/Chronic Spontaneous Urticaria Who Remain Symptomatic Despite Antihistamine Treatment (H1)	omalizumab	Q4882g	Chronic Idiopathic Urticaria (CIU)	Phase 3	http://roche-trials.com/studyResultGet.action?studyResultNumber=Q4882g	https://clinicaltrials.gov/show/NCT01292473		Y	Y	Y	Y	Y	Y	Y	Novartis & Roche co-license the Xolair studies.  Xolair information appears on both Company websites.	1-Jun-2016
4053	Novartis	A Multicenter, Rater-blind, Randomized, Age-stratified, Parallel-group Study Comparing Two Doses of Oxcarbazepine as Monotherapy in Pediatric Patients With Inadequately-controlled Partial Seizures	oxcarbazepine	CTRI476E2339	Epilepsy	Phase 3	https://www.novctrd.com/ctrdweb/trialresult/trialresults/pdf?trialResultId=1634	https://clinicaltrials.gov/show/NCT00050947		Y	Y	Y	Y	Y	Y	Y		1-Jun-2016
4054	Novartis	A Multicenter, Rater-blind, Randomized, Age-stratified, Parallel-group Study Comparing Two Doses of Oxcarbazepine as Adjunctive Therapy in Pediatric Patients With Inadequately-controlled Partial Seizures	oxcarbazepine	CTRI476E2340	Epilepsy	Phase 3	https://www.novctrd.com/ctrdweb/trialresult/trialresults/pdf?trialResultId=1876	https://clinicaltrials.gov/show/NCT00050934		Y	Y	Y	Y	Y	Y	Y		1-Jun-2016
4061	Novartis	A multicenter, randomized, double-blind, parallel group study to assess the safety and tolerability of initiating LCZ696 in heart failure patients comparing two titration regimens	sacubitril/valsartan	CLCZ696B2228	Heart Failure	Phase 2	https://www.novctrd.com/ctrdweb/trialresult/trialresults/pdf?trialResultId=13984	https://clinicaltrials.gov/show/NCT01922089	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001835-33	Y	Y	Y	Y	Y	Y	Y		1-Jun-2016
4062	Novartis	A multicenter, randomized, double-blind, parallel group, active-controlled study to evaluate the efficacy and safety of LCZ696 compared to enalapril on morbidity and mortality in patients with chronic heart failure and reduced ejection fraction	sacubitril/valsartan	CLCZ696B2314	Heart Failure, Chronic (CHF)	Phase 3	https://www.novctrd.com/ctrdweb/trialresult/trialresults/pdf?trialResultId=13786	https://clinicaltrials.gov/show/NCT01035255	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-015834-31	Y	Y	Y	Y	Y	Y	Y		1-Jun-2016
4068	Novartis	A randomized, double-blind, multicenter study of subcutaneous secukinumab, assessing Psoriasis Area and Severity Index (PASI) response and maintenance of response in subjects with moderate to severe chronic plaque-type psoriasis on either a fixed dose regimen or on a retreatment at start of relapse regimen Study Comparing secukinumab Use in Long-term Psoriasis maintenance therapy: fixed regimens vs reTreatment Upon start of RElapse (SCULPTURE	secukinumab	CAIN457A2304	Psoriasis	Phase 3	https://www.novctrd.com/ctrdweb/trialresult/trialresults/pdf?trialResultId=13563	https://www.clinicaltrials.gov/ct2/show/NCT1406938?term=CAIN457A2304	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000767-27	Y	Y	Y	Y	Y	Y	Y		1-Jan-2020
4069	Novartis	A randomized, double-blind, double dummy, multicenter study to assess the safety, tolerability and long-term efficacy of intravenous (10 mg/kg) and subcutaneous (300 mg) secukinumab in patients with moderate to severe chronic plaque-type psoriasis who are partial responders to secukinumab Secukinumab Trial Analyzing the potential of intravenous administration To Upgrade the REsponse in psoriasis (STATURE)	secukinumab	CAIN457A2307	Psoriasis	Phase 3	https://www.novctrd.com/ctrdweb/trialresult/trialresults/pdf?trialResultId=11644	https://www.clinicaltrials.gov/ct2/show/NCT1412944?term=CAIN457A2307	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002510-36	Y	Y	Y	Y	Y	Y	Y		1-Jan-2020
4070	Novartis	A randomized, double-blind, placebo controlled, multicenter study of subcutaneous secukinumab in prefilled syringes to demonstrate efficacy after twelve weeks of treatment, and to assess the safety, tolerability, usability and long-term efficacy in subjects with chronic plaque-type psoriasis	secukinumab	CAIN457A2308	Psoriasis	Phase 3	https://www.novctrd.com/ctrdweb/trialresult/trialresults/pdf?trialResultId=16807	https://www.clinicaltrials.gov/ct2/show/NCT1555125?term=CAIN457A2308&rank=1	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-006057-28	Y	Y	Y	Y	Y	Y	Y		1-Jan-2020
4071	Novartis	A randomized, double-blind, placebo controlled, multicenter study of subcutaneous secukinumab in autoinjectors to demonstrate efficacy after twelve weeks of treatment, and to assess the safety, tolerability, usability and long-term efficacy in subjects with chronic plaque-type psoriasis	secukinumab	CAIN457A2309	Psoriasis	Phase 3	https://www.novctrd.com/ctrdweb/trialresult/trialresults/pdf?trialResultId=16808	https://www.clinicaltrials.gov/ct2/show/NCT1636687?term=CAIN457A2309&rank=1	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002609-22	Y	Y	Y	Y	Y	Y	Y		1-Jan-2020
4074	Novartis	A Multicenter, Double-Masked Study of the Safety and Efficacy of Travoprost Ophthalmic Solution, 0.003 % Compared to Travatan in Patients with Open-Angle Glaucoma or Ocular Hypertension	travoprost ophthalmic solution	C-11-034	Open-Angle Glaucoma; Ocular Hypertension	Phase 3	https://www.novctrd.com/ctrdweb/trialresult/trialresults/pdf?trialResultId=12951	https://clinicaltrials.gov/show/NCT01453855	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004587-29	Y	Y	Y	Y	Y	Y	Y	Alcon is a division of Novartis	1-Jun-2016
4082	Novartis	Multinational, multicenter, double-blind, randomized, active controlled, parallel group study comparing the efficacy and safety of long-term treatment with valsartan, captopril and their combination in high-risk patients after myocardial infarction	valsartan	CVAL489E0108	Hypertension	Phase 3	https://www.novctrd.com/ctrdweb/trialresult/trialresults/pdf?trialResultId=1517	Not available		Y	Y	Y	Y	Y	Y	Y		1-Jun-2016
4083	Novartis	A Prospective, Multinational, Multicenter Trial to Compare the Effects of Amlodipine/Benazepril to Benazepril and Hydrochlorothiazide Combined on the Reduction of Cardiovascular Morbidity and Mortality in Patients With High Risk Hypertension	amlodipine/benazepril hcl	CCIB002I2301	Hypertension	Phase 3	https://www.novctrd.com/ctrdweb/trialresult/trialresults/pdf?trialResultId=2612	https://clinicaltrials.gov/show/NCT00170950		Y	Y	Y	Y	Y	Y	Y		1-Feb-2017
4084	Novartis	A 24-month, Double-blind, Randomized, Multicenter, Placebo-controlled, Parallel-group Study Comparing the Efficacy and Safety of Fingolimod 1.25 mg and 0.5 mg Administered Orally Once Daily Versus Placebo in Patients With Relapsing-remitting Multiple Sclerosis	fingolimod	CFTY720D2301	Multiple Sclerosis	Phase 3	https://www.novctrd.com/ctrdweb/trialresult/trialresults/pdf?trialResultId=3147	https://clinicaltrials.gov/show/NCT00289978	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000365-19	Y	Y	Y	Y	Y	Y	Y		1-Jun-2016
4085	Novartis	A 12-month Double-blind, Randomized, Multicenter, Active-controlled, Parallel-group Study Comparing the Efficacy and Safety of 0.5 mg and 1.25 mg Fingolimod (FTY720) Administered Orally Once Daily Versus Interferon ß-1a (Avonex) Administered im Once Weekly in Patients With Relapsing-remitting Multiple Sclerosis With Optional Extension Phase	fingolimod	CFTY720D2302	Multiple Sclerosis	Phase 3	https://www.novctrd.com/ctrdweb/trialresult/trialresults/pdf?trialResultId=6685	https://clinicaltrials.gov/show/NCT00340834	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000704-17	Y	Y	Y	Y	Y	Y	Y		1-Jun-2016
4086	Novartis	A 24-week, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-finding Evaluation of the Efficacy, Safety, and Tolerability of the Once-daily Rivastigmine Transdermal Patch in Patients With Probable Alzheimer's Disease (MMSE 10-20)	rivastigmine	CENA713D1301	Alzheimer's Disease	Phase 3	https://www.novctrd.com/ctrdweb/trialresult/trialresults/pdf?trialResultId=4162	https://clinicaltrials.gov/show/NCT00423085		Y	Y	Y	Y	Y	Y	Y		1-Jun-2016
4087	Novartis	A Multinational, Randomized, Double-blind, Placebo-controlled, Forced-titration, 2 x 2 Factorial Design Study of the Efficacy and Safety of Long-term Administration of Nateglinide and Valsartan in the Prevention of Diabetes and Cardiovascular Outcomes in Subjects With Impaired Glucose Tolerance (IGT)	valsartan	CDJN608B2302	Diabetes Mellitus, Type 2	Phase 3	https://www.novctrd.com/ctrdweb/trialresult/trialresults/pdf?trialResultId=3223	https://clinicaltrials.gov/show/NCT00097786		Y	Y	Y	Y	Y	Y	Y		1-Jun-2016
4089	Novartis	24-month Double-blind, Randomized, Multicenter, Placebo-controlled, Parallel-group Study Comparing the Efficacy and Safety of 0.5 mg and 1.25 mg Fingolimod (FTY720) Administered Orally Once Daily Versus Placebo in Patients With Relapsing-remitting Multiple Sclerosis With Optional Extension Phase	fingolimod	CFTY720D2309	Multiple Sclerosis	Phase 3	https://www.novctrd.com/ctrdweb/trialresult/trialresults/pdf?trialResultId=6223	https://clinicaltrials.gov/show/NCT00355134	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-002096-27	Y	Y	Y	Y	Y	Y	Y		1-Jun-2016
4095	Novartis	A Multicenter, Randomized, Double Blind, Placebo Controlled Phase III Study of Panobinostat in Combination With Bortezomib and Dexamethasone in Patients With Relapsed Multiple Myeloma	panobinostat	CLBH589D2308	Multiple myeloma (MM); Myelodysplastic syndrome (MDS)	Phase 3	https://www.novctrd.com/ctrdweb/trialresult/trialresults/pdf?trialResultId=13623	https://clinicaltrials.gov/show/NCT01023308	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-015507-52	Y	Y	Y	Y	Y	Y	Y		1-Jun-2016
4107	GSK	Comparative Randomized, Single Dose, Two-way Crossover, Open-label Study to Determine the Bioequivalence of Cefadroxil from Duricef 1 gm Film Coated Tablets (Smithkline Beecham Egypt, LLC Affiliated Co. to GlaxoSmithKline ) and Biodroxil 1 gm Film Coated tablets (Kahira Pharm &Chem .Ind. Co. for Novartis Pharma ) After a Single Oral Dose Administration of Each to Healthy Adults Under Fasting Conditions	cefadroxil	201529	Healthy Subjects	Phase 4	https://www.gsk-studyregister.com/en/trial-details/?id=201529	http://clinicaltrials.gov/show/NCT02446496		N	Y	Y	Y	Y	Y	N	An analysis-ready dataset and reporting and analysis plan are not available for this study.	1-Jun-2016
4108	GSK	A randomised, repeat-dose, placebo-controlled, three-way crossover, double dummy study to evaluate and compare the efficacy of Fluticasone Furoate inhalation powder delivered via the single strip dry powder inhaler when administered either in the morning or in the evening, in male and female asthmatic subjects	fluticasone furoate	FFA117156	Asthma	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=117156	http://clinicaltrials.gov/show/NCT01808339		Y	Y	Y	Y	Y	Y	Y		1-Jun-2016
4109	GSK	A Clinical Outcomes Study to compare the effect of Fluticasone Furoate/Vilanterol Inhalation Powder 100/25mcg with placebo on Survival in Subjects with moderate Chronic Obstructive Pulmonary Disease (COPD) and a history of or at increased risk for cardiovascular disease	fluticasone furoate/vilanterol	HZC113782	Pulmonary Disease, Chronic Obstructive	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=113782	http://clinicaltrials.gov/show/NCT01313676	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-021638-72	Y	Y	Y	Y	Y	Y	Y	There is a Publication Steering Committee for this study.	1-Jun-2016
4110	GSK	"""A Randomised, Double-Blind, Placebo-Controlled, Cross-Over, Single-Centre Study to Investigate the Acute Lung Deflation. Effects of Fluticasone Furoate/Vilanterol Inhalation Powder 100/25mcg Once Daily on Cardiac Biventricular Function and Arterial Stiffness in Adults with Chronic Obstructive Pulmonary Disease (COPD)"""	fluticasone furoate/vilanterol	HZC116601	Pulmonary Disease, Chronic Obstructive	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=116601	http://clinicaltrials.gov/show/NCT01691885	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000927-42	Y	Y	Y	Y	Y	Y	Y		1-Jun-2016
4111	GSK	An Open-Label, Randomised, Two Treatment, Four-Way Cross-Over (Replicate Design), Two Sequence, Repeat Dose, Single Centre Study in Healthy Volunteers to Compare the Pharmacokinetics of Fluticasone Propionate/Salmeterol (100/50 mcg) Delivered Via the Low Airflow Resistance ROTAHALER Inhaler Relative to Fluticasone Propionate/Salmeterol (100/50 mcg) Delivered Via the DISKUS Inhaler	Fluticasone Propionate/Salmeterol	200260	Asthma	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=200260	http://clinicaltrials.gov/show/NCT01890863		Y	Y	Y	Y	Y	Y	Y		1-Jun-2016
4112	GSK	A Phase I Open-Label, Dose-Escalation Study of the Phosphoinositide 3-Kinase Inhibitor GSK2126458 in Subjects with Solid Tumors or Lymphoma	omipalisib	P3K112826	Solid Tumours	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=112826	http://clinicaltrials.gov/show/NCT00972686	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-012339-14	Y	Y	Y	Y	Y	Y	Y		1-Jun-2016
4113	GSK	A study to evaluate the pharmacokinetics, safety and tolerability, immunogenicity, and pharmacodynamics of GSK2800528 in healthy subjects.	GSK2800528	GZL116987	Psoriasis	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=116987	http://clinicaltrials.gov/show/NCT01899755	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-004474-26	Y	Y	Y	Y	Y	Y	Y	This study is available in CDISC format	1-Jun-2016
4114	GSK	A Randomised, Double-Blind, Placebo-Controlled, Single-Centre Study to Provide a Preliminary evaluation of Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Intravenous anti-human interleukin-5 (mepolizumab, 750mg and 1500mg) in the treatment of Eosinophilic Oesophagitis in Adults	mepolizumab	MEE103226	Oesophagitis, Eosinophilic	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=MEE103226	http://clinicaltrials.gov/show/NCT00274703		N	N	Y	Y	Y	Y	N	An annotated case report form is not available for this study. A blank case report form will be provided. An analysis-ready dataset and reporting and analysis plan are not available for this study.	1-Jun-2016
4115	GSK	A Randomized, Parallel-group, Open-label Study to Evaluate the Efficacy and Safety of Umeclidinium (UMEC) 62.5 mcg compared with Glycopyrronium 44 mcg in Subjects with Chronic Obstructive Pulmonary Disease (COPD)	umeclidinium bromide	201315	Pulmonary Disease, Chronic Obstructive	Phase 4	https://www.gsk-studyregister.com/en/trial-details/?id=201315	http://clinicaltrials.gov/show/NCT02236611	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-000885-23	Y	Y	Y	Y	Y	Y	Y	The raw data are included within the analysis-ready data for this study and are not provided separately.	1-Jun-2016
4116	GSK	A Randomized, Blinded, Double-dummy, Parallel-group Study to Evaluate the Efficacy and Safety of Umeclidinium (UMEC) 62.5 mcg compared with Tiotropium 18 mcg in Subjects with Chronic Obstructive Pulmonary Disease (COPD)	umeclidinium bromide	201316	Pulmonary Disease, Chronic Obstructive	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=201316	http://clinicaltrials.gov/show/NCT02207829	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-000884-42	Y	Y	Y	Y	Y	Y	Y	The raw data are included within the analysis-ready data for this study and are not provided separately.	1-Jun-2016
4118	Novartis	Efficacy and Safety of Brinzolamide 10 mg/mL/Brimonidine 2 mg/mL Eye Drops, Suspension Compared to Brinzolamide 10 mg/mL Eye Drops, Suspension Plus Brimonidine 2 mg/mL Eye Drops, Solution in Patients With Open-Angle Glaucoma or Ocular Hypertension	brinzolamide	C-10-041	Open-Angle Glaucoma; Ocular Hypertension	Phase 3	https://www.novctrd.com/ctrdweb/trialresult/trialresults/pdf?trialResultId=12974	https://clinicaltrials.gov/show/NCT01309204	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-024513-31	Y	Y	Y	Y	Y	Y	Y	Alcon is a division of Novartis	1-Jul-2016
4120	Novartis	A Phase I, Multi-center, Open Label Dose Escalation Study of LDK378, Administered Orally in Adult Patients With Tumors Characterized by Genetic Abnormalities in Anaplastic Lymphoma Kinase (ALK)	ceritinib	CLDK378X2101	Tumors Characterized by Genetic Abnormalities of ALK	Phase 1/2	https://www.novctrd.com/ctrdweb/trialresult/trialresults/pdf?trialResultId=12003	https://clinicaltrials.gov/show/NCT01283516		Y	Y	Y	Y	Y	Y	Y		1-Jul-2016
4121	Novartis	A Phase II, Multicenter, Single-arm Study of Oral LDK378 in Adult Patients With ALK-activated Non-small Cell Lung Cancer Previously Treated With Chemotherapy and Crizotinib	ceritinib	CLDK378A2201	Non-small cell lung carcinoma (NSCLC)	Phase 2	https://www.novctrd.com/ctrdweb/trialresult/trialresults/pdf?trialResultId=16109	https://clinicaltrials.gov/show/NCT01685060	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003432-24	Y	Y	Y	Y	Y	Y	Y		1-Jul-2017
4123	Novartis	A Phase II (BRF113710) Single-arm, Open-label Study of GSK2118436 in BRAF Mutant Metastatic Melanoma	dabrafenib	BRF113710	Melanoma	Phase 2	https://www.gsk-clinicalstudyregister.com/study/113710	https://www.clinicaltrials.gov/ct2/show/NCT01153763?term=BRF113710&rank=1		Y	Y	Y	Y	Y	Y	Y		1-Apr-2018
4124	Novartis	BRF113929: An Open-Label, Two-Cohort, Multicentre Study of GSK2118436 as a Single Agent in Treatment Naïve and Previously Treated Subjects With BRAF Mutation-Positive Metastatic Melanoma to the Brain	dabrafenib	BRF113929	Melanoma	Phase 2	https://www.gsk-clinicalstudyregister.com/search/?study_ids=113929	https://clinicaltrials.gov/show/NCT01266967		Y	Y	Y	Y	Y	Y	Y		1-Jun-2017
4131	Novartis	Randomised, Double-Blind, Placebo-Controlled, Multi-Centre Study to Evaluate the Safety and Efficacy of Eltrombopag to Reduce the Need for Platelet Transfusion in Thrombocytopenic Subjects with Chronic Liver Disease Undergoing Elective Invasive Procedures	eltrombopag	TPL104054	Liver Diseases	Phase 3	http://www.gsk-clinicalstudyregister.com/study/TPL104054	http://clinicaltrials.gov/show/NCT00678587		Y	Y	Y	Y	Y	Y	Y		1-Jun-2014
4137	Novartis	Efficacy and Safety Study Comparing Concentration-controlled Everolimus in Two Doses (1.5 and 3.0 mg/Day Starting Doses) With Reduced Cyclosporine Versus 1.44 g Mycophenolic Acid (as Sodium Salt) With Standard Dose Cyclosporine in de Novo Renal Transplant Recipients	everolimus	CRAD001A2309	Kidney Transplantation	Phase 3	https://www.novctrd.com/ctrdweb/trialresult/trialresults/pdf?trialResultId=3401	https://clinicaltrials.gov/show/NCT00251004	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002854-22	Y	Y	Y	Y	Y	Y	Y		1-Jul-2016
4138	Novartis	An Exploratory Evaluation of Early Use of Everolimus (EVE) on Tacrolimus (TAC)-Based Immunosuppressive Regiment vs. Mycophenolate Sodium (MPS) on Cytomegalovirus (CMV) Infection in Renal Transplant Recipients.	everolimus	CRAD001 B201	Kidney Transplantation	Phase 3				Y	Y	Y	Y	Y	Y	Y		1-Jul-2016
4139	Novartis	An Exploratory Evaluation of Early Use of Everolimus (EVE) on Tacrolimus (TAC)-Based Immunosuppressive Regiment vs. Mycophenolate Sodium (MPS) on Cytomegalovirus (CMV) Infection in Renal Transplant Recipients.	everolimus	CRAD001 B251	Kidney Transplantation	Phase 3				Y	Y	Y	Y	Y	Y	Y		1-Jul-2016
4140	Novartis	"Two-year randomized, multi-center, doubleblind, double-dummy study of the efficacy and safety of everolimus versus azathioprine (AZA) as part of a triple immunosuppressive therapy regimen in de novo heart transplant recipients."	everolimus	CRAD001B253	Heart transplantation	Phase 3		Not available		Y	Y	Y	Y	Y	Y	Y		1-Jul-2016
4141	Novartis	A 24 Month, Multicenter, Open-label, Randomized, Controlled Study to Evaluate the Efficacy and Safety of Concentration-controlled Everolimus to Eliminate or to Reduce Tacrolimus Compared to Tacrolimus in de Novo Liver Transplant Recipients	everolimus	CRAD001H2304	Liver Transplantation	Phase 3	https://www.novctrd.com/ctrdweb/trialresult/trialresults/pdf?trialResultId=8503	https://clinicaltrials.gov/show/NCT00622869	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001821-85	Y	Y	Y	Y	Y	Y	Y		1-Jul-2016
4151	Novartis	An Open-Label, Multicenter, Single Arm Phase II Study of Oral GW572016 as Single Agent Therapy in Subjects with Advanced or Metastatic Breast Cancer Who Have Progressed While Receiving HERCEPTIN-Containing Regimens	lapatinib	EGF20008	Neoplasms, Breast	Phase 2	http://www.gsk-clinicalstudyregister.com/study/EGF20008	http://clinicaltrials.gov/show/NCT00062686		Y	Y	Y	Y	Y	N	Y	The raw dataset is included within the analysis-ready dataset.	1-Jun-2014
4154	Novartis	A Randomized, Multicenter, Open-Label, Phase III Study of Lapatinib in Combination with Trastuzumab versus Lapatinib Monotherapy in Subjects with HER2-positive Metastatic Breast Cancer whose disease has progressed on Trastuzumab-Containing Regimens	lapatinib	EGF104900	Neoplasms, Breast	Phase 3	http://www.gsk-clinicalstudyregister.com/study/EGF104900	http://clinicaltrials.gov/show/NCT00320385		Y	Y	Y	Y	Y	N	Y	The raw dataset is included within the analysis-ready dataset.	1-Jun-2014
4155	Novartis	A Randomized, Multicenter, Double-Blind, Placebo-Controlled, 2-Arm, Phase III Study of Oral GW572016 in Combination with Paclitaxel in Subjects Previously Untreated or Advanced or Metastatic Breast Cancer	lapatinib	EGF30001	Neoplasms, Breast	Phase 3	http://www.gsk-clinicalstudyregister.com/study/EGF30001	http://clinicaltrials.gov/show/NCT00075270		Y	Y	Y	Y	Y	N	Y	The raw dataset is included within the analysis-ready dataset.	1-Jun-2014
4163	Novartis	A Randomized Double Blind Phase III Trial of Pazopanib Versus Placebo in Patients With Soft Tissue Sarcoma Whose Disease Has Progressed During or Following Prior Therapy	pazopanib	VEG110727	Sarcoma, Soft tissue	Phase 3	http://www.gsk-clinicalstudyregister.com/study/VEG110727	http://clinicaltrials.gov/show/NCT00753688		Y	Y	Y	Y	Y	Y	Y		1-May-2013
4164	Novartis	A Randomised, Double-blind, Placebo controlled, Multi-center Phase III Study to Evaluate the Efficacy and Safety of Pazopanib (GW786034) Compared to Placebo in Patients with Locally Advanced and/or Metastatic Renal Cell Carcinoma	pazopanib	VEG105192	Carcinoma, Renal Cell	Phase 3	http://www.gsk-clinicalstudyregister.com/study/VEG105192	http://clinicaltrials.gov/show/NCT00334282		Y	Y	Y	Y	Y	Y	Y		1-Sep-2013
4165	Novartis	A Phase II Study of GW786034 Using a Randomised Discontinuation Design in Subjects with Locally Recurrent or Metastatic Clear-Cell Renal Cell Carcinoma	pazopanib	VEG102616	Carcinoma, Renal Cell	Phase 2	http://www.gsk-clinicalstudyregister.com/study/VEG102616	http://clinicaltrials.gov/show/NCT00244764		Y	Y	Y	Y	Y	Y	Y		1-Sep-2013
4178	Novartis	Phase II Study of GW786034 in Patients With Relapsed or Refractory Soft Tissue Sarcoma	pazopanib	VEG20002	Sarcoma, Soft tissue	Phase 2	https://www.gsk-clinicalstudyregister.com/study/VEG20002	https://clinicaltrials.gov/show/NCT00297258		Y	Y	Y	Y	Y	Y	Y		1-Apr-2017
4179	Novartis	A Prospective, Randomized, Multicenter, Double-Blind, Placebo-Controlled, Parallel-Group Study of the Effect of Rivastigmine on the Time to Clinical Diagnosis of Alzheimer’s Disease in Subjects with Mild Cognitive Impairment (MCI)	rivastigmine	CENA713 IA07	Alzheimer's Disease	Phase 3	https://www.novctrd.com/ctrdweb/trialresult/trialresults/pdf?trialResultId=1886	Not available		Y	Y	Y	Y	Y	Y	Y		1-Jul-2016
4180	Novartis	A 24-week Prospective, Randomized, Multicenter, Double-Blind, Placebo-Controlled, Parallel-Group Study of the Efficacy, Tolerability, and Safety of 3-12 mg/day of Rivastigmine Capsules in Patients with Parkinson’s Disease Dementia	rivastigmine	CENA713B2311	Parkinson's Disease Dementia	Phase 3	https://www.novctrd.com/ctrdweb/trialresult/trialresults/pdf?trialResultId=1616	Not available		Y	Y	Y	Y	Y	Y	Y		1-Jul-2016
4183	Novartis	A Randomized, Double-blind, Placebo-controlled, Multicenter Study of Secukinumab to Demonstrate the Efficacy at 24 Weeks and to Assess the Long Term Safety, Tolerability and Efficacy up to 2 Years in Patients With Active Psoriatic Arthritis	secukinumab	CAIN457F2306	Psoriatic Arthritis	Phase 3	https://www.novctrd.com/ctrdweb/trialresult/trialresults/pdf?trialResultId=14231	https://clinicaltrials.gov/show/NCT01392326	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000276-34	Y	Y	Y	Y	Y	Y	Y		1-Jul-2017
4184	Novartis	Efficacy at 24 Weeks With Long Term Safety, Tolerability and Efficacy up to 5 Years of Secukinumab in Patients of Active Psoriatic Arthritis (FUTURE 2)	secukinumab	CAIN457F2312	Psoriatic Arthritis	Phase 3	https://www.novctrd.com/ctrdweb/trialresult/trialresults/pdf?trialResultId=17573	https://www.clinicaltrials.gov/ct2/show/NCT01752634?term=CAIN457F2312&draw=2&rank=1	https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-004439-22/results	N	N	N	N	N	N	N		1-Nov-2022
4187	Novartis	An Open-Label, Multi-Center Study to Investigate the Objective Response Rate, Safety, and Pharmacokinetics of GSK1120212, a MEK Inhibitor, in BRAF Mutation-positive Melanoma Subjects Previously Treated with or without a BRAF Inhibitor	trametinib	MEK113583	Cancer	Phase 2	http://www.gsk-clinicalstudyregister.com/study/113583	http://clinicaltrials.gov/show/NCT01037127		Y	Y	Y	Y	Y	Y	Y		1-Sep-2013
4189	Novartis	Multinational, multicenter, double-blind, randomized, placebo-controlled, parallel group study assessing the efficacy of intravenous zoledronic acid in preventing subsequent osteoporotic fractures after a hip fracture	zoledronic acid	CZOL446H2310	Osteoporosis; Hip Fracture	Phase 3		https://clinicaltrials.gov/show/NCT00046254		Y	Y	Y	Y	Y	Y	Y		1-Jul-2016
4190	Novartis	A multicenter, double-blind, randomized, placebo-controlled study to evaluate the safety and efficacy of zoledronic acid in the treatment of osteoporosis in postmenopausal women taking cal-cium and vitamin D	zoledronic acid	CZOL446H2301	Osteoporosis	Phase 3	https://www.novctrd.com/ctrdweb/trialresult/trialresults/pdf?trialResultId=2323	https://clinicaltrials.gov/show/NCT00049829		Y	Y	Y	Y	Y	Y	Y		1-Jul-2016
4191	Novartis	A 3-year, Double-blind Extension to CZOL446H2301 to Evaluate the Long-term Safety and Efficacy of Zoledronic Acid in the Treatment of Osteoporosis in Postmenopausal Women Taking Calcium and Vitamin D	zoledronic acid	CZOL446H2301E1	Osteoporosis	Phase 3	https://www.novctrd.com/ctrdweb/trialresult/trialresults/pdf?trialResultId=3662	https://clinicaltrials.gov/show/NCT00145327	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000668-17	Y	Y	Y	Y	Y	Y	Y		1-Jul-2016
4192	Novartis	A 3-year, Multicenter, Double-blind, Randomized, Placebo-controlled Extension to CZOL446H2301E1 to Evaluate the Efficacy and Long Term Safety of 6 and 9 Years Zoledronic Acid Treatment of Postmenopausal Women With Osteoporosis	zoledronic acid	CZOL446H2301E2	Osteoporosis	Phase 3	https://www.novctrd.com/ctrdweb/trialresult/trialresults/pdf?trialResultId=10323	https://clinicaltrials.gov/show/NCT00718861	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005383-27	Y	Y	Y	Y	Y	Y	Y		1-Jul-2016
4193	Novartis	A One-year Partial Double-blinded, Randomized, Multi-center, Multi-national Study to Assess the Effects of Combination Therapy of Annual Zoledronic Acid (5 mg) and Daily Subcutaneous Teriparatide (2mcrg) on Postmenopausal Women With Severe Osteoporosis	zoledronic acid	CZOL446H2409	Osteoporosis	Phase 3	https://www.novctrd.com/ctrdweb/trialresult/trialresults/pdf?trialResultId=2856	https://clinicaltrials.gov/show/NCT00439244	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000861-12	Y	Y	Y	Y	Y	Y	Y		1-Jul-2016
4194	Novartis	Randomized, multicenter, double-blind, double-dummy, parallel group study to determine the efficacy and safety of intravenous zoledronic acid 5 mg annually compared to oral alendronate 70 mg weekly for the treatment of osteoporosis in men	zoledronic acid	CZOL446M2308	Osteoporosis	Phase 3	https://www.novctrd.com/ctrdweb/trialresult/trialresults/pdf?trialResultId=2545	https://clinicaltrials.gov/ct2/show/NCT00097825?term=CZOL446M2308&rank=1		Y	Y	Y	Y	Y	Y	Y		1-Jul-2016
4195	Novartis	A Two Year Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Fracture Efficacy and Safety of Intravenous Zoledronic Acid 5 mg Annually for the Treatment of Osteoporosis in Men	zoledronic acid	CZOL446M2309	Osteoporosis, Male	Phase 3	https://www.novctrd.com/ctrdweb/trialresult/trialresults/pdf?trialResultId=4646	https://clinicaltrials.gov/show/NCT00439647	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-004131-57	Y	Y	Y	Y	Y	Y	Y		1-Jul-2016
4196	Novartis	Efficacy and Safety of Zoledronic Acid in the Prevention and Treatment of Corticosteroid Induced Osteoporosis	zoledronic acid	CZOL446O2306	Osteoporosis	Phase 3	https://www.novctrd.com/ctrdweb/trialresult/trialresults/pdf?trialResultId=2456	https://clinicaltrials.gov/show/NCT00100620	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000248-25	Y	Y	Y	Y	Y	Y	Y		1-Jul-2016
4204	Novartis	A Randomised, Double-Blind, Placebo-Controlled, Multi-centre, Phase III Study of Post-Operative Adjuvant Lapatinib or Placebo and Concurrent Chemoradiotherapy Followed by Maintenance Lapatinib or Placebo Monotherapy in High-Risk Subjects With Resected Squamous Cell Carcinoma of the Head and Neck (SCCHN)	lapatinib	EGF102988	Neoplasms, Head and Neck	Phase 3	https://www.gsk-clinicalstudyregister.com/study/EGF102988	https://clinicaltrials.gov/show/NCT00424255		Y	Y	Y	Y	Y	N	Y	The raw dataset is included within the analysis-ready dataset.	1-Feb-2017
4217	GSK	A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multicenter Monotherapy Study to Determine the Efficacy and Safety of 2 Dose Levels of Albiglutide in Subjects with Type 2 Diabetes Mellitus	albiglutide	GLP113121	Diabetes Mellitus, Type 2	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=113121	http://clinicaltrials.gov/show/NCT01733758		Y	Y	Y	Y	Y	Y	Y	This study is available in CDISC format	1-Jul-2016
4219	GSK	A Randomized, Parallel-Group, Open-Label Study to Estimate the Relative Bioavailability, Tolerability and Safety of a Single Dose of Belimumab Administered Subcutaneously to Healthy Subjects by Prefilled Syringe or Autoinjector	belimumab	BEL117100	Systemic Lupus Erythematosus	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=117100	http://clinicaltrials.gov/show/NCT01894360	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003691-12	Y	Y	Y	Y	Y	Y	Y		1-Jul-2016
4220	GSK	A Multi-center, Single-blind, Parallel Group, Clinical Evaluation of the Efficacy and Safety of Clindamycin 1% / Benzoyl Peroxide 3% and Azelaic Acid 20% in the Topical Treatment of Mild to Moderate Acne Vulgaris	benzoyl peroxide/clindamycin phosphate	200398	Acne Vulgaris	Phase 4	https://www.gsk-studyregister.com/en/trial-details/?id=200398	http://clinicaltrials.gov/show/NCT02058628	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004158-81	Y	Y	Y	Y	Y	Y	Y	This study is available in CDISC format.	1-Jul-2016
4221	GSK	An Open Label, Single Sequence, Three Period, Drug-Drug Interaction Study To Examine The Pharmacokinetics Of Dutasteride And Tamsulosin And Their Interactions In Chinese Male Healthy Volunteers	dutasteride	200254	Prostatic Hyperplasia	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=200254	http://clinicaltrials.gov/show/NCT01957189		Y	Y	Y	Y	Y	N	Y	A raw dataset is not available for this study.	1-Jul-2016
4222	GSK	An open label, randomised, six-way crossover, single dose study to determine the pharmacokinetics of GSK961081 and fluticasone furoate when administered alone or in combination	batefenterol; fluticasone furoate	201010	Pulmonary Disease, Chronic Obstructive	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=201010	http://clinicaltrials.gov/show/NCT02064504		Y	Y	Y	Y	Y	Y	Y		1-Jul-2016
4223	GSK	A Relative Bioavailability Study to Compare the Pharmacokinetics of a Fixed Dose Combination of Fluticasone Furoate and Levocabastine with Levocabastine and Fluticasone Furoate Alone	fluticasone furoate/Levocabastine	200284	Rhinitis, Allergic, Perennial and Seasonal	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=200284	http://clinicaltrials.gov/show/NCT01962467		Y	Y	Y	Y	Y	Y	Y		1-Jul-2016
4224	GSK	Study 200165, A Randomized, Double-Blind, Placebo-Controlled, Multi-Center, Parallel-Group Study to Compare the Efficacy of a 2-Week Treatment with Fluticasone Propionate Nasal Spray versus Cetirizine in Adult Subjects with Seasonal Allergic Rhinitis (SAR)	fluticasone propionate	200165	Rhinitis, Allergic, Perennial and Seasonal	Phase 4	https://www.gsk-studyregister.com/en/trial-details/?id=200165	http://clinicaltrials.gov/show/NCT01916226		Y	Y	Y	Y	Y	Y	Y		1-Jul-2016
4225	GSK	A two-part, randomised, placebo-controlled study to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of single and repeat doses of intravenously infused GSK1995057 in healthy subjects.	GSK1995057	TFR110951	Respiratory Disorders	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=110951	http://clinicaltrials.gov/show/NCT01476046	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023836-18	Y	Y	Y	Y	Y	Y	Y		1-Jul-2016
4226	GSK	Immunogenicity and safety study of GSK Biologicals’ quadrivalent influenza vaccine (GSK2282512A) in children 6 to 35 months of age	GSK2282512A; Influenza Vaccine (Quadrivalent)	200806	Influenza	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=200806	http://clinicaltrials.gov/show/NCT01974895		Y	Y	Y	Y	Y	Y	Y		1-Jul-2016
4227	GSK	A single-blind, randomized study to evaluate the immunogenicity and reactogenicity of two production lots of GlaxoSmithKline Biologicals’ combined Vi polysaccharide typhoid and inactivated hepatitis A vaccine stored between 2 °C-8 °C for either 0-12 or 24-36 months and administered as a single dose to healthy adult volunteers	Hepatitis A Vaccine, Inactivated	270362/004 (TypHA-004)	Hepatitis A	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=270362/004			Y	N	Y	Y	Y	Y	N	A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies. An annotated case report form is not available for this study. A blank case report form will be provided. A reporting and analysis plan is not available for this study. An analysis-ready dataset is not available for this study.	1-May-2016
4228	GSK	Phase III study to compare immunogenicity, safety and reactogenicity of GSK Bios’ novel adjuvanted hepatitis B vaccine admind intramuscularly, according to a 0, 6 month schedule, to Engerix™-B 20 mcg admind according to a 0,1,6 month schedule in healthy volunteers positive for the HLA-DQ2 genotype	Hepatitis B Vaccine, Recombinant	208129/034 (HBV-MPL-034)	Hepatitis B	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=208129/034	http://clinicaltrials.gov/show/NCT00697749		Y	N	Y	Y	Y	Y	Y	An annotated case report form is not available for this study. A blank case report form will be provided.	1-Jul-2016
4229	GSK	Study to compare the immunogenicity and safety of GSK Biologicals’ novel adjuvanted HBV vaccine (0, 21-day schedule) to a double dose of Engerix™ -B (0, 7, 21-day schedule), in pre-liver transplant patients ≥ 18 y, boosted at month 6-12	Hepatitis B Vaccine, Recombinant	208129/036 (HBV-MPL-036)	Hepatitis B	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=208129/036	http://clinicaltrials.gov/show/NCT00697554		Y	N	Y	Y	Y	Y	N	A reporting and analysis plan is not available for this study. An annotated case report form is not available for this study. A blank case report form will be provided.	1-Jul-2016
4230	GSK	Evaluating the consistency of 3 consecutive lots of GSK Biologicals' novel adjuvanted HBV vaccine with single-blind safety evaluation using Engerix™-B as a control, administered according to a 0, 1, 2-month schedule in healthy volunteers (15-50y).	Hepatitis B Vaccine, Recombinant	208129/037	Hepatitis B	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=208129/037	http://clinicaltrials.gov/show/NCT00697866		Y	N	Y	Y	Y	Y	Y	An annotated case report form is not available for this study. A blank case report form will be provided.	1-May-2016
4231	GSK	A study to evaluate antibody responses to 10 and 20 µg of licensed recombinant hepatitis B vaccine among elderly patients	Hepatitis B Vaccine, Recombinant	103860/128 (HBV-128)	Hepatitis B	Phase 4	https://www.gsk-studyregister.com/en/trial-details/?id=103860/128			Y	N	Y	Y	N	Y	Y	A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies. An annotated case report form is not available for this study. A blank case report form will be provided. A protocol is not available for this study.	1-May-2016
4232	GSK	Demonstrate the lot-to-lot consistency of 3 consecutive production lots of an adjuvinated influenza vaccine candidate and evaluate the safety of an adjuvinated influenza vaccine candidate versus Fluarix™ administered intramuscularly in elderly	Influenza Vaccine	107192	Influenza	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=107192	http://clinicaltrials.gov/show/NCT00321763	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001169-40	Y	N	Y	Y	Y	Y	N	A follow-on study 107214 was conducted. An annotated case report form is not available for this study. A blank case report form will be provided. A reporting and analysis plan is not available for this study.	1-May-2016
4233	GSK	A Study to Demonstrate the Non-Inferiority of Influenza Vaccine Candidate, Compared With Fluarix™ Administered Intramuscularly in Elderly Aged 60 Years Old and Above	Influenza Vaccine	107022	Influenza	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=107022	http://clinicaltrials.gov/show/NCT00321373	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000939-97	Y	N	Y	Y	Y	Y	N	A follow-on study 107191 was conducted. An annotated case report form is not available for this study. A blank case report form will be provided. A reporting and analysis plan is not available for this study.	1-May-2016
4234	GSK	Study in an elderly population aged over 65 years (>= 65 years-old) in order to evaluate reactogenicity and immunogenicity of GlaxoSmithKline Biologicals' experimental Influenza vaccines, administered intramuscularly as compared to Fluarix vaccine	Influenza Vaccine	103304-001	Influenza	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=103304-001			Y	N	Y	Y	Y	Y	Y	Follow-on studies 104540, 107973 and 110223 were conducted. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies. An annotated case report form is not available for this study. A blank case report form will be provided.	1-May-2016
4235	GSK	Double-blind randomised, multicentre, comparative phase III vaccination study to determine the immunogenicity and reactogenicity of an investigational influenza vaccine formulation versus the standard formulation of Influsplit SSW® 2004/2005 in subjects at least 18 years old.	Influenza Vaccine (Split Virion, Inactivated)	102500-060	Influenza	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=102500-060			Y	N	Y	Y	Y	Y	Y	A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies. An annotated case report form is not available for this study. A blank case report form will be provided.	1-Jul-2016
4236	GSK	Open, multicentre study to assess the safety, reactogenicity and immunogenicity of GlaxoSmithKline Biologicals live attenuated Measles-Mumps-Rubella vaccine (Priorix) given to healthy children at the age of 12 to 15 months or 4- 6 years	Measles, Mumps, Rubella Vaccine	209762/146 (MMR-146)	Measles, Mumps, Rubella	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=209762/146			Y	N	Y	Y	N	Y	N	A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies. A reporting and analysis plan and protocol are not available for this study. An annotated case report form is not available for this study. A blank case report form will be provided.	1-May-2016
4237	GSK	DEFEND-1 Long Term Follow Up: Durable-Response Therapy Evaluation for Early or New Onset Type 1 Diabetes Extension Study	otelixizumab	OTX115496	Diabetes Mellitus, Type 1	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=115496		https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-021259-22	Y	N	Y	Y	Y	Y	Y	This study was not originally sponsored by GSK. A link to clincialtrials.gov and an NCTID number are not available for this study. This is a follow-up study to OTX115495. An annotated case report form is not available for this study. A blank case report form will be provided.	1-Jul-2016
4238	GSK	A Randomized, Double-blind, Placebo Controlled Trial to Evaluate the Clinical Effects of Controlled Release Paroxetine in the Treatment of Major Depressive Disorder	paroxetine	PCR112810	Depressive Disorder	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=112810	http://clinicaltrials.gov/show/NCT00866294		Y	Y	N	Y	Y	Y	Y	A clinical study report is not available for this study because an English language version was not created.	1-Jul-2016
4239	GSK	Open, multicentric, post marketing surveillance study of GlaxoSmithKline Biologicals’ Vi polysaccharide typhoid vaccine (TYPHERIX™) injected in healthy children and adults according to the Indian prescribing information.Typherix™: GlaxoSmithKline Biologicals’ Vi polysaccharide typhoid vaccine (Typh)	Polysaccharide Typhoid Vaccine	219550/012	Typhoid Fever	Phase 4	https://www.gsk-studyregister.com/en/trial-details/?id=219550/012			Y	N	Y	Y	Y	Y	N	A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies. An annotated case report form is not available for this study. A blank case report form will be provided. A reporting and analysis plan is not available for this study.	1-May-2016
4240	GSK	Case-control Study to Evaluate the Vaccine Effectiveness of GlaxoSmithKline (GSK) Biologicals' Live Attenuated Human Rotavirus (HRV) Vaccine (Rotarix™) Against Community-acquired Rotavirus Severe Gastroenteritis (RV SGE) Among Hospitalised Children Born After 1 October 2006, in Belgium	Rotavirus Vaccine	111426	Infections, Rotavirus	Phase 4	https://www.gsk-studyregister.com/en/trial-details/?id=111426	http://clinicaltrials.gov/show/NCT01177826		Y	N	Y	Y	Y	Y	Y	An annotated case report form is not available for this study. A blank case report form will be provided.	1-May-2016
4241	GSK	A multicenter, randomized, double-blind, parallel-group study to evaluate the efficacy and safety of the addition of umeclidinium bromide (62.5mcg) once-daily to fluticasone propionate/salmeterol (250/50mcg) twice-daily, umeclidinium bromide (125mcg) once-daily to fluticasone propionate/salmeterol (250/50mcg) twice-daily versus placebo to fluticasone propionate/salmeterol (250/50mcg) twice-daily over 12 weeks with COPD	umeclidinium bromide	AC4116135	Pulmonary Disease, Chronic Obstructive	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=116135	http://clinicaltrials.gov/show/NCT01772134	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001870-27	Y	N	Y	Y	Y	Y	Y	An annotated case report form is not available for this study. A blank case report form will be provided.	1-Jul-2016
4242	GSK	A multicenter, randomized, double-blind, parallel group study to evaluate the efficacy and safety of the addition of umeclidinium bromide Inhalation Powder (62.5mcg) once-daily to fluticasone propionate/salmeterol (250/50mcg) twice-daily, umeclidinium bromide Inhalation Powder (125mcg) once-daily to fluticasone propionate/salmeterol (250/50mcg) twice-daily versus placebo to fluticasone propionate/salmeterol (250/50mcg) twice-daily over 12 weeks in subjects with COPD.	umeclidinium bromide	AC4116136	Pulmonary Disease, Chronic Obstructive	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=116136	http://clinicaltrials.gov/show/NCT01772147	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001871-35	Y	Y	Y	Y	Y	Y	Y		1-Jul-2016
4243	GSK	DB2116134: A Randomized, Multi-center, Double-blind, Double-dummy, Parallel Group Study to Evaluate the Efficacy and Safety of Umeclidinium bromide/Vilanterol Compared with Fluticasone propionate/Salmeterol Over 12 weeks in Subjects with COPD	umeclidinium bromide/vilanterol	DB2116134	Pulmonary Disease, Chronic Obstructive	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=116134	http://clinicaltrials.gov/show/NCT01822899	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000524-18	Y	Y	Y	Y	Y	Y	Y		1-Jul-2016
4244	GSK	A 12 week, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Evaluate the Efficacy of Umeclidinium/Vilanterol 62.5/25mcg in Subjects with COPD	umeclidinium bromide/vilanterol	201211	Pulmonary Disease, Chronic Obstructive	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=201211	http://clinicaltrials.gov/show/NCT02152605	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-000529-19	Y	Y	Y	Y	Y	Y	Y		1-Jul-2016
4286	GSK	Efficacy of oral alitretinoin treatment in patients with palmo-plantar pustulosis (PPP) inadequately responding to standard topical treatment	alitretinoin	ATN117221	Psoriasis	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=117221	http://clinicaltrials.gov/show/NCT01245140	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022843-39	Y	Y	Y	Y	Y	Y	Y		1-Sep-2016
4287	GSK	A two-part crossover study to assess the pharmacokinetics of amoxicillin after administration with clavulanate of pharmacokinetically enhanced formulations of amoxicillin in healthy volunteers.	amoxicillin/clavulanic acid	25000/552	Infections, Respiratory Tract	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=25000/552			N	Y	Y	Y	Y	Y	N	A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies. An analysis-ready dataset is not available for this study. A reporting and analysis plan is not available for this study.	1-Sep-2016
4288	GSK	An open, randomised, balanced, three period, single dose crossover study to investigate the effect of food on the bioavailability of pharmacokinetically enhanced (PE) oral Augmentin® in healthy male and female volunteers.	amoxicillin/clavulanic acid	25000/553	Infections, Respiratory Tract	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=25000/553			N	Y	Y	Y	Y	Y	N	A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies. An analysis-ready dataset is not available for this study. A reporting and analysis plan is not available for this study.	1-Sep-2016
4289	GSK	A randomized, controlled, phase II study to evaluate the safety and immunogenicity of different formulations of GlaxoSmithKline Biologicals’ 11-valent pneumococcal conjugate vaccine, when administered intramuscularly as a 3-dose primary immunization (2-3-4 month schedule) before 6 months of age	Combined Diphtheria, Tetanus, Acellular Pertussis, Hepatitis B, Inactivated Polio, Haemophilus influenzae Type b Vaccine	103488	acellular pertussis; Diphtheria; Haemophilus influenzae type b; Hepatitis B; Poliomyelitis; Tetanus	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=103488	http://clinicaltrials.gov/show/NCT00169481		Y	N	Y	Y	Y	Y	N	An annotated case report form is not available for this study. A blank case report form will be provided. A Reporing and tanalysis plan is not available for this study	1-Sep-2016
4290	GSK	A Two Part, Phase I, Randomized, Placebo Controlled, Double Blind Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single and Repeat Escalating Doses of GSK1325756 Solution for Infusion, and Absolute Bioavailability Relative of an Oral Dose, in Healthy Adult Subjects Protocol 201022	danirixin	201022	Infections, Respiratory Tract	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=201022	http://clinicaltrials.gov/show/NCT02169583		Y	Y	Y	Y	Y	Y	Y		1-Sep-2016
4291	GSK	A single-centre, double-blind, placebo-controlled study to evaluate the safety, tolerabilty, pharmacokinetics, and pharmacodynamics of single, oral, ascending doses and repeat oral doses of GSK1325756 in healthy male subjects.	danirixin	CX3112483	Pulmonary Disease, Chronic Obstructive	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=112483	http://clinicaltrials.gov/show/NCT01209052	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-013130-24	Y	Y	Y	Y	Y	Y	Y		1-Sep-2016
4292	GSK	A single-dose, open, randomized, crossover investigation of age, gender, food-effect and proton-pump interaction on the pharmacokinetics of GSK1325756 in healthy adult subjects and a single-dose, double blind, parallel-group, placebo- controlled investigation of the pharmacokinetics of GSK1325756	danirixin	CX3113722	Nutritional Status	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=113722	http://clinicaltrials.gov/show/NCT01209104		Y	Y	Y	Y	Y	Y	Y		1-Sep-2016
4293	GSK	A randomized cross-over study to evaluate the pharmacokinetics and pharmacodynamics of twice daily oral administration of GSK1325756, compared to placebo, in healthy subjects; and the pharmacokinetic profile of twice daily oral administration of GSK1325756 in healthy fed and fasted elderly subjects	danirixin	CX3114922	Pulmonary Disease, Chronic Obstructive	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=114922	http://clinicaltrials.gov/show/NCT01267006	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022708-32	Y	Y	Y	Y	Y	Y	Y		1-Sep-2016
4294	GSK	A Single Centre, 5-Period, Randomized Study To Evaluate The Relative Bioavailability Of An Immediate Release Tablet Formulation And Prototype Bio enhanced Formulations Of GSK1325756 In Healthy Elderly Subjects During Suppression Of Gastric Acid Secretion	danirixin	CX3115550	Pulmonary Disease, Chronic Obstructive	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=115550	http://clinicaltrials.gov/show/NCT01453478	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002450-31	Y	Y	Y	Y	Y	Y	Y		1-Sep-2016
4295	GSK	Bioequivalence Study of Dutasteride Capsules-An evaluation of the bioequivalence of dutasteride capsule manufactured at GSK compared to dutasteride capsule manufactured at Catalent in healthy Japanese male subjects	dutasteride	204646	Prostatic Hyperplasia	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=204646	http://clinicaltrials.gov/show/NCT02578953		Y	N	N	Y	N	Y	Y	An annotated case report form is not available for this study. A blank case report form will be provided. A clinical study report and a protocol are not available for this study because English language versions were not created.	1-Sep-2016
4296	GSK	A randomised, double-blind, placebo-controlled, parallel group, multicentre study to evaluate the efficacy and safety of fluticasone furoate/vilanterol trifenatate (FF/VI) inhalation powder delivered once daily for 12 weeks in the treatment of asthma in adolescent and adult subjects of Asian ancestry currently treated with low to mid-strength inhaled corticosteroid or low-strength combination therapy.	fluticasone furoate/vilanterol trifenatate	HZA113719	Asthma	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=113719	http://clinicaltrials.gov/show/NCT01498679		Y	Y	Y	Y	Y	Y	Y	The raw data are included within the analysis-ready data for this study and are not provided separately.	1-Sep-2016
4297	GSK	A randomised, double-blind, double dummy, 3 way cross-over study evaluating the effects of ADOAIR 50/250mcg twice daily plus tiotropium bromide 18mcg once daily compared with the individual treatments (tiotropium bromide 18mcg alone and ADOAIR 50/250mcg alone) in the treatment of Japanese subjects with COPD	fluticasone propionate/salmeterol	SCO116572	Pulmonary Disease, Chronic Obstructive	Phase 4	https://www.gsk-studyregister.com/en/trial-details/?id=116572	http://clinicaltrials.gov/show/NCT01751113		Y	N	N	Y	Y	Y	N	A clinical study report is not available for this study because an English language version was not created. A reporting and analysis plan is not available for this study. An annotated case report form is not available for this study. A blank case report form will be provided	1-Sep-2016
4298	GSK	SAS115359, a Safety and Efficacy Study of Inhaled Fluticasone Propionate/Salmeterol Combination versus Inhaled Fluticasone Propionate in the Treatment of Adolescent and Adult Subjects with Asthma	fluticasone propionate/salmeterol	SAS115359	Asthma	Phase 4	https://www.gsk-studyregister.com/en/trial-details/?id=115359	http://clinicaltrials.gov/show/NCT01475721	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001644-29	Y	Y	Y	Y	Y	Y	Y		1-Sep-2016
4299	GSK	An Open-label Study To Evaluate Plasma and Pulmonary Pharmacokinetics Following Intravenous Administration of GSK2140944 in Healthy Adult Subjects (BTZ116666)	gepotidacin	BTZ116666	Infections, Bacterial	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=116666	http://clinicaltrials.gov/show/NCT01934205		Y	Y	Y	Y	Y	Y	Y	The raw data are included within the analysis-ready data for this study and are not provided separately.	1-Sep-2016
4300	GSK	A Two-Part Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Single and Repeat IV Doses of GSK2140944 in Healthy Adult Subjects.	gepotidacin	BTZ115198	Infections, Respiratory Tract	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=115198	http://clinicaltrials.gov/show/NCT01615796		Y	Y	Y	Y	Y	Y	Y		1-Sep-2016
4301	GSK	A Randomized, Single Blind, Placebo-Controlled Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Repeat Escalating Oral Doses of GSK2140944 in Healthy Adult Subjects (BTZ116778)	gepotidacin	BTZ116778	Infections, Respiratory Tract	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=116778	http://clinicaltrials.gov/show/NCT01706315		Y	Y	Y	Y	Y	Y	Y		1-Sep-2016
4302	GSK	Open Label Study to Assess the Pharmacokinetics of GSK1278863A Coadministered with a High Fat Meal or an Inhibitor of CYP2C8 (gemfibrozil)	daprodustat	PHI113634	Anaemia	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=113634	http://clinicaltrials.gov/show/NCT01376232		Y	Y	Y	Y	Y	Y	Y		1-Sep-2016
4303	GSK	A multi-center, placebo-controlled study to evaluate the safety and efficacy of GSK1278863 vs. placebo in subjects with peripheral artery disease (PAD).	daprodustat	PVD114272	Vascular Disease, Peripheral	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=114272	http://clinicaltrials.gov/show/NCT02135848		Y	Y	Y	Y	Y	Y	Y		1-Sep-2016
4304	GSK	A randomized, open-label, 3-period crossover study in healthy subjects to determine the effect of particle size on the pharmacokinetics of single oral 100mg doses of GSK1278863A	daprodustat	PHI114703	Anaemia	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=114703	http://clinicaltrials.gov/show/NCT01319006		Y	Y	Y	Y	Y	Y	Y		1-Sep-2016
4305	GSK	A Phase I, Randomized, Single-Blind, Placebo-Controlled, Dose-Escalation (Part 1), fixed Sequence and Open-Label (Part 2), Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Single Oral Doses of GSK1278863A in Healthy Subjects	daprodustat	PHI115385	Anaemia	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=115385	http://clinicaltrials.gov/show/NCT02348372		Y	Y	Y	Y	Y	Y	Y		1-Sep-2016
4306	GSK	A randomized, placebo-controlled, study to evaluate the effects of GSK1278863A on pulmonary artery pressure in healthy volunteers	daprodustat	PHI116008	Anaemia	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=116008	http://clinicaltrials.gov/show/NCT01673555		Y	Y	Y	Y	Y	Y	Y		1-Sep-2016
4307	GSK	A four-week Phase IIa, randomized, double-blind, placebo-controlled, parallel-group, multi-center study to evaluate the safety, efficacy and pharmacokinetics of GSK1278863 in subjects with anemia associated with chronic kidney disease who are not taking recombinant human erythropoietin and are not undergoing dialysis	daprodustat	PHI116581	Anaemia	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=116581	http://clinicaltrials.gov/show/NCT01587898	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-004050-29	Y	Y	Y	Y	Y	Y	Y		1-Sep-2016
4308	GSK	A four-week, Phase IIa, randomized, active-controlled, parallel-group, multi-center study to evaluate the safety, efficacy and pharmacokinetics of switching subjects from a stable dose of recombinant human erythropoietin to GSK1278863 in hemodialysis-dependent subjects with anemia associated with chronic kidney disease	daprodustat	PHI116582	Anaemia	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=116582	http://clinicaltrials.gov/show/NCT01587924	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-004049-34	Y	Y	Y	Y	Y	Y	Y		1-Sep-2016
4309	GSK	Cancer immunotherapeutic GSK1572932A as adjuvant therapy for patients with MAGE-A3-positive Non-Small Cell Lung cancer	GSK1572932A	107240	Lung Cancer, Non-Small Cell	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=107240	http://clinicaltrials.gov/show/NCT00455572	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004777-10	Y	Y	Y	Y	Y	Y	Y		1-Sep-2016
4310	GSK	A randomised, double blind, placebo-controlled study to investigate the safety, pharmacodynamics and efficacy against allergic reactivity of repeat intranasal administration of the TLR7 agonist GSK2245035 in subjects with respiratory allergies	GSK2245035	TL7116392	Asthma and Rhinitis	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=116392	http://clinicaltrials.gov/show/NCT01607372		Y	Y	Y	Y	Y	Y	Y		1-Sep-2016
4311	GSK	A randomized, double-blind, placebo-controlled first time into human study to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of intranasal dosing with GSK2245035, a TLR7 agonist, in healthy volunteers and allergic rhinitis	GSK2445053	TL7114450	Rhinitis, Allergic, Seasonal	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=114450	http://clinicaltrials.gov/show/NCT01480271	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023795-78	Y	Y	Y	Y	Y	Y	Y		1-Sep-2016
4312	GSK	A First Time in Human study to assess the safety, tolerability and pharmacokinetics of GSK356278 (PDE4 inhibitor) in healthy volunteers	GSK356278	POD113324	Depressive Disorder and Anxiety Disorders	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=113324	http://clinicaltrials.gov/show/NCT01031186		Y	Y	Y	Y	Y	Y	Y		1-Sep-2016
4313	GSK	A Randomised, Placebo Controlled, Ascending, Repeat Dose Study in Healthy Volunteers Investigating Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GSK356278	GSK356278	POD115719	Huntington Disease	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=115719	http://clinicaltrials.gov/show/NCT01573819	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005314-11	Y	Y	Y	Y	Y	Y	Y		1-Sep-2016
4314	GSK	An open label positron emission tomography study in healthy male subjects to investigate brain PDE4 engagement, pharmacokinetics and safety of single oral doses of GSK356278, using 11C-(R)-rolipram as a PET ligand(s)	GSK356278	POD116038	Huntington Disease	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=116038	http://clinicaltrials.gov/show/NCT01602900	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004118-41	Y	Y	Y	Y	Y	Y	Y		1-Sep-2016
4315	GSK	A Single-Dose, Open-Label, Randomized, Two-Period Crossover Study to Demonstrate the Bioequivalence of Lamotrigine Dispersible/Chewable Tablets (5mg×5) and Lamotrigine Compressed Tablet (25mg) in Healthy Chinese Male Subjects.	lamotrigine	LAM115207	Epilepsy	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=115207	http://clinicaltrials.gov/show/NCT01879423		Y	Y	Y	Y	Y	Y	Y		1-Sep-2016
4316	GSK	A Single-Dose, Open-Label, Randomized, Parallel-Group Study to Demonstrate the Bioequivalence of Lamotrigine Dispersible/Chewable Tablet (100mg) and Lamotrigine Compressed Tablet (100mg) in Healthy Chinese Male Subjects	lamotrigine	200697	Epilepsy	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=200697	http://clinicaltrials.gov/show/NCT02064465		Y	Y	Y	Y	Y	Y	Y		1-Sep-2016
4317	GSK	A multi-center, uncontrolled, open-label, evaluation of Lamotrigine monotherapy on newly diagnosed typical absence seizures in children and adolescents	lamotrigine	LAM115377	Epilepsy	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=115377	http://clinicaltrials.gov/show/NCT01431976	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001514-29	Y	Y	N	Y	Y	Y	Y	A clinical study report and a protocol are not available for this study because English language versions were not created.	1-Sep-2016
4318	GSK	A randomized, placebo-controlled, single-blind study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of multiple doses of otelixizumab in rheumatoid arthritis subjects	otelixizumab	RAO111601	Arthritis, Rheumatoid	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=111601	http://clinicaltrials.gov/show/NCT01077531	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-008206-40	Y	Y	Y	Y	Y	Y	Y		1-Sep-2016
4322	GSK	An open label, randomized, three-period crossover study to compare the pharmacokinetic profile of paroxetine after single doses of the controlled-release paroxetine tablets at the dose levels of 12.5, 25 and 50mg in healthy Japanese male subjects	paroxetine	PCR112811	Depressive Disorder	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=112811	http://clinicaltrials.gov/show/NCT00938184		Y	Y	N	Y	N	Y	Y	A clinical study report and a protocol are not available for this study because English language versions were not created.	1-Sep-2016
4323	GSK	A steady-state, two-period crossover study to compare the pharmacokinetic profile of paroxetine after repeated daily dosing of the controlled-release paroxetine tablet (25 mg) with that of the standard immediate-release paroxetine tablet (20 mg) in healthy Japanese male subjects	paroxetine	PCR112812	Depressive Disorder	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=112812	http://clinicaltrials.gov/show/NCT01000857		Y	Y	N	Y	N	Y	Y	A clinical study report and a protocol are not available for this study because English language versions were not created.	1-Sep-2016
4324	GSK	Impact on nasopharyngeal carriage, acute otitis media, immunogenicity and safety of GSK Biologicals’ pneumococcal conjugate vaccine 1024850A	Pneumococcal Polysaccharide Conjugate Vaccine (Adsorbed)	112595	Infections, Streptococcal	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=112595	http://clinicaltrials.gov/show/NCT00839254	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-006551-51	Y	Y	Y	Y	Y	Y	Y	This is a nested study of 111442	1-Sep-2016
4325	GSK	To evaluate the pharmacokinetics, safety and tolerability of Retosiban (GSK221149) co-administered with EFAVIRENZ	retosiban	OTA116073	Obstetric Labour, Premature	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=116073	http://clinicaltrials.gov/show/NCT01867996		Y	Y	Y	Y	Y	Y	Y	The raw data are included within the analysis-ready data for this study and are not provided separately.	1-Sep-2016
4326	GSK	A Randomized, Placebo-Controlled, Double-Blind, Four-way Crossover Study to Assess the Effect of Single Oral Doses of Retosiban on Cardiac Repolarization, with Moxifloxacin as a Positive Control in Healthy Volunteers	retosiban	OTA113789	Obstetric Labour, Premature	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=113789	http://clinicaltrials.gov/show/NCT01702376		Y	Y	Y	Y	Y	Y	Y		1-Sep-2016
4327	GSK	A two cohort, open-label study to evaluate the pharmacokinetics of GSK2847065, the metabolite of Retosiban (GSK221149) after single and repeat oral doses, the pharmacokinetics of GSK221149 coadministered with a high fat meal, and the pharmacokinetics of GSK221149 coadministered with an inhibitor of CYP3A4 (Ketoconazole)	retosiban	OTA115893	Obstetric Labour, Premature	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=115893	http://clinicaltrials.gov/show/NCT01627587		Y	Y	Y	Y	Y	Y	Y		1-Sep-2016
4328	GSK	A randomized, double-blind, placebo-controlled, dose ranging study to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of GSK221149A administered intravenously and to investigate the pharmacokinetics of GSK221149A administered orally to healthy, pregnant females with uncomplicated pre-term labor between 300/7 and 356/7 weeks’ gestation	retosiban	OTA105256	Obstetric Labour, Premature	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=OTA105256	http://clinicaltrials.gov/show/NCT00404768	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005807-32	Y	Y	Y	Y	Y	Y	Y		1-Sep-2016
4329	GSK	Study DB2116961, A Multicentre, Randomised, Blinded, Parallel Group Study to Compare UMEC/VI (Umeclidinium/Vilanterol) in a Fixed Dose Combination With Indacaterol Plus Tiotropium in Symptomatic Subjects With Moderate to Very Severe COPD	umeclidinium bromide/vilanterol	DB2116961	Pulmonary Disease, Chronic Obstructive	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=116961	http://clinicaltrials.gov/show/NCT02257385	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001827-38	Y	Y	Y	Y	Y	Y	Y		1-Sep-2016
4330	GSK	Phase I study of GW642444M- A randomized, double blind, placebo controlled, parallel-group, 7 day repeat dose study to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of inhaled dose of GW642444M from a novel dry powder device in healthy Japanese male subjects	vilanterol	DB1112017	Pulmonary Disease, Chronic Obstructive	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=112017	http://clinicaltrials.gov/show/NCT00964249		Y	Y	Y	Y	N	Y	N	A reporting and analysis plan and a protocol are not available for this study.	1-Sep-2016
4331	GSK	Phase1 study of GR121167- A double blind, placebo controlled, randomized, dose ascending, single and multiple dose study to investigate the safety and pharmacokinetics following intravenous administration of GR121167 in healthy Japanese males	zanamivir	NAI115070	Influenza, Human	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=115070	http://clinicaltrials.gov/show/NCT01428479		Y	Y	N	Y	Y	Y	Y	A clinical study report is not available for this study.	1-Sep-2016
4332	GSK	An open-label, multi-center, single arm study to evaluate the safety and efficacy of intravenous zanamivir in the treatment of hospitalized patients with confirmed influenza infection (NAI115215)	zanamivir	NAI115215	Influenza, Human	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=115215	http://clinicaltrials.gov/show/NCT01527110		Y	Y	Y	Y	N	Y	Y	A protocol is not available for this study because an English language version was not created.	1-Sep-2016
4372	Astellas	Phase III Study of YM178: A double-blind group comparison study in patients with overactive bladder	mirabegron	178-CL-048	Urinary Bladder, Overactive	Phase 3	https://www.clinicaltrials.astellas.com/study/?pid=178-CL-048	https://clinicaltrials.gov/ct2/show/NCT00966004		Y	Y	Y	Y	Y	Y	Y		1-Sep-2016
4373	Astellas	A randomized, double-blind, parallel group, proof of concept study of YM178 in comparison with placebo and tolterodine in patients with symptomatic overactive bladder	mirabegron	178-CL-008	Urinary Bladder, Overactive	Phase 2	https://www.clinicaltrials.astellas.com/study/?pid=178-CL-008	https://clinicaltrials.gov/ct2/show/NCT01604928		Y	Y	Y	Y	Y	Y	Y		1-Sep-2016
4374	Astellas	A randomized, double-blind, parallel-group, placebo and active controlled, multi-center dose ranging study with beta-3 agonist YM178 in patients with symptomatic overactive bladder (DRAGON)	mirabegron	178-CL-044	Urinary Bladder, Overactive	Phase 2	https://www.clinicaltrials.astellas.com/study/?pid=178-CL-044	https://clinicaltrials.gov/ct2/show/NCT00337090	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002256-17	Y	Y	Y	Y	Y	Y	Y		1-Sep-2016
4399	GSK	A Multicenter, Double-Blind, Randomized Placebo-Controlled Phase II Study to Evaluate the Pharmacodynamics, Safety, Tolerability, and PK of Single Doses of the Oral Motilin Receptor Agonist GSK962040, in Type 1 Diabetic Male and Female Patients with Gastroparesis	camicinal	MOT111809	Gastroparesis	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=111809	http://clinicaltrials.gov/show/NCT00861809	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-008175-34	Y	Y	Y	Y	Y	Y	Y		1-Oct-2016
4400	GSK	A double-blind, randomized, placebo controlled Phase II study to evaluate the pharmacodynamics, safety, tolerability, and pharmacokinetics of Single Doses of the Oral Motilin Receptor Agonist GSK962040, in critically ill male and female patients with enteral feed intolerance	camicinal	MOT112571	Gastroparesis	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=112571	http://clinicaltrials.gov/show/NCT01039805		Y	Y	Y	Y	Y	Y	Y		1-Oct-2016
4401	GSK	A single dose, open label, nonrandomized, study to evaluate the pharmacokinetics and absolute bioavailability of GSK962040 given as an oral dose simultaneously with an intravenous micro tracer dose of [14C]-GSK962040 in healthy volunteers	camicinal	MOT114136	Gastroparesis	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=114136	http://clinicaltrials.gov/show/NCT01267071	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-020409-34	Y	Y	Y	Y	Y	Y	Y		1-Oct-2016
4402	GSK	A First-Time-in-Human Randomized Placebo-Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Escalating Doses of the Oral Motilin Receptor Agonist GSK962040, in Male and Female Healthy Subjects	camicinal	MOT107043	Gastroparesis	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=MOT107043	http://clinicaltrials.gov/show/NCT00562848	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003180-44	Y	N	Y	Y	Y	Y	Y	An annotated case report form is not available for this study. A blank case report form will be provided.	1-Oct-2016
4403	GSK	A randomized, double-blind, ascending dose trial to assess safety, tolerability, pharmacokinetics, and pharmacodynamics, of repeat doses of motilin receptor agonist GSK962040 in male and female healthy volunteers	camicinal	MOT109681	Gastroparesis	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=MOT109681	http://clinicaltrials.gov/show/NCT00733551	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-003388-37	Y	N	Y	Y	Y	Y	Y	An annotated case report form and a blank case report form are not available for this study.	1-Oct-2016
4404	GSK	A Randomized, Double Blind, Parallel Group, Placebo Controlled 28 Day Study to Investigate the Safety, Tolerability and Pharmacodynamics of SB-656933 in Patients with Cystic Fibrosis.	elubrixin	CF2110399	Cystic Fibrosis	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=110399	http://clinicaltrials.gov/show/NCT00903201	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-018738-27	Y	Y	Y	Y	Y	Y	Y		1-Oct-2016
4406	GSK	A Phase II Study to Evaluate: Delay in Intravaginal Ejaculatory Latency Time (IELT), Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Two Oral Doses of GSK557296 in a Randomized, Double Blind, Placebo-Controlled, Parallel Group Study in Men with Premature Ejaculation	epelsiban	OTB109059	Premature Ejaculation	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=109059	http://clinicaltrials.gov/show/NCT01021553	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-011782-92	Y	Y	Y	Y	Y	Y	Y		1-Oct-2016
4407	GSK	A Phase I Non-Randomized Multi Cohort, Open Label, Bridging Study to Evaluate the Pharmacokinetics, Safety and Tolerability of GSK557296 in Healthy Women Volunteers after Single and Repeat Dosing	epelsiban	IVF116741	Embryo Transfer	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=116741	http://clinicaltrials.gov/show/NCT01669083		Y	Y	Y	Y	Y	Y	Y		1-Oct-2016
4408	GSK	A multi-center, randomized, double-blind, dose-ranging study to evaluate GSK573719 in combination with fluticasone furoate, fluticasone furoate alone, and an active control of fluticasone furoate/vilanterol combination in subjects with asthma	fluticasone furoate/umeclidinium bromide	ILA115938	Asthma	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=115938	http://clinicaltrials.gov/show/NCT01573624	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004328-37	Y	Y	Y	Y	Y	Y	Y		1-Oct-2016
4409	GSK	A randomized, double blind, single-dose, three-period, crossover study to investigate pharmacokinetic, safety and tolerability of Fluticasone Furoate with Umeclidinium when administered in combination and as monotherapies in adult healthy volunteer subjects	fluticasone furoate/umeclidinium bromide	ILA116524	Asthma	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=116524	http://clinicaltrials.gov/show/NCT01725685		Y	Y	Y	Y	Y	Y	Y		1-Oct-2016
4410	GSK	An Open Label, Randomised, Four-Period Crossover, Single Dose Study in Healthy Volunteers to Evaluate the Pharmacokinetics of FF/UMEC/VI Combination Administered at Dose Levels 100/62.5/25 mcg and 100/125/25 mcg and in Comparison with FF/VI (100/25 mcg) and UMEC/VI (62.5/25 mcg).	fluticasone furoate/vilanterol/umeclidinium bromide	200587	Pulmonary disease, Chronic Obstructive	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=200587	http://clinicaltrials.gov/show/NCT01894386		Y	Y	Y	Y	Y	Y	Y		1-Oct-2016
4411	GSK	A randomized, double-blind, single dose, four way cross-over study to assess the systemic exposure, systemic pharmacodynamics and safety and tolerability of FluticasoneFuroate, Umeclidinium and Vilanterol following single inhaled doses of Umeclidinium/Vilanterol blend + Fluticasone Furoate, Umeclidinium + Vilanterol, Fluticasone Furoate + Vilanterol and Fluticasone Furoate + Umeclidinium in healthy subjects	fluticasone furoate/vilanterol/umeclidinium bromide	CTT116415	Pulmonary Disease, Chronic Obstructive	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=116415	http://clinicaltrials.gov/show/NCT01691547		Y	Y	Y	Y	Y	Y	Y		1-Oct-2016
4412	GSK	A Randomised, Open-Label, Four Period, Crossover Study to Assess the Systemic Exposure of Fluticasone Propionate from FLIXOTIDE™ 250 HFA pMDI and of Fluticasone Propionate and Salmeterol from SERETIDE™ 250/25 HFA pMDI when given with the VENTOLIN Mini-Spacer Compared to the Aero chamber Plus Spacer in Healthy Subjects	fluticasone propionate	201092	Asthma	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=201092	http://clinicaltrials.gov/show/NCT02045953	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-005023-16	Y	Y	Y	Y	Y	Y	Y		1-Oct-2016
4413	GSK	A Randomized, Double-blind (Sponsor Unblinded), Placebo Controlled, Repeat Dose Study Investigating Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GSK2330672 in Type 2 Diabetes Patients Taking Metformin	linerixibat	200185	Diabetes Mellitus, Type 2	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=200185	http://clinicaltrials.gov/show/NCT01929863		Y	Y	Y	Y	Y	Y	Y		1-Oct-2016
4414	GSK	A first time in human, single blind, randomized, placebo-controlled, dose escalating crossover study to evaluate the safety,tolerability, pharmacokinetic and pharmacodynamic parameters of single doses of GSK2330672 in healthy volunteers	linerixibat	BAT114985	Diabetes Mellitus, Type 2	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=114985	http://clinicaltrials.gov/show/NCT01416324		Y	Y	Y	Y	Y	Y	Y		1-Oct-2016
4415	GSK	A First Time in Human Study Exploring Preliminary Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GSK2618960 in Healthy Volunteers and Patients with Relapsing Remitting Multiple Sclerosis	GSK2618960	I7R116702	Multiple Sclerosis, Relapsing-Remitting	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=116702	http://clinicaltrials.gov/show/NCT01808482	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-005501-43	Y	Y	Y	Y	Y	Y	Y		1-Oct-2016
4416	GSK	A Three Part, Randomised, Placebo-controlled Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single and Repeat Doses of Inhaled and Intravenous GSK2862277 in Healthy Volunteers	GSK2862277	TFR116343	Respiratory Disorders	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=116343	http://clinicaltrials.gov/show/NCT01818024	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002918-39	Y	Y	Y	Y	Y	Y	Y		1-Oct-2016
4417	GSK	A Randomized, Open Label, Parallel-Group Study to Estimate Bioavailability and to Assess the Pharmacokinetic Profile, Safety and Tolerability of GSK933776 Administered by Subcutaneous or Intramuscular Injection Relative to Intravenous Administration to Healthy Volunteers	GSK933776	BA1116891	Atrophy, Geographic	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=116891	http://clinicaltrials.gov/show/NCT02033668		Y	Y	Y	Y	Y	Y	Y	The raw data are included within the analysis-ready data for this study and are not provided separately.	1-Oct-2016
4418	GSK	A Randomised, Single-Blind, Placebo-Controlled Study to Investigate the Safety, Tolerability, Immunogenicity, Pharmacokinetics and Pharmacodynamics of Intravenous Infusion of GSK933776 in Patients with Alzheimer's Disease.	GSK933776	BA1106006	Alzheimer's Disease	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=106006	http://clinicaltrials.gov/show/NCT00459550	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004014-41	Y	N	Y	Y	Y	Y	Y	An annotated case report form is not available for this study. A blank case report form will be provided.	1-Oct-2016
4419	GSK	Modulation of beta-amyloid levels in CSF and plasma by GSK933776 in patients with mild Alzheimer’s disease or mild cognitive impairment	GSK933776	BA1113043	Alzheimer's Disease	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=113043	http://clinicaltrials.gov/show/NCT01424436	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-011463-37	Y	Y	Y	Y	Y	Y	Y		1-Oct-2016
4420	GSK	A Single Center Phase 1 Double Blind Study to Evaluate the Effect of Losmapimod on Cardiac Conduction as Compared to Placebo and Moxifloxacin in Healthy Adult Subjects	losmapimod	PM1116628	Acute Coronary Syndrome	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=116628	http://clinicaltrials.gov/show/NCT01756495		Y	Y	Y	Y	Y	Y	Y		1-Oct-2016
4421	GSK	A randomized, double-blind, placebo-controlled study to evaluate the safety of 12 weeks of dosing with GW856553 and its effects on inflammatory markers, infarct size, and cardiac function in subjects with myocardial infarction without ST-segment elevation	losmapimod	PM1111810	Acute Coronary Syndrome	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=111810	http://clinicaltrials.gov/show/NCT00910962	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-010615-32	Y	Y	Y	Y	Y	Y	Y		1-Oct-2016
4422	GSK	A randomised, double blind study to evaluate the safety and efficacy of the p38 kinase inhibitor, GW856553, in subjects with neuropathic pain from peripheral nerve injury	losmapimod	KIP112967	Pain, Neuropathic	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=112967	http://clinicaltrials.gov/show/NCT00969059	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-010091-17	Y	Y	Y	Y	Y	Y	Y		1-Oct-2016
4423	GSK	A Study to Evaluate the Efficacy and Safety of Losmapimod (GW856553) Tablets Administered Twice Daily compared with Placebo for 24 Weeks in Adult Subjects with Chronic Obstructive Pulmonary Disease (COPD).	losmapimod	MKI113006	Pulmonary Disease, Chronic Obstructive	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=113006	http://clinicaltrials.gov/show/NCT01218126	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-019695-76	Y	Y	Y	Y	Y	Y	Y		1-Oct-2016
4424	GSK	A six week randomized, double-blind, multi-center, placebo-controlled, exploratory, adaptive design study to explore the antidepressant properties of the p38 MAP kinase inhibitor GW856553 compared to placebo in adult subjects with Major Depressive Disorder	losmapimod	PKI113009	Depressive Disorder, Major	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=113009	http://clinicaltrials.gov/show/NCT00976560	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-011200-39	Y	Y	Y	Y	Y	Y	Y		1-Oct-2016
4425	GSK	Evaluation of the safety, tolerability, pharmacokinetics and pharmacodynamics of single intravenous dose(s) and a single oral dose of GW856553 in healthy volunteers	losmapimod	PM1113022	Cardiovascular Disease	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=113022	http://clinicaltrials.gov/show/NCT01039961	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-014939-21	Y	Y	Y	Y	Y	Y	Y		1-Oct-2016
4426	GSK	A randomised, double blind study to evaluate the safety and efficacy of the p38 kinase inhibitor, GW856553, in subjects with neuropathic pain from lumbosacral radiculopathy	losmapimod	KIP113049	Pain, Neuropathic	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=113049	http://clinicaltrials.gov/show/NCT01110057	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-012836-33	Y	Y	Y	Y	Y	Y	Y		1-Oct-2016
4427	GSK	A Phase I, Randomized, Single-Blind, Three-Period Cross-Over, Placebo-Controlled, Single Oral Dose, Dose-Escalation (Part 1), Fixed Sequence, and Repeat Dose (Part 2) Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of losmapimod in Healthy Japanese Subjects.	losmapimod	PM1116681	Acute Coronary Syndrome	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=116681	http://clinicaltrials.gov/show/NCT01648192		Y	Y	Y	Y	Y	Y	Y	The raw data are included within the analysis-ready data for this study and are not provided separately.	1-Oct-2016
4428	GSK	A 12-week, randomised, double-blind, placebo-controlled study to assess the anti-inflammatory activity, efficacy and safety of GW856553 in subjects with chronic obstructive pulmonary disease (COPD)	losmapimod	MKI102428	Pulmonary Disease, Chronic Obstructive	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=MKI102428	http://clinicaltrials.gov/show/NCT00642148	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004033-42	Y	Y	Y	Y	Y	Y	Y		1-Oct-2016
4429	GSK	A double-blind, placebo-controlled, parallel group study to evaluate the effects of two regimens of GW856553, over a period of 3 month, on in-vivo macrophage activity, as assessed by FDG-PET/CT imaging, in the carotid arteries and aorta of subjects with established atherosclerosis	losmapimod	PM1111138	Atherosclerosis	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=PM1111138	http://clinicaltrials.gov/show/NCT00633022	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005338-35	Y	Y	Y	Y	Y	Y	Y		1-Oct-2016
4430	GSK	A Clinical Outcomes Study to Compare the Incidence of Major Adverse Cardiovascular Events in Subjects Presenting with Acute Coronary Syndrome Treated with Losmapimod Compared to Placebo (PM1116197) Losmapimod to Inhibit p38 MAP kinase as a Therapeutic target and modify outcomes after an acute coronary syndrome (LATITUDE)-TIMI 60.	losmapimod	PM1116197	Acute Coronary Syndrome	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=116197	http://clinicaltrials.gov/show/NCT02145468	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-000657-50	Y	Y	Y	Y	Y	Y	Y		1-Oct-2016
4431	GSK	An Open-label, Randomised, Single Dose, Three-Way Crossover, Six Sequence, Pilot Study to Determine the Relative Bioavailability of Montelukast Sodium 5mg from Two Candidate Chewable Tablet Formulations of GW483100 Relative to One 5mg Chewable Tablet of Reference Montelukast Sodium in Healthy Adult Subjects Under Fasting Conditions	montelukast	200107	Respiratory Disorders	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=200107	http://clinicaltrials.gov/show/NCT02322671		Y	Y	Y	Y	Y	Y	Y		1-Oct-2016
4432	GSK	Characterization of Exposure from Topical Administration of [14C] Umeclidinium to Axilla or Palm of Healthy Male Subjects	umeclidinium bromide	LHH117157	Hyperhidrosis	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=117157	http://clinicaltrials.gov/show/NCT01934153	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002456-32	Y	Y	Y	Y	Y	Y	Y		1-Oct-2016
4433	GSK	A multi-national, randomized, double-blind, placebo-controlled, 3-period crossover study with GSK 573719 as monotherapy in adult subjects with asthma	umeclidinium bromide	ALA116402	Asthma	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=116402	http://clinicaltrials.gov/show/NCT01641692	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005244-95	Y	Y	Y	Y	Y	Y	Y		1-Oct-2016
4436	Novartis	Phase II Randomized Trial of Neoadjuvant Trastuzumab and/or Lapatinib plus Chemotherapy (Sequential FEC75 and Paclitaxel) in Women with ErbB2- (HER2/neu-) Overexpressing Invasive Breast Cancer	lapatinib	LPT109096	Cancer, Breast	Phase 2	http://www.gsk-clinicalstudyregister.com/search/?study_ids=lpt109096	https://clinicaltrials.gov/show/NCT00524303		Y	Y	Y	Y	Y	N	Y	The raw dataset is included within the analysis-ready dataset.	1-Nov-2016
4437	Novartis	A Multi-Center, Randomized, Double-Masked, Vehicle and Active Controlled, Parallel-Group Efficacy and Safety Study of AL-4943A Ophthalmic Solution, 0.77% in Patients With Allergic Conjunctivitis Using the Conjunctival Allergen Challenge (CAC) Model	olopatadine hydrochloride	C-10-126	Allergic conjunctivitis	Phase 3	https://www.novctrd.com/ctrdweb/trialresult/trialresults/pdf?trialResultId=12984	https://clinicaltrials.gov/show/NCT01479374		Y	Y	Y	Y	Y	Y	Y	Alcon is a division of Novartis	1-Nov-2016
4438	Novartis	A Multicenter, Randomized, Double-Masked, Vehicle-Controlled, Parallel-Group Study Evaluating the Safety of AL-4943A Ophthalmic Solution Administered Once Daily	olopatadine hydrochloride	C-12-028	Allergic conjunctivitis	Phase 3	https://www.novctrd.com/ctrdweb/trialresult/trialresults/pdf?trialResultId=12985	https://clinicaltrials.gov/show/NCT01698814		Y	Y	Y	Y	Y	Y	Y	Alcon is a division of Novartis	1-Nov-2016
4439	Novartis	Phase 3, Efficacy and Safety Study of AL-4943A Ophthalmic Solution, 0.77% in Patients With Allergic Conjunctivitis Using the Conjunctival Allergen Challenge (CAC) Model	olopatadine hydrochloride	C-12-053	Allergic conjunctivitis	Phase 3	https://www.novctrd.com/ctrdweb/trialresult/trialresults/pdf?trialResultId=12986	https://clinicaltrials.gov/show/NCT01743027		Y	Y	Y	Y	Y	Y	Y	Alcon is a division of Novartis	1-Nov-2016
4478	Astellas	A Phase 3, Randomized, Double-Blind, Parallel Group, Placebo and Active Controlled, Multicenter Study to Assess the Efficacy and Safety of Mirabegron (YM178) in Asian Patients with Symptoms of Overactive Bladder	mirabegron	178-CL-090	Urinary Bladder, Overactive	Phase 3	https://www.clinicaltrials.astellas.com/study/?pid=178-CL-090	https://clinicaltrials.gov/ct2/show/NCT01043666		Y	Y	Y	Y	Y	Y	Y		1-Oct-2016
4479	Astellas	YM178 Phase II study - A Randomized, Double-blind, Parallel-group, Placebo-controlled Study in Patients With Symptomatic Overactive Bladder	mirabegron	178-CL-045	Urinary Bladder, Overactive	Phase 2	https://www.clinicaltrials.astellas.com/study/?pid=178-CL-045	https://clinicaltrials.gov/ct2/show/NCT00527033		Y	Y	Y	Y	Y	Y	Y		1-Oct-2016
4494	GSK	An open-label, randomised, single dose, two-way crossover pilot study to determine the relative bioavailability of one 8mg tablet formulation of candesartan cilexetil (GW615775) relative to one 8mg reference tablet of candesartan cilexetil (Atacand) in healthy adult human subjects under fasting conditions	candesartan	200956	Hypertension	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=200956	http://clinicaltrials.gov/show/NCT02006589		Y	Y	Y	Y	Y	Y	Y		1-Nov-2016
4495	GSK	An Open-Label, Randomised, Single Dose, Two-Way Crossover Pilot Study to Determine the Relative Bioavailability of a Fixed Dose Combination Tablet Formulation of GSK587323 (16mg Candesartan Cilexetil/12.5mg Hydrochlorothiazide) Relative to Respective Reference Dosage Atacand D in Healthy Adult Human Subjects Under Fasting Conditions	candesartan cilexetil/hydrochlorothiazide	200957	Hypertension	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=200957	http://clinicaltrials.gov/show/NCT02094924		Y	Y	Y	Y	Y	Y	Y		1-Nov-2016
4496	GSK	A randomized, double-blind, placebo-controlled cross-over study to determine the bronchodilator effect of a single dose of fluticasone furoate (FF)/ vilanterol (VI) 100/25 mcg combination administered in the morning in adult patients with asthma	fluticasone furoate/vilanterol	HZA116592	Asthma	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=116592	http://clinicaltrials.gov/show/NCT01837316		Y	Y	Y	Y	Y	Y	Y		1-Nov-2016
4497	GSK	A 6-month safety and benefit study of inhaled fluticasone propionate/ salmeterol combination versus inhaled fluticasone propionate in the treatment of 6,200 pediatric subjects 4-11 years old with persistent asthma	fluticasone propionate/salmeterol	SAS115358	Asthma	Phase 4	https://www.gsk-studyregister.com/en/trial-details/?id=115358	http://clinicaltrials.gov/show/NCT01462344	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001643-79	Y	Y	Y	Y	Y	Y	Y		1-Nov-2016
4498	GSK	A study to evaluate GSK Biologicals’ candidate formulations of pneumococcal vaccines (GSK2189241A) in elderly subjects.	GSK2189241A	111652	Infections, Streptococcal	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=111652	http://clinicaltrials.gov/show/NCT00756067	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001145-25	Y	N	Y	Y	Y	Y	N	An annotated case report form is not available for this study. A blank case report form will be provided. A reporting and analysis plan is not available for this study.	1-Nov-2016
4499	GSK	A study to evaluate GSK Biologicals’ candidate formulations of pneumococcal vaccines (GSK2189242A) in young adults.	GSK2189242A	111651	Infections, Streptococcal	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=111651	http://clinicaltrials.gov/show/NCT00707798	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001147-19	Y	N	Y	Y	Y	Y	N	An annotated case report form is not available for this study. A blank case report form will be provided. A reporting and analysis plan is not available for this study. The results of this study 111651 are related to 112993	1-Nov-2016
4500	GSK	A study to evaluate safety and immunogenicity of a booster dose of two formulations of GSK Biologicals’ pneumococcal candidate vaccine in healthy young adults	GSK2189242A	112993	Infections, Streptococcal	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=112993	http://clinicaltrials.gov/show/NCT00896064	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-011022-33	Y	N	Y	Y	Y	Y	N	An annotated case report form is not available for this study. A blank case report form will be provided. A reporting and analysis plan is not available for this study. The results of this study 112993 are related to 111651	1-Nov-2016
4501	GSK	Safety, reactogenicity and immunogenicity of GlaxoSmithKline (GSK) Biologicals’ investigational vaccination regimen in children aged 12-23 months at the time of first vaccination.	GSK2189242A	113171	Infections, Streptococcal	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=113171	http://clinicaltrials.gov/show/NCT00985751	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-012701-19	Y	N	Y	Y	Y	Y	N	An annotated case report form is not available for this study. A blank case report form will be provided. A reporting and analysis plan is not available for this study.	1-Nov-2016
4502	GSK	Impact of GSK Biologicals’ 2189242A vaccine on nasopharyngeal carriage, safety and immunogenicity when co-administered with routine EPI vaccines in infants following safety assessment in children aged 2-4 years in The Gambia	GSK2189242A; Pneumococcal Polysaccharide Conjugate Vaccine (Adsorbed)	114174	Infections, Streptococcal	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=114174	http://clinicaltrials.gov/show/NCT01262872	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002727-15	Y	N	Y	Y	Y	Y	Y	An annotated case report form is not available for this study. A blank case report form will be provided.	1-Nov-2016
4503	GSK	A Single-centre, Randomised, Double-blind, Placebo-controlled, Escalating Dose Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Doses of GSK2256294 in Healthy Volunteers, and Single and Repeat Doses of GSK2256294 in Adult Male Moderately Obese Smokers	GSK2256294	SEH114068	Pulmonary Disease, Chronic Obstructive	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=114068	http://clinicaltrials.gov/show/NCT01762774	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-021246-22	Y	Y	Y	Y	Y	Y	Y	The raw data are included within the analysis-ready data for this study and are not provided separately. The informed consent for this study only allows for further research into COPD and heart disease.	1-Nov-2016
4504	GSK	A Study to Evaluate the Effect of Age, Food and Gender on Tolerability and Pharmacokinetics of GSK2256294 Following a Single Oral Administration in Healthy Fed and Fasted Elderly Subjects. This Study will also Evaluate the Biliary Metabolites in Healthy Young Males Following a Single Dose of GSK2256294	GSK2256294	SEH117023	Pulmonary Disease, Chronic Obstructive	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=117023	http://clinicaltrials.gov/show/NCT02006537		Y	Y	Y	Y	Y	Y	Y	The raw data are included within the analysis-ready data for this study and are not provided separately. The informed consent for this study only allows for further research into the disease studied.	1-Nov-2016
4505	GSK	A Randomised Placebo-controlled Study to Evaluate the Effects of GSK2256294 Following Repeat Dosing on Pulmonary Artery Pressure in Healthy Volunteers Under Normoxic and Hypoxic Conditions	GSK2256294	201402	Pulmonary Disease, Chronic Obstructive	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=201402	http://clinicaltrials.gov/show/NCT02262689		Y	Y	Y	Y	Y	Y	Y		1-Nov-2016
4506	GSK	A single-centre double-blind, placebo controlled three part study to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of single and repeat doses of nebulised GSK2269557 in healthy male subjects	nemiralisib	PII115117	Asthma	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=115117	http://clinicaltrials.gov/show/NCT01462617	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-024433-22	Y	Y	Y	Y	Y	Y	Y		1-Nov-2016
4507	GSK	A Randomized, Placebo Controlled, Repeat Dose, Double Blind (sponsor unblind) Study Investigating Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GSK2330672 Administered with Metformin to Type 2 Diabetes Patients	linerixibat	201351	Diabetes Mellitus, Type 2	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=201351	http://clinicaltrials.gov/show/NCT02202161		Y	Y	Y	Y	Y	Y	Y		1-Nov-2016
4508	GSK	An observer-blind study to evaluate the safety and immunogenicity of GSK Biologicals’ influenza vaccine(s) GSK2789869A and GSK2789868A administered in adults 21 to 64 years of age	GSK2789869A	115415	Influenza	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=115415	http://clinicaltrials.gov/show/NCT01934127		Y	N	Y	Y	Y	Y	Y	An annotated case report form is not available for this study. A blank case report form will be provided.	1-Nov-2016
4509	GSK	An open multicentre, multicountry study to evaluate long-term antibody persistence and immune memory between Years 11 and 15 after the primary study HAB-084 in which healthy adolescents were vaccinated with Twinrix™ Adult following a two-dose schedule or Twinrix™ Junior following a three-dose schedule.	twinrix	110699	Hepatitis A; Hepatitis B	Phase 4	https://www.gsk-studyregister.com/en/trial-details/?id=110699	http://clinicaltrials.gov/show/NCT00875485	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-006083-11	Y	N	Y	Y	Y	Y	N	This is a follow-up study to 208127/084 (HAB-084). An annotated case report form is not available for this study. A blank case report form will be provided. A reporting and analysis plan is not available for this study. The results are summarised with 110700, 110701,110702, 110703, 110704 on the GSK Study Register.	1-Nov-2016
4510	GSK	An open-label study to assess the immunogenicity and safety of GSK Biologicals’ hepatitis B vaccine Engerix™-B (103860) in adults with or without type 2 diabetes mellitus	Hepatitis B Vaccine, Recombinant	115918	Hepatitis B	Phase 4	https://www.gsk-studyregister.com/en/trial-details/?id=115918	http://clinicaltrials.gov/show/NCT01627340		Y	N	Y	Y	Y	Y	Y	An annotated case report form is not available for this study. A blank case report form will be provided.	1-Nov-2016
4511	GSK	Immunogenicity and safety study of GlaxoSmithKline Biologicals' HPV-16/18 L1 AS04 vaccine when administered according to alternative 2-dose schedules in 9 - 14 year old females	Human Papillomavirus Types 16 and 18 Vaccine	114700	Infections, Papillomavirus	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=114700	http://clinicaltrials.gov/show/NCT01381575	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000757-22	Y	N	Y	Y	Y	Y	Y	An annotated case report form is not available for this study. A blank case report form will be provided.	1-Nov-2016
4512	GSK	Follow-up study to evaluate the long-term immunogenicity and safety of GlaxoSmithKline Biologicals’ HPV (580299) vaccine in healthy female subjects	Human Papillomavirus Types 16 and 18 Vaccine	112772	Infections, Papillomavirus	Phase 4	https://www.gsk-studyregister.com/en/trial-details/?id=112772	http://clinicaltrials.gov/show/NCT00947115	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-011357-41	Y	N	Y	Y	Y	Y	N	An annotated case report form is not available for this study. A blank case report form will be provided. A reporting and analysis plan is not available for this study. The results of this study 112772 are related to103514.	1-Nov-2016
4513	GSK	Immunogenicity and safety study of GlaxoSmithKline Biologicals' HPV-16/18 L1 AS04 vaccine and Merck's Gardasil® vaccine when administered according to alternative 2-dose schedules in 9-14 year old females	Human Papillomavirus Types 16 and 18 Vaccine	115411	Infections, Papillomavirus	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=115411	http://clinicaltrials.gov/show/NCT01462357	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002035-26	Y	N	Y	Y	Y	Y	Y	An annotated case report form is not available for this study. A blank case report form will be provided.	1-Nov-2016
4514	GSK	MEA115661: A Multi-centre, Open-label, Long-term Safety Study of Mepolizumab in Asthmatic Subjects who participated in the MEA115588 or MEA115575 trials	mepolizumab	MEA115661	Asthma	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=115661	http://clinicaltrials.gov/show/NCT01842607	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001644-21	Y	Y	Y	Y	Y	Y	Y	This is a follow-up study to MEA115588 and MEA115575. A follow-on study 201312 was conducted. This study is available in CDISC format. The informed consent for this study only allows for further research into the medicine and disease studied.	1-Nov-2016
4515	GSK	Impact of immediate or delayed prophylactic antipyretic treatment on the immunogenicity, reactogenicity and safety of GlaxoSmithKline Biologicals’ pneumococcal vaccine 1024850A and the co-administered DTPa-combined vaccines	Pneumococcal Polysaccharide Conjugate Vaccine (Adsorbed)	112921	Infections, Streptococcal	Phase 4	https://www.gsk-studyregister.com/en/trial-details/?id=112921	http://clinicaltrials.gov/show/NCT01235949	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-019761-28	Y	N	Y	Y	Y	Y	Y	An annotated case report form is not available for this study. A blank case report form will be provided.	1-Nov-2016
4516	GSK	A Two-Period, Randomized, Open-Label, Parallel group, Multiple-Probe Drug Interaction Study to Determine the Effects of NCE on the metabolism of CYP450 Probe Substrates in Healthy Postmenopausal Female Subjects	relacatib	462795/007	Osteoarthritis	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=462795/007			Y	Y	Y	Y	Y	Y	Y	A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Nov-2016
4517	GSK	A randomised, double-blind, placebo-controlled, parallel-group, multicentre study to determine the efficacy and safety of 2 doses of retigabine immediate release (900 mg/day and 600 mg/day) used as adjunctive therapy in adult Asian subjects with drug-resistant partial-onset seizures.	retigabine, ezogabine	RTG114855	Epilepsy	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=114855	http://clinicaltrials.gov/show/NCT01648101		Y	Y	Y	Y	Y	Y	Y	A follow-on study RTG114873 was conducted.	1-Nov-2016
4518	GSK	A single-blind, randomized, placebo-controlled study to investigate the safety, tolerability, and potential effects on betamethasone pharmacokinetics of a co-administered infusion of the new chemical entity (NCE) in healthy female subjects.	retosiban	OTA105036	Obstetric Labour, Premature	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=105036		https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001029-24	Y	Y	Y	Y	Y	Y	Y	A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Nov-2016
4519	GSK	A phase 2a study to evaluate the effect of rilapladib (SB-659032) on biomarkers related to the pathogenesis and progression of Alzheimer’s disease	rilapladib	LPZ114458	Alzheimer's Disease	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=114458	http://clinicaltrials.gov/show/NCT01428453	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-020993-41	Y	Y	Y	Y	Y	Y	Y		1-Nov-2016
4520	GSK	A Randomized, Placebo-Controlled Study to Evaluate the Effect of Tafenoquine (SB252263) on the Electrocardiogram (ECG) with Focus on Cardiac Repolarization (QTc duration) in Healthy Subjects	tafenoquine	TAF114582	Malaria, Vivax	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=114582	http://clinicaltrials.gov/show/NCT01928914		Y	Y	Y	Y	Y	Y	Y		1-Nov-2016
4553	Novartis	A Phase III, Randomized, Double-blind, Triple-dummy, Placebo Controlled, Multicenter, 5-period, Single-dose Complete Block Crossover Study to Determine the Onset of Action of Indacaterol (150 and 300 μg) in Patients With Moderate to Severe COPD Using Salbutamol (200 μg) and Salmeterol/Fluticasone (50/500 μg) as Active Controls	indacaterol	CQAB149B2307	Chronic Obstructive Pulmonary Disease (COPD)	Phase 3	https://www.novctrd.com/ctrdweb/trialresult/trialresults/pdf?trialResultId=2745	https://clinicaltrials.gov/show/NCT00669617	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-006189-14	Y	Y	Y	Y	Y	Y	Y		1-Jan-2017
4556	Novartis	A 76-week Prospective, Open-label, Multicenter Study to Evaluate the Long-term Effect of Rivastigmine Capsule and Transdermal Patch on Worsening of the Underlying Motor Symptoms of PD in Patients With Mild to Moderately Severe Dementia Associated With Parkinson's Disease (PDD)	rivastigmine	CENA713B2315	Parkinson's Disease Dementia	Phase 3	https://www.novctrd.com/ctrdweb/trialresult/trialresults/pdf?trialResultId=4686	https://clinicaltrials.gov/show/NCT00623103	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000350-31	Y	Y	Y	Y	Y	Y	Y		1-Jan-2017
4572	GSK	An Open-Label Single-Arm Study to Evaluate the Reliability of an Autoinjector that Administers Belimumab Subcutaneously in Subjects with Systemic Lupus Erythematosus (SLE)	belimumab	200339	Systemic Lupus Erythematosus	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=200339	http://clinicaltrials.gov/show/NCT02124798		Y	Y	Y	Y	Y	Y	Y	This study is available in CDISC format	1-Jan-2017
4573	GSK	201135 : A Randomised, Double-blind, Multicenter, Parallel-group Study to Compare the Efficacy and Safety of Fluticasone Furoate (FF) 100 mcg Once Daily with Fluticasone Propionate (FP) 250 mcg Twice Daily (BD) and FP 100 mcg BD in Well-controlled Asthmatic Subjects Stepped Down from a Maintenance Therapy with RELVAR® inhaler (FF/VI) 100/25 mcg Once-daily in Japanese Subjects	fluticasone furoate	201135	Asthma	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=201135	http://clinicaltrials.gov/show/NCT02094937		Y	N	Y	Y	Y	Y	N	An annotated case report form is not available for this study. A blank case report form will be provided. A reporting and analysis plan is not available for this study.	1-Jan-2017
4574	GSK	A Patient Preference Evaluation Study of Fluticasone Furoate Nasal Spray and Mometasone Furoate Nasal Spray in Subjects with Allergic Rhinitis	fluticasone furoate	201474	Rhinitis, Allergic, Perennial and Seasonal	Phase 4	https://www.gsk-studyregister.com/en/trial-details/?id=201474	http://clinicaltrials.gov/show/NCT02397915		Y	Y	Y	Y	Y	Y	Y		1-Jan-2017
4575	GSK	A dose-ranging study of fluticasone furoate (FF) inhalation powder in children aged 5-11 years with asthma	fluticasone furoate	HZA106855	Asthma	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=106855	http://clinicaltrials.gov/show/NCT01563029	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-003338-15	Y	Y	Y	Y	Y	Y	Y		1-Jan-2017
4576	GSK	An open-label study of inhaler device attributes investigating critical and overall errors, ease of use, and preference between a number of inhaler devices (ELLIPTA, TURBUHALER, HANDIHALER, BREEZHALER, MDI, and DISKUS/ACCUHALER) in adult subjects with Chronic Obstructive Pulmonary Disease (COPD)	fluticasone furoate/vilanterol	200301	Pulmonary Disease, Chronic Obstructive	Phase 4	https://www.gsk-studyregister.com/en/trial-details/?id=200301	http://clinicaltrials.gov/show/NCT02184624		Y	Y	Y	Y	Y	Y	Y		1-Jan-2017
4577	GSK	A Randomised, Multi-Centre, Double-Blind, Double-Dummy, Two Way Cross-Over, Twelve Weeks Non-inferiority Study to Evaluate the Efficacy, Safety, and Tolerability of Combination Dry Powder of Fluticasone Propionate and Salmeterol 250/50 mcg Twice Daily Delivered through a Capsule-Based Inhaler and a Multi-Dose Inhaler in Adults and Adolescents with Asthma	fluticasone propionate/salmeterol	ASR115645	Asthma	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=115645	http://clinicaltrials.gov/show/NCT01978119		Y	N	Y	Y	Y	Y	Y	An annotated case report form is not available for this study. A blank case report form will be provided	1-Jan-2017
4578	GSK	A First Time In Human Study to Evaluate the Safety, Tolerability and Pharmacokinetics of GSK1399686 after Single and Repeated Oral Dosing in Healthy Volunteers Using a Dose-Escalating, Randomized, Placebo-Controlled Study Design	GSK1399686	MCA111406	Inflammatory Bowel Diseases	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=111406	http://clinicaltrials.gov/show/NCT00721812	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001215-38	Y	Y	Y	Y	Y	Y	Y		1-Jan-2017
4579	GSK	Safety and immunogenicity study of GSK Biologicals’ Herpes Zoster subunit (HZ/su) vaccine GSK1437173A when administered subcutaneously versus intramuscularly in adults aged 50 years or older	Herpes Zoster subunit (HZ/su) vaccine	116760	Herpes Zoster	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=116760	http://clinicaltrials.gov/show/NCT01777321	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-005671-14	Y	Y	Y	Y	Y	Y	Y		1-Jan-2017
4580	GSK	A single blind, randomized, placebo-controlled, dose escalating study to evaluate the safety, tolerability,pharmacokinetic and pharmacodynamic parameters of repeat doses of GSK2330672 in healthy volunteers, given alone and with a single day of dosing with GSK1614235	linerixibat	BSC116511	Diabetes Mellitus, Type 2	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=116511	http://clinicaltrials.gov/show/NCT01607385		Y	Y	Y	Y	Y	Y	Y		1-Jan-2017
4581	GSK	Persistence of hepatitis B antibodies, immunogenicity and safety of GSK Biologicals’ hepatitis B vaccine Engerix™-B Kinder (SKF103860) challenge dose in adolescents vaccinated with four doses of Infanrix™ hexa (SB217744) during infancy	Hepatitis B Vaccine, Recombinant	106793	Hepatitis B	Phase 4	https://www.gsk-studyregister.com/en/trial-details/?id=106793	http://clinicaltrials.gov/show/NCT02052661	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002821-41	Y	Y	Y	Y	Y	Y	Y		1-Jan-2017
4582	GSK	Evaluation of the Effectiveness of Two Vaccination Strategies Using GlaxoSmithKline Biologicals' HPV Vaccine GSK580299 (Cervarix™) Administered in Healthy Adolescents	Human Papillomavirus Types 16 and 18 Vaccine	106636	Infections, Papillomavirus	Phase 4	https://www.gsk-studyregister.com/en/trial-details/?id=106636	http://clinicaltrials.gov/show/NCT00534638	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001731-55	Y	Y	Y	Y	Y	Y	Y		1-Jan-2017
4583	GSK	A Phase III study for the evaluation of the immunogenicity and reactogenicity of GSK Biologicals' Quadrivalent Split Virion Influenza Vaccine Fluarix Tetra (2015 season Southern Hemisphere) in adults 18 years of age and above	Influenza Vaccine (Quadrivalent)	201959	Influenza	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=201959	http://clinicaltrials.gov/show/NCT02369341		Y	Y	Y	Y	Y	Y	Y		1-Jan-2017
4587	GSK	Efficacy, safety and immunogenicity study of GSK Biologicals’ candidate malaria vaccine 257049 in the sporozoite challenge model in healthy malaria-naïve adults	RTS,S Vaccine	117014	Malaria	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=117014	http://clinicaltrials.gov/show/NCT01857869		Y	Y	Y	Y	Y	Y	Y		1-Jan-2017
4588	GSK	An adaptive Phase II study to evaluate the efficacy, pharmacodynamics, safety and tolerability of GSK2586184 in patients with mild to moderate systemic lupus erythematosus	solcitinib	JAK115919	Systemic Lupus Erythematosus	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=115919	http://clinicaltrials.gov/show/NCT01777256	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001645-41	Y	Y	Y	Y	Y	Y	Y	This study is available in CDISC format	1-Jan-2017
4589	GSK	A multi-centre, double-blind, randomised, parallel-group, active controlled study to evaluate the efficacy, safety and tolerability of tafenoquine (SB-252263, WR238605) in subjects with Plasmodium vivax malaria.	tafenoquine	TAF112582	Malaria, Vivax	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=112582	http://clinicaltrials.gov/show/NCT01376167		Y	N	Y	Y	Y	Y	Y	An annotated case report form is not available for this study. A blank case report form will be provided.	1-Jan-2017
4590	GSK	Study in Healthy Children (<2 Years) to Evaluate the Safety and Efficacy of GSK Biologicals' Live Attenuated Varicella Vaccine (VarilrixTM) and of GSK Biologicals' Combined Measles-Mumps-Rubella-Varicella Vaccine	Varicella Vaccine	104105	Varicella	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=100388	http://clinicaltrials.gov/show/NCT00226499		Y	N	Y	Y	Y	Y	Y	This is a follow-up study to 100388. The results of this study 104105 are summarised with studies 100388, 104106, and 103494 on the GSK Study Register. An annotated case report form is not available for this study. A blank case report form will be provided.	1-Jan-2017
4591	GSK	Study in Healthy Children (<2 Years) to Evaluate the Safety and Efficacy of GSK Biologicals' Live Attenuated Varicella Vaccine (VarilrixTM) and of GSK Biologicals' Combined Measles-Mumps-Rubella-Varicella Vaccine	Varicella Vaccine	104106	Varicella	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=100388	http://clinicaltrials.gov/show/NCT00226499		Y	Y	Y	Y	Y	Y	Y	This is a follow-up study to 100388. The results of this study 104106 are summarised with studies 100388, 104105, and 103494 on the GSK Study Register.	1-Feb-2018
4592	GSK	Study in Healthy Children (<2 Years) to Evaluate the Safety and Efficacy of GSK Biologicals' Live Attenuated Varicella Vaccine (VarilrixTM) and of GSK Biologicals' Combined Measles-Mumps-Rubella-Varicella Vaccine	Varicella Vaccine	103494	Varicella	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=100388	http://clinicaltrials.gov/show/NCT00226499		Y	N	Y	Y	Y	Y	Y	This is a follow-up study to 100388. The results of this study 103494 are summarised with studies 100388, 104106, and 104105 on the GSK Study Register. An annotated case report form is not available for this study. A blank case report form will be provided.	1-Jan-2017
4594	Novartis	A Double-blind, Randomized, Multicenter, Placebo-controlled, Parallel-group Study Comparing the Efficacy and Safety of 0.5mg FTY720 Administered Orally Once Daily Versus Placebo in Patients With Primary Progressive Multiple Sclerosis	fingolimod	CFTY720D2306	Multiple Sclerosis	Phase 3	https://www.novctrd.com/ctrdweb/trialresult/trialresults/pdf?trialResultId=15030	https://clinicaltrials.gov/show/NCT00731692	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002627-32	Y	Y	Y	Y	Y	Y	Y		1-Feb-2017
4595	Novartis	A 52-week Treatment, Multi-center, Randomized, Double-blind, Double Dummy, Parallel-group, Active Controlled Study to Compare the Effect of QVA149 (Indacaterol Maleate / Glycopyrronium Bromide) With Salmeterol/Fluticasone on the Rate of Exacerbations in Subjects With Moderate to Very Severe COPD. (FLAME).	indacaterol, glycopyrrolate	CQVA149A2318	Chronic Obstructive Pulmonary Disease (COPD)	Phase 3	https://www.novctrd.com/ctrdweb/trialresult/trialresults/pdf?trialResultId=14907	https://clinicaltrials.gov/show/NCT01782326	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-004966-16	Y	Y	Y	Y	Y	Y	Y		1-Feb-2017
4596	Novartis	Randomized, Double-Masked, Vehicle Controlled, Clinical Evaluation To Assess The Safety And Efficacy Of Nepafenac Ophthalmic Suspension, 0.3% For Improvement In Clinical Outcomes Among Diabetic Subjects Following Cataract Surgery	nepafenac ophthalmic suspension, 0.3%	C-12-067	Cataract	Phase 3	https://www.novctrd.com/ctrdweb/trialresult/trialresults/pdf?trialResultId=14887	https://clinicaltrials.gov/show/NCT01853072		Y	Y	Y	Y	Y	Y	Y	Alcon is a division of Novartis	1-Feb-2017
4597	Novartis	Randomized, Double-Masked, Vehicle Controlled, Clinical Evaluation To Assess The Safety And Efficacy Of Nepafenac Ophthalmic Suspension, 0.3% For Improvement In Clinical Outcomes Among Diabetic Subjects Following Cataract Surgery	nepafenac ophthalmic suspension, 0.3%	C-12-071	Cataract	Phase 3	https://www.novctrd.com/ctrdweb/trialresult/trialresults/pdf?trialResultId=14930	https://clinicaltrials.gov/show/NCT01872611		Y	Y	Y	Y	Y	Y	Y	Alcon is a division of Novartis	1-Feb-2017
4608	Astellas	Long-term Study of ASP1941 — Long-term Study in Patients with Type 2 Diabetes Mellitus with Decreased Renal Function (Japanese) —	ipragliflozin	1941-CL-0072	Diabetes Mellitus, Type 2	Phase 3	https://www.clinicaltrials.astellas.com/study/?pid=1941-CL-0072	https://clinicaltrials.gov/ct2/show/NCT01316094		Y	Y	Y	N	N	Y	Y	Formats available for datasets without specifications	1-Jan-2017
4609	Astellas	Phase III Study of ASP1941 –A Phase III, Randomized, Double-Blind, Placebo-controlled, Monotherapy Study to Assess the Efficacy, Safety, and Tolerability of ASP1941 in Japanese Patients with Type 2 Diabetes Mellitus–	ipragliflozin	1941-CL-0105	Diabetes Mellitus, Type 2	Phase 3	https://www.clinicaltrials.astellas.com/study/?pid=1941-CL-0105	https://clinicaltrials.gov/ct2/show/NCT01057628		Y	Y	Y	N	N	Y	Y	Formats available for datasets without specifications	1-Jan-2017
4610	Astellas	A Phase 3 Study to Assess the Efficacy and Safety of ASP1941 in Combination with Metformin in Patients with Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Metformin Alone	ipragliflozin	1941-CL-0106	Diabetes Mellitus, Type 2	Phase 3	https://www.clinicaltrials.astellas.com/study/?pid=1941-CL-0106	https://clinicaltrials.gov/ct2/show/NCT01135433		Y	Y	Y	N	N	Y	Y	Formats available for datasets without specifications	1-Jan-2017
4611	Astellas	A Phase III Study to Assess the Efficacy, Safety and Tolerability of ASP1941 in Combination with Pioglitazone in Patients with Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Pioglitazone Alone	ipragliflozin	1941-CL-0107	Diabetes Mellitus, Type 2	Phase 3	https://www.clinicaltrials.astellas.com/study/?pid=1941-CL-0107	https://clinicaltrials.gov/ct2/show/NCT01225081		Y	Y	Y	N	N	Y	Y	Formats available for datasets without specifications	1-Jan-2017
4612	Astellas	Phase III Study of ASP1941 - Open-label, Non-comparative Study to Assess the Long-term Safety, Tolerability and Efficacy of ASP1941 in Combination with an α-Glucosidase Inhibitor in Japanese Patients with Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control with an α-Glucosidase Inhibitor Alone	ipragliflozin	1941-CL-0108	Diabetes Mellitus, Type 2	Phase 3	https://www.clinicaltrials.astellas.com/study/?pid=1941-CL-0108	https://clinicaltrials.gov/ct2/show/NCT01242202		Y	Y	Y	N	N	Y	Y	Formats available for datasets without specifications	1-Jan-2017
4613	Astellas	A Phase III Study to Assess the Efficacy, Safety and Tolerability of ASP1941 in Combination with Sulfonylurea in Patients with Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Sulfonylurea Alone	ipragliflozin	1941-CL-0109	Diabetes Mellitus, Type 2	Phase 3	https://www.clinicaltrials.astellas.com/study/?pid=1941-CL-0109	https://clinicaltrials.gov/ct2/show/NCT01242215		Y	Y	Y	N	N	Y	Y	Formats available for datasets without specifications	1-Jan-2017
4614	Astellas	Phase III Study of ASP1941 - Open-label, Non-comparative Study to Assess the Long-term Safety, Tolerability and Efficacy of ASP1941 in Combination with a Dipeptidyl Peptidase-4 Inhibitor in Japanese Patients with Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control with a Dipeptidyl Peptidase-4 Inhibitor Alone -	ipragliflozin	1941-CL-0110	Diabetes Mellitus, Type 2	Phase 3	https://www.clinicaltrials.astellas.com/study/?pid=1941-CL-0110	https://clinicaltrials.gov/ct2/show/NCT01242228		Y	Y	Y	N	N	Y	Y	Formats available for datasets without specifications	1-Jan-2017
4615	Astellas	Phase III Study of ASP1941 - Open-label, Non-comparative Study to Assess the Long-term Safety, Tolerability and Efficacy of ASP1941 in Combination with Nateglinide in Japanese Patients with Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control with Nateglinide Alone -	ipragliflozin	1941-CL-0111	Diabetes Mellitus, Type 2	Phase 3	https://www.clinicaltrials.astellas.com/study/?pid=1941-CL-0111	https://clinicaltrials.gov/ct2/show/NCT01316107		Y	Y	Y	N	N	Y	Y	Formats available for datasets without specifications	1-Jan-2017
4616	Astellas	Long-term Study of ASP1941 - A Phase III, Open-Label, Uncontrolled, Monotherapy Study to Assess the Long-term Safety, Tolerability and Efficacy of ASP1941 in Japanese Patients with Type 2 Diabetes Mellitus -	ipragliflozin	1941-CL-0121	Diabetes Mellitus, Type 2	Phase 3	https://www.clinicaltrials.astellas.com/study/?pid=1941-CL-0121	https://clinicaltrials.gov/ct2/show/NCT01054092		Y	Y	Y	N	N	Y	Y	Formats available for datasets without specifications	1-Jan-2017
4617	Eisai	A Double-blind, Randomized, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of Adjunctive Perampanel in Primary Generalized Tonic Clonic Seizures	perampanel	E2007-G000-332	Seizure Disorder Generalized Tonic Clonic	Phase 3		https://clinicaltrials.gov/ct2/show/NCT01393743	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000265-12	Y	Y	Y	Y	Y	Y	Y	Sharing of clinical data is restricted for the following countries: Netherlands, Thailand, Czech Republic, Poland, France, Lithuania, Korea, Serbia, Greece, China, Australia, Germany, Austria, Latvia and Hungary.	1-Jun-2016
4618	Eisai	A Double-blind, Randomized, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of Adjunctive Perampanel in Primary Generalized Tonic Clonic Seizures	perampanel	E2007-G000-332EXT	Seizure Disorder Generalized Tonic Clonic	Phase 3		https://clinicaltrials.gov/ct2/show/NCT01393743	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000265-12	Y	Y	Y	Y	Y	Y	Y	Sharing of clinical data is prevented for the following countries; Netherlands, Thailand, Czech Republic, Poland, France, Lithuania, Korea, Serbia, Greece, China, Australia, Germany, Austria, Latvia and Hungary.	1-Jun-2016
4630	GSK	A Randomized, Open-label, Single-dose, Two-period, Crossover Study to Demonstrate the Bioequivalence of the Fixed Dose Combination (FDC) of lamivudine and adefovir dipivoxil (100mg/10mg) to Heptodin® (100mg ) and Hepsera® (10mg)	adefovir/lamivudine	LAF114957	Hepatitis B, Chronic	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=114957	http://clinicaltrials.gov/show/NCT01353742		Y	Y	Y	Y	Y	Y	Y		1-Feb-2017
4631	GSK	A 52-Week, Open-Label, Multicenter Study to Determine the Long Term Safety and Efficacy of Albiglutide in Combination with Monotherapy of Oral Antihyperglycemic Medications in Japanese Patients With Type 2 Diabetes Mellitus	albiglutide	GLP116170	Diabetes Mellitus, Type 2	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=116170	http://clinicaltrials.gov/show/NCT01777282		Y	N	Y	Y	Y	Y	Y	"This study is available in CDISC format. An annotated case report form is not available for this study. A blank case report form will be provided."	1-Feb-2017
4632	GSK	Immunogenicity and safety study of GlaxoSmithKline Biologicals’ Infanrix hexa™ vaccine in healthy infants in India	Combined Diphtheria, Tetanus, Acellular Pertussis, Hepatitis B, Inactivated Polio, Haemophilus influenzae Type b Vaccine	111157	Poliomyelitis; Tetanus; Acellular Pertussis; Haemophilus influenzae type b; Diphtheria; Hepatitis B	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=111157	http://clinicaltrials.gov/show/NCT01353703	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003427-10	Y	N	Y	Y	Y	Y	Y	An annotated case report form is not available for this study. A blank case report form will be provided.	1-Feb-2017
4633	GSK	Safety and reactogenicity of GlaxoSmithKline Biologicals’ DTPa-IPV/Hib (Infanrix-IPV+HibTM) in healthy Vietnamese toddlers	Combined Diphtheria, Tetanus, Acellular Pertussis, Inactivated Polio, Haemophilus influenzae Type b Conjugate Vaccine	115389	Acellular pertussis; Haemophilus influenzae type b; Tetanus; Poliomyelitis; Diphtheria	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=115389	http://clinicaltrials.gov/show/NCT01577732	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002538-18	Y	N	Y	Y	Y	Y	Y	An annotated case report form is not available for this study. A blank case report form will be provided.	1-Feb-2017
4634	GSK	A 12-month, open label, randomised, effectiveness study to evaluate fluticasone furoate (FF, GW685698)/vilanterol (VI, GW642444) Inhalation Powder delivered once daily via a Novel Dry Powder Inhaler (NDPI) compared with the existing COPD maintenance therapy alone in subjects with Chronic Obstructive Pulmonary Disease (COPD)	fluticasone furoate/vilanterol	HZC115151	Pulmonary Disease, Chronic Obstructive	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=115151	http://clinicaltrials.gov/show/NCT01551758	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002452-13	Y	Y	Y	Y	Y	Y	Y	Medical record information for patients who participated in this study will not be provided as this information is held in a third-party database which is not owned by GSK.	1-Feb-2017
4635	GSK	A 24-week study to evaluate the effect of fluticasone furoate/vilanterol 100/25 mcg Inhalation Powder delivered once-daily via a Novel Dry Powder Inhaler on arterial stiffness compared with placebo and vilanterol in subjects with Chronic Obstructive Pulmonary Disease (COPD).	fluticasone furoate/vilanterol	HZC113108	Pulmonary Disease, Chronic Obstructive	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=113108	http://clinicaltrials.gov/show/NCT01336608	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023091-10	Y	Y	Y	Y	Y	Y	Y		1-Feb-2017
4636	GSK	A 12-Week Study to Evaluate the Efficacy and Safety of Fluticasone Furoate/Vilanterol Inhalation Powder (FF/VI) 100/25 mcg Once Daily Compared with Vilanterol Inhalation Powder (VI) 25 mcg Once Daily in Subjects with Chronic Obstructive Pulmonary Disease (COPD)	fluticasone furoate/vilanterol	200820	Pulmonary Disease, Chronic Obstructive	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=200820	http://clinicaltrials.gov/show/NCT02105974	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004548-44	Y	Y	Y	Y	Y	Y	Y	The raw data are included within the analysis-ready data for this study and are not provided separately.	1-Feb-2017
4637	GSK	An open-label study investigating critical and overall errors following 14 days of treatment with SERETIDE Metered Dose Inhaler (EVOHALER) in adult subjects with controlled asthma currently using the SERETIDE DISKUS Inhaler	fluticasone propionate/salmeterol	201909	Asthma	Phase 4	https://www.gsk-studyregister.com/en/trial-details/?id=201909	http://clinicaltrials.gov/show/NCT02416180	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004466-18	Y	N	Y	Y	Y	Y	Y	An annotated case report form is not available for this study. A blank case report form will be provided.	1-Feb-2017
4638	GSK	A randomized, double-blind, placebo-controlled, crossover study to evaluate the influence of the A118G polymorphism in the mu opioid receptor gene (OPRM1) on effects of GSK1521498 and naltrexone on physiological and behavioral markers of brain function in healthy social drinkers	GSK1521498	OAA116753	Alcoholism	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=116753	http://clinicaltrials.gov/show/NCT01738867	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002479-32	Y	Y	Y	Y	Y	Y	Y		1-Feb-2017
4639	GSK	A Randomised, Multicenter, Placebo-Controlled Study to Assess the Efficacy and Optimal Duration of Lamivudine Treatment in Patients with Pre-core Mutant HBV	lamivudine	NUC30935	Hepatitis B	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=NUC30935			N	Y	Y	Y	Y	Y	Y	A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies. An analysis-ready dataset is not available for this study.	1-Feb-2017
4640	GSK	A Double-blind Placebo Controlled Clinical End-points Trial of Lamivudine in Patients with Hepatitis B Related Cirrhosis	lamivudine	NUCB4006	Hepatitis B	Phase 4	https://www.gsk-studyregister.com/en/trial-details/?id=NUCB4006			N	Y	Y	Y	Y	Y	N	A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies. An analysis-ready dataset and a reporting and analysis plan are not available for this study.	1-Feb-2017
4641	GSK	Adjuvant justification study of candidate malaria vaccines (257049), administered according to a 0, 1, 2 months schedule .	RTS,S Vaccine	107731	Malaria	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=107731	http://clinicaltrials.gov/show/NCT00443131	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002095-18	Y	N	Y	Y	Y	Y	Y	An annotated case report form is not available for this study. A blank case report form will be provided.	1-Feb-2017
4642	GSK	Bridging Safety & Immunogenicity study of GSK Biologicals' Candidate Malaria Vaccine RTS,S/AS01E (0.5 mL Dose) to RTS,S/AS02D (0.5 mL Dose) Administered IM According to a 0, 1, 2-Month Schedule in Gabonese Children Aged 18 Months to 4 Years	RTS,S Vaccine	105874	Malaria	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=105874	http://clinicaltrials.gov/show/NCT00307021		Y	N	Y	Y	Y	Y	Y	An annotated case report form is not available for this study. A blank case report form will be provided.	1-Feb-2017
4643	GSK	A Phase I/IIb randomized, double-blind, controlled study of the safety, immunogenicity and proof-of-concept of RTS,S/AS02D, a candidate malaria vaccine in infants living in a malaria-endemic region	RTS,S Vaccine	103967	Malaria	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=103967	http://clinicaltrials.gov/show/NCT00197028	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-001538-25	Y	N	Y	Y	Y	Y	Y	An annotated case report form is not available for this study. A blank case report form will be provided.	1-Feb-2017
4644	GSK	A partially-blind (observer-blind) study to evaluate the safety and immunogenicity of 3 different vaccination schedules with 2 GSK Biologicals candidate Plasmodium falciparum vaccines in children aged 5 to 17 months living in Ghana	RTS,S Vaccine	106367	Malaria	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=106367	http://clinicaltrials.gov/show/NCT00360230		Y	N	Y	Y	Y	Y	Y	An annotated case report form is not available for this study. A blank case report form will be provided.	1-Feb-2017
4645	GSK	A study of the efficacy against episodes of clinical malaria due to P. falciparum infection of GSK Biologicals candidate vaccine RTS,S/AS01, administered according to a 0,1,2-months schedule in children aged 5 to 17 months living in Tanzania & Kenya	RTS,S Vaccine	106464	Malaria	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=106464	http://clinicaltrials.gov/show/NCT00380393		Y	N	Y	Y	Y	Y	Y	An annotated case report form is not available for this study. A blank case report form will be provided.	1-Feb-2017
4646	GSK	A Phase IIb randomized, double-blind, controlled study of the safety, immunogenicity and proof-of-concept of RTS,S/AS02D, a candidate malaria vaccine, when incorporated into an Expanded Program on Immunization (EPI) regimen that includes DTPw/Hib in infants living in a malaria-endemic region.	RTS,S Vaccine	104298	Malaria	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=104298	http://clinicaltrials.gov/show/NCT00289185	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-001539-19	Y	N	Y	Y	Y	Y	Y	An annotated case report form is not available for this study. A blank case report form will be provided.	1-Feb-2017
4647	GSK	Safety and immunogenicity study of GSK Biologicals investigational vaccination regimen Malaria Vaccine 257049, when incorporated into an Expanded Program on Immunization (EPI) regimen that includes Tritanrix HepB/Hib, OPV, measles and yellow fever vaccination in infants	RTS,S Vaccine	106369	Malaria	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=106369	http://clinicaltrials.gov/show/NCT00436007	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-005695-34	Y	N	Y	Y	Y	Y	Y	An annotated case report form is not available for this study. A blank case report form will be provided.	1-Feb-2017
4648	GSK	Consistency of immunogenicity and non inferiority of three production lots of GSK Biologicals candidate malaria vaccine in children	RTS,S Vaccine	113398	Malaria	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=113398	http://clinicaltrials.gov/show/NCT01323972		Y	N	Y	Y	Y	Y	Y	An annotated case report form is not available for this study. A blank case report form will be provided.	1-Feb-2017
4649	GSK	Safety, immunogenicity and efficacy against malaria in the sporozoite challenge model of one dose of Ad35.CS.01 malaria vaccine followed by two doses of malaria 257049 vaccine in healthy malaria-naïve adults	RTS,S Vaccine	114460	Malaria	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=114460	http://clinicaltrials.gov/show/NCT01366534		Y	N	Y	Y	Y	Y	Y	An annotated case report form is not available for this study. A blank case report form will be provided.	1-Feb-2017
4650	GSK	Safety and immunogenicity study of GSK Biologicals Plasmodium falciparum malaria vaccine 257049 administered to HIV infected infants and children	RTS,S Vaccine	112745	Malaria	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=112745	http://clinicaltrials.gov/show/NCT01148459		Y	N	Y	Y	Y	Y	Y	An annotated case report form is not available for this study. A blank case report form will be provided.	1-Feb-2017
4651	GSK	Efficacy of GSK Biologicals’ candidate malaria vaccine (257049) against malaria disease caused by P. falciparum infection in infants and children in Africa	RTS,S Vaccine	110021	Malaria	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=110021	http://clinicaltrials.gov/show/NCT00866619	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-005716-26	Y	N	Y	Y	Y	Y	Y	An extension study 200559 was conducted. An annotated case report form is not available for this study. A blank case report form will be provided.	1-Feb-2017
4654	Novartis	An Open Label Study to Assess the Utility of Measuring Markers of Inflammation, to Detect Transition From Optimal to Sub-Optimal Inhaled Corticosteroid Therapy in Moderate-Severe Bronchial Asthma	fluticasone propionate	CQAE397A2202	Asthma	Phase 2	https://www.novctrd.com/ctrdweb/trialresult/trialresults/pdf?trialResultId=14396	https://clinicaltrials.gov/show/NCT00411567		Y	Y	Y	Y	Y	Y	Y		1-Mar-2017
4660	GSK	An Open Label, Randomized, Two Part Study to Evaluate the CYP2C8- and OATP1B1-Mediated Drug-Drug Interaction Potential of GSK1278863 with Pioglitazone and Rosuvastatin as Victims and Trimethoprim as Perpetrator in Healthy Adult Volunteers	daprodustat	200229	Anaemia	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=200229	http://clinicaltrials.gov/show/NCT02371603		Y	N	Y	Y	Y	Y	Y	An annotated case report form is not available for this study. A blank case report form will be provided.	1-Mar-2017
4661	GSK	Single-blind, randomised, placebo-controlled study to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of repeat doses of GSK2647544 and its potential pharmacokinetic interaction with simvastatin in healthy volunteers	GSK2647544	200592	Alzheimer's Disease	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=200592	http://clinicaltrials.gov/show/NCT01978327	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003339-31	Y	Y	Y	Y	Y	Y	Y		1-Mar-2017
4662	GSK	An observer-blind study to evaluate the safety and immunogenicity of GSK Biologicals’ influenza vaccine(s) GSK3206641A and GSK3206640A administered in adults 18 to 64 years of age	GSK3206641A	201072	Influenza	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=201072	http://clinicaltrials.gov/show/NCT01999842		Y	Y	Y	Y	Y	Y	Y		1-Mar-2017
4663	GSK	A Study of Extended Lamivudine Treatment for Hepatitis B Subjects Previously Enrolled in Phase II or Phase III Lamivudine Trials.	lamivudine	NUCB3017	Hepatitis B	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=NUCB3017			N	Y	Y	Y	Y	Y	N	A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies. An analysis-ready dataset is not available for this study. A report and analysis plan is not available for this study.	1-Mar-2017
4664	GSK	An Extended, Observational Study in Pediatric Patients with Chronic Hepatitis B Who Have Previously Received Long-Term Lamivudine Treatment	lamivudine	NUC40040	Hepatitis B, Chronic	Phase 4	https://www.gsk-studyregister.com/en/trial-details/?id=NUC40040			N	Y	Y	Y	Y	Y	Y	This is a follow-up study to NUC30926. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies. An analysis-ready dataset is not available for this study.	1-Mar-2017
4665	GSK	An Open-Label Extension Study to Study MHE100185, to Evaluate Long-term Safety, Efficacy and Optimal Dosing Frequency of 750 mg Intravenous Mepolizumab in Subjects with Hypereosinophilic Syndromes	mepolizumab	MHE100901	Hypereosinophilic Syndrome	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=100901	http://clinicaltrials.gov/show/NCT00097370	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000930-35	Y	Y	Y	Y	Y	Y	Y	This is a follow-up study to MHE100185.	1-Mar-2017
4666	GSK	A Multicenter, Double-blind, Placebo-controlled, Study to  Evaluate the Corticosteroid- sparing effects of Mepolizumab in Subjects with Hypereosinophilic Syndromes (HES) and Evaluate Efficacy and Safety of Mepolizumab in Controlling the Clinical Signs and Symptoms of subjects with HES	mepolizumab	MHE100185	Hypereosinophilic Syndrome	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=100185	http://clinicaltrials.gov/show/NCT00086658	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000929-30	Y	Y	Y	Y	Y	Y	Y	A follow-on study MHE100901 was conducted.	1-Mar-2017
4667	GSK	Immunogenicity and safety of a booster dose of GlaxoSmithKline Biologicals’ IPV (PoliorixTM) in healthy Chinese toddlers	Poliomyelitis Vaccine (Inactivated)	114306	Poliomyelitis	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=114306	http://clinicaltrials.gov/show/NCT01323647	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-004513-14	Y	N	Y	Y	Y	Y	Y	An annotated case report form is not available for this study. A blank case report form will be provided. This study is a booster of study IPV-018 (112679)	1-Mar-2017
4668	GSK	A fixed dose, dose response study for ropinirole prolonged release (PR) in patients with early stage Parkinson's Disease	ropinirole	ROP111662	Parkinson Disease	Phase 4	https://www.gsk-studyregister.com/en/trial-details/?id=111662	http://clinicaltrials.gov/show/NCT01485172	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002827-17	Y	N	Y	Y	Y	Y	Y	An annotated case report form is not available for this study. A blank case report form will be provided.	1-Mar-2017
4669	GSK	A fixed dose, dose-response study of ropinirole prolonged release (PR) as adjunctive treatment to L-dopa in patients with advanced Parkinson’s disease	ropinirole	ROP111569	Parkinson Disease	Phase 4	https://www.gsk-studyregister.com/en/trial-details/?id=111569	http://clinicaltrials.gov/show/NCT01494532	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002828-41	Y	N	Y	Y	Y	Y	Y	The raw data are included within the analysis-ready data for this study and are not provided separately. An annotated case report form is not available for this study. A blank case report form will be provided.	1-Mar-2017
4670	GSK	A multicenter study of the immunogenicity & safety of 2 doses of GSK Biologicals’ oral live attenuated human rotavirus vaccine (RIX4414) as primary dosing of healthy infants in India aged approximately 8 wks at the time of the first dose	Rotavirus Vaccine	103792	Infections, Rotavirus	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=103792	http://clinicaltrials.gov/show/NCT00289172	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004071-36	Y	N	Y	Y	Y	Y	Y	An annotated case report form is not available for this study. A blank case report form will be provided.	1-Mar-2017
4671	GSK	An open-label, randomised, cross-over, two cohort, single dose study in healthy volunteers to evaluate the Unit Dose Dry Powder Inhaler (UD-DPI) for the delivery of salbutamol and to compare the pharmacokinetic profile with the MDI and Diskus presentations.	salbutamol	200921	Asthma	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=200921	http://clinicaltrials.gov/show/NCT01984086		Y	Y	Y	Y	Y	Y	Y		1-Mar-2017
4672	GSK	Staggered study to evaluate safety and immunogenicity of GSK Biologicals RTS,S/AS02 candidate malaria vaccine, administered intramuscularly according to a 0,1,3-month schedule in semi-immune children aged 6 to 11 years in Gambia, a malaria endemic region	RTS,S Vaccine	257049/015	Malaria	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=257049/015			Y	N	Y	Y	Y	Y	Y	A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies. An annotated case report form is not available for this study. A blank case report form will be provided.	1-Mar-2017
4673	GSK	A phase I, double-blind, randomized, controlled, study to evaluate the safety and immunogenicity of GlaxoSmithKline Biologicals’ candidate vaccine, administered intramuscularly according to a 0, 1, 2-month vaccination schedule in children aged 1 through 4	RTS,S Vaccine	257049/025	Malaria	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=257049/025			Y	N	Y	Y	Y	Y	Y	A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies. An annotated case report form is not available for this study. A blank case report form will be provided.	1-Mar-2017
4674	GSK	Double-blind, randomized phase I/IIa human challenge study, to evaluate the safety, reactogenicity, immunogenicity, and preliminary efficacy after primary sporozoite challenge and rechallenge, of GSK Biologicals’ candidate malaria vaccines containing the antigen RTS,S adjuvanted with either AS02A or AS01B and administered intramuscularly at months 0, 1, 2 in healthy malaria-naive volunteers aged 18 - 45 years	RTS,S Vaccine	257049/027	Malaria	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=257049/027			Y	N	Y	Y	Y	Y	Y	A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies. An annotated case report form is not available for this study. A blank case report form will be provided.	1-Mar-2017
4687	Novartis	An Open-label Extension Study to Assess the Safety and Efficacy of Pazopanib in Subjects With Renal Cell Carcinoma Previously Enrolled on Protocol VEG105192	pazopanib	VEG107769	Carcinoma, Renal Cell	Phase 3	https://www.gsk-clinicalstudyregister.com/study/VEG107769	https://clinicaltrials.gov/show/NCT00387764		Y	Y	Y	Y	Y	Y	Y		1-Apr-2017
4688	Novartis	Efficacy and Safety of the Rivastigmine Transdermal Patch in Patients With Probable Alzheimer's Disease	rivastigmine	CENA713D2320	Alzheimer's Disease	Phase 3	https://www.novctrd.com/ctrdweb/trialresult/trialresults/pdf?trialResultId=2255	https://clinicaltrials.gov/show/NCT00099242		Y	Y	Y	Y	Y	Y	Y		1-Apr-2017
4689	Novartis	A 48-Week, Multicenter, Randomized, Double-Blind, Parallel-Group Evaluation of the Com-parative Efficacy, Safety, and Tolerability of Exelon® 10 and 15 cm2 Patch in Patients with Alzheimer’s Disease Showing Cognitive Decline during an Initial Open-Label Treatment Phase	rivastigmine	CENA713D2340	Alzheimer's Disease	Phase 3	https://www.novctrd.com/ctrdweb/trialresult/trialresults/pdf?trialResultId=6023	https://clinicaltrials.gov/show/NCT00506415		Y	Y	Y	Y	Y	Y	Y		1-Apr-2017
4731	GSK	Efficacy, safety and tolerability of amoxicillin + clavulanic acid (875mg/125mg) two times a day compared to clindamycin (150mg) four times a day for 5-7 days in treatment of acute odontogenic infection with or without abscess	amoxicillin/clavulanic acid	AUG117044	Focal Infection, Dental	Phase 4	https://www.gsk-studyregister.com/en/trial-details/?id=117044	http://clinicaltrials.gov/show/NCT02141217		N	N	Y	Y	Y	Y	Y	An analysis-ready dataset is not available for this study. An annotated case report form is not available for this study. A blank case report form will be provided.	1-Apr-2017
4732	GSK	A Multicenter, Open-Label Study To Assess The Efficacy And Safety Of Potassium Clavulanate/Amoxicillin (CVA/AMPC 1:14 combination) In The Treatment Of Children With Acute Bacterial Rhinosinusitis	amoxicillin/clavulanic acid	AUG117150	Sinusitis, Acute	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=117150	http://clinicaltrials.gov/show/NCT01934231		Y	Y	Y	Y	Y	Y	Y		1-Apr-2017
4733	GSK	A Multi-Centre, Randomised, Double-Blind, Placebo-Controlled, One-Year Study to Evaluate the Efficacy and Safety of Bupropion Hydrochloride (SR) (Sustained-Release Tablets) for the Treatment of Nicotine Dependence as an Aid to Smoking Cessation.	bupropion	ZYB40017	Smoking Cessation	Phase 4	https://www.gsk-studyregister.com/en/trial-details/?id=ZYB40017			N	N	N	Y	Y	Y	N	A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies. An analysis-ready dataset is not available for this study. A blank and an annotated case report form is not available for this study. A clinical study report and reporting and analysis plan are not available for this study.	1-Apr-2017
4734	GSK	An open-label, single dose, randomized, two-period crossover study to investigate the bioavailability of a novel dosage form of dutasteride in healthy male subjects	dutasteride	ARI115148	Prostatic Hyperplasia	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=115148	http://clinicaltrials.gov/show/NCT01577693		Y	Y	Y	Y	Y	Y	Y		1-Apr-2017
4735	GSK	A randomised, double-blind, placebo-controlled study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of repeat doses of GSK2330672 administration in patients with primary biliary cirrhosis (PBC) and symptoms of pruritus	linerixibat	BAT117213	Cholestasis, Intrahepatic	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=117213	http://clinicaltrials.gov/show/NCT01899703	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-005531-84	Y	Y	Y	Y	Y	Y	Y		1-Apr-2017
4736	GSK	An Evaluator-Blinded Study to Evaluate the Cumulative Irritation Potential of Topically-Applied GSK2894512 Cream in Healthy Subjects	tapinarof	IPS117191	Psoriasis	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=117191	http://clinicaltrials.gov/show/NCT01984775	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-005156-15	N	N	Y	Y	Y	Y	Y	GSK has divested GSK2894512 and the associated data to Dermavant, and is no longer able to share the data associated with these studies.	1-Apr-2017
4737	GSK	A Phase II Study of Lamivudine Compared to Lamivudine Plus Adefovir Dipivoxil for Subjects With Chronic Hepatitis B	lamivudine	NUC20912	Hepatitis B, Chronic	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=NUC20912			Y	Y	Y	Y	Y	Y	Y	A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Apr-2017
4738	GSK	A randomized, double blind, placebo controlled study to explore the antidepressant properties of P38a Kinase inhibitor GW856553X 15mg compared to PBO in Subjects with Major Depressive Disorder exhibiting symptoms of loss of energy and interest and psychomotor retardation, for a six week treatment period	losmapimod	PKI108574	Depressive Disorder, Major	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=PKI108574	http://clinicaltrials.gov/show/NCT00569062	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005578-39	Y	N	Y	Y	Y	Y	Y	An annotated and a blank case report form are not available for this study.	1-Apr-2017
4739	GSK	DB2116960: A Randomized, Double-Dummy, Parallel Group, Multicenter Trial Comparing the Efficacy and Safety of UMEC/VI (a fixed combination of Umeclidinium and Vilanterol) With Tiotropium In Subjects with COPD Who Continue To Have Symptoms on Tiotropium	umeclidinium bromide/vilanterol	DB2116960	Pulmonary Disease, Chronic Obstructive	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=116960	http://clinicaltrials.gov/show/NCT01899742	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-005007-41	Y	Y	Y	Y	Y	Y	Y	The raw data are included within the analysis-ready data for this study and are not provided separately.	1-Apr-2017
4740	GSK	A Phase III international, randomized, double-blind, double-dummy study to evaluate the efficacy and safety of 300 mg or 600 mg of intravenous zanamivir twice daily compared to 75 mg of oral oseltamivir twice daily in the treatment of hospitalized adults and adolescents with influenza	zanamivir	NAI114373	Influenza, Human	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=114373	http://clinicaltrials.gov/show/NCT01231620	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-021621-12	Y	Y	Y	Y	Y	Y	Y		1-Apr-2017
4749	Novartis	A 24 Week, Prospective, Randomized, Parallel-group, Double-blind, Multi-center Study (ENA713DUS44) Comparing the Effects of Rivastigmine Patch 15 cm^2 vs. Rivastigmine Patch 5 cm^2 on ACTivities of Daily Living and CognitION in Patients With Severe Dementia of the Alzheimer's Type (ACTION) and a 24-week Open-label Extension to Study ENA713DUS44	rivastigmine	CENA713DUS44	Alzheimer's Disease	Phase 4	https://www.novctrd.com/ctrdweb/trialresult/trialresults/pdf?trialResultId=7723	https://clinicaltrials.gov/show/NCT00948766		Y	Y	Y	Y	Y	Y	Y		1-May-2017
4753	Novartis	A 2-year Randomized, Multicenter, Double-blind, Placebo-controlled Study to Determine the Efficacy and Safety of Intravenous Zoledronic Acid 5 mg Administered Either Annually at Randomization and 12 Months, or Administered at Randomization Only in the Prevention of Bone Loss in Postmenopausal Women With Osteopenia	zoledronic acid	CZOL446N2312	Osteopenia	Phase 3	https://www.novctrd.com/ctrdweb/trialresult/trialresults/pdf?trialResultId=2621	https://clinicaltrials.gov/show/NCT00132808	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000638-35	Y	Y	Y	Y	Y	Y	Y		1-May-2017
4774	GSK	An open label, balanced, randomized, three-treatment, three-period, six-sequence, cross-over, single dose, comparative bioavailability pilot study of two test formulations of fixed dose combination capsules of acetylsalicylic acid (ASA) and pantoprazole (Each capsule contains ASA 100 mg and pantoprazole 20 mg) manufactured by Piramal Healthcare Limited, India for GSK comparing with Aspirin® Protect 100 mg tablets by Bayer vital GmbH, and Protium® 20 mg gastro-resistant tablets by Nycomed GmbH, in healthy, adult, human subjects, under fasting conditions	acetylsalicylic acid/pantoprazole	APP116480	Ulcers, Duodenal and Gastric	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=116480	http://clinicaltrials.gov/show/NCT01847404		N	N	Y	Y	Y	Y	Y	An analysis-ready dataset is not available for this study. An annotated case report form is not available for this study. A blank case report form will be provided.	1-May-2017
4775	GSK	An open label, balanced, randomized, three-treatment, three-period, six-sequence, cross-over, single dose, comparative bioavailability pilot study of two test formulations of fixed dose combination capsules of acetylsalicylic acid (ASA) and pantoprazole (Each capsule contains ASA 100 mg and pantoprazole 20 mg) manufactured by Piramal Healthcare Limited, India for GSK comparing with Aspirin® Protect 100 mg tablets by Bayer vital GmbH, and Protium® 20 mg gastro-resistant tablets by Nycomed GmbH, in healthy, adult, human subjects, under fed conditions	acetylsalicylic acid/pantoprazole	APP116498	Ulcers, Duodenal and Gastric	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=116498	http://clinicaltrials.gov/show/NCT01847417		N	N	Y	Y	Y	Y	Y	An analysis-ready dataset is not available for this study. An annotated case report form is not available for this study. A blank case report form will be provided.	1-May-2017
4776	GSK	A multi-center, placebo-controlled study to evaluate the safety of GSK716155 and its effects on myocardial metabolism, myocardial function, and exercise capacity in patients with NYHA Class II/III congestive heart failure	albiglutide	GHF112670	Heart failure, Congestive	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=112670	http://clinicaltrials.gov/show/NCT01357850	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-020352-59	Y	Y	Y	Y	Y	Y	Y		1-May-2017
4777	GSK	An open-label, randomized, single sequence, two period study to assess the effect of repeat oral dosing of ketoconazole on the pharmacokinetics of a single oral dose of GSK962040 in healthy volunteers	camicinal	MOT112648	Gastroparesis	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=112648	http://clinicaltrials.gov/show/NCT01039974		Y	Y	Y	Y	Y	Y	Y		1-May-2017
4778	GSK	A double blind randomised placebo controlled two way cross over study to determine the effect of GSK962040 on oesophageal function and gastric emptying in healthy male volunteers.	camicinal	MOT114639	Gastrointestinal Motility	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=114639	http://clinicaltrials.gov/show/NCT01366560	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-021503-25	Y	Y	Y	Y	Y	Y	Y		1-May-2017
4779	GSK	A 4-Week, Phase II, Randomized, Double-Blind, Dose-Ranging, Placebo-Controlled, Parallel-Group, Multi-Center Study to Evaluate the Safety, Efficacy and Pharmacokinetics of GSK1278863 in Japanese Hemodialysis-Dependent Subjects with Anemia Associated with Chronic Kidney Disease	daprodustat	PHI116099	Anaemia	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=116099	http://clinicaltrials.gov/show/NCT02019719		Y	Y	Y	Y	Y	Y	Y	This study is available in CDISC format	1-May-2017
4781	GSK	An Open-Label, Three Period, Single Sequence Study To Determine The Effect Of Repeat Oral Dosing Of Diltiazem On The Pharmacokinetics Of Repeat Oral Dosing Of Darapladib (SB-480848).	darapladib	LPL115679	Atherosclerosis	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=115679	http://clinicaltrials.gov/show/NCT01852565		Y	Y	Y	Y	Y	Y	Y		1-May-2017
4782	GSK	A Randomised Multi-Centre, Double-Blind, Double-Dummy, Two Way Cross-Over, Twelve Weeks Non-inferiority Study to Evaluate The Efficacy, Safety, and Tolerability of Combination Dry Powder of Fluticasone Propionate and Salmeterol 250/50 mcg Twice Daily Delivered Through a Capsule-Based Inhaler and a Multi-Dose Inhaler for the Treatment of Chronic Obstructive Pulmonary Disease (COPD)	fluticasone propionate/salmeterol	ASR115646	Pulmonary Disease, Chronic Obstructive	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=115646	http://clinicaltrials.gov/show/NCT01978145		Y	Y	Y	Y	Y	Y	Y		1-May-2017
4783	GSK	A comparative bioavailability study to compare the pharmacokinetic (PK) and pharmacodynamic (PD) effects of Fluticasone propionate and Salmeterol delivered by Fluticasone propionate/ Salmeterol combination in a capsule-based inhaler and a multi-dose dry powder inhaler, in moderate asthma patients and moderate to severe Chronic obstructive pulmonary disease (COPD) patients.	fluticasone propionate/salmeterol	ASR114334	Asthma	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=114334	http://clinicaltrials.gov/show/NCT01494610		Y	Y	Y	Y	Y	Y	Y		1-May-2017
4784	GSK	A Phase 1/2, Open-Label, Multicenter Study of GSK1363089G in Adult Subjects with Hepatocellular Carcinoma	foretinib	MET111645	Carcinoma, Hepatocellular	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=111645	http://clinicaltrials.gov/show/NCT00920192		Y	N	Y	Y	Y	Y	Y	An annotated case report form is not available for this study. A blank case report form will be provided.	1-May-2017
4785	GSK	An Open-Label, Non-Randomized, Two-Period, Cross-Over, Mass Balance Study to Investigate the Recovery, Excretion and Pharmacokinetics of 14C-GSK2140944 Administered as a Single Intravenous and Single Oral Dose to Healthy Adult Male Subjects (BTZ115774)	gepotidacin	BTZ115774	Infections, Respiratory Tract	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=115774	http://clinicaltrials.gov/show/NCT02000765	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002835-10	Y	Y	Y	Y	Y	Y	Y	The raw data are included within the analysis-ready data for this study and are not provided separately.	1-May-2017
4786	GSK	A Phase I, Randomized, Double-Blinded, Placebo- and Moxifloxacin-Controlled, 4-Period Crossover Study to Evaluate the Effect of GSK2140944 on Cardiac Conduction as Assessed by 12-lead Electrocardiogram in Healthy Volunteers	gepotidacin	BTZ115775	Infections, Respiratory Tract	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=115775	http://clinicaltrials.gov/show/NCT02257398		Y	Y	Y	Y	Y	Y	Y	The raw data are included within the analysis-ready data for this study and are not provided separately.	1-May-2017
4787	GSK	A Single-Center, Three-Part, Open Label Study to Evaluate the Relative Bioavailability of Two Formulations, Food Effect, and Interaction with Itraconazole Following Single Dose of GSK2140944 in Healthy Subjects and Effect of Food on Safety, Tolerability, and Pharmacokinetics Following Multiple Doses of GSK2140944 in Healthy Elderly Subjects	gepotidacin	BTZ117349	Infections, Bacterial	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=117349	http://clinicaltrials.gov/show/NCT02045849		Y	Y	Y	Y	Y	Y	Y	The raw data are included within the analysis-ready data for this study and are not provided separately.	1-May-2017
4788	GSK	A Three-Part Phase I, Open-Label, Single Ascending Dose, and A Single-Blind, Placebo-Controlled, Repeat Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, and Relative Bioavailability of Intravenous and Oral GSK1322322 in Healthy Volunteers and Healthy Male Japanese Subjects	GSK1322322	PDF116266	Infections, Bacterial	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=116266	http://clinicaltrials.gov/show/NCT01818011		Y	Y	Y	Y	Y	Y	Y		1-May-2017
4789	GSK	Immunogenicity and safety of GSK Biologicals’ Herpes Zoster vaccine GSK1437173A in adults with a prior episode of herpes zoster	Herpes Zoster subunit (HZ/su) vaccine	ZOS116796	Herpes Zoster	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=116796	http://clinicaltrials.gov/show/NCT01827839	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003643-30	Y	Y	Y	Y	Y	Y	Y		1-May-2017
4790	GSK	GSK1572932A Antigen-Specific Cancer Immunotherapeutic as adjuvant therapy in patients with resectable MAGE-A3 positive Non-Small Cell Lung Cancer	GSK1572932A	109493	Lung Cancer, Non-Small Cell	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=109493	http://clinicaltrials.gov/show/NCT00480025	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001283-73	Y	Y	Y	Y	Y	Y	Y		1-May-2017
4791	GSK	A Single-Centre, Double-Blind, Placebo Controlled Two Part Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Single and Repeat Doses of GSK2269557 as a Dry Powder in Healthy Subjects who Smoke Cigarettes	nemiralisib	PII116617	Pulmonary Disease, Chronic Obstructive	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=116617	http://clinicaltrials.gov/show/NCT01762878	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-004262-17	Y	Y	Y	Y	Y	Y	Y		1-May-2017
4792	GSK	Immunogenicity and safety study of GSK Biologicals’ quadrivalent influenza vaccine (GSK2282512A) compared to Fluzone® Quadrivalent in children 6 to 35 months of age	GSK2282512A	201234	Influenza	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=201234	http://clinicaltrials.gov/show/NCT02242643		Y	Y	Y	Y	Y	Y	Y		1-May-2017
4793	GSK	Skin Irritation Study of GSK2894512 Cream-An Evaluator-Blinded Study to Evaluate the Skin Irritation of GSK2894512 Cream and Placebo following Single Application by Simple-Patch Test and Photo-Patch Test, and Repeat Application under non-occlusive condition in Healthy Japanese Subjects	tapinarof	200920	Dermatitis, Atopic	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=200920	http://clinicaltrials.gov/show/NCT02637206		Y	Y	Y	Y	Y	Y	Y	GSK has divested GSK2894512 and the associated data to Dermavant, and is no longer able to share the data associated with these studies.	1-May-2017
4794	GSK	A randomised, stratified, double-blind, multicentre study of the safety and efficacy of 52 weeks treatment with adefovir dipivoxil and lamivudine for subjects with chronic hepatitis B who have developed hepatitis B virus variants and evidence of reduced therapeutic response to lamivudine	lamivudine	NUC20904	Hepatitis B, Chronic	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=NUC20904			N	Y	Y	Y	Y	Y	Y	A follow-on study NUC20917 was conducted. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies. An analysis-ready dataset is not available for this study.	1-May-2017
4795	GSK	A double-blind, active-controlled, randomized 52-week extended follow-on study to investigate the long-term efficacy and safety of adefovir dipivoxil 10mg and lamivudine 100mg treatment for subjects with hepatitis B who have completed the previous Phase II protocol NUC20904	lamivudine	NUC20917	Hepatitis B	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=NUC20917			N	Y	Y	Y	Y	Y	Y	This is a follow-up study to NUC20904. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies. An analysis-ready dataset is not available for this study.	1-May-2017
4796	GSK	A Stratified, Partially Randomised (Stratum B only), Double Blind, Multicentre Trial of Lamivudine and Adefovir Dipivoxil Treatment for Patients with Chronic Hepatitis B Who Have Shown Disease Progression by Reaching a Clinical Endpoint	lamivudine	NUC40021	Hepatitis B, Chronic	Phase 4	https://www.gsk-studyregister.com/en/trial-details/?id=NUC40021			N	Y	Y	Y	Y	Y	Y	A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies. An analysis-ready dataset is not available for this study.	1-May-2017
4797	GSK	Primary and booster vaccination course in human immunodeficiency virus (HIV) infected infants, HIV exposed uninfected infants and unexposed uninfected infants receiving the pneumococcal vaccine GSK 1024850A.	Pneumococcal Polysaccharide Conjugate Vaccine (Adsorbed)	111634	Infections, Streptococcal	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=111634	http://clinicaltrials.gov/show/NCT00829010	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002077-35	Y	Y	Y	Y	Y	Y	Y		1-May-2017
4798	GSK	Study MAG104615, a Proof of Concept Study for GSK249320 versus placebo in Stroke Patients	refanezumab	MAG104615	Cerebrovascular Accident	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=104615	http://clinicaltrials.gov/show/NCT01808261	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-004494-23	Y	Y	Y	Y	Y	Y	Y		1-May-2017
4799	GSK	A Five-cohort, Randomized, Open-label, Parallel-group Study to Evaluate the Pharmacokinetics of a Single Dose of Tafenoquine (SB252263) 300mg when Co-administered with the Artemisinin-based Combination Therapies (ACT) Artemether + Lumefantrine (AL) and Dihydroartemisinin + Piperaquine tetraphosphate (DHA+PQP)	tafenoquine	200951	Malaria, Vivax	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=200951	http://clinicaltrials.gov/show/NCT02184637		Y	Y	Y	Y	Y	Y	Y	The raw data are included within the analysis-ready data for this study and are not provided separately.	1-May-2017
4800	GSK	A randomized, parallel group study to evaluate the effect of Umeclidinium (UMEC) added to Inhaled corticosteroid/ long-acting beta-agonist combination therapy in subjects with Chronic Obstructive Pulmonary Disease COPD	umeclidinium bromide	201314	Pulmonary Disease, Chronic Obstructive	Phase 4	https://www.gsk-studyregister.com/en/trial-details/?id=201314	http://clinicaltrials.gov/show/NCT02257372	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-000611-14	Y	Y	Y	Y	Y	Y	Y	The raw data are included within the analysis-ready data for this study and are not provided separately.	1-May-2017
4810	Novartis	A multicenter, double-blind, randomized, placebo-controlled, crossover study evaluating the efficacy and safety of methylphenidate hydrocholoride in female adolescents diagnosed with attention deficit/hyperactivity disorder	methylphenidate	CRIT124DUS02	Attention deficit hyperactivity disorder (ADHD)	Phase 4	https://www.novctrd.com/ctrdweb/trialresult/trialresults/pdf?trialResultId=1624	Not available		Y	Y	Y	Y	Y	Y	Y		1-Jun-2017
4829	Astellas	A Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Assess the Efficacy and Safety of CDP870 in Patients With Early-stage Rheumatoid Arthritis Who Are Naïve to Methotrexate and Have Poor Prognostic Factors	certolizumab pegol	CDP870-275-11-001	Rheumatoid Arthritis	Phase 3	https://www.clinicaltrials.astellas.com/study/?pid=CDP870-275-11-001	https://clinicaltrials.gov/ct2/show/NCT01451203		Y	N	Y	N	Y	Y	Y		1-Jun-2017
4831	Astellas	Postmarketing Clinical Study of Ipragliflozin - Double-blind, Parallel-group Study in Combination with Insulin in Patients with Type 2 Diabetes Mellitus -	ipragliflozin	1941-CL-0131	Diabetes Mellitus, Type 2	Phase 4	https://www.clinicaltrials.astellas.com/study/?pid=1941-CL-0131	https://clinicaltrials.gov/ct2/show/NCT02175784		Y	Y	Y	Y	Y	Y	Y		1-Jun-2017
4832	Astellas	A Phase 3b, Open-label, Parallel Group, Randomized, Multicenter Study to Assess Regadenoson Administration following an Inadequate Exercise Stress Test as Compared to Regadenoson Alone For Myocardial Perfusion Imaging (MPI) Using Single Photon Emission Computed Tomography (SPECT)	regadenoson	3606-CL-3004	Myocardial Perfusion Imaging	Phase 3	https://www.clinicaltrials.astellas.com/study/?pid=3606-CL-3004	https://clinicaltrials.gov/ct2/show/NCT01618669		Y	Y	Y	Y	Y	Y	Y		1-Jun-2017
4876	GSK	Study ARI114264: A Long-Term Study of the Safety and Efficacy of Dutasteride in the Treatment of Male Subjects with Androgenetic Alopecia	dutasteride	ARI114264	Alopecia	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=114264	http://clinicaltrials.gov/show/NCT01831791		Y	Y	Y	Y	Y	Y	Y		1-Jun-2017
4877	GSK	A Phase I Open-Label Dose Escalation Study of the Focal Adhesion Kinase Inhibitor, GSK2256098, in Subjects with Solid Tumors	GSK2256098	FAK113517	Cancer	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=113517	http://clinicaltrials.gov/show/NCT01138033	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-019644-40	Y	N	Y	Y	Y	Y	Y	An annotated case report form is not available for this study. A blank case report form will be provided.	1-Jun-2017
4878	GSK	A Randomised, Double-blind, Placebo-controlled, Parallel-group, Multi-centre 24-week Study to Evaluate the Efficacy and Safety of Mepolizumab Adjunctive Therapy in Subjects with Severe Eosinophilic Asthma on Markers of Asthma Control	mepolizumab	200862	Asthma	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=200862	http://clinicaltrials.gov/show/NCT02281318	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-002513-27	Y	Y	Y	Y	Y	Y	Y	This study is available in CDISC format	1-Jun-2017
4879	GSK	Validation Study of Simultaneous Administration of Multiple Cytochrome P450/Transporter Probes for Drug Interaction Evaluation in Healthy Adult Subjects	rosiglitazone	EMI112684	Healthy Subjects	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=112684	http://clinicaltrials.gov/show/NCT00964106		Y	Y	Y	Y	Y	Y	Y		1-Jun-2017
4880	GSK	A study in patients with Crohn's Disease to evaluate the effect of AVANDIA™ on inflammatory activity mediated by monocytes/macrophages.	rosiglitazone	999910/150	Crohn's Disease	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=999910/150			Y	N	Y	Y	Y	N	Y	A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies. A raw dataset is not available for this study. An annotated case report form is not available for this study. A blank case report form will be provided.	1-Jun-2017
4899	Novartis	A 6-month, Double-blind, Randomized, Placebo-controlled, Parallel-group, Multicenter Study Comparing Efficacy and Safety of FTY720 0.5 mg and 1.25 mg Administered Orally Once Daily in Patients With Relapsing Multiple Sclerosis	fingolimod	CFTY720D1201	Multiple Sclerosis	Phase 2	https://www.novctrd.com/ctrdweb/trialresult/trialresults/pdf?trialResultId=3963	https://clinicaltrials.gov/show/NCT00537082		Y	Y	Y	Y	Y	Y	Y		1-Aug-2017
4900	Novartis	An Extension of the 6-month, Double-blind, Randomized, Placebo-controlled, Parallel-group, Multicenter Study Comparing Efficacy and Safety of FTY720 0.5 mg and 1.25 mg Administered Orally Once Daily in Patients With Relapsing Multiple Sclerosis	fingolimod	CFTY720D1201E1	Multiple Sclerosis	Phase 2	https://www.novctrd.com/ctrdweb/trialresult/trialresults/pdf?trialResultId=8343	https://clinicaltrials.gov/show/NCT00670449		Y	Y	Y	Y	Y	Y	Y		1-Aug-2017
4907	Astellas	A Prospective, Double-Blind, Randomized, Two-Period Crossover, Multi-Center Study to Evaluate the Tolerability and Patient Preference Between Myrbetriq® and Detrol® LA in Subjects with Overactive Bladder (OAB)	mirabegron	178-MA-1001	Urinary Bladder, Overactive	Phase 4	https://www.clinicaltrials.astellas.com/study/?pid=178-MA-1001	https://clinicaltrials.gov/ct2/show/NCT02138747		Y	Y	Y	Y	Y	Y	Y		1-Aug-2017
4908	Astellas	A multicenter, 2-arm, randomized, open-label clinical study investigating renal function in an Advagraf®-based immunosuppressive regimen with or without sirolimus in kidney transplant patients	tacrolimus	PMR-EC-1212	Transplantation, Kidney	Phase 4	https://www.clinicaltrials.astellas.com/study/?pid=PMR-EC-1212	https://clinicaltrials.gov/ct2/show/NCT01363752	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-019639-37	Y	Y	N	Y	Y	Y	Y		1-Aug-2017
4909	Astellas	Investigating New Onset Diabetes Mellitus in Kidney Transplant Recipients Receiving an Advagraf-Based Immunosuppressive Regimen With or Without Corticosteroids – A Multicenter, Two Arm, Randomized, Open Label Clinical Study	tacrolimus	PMR-EC-1211	Transplantation, Kidney	Phase 4	https://www.clinicaltrials.astellas.com/study/?pid=PMR-EC-1211	https://clinicaltrials.gov/ct2/show/NCT01304836	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-019638-28	Y	Y	Y	Y	Y	Y	Y		1-Aug-2017
4913	GSK	A multicenter, randomised, double-blind, double dummy, parallel group study to compare the salmeterol/fluticasone propionate combination (SeretideTM) at a dose of 50/100µg twice daily and fluticasone propionate (FlixotideTM) at a dose of 200µg twice daily, both delivered via a dry powder inhaler (DiskusTM) for 12 weeks in asthma in children aged 4-11 years not controlled by inhaled corticosteroids alone at medium dose	fluticasone propionate/salmeterol	SAM104926	Asthma	Phase 4	https://www.gsk-studyregister.com/en/trial-details/?id=SAM104926	http://clinicaltrials.gov/show/NCT00353873	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002949-40	Y	Y	Y	Y	Y	Y	Y		1-Jul-2017
4914	GSK	A Phase II, Randomized, Two-Part, Multicenter, Dose-Ranging Study in Adult Subjects Evaluating the Safety, Tolerability, and Efficacy of GSK2140944 in the Treatment of Subjects with Suspected or Confirmed Gram-Positive Acute Bacterial Skin and Skin Structure Infections	gepotidacin	BTZ116704	Infections, Bacterial	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=116704	http://clinicaltrials.gov/show/NCT02045797		Y	Y	Y	Y	Y	Y	Y	This study is available in CDISC format	1-Jul-2017
4915	GSK	A Double-Blind, Double-Dummy, Placebo- and Active-Controlled Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Anti-Inflammatory Effects of GSK1399686 in Patients with Mild to Moderately Active Ulcerative Colitis	GSK1399686	MCA111407	Colitis, Ulcerative	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=111407	http://clinicaltrials.gov/show/NCT01036022	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-011608-51	Y	Y	Y	Y	Y	Y	Y		1-Jul-2017
4916	GSK	A Single-Blind, Randomized, Placebo-Controlled Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single, Oral Escalating Doses of GSK2647544 in Healthy Volunteers	GSK2647544	LPC116698	Alzheimer's Disease	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=116698	http://clinicaltrials.gov/show/NCT01702467		Y	Y	Y	Y	Y	Y	Y		1-Jul-2017
4918	GSK	Valproate dose reduction and its clinical evaluation by introducing lamotrigine in Japanese women with epilepsy – single arm, multicenter, and open-label study	lamotrigine	200776	Epilepsy	Phase 4	https://www.gsk-studyregister.com/en/trial-details/?id=200776	http://clinicaltrials.gov/show/NCT02100644	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001515-36	Y	Y	N	Y	Y	Y	Y	A clinical study report is not available for this study because an English language version was not created.	1-Jul-2017
4919	GSK	A study to assess the effectiveness and tolerance of paroxetine by double-blind comparison with placebo	paroxetine	29060/274	Depressive Disorder, Major	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=29060/274			Y	N	Y	Y	Y	N	N	The data from this study is provided in combined datasets containing data from other paroxetine studies. A raw dataset is not available for this study. An annotated case report form and a reporting and analysis plan are not available for this study. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-May-2014
4920	GSK	Comparative Randomized, Single dose, Two-way Crossover Open-label Study to Determine the Bioequivalence of Rabeprazole from Idiazole 20mg DR tabs (GSK, Egypt) and PARIET 20 mg DR tabs (JANSSEN, EGYPT) after a Single Oral Dose Administration of each to Healthy Adults under Fasting Conditions	rabeprazole	201527	Gastrointestinal Diseases	Phase 4	https://www.gsk-studyregister.com/en/trial-details/?id=201527	http://clinicaltrials.gov/show/NCT02446483		N	N	Y	Y	Y	Y	N	An analysis-ready dataset is not available for this study. An annotated case report form is not available for this study. A blank case report form will be provided. A reporting and analysis plan is not available for this study.	1-Jul-2017
4921	GSK	Comparative randomized, single dose, two-way crossover open-label study to determine the bioequivalence of Rabeprazole from Raperazole 20mg DR tabs (GSK, Egypt) and PARIET 20 mg DR tabs (JANSSEN, EGYPT) after a single oral dose administration of each to healthy adults under fed conditions	rabeprazole	201528	Gastrointestinal Diseases	Phase 4	https://www.gsk-studyregister.com/en/trial-details/?id=201528	http://clinicaltrials.gov/show/NCT02605395		N	N	Y	Y	N	Y	N	An analysis-ready dataset is not available for this study. An annotated case report form is not available for this study. A blank case report form will be provided. A protocol, and reporting and analysis plan are not available for this study.	1-Jul-2017
4922	GSK	A Multicenter, Open-Label, Long-Term, Safety, Tolerability and Efficacy Study of Retigabine in Adult Epilepsy Patients With Partial-Onset Seizures (Extension of Study VRX-RET-E22-302)	retigabine, ezogabine	VRX-RET-E22-304	Epilepsy	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=VRX-RET-E22-304	http://clinicaltrials.gov/show/NCT00310388	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000956-42	Y	N	Y	Y	Y	Y	Y	This is a follow-up study to VRX-RET-E22-302. An annotated case report form is not available for this study. A blank case report form will be provided.	1-Jul-2017
4923	GSK	A Study ROP116991, Clinical Evaluation of 18 to 24mg/day Ropinirole CR for Parkinson’s disease.	ropinirole	ROP116991	Parkinson Disease	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=116991	http://clinicaltrials.gov/show/NCT01929317		Y	N	N	Y	N	Y	N	A clinical study report, protocol, reporting and analysis plan and annotated or blank case report form are not available for this study because English language versions were not created.	1-Jul-2017
4952	GSK	An Open-label, Randomized, Single Dose, three-way Crossover study to determine the Bioavailability of Two Fixed Dose Combination Capsule Formulations of Dutasteride and Tamsulosin Hydrochloride (0.5mg/0.2mg) Relative to Co-administration of Dutasteride 0.5mg capsules and Tamsulosin Hydrochloride 0.2mg tablets in Healthy Male Subjects in the fed and fasted states	dutasteride	ARI117057	Prostatic Hyperplasia	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=117057	http://clinicaltrials.gov/show/NCT02184585		Y	Y	Y	Y	Y	Y	Y		1-Sep-2017
4953	GSK	An Open-label, Randomized, Single Dose, Two-way Crossover study to Determine the Bioavailability of one Fixed Dose Combination Capsule Formulation of Dutasteride and Tamsulosin Hydrochloride (0.5 mg/0.2 mg) Relative to Coadministration of one Dutasteride 0.5 mg capsule and one Tamsulosin Hydrochloride 0.2 mg tablet in Healthy Male Subjects in the Fed and Fasted States	dutasteride	201897	Prostatic Hyperplasia	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=201897	http://clinicaltrials.gov/show/NCT02509104		Y	Y	Y	Y	Y	Y	Y		1-Sep-2017
4954	GSK	An Open-Label Exploratory Study to Investigate the Feasibility of Administering Exenatide by Continuous Subcutaneous Infusion to Healthy Subjects	exenatide	200016	Obesity	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=200016	http://clinicaltrials.gov/show/NCT01857895		Y	Y	Y	Y	Y	Y	Y		1-Sep-2017
4955	GSK	A randomised, double-blind, two-way crossover study to investigate the effect of inhaled fluticasone furoate on short-term growth in paediatric subjects with asthma	fluticasone furoate	HZA107112	Asthma	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=107112	http://clinicaltrials.gov/show/NCT02502734	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000841-22	Y	Y	Y	Y	Y	Y	Y		1-Sep-2017
4956	GSK	A Phase III, 24 Week, Randomized, Double Blind, Double Dummy, Parallel Group Study (with an Extension to 52 Weeks in a Subset of Subjects) Comparing the Efficacy, Safety and Tolerability of the Fixed Dose Triple Combination FF/UMEC/VI Administered Once Daily in the Morning via a Dry Powder Inhaler with Budesonide/Formoterol 400mcg/12mcg Administered Twice-Daily via a Reservoir Inhaler in Subjects with Chronic Obstructive Pulmonary Disease	fluticasone furoate/vilanterol/umeclidinium bromide	CTT116853	Pulmonary Disease, Chronic Obstructive	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=116853	http://clinicaltrials.gov/show/NCT02345161	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003073-10	Y	Y	Y	Y	Y	Y	Y	This study is available in CDISC format	1-Sep-2017
4957	GSK	Steroid-sparing management of the salmeterol/fluticasone 50/100µg b.i.d. combination compared to fluticasone 200µg b.i.d. in children and adolescents with moderate asthma	fluticasone propionate/salmeterol	SAM102318	Asthma	Phase 4	https://www.gsk-studyregister.com/en/trial-details/?id=102318	http://clinicaltrials.gov/show/NCT00315744		N	N	Y	Y	Y	Y	Y	An analysis-ready dataset is not available for this study. An annotated case report form is not available for this study. A blank case report form will be provided.	1-Sep-2017
4958	GSK	Long term immunogenicity and safety of GSK Biologicals’ Herpes Zoster vaccine 1437173A in healthy subjects	Herpes Zoster subunit (HZ/su) vaccine	114825	Herpes Zoster	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=114825	http://clinicaltrials.gov/show/NCT01295320	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022248-19	Y	Y	Y	Y	Y	Y	Y	This is an extension study to 108494.	1-Sep-2017
4959	GSK	Immunogenicity and safety study of different formulations of GSK Biologicals’ herpes zoster vaccine 1437173A when administered twice in adults aged 50 years and older	Herpes Zoster subunit (HZ/su) vaccine	112077	Herpes Zoster	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=112077	http://clinicaltrials.gov/show/NCT00802464	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-005120-86	Y	Y	Y	Y	Y	Y	Y		1-Sep-2017
4960	GSK	A phase II, single-blind, randomized, controlled, multicentre vaccination study to evaluate the safety and immune response of the GSK Biologicals Zoster vaccine, gE/AS01B, and to compare 3 doses of gE with AS01B adjuvant in healthy elderly subjects, aged 60 to 69 years and 70 years and above.	Herpes Zoster subunit (HZ/su) vaccine	108494	Herpes Zoster	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=108494	http://clinicaltrials.gov/show/NCT00434577	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004863-69	Y	Y	Y	Y	Y	Y	Y	Follow-on studies 108516,108518,108520 were conducted. Extension study 114825 was conducted.	1-Sep-2017
4961	GSK	Safety and immunogenicity of GlaxoSmithKline Biologicals’ herpes zoster vaccine 1437173A in adult HIV-infected subjects	Herpes Zoster subunit (HZ/su) vaccine	112673	Herpes Zoster	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=112673	http://clinicaltrials.gov/show/NCT01165203	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-017809-11	Y	Y	Y	Y	Y	Y	Y		1-Sep-2017
4962	GSK	GSK2132231A Antigen-Specific Cancer Immunotherapeutic as first-line treatment of patients with unresectable metastatic melanoma	GSK2132231A	111476	Melanoma	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=111476	http://clinicaltrials.gov/show/NCT00942162	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-004007-64	Y	Y	Y	Y	Y	Y	Y		1-Sep-2017
4963	GSK	A Randomized, Placebo-Controlled, Single-Blind, Dose-Escalation, First-Time-in-Human Study to Assess the Safety and Pharmacokinetics of Single and Repeat Doses of SRT3025 in Normal Healthy Volunteers	GSK2245851	SIR115444	Diabetes Mellitus, Type 2	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=115444	http://clinicaltrials.gov/show/NCT01340911		Y	N	Y	Y	Y	Y	Y	An annotated case report form is not available for this study. A blank case report form will be provided.	1-Sep-2017
4964	GSK	A double-blind [sponsor unblinded], randomized, placebo-controlled, staggered-parallel study to investigate the safety, tolerability, and pharmacodynamics of GSK2890457 in healthy volunteers and subjects with type 2 diabetes	GSK2890457	SMP116623	Obesity	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=116623	http://clinicaltrials.gov/show/NCT01725126		Y	Y	Y	Y	Y	Y	Y		1-Sep-2017
4965	GSK	A single-centre, masked, placebo-controlled four part study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of single and repeat doses of the CC-chemokine receptor 3 (CCR3) antagonist, GW824575, coadministered with or without food in healthy male subjects	GW824575	CA3115802	Retinal Diseases	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=115802	http://clinicaltrials.gov/show/NCT01551771	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-003287-70	Y	Y	Y	Y	Y	Y	Y		1-Sep-2017
4966	GSK	A Randomized, Multi-Center, Blinded, Placebo-Controlled Study Of Mapatumumab ([HGS1012], A Fully Monoclonal Antibody To TRAIL-R1) In Combination With Sorafenib As A First-Line Therapy In Subjects With Advanced Hepatocellular Carcinoma	mapatumumab	200149	Carcinoma, Hepatocellular	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=200149	http://clinicaltrials.gov/show/NCT01258608		Y	N	Y	Y	Y	Y	Y	An annotated case report form is not available for this study. A blank case report form will be provided.	1-Sep-2017
4967	GSK	TRX4 Therapeutic Evaluation of Different Multi-Dose Regimens in Type 1 Diabetes Mellitus (TTEDD)	otelixizumab	OTX115493	Diabetes Mellitus, Type 1	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=115493	http://clinicaltrials.gov/show/NCT00451321		Y	Y	Y	Y	Y	Y	Y		1-Sep-2017
4968	GSK	A single centre, single blind study to investigate the safety, tolerability and pharmacokinetics of single doses of oxytocin (GR121619) administered via an inhaled route in healthy female volunteers	oxytocin	201558	Postpartum Hemorrhage	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=201558	http://clinicaltrials.gov/show/NCT02542813	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-001930-10	Y	Y	Y	Y	Y	Y	Y		1-Sep-2017
4969	GSK	Immunogenicity, safety and reactogenicity of GSK Biologicals’ pneumococcal vaccine 1024850A when administered to children between 8 weeks and 2 years of age	Pneumococcal Polysaccharide Conjugate Vaccine (Adsorbed)	114056	Infections, Streptococcal	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=114056	http://clinicaltrials.gov/show/NCT01175083	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000254-64	Y	Y	Y	Y	Y	Y	Y		1-Sep-2017
4970	GSK	A Phase IIB Study to Assess the Efficacy of GSK 249553 as Adjuvant Therapy Given to MAGE-3-Positive Patients With Non-Small-Cell Lung Cancer in Stage IB (T2/N0) or II (T1/N1 or T2/N1 or T3/N0), Who Have Had Complete Surgical Resection	SB249553	249553/004	Lung Cancer, Non-Small Cell	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=249553/004	http://clinicaltrials.gov/show/NCT00290355		Y	Y	Y	Y	Y	Y	Y		1-Sep-2017
4971	GSK	A multicenter, open-label Phase I/II trial of the safety and efficacy of the dHER2 recombinant protein combined with immunological adjuvant AS15 in patients with metastatic breast cancer overexpressing HER2/neu	SB719125	100633	Neoplasms, Breast	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=100633	http://clinicaltrials.gov/show/NCT00140738	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001120-20	Y	N	Y	Y	Y	Y	Y	An annotated case report form is not available for this study. A blank case report form will be provided.	1-Sep-2017
4972	GSK	An open single centre study to evaluate the long-term antibody persistence and immune memory between 16 and 20 years after the primary study HAB-032 (208127/022) in which healthy adults were vaccinated with Twinrix Adult following a three-dose schedule.	twinrix	112266	Hepatitis A; Hepatitis B	Phase 4	https://www.gsk-studyregister.com/en/trial-details/?id=112266	http://clinicaltrials.gov/show/NCT01037114	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-014853-33	Y	Y	Y	Y	Y	Y	Y	This is a follow-up study to 208127/118. The results of this study 112266 are summarised with studies 100556,100557, 100558, 100559, and 100560 on the GSK Study Register.	1-Sep-2017
4973	GSK	An open single centre study to evaluate the long-term antibody persistence and immune memory between 16 and 20 years after the primary study HAB-028 (208127/021) in which healthy adults were vaccinated with Twinrix Adult following a three-dose schedule.	twinrix	112267	Hepatitis A; Hepatitis B	Phase 4	https://www.gsk-studyregister.com/en/trial-details/?id=112267	http://clinicaltrials.gov/show/NCT01000324	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-014275-53	Y	Y	Y	Y	Y	Y	Y	This is a follow-up study to 208127/021, 208127/115 and 208127/119, 100551, 100552, 100553, 100554 and 100555.	1-Sep-2017
4993	GSK	An open-label, randomised, single dose, two-way crossover pilot study to determine the relative bioavailability of one 16mg tablet formulation of candesartan cilexetil (GW615775) relative to one 16mg reference tablet of candesartan cilexetil (Atacand) in healthy adult human subjects under fasting conditions	candesartan	201011	Hypertension	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=201011	http://clinicaltrials.gov/show/NCT02006602		Y	Y	Y	Y	Y	Y	Y		1-Oct-2017
4994	GSK	An Open-label, Randomized, Single Dose, Three-way Crossover, Six Sequence Pilot Study to Determine the Relative Bioavailability of Candesartan Cilexetil 16mg From Two Candidate Tablet Formulations of GW615775 Relative to One 16mg Tablet of Reference Candesartan Cilexetil in Healthy Adult Human Subjects Under Fasting Conditions	candesartan	201713	Respiratory Disorders	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=201713	http://clinicaltrials.gov/show/NCT02254447		Y	Y	Y	Y	Y	Y	Y		1-Oct-2017
4995	GSK	Immunogenicity and safety study of GSK Biologicals’ Herpes Zoster vaccine GSK1437173A when co-administered with GSK Biologicals’ seasonal influenza vaccine GSK2321138A in adults aged 50 years and older	Herpes Zoster subunit (HZ/su) vaccine	ZOS117036	Herpes Zoster	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=117036	http://clinicaltrials.gov/show/NCT01954251	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-000372-15	Y	Y	Y	Y	Y	Y	Y		1-Oct-2017
4996	GSK	A randomized, double blind, placebo-controlled study to investigate the safety, pharmacodynamics and effect on allergic reactivity of repeat intranasal administration of the TLR7 agonist GSK2245035 in subjects with respiratory allergies	GSK2245035	TL7116958	Mild Asthma and Allergic Rhinitis	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=116958	http://clinicaltrials.gov/show/NCT01788813		Y	Y	Y	Y	Y	Y	Y	A follow-on study 204509 was conducted.	1-Oct-2017
4997	GSK	A single-centre, follow-up study to investigate the effect of GSK2245035 on nasal allergic reactivity in subjects who completed treatment in study TL7116958 in 2014	GSK2245035	204509	Asthma and Rhinitis	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=204509	http://clinicaltrials.gov/show/NCT02446613		Y	Y	Y	Y	Y	N	Y	This is a follow-up study to TL7116958. A raw dataset is not available for this study.	1-Oct-2017
4998	GSK	Neisseria meningitidis carriage study	GSK2647155A	BEP114991	Infections, Meningococcal	N/A	https://www.gsk-studyregister.com/en/trial-details/?id=114991	http://clinicaltrials.gov/show/NCT01808365		Y	Y	Y	Y	Y	Y	Y		1-Oct-2017
4999	GSK	Efficacy and safety of long-term inhaled salmeterol and beclomethasone dipropionate in corticosteroid-naïve children with mild to moderate, chronic, stable asthma.	salmeterol	SMS40065 (521/120 [SLPT10])	Asthma	Phase 4	https://www.gsk-studyregister.com/en/trial-details/?id=SMS40065			N	N	Y	Y	N	Y	N	A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies. A Raw dataset related to efficacy data is not available for this study. An analysis-ready dataset is not available for this study. An annotated and a blank case report form are not available for this study. A reporting and analysis plan is not available for this study. A protocol is not available for this study.	1-Oct-2017
5006	Novartis	A Randomized, Double-blind, Placebo-controlled, Multicenter Study of Secukinumab to Demonstrate the 16 Week Efficacy and to Assess the Long Term Safety, Tolerability and Efficacy up to 2 Years in Patients With Active Ankylosing Spondylitis	secukinumab	CAIN457F2305	Ankylosing Spondylitis	Phase 3	https://www.novctrd.com/ctrdweb/trialresult/trialresults/pdf?trialResultId=14387	https://clinicaltrials.gov/show/NCT01358175	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-024529-18	Y	Y	Y	Y	Y	Y	Y		1-Nov-2017
5021	GSK	A randomized, double-blind, single-dose, placebo controlled, 2-way cross-over study evaluating effect of albiglutide on cholecystokinin-induced gallbladder emptying in fasting healthy subjects	albiglutide	201834	Diabetes Mellitus, Type 2	Phase 4	https://www.gsk-studyregister.com/en/trial-details/?id=201834	http://clinicaltrials.gov/show/NCT02496221		Y	Y	Y	Y	Y	Y	Y		1-Nov-2017
5022	GSK	A Multicenter Evaluation of Wellbutrin (Bupropion Hydrochloride) Sustained Release, Habitrol (Nicotine Transdermal System), and Combination Wellbutrin Sustained Release/Habitrol Treatment Versus Placebo as Aids to Smoking Cessation	bupropion	ZYB AK1A405	Smoking Cessation	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=AK1A405			N	N	Y	Y	Y	Y	N	A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies. An analysis-ready dataset is not available for this study. An annotated and a blank case report form are not available for this study. A reporting and analysis plan is not available for this study.	1-Nov-2017
5023	GSK	A multicenter dose response evaluation of Wellbutrin† (Bupropion hydrochloride) sustained release versus placebo as an aid to smoking cessation	bupropion	AK1A403	Smoking Cessation	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=AK1A403			N	N	Y	Y	Y	Y	N	A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies. An analysis-ready dataset is not available for this study. An annotated case report form is not available for this study. A blank case report form will be provided. A reporting and analysis plan is not available for this study.	1-Nov-2017
5024	GSK	A multicenter comparison of bupropion hydrochloride sustained-release versus placebo for the prevention of relapse in patients who quit smoking while taking bupropion sustained-release	bupropion	ZYB AK1A406	Smoking Cessation	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=AK1A406			N	N	Y	Y	Y	Y	N	A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies. An analysis-ready dataset is not available for this study. An annotated case report form is not available for this study. A blank case report form will be provided. A reporting and analysis plan is not available for this study.	1-Nov-2017
5025	GSK	A Multi-Center, Double-Blind, Double-Dummy, Placebo-Controlled, Randomized, Parallel Group, Dose Response Evaluation of a New Chemical Entity (NCE) and ZYBAN (bupropion hydrochloride) Sustained Release (300mg/day) versus Placebo As Aids to Smoking Cessation	bupropion	SMK20001	Smoking Cessation	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=SMK20001			N	N	Y	Y	Y	Y	N	A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies. An analysis-ready dataset is not available for this study. An annotated case report form is not available for this study. A blank case report form will be provided. A reporting and analysis plan is not available for this study.	1-Nov-2017
5026	GSK	A multicentre, randomised, double- blind, placebo controlled study to evaluate the efficacy and tolerability of bupropion hydrochloride (SR) sustained release (2 x 150mg per day) versus placebo as an aid to smoking cessation in smokers with at least one cardiovascular (CV) risk factor	bupropion	ZYB 30011	Smoking Cessation	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=ZYB 30011			N	N	N	Y	N	Y	N	A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies. An analysis-ready dataset is not available for this study. An annotated and a blank case report form are not available for this study. A reporting and analysis plan and protocol are not available for this study. A clinical study report is not available for this study because there is no evidence in the archives that a document was authored.	1-Nov-2017
5027	GSK	A multi-centre, randomised, double-blind, placebo controlled, 6 month study to evaluate the efficacy and tolerability of bupropion hydrochloride sustained release tablets for the treatment of nicotine dependence as an aid to smoking cessation in a healthcare professionals and hospital staff population at hospitals in Denmark	bupropion	ZYB30009	Smoking Cessation	Phase 4	https://www.gsk-studyregister.com/en/trial-details/?id=ZYB30009			N	N	N	Y	Y	Y	N	A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies. An analysis-ready dataset is not available for this study. An annotated and a blank case report form are not available for this study. A reporting and analysis plan is not available for this study. A clinical study report is not available for this study because there is no evidence in the archives that a document was authored.	1-Nov-2017
5028	GSK	A randomized, double-blind, placebo-controlled, 12-week smoking cessation trial of Zyban (150 mg bid) in adult smokers previously treated with Zyban	bupropion	ZYB40001	Smoking Cessation	Phase 4	https://www.gsk-studyregister.com/en/trial-details/?id=ZYB40001			N	Y	N	Y	N	Y	Y	A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies. An analysis-ready dataset is not available for this study. A reporting and analysis plan and protocol is not available for this study. A clinical study report is not available for this study because there is no evidence in the archives that a document was authored.	1-Nov-2017
5029	GSK	A multi-centre, randomised, double-blind, placebo-controlled, one-year study to evaluate the efficacy and tolerability of bupropion hydrochloride (SR) (sustained release tablets) for the treatment of nicotine dependence as an aid to smoking cessation in population of healthcare professionals	bupropion	ZYB40011	Smoking Cessation	Phase 4	https://www.gsk-studyregister.com/en/trial-details/?id=ZYB40011			N	N	N	Y	N	Y	N	A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies. An analysis-ready dataset is not available for this study. An annotated and a blank case report form are not available for this study. A reporting and analysis plan and protocol is not available for this study. A clinical study report is not available for this study because there is no evidence in the archives that a document was authored.	1-Nov-2017
5030	GSK	Evaluation of efficacy of safety of ZybanTM (bupropion hydrochloride extended release tablet) in smoking cessation aid in nicotine-dependent patients. Multicentre, randomized, double blind, placebo-controlled study, 6 months length	bupropion	ZYBF4001	Smoking Cessation	Phase 4	https://www.gsk-studyregister.com/en/trial-details/?id=ZYBF4001			N	N	N	Y	N	Y	N	A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies. An analysis-ready dataset is not available for this study. An annotated and a blank case report form are not available for this study. A reporting and analysis plan and protocol are not available for this study. A clinical study report is not available for this study because there is no evidence in the archives that a document was authored.	1-Nov-2017
5031	GSK	Safety and Immunogenicity of GSK Biologicals’ Herpes Zoster vaccine 1437173A in healthy ethnic Japanese adults	Herpes Zoster subunit (HZ/su) vaccine	113819	Herpes Zoster	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=113819	http://clinicaltrials.gov/show/NCT01086449		Y	Y	Y	Y	Y	Y	Y		1-Nov-2017
5032	GSK	Immunogenicity and safety study of GSK Biologicals’ Herpes Zoster vaccine GSK1437173A in adults ≥ 65 years of age with and without Zostavax® vaccination at least 5 years earlier	Herpes Zoster subunit (HZ/su) vaccine	201198	Herpes Zoster	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=201198	http://clinicaltrials.gov/show/NCT02581410		Y	Y	Y	Y	Y	Y	Y		1-Nov-2017
5033	GSK	Contribution of infectious pathogens to acute respiratory illness in adults and elderly	GSK2231395A	BEP114378	Respiratory Disorders	N/A	https://www.gsk-studyregister.com/en/trial-details/?id=114378	http://clinicaltrials.gov/show/NCT01360398		Y	Y	Y	Y	Y	Y	Y	There is a Publication Steering Committee for this study.	1-Nov-2017
5034	GSK	GSK2302032A Antigen-Specific Cancer Immunotherapeutic as adjuvant therapy in patients with Non-Small Cell Lung Cancer	GSK2302032A	116389	Lung Cancer, Non-Small Cell	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=116389	http://clinicaltrials.gov/show/NCT01853878	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002790-55	Y	Y	Y	Y	Y	Y	Y		1-Nov-2017
5035	GSK	Immunogenicity and safety study of GSK Biologicals’ Quadrivalent Split Virion Influenza Vaccine 2014/2015 Influsplit™ Tetra (Fluarix™ Tetra) (GSK2321138A) when co-administered with Pneumovax™ 23 in adults 50 years of age and older	Influenza Vaccine (Quadrivalent)	117276	Influenza	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=117276	http://clinicaltrials.gov/show/NCT02218697	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001118-24	Y	Y	Y	Y	Y	Y	Y		1-Nov-2017
5036	GSK	A Two-Part, Randomised, Double-Blind, Placebo Controlled, Multi-Center Study To Investigate The Use Of Mepolizumab (Sb-240563) In Reducing The Need For Surgery In Subjects With Severe Bilateral Nasal Polyposis	mepolizumab	MPP111782	Polyps, Nasal	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=111782	http://clinicaltrials.gov/show/NCT01362244	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-003772-21	Y	Y	Y	Y	Y	Y	Y		1-Nov-2017
5037	GSK	An International, Double-Blind, Controlled Trial Comparing Oral Acyclovir to Oral Valaciclovir for the Treatment of Herpes Zoster in Immunocompetent Patients 50 Years of Age or Older	valaciclovir	123-005	Herpes Zoster	Phase 3				Y	Y	Y	Y	Y	N	Y	There is no GSK Study Register entry for this study. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies. A raw dataset is not available for this study. A single analysis-ready dataset is available for the primary efficacy endpoints.	1-Nov-2017
5038	GSK	A multicenter, double-blind, placebo-controlled trial evaluating oral 256U87 for the treatment of herpes zoster in immunocompetent patients less than 50 years old	valaciclovir	123-006	Herpes Zoster	Phase 3				Y	Y	Y	Y	Y	N	Y	There is no GSK Study Register entry for this study. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies. A raw dataset is not available for this study. A single analysis-ready dataset is available for the primary efficacy endpoints.	1-Nov-2017
5039	ViiV	A DOUBLE BLIND (3rd PARTY OPEN), PLACEBO CONTROLLED, DOSE ESCALATING, CROSSOVER STUDY TO INVESTIGATE THE SAFETY, TOLERATION AND PHARMACOKINETICS OF SINGLE ORAL DOSES (SOLUTION) OF UK-427,857 IN HEALTHY MALE VOLUNTEERS IN THE FED AND FASTED STATES	maraviroc	A4001001	Infection, Human Immunodeficiency Virus	Phase 1				Y	N	Y	Y	Y	Y	Y	There is no GSK Study Register entry for this study. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies. An annotated and a blank case report form are not available for this study.	1-Nov-2017
5040	ViiV	A DOUBLE BLIND (3RD PARTY OPEN), PARALLEL GROUP, PLACEBO CONTROLLED SINGLE DOSE AND MULTIPLE ESCALATING ORAL DOSE STUDY TO INVESTIGATE THE SAFETY, TOLERATION AND PHARMACOKINETICS OF UK-427,857 IN HEALTHY MALE SUBJECTS	maraviroc	A4001002	Infection, Human Immunodeficiency Virus	Phase 1				Y	N	Y	Y	Y	Y	Y	There is no GSK Study Register entry for this study. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies. An annotated and a blank case report form are not available for this study.	1-Nov-2017
5047	Astellas	A Phase 2, Open-Label, Randomized, Cross-Over Study of Regadenoson in Subjects Undergoing Stress Myocardial Perfusion Imaging by Multidetector Computed Tomography (MDCT) and Single Photon Emission Computed Tomography (SPECT)	regadenoson	3606-CL-2001	Coronary Artery Disease	Phase 2	https://www.clinicaltrials.astellas.com/study/?pid=3606-CL-2001	https://clinicaltrials.gov/ct2/show/NCT01334918		Y	N	Y	Y	Y	Y	Y		1-Dec-2017
5048	Eisai	A Randomized, Open-label, Multicenter, Phase 3 Study to Compare the Efficacy and Safety of Eribulin With Dacarbazine in Subjects With Soft Tissue Sarcoma	eribulin mesilate	E7389-G000-309	Soft Tissue Sarcoma	Phase 3		https://clinicaltrials.gov/ct2/show/NCT01327885	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-024483-17	Y	Y	Y	Y	Y	Y	Y	No restrictions	1-Nov-2017
5049	Eisai	Phase II Study of E7389 Administered as an IV Bolus Infusion Day 1 and Day 8 Every 3 Weeks in Pre-Treated Patients With Advanced and/or Metastatic Soft Tissue Sarcoma	eribulin mesilate	E7389-E044-207	Soft Tissue Sarcoma	Phase 2		https://clinicaltrials.gov/ct2/show/NCT00413192	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004272-20	Y	Y	Y	Y	Y	Y	Y	No restrictions.	1-Nov-2017
5050	Eisai	An Open-label, Multicenter, Phase 2 Study to Evaluate the Efficacy and Safety of Eribulin Mesylate in Previously Treated Subjects With Advanced or Metastatic Soft Tissue Sarcoma	eribulin mesilate	E7389-J081-217	Soft Tissue Sarcoma	Phase 2		https://clinicaltrials.gov/ct2/show/NCT01458249		Y	Y	Y	Y	Y	Y	Y	No restrictions. Note: Japan is the only country participating in this study.	1-Nov-2017
5051	Eisai	An Open-Label, Multicenter, Phase 1b/2 Study of E7080 Alone, and in Combination With Everolimus in Subjects With Unresectable Advanced or Metastatic Renal Cell Carcinoma Following One Prior VEGF-Targeted Treatment	lenvatinib	E7080-G000-205 Ph1b	Metastatic Renal Cell Carcinoma	Phase 1		https://clinicaltrials.gov/ct2/show/NCT01136733	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-019484-10	Y	Y	Y	Y	N	Y	N	No restrictions. Note: The Protocol and Statistical Analysis Plan are part of the phase 2 study documents.	1-Nov-2017
5052	Eisai	An Open-Label, Multicenter, Phase 1b/2 Study of E7080 Alone, and in Combination With Everolimus in Subjects With Unresectable Advanced or Metastatic Renal Cell Carcinoma Following One Prior VEGF-Targeted Treatment	lenvatinib	E7080-G000-205 Ph2	Metastatic Renal Cell Carcinoma	Phase 2		https://clinicaltrials.gov/ct2/show/NCT01136733	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-019484-10	Y	Y	Y	Y	Y	Y	N	Sharing of clinical data is prevented for the following country: Czech Republic.	1-Nov-2017
5053	Eisai	A Multicenter, Randomized, Controlled, Open-label Study to Evaluate the Cognitive Development Effects and Safety, and Pharmacokinetics of Adjunctive Rufinamide Treatment in Pediatric Subjects 1 to Less Than 4 Years of Age With Inadequately Controlled Lennox-Gastaut Syndrome	rufinamide	E2080-G000-303	Lennox-Gastaut Syndrome	Phase 3		https://clinicaltrials.gov/ct2/show/NCT01405053	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023505-36	Y	Y	Y	Y	Y	Y	Y		1-Nov-2017
5088	GSK	Clinical Evaluation of Efficacy at 2 Weeks of Duac® Fixed Dose Combination Gel in Treatment of Facial Acne Vulgaris in Japanese Subjects	benzoyl peroxide/clindamycin phosphate	201884	Acne Vulgaris	Phase 4	https://www.gsk-studyregister.com/en/trial-details/?id=201884	http://clinicaltrials.gov/show/NCT02557399	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001575-23	Y	Y	Y	Y	Y	Y	Y		1-Feb-2018
5089	GSK	A multi-centre, randomised, double-blind, placebo controlled study to evaluate the efficacy and tolerability of bupropion hydrochloride (SR) sustained release versus placebo as an aid to smoking cessation in a population of smokers with Chronic Obstructive Pulmonary Disease.	bupropion	ZYB40030	Smoking Cessation	Phase 4	https://www.gsk-studyregister.com/en/trial-details/?id=ZYB40030			N	N	N	Y	Y	Y	N	A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies. An analysis-ready dataset is not available for this study. An annotated case report form is not available for this study. A blank case report form will be provided. A reporting and analysis plan is not available for this study. A clinical study report is not available for this study because there is no evidence in the archives that a document was authored.	1-Feb-2018
5090	GSK	A single center evaluation of Wellbutrin (bupropion hydrochloride) versus placebo as an aid to smoking cessation (study 402)	bupropion	ZYBAKIA402	Depressive Disorder, Major	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=ZYBAKIA402			N	N	N	Y	N	Y	N	A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies. An analysis-ready dataset is not available for this study. An annotated and a blank case report form are not available for this study. A protocol and a reporting and analysis plan are not available for this study. A clinical study report is not available for this study because there is no evidence in the archives that a document was authored.	1-Feb-2018
5091	GSK	A Single Centre, Open-label, 5-Period, Cross over, Randomized Study in Healthy Elderly Subjects to Evaluate the Relative Bioavailability of Hydrobromide Salt and Free Base Immediate Release Tablet Formulations of Danirixin in the Fed State, and to Evaluate the Effect of Food and Gastric Acid Secretion Suppression on Danirixin Pharmacokinetics Following Administration of Hydrobromide Salt Tablets	danirixin	201037	Pulmonary Disease, Chronic Obstructive	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=201037	http://clinicaltrials.gov/show/NCT02453022		Y	Y	Y	Y	Y	Y	Y	This study is available in CDISC format	1-Feb-2018
5092	GSK	A randomized, open-label, parallel-group study, to assess the pharmocodynamic effect on dihydrotestosterone regulated gene expression, longitudinally and in a dose dependent manner, of 0.5mg and 3.5mg dutasteride administered orally once daily, for one year in men with symptomatic benign prostatic hyperplasia and during a two month period between baseline and radical prostatectomy in men with biopsy-proven, clinically localized prostate cancer	dutasteride	104274	Prostatic Hyperplasia	Phase 4	https://www.gsk-studyregister.com/en/trial-details/?id=104274	http://clinicaltrials.gov/show/NCT00375765		N	N	N	Y	Y	Y	N	An analysis-ready dataset is not available for this study. An annotated and a blank case report form are not available for this study. A reporting and analysis plan is not available for this study. A clinical study report is not available for this study because an English language version was not created.	1-Feb-2018
5093	GSK	An randomised, double-blind, placebo-controlled, parallel group study to assess the efficacy and safety of dutasteride 0.5mg once daily for 6 months in the treatment of male subjects with androgenetic alopecia (Norwood-Hamilton classification type IIIv, IV and V)	dutasteride	106377	Alopecia	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=106377	http://clinicaltrials.gov/show/NCT00441116		Y	N	Y	Y	Y	Y	Y	An annotated case report form is not available for this study. A blank case report form will be provided.	1-Feb-2018
5094	GSK	A Prospective Study of Sexual Function in Men Taking Dutasteride for the Treatment of Androgenetic Alopecia	dutasteride	200209	Alopecia	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=200209	http://clinicaltrials.gov/show/NCT02014584		Y	Y	Y	Y	Y	Y	Y		1-Feb-2018
5095	GSK	A randomized, double-blind, placebo-controlled, six-month parallel-group study to assess efficacy and safety of dutasteride 0.5mg once daily in Chinese patients with Benign Prostatic Hyperplasia (BPH), followed by a 12-month open-label treatment phase	dutasteride	ARI108898	Prostatic Hyperplasia	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=ARI108898	http://clinicaltrials.gov/show/NCT00527605		Y	N	N	Y	N	N	N	A raw dataset is not available for this study. An annotated and a blank case report form are not available for this study. A reporting and analysis plan is not available for this study. A Protocol is not available for this study because an English language version was not created. A clinical study report is not available for this study because there is no evidence in the archives that a document was authored.	1-Feb-2018
5096	GSK	A Randomised, Double-Blind, Placebo-Controlled Trial Assessing the Efficacy and Safety of Dutasteride (AVODART™) 0.5 mg in Extending the Time to PSA Doubling in Men with Prostate Cancer and Biochemical Failure (PSA increase) after Radical Therapy with Curative Intent	dutasteride	ARI109924	Neoplasms, Prostate	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=ARI109924	http://clinicaltrials.gov/show/NCT00558363	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001703-38	Y	Y	Y	Y	Y	Y	Y		1-Feb-2018
5097	GSK	A Phase II, 28-Day, Randomized, Parallel-Group, Open-Label Study Evaluating the Efficacy and Safety of Twice Daily Oral Doses of Testosterone (150-400mg) Co-administered with 0.25mg Dutasteride Compared with 400mg Testosterone Alone and 0.25mg Dutasteride Alone in the Treatment of Hypogonadism	dutasteride	TDC106220	Hypogonadism, Male	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=TDC106220	http://clinicaltrials.gov/show/NCT00398580		Y	Y	Y	Y	Y	Y	Y		1-Feb-2018
5098	GSK	A randomized, double-blind, parallel group study to compare the efficacy and safety of combination treatment with dutasteride (0.5mg) and tamsulosin (0.2mg) with tamsulosin (0.2mg) monotherapy, administered once daily for 2 years, on the improvement of symptoms and health outcomes in men with moderate to severe benign prostatic hyperplasia	dutasteride/tamsulosin	ARI114265	Prostatic Hyperplasia	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=114265	http://clinicaltrials.gov/show/NCT02058368		Y	Y	Y	Y	Y	Y	Y		1-Feb-2018
5099	GSK	A pivotal, open-label trial assessing the safety and efficacy of the 0.5 mg dutasteride and 0.4 mg tamsulosin combination once daily for six months in patients with benign prostatic hyperplasia	dutasteride/tamsulosin	FDC114785	Prostatic Hyperplasia	Phase 4	https://www.gsk-studyregister.com/en/trial-details/?id=114785	http://clinicaltrials.gov/show/NCT01673490		Y	Y	Y	Y	Y	Y	Y		1-Feb-2018
5100	GSK	A prospective study of sexual function in sexually active men treated for BPH	dutasteride/tamsulosin	FDC116115	Prostatic Hyperplasia	Phase 4	https://www.gsk-studyregister.com/en/trial-details/?id=116115	http://clinicaltrials.gov/show/NCT01777269	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002047-26	Y	Y	Y	Y	Y	Y	Y		1-Feb-2018
5101	GSK	Comparative efficacy of Dutasteride plus tamsulosin with lifestyle advice versus watchful waiting plus lifestyle advice with step-up therapy to tamsulosin in the management of treatment naïve men with moderately symptomatic benign prostatic hyperplasia and prostate enlargement.	dutasteride/tamsulosin	FDC114615	Prostatic Hyperplasia	Phase 4	https://www.gsk-studyregister.com/en/trial-details/?id=114615	http://clinicaltrials.gov/show/NCT01294592	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022111-19	Y	Y	Y	Y	Y	Y	Y		1-Feb-2018
5103	GSK	An open-label, randomised, cross-over, single dose study in healthy volunteers to evaluate the Unit Dose Dry Powder Inhaler (UD-DPI) with four different formulations for the delivery of fluticasone fuorate and to compare the pharmacokinetic profile with the fluticasone fuorate ELLIPTA presentation	fluticasone furoate	200939	Asthma	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=200939	http://clinicaltrials.gov/show/NCT02218723		Y	Y	Y	Y	Y	Y	Y		1-Feb-2018
5104	GSK	200699: A Clinical Study to Evaluate Four Doses of Umeclidinium Bromide in Combination with Fluticasone Furoate in COPD Subjects with an Asthmatic Component	fluticasone furoate/umeclidinium bromide	200699	Pulmonary Disease, Chronic Obstructive	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=200699	http://clinicaltrials.gov/show/NCT02164539	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-000883-16	Y	Y	Y	Y	Y	Y	Y	This study is available in CDISC format	1-Feb-2018
5105	GSK	Open-label study to evaluate the safety and immunogenicity of GSK Biologicals’ Herpes Zoster vaccine GSK1437173A in adults aged 50 years or older	Herpes Zoster subunit (HZ/su) vaccine	116697	Herpes Zoster	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=116697	http://clinicaltrials.gov/show/NCT01751165	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-004456-11	Y	Y	Y	Y	Y	Y	Y		1-Feb-2018
5106	GSK	Comparison of the immunogenicity and safety of various investigational and licensed formulations of Hepatitis B surface antigen (HBsAg) vaccines.	GSK2231392A	112115	Hepatitis B	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=112115	http://clinicaltrials.gov/show/NCT00805389	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-004455-29	Y	Y	Y	Y	Y	Y	Y		1-Feb-2018
5107	GSK	Study of GSK2302025A Antigen-Specific Cancer Immunotherapeutic in patients with metastatic melanoma	GSK2302025A	113173	Melanoma	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=113173	http://clinicaltrials.gov/show/NCT01149343	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-016636-13	Y	Y	Y	Y	Y	Y	Y		1-Feb-2018
5108	GSK	A Single Dose First in Human Study of GSK2398852 Co-Administered with GSK2315698 in Patients with Systemic Amyloidosis	GSK2315698/GSK2398852	SAP115570	Amyloidosis	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=115570	http://clinicaltrials.gov/show/NCT01777243	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003345-15	Y	Y	Y	Y	Y	Y	Y	The informed consent for this study allows for further research into the medicine studied but not the disease.	1-Feb-2018
5109	GSK	An observer-blind study to evaluate the safety and immunogenicity of GSK Biologicals’ influenza vaccines GSK2654911A and GSK2654909A administered to adults 18 to 64 years of age	GSK2654911A	116358	Influenza	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=116358	http://clinicaltrials.gov/show/NCT01659086		Y	Y	Y	Y	Y	Y	Y		1-Feb-2018
5110	GSK	A Randomized Double Blinded (Sponsor Unblind), Placebo-Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the Selective Androgen Receptor Modulator (SARM) in Single and Repeat Doses in Healthy Male Subjects	GSK2881078	200181	Cachexia	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=200181	http://clinicaltrials.gov/show/NCT02045940		Y	Y	Y	Y	Y	Y	Y		1-Feb-2018
5111	GSK	Phase III, partially double-blind study to evaluate consistency and immunogenicity of 3 lots of GSK Biologicals' Hib conjugate vaccine 208108 versus ActHIB and Pentacel at 2, 4, 6 and 15-18 months of age in healthy infants	Haemophilus influenzae Type b Vaccine	112957	Haemophilus influenzae type b	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=112957	http://clinicaltrials.gov/show/NCT01000974	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004194-27	Y	Y	Y	Y	Y	Y	Y		1-Feb-2018
5112	GSK	Safety study of GSK Biologicals’ human papillomavirus vaccine (GSK580299) in female American and Canadian subjects who had received control vaccine in study 580299/008	Human Papillomavirus Types 16 and 18 Vaccine	111955	Infections, Papillomavirus	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=111955	http://clinicaltrials.gov/show/NCT00799825		Y	Y	Y	Y	Y	Y	Y	This is a follow-up study to 580299/008	1-Feb-2018
5113	GSK	Gynaecological follow-up of a subset of 580299/008 study subjects	Human Papillomavirus Types 16 and 18 Vaccine	112024	Infections, Papillomavirus	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=112024	http://clinicaltrials.gov/show/NCT00937950	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-008124-33	Y	Y	Y	Y	Y	Y	Y	This is a follow-up study to 580299/008	1-Feb-2018
5114	GSK	Safety study of GSK Biologicals’ human papillomavirus vaccine (GSK-580299) in healthy female control subjects from the GSK HPV-023 study	Human Papillomavirus Types 16 and 18 Vaccine	114379	Infections, Papillomavirus	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=114379	http://clinicaltrials.gov/show/NCT01418937		Y	Y	Y	Y	Y	Y	Y	This is a safety follow-up study of the placebo cohort to 580299/001 (HPV-001).	1-Feb-2018
5115	GSK	Immunogenicity and safety study of GSK Biologicals' Quadrivalent Split Virion Influenza Vaccine (GSK2321138A) Fluarix/Influsplit Tetra® (2013/2014 season) in adults 18 years of age and older	Influenza Vaccine (Quadrivalent)	200188	Influenza	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=200188	http://clinicaltrials.gov/show/NCT01878812	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001094-25	Y	Y	Y	Y	Y	Y	Y		1-Feb-2018
5116	GSK	An efficacy study of GSK Biologicals’ quadrivalent influenza vaccine GSK2321138A (FLU D-QIV) when administered in children	Influenza Vaccine (Quadrivalent)	115345	Influenza	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=115345	http://clinicaltrials.gov/show/NCT01439360	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000758-41	Y	Y	Y	Y	Y	Y	Y	There is a Publicaton Steering Committee for this study.	1-Feb-2018
5117	GSK	Study for evaluation of immunogenicity and reactogenicity of Fluarix/Influsplit SSW 2013/2014 in people 18 years of age and above	Influenza Vaccine (Split Virion, Inactivated)	200160	Influenza	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=200160	http://clinicaltrials.gov/show/NCT01884519	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-000855-42	Y	Y	Y	Y	Y	Y	Y		1-Feb-2018
5118	GSK	Immunogenicity and safety study of GSK Biologicals’ Trivalent Split Virion Influenza Vaccine (GSK1536489A) Fluviral™ (2013-2014 Season) in adults aged 18 years and older	Influenza Vaccine (Split Virion, Inactivated, Fluviral)	200190	Influenza	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=200190	http://clinicaltrials.gov/show/NCT01878825		Y	Y	Y	Y	Y	Y	Y		1-Feb-2018
5119	GSK	A Phase 3, Open Label, Randomized, Controlled, Multi-Center Study to Evaluate the Safety and Immunogenicity of GSK Biologicals' Meningococcal B Recombinant Vaccine When Administered concomitantly with Routine Vaccines to Healthy Infants in Taiwan.	Meningococcal group-B vaccine (rDNA, component, adsorbed) rMenB+OMV NZ	205249	Meningococcal disease	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=205249	http://clinicaltrials.gov/show/NCT02173704	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-005568-14	Y	Y	Y	Y	Y	Y	Y		1-Feb-2018
5120	GSK	Immunogenicity, safety and reactogenicity study of GSK Biologicals’ pneumococcal vaccine (Synflorix™) when administered to children who are at an increased risk of pneumococcal infection	Pneumococcal Polysaccharide Conjugate Vaccine (Adsorbed)	115884	Infections, Streptococcal	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=115884	http://clinicaltrials.gov/show/NCT01746108	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-006013-34	Y	Y	Y	Y	Y	Y	Y		1-Feb-2018
5121	GSK	Study to compare immunogenicity of GSK Biologicals' 10Pn-PD-DiT 4-dose presentation to the licensed Synflorix™ (10Pn-PD-DiT) vaccine when co-administered with DTPw-combination vaccine in healthy infants	Pneumococcal Polysaccharide Conjugate Vaccine (Adsorbed)	200799	Infections, Streptococcal	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=200799	http://clinicaltrials.gov/show/NCT02447432	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-000750-11	Y	Y	Y	Y	Y	Y	Y		1-Feb-2018
5122	GSK	A Multi-Centre, Randomised, Double-Blind, Placebo-Controlled, Parallel-Group Study to Investigate the Effect of 12 Months Treatment With Salmeterol (50mcg bd), Delivered via the DISKUS* Inhaler, on the Incidence of Moderate and Severe Exacerbations in Subjects With Chronic Obstructive Pulmonary Disease (COPD) When Added to Their Usual Treatment Regimen	salmeterol	SMS40026	Pulmonary Disease, Chronic Obstructive	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=SMS40026			N	N	Y	Y	Y	Y	N	A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies. An analysis-ready dataset is not available for this study. An annotated case report form is not available for this study. A blank case report form will be provided. A reporting and analysis plan is not available for this study.	1-Feb-2018
5123	GSK	Epidemiology Study of Malaria Transmission Intensity in Sub-Saharan Africa	RTS,S Vaccine	BEP114001	Malaria	N/A	https://www.gsk-studyregister.com/en/trial-details/?id=114001	http://clinicaltrials.gov/show/NCT01190202		Y	Y	Y	Y	Y	Y	Y		1-Feb-2018
14488	GSK	A Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, 52-Week Study to Evaluate the Efficacy and Safety of Belimumab (HGS1006) Administered Subcutaneously (SC) to Subjects with Systemic Lupus Erythematosus (SLE)	belimumab	HGS1006-C1115	Systemic Lupus Erythematosus	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=112341	http://clinicaltrials.gov/show/NCT01484496		Y	Y	Y	Y	Y	Y	Y	A follow-on study BEL114333 was conducted.	1-Jun-2017
14489	GSK	Long-term persistence of hepatitis B antibodies and immune response to a challenge dose of GSK Biologicals’ Hepatitis B Virus vaccine, Engerix™-B Kinder (SKF103860), in 15-16 years old adolescents, vaccinated in infancy with Engerix™-B Kinder	Hepatitis B Vaccine, Recombinant	116722	Hepatitis B	Phase 4	https://www.gsk-studyregister.com/en/trial-details/?id=116722	http://clinicaltrials.gov/show/NCT01847430	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003950-10	Y	Y	Y	Y	Y	Y	Y		1-Mar-2018
14490	GSK	Safety and reactogenicity of GSK Biologicals’ dTpa vaccine (Boostrix™) in healthy Vietnamese children	Combined Reduced Antigen Content Diphtheria, Tetanus, Acellular Pertussis Vaccine	115739	Diphtheria; Tetanus; Acellular pertussis	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=115739	http://clinicaltrials.gov/show/NCT01988857	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003859-37	Y	Y	Y	Y	Y	Y	Y		1-Mar-2018
14491	GSK	A multicentre, randomised, double-blind, parallel group study to compare the efficacy and safety of Salmeterol/Fluticasone propionate combination product (Seretide®) 50/100 mcg with Fluticasone propionate (Flixotide® ) 200 mcg, both delivered twice daily via the DISKUS inhaler, in the treatment of children aged 6-12 years with symptomatic asthma	fluticasone propionate/salmeterol	SAM101667	Asthma	Phase 4	https://www.gsk-studyregister.com/en/trial-details/?id=SAM101667	http://clinicaltrials.gov/show/NCT00197106	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002456-33	N	Y	Y	Y	Y	Y	Y	An analysis-ready dataset is not available for this study. Only limited raw data are available for this study.	1-Mar-2018
14492	GSK	A Phase 1, Randomized, Double-Blind (sponsor open), Placebo-Controlled, Single Dose Escalation Trial to Evaluate the Safety, Tolerability Pharmacokinetics and Pharmacodynamics of GSK3050002 (anti-CCL20 monoclonal antibody) in Healthy Male Volunteers	GSK3050002	200784	Colitis, Ulcerative	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=200784	http://clinicaltrials.gov/show/NCT01984047	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004050-19	Y	Y	Y	Y	Y	Y	Y		1-Mar-2018
14493	GSK	Study IVF116828:A Multi-Cohort Phase I Study to Investigate the Pharmacokinetics, Pharmacodynamics and Tissue Concentrations of Epelsiban (GSK557296) in Healthy Female Volunteers During Control and Challenge States With and Without Oxytocin	epelsiban	IVF116828	Embryo Transfer	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=116828	http://clinicaltrials.gov/show/NCT02213029		Y	Y	Y	Y	Y	Y	Y		1-Mar-2018
14494	GSK	A Phase I/IIa, First Time in Human, open-label dose-escalation study of GSK2636771 in subjects with advanced solid tumors with PTEN deficiency	GSK2636771	P3B115717	Cancer	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=115717	http://clinicaltrials.gov/show/NCT01458067	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-003778-94	Y	Y	Y	Y	Y	Y	Y		1-Mar-2018
14495	GSK	201496: A Study to Evaluate the Efficacy and Safety of 15mg BID Losmapimod (GW856553) Compared to Placebo in Frequently Exacerbating Subjects with Chronic Obstructive Pulmonary Disease (COPD)	losmapimod	201496	Pulmonary Disease, Chronic Obstructive	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=201496	http://clinicaltrials.gov/show/NCT02299375	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-002992-27	Y	Y	Y	Y	Y	Y	Y		1-Mar-2018
14496	GSK	A Phase I Study to Investigate the Hemolytic Potential of Tafenoquine in Healthy Subjects with Glucose-6-phosphate Dehydrogenase Deficiency and the Safety and Tolerability of Tafenoquine in Acute Plasmodium vivax Malaria Patients with Glucose-6-phosphate Dehydrogenase Deficiency	tafenoquine	TAF110027	Malaria	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=110027	http://clinicaltrials.gov/show/NCT01205178		Y	Y	Y	Y	Y	Y	Y	A follow-on study TAF115016 was conducted. The raw data are included within the analysis-ready data for this study and are not provided separately.	1-Mar-2018
14497	GSK	A Randomised, Double-Blind, Placebo-Controlled, Parallel Group Study to Measure the Efficacy and Safety of Nicotine Lozenges (2 mg and 4 mg) in Smoking Cessation	Nicotine Polacrilex Lozenge 2 mg and 4 mg	209357	Smoking Cessation	Phase 3				Y	Y	Y	Y	Y	Y	Y	There is no GSK Study Register entry for this study. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Mar-2018
14518	GSK	An observer-blind study to assess the safety, reactogenicity and immunogenicity of different formulations of GSK Biologicals’ investigational RSV vaccine (GSK3003891A), in healthy women	GSK3003891A	201510	Respiratory Syncytial Virus Infections	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=201510	http://clinicaltrials.gov/show/NCT02360475	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-002688-14	Y	Y	Y	Y	Y	Y	Y		1-Apr-2018
14519	GSK	Immunogenicity of the hepatitis B antigen of the GSK Biologicals’ candidate malaria vaccine (257049)	RTS,S Vaccine	113681	Hepatitis B	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=113681	http://clinicaltrials.gov/show/NCT01345240	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001508-37	Y	Y	Y	Y	Y	Y	Y		1-Apr-2018
14520	GSK	An observer-blind safety and reactogenicity study to assess GlaxoSmithKline (GSK) Biologicals’ investigational respiratory syncytial virus (RSV) vaccine (GSK3003891A) in healthy women	GSK3003891A	204813	Respiratory Syncytial Virus Infections	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=204813	http://clinicaltrials.gov/show/NCT02753413	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-005742-58	Y	Y	Y	Y	Y	Y	Y		1-Apr-2018
14521	GSK	Evaluation of the kinetics of mRNA expression after two doses of GSK Biologicals’ candidate tuberculosis (Tuberculosis) vaccine GSK 692342 in healthy adults	SB692342	116777	Tuberculosis	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=116777	http://clinicaltrials.gov/show/NCT01669096	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002541-37	Y	Y	Y	Y	Y	Y	Y		1-Apr-2018
14522	GSK	Safety and immunogenicity of GSK Biologicals’ candidate malaria vaccine 257049 when administered on different schedules to infants in Africa	RTS,S Vaccine	111315	Malaria	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=111315	http://clinicaltrials.gov/show/NCT01231503	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-005718-20	Y	Y	Y	Y	Y	Y	Y		1-Apr-2018
14523	GSK	Efficacy, safety, and immunogenicity study of GSK Biologicals’ Herpes Zoster vaccine GSK1437173A in adults aged 50 years or older	Herpes Zoster subunit (HZ/su) vaccine	110390	Herpes Zoster	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=110390	http://clinicaltrials.gov/show/NCT01165177	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000367-42	Y	Y	Y	Y	Y	Y	Y	A nested study 204486 was conducted. There is a Publication Steering Committee for this study.	1-Apr-2018
14524	GSK	Efficacy, safety and immunogenicity study of GSK Biologicals’ Herpes Zoster vaccine GSK1437173A in adults aged 70 years or older	Herpes Zoster subunit (HZ/su) vaccine	113077	Herpes Zoster	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=113077	http://clinicaltrials.gov/show/NCT01165229	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-015791-94	Y	Y	Y	Y	Y	Y	Y	A nested study 204486 was conducted. There is a Publication Steering Committee for this study.	1-Apr-2018
14525	GSK	Consistency, immunogenicity and safety study of GSK Biologicals’ Herpes Zoster vaccine GSK1437173A in adults 50 years of age or older	Herpes Zoster subunit (HZ/su) vaccine	117177	Herpes Zoster	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=117177	http://clinicaltrials.gov/show/NCT02075515	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-000373-76	Y	Y	Y	Y	Y	Y	Y		1-Apr-2018
14526	GSK	Immunogenicity and safety of GSK Biologicals’ dTpa-IPV vaccine (Boostrix Polio) as a booster dose in 3 and 4-year-old children	Combined Reduced Antigen Content Diphtheria, Tetanus, Acellular Pertussis, Inactivated Polio Vaccine	111763	acellular pertussis; Diphtheria; Poliomyelitis; Tetanus	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=111763	http://clinicaltrials.gov/show/NCT01245049	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-012202-39	Y	Y	Y	Y	Y	Y	Y		1-Apr-2018
14527	GSK	A randomized, controlled, phase II study to evaluate the safety and immunogenicity of 7 different formulations of an investigational vaccination regimen, when administered as a 3-dose primary immunization schedule before 6 months of age, followed by a fourth dose during the second year of life	Combined Diphtheria, Tetanus, Acellular Pertussis, Hepatitis B, Inactivated Polio, Haemophilus influenzae Type b Vaccine	759348/002	acellular pertussis; Diphtheria; Haemophilus influenzae type b; Hepatitis B; Poliomyelitis; Tetanus	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=759348/002			Y	N	Y	Y	Y	Y	N	A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies. An annotated case report form is not available for this study. A blank case report form will be provided.The analysis plan is not available for this study.	1-Apr-2018
14528	GSK	A randomized, controlled, phase II study to evaluate the safety and immunogenicity of five formulations of GlaxoSmithKline Biologicals’ investigational vaccination regimen, when administered intramuscularly as a 3-dose primary immunization schedule (2-3-4 month schedule) before 6 months of age.	Combined Diphtheria, Tetanus, Acellular Pertussis, Hepatitis B, Inactivated Polio, Haemophilus influenzae Type b Vaccine	759348/007	acellular pertussis; Diphtheria; Haemophilus influenzae type b; Hepatitis B; Poliomyelitis; Tetanus	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=759348/007			Y	N	Y	Y	Y	Y	N	A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies. An annotated case report form is not available for this study. A blank case report form will be provided. The analysis plan is not available for this study.	1-Apr-2018
14529	GSK	A randomized, controlled, phase II study to evaluate the safety and immunogenicity of GlaxoSmithKline Biologicals’ investigational vaccination regimen, when administered intramuscularly as a 3-dose primary immunization (2-3-4 month schedule) before 6 months of age.	Combined Diphtheria, Tetanus, Acellular Pertussis, Hepatitis B, Inactivated Polio, Haemophilus influenzae Type b Vaccine	101853	acellular pertussis; Diphtheria; Haemophilus influenzae type b; Hepatitis B; Poliomyelitis; Tetanus	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=101853			Y	N	Y	Y	Y	Y	N	A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies. An annotated case report form is not available for this study. A blank case report form will be provided. The analysis plan is not available for this study.	1-Apr-2018
14530	GSK	A Two-part Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of a High, Single Oral Dose of GSK1278863 (Part A), and a Randomized, Single-blind, Placebo- and Positive-controlled, Four-way Crossover Study to Assess the Effect of Single, Oral Dose of GSK1278863 on Cardiac Repolarization (Part B) in Healthy Volunteers	daprodustat	PHI113635	Anaemia	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=113635	http://clinicaltrials.gov/show/NCT02293148		Y	Y	Y	Y	Y	Y	Y	This study is available in CDISC format	1-Apr-2018
14531	GSK	A Phase I, Subject and Investigator Blind Randomized, Study to Investigate the Pharmacokinetics, Safety and Tolerability of Retosiban in Healthy Japanese Women	retosiban	OTA117168	Obstetric Labour, Premature	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=117168	http://clinicaltrials.gov/show/NCT02377414		Y	Y	Y	Y	Y	Y	Y		1-Apr-2018
14532	GSK	A Phase 4, Multi-Center, Randomized, Open-Label Study to Evaluate the Effect of BENLYSTA™ (belimumab; HGS1006) on Vaccine Responses in Subjects with Systemic Lupus Erythematosus (SLE)	belimumab	BEL115470	Systemic Lupus Erythematosus	Phase 4	https://www.gsk-studyregister.com/en/trial-details/?id=115470	http://clinicaltrials.gov/show/NCT01597492		Y	Y	Y	Y	Y	Y	Y	This study is available in CDISC format	1-Apr-2018
14533	GSK	A Randomized, Single-Blind, Dose Escalation, First Time in Human Study to Assess the Safety, Tolerability, and Pharmacokinetics of Single and Repeat Doses of GSK2878175 in Healthy Adults	GSK2878175	H5B116973	Hepatitis C, Chronic	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=116973	http://clinicaltrials.gov/show/NCT01879462		Y	Y	Y	Y	Y	Y	Y	This study is available in CDISC format	1-Apr-2018
14534	GSK	A Randomized, Single Blind, Dose Escalation, Placebo-Controlled Study to Assess the Safety, Pharmacokinetics, and Antiviral Activity of Repeat Doses of GSK2878175 in Subjects with Chronic Hepatitis C.	GSK2878175	H5B116976	Hepatitis C, Chronic	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=116976	http://clinicaltrials.gov/show/NCT02014571		Y	Y	Y	Y	Y	Y	Y		1-Apr-2018
14535	GSK	Study MEA117106: Mepolizumab vs. placebo as add-on treatment for frequently exacerbating COPD patients	mepolizumab	MEA117106	Pulmonary Disease, Chronic Obstructive	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=117106	http://clinicaltrials.gov/show/NCT02105948	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004298-28	Y	Y	Y	Y	Y	Y	Y	This study is available in CDISC format	1-Apr-2018
14536	GSK	Study MEA117113: Mepolizumab vs. Placebo as Add-on Treatment for Frequently Exacerbating COPD Patients Characterized by Eosinophil Level	mepolizumab	MEA117113	Pulmonary Disease, Chronic Obstructive	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=117113	http://clinicaltrials.gov/show/NCT02105961	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004297-98	Y	Y	Y	Y	Y	Y	Y	This study is available in CDISC format	1-Apr-2018
14537	GSK	A 12-month, open label, randomised, effectiveness study to evaluate fluticasone furoate (FF, GW685698)/vilanterol (VI, GW642444) Inhalation Powder delivered once daily via a Novel Dry Powder Inhaler compared with usual maintenance therapy in subjects with Asthma	fluticasone furoate/vilanterol	HZA115150	Asthma	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=115150	http://clinicaltrials.gov/show/NCT01706198	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005553-31	Y	Y	Y	Y	Y	Y	Y	Medical record information for patients who participated in this study will not be provided as this information is held in a third-party database which is not owned by GSK.	1-Apr-2018
14538	GSK	Estimation of Skeletal Muscle Mass with Deuterium Labeled d3 Creatine in Subjects with Chronic Disease	CCI21130	RES117245	Atrophy, Muscular	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=117245			Y	N	Y	Y	Y	Y	Y	A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies. An annotated case report form is not available for this study. A blank case report form will be provided.	1-Apr-2018
14539	GSK	A Randomized, Open-Label, 8-Week Cross-Over Study to Compare Umeclidinium/Vilanterol with Tiotropium/Olodaterol Once-Daily in Subjects with Chronic Obstructive Pulmonary Disease (COPD)	umeclidinium bromide/vilanterol	204990	Pulmonary Disease, Chronic Obstructive	Phase 4	https://www.gsk-studyregister.com/en/trial-details/?id=204990	http://clinicaltrials.gov/show/NCT02799784	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000585-36	Y	Y	Y	Y	Y	Y	Y		1-Apr-2018
14540	GSK	A Randomized, Double-Blind, Placebo-Controlled Evaluation of the Effect of the Combination of Umeclidinium and Vilanterol on Exercise Endurance Time in Subjects with COPD	umeclidinium bromide/vilanterol	201317	Pulmonary Disease, Chronic Obstructive	Phase 4	https://www.gsk-studyregister.com/en/trial-details/?id=201317	http://clinicaltrials.gov/show/NCT02275052		Y	Y	Y	Y	Y	Y	Y		1-Apr-2018
14542	GSK	A Phase 1/2, Double-Blind, Placebo-Controlled Study of the Pharmacokinetics, Safety and Tolerability of GSK3196165 in Combination with Methotrexate Therapy, in Japanese Subjects with Active Moderate-Severe Rheumatoid Arthritis Despite Treatment with Methotrexate	otilimab	201789	Arthritis, Rheumatoid	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=201789	http://clinicaltrials.gov/show/NCT03028467		Y	N	N	Y	N	Y	Y	A clinical study report and a protocol are not available for this study because English language versions were not created. An annotated case report form is not available for this study. A blank case report form will be provided.	1-Apr-2018
14543	GSK	An open-label study to evaluate the preference attributes of the ELLIPTA™ dry powder inhaler (DPI) compared to the HandiHaler™ DPI in subjects with Chronic Obstructive Pulmonary Disease (COPD)	fluticasone furoate/vilanterol	204983	Pulmonary Disease, Chronic Obstructive	Phase 4	https://www.gsk-studyregister.com/en/trial-details/?id=204983	http://clinicaltrials.gov/show/NCT02786927		Y	Y	Y	Y	Y	Y	Y		1-Apr-2018
14544	GSK	A Phase 2a Study to Evaluate the Pharmacokinetic, Safety, Tolerability and Clinical Effect of Topically Applied Umeclidinium/GSK573719 in Subjects with Primary Axillary Hyperhidrosis	umeclidinium bromide	202093	Hyperhidrosis	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=202093	http://clinicaltrials.gov/show/NCT02563899		Y	Y	Y	Y	Y	Y	Y	This study is available in CDISC format	1-Apr-2018
14545	GSK	A multicenter, randomized, single blind, active controlled, parallel group study to determine efficacy and safety of nebulized fluticasone propionate 1mg BID compared with nebulized budesonide 2mg BID administered for 12 weeks in Chinese adult and adolescent patients with severe persistent asthma	fluticasone	LOC114219	Asthma	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=114219	http://clinicaltrials.gov/show/NCT01687283		Y	Y	Y	Y	Y	Y	Y		1-Apr-2018
14546	GSK	An open-label, fixed sequence study to evaluate pharmacokinetics, safety and tolerability of single and repeated dose of extended-release bupropion hydrochloride (bupropion XL) tablets 150 mg and 300 mg once daily in Chinese healthy volunteers	bupropion	LOC114883	Depressive Disorder, Major	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=114883	http://clinicaltrials.gov/show/NCT02698553		Y	Y	Y	Y	Y	Y	Y		1-Apr-2018
14547	GSK	A Randomised, Double-blind (Sponsor Unblind), Placebo-controlled, Two Part Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Food Effect of Single or Repeat Doses of GSK2793660 in Healthy Subjects	GSK2793660	200186	Bronchiectasis	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=200186	http://clinicaltrials.gov/show/NCT02058407	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001828-19	Y	Y	Y	Y	Y	Y	Y		1-Apr-2018
14548	GSK	A phase IIIB, 24-week randomised, double-blind study to compare ‘closed’ triple therapy (FF/UMEC/VI) with 'open' triple therapy (FF/VI + UMEC), in subjects with chronic obstructive pulmonary disease (COPD)	fluticasone furoate/vilanterol/umeclidinium bromide	200812	Pulmonary Disease, Chronic Obstructive	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=200812	http://clinicaltrials.gov/show/NCT02729051	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-005212-14	Y	Y	Y	Y	Y	Y	Y	This study is available in CDISC format	1-Apr-2018
14549	GSK	An Open Label Positron Emission Tomography (PET) Imaging Study Using 89Zirconium to Investigate the Biodistribution of Anti-HER3 monoclonal Antibody (mAb) GSK2849330 and Characterize its Dose-receptor Occupancy Relationship in Subjects with Advanced HER3-Positive Solid Tumors	GSK2849330	200980	Cancer	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=200980	http://clinicaltrials.gov/show/NCT02345174		Y	Y	Y	Y	Y	Y	Y		1-Apr-2018
14550	GSK	A Phase 1 double-blind, randomised, placebo-controlled, dose escalating study to assess the safety and tolerability of single and multiple oral doses of CHR-5154 and the effect of the fasted and fed state on pharmacokinetics of CHR-5154 and CHR-5426 in healthy male volunteers	GSK3117391	201302	Arthritis, Rheumatoid	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=201302	http://clinicaltrials.gov/show/NCT01934101	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002197-49	Y	N	Y	Y	Y	Y	Y	An annotated case report form is not available for this study. A blank case report form will be provided.	1-Apr-2018
14551	GSK	A Phase 1, Open Label, Ascending Cohort, Dose Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Epelsiban and its Metabolite in Healthy Female Volunteers Following Administration of Epelsiban	epelsiban	201691	Embryo Transfer	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=201691	http://clinicaltrials.gov/show/NCT02257359		Y	Y	Y	Y	Y	Y	Y	This study is available in CDISC format	1-Apr-2018
14552	GSK	A Randomized, Placebo-controlled, Double-Blind (Sponsor Unblind), Repeat Dose, Ascending Cohort, Dose Escalation Phase I Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Epelsiban and its Major Metabolite in Healthy Women Volunteers Following Administration of Repeat Dosing of Epelsiban	epelsiban	201752	Embryo Transfer	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=201752	http://clinicaltrials.gov/show/NCT02703181		Y	Y	Y	Y	Y	Y	Y	This study is available in CDISC format	1-Apr-2018
14554	GSK	A Microdose Study to Describe the Intravenous Pharmacokinetics of GSK3191607 in Healthy Male Subjects Following Administration of [14C]-GSK3191607	GSK3191607	204853	Malaria, Falciparum	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=204853	http://clinicaltrials.gov/show/NCT02737007	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-003655-21	Y	N	Y	Y	Y	Y	Y	This study is available in CDISC format. An annotated case report form is not available for this study. A blank case report form will be provided.	1-Apr-2018
14556	GSK	A randomised, open, placebo-controlled 5-way crossover trial of single doses of intranasal GSK256066 in subjects with seasonal allergic rhinitis (SAR).	GSK256066	IPR109764	Rhinitis, Allergic, Seasonal	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=IPR109764	http://clinicaltrials.gov/show/NCT00464568	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006710-15	Y	N	Y	Y	Y	Y	Y	An annotated case report form is not available for this study. A blank case report form will be provided.	1-Apr-2018
14557	GSK	Single-blind, placebo-controlled, randomized study testing single ascending doses of GSK369796 in healthy subjects	GSK369796	ISO105774	Malaria	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=ISO105774	http://clinicaltrials.gov/show/NCT00675064	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000563-29	Y	N	Y	Y	Y	Y	Y	An annotated case report form is not available for this study. A blank case report form will be provided.	1-Apr-2018
14558	GSK	A Double-Blind (sponsor unblind), Placebo Controlled, Randomised, Parallel Group Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Multiple Doses of GSK2269557 Administered as a Dry Powder to COPD Patients and Assessment of Dose Response using Sputum Biomarkers	nemiralisib	PII115119	Pulmonary Disease, Chronic Obstructive	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=115119	http://clinicaltrials.gov/show/NCT02130635	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-000313-31	Y	Y	Y	Y	Y	N	Y	A raw dataset is not available for this study.	1-Apr-2018
14559	GSK	A Single-Dose, Randomised, Open-Label, Two-Period Crossover Study to Determine the Bioequivalence of the Second Generation Dutasteride and Tamsulosin HCl Combination Capsule in the Fasted State in Healthy Adult Male Subjects	dutasteride	ARI116897	Urologic Diseases	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=116897	http://clinicaltrials.gov/show/NCT02052713	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001126-26	Y	N	Y	Y	Y	Y	Y	An annotated case report form is not available for this study. A blank case report form will be provided.	1-Apr-2018
14560	GSK	A Single-Dose, Randomised, Open-Label, Two-Period Crossover Study to Determine the Bioequivalence of the Second Generation Dutasteride and Tamsulosin HCl Combination Capsule in the Fed State in Healthy Adult Male Subjects	dutasteride	ARI116108	Urologic Diseases	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=116108	http://clinicaltrials.gov/show/NCT02058576	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001125-49	Y	N	Y	Y	Y	Y	Y	An annotated case report form is not available for this study. A blank case report form will be provided.	1-Apr-2018
14561	GSK	Study of GSK2302032A Antigen-Specific Cancer Immunotherapeutic in patients with resectable Non-Small Cell Lung Cancer	GSK2302032A	113174	Lung Cancer, Non-Small Cell	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=113174	http://clinicaltrials.gov/show/NCT01159964	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-016624-31	Y	Y	Y	Y	Y	Y	Y		1-Apr-2018
14562	GSK	Safety and immunogenicity study of GSK Biologicals’ candidate tuberculosis (TB) vaccine GSK 692342 when administered to adults with TB disease	SB692342	114886	Tuberculosis	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=114886	http://clinicaltrials.gov/show/NCT01424501	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001820-36	Y	Y	Y	Y	Y	Y	Y		1-Apr-2018
14567	Novartis	Comparison Trial of Letrozole to Anastrozole in the Adjuvant Treatment of Postmenopausal Women With Hormone Receptor and Node Positive Breast Cancer	letrozole	CFEM345D2411	Breast Cancer	Phase 3	https://www.novctrd.com/ctrdweb/trialresult/trialresults/pdf?trialResultId=14105	https://www.clinicaltrials.gov/ct2/show/NCT00248170?term=CFEM345D2411&rank=1	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004263-35	Y	Y	Y	Y	Y	Y	Y		1-Apr-2018
14569	Novartis	A Phase IIIB, Multi-Center, Open Label Study For Postmenopausal Women With Estrogen Receptor Positive Locally Advanced or Metastatic Breast Cancer Treated With Everolimus (RAD001) in Combination With Exemestane: 4EVER - Efficacy, Safety, Health Economics, Translational Research	everolimus	CRAD001JDE49	Metastatic Breast Cancer	Phase 3	https://www.novctrd.com/ctrdweb/trialresult/trialresults/pdf?trialResultId=13063	https://www.clinicaltrials.gov/ct2/show/NCT01626222?term=CRAD001JDE49&rank=1	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-006111-62	Y	Y	Y	Y	Y	Y	Y		1-Apr-2018
14570	Novartis	A Phase II, Single Arm Study of the Use of Steroid-based Mouthwash to Prevent Stomatitis in Postmenopausal Women With Advanced or Metastatic Hormone Receptor Positive Breast Cancer Being Treated With Everolimus Plus Exemestane	everolimus	CRAD001JUS226	Advanced Breast Cancer	Phase 2	https://www.novctrd.com/ctrdweb/trialresult/trialresults/pdf?trialResultId=15368	https://www.clinicaltrials.gov/ct2/show/NCT02069093?term=CRAD001JUS226&rank=1		Y	Y	Y	Y	Y	Y	Y		1-Apr-2018
14572	Astellas	A Phase 2a Enriched Enrollment Randomized Withdrawal Study to Assess Analgesic Efficacy and Safety of ASP8477 in Subjects with Peripheral Neuropathic Pain	ASP8477	8477-CL-0020	Peripheral Neuropathic Pain	Phase 2	https://www.clinicaltrials.astellas.com/study/?pid=8477-CL-0020	https://clinicaltrials.gov/ct2/show/NCT02065349	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002521-27	Y	Y	Y	Y	Y	Y	Y		1-May-2018
14583	ViiV	A Phase 2b study to select a once daily oral dose of GSK2248761 in HIV-1 infected antiretroviral therapy experienced adults with non-nucleoside reverse transcriptase inhibitor (NNRTI) resistance	fosdevirine	113399	Infection, Human Immunodeficiency Virus	Phase 2	https://www.viiv-studyregister.com/study/19533	http://clinicaltrials.gov/show/NCT01199731		Y	Y	Y	Y	Y	Y	Y		1-Apr-2018
14584	ViiV	Phase 2b study to select a once daily oral dose of GSK2248761 administered with tenofovir/emtricitabine or abacavir/lamivudine in HIV-1 infected antiretroviral therapy naive adult subjects	fosdevirine	113404	Infection, Human Immunodeficiency Virus	Phase 2	https://www.viiv-studyregister.com/study/19534	http://clinicaltrials.gov/show/NCT01231555		Y	Y	Y	Y	Y	Y	Y		1-Apr-2018
14587	Astellas	A randomized, double-blind, double-dummy, placebo-controlled study to evaluate the efficacy and safety of solifenacin succinate (5 and 10 mg once daily) against placebo and oxybutynin hydrochloride (5 mg three times daily) in the treatment of subjects with neurogenic detrusor overactivity	solifenacin succinate	905-EC-005	Neurogenic detrusor overactivity	Phase 4	https://www.clinicaltrials.astellas.com/study/?pid=905-EC-005	https://clinicaltrials.gov/ct2/show/NCT00629642	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005523-42	Y	N	Y	Y	Y	Y	Y		1-Jun-2018
16026	GSK	A multi-centre, randomized, double-blind, placebo-controlled, cross-over study to evaluate the effects of SB-649868 (10, 30 mg and 60 mg) on sleep continuity, PSG sleep recordings, subjective sleep assessment, and daytime cognitive function in subjects with primary insomnia	SB649868	OXS107714	Sleep Initiation and Maintenance Disorders	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=OXS107714	http://clinicaltrials.gov/show/NCT00426816	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002131-24	Y	Y	Y	Y	Y	Y	Y		1-May-2018
16027	GSK	A Phase IIB, Randomized, Blinded, Dose-ranging, Active-controlled, Parallel-group, Multi-center study to Evaluate the Dose Response Relationship of GSK1278863 over the first 4 weeks of Treatment and Evaluate the Safety and Efficacy of GSK1278863 over 24 weeks in Hemodialysis-Dependent Subjects with Anemia associated with Chronic Kidney Disease who Switch from Recombinant Human Erythropoietin	daprodustat	PHI113633	Anaemia	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=113633	http://clinicaltrials.gov/show/NCT01977482	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002682-19	Y	Y	Y	Y	Y	Y	Y		1-May-2018
16029	GSK	A Pilot Study to Evaluate Relief of Provoked Acute Craving by Nicotine Mouth Strip, Nicorette ® Nicotine Lozenge and Gum	nicotine	S2111378	Smoking Cessation	Phase 2		http://clinicaltrials.gov/show/NCT01476202		Y	Y	Y	Y	Y	Y	Y	There is no GSK Study Register entry for this study.	1-May-2018
16037	GSK	A Phase 2, open-label, controlled, multi-center extension study to evaluate 4-year antibody persistence and booster response following MenABCWY vaccination in healthy adolescents and young adults who previously participated in studies V102_02 (NCT01210885) and V102_02E1 (NCT01367158)	GSK3536819A	205213	Meningococcal disease	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=205213	http://clinicaltrials.gov/show/NCT02451514	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004420-29	Y	N	Y	Y	Y	Y	N	An annotated case report form is not available for this study. A blank case report form will be provided. A reporting and analysis plan is not available for this study.	1-May-2018
16038	GSK	GSK2132231A Antigen-Specific Cancer Immunotherapeutic as adjuvant therapy in patients with resected melanoma	GSK2132231A	111482	Melanoma	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=111482	http://clinicaltrials.gov/show/NCT00796445	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-002447-16	Y	N	Y	Y	Y	Y	Y	An annotated case report form is not available for this study. A blank case report form will be provided.	1-May-2018
16039	GSK	Safety and immunogenicity of GSK Biologicals’ HPV-16/18 L1 VLP AS04 vaccine (GSK-580299) in healthy female children 4-6 years old	Human Papillomavirus Types 16 and 18 Vaccine	115887	Infections, Papillomavirus	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=115887	http://clinicaltrials.gov/show/NCT01627561	https://www.clinicaltrialsregister.eu/ctr-search/search?query=/2011-005604-15	Y	Y	Y	Y	Y	Y	Y		1-May-2018
16040	GSK	Evaluation of immunogenicity and safety of GSK Biologicals' Tdap booster vaccine (Boostrix™) in young adults, administered 10 years after previous Tdap boosting	Combined Reduced Antigen Content Diphtheria, Tetanus, Acellular Pertussis Vaccine	116570	Diphtheria; Tetanus; Acellular pertussis	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=116570	http://clinicaltrials.gov/show/NCT01738477		Y	N	Y	Y	Y	Y	Y	An annotated case report form is not available for this study. A blank case report form will be provided.	1-May-2018
16041	GSK	Safety and immunogenicity study of GSK Biologicals’ Quadrivalent Influenza Candidate Vaccine (GSK23211381A) manufactured with a new process in adults and children	Influenza Vaccine (Quadrivalent)	201251	Influenza	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=201251	http://clinicaltrials.gov/show/NCT02207413	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-000955-10	Y	N	Y	Y	Y	Y	Y	An annotated case report form is not available for this study. A blank case report form will be provided.	1-May-2018
16042	GSK	Long term immunogenicity and safety study of GSK Biologicals’ Herpes Zoster subunit (HZ/su) vaccine 1437173A and assessment of re-vaccination with 2 additional doses, in healthy subjects aged 60 years of age and older	Herpes Zoster subunit (HZ/su) vaccine	204926	Herpes Zoster	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=204926	http://clinicaltrials.gov/show/NCT02735915	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-004400-30	Y	N	N	Y	Y	Y	Y	An annotated case report form is not available for this study. A blank case report form will be provided. The finalized CSR is not yet available.	1-May-2018
16043	GSK	Clinical activity, safety and immunogenic properties of cancer immunotherapeutic GSK2132231A in patients with unresectable and progressive metastatic cutaneous melanoma	GSK2132231A	111473	Melanoma	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=111473	http://clinicaltrials.gov/show/NCT00896480	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001301-42	Y	N	Y	Y	Y	Y	Y	An annotated case report form is not available for this study. A blank case report form will be provided.	1-May-2018
16044	GSK	Immunogenicity and safety study of GSK Biologicals’ Herpes Zoster vaccine GSK1437173A when co-administered with Pneumovax 23™ in adults aged 50 years and older	Herpes Zoster subunit (HZ/su) vaccine	116889	Herpes Zoster	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=116889	http://clinicaltrials.gov/show/NCT02045836	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-005314-19	Y	N	Y	Y	Y	Y	Y	An annotated case report form is not available for this study. A blank case report form will be provided.	1-May-2018
16045	GSK	Persistence of hepatitis B antibodies, immunogenicity and safety of GlaxoSmithKline (GSK) Biologicals’ hepatitis B vaccine, Engerix™-B Kinder (SKF103860) challenge dose, in adolescents vaccinated with four doses of Infanrix™ hexa (SB217744) during infancy	INFANRIX PENTA/INFANRIX HEXA / PEDIARIX	106794	Hepatitis B	Phase 4	https://www.gsk-studyregister.com/en/trial-details/?id=106794	http://clinicaltrials.gov/show/NCT02798952	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-003391-74	Y	N	Y	Y	Y	Y	Y	An annotated case report form is not available for this study. A blank case report form will be provided.	1-May-2018
16046	GSK	Immunogenicity and safety study of GSK Biologicals’ combined measles-mumps-rubella vaccine in subjects seven years and older (209762)	Measles, Mumps, Rubella Vaccine	115231	Measles; Mumps; Rubella	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=115231	http://clinicaltrials.gov/show/NCT02058563	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-003672-36	Y	N	Y	Y	Y	Y	Y	An annotated case report form is not available for this study. A blank case report form will be provided.	1-May-2018
16047	GSK	An Open Label, Single-arm Study Evaluating a New Thermostable Formulation of FLOLAN™ in Japanese Subjects with Pulmonary Arterial Hypertension (PAH)	epoprostenol	201614	Cardiovascular Disease	Phase 4	https://www.gsk-studyregister.com/en/trial-details/?id=201614	http://clinicaltrials.gov/show/NCT02705807		Y	Y	Y	Y	Y	N	Y	A raw dataset is not available for this study.	1-May-2018
16058	ViiV	A Single-arm Study of the Safety, Efficacy and Central Nervous System and Plasma PK of GSK1349572 (Dolutegravir, DTG) 50 mg Once Daily in Combination with the Abacavir/Lamivudine Fixed Dose Combination Tablet over 96 Weeks in HIV-1 Infected Antiretroviral Naive Adult Subjects	dolutegravir	ING116070	Infection, Human Immunodeficiency Virus	Phase 3	https://www.viiv-studyregister.com/study/19559	http://clinicaltrials.gov/show/NCT01499199		Y	Y	Y	Y	Y	Y	Y		1-May-2018
16059	ViiV	A Phase III Randomized, Double-blind Trial Investigating the Activity of Dolutegravir 50 mg BID vs Placebo over 7 Days in HIV-1-infected Subjects with RAL/ELV resistance, Followed by an Open-label Phase with an Optimized Background Regimen	dolutegravir	ING116529	Infection, Human Immunodeficiency Virus	Phase 3	https://www.viiv-studyregister.com/study/19567	http://clinicaltrials.gov/show/NCT01568892		Y	Y	Y	Y	Y	Y	Y		1-May-2018
16060	GSK	Long-term follow-up of participants from studies evaluating the HIV vaccine 732462	SB732462	114083	Infection, Human Immunodeficiency Virus	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=114083	http://clinicaltrials.gov/show/NCT01092611	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-018097-64	Y	Y	Y	Y	Y	Y	Y	This is a follow-up study to 111679 and 112353.	1-Jun-2018
16061	GSK	Persistence study of GSK Biologicals’ Tdap vaccine (776423), 1, 3, 5 and 9 years following administration as a single dose in NCT00346073 study and to evaluate the immunogenicity and safety of Boostrix as a second dose of Tdap, when administered at Year 9	Combined Reduced Antigen Content Diphtheria, Tetanus, Acellular Pertussis Vaccine	110084	Diphtheria; Tetanus; Acellular pertussis	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=110080	http://clinicaltrials.gov/show/NCT00489970		Y	Y	Y	Y	Y	Y	N	This is a follow-up study to 106316. Follow-on studies were conducted: 110080, 110082, 110086 and posted under 110080 on the GSK Study Register. A reporting and analysis plan is not available for this study.	1-Jun-2018
16062	GSK	Persistence study of GSK Biologicals’ Tdap vaccine (776423), 1, 3, 5 and 9 years following administration as a single dose in NCT00346073 study and to evaluate the immunogenicity and safety of Boostrix as a second dose of Tdap, when administered at Year 9	Combined Reduced Antigen Content Diphtheria, Tetanus, Acellular Pertussis Vaccine	110086	Diphtheria; Tetanus; Acellular pertussis	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=110080	http://clinicaltrials.gov/show/NCT00489970		Y	Y	Y	Y	Y	Y	Y	This is a follow-up study to 106316. Follow-on studies were conducted: 110080, 110084, 110086 and posted under 110080 on the GSK Study Register.	1-Jun-2018
16063	GSK	Persistence study of GSK Biologicals’ Tdap vaccine (776423), 1, 3, 5 and 9 years following administration as a single dose in NCT00346073 study and to evaluate the immunogenicity and safety of Boostrix as a second dose of Tdap, when administered at Year 9	Combined Reduced Antigen Content Diphtheria, Tetanus, Acellular Pertussis Vaccine	110082	Diphtheria; Tetanus; Acellular pertussis	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=110080	http://clinicaltrials.gov/show/NCT00489970		Y	Y	Y	Y	Y	Y	Y	This is a follow-up study to 106316. Follow-on studies were conducted: 110080, 110084, 110086 and posted under 110080 on the GSK Study Register.	1-Jun-2018
16064	GSK	Persistence study of GSK Biologicals’ Tdap vaccine (776423), 1, 3, 5 and 9 years following administration as a single dose in NCT00346073 study and to evaluate the immunogenicity and safety of Boostrix as a second dose of Tdap, when administered at Year 9	Combined Reduced Antigen Content Diphtheria, Tetanus, Acellular Pertussis Vaccine	110080	Diphtheria; Tetanus; Acellular pertussis	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=110080	http://clinicaltrials.gov/show/NCT00489970		Y	Y	Y	Y	Y	Y	Y	This is a follow-up study to 106316. Follow-on studies were conducted: 110082, 110084, 110086 and posted under 110080 on the GSK Study Register.	1-Jun-2018
16065	GSK	A Phase 2a, Observer Blind, Randomized, Controlled, Single Center Study To Evaluate The Safety, Reactogenicity And Immunogenicity Of 2 Doses Of The GVGH 1790GAHB Vaccine Against Shigella Sonnei, Administered Intramuscularly In Adult Subjects From A Country Endemic For Shigellosis	GSK3536852A	205494	Shigella sonnei infection	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=205494	http://clinicaltrials.gov/show/NCT02676895		Y	N	Y	Y	Y	Y	N	An annotated case report form is not available for this study. A blank case report form will be provided. The reporting and analysis plan is not available for this study.	1-Jun-2018
16066	GSK	Study of GSK2130579A Tumor-Antigen-Specific Cancer Immunotherapeutic in adult Acute Myeloid Leukemia patients with a suboptimal clinical response to induction chemotherapy	GSK2130579A	111727	Leukaemia, Myelocytic, Acute	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=111727	http://clinicaltrials.gov/show/NCT01051063	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-005348-17	Y	Y	Y	Y	Y	Y	Y		1-Jun-2018
16067	GSK	Study of GSK2130579A Tumor-Antigen-Specific Cancer Immunotherapeutic as post-consolidation therapy in adult patients with Acute Myeloid Leukemia	GSK2130579A	111444	Leukaemia, Myelocytic, Acute	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=111444	http://clinicaltrials.gov/show/NCT00725283	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023886-24	Y	Y	Y	Y	Y	Y	Y		1-Jun-2018
16068	GSK	Efficacy and safety of HIV Vaccine 732462 in ART-naïve HIV-1 infected persons	SB732462	111679	Infection, Human Immunodeficiency Virus	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=111679	http://clinicaltrials.gov/show/NCT01218113	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-021356-26	Y	Y	Y	Y	Y	Y	Y	A follow-on study 114083 was conducted	1-Jun-2018
16069	GSK	Study to evaluate the safety and reactogenicity of the HIV Vaccine 732461 in HIV infected subjects aged 18 to 55 years old	SB732462	112353	Infection, Human Immunodeficiency Virus	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=112353	http://clinicaltrials.gov/show/NCT00814762	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-005009-20	Y	Y	Y	Y	Y	Y	Y	A follow-on study 114083 was conducted	1-Jun-2018
16070	GSK	A study to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of GSK2586184 following a single dose of 800mg and repeat oral tablet doses of 800mg b.d and the effect of food and gender on the pharmacokinetics of oralGSK2586184 in healthy subjects	solcitinib	JAK116439	Systemic Lupus Erythematosus	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=116439	http://clinicaltrials.gov/show/NCT01687309	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001265-32	Y	Y	Y	Y	Y	Y	Y		1-Jun-2018
16071	GSK	A Randomized, Double Blinded, Parallel Study to Evaluate the Pharmacokinetics of Zanamivir after Single and Repeated Dose (300 mg and 600 mg) Infusion Administration in Healthy Chinese Adults	zanamivir	NAI117104	Influenza, Human	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=117104	http://clinicaltrials.gov/show/NCT02377401		Y	Y	Y	Y	Y	Y	Y		1-Jun-2018
16072	GSK	A comparison of the effects of AVANDIA® on arterial stiffness in obese subjects and healthy non-obese control subjects	rosiglitazone	999910/189	Insulin Resistance	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=999910/189			N	N	Y	Y	Y	Y	N	A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies. An analysis-ready dataset is not available for this study. An annotated case report form is not available for this study. A blank case report form will be provided. The Reporting and analysis plan is not available for this study.	1-Jun-2018
16073	GSK	A phase III, 52 week, randomized, double-blind, 3-arm parallel group study, comparing the efficacy, safety and tolerability of the fixed dose triple combination FF/UMEC/VI with the fixed dose dual combinations of FF/VI and UMEC/VI, all administered once-daily in the morning via a dry powder inhaler in subjects with chronic obstructive pulmonary disease	fluticasone furoate/vilanterol/umeclidinium bromide	CTT116855	Pulmonary Disease, Chronic Obstructive	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=116855	http://clinicaltrials.gov/show/NCT02164513	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003075-35	Y	Y	Y	Y	Y	Y	Y	There is a Publication Steering Committee for this study.	1-Jun-2018
16074	GSK	A Multicenter, Double–Blind, Placebo–Controlled, Flexible Dose (100–400mg) 10 Week Evaluation Of the Safety and Efficacy of LAMICTAL (Lamotrigine) in the Treatment of a Major Depressive Episode in Patients with Bipolar Disorder	lamotrigine	SCAA2010	Depressive Disorder, Major	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=SCAA2010			N	N	Y	Y	Y	Y	N	A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies. An analysis-ready dataset is not available for this study. An annotated case report form is not available for this study. A blank case report form will be provided. A reporting and analysis plan is not available for this study.	1-Jun-2018
16075	GSK	A Multicenter, Double–Blind, Placebo–Controlled, Fixed Dose (50 or 200mg per day) 7 Week Evaluation of the Safety and Efficacy of LAMICTAL (Lamotrigine) in the Treatment of a Major Depressive Episode in Patients Suffering From Bipolar Disorder	lamotrigine	SCAB2001	Depressive Disorder, Major	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=SCAB2001			N	N	Y	Y	Y	Y	N	A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies. An analysis-ready dataset is not available for this study. An annotated case report form is not available for this study. A blank case report form will be provided. A reporting and analysis plan is not available for this study.	1-Jun-2018
16107	GSK	Study of GSK2132231A Antigen-Specific Cancer Immunotherapeutic in association with chemotherapy in patients with unresectable and progressive metastatic cutaneous melanoma	GSK2132231A	111714	Melanoma	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=111714	http://clinicaltrials.gov/show/NCT00849875	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001918-25	Y	Y	Y	Y	Y	Y	Y		1-Jul-2018
16108	GSK	Safety and immunogenicity of GSK Biologicals’ candidate tuberculosis vaccine (692342) when administered to HIV-positive adults living in a Tuberculosis endemic region	SB692342	113935	Tuberculosis	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=113935	http://clinicaltrials.gov/show/NCT01262976		Y	Y	Y	Y	Y	Y	Y		1-Jul-2018
16109	GSK	A Double-Blind, Randomized, Controlled Phase III Study to Assess the Prophylactic Efficacy and Safety of gD-Alum/MPL Vaccine in the Prevention of Genital Herpes Disease in Young Women Who are HSV-1 and -2 Seronegative	SB208141	208141/039	Herpes Simplex	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=208141/039	http://clinicaltrials.gov/show/NCT00057330		Y	N	Y	Y	Y	Y	Y	An annotated case report form is not available for this study. A blank case report form will be provided.	1-Jul-2018
16110	GSK	A study to evaluate GlaxoSmithKline (GSK) Biologicals’ investigational vaccination regimen in healthy young adults	Hepatitis B Vaccine, Recombinant	112076	Hepatitis B	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=112076	http://clinicaltrials.gov/show/NCT00814489	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-004715-35	Y	Y	Y	Y	Y	Y	Y		1-Jul-2018
16111	GSK	A partially blind study to evaluate the safety, reactogenicity and immunogenicity of GSK Biologicals’ Staphylococcal 4-component investigational vaccine (GSK2392102A) in healthy adults	GSK2392102A	113949	Infections, Staphylococcal	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=113949	http://clinicaltrials.gov/show/NCT01160172	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-018978-21	Y	Y	Y	Y	Y	Y	Y		1-Jul-2018
16112	GSK	Dose range study evaluating safety and immunogenicity study of GSK Biologicals' candidate tuberculosis vaccines (692342) when administered to healthy adults aged 18 to 45 years.	SB692342	110345	Tuberculosis	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=110345	http://clinicaltrials.gov/show/NCT00621322		Y	Y	Y	Y	Y	Y	Y		1-Jul-2018
16113	GSK	Safety and immunogenicity study of GSK Biologicals’ candidate tuberculosis vaccine (692342) when administered to healthy HIV-negative adolescents living in a TB endemic region	SB692342	112898	Tuberculosis	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=112898	http://clinicaltrials.gov/show/NCT00950612		Y	Y	Y	Y	Y	Y	Y		1-Jul-2018
16114	GSK	Safety and immunogenicity of a candidate tuberculosis (TB) vaccine (692342) in HIV-positive adults.	SB692342	111517	Tuberculosis	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=111517	http://clinicaltrials.gov/show/NCT00707967		Y	Y	Y	Y	Y	Y	Y		1-Jul-2018
16115	GSK	Safety and immunogenicity study of GSK Biologicals’ candidate tuberculosis vaccine (692342) when administered to healthy infants	SB692342	112899	Tuberculosis	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=112899	http://clinicaltrials.gov/show/NCT01098474	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-004380-44	Y	Y	Y	Y	Y	Y	Y		1-Jul-2018
16116	GSK	A randomized, double-blind, placebo-controlled, parallel group, dose ranging study to assess the effect of repeat doses of GSK962040 on the pharmacokinetics of L-DOPA in subjects with Parkinson’s disease exhibiting delayed gastric emptying	camicinal	MOT115816	Gastroparesis	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=115816	http://clinicaltrials.gov/show/NCT01602549	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004438-32	Y	Y	Y	Y	Y	Y	Y		1-Jul-2018
16117	GSK	A Pharmacokinetic Study for Systemic Exposure of Twice Daily Topically applied GSK2894512 Cream in Subjects with Atopic Dermatitis	tapinarof	201851	Dermatitis, Atopic	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=201851	http://clinicaltrials.gov/show/NCT02466152		Y	Y	Y	Y	Y	Y	Y	GSK has divested GSK2894512 and the associated data to Dermavant, and is no longer able to share the data associated with these studies.	1-Jul-2018
16118	GSK	A FTIH study with GSK3008348 in healthy volunteers and patients with Idiopathic Pulmonary Fibrosis	GSK3008348	200262	Idiopathic Pulmonary Fibrosis	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=200262	http://clinicaltrials.gov/show/NCT02612051	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-001470-17	Y	Y	Y	Y	Y	Y	Y	This study is available in CDISC format	1-Jul-2018
16119	GSK	A randomized, open-label, single-period, parallel-group study in healthy subjects to determine the effects of dissolution profile on the pharmacokinetics (via both venous and peripheral micro-samples) of single oral 300 mg doses of Tafenoquine (SB-252263) tablets + 30 mg Tafenoquine stable isotope labelled (SIL) solution	tafenoquine	201780	Malaria, Vivax	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=201780	http://clinicaltrials.gov/show/NCT02751294		Y	Y	Y	Y	Y	Y	Y	This study is available in CDISC format	1-Jul-2018
16120	GSK	A Phase I Trial to Evaluate Safety and Efficacy of Topically Applied GSK2981278 Ointment in a Psoriasis Plaque Test	GSK2981278	201465	Psoriasis	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=201465	http://clinicaltrials.gov/show/NCT02548052		Y	Y	Y	Y	Y	Y	Y	This study is available in CDISC format	1-Jul-2018
16128	Novartis	A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase III Study Comparing GW572016 and Letrozole Versus Letrozole in Subjects With Estrogen/Progesterone Receptor-Positive Advanced or Metastatic Breast Cancer	lapatinib	CLAP016A2308	Breast Cancer	Phase 3	NA	https://www.clinicaltrials.gov/ct2/show/NCT00073528?term=EGF30008&rank=1		Y	Y	Y	Y	Y	Y	Y		1-Jul-2018
16129	Novartis	A 26-week Treatment Multi-center, Randomized, Double-blind, Parallel-group, Placebo and Active Controlled (Open Label) Study to Assess the Efficacy, Safety and Tolerability of QVA149 (110/50 μg q.d.) in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)	Indacterol	CQVA149A2303	Chronic obstructive pulmonary disease (COPD)	Phase 3	https://www.novctrd.com/ctrdweb/trialresult/trialresults/pdf?trialResultId=7983	https://www.clinicaltrials.gov/ct2/show/NCT01202188?term=CQVA149A2303&rank=1	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-017772-25	Y	Y	Y	Y	Y	Y	Y		1-Jul-2018
16130	Novartis	A Placebo and Active Controlled Study to Assess the Long-term Safety of Once Daily QVA149 for 52 Weeks in Chronic Obstructive Pulmonary Disease (COPD) Patients With Moderate to Severe Airflow Limitation	indacterol	CQVA149A2339	Chronic obstructive pulmonary disease (COPD)	Phase 3	https://www.novctrd.com/ctrdweb/trialresult/trialresults/pdf?trialResultId=14547	https://www.clinicaltrials.gov/ct2/show/NCT01610037?term=CQVA149A2339&rank=1	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002057-38	Y	Y	Y	Y	Y	Y	Y		1-Jul-2018
16131	Novartis	A 12-week Treatment, Multi-center, Randomized, Double-blind, Parallel-group, Placebo and Active Controlled Study to Assess the Efficacy, Safety, and Tolerability of Indacaterol Maleate / Glycopyrronium Bromide in COPD Patients With Moderate to Severe Airflow Limitation.	indacterol	CQVA149A2336	Chronic obstructive pulmonary disease (COPD)	Phase 3	https://www.novctrd.com/ctrdweb/trialresult/trialresults/pdf?trialResultId=13823	https://www.clinicaltrials.gov/ct2/show/NCT01727141?term=CQVA149A2336&rank=1	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003346-32	Y	Y	Y	Y	Y	Y	Y		1-Jul-2018
16132	Novartis	A 12-week Treatment, Multi-center, Randomized, Double-blind, Parallel-group, Placebo and Active Controlled Study to Assess the Efficacy, Safety, and Tolerability of Indacaterol Maleate / Glycopyrronium Bromide in COPD Patients With Moderate to Severe Airflow Limitation	indacterol	CQVA149A2337	Chronic obstructive pulmonary disease (COPD)	Phase 3	https://www.novctrd.com/ctrdweb/trialresult/trialresults/pdf?trialResultId=13824	https://www.clinicaltrials.gov/ct2/show/NCT01712516?term=CQVA149A2337&rank=1	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003347-30	Y	Y	Y	Y	Y	Y	Y		1-Jul-2018
16133	Novartis	A 64-week Treatment, Multi-center, Randomized, Double-blind, Parallel-group, Active Controlled Study to Evaluate the Effect of QVA149 (110/50 μg o.d.) vs NVA237 (50 μg o.d.) and Open-label Tiotropium (18 μg o.d.) on COPD Exacerbations in Patients With Severe to Very Severe Chronic Obstructive Pulmonary Disease (COPD)	indacterol	CQVA149A2304	Chronic obstructive pulmonary disease (COPD)	Phase 3	https://www.novctrd.com/ctrdweb/trialresult/trialresults/pdf?trialResultId=9283	https://www.clinicaltrials.gov/ct2/show/NCT01120691?term=CQVA149A2304&rank=1	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-013256-69	Y	Y	Y	Y	Y	Y	Y		1-Jul-2018
16134	Novartis	A 52-week Treatment, Multi-center, Randomized, Open Label, Parallel Group Study to Assess the Long Term Safety and Tolerability of QVA149 (110 Mcg Indacaterol / 50 Mcg Glycopyrrolate o.d.) Using Tiotropium (18 Mcg o.d.) as an Active Control in Japanese Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)	indacterol	CQVA149A1301	Chronic obstructive pulmonary disease (COPD)	Phase 3	https://www.novctrd.com/ctrdweb/trialresult/trialresults/pdf?trialResultId=9763	https://www.clinicaltrials.gov/ct2/show/NCT01285492?term=CQVA149A1301&rank=1		Y	Y	Y	Y	Y	Y	Y		1-Jul-2018
16135	Novartis	A Multicener, Randomised, Double-blind, Placebo-controlled Study, to Assess the Long Term Safety of 52 Weeks Treatment With QVA149 (110 ug Indacaterol/50ug Glycopyrrolate) in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)	indacterol	CQVA149A2307	Chronic obstructive pulmonary disease (COPD)	Phase 3	https://www.novctrd.com/ctrdweb/trialresult/trialresults/pdf?trialResultId=7603	https://www.clinicaltrials.gov/ct2/show/NCT01120717?term=CQVA149A2307&rank=1	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-013235-38	Y	Y	Y	Y	Y	Y	Y		1-Jul-2018
16137	Novartis	A Multi-centre Randomized Double Blind 52-week Study to Assess the Safety of QVA149 Compared to QAB149 in Patients With COPD Who Have Moderate to Severe Airflow Limitation	indacterol	CQVA149A2340	Chronic obstructive pulmonary disease (COPD)	Phase 3	https://www.novctrd.com/ctrdweb/trialresult/trialresults/pdf?trialResultId=13903	https://www.clinicaltrials.gov/ct2/show/NCT01682863?term=CQVA149A2340&rank=1	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001998-93	Y	Y	Y	Y	Y	Y	Y		1-Jul-2018
16139	Astellas	A Phase 1, Open-Label Study Of The Safety And Pharmacokinetics Of Repeated-Dose Micafungin (FK463) In Children (2-5 Years AND 6-11 Years) And Adolescents (12-16 Years) With Esophageal Candidiasis Or Other Invasive Candidiasis	micafungin	9463-CL-2101	Invasive Candidiasis	Phase 1	https://www.clinicaltrials.astellas.com/study/?pid=9463-CL-2101	https://clinicaltrials.gov/ct2/show/NCT00608335		Y	Y	Y	Y	Y	Y	Y		1-Aug-2018
16153	Novartis	Neoadjuvant Therapy for Postmenopausal Women With ER and/or PgR Positive Breast Cancer. A Randomized Open Phase II Trial Evaluating the Efficacy of a 6 Months Preoperative Treatment With Letrozole (2.5 mg/Day) With or Without Zoledronic Acid (4 mg Every 4 Weeks)	zoledronic acid	CZOL446GDE19	Breast Neoplasms	Phase 4	https://www.novctrd.com/ctrdweb/trialresult/trialresults/pdf?trialResultId=5783	https://www.clinicaltrials.gov/ct2/show/NCT00375752?term=CZOL446+GDE19&rank=1	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-004007-37	Y	Y	Y	Y	Y	Y	Y		1-Jul-2018
16154	Novartis	A Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Study to Evaluate the Efficacy, Safety and Tolerability of Serelaxin When Added to Standard Therapy in Acute Heart Failure Patients	seralaxin	CRLX030A2301	Heart Failure	Phase 3	https://www.novctrd.com/ctrdweb/trialresult/trialresults/pdf?trialResultId=16969	https://www.clinicaltrials.gov/ct2/show/NCT01870778?term=CRLX030A2301&rank=1	https://www.clinicaltrialsregister.eu/ctr-search/search?query=CRLX030A2301	Y	Y	Y	Y	Y	Y	Y		1-Aug-2018
16155	Novartis	A multicenter, prospective, randomized, open-label study to assess the effect of serelaxin versus Standard of Care in Acute Heart Failure (AHF) patients	seralaxin	CRLX030A3301	Heart Failure	Phase 3	https://www.novctrd.com/ctrdweb/trialresult/trialresults/pdf?trialResultId=17081	https://www.clinicaltrials.gov/ct2/show/NCT02064868?term=crlx030a3301&rank=1	https://www.clinicaltrialsregister.eu/ctr-search/search?query=CRLX030A3301	Y	Y	Y	Y	Y	Y	Y		1-Aug-2018
16156	Novartis	A Phase II/III, Multicenter, Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Relaxin in Subjects With Acute Heart Failure	seralaxin	CRLX CHF 003	Heart Failure	Phase 2/3	https://www.novctrd.com/	https://www.clinicaltrials.gov/ct2/show/NCT00520806?term=RLX+CHF+003&rank=1		Y	Y	Y	Y	Y	Y	Y		1-Aug-2018
16157	Novartis	A Multicenter, Randomized, Double-blind, Placebo Controlled Phase III Study to Evaluate the Efficacy, Safety and Tolerability of Serelaxin When Added to Standard Therapy in Acute Heart Failure Patients	seralaxin	CRLX030A2302	Heart Failure	Phase 3		https://www.clinicaltrials.gov/ct2/show/NCT02007720?term=CRLX030A2302&rank=1		Y	Y	Y	Y	Y	Y	Y		1-Aug-2018
16158	Novartis	A randomised double-blind cross-over patient preference study of pazopanib versus sunitinib in treatment naïve locally advanced or metastatic renal cell carcinoma	pazopanib	VEG113046	Renal cell carcinoma	Phase 3	https://www.novctrd.com/ctrdweb/trialresult/trialresults/pdf?trialResultId=15450	https://www.clinicaltrials.gov/ct2/show/NCT01064310?term=NCT01064310&rank=1	https://www.clinicaltrialsregister.eu/ctr-search/search?query=VEG113046	Y	Y	Y	Y	Y	Y	Y		1-Aug-2018
16159	Novartis	A Randomized Double-Blind, Placebo-Controlled Study of Everolimus in Combination With Exemestane in the Treatment of Postmenopausal Women With Estrogen Receptor Positive Locally Advanced or Metastatic Breast Cancer Who Are Refractory to Letrozole or Anastrozole	everolimus	CRAD001Y2301	Breast Cancer	Phase 3	https://www.novctrd.com/ctrdweb/trialresult/trialresults/pdf?trialResultId=6843	https://www.clinicaltrials.gov/ct2/show/NCT00863655?term=CRAD001Y2301&rank=1	https://www.clinicaltrialsregister.eu/ctr-search/search?query=CRAD001Y2301	Y	Y	Y	Y	Y	Y	Y		1-Aug-2018
16160	Novartis	A Randomised Double-blind Cross-over Patient Preference Study of Pazopanib Versus Sunitinib in Treatment naïve Locally Advanced or Metastatic Renal Cell Carcinoma	pazopanib	113046	Renal cell carcinoma	Phase 3	https://www.novctrd.com/ctrdweb/trialresult/trialresults/pdf?trialResultId=15450	https://www.clinicaltrials.gov/ct2/show/study/NCT01064310?term=113046&rank=1		Y	Y	Y	Y	Y	Y	Y		1-Aug-2018
19523	Novartis	A Two Part, Double-blind, Randomized, Placebo-controlled and Open-label Study to Investigate the Efficacy, Safety and Tolerability of Eltrombopag, a Thrombopoietin Receptor Agonist, in Pediatric Patients With Previously Treated Chronic Immune (Idiopathic) Thrombocytopenic Purpura (ITP). PETIT2: Eltrombopag in PEdiatric Patients With Thrombocytopenia From ITP	eltrombopag	CETB115B2304/TRA115450	Idiopathic Thrombocytopenic Purpura	Phase 3		https://www.clinicaltrials.gov/ct2/show/NCT01520909?term=115450&rank=2	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002184-17+	Y	Y	Y	Y	Y	Y	Y		1-Sep-2018
19531	GSK	AN OPEN LABEL, BALANCED, RANDOMIZED, TWO-TREATMENT, TWO-PERIOD, TWO-SEQUENCE, CROSSOVER, SINGLE ORAL DOSE, BIOEQUIVALENCE STUDY OF MELOXICAM GSK 15 MG TABLETS MANUFACTURED BY SAVIPHARM J.S.C, VIETNAM AND MOBIC® 15 MG TABLETS OF BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG BINGER STR.173, 5521 INGELHEIM AM RHEIN, GERMANY, IN HEALTHY, ADULT, HUMAN MALE SUBJECTS UNDER FED CONDITION.	meloxicam	117176	Arthritis, Rheumatoid	N/A	https://www.gsk-studyregister.com/en/trial-details/?id=117176	http://clinicaltrials.gov/show/NCT01750931		Y	Y	Y	Y	Y	N	N	A raw dataset is not available for this study. A reporting and analysis plan is not available for this study.	1-Sep-2018
19532	GSK	A randomized, open-label, comparative study to evaluate an intermittent dosing regimen of fluticasone propionate 0.05% cream (twice per week) in reducing the risk of relapse when added to regular daily moisturization using PHYSIOGEL Lotion in paediatric subjects with stabilized atopic dermatitis	fluticasone propionate	FPC117291	Skin Diseases	Phase 4	https://www.gsk-studyregister.com/en/trial-details/?id=117291	http://clinicaltrials.gov/show/NCT01915914	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001574-42	Y	Y	Y	Y	Y	N	Y	A raw dataset is not available for this study.	1-Sep-2018
19533	GSK	NUTRItional Adequacy Therapeutic Enhancement in the critically ill: A randomized double blind, placebo-controlled trial of the motilin receptor agonist GSK962040. The NUTRIATE Study	camicinal	MOT113445	Gastroparesis	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=113445	http://clinicaltrials.gov/show/NCT01934192		Y	Y	Y	Y	Y	Y	Y		1-Sep-2018
19534	GSK	A Phase II, Randomized, Multicenter, Dose-Ranging Study in Adult Subjects Evaluating the Efficacy, Safety, and Tolerability of Single Doses of GSK2140944 in the Treatment of Uncomplicated Urogenital Gonorrhea Caused by Neisseria gonorrhoeae	gepotidacin	BTZ116576	Gonorrhea	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=116576	http://clinicaltrials.gov/show/NCT02294682	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-005120-26	Y	N	Y	Y	Y	Y	Y	This study is available in CDISC format. An annotated case report form is not available for this study. A blank case report form will be provided.	1-Sep-2018
19536	GSK	A randomized, open-label, cross-over, placebo-device study investigating critical and over all errors, training/teaching time, and preference attributes of the ELLIPTA dry powder Inhaler (DPI) as compared to HANDIHALER DPI used in combination with either DISKUS DPI or TURBUHALER DPI, in adult patients with Chronic Obstructive Pulmonary Disease (COPD)	fluticasone furoate/vilanterol/umeclidinium bromide	206215	Pulmonary Disease, Chronic Obstructive	Phase 4	https://www.gsk-studyregister.com/en/trial-details/?id=206215	http://clinicaltrials.gov/show/NCT02982187		Y	Y	Y	Y	Y	Y	Y		1-Sep-2018
19537	GSK	A 6-month, open label, randomised, efficacy study to evaluate fluticasone furoate (FF, GW685698)/vilanterol (VI, GW642444) Inhalation Powder delivered once daily via the Dry Powder Inhaler ELLIPTA™ compared with usual ICS/LABA maintenance therapy delivered by Dry Powder Inhaler in subjects with Persistent Asthma	fluticasone furoate/vilanterol	HZA116492	Asthma	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=116492	http://clinicaltrials.gov/show/NCT02446418	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-000551-81	Y	Y	Y	Y	Y	Y	Y	This study is available in CDISC format.	1-Sep-2018
19538	GSK	BEL114424: A Phase 2 Pilot, Multicentered, Randomised, Double Blind, Placebo-Controlled Study to Evaluate the Potential for Efficacy and the Safety of Belimumab plus Standard of Care versus Placebo plus Standard of Care in the Prevention of Allograft Rejection in Adult Subjects After Renal Transplantation	belimumab	BEL114424	Transplantation, Organ	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=114424	http://clinicaltrials.gov/show/NCT01536379	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-006215-56	Y	Y	Y	Y	Y	Y	Y		1-Sep-2018
19539	GSK	An open-label study to evaluate the pharmacokinetics, safety and tolerability of repeat dosing lamotrigine in healthy Chinese subjects	lamotrigine	SCA114536	Bipolar Disorder	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=114536	http://clinicaltrials.gov/show/NCT02513654		Y	Y	Y	Y	Y	Y	Y		1-Sep-2018
19540	GSK	A Glucose-6-Phosphate Dehydrogenase (G6PD) enzyme assay validation protocol	tafenoquine	TAF115226	Malaria	N/A				Y	Y	Y	Y	Y	Y	Y	A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies. There is no GSK Study Register entry for this study.	1-Sep-2018
19541	GSK	Safety, Reactogenicity & Immunogenicity of 2 Formulations of Tuberculosis Vaccine GSK692342 Administered Intramuscularly According to a Schedule of 0, 1 Month, to Healthy Adults Aged 18 to 50 Years	SB692342	106227	Tuberculosis	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=106227	http://clinicaltrials.gov/show/NCT00397943	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004497-24	Y	Y	Y	Y	Y	Y	Y	The results are summarised with studies 106228,108736 and 108738 on the GSK Study Register.	1-Sep-2018
19542	GSK	Observer-blinded, randomised, controlled, phase I/II study, to evaluate the safety , reactogenicity and immunogenicity of GSK Biologicals' candidate  tuberculosis vaccines M72/AS01B and M72/AS02A when administered intramuscularly according to a vaccination schedule of 0, 1 month, to healthy PPD-negative adults aged 18 to 50 years.	SB692342	106228	Tuberculosis	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=106227	http://clinicaltrials.gov/show/NCT00397943	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004497-24	Y	N	Y	Y	Y	Y	N	An annotated case report form is not available for this study.  A blank case report form will be provided. A reporting and analysis plan is not available for this study. The results are summarised under study 106227 with studies 108736 and 108738 on the GSK Study Register.	1-Sep-2018
19543	GSK	Observer-blinded, randomised, controlled, phase I/II study, to evaluate the safety , reactogenicity and immunogenicity of GSK Biologicals' candidate  tuberculosis vaccines M72/AS01B and M72/AS02A when administered intramuscularly according to a vaccination schedule of 0, 1 month, to healthy PPD-negative adults aged 18 to 50 years.	SB692342	108736	Tuberculosis	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=106227	http://clinicaltrials.gov/show/NCT00397943	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004497-24	Y	N	Y	Y	Y	Y	N	An annotated case report form is not available for this study.  A blank case report form will be provided. A reporting and analysis plan is not available for this study. The results are summarised under study 106227 with studies 106228 and 108738 on the GSK Study Register.	1-Sep-2018
19544	GSK	Observer-blinded, randomised, controlled, phase I/II study, to evaluate the safety , reactogenicity and immunogenicity of GSK Biologicals' candidate  tuberculosis vaccines M72/AS01B and M72/AS02A when administered intramuscularly according to a vaccination schedule of 0, 1 month, to healthy PPD-negative adults aged 18 to 50 years.	SB692342	108738	Tuberculosis	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=106227	http://clinicaltrials.gov/show/NCT00397943	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004497-24	Y	N	Y	Y	Y	Y	N	An annotated case report form is not available for this study.  A blank case report form will be provided. A reporting and analysis plan is not available for this study. The results are summarised under study 106227 with studies 108736 and 106228 on the GSK Study Register.	1-Sep-2018
19545	GSK	A study to evaluate the safety and immunogenicity of a booster dose of GSK Biologicals’ HIV candidate vaccine (732461) after administration of chloroquine in healthy adults.	SB732461	113165	AIDS	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=113165	http://clinicaltrials.gov/show/NCT00972725	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-012223-29	Y	Y	Y	Y	Y	Y	Y	This is a booster study to 108706.	1-Sep-2018
19546	GSK	A dose-ranging study to compare the safety and immunogenicity of a candidate Human deficiency virus (HIV) vaccine 732461, adjuvanted or not, administered according to a 0, 1 month schedule to healthy adult HIV seronegative volunteers.	SB732461	108706	AIDS	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=108706	http://clinicaltrials.gov/show/NCT00434512	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003796-12	Y	Y	Y	Y	Y	Y	Y	A booster study 113165 was conducted.	1-Sep-2018
19547	GSK	Safety study of GSK Biologicals’ human papillomavirus vaccine (GSK580299) in female Brazilian, Taiwanese and Thai subjects who had received control vaccine in study 580299/008	Human Papillomavirus Types 16 and 18 Vaccine	111758	Infections, Papillomavirus	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=111758	http://clinicaltrials.gov/show/NCT00849381		Y	Y	Y	Y	Y	Y	Y	This is an extension study to 580299/008.	1-Sep-2018
19548	GSK	An open multicentre, multicountry study to evaluate long-term antibody persistence and immune memory between Years 11 and 15 after the primary study HAB-084 in which healthy adolescents were vaccinated with Twinrix™ Adult following a two-dose schedule or Twinrix™ Junior following a three-dose schedule.	Hepatitis A (Inactivated), Hepatitis B (Recombinant) Vaccine	110704	Hepatitis A; Hepatitis B	Phase 4	https://www.gsk-studyregister.com/en/trial-details/?id=110699	http://clinicaltrials.gov/show/NCT00875485		Y	Y	Y	Y	Y	Y	Y	This is a follow-up study to 208127/084 (HAB-084). Further follow-up studies 110699, 110700, 110701, 110702 and 110703 were conducted. The results are summarised under study 110699 with studies 110700, 110701,110702 and 110703 on the GSK Study Register.	1-Sep-2018
19549	GSK	An open multicentre, multicountry study to evaluate long-term antibody persistence and immune memory between Years 11 and 15 after the primary study HAB-084 in which healthy adolescents were vaccinated with Twinrix™ Adult following a two-dose schedule or Twinrix™ Junior following a three-dose schedule.	Hepatitis A (Inactivated), Hepatitis B (Recombinant) Vaccine	110700	Hepatitis A; Hepatitis B	Phase 4	https://www.gsk-studyregister.com/en/trial-details/?id=110699	http://clinicaltrials.gov/show/NCT00875485		Y	Y	Y	Y	Y	Y	Y	This is a follow-up study to 208127/084 (HAB-084). Further follow-up studies 110699, 110701, 110702, 110703 and 110704 were conducted. The results are summarised under study 110699 with studies 110701,110702, 110703 and 110704 on the GSK Study Register.	1-Sep-2018
19550	GSK	An open multicentre, multicountry study to evaluate long-term antibody persistence and immune memory between Years 11 and 15 after the primary study HAB-084 in which healthy adolescents were vaccinated with Twinrix™ Adult following a two-dose schedule or Twinrix™ Junior following a three-dose schedule.	Hepatitis A (Inactivated), Hepatitis B (Recombinant) Vaccine	110701	Hepatitis A; Hepatitis B	Phase 4	https://www.gsk-studyregister.com/en/trial-details/?id=110699	http://clinicaltrials.gov/show/NCT00875485		Y	Y	Y	Y	Y	Y	Y	This is a follow-up study to 208127/084 (HAB-084). Further follow-up studies 110699, 110700, 110702, 110703 and 110704 were conducted. The results are summarised under study 110699 with studies 110700, 110702, 110703 and 110704 on the GSK Study Register.	1-Sep-2018
19551	GSK	An open multicentre, multicountry study to evaluate long-term antibody persistence and immune memory between Years 11 and 15 after the primary study HAB-084 in which healthy adolescents were vaccinated with Twinrix™ Adult following a two-dose schedule or Twinrix™ Junior following a three-dose schedule.	Hepatitis A (Inactivated), Hepatitis B (Recombinant) Vaccine	110702	Hepatitis A; Hepatitis B	Phase 4	https://www.gsk-studyregister.com/en/trial-details/?id=110699	http://clinicaltrials.gov/show/NCT00875485		Y	Y	Y	Y	Y	Y	Y	This is a follow-up study to 208127/084 (HAB-084). Further follow-up studies 110699, 110700, 110701, 110703 and 110704 were conducted. The results are summarised under study 110699 with studies 110700, 110701,110703 and 110704 on the GSK Study Register.	1-Sep-2018
19552	GSK	An open multicentre, multicountry study to evaluate long-term antibody persistence and immune memory between Years 11 and 15 after the primary study HAB-084 in which healthy adolescents were vaccinated with Twinrix™ Adult following a two-dose schedule or Twinrix™ Junior following a three-dose schedule.	Hepatitis A (Inactivated), Hepatitis B (Recombinant) Vaccine	110703	Hepatitis A; Hepatitis B	Phase 4	https://www.gsk-studyregister.com/en/trial-details/?id=110699	http://clinicaltrials.gov/show/NCT00875485		Y	Y	Y	Y	Y	Y	Y	This is a follow-up study to 208127/084 (HAB-084). Further follow-up studies 110699, 110700, 110701, 110702 and 110704 were conducted. The results are summarised under study 110699 with studies 110700, 110701,110702 and 110704 on the GSK Study Register.	1-Sep-2018
19553	GSK	An open, randomised study to compare the immunogenicity, safety and reactogenicity of SmithKline Beecham combined hepatitis A/hepatitis B vaccine Twinrix administered following a 2 dose schedule (0-6 mths) to that of Twinrix. Junior administered following a 3 dose schedule (0, 1, 6 months) in healthy volunteers aged 12-15 years	Hepatitis A (Inactivated), Hepatitis B (Recombinant) Vaccine	208127/084 (HAB-084)	Hepatitis A; Hepatitis B	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=208127/084	http://clinicaltrials.gov/show/NCT00875485		Y	Y	Y	Y	Y	Y	Y	Follow-on studies 110699, 110700, 110701, 110702, 110703 and 110704 were conducted.	1-Sep-2018
19554	GSK	A Phase 2b, Controlled, Observer-Blind, Multi-Center Study Assessing the Effectiveness, Immunogenicity and Safety of the 3rd Dose of Novartis Meningococcal ABCWY Vaccine Administered to Healthy Adolescents in the U.S.	GSK3536819A	205232	Meningococcal Disease	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=205232	http://clinicaltrials.gov/show/NCT02285777	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-001030-16	Y	Y	Y	Y	Y	Y	Y	This is an extension study to NCT02140762 (Sponsor: Novartis).	1-Sep-2018
19555	GSK	Immunogenicity and safety study of GSK Biologicals’ Priorix vaccine (209762) at an end of shelf-life potency compared to Merck & Co., Inc.’s measles-mumps-rubella (MMR) vaccine when both are given on a 2-dose schedule to healthy children in their 2nd year of life	Measles, Mumps, Rubella Vaccine	115649	Measles; Mumps; Rubella	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=115649	http://clinicaltrials.gov/show/NCT01681992	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004905-26	Y	Y	Y	Y	Y	Y	Y		1-Sep-2018
19556	GSK	Safety and immunogenicity study of GSK Biologicals’ measles-mumps-rubella (MMR) vaccine (209762) comparing immunogenicity and safety to Merck & Co., Inc.’s MMR vaccine, in healthy children 12 to 15 months of age	Measles, Mumps, Rubella Vaccine	115650	Measles; Mumps; Rubella	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=115650	http://clinicaltrials.gov/show/NCT02184572	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-006161-18	Y	Y	Y	Y	Y	Y	Y		1-Sep-2018
19557	GSK	A randomized, double-blind, double-dummy, parallel group, multicenter study of once daily Fluticasone Furoate/Vilanterol 100/25 mcg Inhalation Powder, twice daily Fluticasone Propionate/Salmeterol 250/50 mcg Inhalation Powder, and twice daily Fluticasone Propionate 250 mcg Inhalation Powder in the treatment of persistent asthma in adults and adolescents already adequately controlled on twice-daily inhaled corticosteroid and long-acting beta2 agonist	fluticasone furoate/vilanterol	201378	Asthma	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=201378	http://clinicaltrials.gov/show/NCT02301975		Y	Y	Y	Y	Y	Y	Y		1-Sep-2018
19558	GSK	A single-centre, randomized, double-blind (sponsor unblinded), placebo-controlled two-part study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of GSK2982772, in single (in both fed and fasted states) and repeat oral doses in healthy male subjects	GSK2982772	200975	Inflammatory Bowel Diseases	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=200975	http://clinicaltrials.gov/show/NCT02302404	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001776-66	Y	Y	Y	Y	Y	Y	Y		1-Sep-2018
19580	GSK	A Multicenter, Double-Blind, Double-Dummy, Placebo-Controlled, Randomized, Parallel Group Evaluation of the Efficacy and Safety of a Fixed-Dose of Talnetant Versus Placebo Versus Risperidone in Subjects with Schizophrenia	talnetant	223412/093	Schizophrenia	Phase 2		http://clinicaltrials.gov/show/NCT00103727		N	Y	Y	Y	Y	Y	Y	An analysis-ready dataset is not available for this study. There is no GSK Study Register entry for this study.	1-Oct-2018
19581	GSK	A Multi Centre, Double-Blind, Double-Dummy, Placebo-Controlled, Randomised, Adaptive, Dose-Range Study To Evaluate the Safety and Efficacy of SB-773812 Administered Once Daily for 12 Weeks in Adults With Schizophrenia	SB773812	NAA104606	Schizophrenia	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=NAA104606	http://clinicaltrials.gov/show/NCT00259870	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002883-27	Y	Y	Y	Y	Y	Y	Y		1-Oct-2018
19582	GSK	A Two Part, Phase IIa, Randomized, Placebo-controlled Study To Investigate The Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Clinical Efficacy of Oral Danirixin (GSK1325756) in Symptomatic COPD Subjects with Mild to Moderate Airflow Limitation at Risk for Exacerbations	danirixin	200163	Pulmonary Disease, Chronic Obstructive	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=200163	http://clinicaltrials.gov/show/NCT02130193	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003510-41	Y	Y	Y	Y	Y	Y	Y		1-Oct-2018
19583	GSK	Evaluating the control of COPD symptoms in patients treated with tiotropium bromide 18mcg once daily alone, ADOAIR 50/250mcg twice daily alone or ADOAIR 50/250mcg plus tiotropium bromide 18mcg	fluticasone propionate/salmeterol	SCO116717	Pulmonary Disease, Chronic Obstructive	Phase 4	https://www.gsk-studyregister.com/en/trial-details/?id=116717	http://clinicaltrials.gov/show/NCT01762800		Y	Y	Y	Y	Y	Y	Y		1-Oct-2018
19584	GSK	A multi-centre, randomised, double-blind, placebo-controlled, crossover study to investigate the efficacy, safety, and tolerability of repeat doses of inhaled GSK2269557 in adults with persistent, uncontrolled asthma	nemiralisib	201543	Pulmonary Disease, Chronic Obstructive	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=201543	http://clinicaltrials.gov/show/NCT02567708	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003808-77	Y	Y	Y	Y	Y	Y	Y		1-Oct-2018
19585	GSK	Skin Residency Study of Topically Applied GSK2894512 Cream in Healthy Volunteers	tapinarof	201661	Dermatitis, Atopic	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=201661	http://clinicaltrials.gov/show/NCT02411162		Y	Y	Y	Y	Y	Y	Y	GSK has divested GSK2894512 and the associated data to Dermavant, and is no longer able to share the data associated with these studies.	1-Oct-2018
19586	GSK	A single centre, three part, randomised, study to evaluate the safety, tolerability and pharmacokinetics of GSK2269557 administered via the ELLIPTA™ dry powder inhaler to Healthy Subjects	nemiralisib	201544	Pulmonary Disease, Chronic Obstructive	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=201544	http://clinicaltrials.gov/show/NCT02691325		Y	Y	Y	Y	Y	Y	Y	This study is available in CDISC format.	1-Oct-2018
19587	GSK	A Phase I, Randomised, Double-blind (sponsor open), Placebo-Controlled Single Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GSK2330811 in Healthy Subjects	GSK2330811	201246	Scleroderma, Systemic	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=201246	http://clinicaltrials.gov/show/NCT02386436	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004967-19	Y	Y	Y	Y	Y	Y	Y		1-Oct-2018
19588	GSK	A Randomized, Double-blind, Single-dose, Crossover Study to Compare Two Albiglutide Drug Products for Bioequivalence in Healthy Adult Subjects	albiglutide	201287	Diabetes Mellitus, Type 2	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=201287	http://clinicaltrials.gov/show/NCT02660736		Y	Y	Y	Y	Y	Y	Y	This study is available in CDISC format.	1-Oct-2018
19589	GSK	Study 203121: A Randomized, Blinded, Vehicle-Controlled, Dose-Finding Study of GSK2894512 Cream for the Treatment of Atopic Dermatitis	tapinarof	203121	Dermatitis, Atopic	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=203121	http://clinicaltrials.gov/show/NCT02564055		Y	Y	Y	Y	Y	Y	Y	GSK has divested GSK2894512 and the associated data to Dermavant, and is no longer able to share the data associated with these studies.	1-Oct-2018
19590	GSK	A Sponsor un-blinded, Placebo-controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single and Repeat, Ascending Doses of GSK2798745 in Healthy Subjects and Stable Heart Failure Patients	GSK2798745	TR4117387	Oedema, Pulmonary	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=117387	http://clinicaltrials.gov/show/NCT02119260	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004547-23	Y	Y	Y	Y	Y	Y	Y		1-Oct-2018
19591	GSK	A double-blind, randomized, placebo controlled, dose escalating crossover study to evaluate the safety, tolerability, pharmacokinetic and pharmacodynamic parameters of single doses of GSK2330672 in Japanese healthy male volunteers	linerixibat	205808	Cholestasis	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=205808	http://clinicaltrials.gov/show/NCT02801981		Y	Y	Y	Y	Y	Y	Y		1-Oct-2018
19592	GSK	Safety, Tolerability, and Pharmacokinetic Study of Concomitant Chloroquine and Tafenoquine in Healthy Volunteers	tafenoquine	TAF106491	Malaria	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=106491	http://clinicaltrials.gov/show/NCT00871156		Y	Y	Y	Y	Y	Y	Y	The raw data are included within the analysis-ready data for this study and are not provided separately.	1-Oct-2018
19593	GSK	A Randomized, Single Blind, Placebo Controlled Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Single Escalating Oral Doses of GSK2140944 in Healthy Adult Subjects	gepotidacin	BTZ114595	Infections, Respiratory Tract	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=114595	http://clinicaltrials.gov/show/NCT02202187		Y	Y	Y	Y	Y	Y	Y		1-Oct-2018
19594	GSK	A microdose Study to Evaluate the Biodistribution of [11C]-GSK2256098 in the Lungs and Heart of Healthy Subjects and Idiopathic Pulmonary Arterial Hypertension (PAH) Patients using Positron Emission Tomography (PET)	GSK2256098	204746	Hypertension, Pulmonary	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=204746	http://clinicaltrials.gov/show/NCT02551653	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-002626-40	Y	Y	Y	Y	Y	Y	Y	This study is available in CDISC format.	1-Oct-2018
19595	GSK	A randomised, placebo-controlled, double-blind, two period crossover study to characterise the exhaled nitric oxide time profile as a biomarker of airway inflammation in adult asthma patients following repeat administration of inhaled Fluticasone Furoate (FF)/ Vilanterol (VI) 100/25 mcg.	fluticasone furoate/vilanterol	201499	Asthma	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=201499	http://clinicaltrials.gov/show/NCT02712047		Y	Y	Y	Y	Y	Y	Y		1-Oct-2018
19596	GSK	An open label, six-period cross-over, single and repeat dose study to determine the pharmacokinetics of fluticasone furoate and GSK961081 when administered alone, in combination, or concurrently via the ELLIPTA	batefenterol	201958	Pulmonary Disease, Chronic Obstructive	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=201958	http://clinicaltrials.gov/show/NCT02666287	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-003432-12	Y	Y	Y	Y	Y	Y	Y	This study is available in CDISC format.	1-Oct-2018
19597	GSK	An open-label study in healthy male subjects, to determine the excretion balance and pharmacokinetics of [14C]-GSK961081, administered as a single intravenous microtracer (concomitant with an inhaled non-radiolabelled dose) and a single oral dose	batefenterol	201003	Pulmonary Disease, Chronic Obstructive	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=201003	http://clinicaltrials.gov/show/NCT02663089	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-003442-98	Y	Y	Y	Y	Y	Y	Y	This study is available in CDISC format.	1-Oct-2018
19598	GSK	An Open Label, Randomized, Single Dose, Crossover study to determine the Pharmacokinetics of Three Tablet Formulations of GSK2798745 in Healthy Subjects	GSK2798745	204725	Heart failure, Congestive	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=204725	http://clinicaltrials.gov/show/NCT02925546		Y	Y	Y	Y	Y	Y	Y	This study is available in CDISC format.	1-Oct-2018
19599	GSK	A multicenter, open-label Phase I/II trial to evaluate the safety and activity of CPC-P501 protein formulated with the adjuvant AS15 as first-line treatment in patients with hormone-sensitive prostate cancer who show rising PSA	GSK560417A	102238	Neoplasms, Prostate	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=102238	http://clinicaltrials.gov/show/NCT00148928	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001669-16	Y	N	Y	Y	Y	Y	Y	Extension study 104634 was conducted. An annotated case report form is not available for this study. A blank case report form will be provided. The results are summarised with study 104634 on the GSK Study register.	1-Oct-2018
19600	GSK	A multicenter, open label phase I/II trial to evalute the safety and activity of CPC-P501 protein formulated with the adjuvant AS15 as first-line treatment in patients with hormone-sensitive prostate cancer who show rising PSA	GSK560417A	104634	Neoplasms, Prostate	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=102238	http://clinicaltrials.gov/show/NCT00148928	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001669-16	Y	N	Y	Y	Y	Y	Y	This is an extension to study 102238. An annotated case report form is not available for this study. A blank case report form will be provided. The results are summarised under study 102238 on the GSK Study register.	1-Oct-2018
19601	GSK	A multicenter Phase I open-label dose-escalation vaccine trial of dHER2 protein with AS15 adjuvant in HER2-overexpressing patients with high-risk breast cancer	SB719125	719125/002	Neoplasms, Breast	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=719125/002	http://clinicaltrials.gov/show/NCT00058526		Y	N	Y	Y	Y	Y	Y	A follow-on study 104482 was conducted. An annotated case report form is not available for this study. A blank case report form will be provided. This study has limited subjects enrolled. The results are summarised with study 104482 on the GSK Study Register.	1-Oct-2018
19602	GSK	A multicenter Phase I open-label dose-escalation vaccine trial of dHER2 prot. with AS15 adj. in HER2-overexpressing patients with high-risk breast cancer.	SB719125	104482	Neoplasms, Breast	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=719125/002	http://clinicaltrials.gov/show/NCT00058526		Y	N	Y	Y	Y	Y	Y	This is a follow-up study to 719125/002. The results are summarised under study 719125/002 on the GSK Study Register. An annotated case report form is not available for this study. A blank case report form will be provided. This study has limited subjects enrolled.	1-Oct-2018
19603	GSK	Immunogenicity, safety and reactogenicity of GSK Biologicals’ Hib-MenCY-TT (MenHibrix®) vaccine 792014 compared to Merck & Co, Inc. Haemophilus b Conjugate Vaccine (Meningococcal Protein Conjugate) vaccine in healthy infants and toddlers	Haemophilus influenzae Type b, Meningococcal C and Y-Tetanus Toxoid Conjugate Vaccine	112931	Haemophilus influenzae type b; Neisseria Meningitidis	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=112931	http://clinicaltrials.gov/show/NCT01978093	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003459-39	Y	Y	Y	Y	Y	Y	Y		1-Oct-2018
19604	GSK	A long-term open, age-stratified follow-up of the immunogenicity and safety of an HPV-16/18 VLP vaccine in healthy female subjects vaccinated in study HPV-014	Human Papillomavirus Types 16 and 18 Vaccine	105879	Infections, Papillomavirus	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=103514	http://clinicaltrials.gov/show/NCT00196937		Y	N	Y	Y	Y	Y	Y	This is an extension study to 103514. The results are summarised under study 103514 with studies 105880, 105881 and 105882 on the GSK Study Register. An annotated case report form is not available for this study. A blank case report form will be provided.	1-Oct-2018
19605	GSK	A long-term open, age-stratified follow-up of the immunogenicity and safety of GlaxoSmithKline Biologicals'HPV-16/18 L1 AS04 vaccine in healthy female subjects vaccinated in study HPV-014	Human Papillomavirus Types 16 and 18 Vaccine	105882	Infections, Papillomavirus	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=103514	http://clinicaltrials.gov/show/NCT00196937		Y	Y	Y	Y	Y	Y	Y	This is an extension study to 103514. The results are summarised under study 103514 with studies 105879, 105880 and 105881 on the GSK Study Register.	1-Oct-2018
19606	GSK	An observer-blind study to evaluate the safety, reactogenicity and immunogenicity of GSK Biologicals’ Non-typeable Haemophilus influenzae (NTHi) investigational vaccine (GSK2838497A) in current and former smokers	GSK2838497A	116647	Respiratory Disorders	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=116647	http://clinicaltrials.gov/show/NCT01678677	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001238-32	Y	Y	Y	Y	Y	Y	Y		1-Oct-2018
19607	GSK	An observer-blind study to evaluate the safety, reactogenicity and immunogenicity of GSK Biologicals’ Non-typeable Haemophilus influenzae (NTHi) investigational vaccine (GSK2838497A) in healthy adults	GSK2838497A	116018	Respiratory Disorders	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=116018	http://clinicaltrials.gov/show/NCT01657526		Y	Y	Y	Y	Y	Y	Y		1-Oct-2018
19608	GSK	Immunogenicity and safety study of GlaxoSmithKline Biological's live attenuated measles mumps rubella varicella vaccine (PriorixTetra™) when co-administered with conjugated Meningococcal C vaccine (Meningitec®, Nuron Biotechs’ Vaccine) in healthy children	Combined Measles, Mumps, Rubella, Varicella Vaccine	115555	Measles; Mumps; Rubella; Varicella	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=115555	http://clinicaltrials.gov/show/NCT01506193	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001608-37	Y	Y	Y	Y	Y	Y	Y		1-Oct-2018
19610	GSK	Study of GSK2302024A Antigen-Specific Cancer Immunotherapeutic combined with standard neoadjuvant treatment in patients with WT1-positive primary invasive breast cancer	GSK2302024A	113172	Neoplasms, Breast	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=113172	http://clinicaltrials.gov/show/NCT01220128	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-019909-42	Y	Y	Y	Y	Y	Y	Y		1-Oct-2018
19611	ViiV	A Phase III, Randomized, Multicenter, Parallel-group, Non-inferiority Study Evaluating the Efficacy, Safety, and Tolerability of Switching to Dolutegravir Plus Rilpivirine From Current INI-, NNRTI-, or PI-based Antiretroviral Regimen in HIV-1-Infected Adults who are Virologically Suppressed	dolutegravir	201636	Infection, Human Immunodeficiency Virus	Phase 3	https://www.viiv-studyregister.com/study/19595	http://clinicaltrials.gov/show/NCT02429791	https://www.clinicaltrialsregister.eu/show/2014-005147-40	Y	Y	Y	Y	Y	Y	Y	A follow-on study 202094 was conducted. This study is still ongoing, however data related to the publication(s) is available. This study is available in CDISC format.	1-Oct-2018
19612	ViiV	A Phase III, Randomized, Multicenter, Parallel-group, Non-inferiority Study Evaluating the Efficacy, Safety, and Tolerability of Switching to Dolutegravir Plus Rilpivirine From Current INI-, NNRTI-, or PI-based Antiretroviral Regimen in HIV-1-Infected Adults who are Virologically Suppressed (SWORD-2)	dolutegravir	201637	Infection, Human Immunodeficiency Virus	Phase 3	https://www.viiv-studyregister.com/study/19596	http://clinicaltrials.gov/show/NCT02422797	https://www.clinicaltrialsregister.eu/show/2014-005148-16	Y	Y	Y	Y	Y	Y	Y	A follow-on study 202094 was conducted. This study is still ongoing, however data related to the publication(s) is available. This study is available in CDISC format.	1-Oct-2018
19613	ViiV	An Open-label Single-Center, 4-Period William’s Cross-Over Design Drug Interaction Trial to Determine the Effects of Sorbitol-Containing Solutions on Lamivudine Exposure Following Administration of Lamivudine Oral Solution in Healthy Adult Subjects	lamivudine	204857	Infection, Human Immunodeficiency Virus	Phase 4	https://www.viiv-studyregister.com/study/19607	http://clinicaltrials.gov/show/NCT02634073		Y	Y	Y	Y	Y	Y	Y		1-Oct-2018
19614	Novartis	A Randomized Phase III, Double-Blind, Placebo-Controlled Multicenter Trial of Everolimus in Combination With Trastuzumab and Paclitaxel, as First Line Therapy in Women With HER2 Positive Locally Advanced or Metastatic Breast Cancer	everolimus	CRAD001J2301	Breast Cancer	Phase 3	https://www.novctrd.com/ctrdweb/trialresult/trialresults/pdf?trialResultId=17258	https://www.clinicaltrials.gov/ct2/show/NCT00876395?term=CRAD001J2301&rank=1	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-006556-21	Y	Y	Y	Y	Y	Y	Y		1-Oct-2018
19615	Novartis	A Randomized Phase III, Double-blind, Placebo-controlled Multicenter Trial of Daily Everolimus in Combination With Trastuzumab and Vinorelbine, in Pretreated Women With HER2/Neu Over-expressing Locally Advanced or Metastatic Breast Cancer	everolimus	CRAD001W2301	HER2/Neu Over-expressing Locally Advanced Breast Cancer or Metastatic Breast Cancer	Phase 3	https://www.novctrd.com/ctrdweb/trialresult/trialresults/pdf?trialResultId=14989	https://www.clinicaltrials.gov/ct2/show/NCT01007942?term=CRAD001W2301&rank=1	https://www.clinicaltrialsregister.eu/ctr-search/search?query=CRAD001W2301	Y	Y	Y	Y	Y	Y	Y		1-Oct-2018
19621	GSK	Immunogenicity and safety study of GlaxoSmithKline Biologicals’ Infanrix hexa vaccine in healthy infants	Combined Diphtheria, Tetanus, Acellular Pertussis, Hepatitis B, Inactivated Polio, Haemophilus influenzae Type b Vaccine	103506	Acellular pertussis; Diphtheria; Haemophilus influenzae type b; Hepatitis B; Poliomyelitis; Tetanus	Phase 4	https://www.gsk-studyregister.com/en/trial-details/?id=103506	http://clinicaltrials.gov/show/NCT00753649	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003428-34	Y	Y	Y	Y	Y	Y	Y		1-Nov-2018
19622	GSK	An observer-blind study to evaluate the safety and immunogenicity of GSK Biologicals’ influenza vaccine(s) GSK2789869A administered in adults 65 years of age and older	GSK2789869A	200613	Influenza	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=200613	http://clinicaltrials.gov/show/NCT01949090		Y	Y	Y	Y	Y	Y	Y		1-Nov-2018
19623	GSK	An observer-blind study to evaluate the safety, reactogenicity and immunogenicity of GSK Biologicals’ Respiratory Syncytial Virus (RSV) investigational vaccine (GSK3003891A) in healthy men	GSK3003891A	116969	Infections, Respiratory Syncytial Virus	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=116969	http://clinicaltrials.gov/show/NCT01905215		Y	Y	Y	Y	Y	Y	Y		1-Nov-2018
19624	GSK	Immunogenicity: 3 consecutive lots of GSK Biologicals’ HPV-16/18 vaccine administered intramuscularly at 0,1,6 month schedule in healthy females aged 10–25 years and demonstrate non-inferiority of candidate HPV vaccine manufactured by modified production process	Human Papillomavirus Types 16 and 18 Vaccine	107481	Infections, Papillomavirus	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=580299/012	http://clinicaltrials.gov/show/NCT00337818		Y	N	Y	Y	Y	Y	Y	This is an extension study to 580299/012. The results are summarised under study 580299/012 (HPV-012) on the GSK Study Register with studies 107476 (M18), 107477 (M24) and 107479 (M36). An annotated case report form is not available for this study. A blank case report form will be provided.	1-Nov-2018
19625	GSK	Subject Understanding of the Risks Associated with ZYBAN®, WELLBUTRIN®, WELLBUTRIN SR®, and WELLBUTRIN XL®	bupropion	205913	Depressive Disorder, Major	Phase 4	https://www.gsk-studyregister.com/en/trial-details/?id=205913	http://clinicaltrials.gov/show/NCT03001440		Y	N	Y	Y	Y	Y	N	An annotated case report form, a blank case report form and a Reporting and Analysis Plan are not available for this study.	1-Nov-2018
19638	Astellas	A phase IIIb/IV randomized, controlled, open label, parallel group study to compare the efficacy of vancomycin therapy to extended duration fidaxomicin therapy in the sustained clinical cure of Clostridium difficile infection in an older population.	fidaxomicin	2819-MA-1002	Clostridium difficile infection	Phase 4	https://www.clinicaltrials.astellas.com/study/?pid=2819-MA-1002	https://clinicaltrials.gov/ct2/show/NCT02254967	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004619-31	Y	Y	Y	Y	Y	Y	Y		1-Dec-2018
19652	Eisai	A Multicenter, Randomized, Open-Label, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib (E7080) Versus Sorafenib in First-Line Treatment of Subjects With Unresectable Hepatocellular Carcinoma	lenvatinib	E7080-G000-304	Hepatocellular Carcinoma (HCC)	Phase 3		https://clinicaltrials.gov/ct2/show/NCT01761266	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002992-33	Y	Y	Y	Y	Y	Y	Y	No restrictions.	1-Nov-2018
19653	Eisai	Phase I/II Study of E7080 in Patients With Advanced Hepatocellular Carcinoma (HCC)	lenvatinib	E7080-J081-202	Hepatocellular Carcinoma (HCC)	Phase 1 / Phase 2		https://clinicaltrials.gov/ct2/show/NCT00946153		Y	Y	Y	Y	Y	Y	Y	No restrictions.	1-Nov-2018
19654	Eisai	A Double-blind, Placebo-controlled, Parallel-group Study With an Open-label Extension Phase to Evaluate the Efficacy and Safety of Perampanel (E2007) Administered as an Adjunctive Therapy in Subjects With Refractory Partial-onset Seizures	perampanel	E2007-J000-335	Partial-onset Seizures	Phase 3		https://clinicaltrials.gov/ct2/show/NCT01618695		N	N	N	N	Y	N	N	No restrictions.	1-Nov-2018
19655	Eisai	A Double-Blind, Placebo-Controlled, Dose-Escalation, Parallel-Group Study to Evaluate the Efficacy and Safety of E2007 (Perampanel) Given as Adjunctive Therapy in Subjects With Refractory Partial Seizures	perampanel	E2007-G000-304	Refractory Partial Seizures	Phase 3		https://clinicaltrials.gov/ct2/show/NCT00699972	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-006191-11	N	N	N	N	Y	N	N	No restrictions.	1-Nov-2018
19656	Eisai	A Double-Blind, Placebo-Controlled, Dose-Escalation, Parallel-Group Study to Evaluate the Efficacy and Safety of E2007 (Perampanel) Given as Adjunctive Therapy in Subjects With Refractory Partial Seizures	perampanel	E2007-G000-305	Refractory Partial Seizures	Phase 3		https://clinicaltrials.gov/ct2/show/NCT00699582	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-006168-31	N	N	N	N	Y	N	N	No restrictions.	1-Nov-2018
19657	Eisai	A Double-Blind, Placebo-Controlled, Dose-Escalation, Parallel-Group Study to Evaluate the Efficacy and Safety of E2007 (Perampanel) Given as Adjunctive Therapy in Subjects With Refractory Partial Seizures	perampanel	E2007-G000-306	Refractory Partial Seizures	Phase 3		https://clinicaltrials.gov/ct2/show/NCT00700310	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-006169-33	N	N	N	N	Y	N	N	No restrictions.	1-Nov-2018
19658	Eisai	A Double-Blind, Placebo-Controlled, Dose-Escalation, Parallel-Group Study of E2007 Given as Adjunctive Therapy in Patients With Refractory Partial Seizures	perampanel	E2007-A001-206	Epilepsy	Phase 2		https://clinicaltrials.gov/ct2/show/NCT00144690	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004199-18	N	N	N	N	Y	N	N	No restrictions.	1-Nov-2018
19659	Eisai	A Randomized, Double-blind, Placebo-controlled, Parallel-group Study With an Open-label Extension Phase to Evaluate the Effect of Perampanel (E2007) on Cognition, Growth, Safety, Tolerability, and Pharmacokinetics When Administered as an Adjunctive Therapy in Adolescents (12 to Less Than 18 Years of Age) With Inadequately Controlled Partial-onset Seizures	perampanel	E2007-G000-235	Epilepsy	Phase 2		https://clinicaltrials.gov/ct2/show/NCT01161524	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-018518-56	N	N	N	N	Y	N	N	No restrictions.	1-Nov-2018
19668	GSK	A Phase 3b, Open-Label, Randomized, Multicenter Study to Assess the Safety and Immunogenicity of GlaxoSmithKline Biologicals Meningococcal group B Vaccine When Administered Concomitantly with GlaxoSmithKline Biologicals MenACWY Conjugate Vaccine to Healthy Infants	GSK3536829A	205240	Infections, Meningococcal	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=205240	http://clinicaltrials.gov/show/NCT02106390	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-005117-44	Y	Y	Y	Y	Y	Y	Y		1-Dec-2018
19669	GSK	SCALE: A cross-sectional, multi-centric, epi study on HPV type distribution in adult women diagnosed with invasive cervical cancer	N/A	108288	Infections, Papillomavirus	N/A	https://www.gsk-studyregister.com/en/trial-details/?id=108288			Y	N	Y	Y	Y	Y	Y	An annotated case report form is not available for this study. A blank case report form will be provided. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Dec-2018
19670	GSK	Immunogenicity and safety study of GSK Biologicals’ Infanrix hexa at 2, 4 and 6 months of age in healthy infants	Combined Diphtheria, Tetanus, Acellular Pertussis Adsorbed, Hepatitis B (Recombinant), Inactivated Polio Vaccine; Haemophilus influenzae type b	117119	acellular pertussis; Diphtheria; Haemophilus influenzae type b; Hepatitis B; Poliomyelitis; Tetanus	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=117119	http://clinicaltrials.gov/show/NCT02096263	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004304-19	Y	Y	Y	Y	Y	Y	Y		1-Dec-2018
19671	GSK	A multi-center, randomized, active controlled, double-blind, parallel group comparison study and subsequent open-label study of GSK548470 in patients with compensated chronic hepatitis B untreated with nucleic acid analogue	tenofovir disoproxil fumarate	LOC115409	Hepatitis B, Chronic	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=115409	http://clinicaltrials.gov/show/NCT01480284		Y	Y	Y	Y	Y	Y	Y		1-Dec-2018
19672	GSK	An International, Multicentre, Randomised, Double-blind, Placebo-controlled, Two-parallel Group, Phase III Study to Evaluate the Efficacy and Safety of ARIXTRA (2.5mg subcutaneously) for the Treatment of Patients with Acute Symptomatic Isolated Superficial Thrombophlebitis of the Lower Limbs to prevent Thromboembolic Complications	fondaparinux sodium	ART108053	Thrombosis, Venous	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=ART108053	http://clinicaltrials.gov/show/NCT00443053	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004774-27	Y	Y	Y	Y	Y	Y	Y		1-Dec-2018
19673	GSK	A 24-week, Phase IIB, Randomized, Controlled, Parallel group, Multi-center Study to Evaluate the Safety and Efficacy of GSK1278863 in Subjects with Anemia Associated with Chronic Kidney Diseases who are not on Dialysis.	daprodustat	PHI113747	Anaemia	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=113747	http://clinicaltrials.gov/show/NCT01977573	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002681-39	Y	Y	Y	Y	Y	Y	Y	This study is available in CDISC format.	1-Dec-2018
19674	GSK	A Double-Blind, Randomized, Placebo-Controlled, Continuation Single Dose Escalation Study to Investigate the Safety, Tolerability and Pharmacokinetics of GSK2838232 with and without Ritonavir, and to Evaluate Different Formulations of GSK2838232, in Healthy Subjects	GSK2838232	200912	Infection, Human Immunodeficiency Virus	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=200912	http://clinicaltrials.gov/show/NCT02289482		Y	Y	Y	Y	Y	Y	Y		1-Dec-2018
19675	GSK	A Double Blind, Placebo Controlled, Single and Repeat Dose Escalation Study of GSK2838232 with and without Ritonavir for 8-11 days in Healthy Subjects	GSK2838232	200207	Infection, Human Immunodeficiency Virus	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=200207	http://clinicaltrials.gov/show/NCT02289495		Y	Y	Y	Y	Y	Y	Y		1-Dec-2018
19676	GSK	A Double-Blind (Sponsor Unblinded), Randomized, Placebo-Controlled, Continuation Single and Repeated Dose Escalation Study to Investigate the Safety, Tolerability and Pharmacokinetics of GSK2838232 with Ritonavir, in Healthy Subjects	GSK2838232	204953	Infection, Human Immunodeficiency Virus	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=204953	http://clinicaltrials.gov/show/NCT02795754		Y	N	Y	Y	Y	Y	Y	An annotated case report form is not available for this study. A blank case report form will be provided. This study is available in CDISC format.	1-Dec-2018
19677	GSK	A Double-Blind, Randomized, Placebo-Controlled, Single Dose Escalation First Time in Human Study to Investigate the Safety, Tolerability and Pharmacokinetics of GSK2838232 and to Evaluate the Effect of Food and Ritonavir on GSK2838232 in Healthy Subjects	GSK2838232	HMI116787	Infection, Human Immunodeficiency Virus	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=116787	http://clinicaltrials.gov/show/NCT01802918		Y	Y	Y	Y	Y	Y	Y		1-Dec-2018
19678	GSK	A Phase 1, Randomized, Placebo-Controlled, Double-Blind, Ascending Dose Escalating, 4 Period Crossover Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Food Effect of Single Doses of GSK3179106, a REarranged during Transfection (RET) Growth Factor Receptor Tyrosine Kinase Inhibitor, in Normal Healthy Volunteers	GSK3179106	204729	Irritable Bowel Syndrome	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=204729	http://clinicaltrials.gov/show/NCT02727283		Y	Y	Y	Y	Y	Y	Y	This study is available in CDISC format.	1-Dec-2018
19679	GSK	A Phase I, 14 Day, Randomized, Double-Blind (sponsor unblinded), Placebo-Controlled, Repeat Dose, Ascending Cohort Study to Evaluate the Safety, Tolerability Pharmacokinetics, Gastrointestinal Transit Time and Pharmacodynamic biomarkers of GSK3179106, a REarranged during Transfection (RET) Growth Factor Receptor Tyrosine Kinase Inhibitor, in Normal Healthy Volunteers	GSK3179106	205181	Irritable Bowel Syndrome	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=205181	http://clinicaltrials.gov/show/NCT02798991		Y	N	Y	Y	Y	Y	Y	An annotated case report form is not available for this study. A blank case report form will be provided. This study is available in CDISC format.	1-Dec-2018
19680	GSK	A randomized, double-blind, placebo-controlled, dose ascending, 3-cohort parallel group study to measure the systemic cortisol profile and evaluate the safety, tolerability and pharmacokinetics of GW870086X, administered as single doses (12mg and 15mg), and repeat doses over 3 days (6mg, 12mg and 15mg) in healthy male subjects	GW870086	SIG110405	Asthma	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=SIG110405	http://clinicaltrials.gov/show/NCT00549497		Y	Y	Y	Y	Y	Y	Y		1-Dec-2018
19681	GSK	A single center, double-blind, randomized, placebo-controlled, parallel, single and repeat, dose-ascending study to evaluate the safety, tolerability and pharmacokinetics of GSK2269557 administered via the ELLIPTA™ dry powder inhaler to healthy Japanese subjects	nemiralisib	205759	Pulmonary Disease, Chronic Obstructive	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=205759	http://clinicaltrials.gov/show/NCT02972905		Y	Y	Y	Y	Y	Y	Y		1-Dec-2018
19682	GSK	Study 203120: A Randomized, Blinded, Vehicle-Controlled, Dose-Finding Study of GSK2894512 Cream for the Treatment of Plaque Psoriasis	tapinarof	203120	Psoriasis	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=203120	http://clinicaltrials.gov/show/NCT02564042		Y	Y	Y	Y	Y	Y	Y	GSK has divested GSK2894512 and the associated data to Dermavant, and is no longer able to share the data associated with these studies.	1-Dec-2018
19683	GSK	An Open Label Study to Evaluate the Pharmacokinetics of Fluticasone Furoate /Umeclidinium Bromide/Vilanterol (100/62.5/25 mcg) after Single and Repeat Dose Administration from a Dry Powder Inhaler in Healthy Chinese Subjects	fluticasone furoate/vilanterol/umeclidinium bromide	200558	Pulmonary Disease, Chronic Obstructive	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=200558	http://clinicaltrials.gov/show/NCT02837380		N	Y	Y	Y	Y	Y	Y	An analysis-ready dataset is not available for this study. This study is available in CDISC format.	1-Dec-2018
19684	GSK	MEA115666: A multi-centre, open-label, long term safety study of mepolizumab in asthmatic subjects who participated in the MEA112997 trial	mepolizumab	MEA115666	Asthma	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=115666	http://clinicaltrials.gov/show/NCT01691859	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001643-51	Y	Y	Y	Y	Y	Y	Y	This is a follow-up study to MEA112997. This study is available in CDISC format.	1-Dec-2018
19685	Novartis	A Multicentre, Randomized, Double-blind, Placebo Controlled, Parallel-group Study in Children With Inadequately Controlled Partial Onset Seizures to Investigate Efficacy, Safety and Tolerability of TRI476 (Oxcarbazepine) as Adjunctive Therapy	oxcarbazepine	CTRI476B1301	Partial Onset Seizures	Phase 2/3	https://www.novctrd.com/ctrdweb/trialresult/trialresults/pdf?trialResultId=10103	https://www.clinicaltrials.gov/ct2/show/NCT00975715?term=CTRI476B1301&rank=2	https://www.clinicaltrialsregister.eu/ctr-search/search?query=CTRI476B1301	Y	Y	Y	Y	Y	Y	Y		1-Dec-2018
19686	Novartis	A 12 Month, Multi-center, Randomized, Open-label Non-inferiority Study Comparing Safety and Efficacy of Concentration-controlled Everolimus With Low Dose Tacrolimus to Mycophenolate Mofetil With Standard Dose Tacrolimus in de Novo Renal Transplant Recipients	everolimus	CRAD001AUS92	Kidney Transplantation	Phase 3	https://www.novctrd.com/ctrdweb/trialresult/trialresults/pdf?trialResultId=11223	https://www.clinicaltrials.gov/ct2/show/NCT01025817?term=CRAD001AUS92&rank=1		Y	Y	Y	Y	Y	Y	Y		1-Dec-2018
19687	Novartis	A 24-month, multi-center, open-label, randomized, controlled trial to investigate efficacy, safety and evolution of cardiovascular parameters in de novo renal transplant recipients after early calcineurin inhibitor to everolimus conversion.	everolimus	CRAD001A2429	Kidney Transplantation	Phase 3	https://www.novctrd.com/ctrdweb/trialresult/trialresults/pdf?trialResultId=14245	https://www.clinicaltrials.gov/ct2/show/NCT01114529?term=CRAD001A2429&rank=1	https://www.clinicaltrialsregister.eu/ctr-search/search?query=CRAD001A2429	Y	Y	Y	Y	Y	Y	Y		1-Dec-2018
19688	Novartis	A phase III, randomized, double-blind, placebo-controlled multicenter study of subcutaneous secukinumab (150 mg) in pre-filled syringe, with or without loading regimen, to demonstrate efficacy, safety and tolerability up to 2 years in patients with active psoriatic arthritis (FUTURE 4)	secukinumab	CAIN457F2336	Psoriatic arthritis	Phase 3	https://www.novctrd.com/ctrdweb/trialresult/trialresults/pdf?trialResultId=17261	https://www.clinicaltrials.gov/ct2/show/NCT02294227?term=CAIN457F2336&rank=1	https://www.clinicaltrialsregister.eu/ctr-search/search?query=CAIN457F2336	Y	Y	Y	Y	Y	Y	Y		1-Dec-2018
19695	ViiV	A Phase 1, Open Label, Single Sequence, Three Period Study to Evaluate the Single Dose Pharmacokinetics of GSK1349572 100mg versus 50mg and the Effect of Efavirenz 600mg Once Daily on the Pharmacokinetics, Safety and Tolerability of GSK1349572 50mg Once Daily in Healthy Adult Subjects (ING114005)	dolutegravir	ING114005	Infections, Human Immunodeficiency Virus and Herpesviridae	Phase 1	https://www.viiv-studyregister.com/study/19541	http://clinicaltrials.gov/show/NCT01098526		Y	Y	Y	Y	Y	Y	Y		1-Dec-2018
19696	ViiV	An Open-label, Randomized, Two-way Crossover, Single dose, Pivotal Bioequivalence Study of a Fixed-dose Combination of Dolutegravir and Rilpivirine in Healthy Volunteers	dolutegravir/rilpivirine	201676	Infection, Human Immunodeficiency Virus	Phase 1	https://www.viiv-studyregister.com/study/19598	http://clinicaltrials.gov/show/NCT02741557		Y	Y	Y	Y	Y	Y	Y	This study is available in CDISC format.	1-Dec-2018
19758	GSK	An open-label, randomised, single-dose, two-period cross-over study to evaluate bioequivalence of GR37547 ciprofloxacin 500 mg tablet versus ciprofloxacin 500 mg tablet reference product in healthy adult participants under fasting conditions	ciprofloxacin	205730	Infections, Bacterial	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=205730	http://clinicaltrials.gov/show/NCT03150082		Y	N	Y	Y	Y	Y	Y	An annotated case report form is not available for this study. A blank case report form will be provided. The Reporting Analysis Plan is provided as an appendix to the Protocol and will not be provided separately.	1-Jan-2019
19759	GSK	A Phase I Randomized, Placebo-Controlled, Single-Blind, Multiple-Dose, Dose-Escalation Clinical Study to Assess the Safety and Pharmacokinetics of SRT2104 in Normal Healthy Male Volunteers	GSK2245840	SIR113259	Diabetes Mellitus, Type 2	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=113259	http://clinicaltrials.gov/show/NCT00933530		N	Y	Y	Y	Y	Y	Y	An analysis-ready dataset is not available for this study.	1-Jan-2019
19760	GSK	A Phase I Study to Evaluate the Intravenous Pharmacokinetics and the Absolute Bioavailability of SRT2104 given as a 250mg Oral Suspension in Healthy Subjects	GSK2245840	SIR113260	Diabetes Mellitus, Type 2	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=113260	http://clinicaltrials.gov/show/NCT00937872		N	Y	Y	Y	Y	Y	Y	An analysis-ready dataset is not available for this study.	1-Jan-2019
19761	GSK	A randomized double-blind (sponsor unblind) placebo controlled study in healthy subjects to evaluate: safety, tolerability, pharmacokinetics, and pharmacodynamics of the repeat doses of GSK2881078, the Selective Androgen Receptor Modulator with an open label dosing arm to evaluate the effect of CYP3A4 inhibition on pharmacokinetics of GSK2881078	GSK2881078	204699	Cachexia	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=204699	http://clinicaltrials.gov/show/NCT02567773		Y	Y	Y	Y	Y	Y	Y	The data is available in CDISC format.	1-Jan-2019
19762	GSK	Clinical assessment of fluticasone propionate/ salmeterol xinafoate HFA MDI in 6-month to 4-year-old Japanese patients with bronchial asthma	fluticasone propionate/salmeterol	200860	Asthma	Phase 4	https://www.gsk-studyregister.com/en/trial-details/?id=200860	http://clinicaltrials.gov/show/NCT02113436		Y	Y	Y	Y	Y	Y	Y		1-Jan-2019
19763	GSK	An open-label study of the correct use and ease of use of placebo ELLIPTA dry powder inhaler in subjects with chronic obstructive pulmonary disease (COPD)	fluticasone furoate/vilanterol	201071	Pulmonary Disease, Chronic Obstructive	Phase 4	https://www.gsk-studyregister.com/en/trial-details/?id=201071	http://clinicaltrials.gov/show/NCT02586493		Y	Y	Y	Y	Y	Y	Y		1-Jan-2019
19764	GSK	An open-label study of the ease of use and correct use of placebo ELLIPTA dry powder inhaler in subjects with asthma	fluticasone furoate/vilanterol	201594	Asthma	Phase 4	https://www.gsk-studyregister.com/en/trial-details/?id=201594	http://clinicaltrials.gov/show/NCT02586506		Y	Y	Y	Y	Y	Y	Y		1-Jan-2019
19766	GSK	GSK1550188 A 52 week study of belimumab versus placebo in the treatment of subjects with systemic lupus erythematosus (SLE) located in Northeast Asia	belimumab	BEL113750	Systemic Lupus Erythematosus	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=113750	http://clinicaltrials.gov/show/NCT01345253		Y	Y	Y	Y	Y	Y	Y	A follow-on study BEL114333 was conducted. The data is available in CDISC format.	1-Jan-2019
19767	GSK	A Multi-Center, Continuation Trial of Belimumab (HGS1006, LymphoStat-B™), a Fully Human Monoclonal Anti-BLyS Antibody, in Subjects with Systemic Lupus Erythematosus (SLE) who Completed the Phase 3 Protocol HGS1006-C1056 in the United States	belimumab	BEL112233	Systemic Lupus Erythematosus	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=112233	http://clinicaltrials.gov/show/NCT00724867		Y	Y	Y	Y	Y	Y	Y	This is a follow-up study to HGS1006-C1056. The data is available in CDISC format.	1-Jan-2019
19768	GSK	A multicentric, post-marketing surveillance to monitor the safety and reactogenicity of GlaxoSmithKline Biologicals Hepatitis A vaccine administered in Korean population.	Hepatitis A Vaccine, Inactivated	104147	Hepatitis A	Phase 4	https://www.gsk-studyregister.com/en/trial-details/?id=104147	http://clinicaltrials.gov/show/NCT00237991		Y	N	Y	Y	Y	Y	Y	An annotated case report form is not available for this study. A blank case report form will be provided.	1-Jan-2019
19769	GSK	A double-blind, controlled, randomised, phase I dose-range study to assess the safety and imunogenicity of an HPV-VLP vaccine against Human Papillomavirus Types 31 and 45 evaluated in Healthy Adult Female Volunteers in a 0, 1, 6 months schedule	GSK568893A	102114	Infections, Papillomavirus	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=102114			Y	N	Y	Y	Y	Y	Y	An annotated case report form is not available for this study. A blank case report form will be provided. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Jan-2019
19770	GSK	Safety, reactogenicity & immunogenicity of GSK Biologicals’ pneumococcal vaccine 2189242A when co-administered with DTPa-HBV-IPV/Hib vaccine in healthy infants	GSK2189242A	113994	Infections, Streptococcal	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=113994	http://clinicaltrials.gov/show/NCT01204658	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-019730-27	Y	Y	Y	Y	Y	Y	Y		1-Jan-2019
19790	Novartis	A Randomized, Double-blind, Multicenter, Placebo-controlled Study of Adjuvant Lapatinib (GW572016) in Women With Early-Stage ErbB2 Overexpressing Breast Cancer	lapatinib	EGF105485	Neoplasms, Breast	Phase 3		https://www.clinicaltrials.gov/ct2/show/NCT00374322?term=EGF105485&rank=1	https://www.clinicaltrialsregister.eu/ctr-search/search?query=EGF105485	Y	Y	Y	Y	Y	Y	Y		1-Feb-2019
19797	ViiV	AN OPEN-LABEL, MULTICENTER, MULTIPLE-DOSE PHARMACOKINETIC, SAFETY AND EFFICACY TRIAL OF MARAVIROC IN COMBINATION WITH OPTIMIZED BACKGROUND THERAPY FOR THE TREATMENT OF ANTIRETROVIRAL-EXPERIENCED CCR5-TROPIC HIV-1 INFECTED CHILDREN 2-<18 YEARS OF AGE	maraviroc	A4001110	Infection, Human Immunodeficiency Virus	Phase 2	https://www.viiv-studyregister.com/study/19684	http://clinicaltrials.gov/show/NCT02625207		Y	N	Y	Y	Y	Y	Y	An annotated case report form and a blank case report form are not available for this study.	1-Feb-2019
19798	ViiV	A Phase 1, Open-label, Parallel-group Study To Assess The Effect Of Cyp3a5 Genotype On The Pharmacokinetics Of Maraviroc And Cyp3a5-derived Metabolites With And Without Darunavir/Cobicistat In African-american And Caucasian Healthy Volunteers	maraviroc	A4001031	Infection, Human Immunodeficiency Virus	Phase 1	https://www.viiv-studyregister.com/study/19676	http://clinicaltrials.gov/show/NCT00791700	https://www.clinicaltrialsregister.eu/ctr-search/search?query=/2008-006873-33	Y	Y	Y	Y	Y	Y	Y	This study is still ongoing, however data related to the publication(s) is available.	1-Feb-2019
19799	GSK	A long term, randomised, double blind, placebo-controlled study to determine the effect of albiglutide, when added to standard blood glucose lowering therapies, on major cardiovascular events in patients with Type 2 diabetes mellitus	albiglutide	GLP116174	Diabetes Mellitus, Type 2	Phase 4	https://www.gsk-studyregister.com/en/trial-details/?id=116174	http://clinicaltrials.gov/show/NCT02465515	https://www.clinicaltrialsregister.eu/ctr-search/search?query=/2014-001824-32	Y	N	Y	Y	Y	Y	Y	This study is available in CDISC Format. An annotated case report form is not available. A blank case report form will be provided. There is a Publication Steering Committee for this study. Data for some subjects is not available due to lack of consent.	1-Feb-2019
19800	GSK	A Phase 3, Multi-Center, Multinational, Randomized, Double-Blind, Study to Evaluate the Efficacy and Safety of Belimumab (HGS1006) in Combination with Azathioprine for the Maintenance of Remission in Wegener's Granulomatosis and Microscopic Polyangiitis	belimumab	BEL115466	Vasculitis	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=115466	http://clinicaltrials.gov/show/NCT01663623	https://www.clinicaltrialsregister.eu/ctr-search/search?query=/2011-004569-33	Y	Y	Y	Y	Y	Y	Y	The informed consent for this study only allows for further research into the medicine and disease studied.	1-Feb-2019
19801	GSK	Epidemiology study of malariometric determinants in selected Post-Approval Programme study sites in sub-Saharan Western Africa	RTS,S Vaccine	200187	Malaria	N/A	https://www.gsk-studyregister.com/en/trial-details/?id=200187	http://clinicaltrials.gov/show/NCT01954264		Y	N	Y	Y	Y	Y	Y	An annotated case report form is not available for this study. A blank case report form will be provided.	1-Feb-2019
19802	GSK	A Phase 3b, Open Label, Controlled, Multi-Center, Extension Study to Assess the Persistence of Bactericidal Activity at 4 to 7.5 Years After Two Dose Primary Series of GlaxoSmithKline Biologicals Meningococcal B Recombinant Vaccine and the Response to a Third Dose in Adolescents and Young Adult Subjects who Previously Participated in Parent Studies V72_41 (NCT01423084) and V72P10 (NCT00661713), Compared to Naïve Healthy Controls	GSK3536829A	205218	Infections, Meningococcal	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=205218	http://clinicaltrials.gov/show/NCT02446743	https://www.clinicaltrialsregister.eu/ctr-search/search?query=/2017-000093-11	Y	Y	Y	Y	Y	Y	Y	This is an extension study to V72_41 (NCT01423084) and V72P10 (NCT00661713) (Sponsor: Novartis)	1-Feb-2019
19803	GSK	Safety study of GSK Biologicals’ human papillomavirus vaccine (GSK-580299) in healthy female control subjects from the primary NCT00294047 study	Human Papillomavirus Types 16 and 18 Vaccine	113618	Infections, Papillomavirus	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=113618	http://clinicaltrials.gov/show/NCT01249365	https://www.clinicaltrialsregister.eu/ctr-search/search?query=/2010-020227-48	Y	Y	Y	Y	Y	Y	Y	This is a follow-up study to 104820.	1-Feb-2019
19804	GSK	A study to evaluate the safety, reactogenicity and immunogenicity of the pneumococcal protein PhtD vaccine without or with adjuvant, administered at 2 different concentrations according to a 0-2 month schedule, in healthy adults	GSK560410A	100417	Infections, Streptococcal	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=100417	http://clinicaltrials.gov/show/NCT01767402		Y	N	Y	Y	Y	Y	Y	An annotated case report form is not available for this study. A blank case report form will be provided.	1-Feb-2019
19805	GSK	A Study to Evaluate the Safety, Reactogenicity & Immunogenicity of the GSK Biologicals Candidate Pneumococcal Vaccine Without or With Adjuvant, Administered at 2 Different Concentrations, in Healthy Elderly Subjects	SB513026	100409	Infections, Streptococcal	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=100409	http://clinicaltrials.gov/show/NCT00307528		Y	N	Y	Y	Y	Y	Y	Follow-on studies 100463 and 100464 were conducted. An annotated case report form is not available for this study. A blank case report form will be provided.	1-Feb-2019
19806	GSK	A phase I-II, randomized, controlled, single-blind study to evaluate the safety, reactogenicity and immunogenicity of the pneumococcal protein PhtD vaccine without or with adjuvant (AlPO4 or AS02V), administered at 2 differrent concentrations according to a 0-2 month schedule, in healthy elderly subjects	SB513026	100463	Infections, Streptococcal	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=100463	http://clinicaltrials.gov/show/NCT00307528		Y	N	Y	Y	Y	Y	Y	This is a follow-up study to 100409. A follow-on study 100464 was conducted. An annotated case report form is not available for this study. A blank case report form will be provided.	1-Feb-2019
19807	GSK	A phase I-II, randomized, controlled, single-blind study to evaluate the safety, reactogenicity and immunogenicity of the pneumococcal protein PhtD vaccine without or with adjuvant (AlPO4 or AS02V), administered at 2 different concentrations according to a 0-2 month schedule, in healthy elderly subjects	SB513026	100464	Infections, Streptococcal	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=100464	http://clinicaltrials.gov/show/NCT00307528		Y	N	Y	Y	Y	Y	Y	This is a follow-up study to 100409 and 100463. An annotated case report form is not available for this study. A blank case report form will be provided.	1-Feb-2019
19808	GSK	A bridging study to evaluate the safety and immunogenicity of GSK Biologicals’ candidate vaccines RTS,S/AS02D (0.5 mL dose) and RTS,S/AS02A (0.25 mL dose) administered according to a 0, 1, 2 month vaccination schedule in children aged 3 to 5 years living in a malaria-endemic region of Mozambique.	RTS,S Vaccine	257049/034	Malaria	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=257049/034	http://clinicaltrials.gov/show/NCT00197067		Y	N	Y	Y	Y	Y	Y	An annotated case report form is not available for this study. A blank case report form will be provided.	1-Feb-2019
19809	GSK	A Phase IIb randomized, double-blind, controlled study of the safety, immunogenicity and proof-of-concept of RTS,S/AS02A, and RTS,S/AS01B, two candidate malaria vaccines in malaria-experienced adults living in Western Kenya.	RTS,S Vaccine	104743	Malaria	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=104743	http://clinicaltrials.gov/show/NCT00197054		Y	N	Y	Y	Y	Y	Y	An annotated case report form is not available for this study. A blank case report form will be provided.	1-Feb-2019
19810	GSK	A phase 2, multi-centre, randomised, double-masked, placebo-controlled, parallel-group study to investigate the safety, tolerability, efficacy, pharmacokinetics and pharmacodynamics of GSK933776 in adult patients with geographic atrophy (GA) secondary to age-related macular degeneration (AMD)	GSK933776	BAM114341	Atrophy, Geographic	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=114341	http://clinicaltrials.gov/show/NCT01342926		Y	Y	Y	Y	Y	Y	Y		1-Feb-2019
19811	GSK	A two-part, randomised, placebo-controlled study to investigate the safety, tolerability, pharmacokinetics and pharmacodynamicsof single doses of inhaled GSK1995057 in healthy subjects	GSK1995057	TFR116236	Respiratory Disorders	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=116236	http://clinicaltrials.gov/show/NCT01587807	https://www.clinicaltrialsregister.eu/ctr-search/search?query=/2011-005245-13	Y	Y	Y	Y	Y	Y	Y		1-Feb-2019
19812	GSK	A Randomized, Double-blind, Sponsor un-blinded, Placebo-controlled, Phase 2a Crossover Study to Evaluate the Effect of the TRPV4 Channel Blocker, GSK2798745, on Pulmonary Gas Transfer and Respiration in Patients with Congestive Heart Failure	GSK2798745	201881	Heart Failure	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=201881	http://clinicaltrials.gov/show/NCT02497937		Y	Y	Y	Y	Y	Y	Y		1-Feb-2019
19813	Novartis	A 2 Year, Double-blind, Randomized, Multicenter, Active-controlled Core Phase to Evaluate Safety & Efficacy of Daily Fingolimod vs Weekly Interferon β-1a im in Pediatric Patients With Multiple Sclerosis and 5 Year Fingolimod Extension Phase	fingolimod	CFTY720D2311 (core)	Multiple Sclerosis	Phase 3	https://www.novctrd.com/ctrdweb/trialresult/trialresults/pdf?trialResultId=17143	https://www.clinicaltrials.gov/ct2/show/NCT01892722?term=CFTY720D2311&rank=1	https://www.clinicaltrialsregister.eu/ctr-search/search?query=CFTY720D2311	Y	Y	Y	Y	Y	Y	Y		1-Mar-2019
19828	GSK	A Randomised, Double-Blind (Sponsor Unblind), Placebo-Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Immunogenicity of Single Ascending Doses of a Fully Humanized Anti-IL-7 Receptor α Monoclonal Antibody (GSK2618960) in Healthy Volunteers	GSK2618960	200902	Autoimmune Diseases	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=200902	http://clinicaltrials.gov/show/NCT02293161		Y	Y	Y	Y	Y	Y	Y		1-Mar-2019
19829	GSK	A Phase I, Randomized, Double-Blind (Sponsor Unblinded), Single-Center, Placebo-Controlled, Two-Part Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Ascending Single and Repeat Intravenous Doses of GSK3342830 in Healthy Adult Subjects	GSK3342830	204847	Infections, Bacterial	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=204847	http://clinicaltrials.gov/show/NCT02751424		Y	Y	Y	Y	Y	Y	Y	The data for this study is available in CDISC format.	1-Mar-2019
19831	GSK	A repeat-dose, open-label, parallel-group study to assess the pharmacokinetics of GSK1278863 and metabolites in normal subjects and subjects with impaired renal function	daprodustat	PHI115573	Anaemia	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=115573	http://clinicaltrials.gov/show/NCT01406340		Y	Y	Y	Y	Y	Y	Y	The data for this study is available in CDISC format.	1-Mar-2019
19832	GSK	A Single-Blind Study to Evaluate the Irritation Potential of Repeat Topical Applications of GSK1940029 Gel on the Intact Skin of Healthy Human Subjects and Acne Patients	GSK1940029	SCD117225	Acne Vulgaris	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=117225	http://clinicaltrials.gov/show/NCT01984801		Y	Y	Y	Y	Y	Y	Y	The data for this study is available in CDISC format.	1-Mar-2019
19833	GSK	A Randomized, Single-Blind, Dose-Rising Study to Evaluate the Safety, Tolerability and Preliminary Pharmacokinetics of Single and 14 Day Repeat Topical Applications of GSK1940029 Gel on the Intact Skin of Healthy Human Subjects	GSK1940029	SCD117226	Acne Vulgaris	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=117226	http://clinicaltrials.gov/show/NCT01938482		Y	Y	Y	Y	Y	Y	Y	The data for this study is available in CDISC format.	1-Mar-2019
19834	GSK	Phase I Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Doses of Topical GSK1278863 in Healthy Volunteers and Diabetic Patients, and Repeat Doses of GSK1278863 in Diabetic Patients for the Treatment of Diabetic Foot Ulcer	daprodustat	PWH115760	Wound Healing	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=115760	http://clinicaltrials.gov/show/NCT01831804		Y	Y	Y	Y	Y	Y	Y		1-Mar-2019
19835	GSK	A Randomized, Double-Blind, Double Dummy, Comparative, Multicenter Study to Assess the Incidence of Hemolysis, Safety, and Efficacy of Tafenoquine (SB-252263, WR238605) versus Primaquine in the Treatment of Subjects with Plasmodium vivax Malaria	tafenoquine	TAF116564	Malaria, Vivax	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=116564	http://clinicaltrials.gov/show/NCT02216123		Y	Y	Y	Y	Y	Y	Y	The data for this study is available in CDISC format.	1-Mar-2019
19836	GSK	Safety and immunogenicity study of 2 formulations of GSK Biologicals’ varicella vaccines given as a 2-dose course in the second year of life.	Varicella Vaccine	200147	Varicella	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=200147	http://clinicaltrials.gov/show/NCT02570126	https://www.clinicaltrialsregister.eu/ctr-search/search?query=/2013-003535-30	Y	Y	Y	Y	Y	Y	Y		1-Mar-2019
19837	GSK	A Phase 1, open label, non-randomized, single center study to evaluate the safety and immunogenicity of 1 booster vaccination with (GVGH Shigella sonnei 1790GAHB) vaccine administered intramuscularly in healthy adults previously primed with three doses of the same vaccine in study H03_01TP compared to 1 vaccination with (1790GAHB) administered intramuscularly either to subjects who received placebo in the H03_01TP study or naïve subjects who were not part of H03_01TP study	GSK3536852A	205905	Dysentery, Bacillary	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=205905	http://clinicaltrials.gov/show/NCT03089879		Y	Y	Y	Y	Y	Y	Y	This is a follow-up study to H03_01TP.	1-Mar-2019
19838	GSK	Immunogenicity and safety study of GSK Biologicals’ combined measles-mumps-rubella vaccine in subjects four to six years of age (209762)	Measles, Mumps, Rubella Vaccine	115158	Measles, Mumps, Rubella	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=115158	http://clinicaltrials.gov/show/NCT01621802	https://www.clinicaltrialsregister.eu/ctr-search/search?query=/2011-004638-32	Y	Y	Y	Y	Y	Y	Y		1-Mar-2019
19839	GSK	Immunogenicity and safety of the diphtheria, tetanus, pertussis and inactivated poliovirus (DPT-IPV) vaccine Squarekids co-administered with GSK Biologicals’ human rotavirus (HRV) vaccine Rotarix (GSK444563) in healthy infants	Rotavirus Vaccine	114720	Infections, Rotavirus	Phase 4	https://www.gsk-studyregister.com/en/trial-details/?id=114720	http://clinicaltrials.gov/show/NCT02907216	https://www.clinicaltrialsregister.eu/ctr-search/search?query=/2014-005282-78	Y	Y	Y	Y	Y	Y	Y		1-Mar-2019
19840	GSK	An observer-blind study to evaluate immunogenicity and safety of GSK Biologicals’ Herpes Zoster vaccine GSK1437173A in adults 18 years of age or older with solid tumours receiving chemotherapy	Herpes Zoster subunit (HZ/su) vaccine	116427	Herpes Zoster	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=116427	http://clinicaltrials.gov/show/NCT01798056	https://www.clinicaltrialsregister.eu/ctr-search/search?query=/2012-002966-11	Y	Y	Y	Y	Y	Y	Y		1-Mar-2019
19841	GSK	Observer-blind study to evaluate immunogenicity and safety of GSK Biologicals’ Herpes Zoster subunit (HZ/su) vaccine GSK1437173A in adults 18 years of age or older with renal transplant	Herpes Zoster subunit (HZ/su) vaccine	116886	Herpes Zoster	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=116886	http://clinicaltrials.gov/show/NCT02058589	https://www.clinicaltrialsregister.eu/ctr-search/search?query=/2012-005059-18	Y	Y	Y	Y	Y	Y	Y		1-Mar-2019
19842	GSK	A double-blind, controlled, randomised, phase II study of the safety and immunogenicity of an HPV-VLP vaccine against Human Papillomavirus Types 16, 18, 31 and 45 evaluated in Healthy Adult Female Volunteers in a 0, 1, 6 months schedule	GSK568893A	107918	Infections, Papillomavirus	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=102115	http://clinicaltrials.gov/show/NCT00359619	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-003766-14	Y	N	Y	Y	Y	Y	Y	This is a follow-up study to 102115, 108052, 107919 and 107921. The results of this study are summarised under study 102115 on the GSK Study Register with studies 108052, 107919 and 107921. An annotated case report form is not available for this study. A blank case report form will be provided.	1-Mar-2019
19843	GSK	A double-blind, controlled, randomised, phase II study of the safety and immunogenicity of an HPV-VLP vaccine against Human Papillomavirus Types 16, 18, 31 and 45 evaluated in Healthy Adult Female Volunteers in a 0, 1, 6 months schedule	GSK568893A	107921	Infections, Papillomavirus	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=102115	http://clinicaltrials.gov/show/NCT00359619	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-003766-14	Y	N	Y	Y	Y	Y	Y	This is a follow-up study to 102115, 108052 and 107919. A follow-on study 107918 was conducted. The results of this study are summarised under study 102115 on the GSK Study Register with studies 108052, 107919 and 107918. An annotated case report form is not available for this study. A blank case report form will be provided.	1-Mar-2019
19844	GSK	A post-marketing surveillance (PMS) study to monitor the safety and reactogenicity of GlaxoSmithKline (GSK) Biologicals’ human papillomavirus (HPV) vaccine (Cervarix) in 3,000 healthy female Filipino subjects when administered according to the Prescribing Information from the age of 10 years onwards.	Human Papillomavirus Types 16 and 18 Vaccine	108160	Infections, Papillomavirus	Phase 4	https://www.gsk-studyregister.com/en/trial-details/?id=108160	http://clinicaltrials.gov/show/NCT00730847	https://www.clinicaltrialsregister.eu/ctr-search/search?query=/2017-000458-20	Y	N	Y	Y	Y	Y	Y	An annotated case report form is not available for this study. A blank case report form will be provided.	1-Mar-2019
19845	GSK	Safety Study of GSK Biologicals' Human Papillomavirus Vaccine (GSK-580299) in Healthy Female Control Subjects From the Primary NCT00294047 Study	Human Papillomavirus Types 16 and 18 Vaccine	113621	Infections, Papillomavirus	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=113621	http://clinicaltrials.gov/show/NCT01190189		Y	Y	Y	Y	Y	Y	Y	This is a follow-up study to 104820.	1-Mar-2019
19846	GSK	A Randomized, Placebo-Controlled, Double-Blind (Sponsor Unblinded) Study to Investigate Protective Effects of GSK1278863 on Eccentric Exercise Induced Muscle Damage in Healthy Male Volunteers	daprodustat	200884	Tendon Injuries	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=200884	http://clinicaltrials.gov/show/NCT02231190		Y	Y	Y	Y	Y	Y	Y		1-Mar-2019
19847	Novartis	A 24 Month, Multicenter, Randomized, Open-label Safety and Efficacy Study of Concentration-controlled Everolimus With Reduced Calcineurin Inhibitor vs Mycophenolate With Standard Calcineurin Inhibitor in de Novo Renal Transplantation	everolimus	CRAD001A2433	Kidney Transplantation	Phase 4	https://www.novctrd.com/ctrdweb/trialresult/trialresults/pdf?trialResultId=17233	https://www.clinicaltrials.gov/ct2/show/NCT01950819?term=CRAD001A2433&rank=1	https://www.clinicaltrialsregister.eu/ctr-search/search?query=CRAD001A2433	Y	Y	Y	Y	Y	Y	Y		1-Apr-2019
19878	GSK	204980: An open-label study to evaluate the correct use of placebo ELLIPTA™ dry powder inhaler (DPI) compared to placebo metered dose inhalers (MDI) in subjects with moderate persistent asthma	fluticasone furoate/vilanterol	204980	Asthma	Phase 4	https://www.gsk-studyregister.com/en/trial-details/?id=204980	http://clinicaltrials.gov/show/NCT02794480		Y	Y	Y	Y	Y	Y	Y		1-Apr-2019
19879	GSK	A Multi-Center, Open-Label, Continuation Trial LymphoStat-B™ Antibody (Monoclonal Anti-BLyS Antibody) in Subjects With Systemic Lupus Erythematosus (SLE) who Completed the Phase 2 Protocol LBSL02	belimumab	BEL112626	Systemic Lupus Erythematosus	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=112626	http://clinicaltrials.gov/show/NCT00583362		Y	Y	Y	Y	Y	Y	Y	This study is available in CDISC format.	1-Apr-2019
19880	GSK	A Double-Blind, Placebo-Controlled, Dose-Escalation, First Time in Human Study to Assess the Safety, Tolerability and Pharmacokinetics of Single and Multiple Ascending Doses of GSK3389404 in Healthy Subjects	GSK3389404	202007	Hepatitis B	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=202007	http://clinicaltrials.gov/show/NCT02647281		Y	Y	Y	Y	Y	Y	Y	This study is available in CDISC format.	1-Apr-2019
19881	GSK	201832: A Randomised, Double-Blind, Double-Dummy, Crossover Comparison of Fluticasone Furoate/Vilanterol 100/25 mcg Once Daily Versus Fluticasone Propionate 250 mcg Twice Daily in Adolescent and Adult Subjects with Asthma and Exercise-Induced Bronchoconstriction	fluticasone furoate/vilanterol	201832	Asthma	Phase 4	https://www.gsk-studyregister.com/en/trial-details/?id=201832	http://clinicaltrials.gov/show/NCT02730351	https://www.clinicaltrialsregister.eu/ctr-search/search?query=/2017-001516-11	Y	Y	Y	Y	Y	Y	Y		1-Apr-2019
19882	GSK	Study 201012: A Dose-Finding Study of batefenterol (GSK961081) via Dry Powder Inhaler in Patients with COPD	batefenterol	201012	Pulmonary Disease, Chronic Obstructive	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=201012	http://clinicaltrials.gov/show/NCT02570165	https://www.clinicaltrialsregister.eu/ctr-search/search?query=/2015-001409-15	Y	Y	Y	Y	Y	Y	Y	This study is available in CDISC format.	1-Apr-2019
19883	GSK	A PHASE 1B, MULTI-CENTER, OPEN-LABEL, DOSE ESCALATION STUDY OF MAPATUMUMAB ([HGS1012], A FULLY-HUMAN MONOCLONAL ANTIBODY TO TRAIL-R1) IN COMBINATION WITH SORAFENIB AS A FIRST-LINE THERAPY IN SUBJECTS WITH ADVANCED HEPATOCELLULAR CARCINOMA	mapatumumab	200178	Carcinoma, Hepatocellular	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=200178			Y	Y	Y	Y	Y	Y	Y	A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Apr-2019
19884	GSK	A study to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of administering multiple oral doses of GSK1292263 alone and with atorvastatin	GSK1292263	GPR113779	Dyslipidaemias	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=113779	http://clinicaltrials.gov/show/NCT01218204		Y	Y	Y	Y	Y	Y	Y		1-Apr-2019
19885	GSK	Effects of SB-649868 and Alprazolam on the Neuroendocrine and Sympathetic Responses to Insulin-Induced Hypoglycaemia in Healthy Male Subjects	SB649868	EMI115268	Anxiety Disorders	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=115268			Y	N	Y	Y	Y	Y	Y	An annotated case report form is not available for this study. A blank case report form will be provided. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Apr-2019
19886	GSK	Gynaecological Follow-up of a Subset of HPV-015 Study Subjects	Human Papillomavirus Types 16 and 18 Vaccine	113617	Infections, Papillomavirus	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=113617	http://clinicaltrials.gov/show/NCT01190176	https://www.clinicaltrialsregister.eu/ctr-search/search?query=/2009-017282-35	Y	Y	Y	Y	Y	Y	Y	This is a follow-up study to 104820.	1-Apr-2019
19887	GSK	Consistency study of GSK Biologicals’ measles-mumps-rubella (MMR) vaccine (209762) (Priorix) comparing immunogenicity and safety to Merck & Co., Inc.’s MMR vaccine (M-M-R II), in healthy children 12 to 15 months of age	SB209762	115648	Measles, Mumps, Rubella	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=115648	http://clinicaltrials.gov/show/NCT01702428	https://www.clinicaltrialsregister.eu/ctr-search/search?query=/2011-004891-12	Y	Y	Y	Y	Y	Y	Y		1-Apr-2019
19888	Novartis	A Randomized Phase Lll Study of Imatinib Dose Optimization Compared With Nilotinib in Patients With Chronic Myelogenous Leukemia and Suboptimal Response to Standard-dose Imatinib	nilotinib	CAMN107A2404	Chronic Myelogenous Leukemia	Phase 3	https://www.novctrd.com/ctrdweb/trialresult/trialresults/pdf?trialResultId=13949	https://www.clinicaltrials.gov/ct2/show/NCT00802841?term=CAMN107A2404&rank=1	https://www.clinicaltrialsregister.eu/ctr-search/search?query=CAMN107A2404	Y	Y	Y	Y	Y	Y	Y		1-May-2019
19889	ViiV	A MULTICENTER, RANDOMIZED, DOUBLE BLIND, COMPARATIVE TRIAL OF MARAVIROC + DARUNAVIR/RITONAVIR VERSUS EMTRICITABINE/TENOFOVIR +DARUNAVIR/RITONAVIR FOR THE TREATMENT OF TREATMENT NAÏVE HIV INFECTED PATIENTS WITH CCR5 TROPIC HIV 1	maraviroc	A4001095	Infection, Human Immunodeficiency Virus	Phase 3	https://www.viiv-studyregister.com/study/19679	http://clinicaltrials.gov/show/NCT01345630	https://www.clinicaltrialsregister.eu/ctr-search/search?query=/2010-021785-30	Y	Y	Y	Y	Y	Y	Y		1-May-2019
19890	GSK	A Phase I, Randomized, Placebo-Controlled, Double-Blind (sponsor unblind), Three Part Study to Evaluate the Safety, Tolerability, Preliminary PK and PD of Single and Repeat Oral Doses of GSK3008356 in Healthy Subjects and Obese Subjects	GSK3008356	204856	Healthy Volunteers	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=204856	http://clinicaltrials.gov/show/NCT02742766		Y	N	Y	Y	Y	Y	Y	An annotated case report form is not available for this study. A blank case report form will be provided. The data for this study is available in CDISC format.	1-May-2019
19892	GSK	A single-centre, double-blind (sponsor open), placebo controlled two part study to evaluate the safety, tolerability and pharmacokinetics of single and repeat doses of GSK2292767 as a dry powder in healthy participants who smoke cigarettes	GSK2292767	202062	Asthma	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=202062	http://clinicaltrials.gov/show/NCT03045887	https://www.clinicaltrialsregister.eu/ctr-search/search?query=/2016-003188-21	Y	N	Y	Y	Y	Y	Y	An annotated case report form is not available for this study. A blank case report form will be provided.	1-May-2019
19893	GSK	A randomized, double-blind, placebo controlled study to evaluate the safety, tolerability and clinical effect of oral danirixin (GSK1325756) in the treatment of healthy adults with acute, uncomplicated influenza (201682)	danirixin	201682	Virus Diseases	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=201682	http://clinicaltrials.gov/show/NCT02469298		Y	Y	Y	Y	Y	Y	Y		1-May-2019
19895	GSK	A Repeat-dose Study in Subjects with Type 2 Diabetes Mellitus to Assess the Efficacy, Safety, Tolerability and Pharmacodynamics, of Albiglutide Liquid Drug Product	albiglutide	200952	Diabetes Mellitus, Type 2	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=200952	http://clinicaltrials.gov/show/NCT02683746		Y	N	Y	Y	Y	Y	Y	An annotated case report form is not available for this study. A blank case report form will be provided. The data for this study is available in CDISC format. Data for some subjects is not available due to lack of consent.	1-May-2019
19896	GSK	An open-label, single arm, repeat dose, multi-centre study to evaluate the use of a safety syringe for the subcutaneous administration of mepolizumab in subjects with severe eosinophilic asthma (Study 205667)	mepolizumab	205667	Asthma	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=205667	http://clinicaltrials.gov/show/NCT03021304	https://www.clinicaltrialsregister.eu/ctr-search/search?query=/2016-001831-10	Y	Y	Y	Y	Y	Y	Y	The data for this study is available in CDISC format.	1-May-2019
19897	GSK	A Phase 1b, multi-center, open-label, dose escalation study of GSK2256098 (FAK inhibitor) in combination with Trametinib (MEK inhibitor) in subjects with advanced solid tumors	GSK2256098; trametinib	FAK114746	Neoplasms	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=114746	http://clinicaltrials.gov/show/NCT01938443	https://www.clinicaltrialsregister.eu/ctr-search/search?query=/2013-000784-85	Y	Y	Y	Y	Y	Y	Y		1-May-2019
19898	GSK	Seroprevalence of Bordetella pertussis in adults in Hungary	GSK2647153A	BEP116804	Pertussis	N/A	https://www.gsk-studyregister.com/en/trial-details/?id=116804	http://clinicaltrials.gov/show/NCT02014519		Y	Y	Y	Y	Y	Y	Y		1-May-2019
19899	GSK	A Phase 1 Randomized, Observer Blind, Placebo Controlled, Dosage-Escalation Single Center Study to Evaluate the Safety and Immunogenicity of an RSV Fusion Glycoprotein (F) Subunit Vaccine in Healthy Adults	GSK3536853A	205219	Respiratory Syncytial Virus Infections	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=205219	http://clinicaltrials.gov/show/NCT02298179	https://www.clinicaltrialsregister.eu/ctr-search/search?query=/2014-000145-69	Y	Y	Y	Y	Y	Y	Y		1-May-2019
19900	GSK	An observer-blind study to evaluate the safety, reactogenicity and immunogenicity of the investigational GSK Biologicals’ GSK3277511A vaccine in adults.	GSK3277511A	201281	Respiratory Disorders	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=201281	http://clinicaltrials.gov/show/NCT02547974	https://www.clinicaltrialsregister.eu/ctr-search/search?query=/2015-000378-36	Y	Y	Y	Y	Y	Y	Y		1-May-2019
19907	Novartis	A 24-week Randomized Placebo-controlled, Double-blind Multi-center Clinical Trial Evaluating the Efficacy and Safety of Oral QTI571 as an add-on Therapy in the Treatment of Severe Pulmonary Arterial Hypertension: Imatinib in Pulmonary Arterial Hypertension, a Randomized, Efficacy Study (IMPRES)	imatinib mesilate	CQTI571A2301	Pulmonary Arterial Hypertension	Phase 3	https://www.novctrd.com/ctrdweb/trialresult/trialresults/pdf?trialResultId=8543	https://clinicaltrials.gov/ct2/show/NCT00902174	https://www.clinicaltrialsregister.eu/ctr-search/search?query=CQTI571A2301	Y	Y	Y	Y	Y	Y	Y		1-Jun-2019
19908	Novartis	An open phase III trial with Letrozole (Femara®) alone or in combination with Zoledronic acid (Zometa®) as extended adjuvant treatment of postmenopausal patients with primary breast cancer	letrozole	CFEM345DDE09	Breast cancer	Phase 3	https://www.novctrd.com/ctrdweb/trialresult/trialresults/pdf?trialResultId=4346	https://clinicaltrials.gov/ct2/show/NCT00332709?term=CFEM345DDE09&rank=1	https://www.clinicaltrialsregister.eu/ctr-search/search?query=CFEM345DDE09	Y	Y	Y	Y	Y	Y	Y		1-Jun-2019
19909	Novartis	Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial to Evaluate the Safety and Efficacy of Zoledronate (4 and 8 mg) Administered Intravenously as an Adjuvant to Anticancer Therapy to Patients With Any Cancer With Bone Metastases Other Than Breast Cancer, Multiple Myeloma or Prostate Cancer	zoledronic acid	CZOL446 0011E1	Solid Tumor cancer with Bone metastases	Phase 3		https://clinicaltrials.gov/ct2/show/NCT00003884?term=NCT00003884&rank=1		Y	Y	Y	Y	Y	Y	Y		1-Jun-2019
19917	GSK	Safety and tolerability of GSK 1557484A vaccine in adults at occupational risk for influenza A (H5N1) exposure	GSK1557484A	116861	Influenza	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=116861	http://clinicaltrials.gov/show/NCT01788228	https://www.clinicaltrialsregister.eu/ctr-search/search?query=/	Y	Y	Y	Y	Y	Y	Y		1-Jun-2019
19918	GSK	Immunogenicity and safety study of two formulations of GlaxoSmithKline (GSK) Biologicals’ pneumococcal vaccine (2830929A and 2830930A) when administered in healthy infants	GSK2830929A; GSK2830930A	116485	Streptococcus pneumoniae	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=116485	http://clinicaltrials.gov/show/NCT01616459	https://www.clinicaltrialsregister.eu/ctr-search/search?query=/2011-005743-27	Y	Y	Y	Y	Y	Y	Y		1-Jun-2019
19919	GSK	Development of read-outs to detect and characterise the early and adaptive immune responses in healthy, hepatitis B virus naive adults vaccinated with the hepatitis B surface antigen in combination with a GSK Biologicals’ Adjuvant System	GSK2231392A; SKF103860	116640	Hepatitis B	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=116640	http://clinicaltrials.gov/show/NCT01777295	https://www.clinicaltrialsregister.eu/ctr-search/search?query=/2012-001344-22	Y	Y	Y	Y	Y	Y	Y	There is a Publicaton Steering Committee for this study.	1-Jun-2019
19920	GSK	Long-term persistence of immunity to hepatitis B in adults vaccinated 20 to 30 years ago with Engerix-B	SKF103860	116811	Hepatitis B	Phase 4	https://www.gsk-studyregister.com/en/trial-details/?id=116811	http://clinicaltrials.gov/show/NCT02901951	https://www.clinicaltrialsregister.eu/ctr-search/search?query=/2015-004099-31	Y	Y	Y	Y	Y	Y	Y		1-Jun-2019
19921	GSK	A phase II, open, controlled study to evaluate the reactogenicity and the immunogenicity of GlaxoSmithKline Biologicals' adjuvanted influenza vaccine in elderly adults previously vaccinated with either Fluarix™ or the adjuvanted vaccine.	GSK576389A	107973	Influenza	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=107973	http://clinicaltrials.gov/show/NCT00386113	https://www.clinicaltrialsregister.eu/ctr-search/search?query=/2006-003237-32	Y	N	Y	Y	Y	Y	Y	This is a follow-up study to 103304-001 and 104540. A follow-on study 110223 was conducted. An annotated case report form is not available for this study. A blank case report form will be provided.	1-Jun-2019
19922	GSK	A partially-blind multi-centric study in adults aged between 18-60 years designed to evaluate the reactogenicity and immunogenicity of 1 and 2 doses of pandemic monovalent (H5N1) influenza vaccines (whole virus formulation) administered at different doses and adjuvanted or not	GSK1119711A	106378	Influenza	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=106378	http://clinicaltrials.gov/show/NCT00309647	https://www.clinicaltrialsregister.eu/ctr-search/search?query=/2005-006028-83	Y	Y	Y	Y	Y	Y	Y		1-Jun-2019
19923	GSK	Multi-arm, Non-randomized, Open-Label Phase IB Study to Evaluate GSK3052230 in Combination with paclitaxel and carboplatin, or docetaxel or as Single Agent in Subjects with Solid Malignancies and Deregulated FGF Pathway Signaling	GSK3052230	FGF117360	Neoplasms	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=117360	http://clinicaltrials.gov/show/NCT01868022	https://www.clinicaltrialsregister.eu/ctr-search/search?query=/2013-000354-21	Y	Y	Y	Y	Y	Y	Y		1-Jun-2019
19925	GSK	A multi-centre, open label, single arm, 32-week treatment study in subjects with severe eosinophilic asthma not optimally controlled with current omalizumab treatment who are switched from omalizumab to mepolizumab 100mg subcutaneous (study number 204471- the OSMO study)	mepolizumab	204471	Asthma	Phase 4	https://www.gsk-studyregister.com/en/trial-details/?id=204471	http://clinicaltrials.gov/show/NCT02654145	https://www.clinicaltrialsregister.eu/ctr-search/search?query=/2015-003697-32	Y	N	Y	Y	Y	Y	Y	An annotated case report form is not available for this study. A blank case report form will be provided. This study is available in CDISC format.	1-Jun-2019
19926	GSK	Evaluation of the nicotine lozenge in relief of provoked acute craving	nicotine polacrilex	S7120994	Tobacco Use Disorder	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=S7120994	http://clinicaltrials.gov/show/NCT01466361		Y	Y	Y	Y	Y	Y	Y		1-Jun-2019
19927	GSK	Evaluation of the Nicotine Mini Lozenge in Relief of Provoked Acute Craving	nicotine polacrilex	S7121359	Tobacco Use Disorder	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=S7121359	http://clinicaltrials.gov/show/NCT01506908		Y	Y	Y	Y	Y	Y	Y		1-Jun-2019
19928	GSK	A randomised, double-blind, parallel group study to evaluate the safety, tolerability and pharmacokinetics of a single dose of GSK2269557 administered via the ELLIPTA™ dry powder inhaler to healthy participants	nemiralisib	207674	Pulmonary Disease, Chronic Obstructive	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=207674	http://clinicaltrials.gov/show/NCT03189589	https://www.clinicaltrialsregister.eu/ctr-search/search?query=/2017-001073-16	Y	N	Y	Y	Y	Y	Y	An annotated case report form is not available for this study. A blank case report form will be provided. This study is available in CDISC format.	1-Jun-2019
19935	GSK	Effects of Medium-Chain Triglycerides on Cognitive Function in Older Subjects with Age-Related Cognitive Decline	GSK2981710	EMI116713	Alzheimer's Disease	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=116713	http://clinicaltrials.gov/show/NCT01702480		Y	Y	Y	Y	Y	Y	Y		1-Jul-2019
19936	GSK	An open label positron emission tomography (PET) imaging study using 89Zirconium labeled GSK3128349 to investigate the biodistribution and clearance of an albumin binding domain antibody (AlbudAb) GSK3128349 following single dose intravenous administration in healthy male subjects	GSK3128349	RES117169	Drug-Related Side Effects and Adverse Reactions	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=117169	http://clinicaltrials.gov/show/NCT02829307		Y	Y	Y	Y	Y	Y	Y		1-Jul-2019
19937	GSK	A Single Centre, Double Blind (Sponsor Open), Placebo Controlled, 3-Period Crossover, Ascending Dose Study in Japanese Healthy Elderly Male Subjects to Evaluate the Safety, Tolerability and Pharmacokinetics of Danirixin in the Fed State (Part1) and an open label, 2-way crossover to evaluate food effect on the pharmacokinetics of Danirixin (Part2)	danirixin	206817	Pulmonary Disease, Chronic Obstructive	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=206817	http://clinicaltrials.gov/show/NCT03136380		Y	Y	Y	Y	Y	Y	Y		1-Jul-2019
19938	GSK	A Phase 1, Multi-center, Single-masked, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Ophthalmologic Safety and Pharmacodynamics of 300mg Single Doses of Tafenoquine (SB 252263) in Adult Healthy Volunteers	tafenoquine	201807	Malaria, Vivax	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=201807	http://clinicaltrials.gov/show/NCT02658435		Y	Y	Y	Y	Y	Y	Y	This study is available in CDISC format.	1-Jul-2019
19939	GSK	An open-label, single arm, repeat dose, multi-centre study to evaluate the use of an autoinjector for the subcutaneous administration of mepolizumab in subjects with severe eosinophilic asthma (Study 204959)	mepolizumab	204959	Asthma	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=204959	http://clinicaltrials.gov/show/NCT03099096	https://www.clinicaltrialsregister.eu/ctr-search/search?query=/2016-001832-36	Y	Y	Y	Y	Y	Y	Y	This study is available in CDISC format.	1-Jul-2019
19940	ViiV	ING117175: a Phase IIIb, randomized, open-label study of the safety and efficacy of dolutegravir or efavirenz each administered with two NRTIs in HIV-1-infected antiretroviral therapy-naïve adults starting treatment for rifampicin-sensitive tuberculosis	dolutegravir	ING117175	Infection, Human Immunodeficiency Virus	Phase 3	http://www.viiv-clinicalstudyregister.com/study/117175	http://clinicaltrials.gov/show/NCT02178592		Y	N	Y	Y	Y	Y	Y	An annotated case report form is not available for this study. A blank case report form will be provided. This study is still ongoing, however data related to the publication(s) is available. This study is available in CDISC format.	1-Jul-2019
19941	ViiV	Phase 1, open label, two arm, fixed sequence study to evaluate the effect of rifampin and rifabutin on GSK1349572 pharmacokinetics in healthy male and female volunteers	dolutegravir	ING113099	Infection, Human Immunodeficiency Virus	Phase 1	http://www.viiv-clinicalstudyregister.com/study/113099	http://clinicaltrials.gov/show/NCT01231542		Y	N	Y	Y	Y	Y	N	An annotated case report form and a reporting and analysis plan are not available for this study. A blank case report form will be provided.	1-Jul-2019
19970	Eisai	Clinical efficacy and safety of donepezil on cognitive and global function in patients with Alzheimer's disease. A 24-week, multicenter, double-blind, placebo-controlled study in Japan.	donepezil	E2020-J081-161	Alzheimer's Disease	Phase 2/3	not available	not available	not available	N	N	N	N	N	Y	N	No restrictions.	1-Aug-2019
19971	Eisai	A Preliminary, Multi-Center, Randomized, Double-Blind, Placebo-Controlled Evaluation of the Safety and Efficacy of E2020 in Patients with Alzheimer's Disease.	donepezil	E2020-A001-201	Alzheimer's Disease	Phase 2	not available	not available	not available	N	N	Y	N	N	Y	N	No restrictions.	1-Aug-2019
19972	Eisai	A 15-week, Multi-Center, Randomized, Double-Blind, Placebo-Controlled Evaluation of the Safety and Efficacy of E2020 in Patients with Alzheimer's Disease.	donepezil	E2020-A001-301	Alzheimer's Disease	Phase 3	not available	not available	not available	N	N	Y	N	N	Y	N	No restrictions.	1-Aug-2019
19973	Eisai	A 30-Week, Multi-Center, Randomized, Double-Blind, Placebo-Controlled Evaluation of the Safety and Efficacy of E2020 in Patients with Alzheimer's Disease.	donepezil	E2020-A001-302	Alzheimer's Disease	Phase 3	not available	not available	not available	N	N	Y	N	N	Y	N	No restrictions.	1-Aug-2019
19974	Eisai	A 30-Week, Multi-Center, Randomized, Double-Blind, Placebo-Controlled Evaluation of the Safety and Efficacy of E2020 in Patients with Alzheimer's Disease.	donepezil	E2020-A044-304	Alzheimer's Disease	Phase 3	not available	not available	not available	N	N	Y	N	N	Y	N	No restrictions.	1-Aug-2019
19975	Eisai	A Multi-Center, Randomized, Double-Blind, Parallel Group Study With 3 Groups Receiving Placebo, 5 mg of E2020 and 10 mg of E2020	donepezil	E2020-J081-231	Alzheimer's Disease	Phase 2	not available	https://clinicaltrials.gov/ct2/show/NCT00165659	not available	N	N	N	N	N	Y	N	No restrictions.	1-Aug-2019
19976	Eisai	A 24 Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled Evaluation of the Safety and Efficacy of Donepezil Hydrochloride (E2020) in Patients With Severe Alzheimer's Disease Followed by a 12 Week Open-Label Extension Period	donepezil	E2020-A001-315	Alzheimer's Disease	Phase 3	not available	https://clinicaltrials.gov/ct2/show/NCT00096473	not available	N	N	Y	N	Y	Y	N	No restrictions.	1-Aug-2019
19977	Eisai	A Randomized, Double-Blind, Placebo-Controlled Evaluation of the Effects of Donepezil Hydrochloride (E2020) in the Management of Patients with Alzheimer's Disease in a Nursing Home Facility.	donepezil	E2020-A001-311	Alzheimer's Disease	Phase 3	not available	not available	not available	N	N	Y	N	N	Y	N	No restrictions.	1-Aug-2019
19978	Eisai	A 54-week, Randomized, Double-Blind, Placebo-Controlled Evaluation of the Effects of Donepezil Hydrochloride (E2020) on Functional Outcomes in Patients with Alzheimer's Disease.	donepezil	E2020-A001-312	Alzheimer's Disease	Phase 3	not available	not available	not available	N	N	Y	N	N	Y	N	No restrictions.	1-Aug-2019
19979	Eisai	Comparison of 23 mg Donepezil Sustained Release (SR) to 10 mg Donepezil Immediate Release (IR) in Patients With Moderate to Severe Alzheimer's Disease	donepezil	E2020-G000-326	Alzheimer's Disease	Phase 3	not available	https://clinicaltrials.gov/ct2/show/NCT00478205	https://www.clinicaltrialsregister.eu/ctr-search/trial/2006-004888-54/results	N	N	Y	N	N	Y	N	No restrictions.	1-Aug-2019
19980	Eisai	A 24-weeks, Multi-center, Randomized, Double-blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of Donepezil Hydrochloride in Chinese Subjects With Severe Alzheimer's Disease	donepezil	E2020-C086-339	Alzheimer's Disease	Phase 3	not available	https://clinicaltrials.gov/ct2/show/NCT01404169	not available	N	N	N	N	N	Y	N	Sharing of clinical data is restricted for the following country: China	1-Aug-2019
19986	Novartis	A Randomized, Double-blind, Placebo Controlled Study of Canakinumab in Patients With Hereditary Periodic Fevers (TRAPS, HIDS, or crFMF), With Subsequent Randomized Withdrawal/Dosing Frequency Reduction and Open-label Long-term Treatment Epochs	canakinumab	CACZ885N2301	Hereditary Periodic Fevers	Phase 3	https://www.novctrd.com/ctrdweb/trialresult/trialresults/pdf?trialResultId=16933	https://www.clinicaltrials.gov/ct2/show/NCT02059291?term=CACZ885N2301&rank=3	https://www.clinicaltrialsregister.eu/ctr-search/search?query=CACZ885N2301	Y	Y	Y	Y	Y	Y	Y		1-Jul-2019
19987	Novartis	A Multi-center, Randomized, Double-blind, 52-week Study to Assess the Safety of NVA237 Compared to QAB149 in Patients With Chronic Obstructive Pulmonary Disease (COPD) Who Have Moderate to Severe Airflow Limitation	glycopyrronium bromide	CNVA237A2319	Chronic Obstructive Pulmonary Disease (COPD)	Phase 3	https://www.novctrd.com/ctrdweb/trialresult/trialresults/pdf?trialResultId=14285	https://www.clinicaltrials.gov/ct2/show/NCT01697696?term=CNVA237A2319&rank=1		Y	Y	Y	Y	Y	Y	Y		1-Jul-2019
20036	Novartis	A Phase II, Multi-centre Study Investigating the Safety and Efficacy of Ofatumumab and Bendamustine Combination in Patients with Untreated or Relapsed Chronic Lymphocytic Leukaemia (CLL)	ofatumumab	COMB157B2201	Chronic Lymphocytic Leukemia (CLL)	Phase 2	https://www.novctrd.com/ctrdweb/trialresult/trialresults/pdf?trialResultId=15449	https://www.clinicaltrials.gov/ct2/show/NCT01520922?term=NCT01520922&rank=1	https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-005178-43/results	Y	Y	Y	Y	Y	Y	Y		1-Jul-2019
20037	Novartis	Presentation of Renal Function in Liver Transplant Recipients With Certican Therapy: PROTECT Study A Twelve-month, Multicenter, Randomized, Open-label Study of Safety, Tolerability and Efficacy of Certican-based Regimen Versus Calcineurin Inhibitor-based Regimen in de Novo Liver Transplant Recipients	everolimus	CRAD001HDE10	Liver Transplantation	Phase 3	https://www.novctrd.com/ctrdweb/trialresult/trialresults/pdf?trialResultId=10843	https://www.clinicaltrials.gov/ct2/show/NCT00378014?term=CRAD001HDE10&rank=1	https://www.clinicaltrialsregister.eu/ctr-search/search?query=CRAD001HDE10+	Y	Y	Y	Y	Y	Y	Y		1-Sep-2019
20045	GSK	Extension to study MALARIA-055 PRI (NCT00866619) for evaluation of long-term efficacy, safety and immunogenicity of GSK Biologicals’ candidate malaria vaccine (SB257049) in infants and children in Africa	RTS,S Vaccine	200599	Malaria	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=200599	http://clinicaltrials.gov/show/NCT02207816		Y	Y	Y	Y	Y	Y	Y	This is an extension study to 110021.	1-Sep-2019
20046	GSK	Study to evaluate safety and immunogenicity of GSK Biologicals' Herpes Zoster vaccine GSK1437173A in adults aged 18 years and older with haematologic malignancies	Herpes Zoster subunit (HZ/su) vaccine	116428	Herpes Zoster	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=116428	http://clinicaltrials.gov/show/NCT01767467	https://www.clinicaltrialsregister.eu/ctr-search/search?query=/2012-003438-18	Y	Y	Y	Y	Y	Y	Y		1-Sep-2019
20047	GSK	A Phase 2, Non-Randomized, Controlled, Open-Label, Parallel-Group, Extension Study to Evaluate the Immunogenicity and Safety of the Second Dose of GBS Trivalent Vaccine in Healthy Non-pregnant Subjects.	GSK3536855A	205421	Streptococcus agalactiae	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=205421	http://clinicaltrials.gov/show/NCT02690181	https://www.clinicaltrialsregister.eu/ctr-search/search?query=/2015-003094-15	Y	Y	Y	Y	Y	Y	Y	This is an extension study to 205468 (NCT01150123).	1-Sep-2019
20048	GSK	A study to evaluate safety, reactogenicity and immunogenicity of GSK Biologicals’ RSV investigational vaccine based on viral proteins encoded by chimpanzee-derived adenovector (ChAd155-RSV) (GSK3389245A) in healthy adults	GSK3389245A	201974	Respiratory Syncytial Virus Infections	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=201974	http://clinicaltrials.gov/show/NCT02491463	https://www.clinicaltrialsregister.eu/ctr-search/search?query=/2014-005333-31	Y	Y	Y	Y	Y	Y	Y		1-Sep-2019
20049	GSK	Observer-blind study to evaluate efficacy, safety, and immunogenicity of GSK Biologicals’ Herpes Zoster vaccine GSK1437173A	Herpes Zoster subunit (HZ/su) vaccine	115523	Herpes Zoster	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=115523	http://clinicaltrials.gov/show/NCT01610414	https://www.clinicaltrialsregister.eu/ctr-search/search?query=/2012-000138-20	Y	Y	Y	Y	Y	Y	Y	There is a Publicaton Steering Committee for this study.	1-Sep-2019
20050	GSK	Immunogenicity and safety study of GSK Biologicals’ Herpes Zoster vaccine GSK1437173A when co-administered with Boostrix® in adults aged 50 years and older	Herpes Zoster subunit (HZ/su) vaccine	116887	Herpes Zoster	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=116887	http://clinicaltrials.gov/show/NCT02052596	https://www.clinicaltrialsregister.eu/ctr-search/search?query=/2012-005316-25	Y	Y	Y	Y	Y	Y	Y		1-Sep-2019
20051	GSK	Safety and immunogenicity of a booster dose of new formulations of GlaxoSmithKline Biologicals’ DTPa-HBV-IPV/Hib vaccine (GSK217744)	SB217744	114843	Acellular pertussis; Diphtheria; Hepatitis B; Poliomyelitis; Tetanus	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=114843	http://clinicaltrials.gov/show/NCT01453998	https://www.clinicaltrialsregister.eu/ctr-search/search?query=/2011-000876-33	Y	Y	Y	Y	Y	Y	Y	This is a booster study to 113948.	1-Sep-2019
20052	GSK	An observer-blind study to evaluate the safety, reactogenicity and immunogenicity of GSK Biologicals’ investigational vaccine GSK2838504A when administered to Chronic Obstructive Pulmonary Disease (COPD) patients	GSK2838497A	200157	Respiratory Disorders	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=200157	http://clinicaltrials.gov/show/NCT02075541	https://www.clinicaltrialsregister.eu/ctr-search/search?query=/2013-003062-13	Y	Y	Y	Y	Y	Y	Y		1-Sep-2019
20053	GSK	A Phase IV, Open-Label, Multi-Center Study to Evaluate the Safety and the 1-year Persistence of Antibody Response Among Children Who Received 4 Doses of the GSK MenACWY Conjugate Vaccine at 2, 4, 6 and 12 Months of Age in South Korea	GSK3536820A	205336	Infections, Meningococcal	Phase 4	https://www.gsk-studyregister.com/en/trial-details/?id=205336	http://clinicaltrials.gov/show/NCT02446691	https://www.clinicaltrialsregister.eu/ctr-search/search?query=/2014-005392-90	Y	Y	Y	Y	Y	Y	Y		1-Sep-2019
20054	GSK	An observer-blind study to rank different formulations of GSK Biologicals’ investigational RSV vaccine (GSK3003891A) administered to healthy women	GSK3003891A	204812	Respiratory Syncytial Virus Infections	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=204812	http://clinicaltrials.gov/show/NCT02956837	https://www.clinicaltrialsregister.eu/ctr-search/search?query=/2016-001135-12	Y	Y	Y	Y	Y	Y	Y		1-Sep-2019
20055	GSK	A Multi-Center, Continuation Trial of Belimumab (HGS1006, LymphoStat-B™)a Fully Human Monoclonal Anti-BLyS Antibody in Subjects with Systemic Lupus Erythematosus (SLE) who completed the Phase 3 Protocol HGS1006-C1056 or HGS1006-C1057	belimumab	BEL112234	Systemic Lupus Erythematosus	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=112234	http://clinicaltrials.gov/show/NCT00712933	https://www.clinicaltrialsregister.eu/ctr-search/search?query=/2007-007648-85	Y	Y	Y	Y	Y	Y	Y	This is a follow-up study to HGS1006-C1056 and HGS1006-C1057. This study is available in CDISC format.	1-Sep-2019
20056	GSK	A randomised, placebo-controlled, double-blind, repeat dose escalation study with GSK2126458 in patients with Idiopathic Pulmonary Fibrosis (IPF)	omipalisib	IPF116711	Idiopathic Pulmonary Fibrosis	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=116711	http://clinicaltrials.gov/show/NCT01725139	https://www.clinicaltrialsregister.eu/ctr-search/search?query=/2012-001376-11	Y	Y	Y	Y	Y	Y	Y		1-Sep-2019
20057	GSK	An open-label study to characterize the pharmacokinetics and pharmacodynamics of mepolizumab administered subcutaneously in children from 6 to 11 years of age with severe eosinophilic asthma	mepolizumab	200363	Asthma	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=200363	http://clinicaltrials.gov/show/NCT02377427	https://www.clinicaltrialsregister.eu/ctr-search/search?query=/2014-002666-76	Y	Y	Y	Y	Y	Y	Y	This study is available in CDISC format.	1-Sep-2019
20058	GSK	A Phase I Open-label, Dose Escalation Study to Investigate The Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of GSK2879552 Given Orally in Subjects with Relapsed/Refractory Small Cell Lung Carcinoma	GSK2879552	200858	Carcinoma, Small Cell	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=200858	http://clinicaltrials.gov/show/NCT02034123	https://www.clinicaltrialsregister.eu/ctr-search/search?query=/2013-003451-38	Y	Y	Y	Y	Y	Y	Y		1-Sep-2019
20059	GSK	A Multi-Centre, Open-Label, Study of Mepolizumab in a Subset of Subjects with a History of Life Threatening/Seriously Debilitating Asthma Who Participated in the MEA115661 Trial	mepolizumab	201312	Asthma	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=201312	http://clinicaltrials.gov/show/NCT02135692	https://www.clinicaltrialsregister.eu/ctr-search/search?query=/2014-000314-54	Y	Y	Y	Y	Y	Y	Y	This study is linked to study MEA115661. This study is available in CDISC format.	1-Sep-2019
20060	GSK	An open label, randomised, three arm, single dose, multicentre, parallel group study in healthy subjects to compare the pharmacokinetics of subcutaneous mepolizumab when delivered as a liquid drug product in a safety syringe or an auto injector with a reconstituted lyophilised drug product from a vial	mepolizumab	204958	Asthma	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=204958	http://clinicaltrials.gov/show/NCT03014674	https://www.clinicaltrialsregister.eu/ctr-search/search?query=/2016-002405-19	Y	Y	Y	Y	Y	Y	Y	This study is available in CDISC format.	1-Sep-2019
20061	GSK	A two part, multicenter Phase IIa, placebo controlled study, to examine the safety, tolerability, and effects of GSK256073 on lipids in subjects with dyslipidemia	GSK256073	HMA112795	Dyslipidaemias	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=112795	http://clinicaltrials.gov/show/NCT00903617		Y	Y	Y	Y	Y	Y	Y		1-Sep-2019
20062	GSK	A 24-week, Phase III, open-label, non-comparative, multi-center study to evaluate efficacy and safety of GSK1278863 in Japanese hemodialysis subjects with anemia associated with chronic kidney disease who are not taking erythropoiesis stimulating agents	daprodustat	204716	Anaemia	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=204716	http://clinicaltrials.gov/show/NCT02829320		Y	Y	Y	Y	Y	Y	Y	This study is available in CDISC format.	1-Sep-2019
20064	GSK	Phase II Study Of Iodine-131 Anti-B1 Antibody Plus CHOP For Patients With Previously Untreated Mantle Cell Lymphoma	tositumomab	393229/005	Lymphoma, Mantle-Cell	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=393229/005	http://clinicaltrials.gov/show/NCT00992992		Y	Y	Y	Y	Y	Y	Y		1-Sep-2019
20065	GSK	Early clinical evaluation of a new antidepressant: A double-blind parallel study comparing paroxetine 30mg daily with amitriptyline 150mg daily	paroxetine	PAR 29060.308 (HP/81/74A)	Depressive Disorder	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=29060/308			Y	N	Y	Y	N	N	N	The data from this study is provided in combined datasets containing data from other paroxetine studies. A raw dataset is not available for this study. An annotated and a blank case report form are not available for this study. A reporting and analysis plan and a protocol are not available for this study. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Sep-2019
20066	GSK	Early Clinical Evaluation of a New Antidepressant: A Double-Blind Parallel Study Comparing Paroxetine 30mg Daily with Amitriptyline 100mg Daily	paroxetine	PAR 29060.309 HP/81/162A	Depressive Disorder	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=29060/309			Y	N	Y	Y	N	N	N	The data from this study is provided in combined datasets containing data from other paroxetine studies. A raw dataset is not available for this study. A reporting and analysis plan and a protocol are not available for this study. An annotated and a blank case report form are not available for this study. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Sep-2019
20067	GSK	Early Clinical Evaluation of a New Antidepressant: Double-Blind Parallel Study Comparing Paroxetine 30mg Daily with Amitriptyline 150mg Daily	paroxetine	PAR 29060.310 (HP 81/85A)	Depressive Disorder	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=29060/310			Y	N	Y	Y	N	N	N	The data from this study is provided in combined datasets containing data from other paroxetine studies. A raw dataset is not available for this study. A reporting and analysis plan and a protocol are not available for this study. An annotated and a blank case report form are not available for this study. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Sep-2019
20068	GSK	Early Clinical Evaluation of a New Antidepressant: A Double-Blind Parallel Study Comparing Paroxetine 30mg Daily with Amitriptyline 150mg Daily	paroxetine	PAR 29060.316 (HP/82/47A)	Depressive Disorder	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=29060/316			Y	N	Y	Y	N	N	N	The data from this study is provided in combined datasets containing data from other paroxetine studies. A raw dataset is not available for this study. A reporting and analysis plan and a protocol are not available for this study. An annotated and a blank case report form are not available for this study. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Sep-2019
20069	GSK	Double Blind Parallel Study Comparing Paroxetine, 30mg Daily, and Amitriptyline, 150mg Daily, in Depressed Patients	paroxetine	PAR 29060.314 (HP 82/134)	Depressive Disorder	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=29060/314			Y	N	Y	Y	N	N	N	The data from this study is provided in combined datasets containing data from other paroxetine studies. A raw dataset is not available for this study. A reporting and analysis plan and a protocol are not available for this study. An annotated and a blank case report form are not available for this study. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Sep-2019
20070	GSK	A trial to assess the effectiveness and tolerance of paroxetine by double-blind comparison with amitriptyline in the treatment of depressed patients in General Practice	paroxetine	PAR 29060/281	Depressive Disorder	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=29060/281			Y	N	Y	Y	N	N	N	The data from this study is provided in combined datasets containing data from other paroxetine studies. A raw dataset is not available for this study. A reporting and analysis plan and a protocol are not available for this study. An annotated and a blank case report form are not available for this study. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Sep-2019
20071	GSK	A prospective, randomized, double-blind, multicentre study of the efficacy and tolerance of paroxetine versus clomipramine in the treatment of endogenous depression in the elderly	paroxetine	PAR 290 MDF 29060 1727 M	Depressive Disorder	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=29060/290			Y	N	Y	Y	N	N	N	The data from this study is provided in combined datasets containing data from other paroxetine studies. A raw dataset is not available for this study. A reporting and analysis plan and a protocol are not available for this study. An annotated and a blank case report form are not available for this study. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Sep-2019
20072	GSK	A Multi-Centre Double-Blind Study to Investigate the Safety and Efficacy of Paroxetine in Comparison with Clomipramine in the Treatment of Reactive Depression in Elderly Patients.	paroxetine	PAR MDED/29060/III/86/1728M291	Depressive Disorder	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=29060/291			Y	N	Y	Y	N	N	N	The data from this study is provided in combined datasets containing data from other paroxetine studies. A raw dataset is not available for this study. A reporting and analysis plan and a protocol are not available for this study. An annotated and a blank case report form are not available for this study. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Sep-2019
20073	GSK	A multicentre, double-blind, parallel group, randomised dose study comparing the efficacy of paroxetine 20mg increasing to 30mg daily if there is insufficient response and clomipramine 60mg increasing to 75mg daily, in outpatients (age >60 years) with moderate depression according to feighner's criteria	paroxetine	MDF/29060/III/070/88/MC	Depressive Disorder	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=29060/070			N	N	Y	Y	Y	Y	N	Analysis-ready data is not available for this study. A reporting and analysis plan is not available for this study. An annotated and a blank case report form are not available for this study. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Sep-2019
20074	GSK	A Multicentre, Parallel Group Study to Compare the Efficacy and Tolerability of Paroxetine with Clomipramine in Elderly Patients.	paroxetine	MY-1001/BRL-029060/1/CPMS 069	Depressive Disorder	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=29060/069			N	N	Y	Y	Y	Y	N	An analysis-ready dataset is not available for this study. A reporting and analysis plan is not available for this study. An annotated and a blank case report form are not available for this study. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Sep-2019
20075	GSK	A multicentre, double-blind, randomised dose titration study comparing the pharmacodynamics and pharmacokinetics of paroxetine 20mg increasing to 30mg daily and amitriptyline 100mg increasing to 150mg daily in geriatric patients (age >65 years) with major depression.	paroxetine	MY-060/BRL-029060/1.	Depressive Disorder	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=MY-060/BRL-029060/1.			N	N	Y	Y	Y	Y	N	An analysis-ready dataset is not available for this study. A reporting and analysis plan is not available for this study. An annotated and a blank case report form are not available for this study. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Sep-2019
20076	GSK	A Double-blind Comparative Study Comparing Paroxetine b.d. (twice daily) with Fluoxetine b.d. (twice daily) in Geriatric Patients with Major Depression	paroxetine	MY 1021/BRL 029060/1/CPMS/061	Depressive Disorder	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=29060/061			N	N	Y	Y	Y	Y	N	An analysis-ready dataset is not available for this study. A reporting and analysis plan is not available for this study. An annotated and a blank case report form are not available for this study. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Sep-2019
20077	GSK	A Multicentre Double Blind Study Comparing Paroxetine at a Dose of 20mg Increasing to 30mg Taken in the Morning and Amitriptyline 75mg Increasing to 150mg in Divided Doses in Adult Patients with Major Depressive Disorder	paroxetine	PAR 29060/078	Depressive Disorder	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=29060/078			N	N	Y	Y	Y	Y	N	An analysis-ready dataset is not available for this study. A reporting and analysis plan is not available for this study. An annotated and a blank case report form are not available for this study. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Sep-2019
20078	GSK	A double blind randomised trial comparing the effects on sleep of paroxetine 30mg daily and amitriptyline 150mg daily in patients with major depression.	paroxetine	29060/063	Depressive Disorder	Phase 4	https://www.gsk-studyregister.com/en/trial-details/?id=29060/063			N	N	Y	Y	Y	Y	N	An analysis-ready dataset is not available for this study. A reporting and analysis plan is not available for this study. An annotated and a blank case report form are not available for this study. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Sep-2019
20079	GSK	A double-blind, multicentre study to compare the effectiveness and tolerance of paroxetine versus fluvoxamine in depressed patients	paroxetine	MY-1005/BRL-029060/1/CPMS-112	Depressive Disorder	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=29060/112			N	N	Y	Y	Y	Y	N	An analysis-ready dataset is not available for this study. A reporting and analysis plan is not available for this study. An annotated case report form is not available for this study. A blank case report form will be provided. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Sep-2019
20080	GSK	A Double-blind Comparative Multicentre Study Comparing Paroxetine b.d. (twice daily) with Fluoxetine b.d. (twice daily) in Depressed Patients	paroxetine	29060/064	Depressive Disorder	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=29060/064			N	N	Y	Y	Y	Y	N	An analysis-ready dataset is not available for this study. A reporting and analysis plan is not available for this study. An annotated case report form is not available for this study. A blank case report form will be provided. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Sep-2019
20081	GSK	A double-blind comparative multicentre study comparing paroxetine b.d. (twice daily) with fluoxetine (Prozac®) b.d. (twice daily) in depressed patients	paroxetine	MY-1010/BRL029060/1/CPMS 079	Depressive Disorder	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=29060/079			N	N	Y	Y	Y	Y	N	An analysis-ready dataset is not available for this study. An annotated and a blank case report form are not available for this study. A reporting and analysis plan is not available for this study. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Sep-2019
20082	GSK	A Multicentre, Double-blind Randomised Dose Titration Study Comparing the Efficacy and Safety Profiles of an Increasing Dose Regimen of Oral Paroxetine and Oral Amitriptyline in Adult Patients with Major Depression	paroxetine	MY-059.073/29060/1	Depressive Disorder	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=29060/073			N	N	Y	Y	N	Y	N	This is a combination of two study groups (29060/059 and 29060/073) which were conducted under the same protocol. An analysis-ready dataset is not available for this study. A reporting and analysis plan and a protocol are not available for this study. An annotated and a blank case report form are not available for this study. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Sep-2019
20083	GSK	A Double-Blind, Multicentre Study in Primary Care Comparing Paroxetine and Clomipramine in Patients with Depression with Associated Anxiety	paroxetine	MY-1055/BRL-029060/1/CPMS-245 PAR 245	Depressive Disorder	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=29060/245			N	N	Y	Y	Y	Y	N	An analysis-ready dataset is not available for this study. A reporting and analysis plan is not available for this study. An annotated case report form are not available for this study. A blank case report form will be provided. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Sep-2019
20084	GSK	A Double-Blind, Randomized, Multicentre Comparison of Paroxetine and Fluoxetine in the Treatment of Patients With Major Depression With Regard to Antidepressant Efficacy, Tolerance and Anxiolytic Effect	paroxetine	29060/131	Depressive Disorder	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=29060/131			N	N	Y	Y	N	Y	N	An analysis-ready dataset is not available for this study. A reporting and analysis plan and a protocol are not available for this study. An annotated and a blank case report form are not available for this study. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Sep-2019
20085	GSK	The Effects of Paroxetine Versus Those of Maprotiline and Placebo on Fundamental Cognitive Functions, Perceptual-Motor Skills and Eye Movements in Depressed Patients	paroxetine	MY-1008/BRL-029060/2/CPMS-076	Depressive Disorder	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=29060/076			N	N	Y	Y	Y	Y	N	An analysis-ready dataset is not available for this study. A reporting and analysis plan is not available for this study. An annotated and a blank case report form are not available for this study. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Sep-2019
20087	GSK	Six-week, parallel, double-blind, randomized comparison of bupropion and trazodone (150-400mg/day) in outpatients	bupropion	89	Depressive Disorder	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=89			N	N	N	Y	Y	Y	N	An analysis-ready dataset is not available for this study. A reporting and analysis plan is not available for this study. An annotated and a blank case report form are not available for this study. A clinical study report is not available for this study because there is no evidence in the archives that a document was authored. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Sep-2019
20088	GSK	A Multicenter Evaluation of the Safety and Efficacy of 150mg/day and 300mg/day of Bupropion HCl Sustained-Release Versus Placebo in Depressed Outpatients	bupropion	WELL 203	Depressive Disorder, Major	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=WELL 203			N	N	Y	Y	Y	Y	N	An analysis-ready dataset is not available for this study. A reporting and analysis plan is not available for this study. An annotated case report form is not available for this study. A blank case report form will be provided. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Sep-2019
20089	GSK	The Safety and Efficacy of Wellbutrin Sustained Release and Sertraline in Depressed Outpatients	bupropion	Well 209	Depressive Disorder, Major	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=Well 209			N	N	Y	Y	N	Y	N	An analysis-ready dataset is not available for this study. A reporting and analysis plan and a protocol are not available for this study. An annotated and a blank case report form are not available for this study. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Sep-2019
20090	GSK	A multicenter evaluation of the safety and efficacy of two flexible doses of WELLBUTRIN sustained-release versus placebo in depressed outpatients	bupropion	WELL 212	Depressive Disorder, Major	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=WELL 212			N	N	Y	Y	Y	Y	N	An analysis-ready dataset is not available for this study. A reporting and analysis plan is not available for this study. An annotated case report form is not available for this study. A blank case report form will be provided. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Sep-2019
20091	GSK	A Multicenter, Double-Blind, Placebo-Controlled Comparison of the Effects on Sexual Functioning of Wellbutrin (Bupropion HCl) Sustained Release and Sertraline in Outpatients with Moderate to Severe Recurrent Major Depression	bupropion	WELL AK1A4002	Depressive Disorder, Major	Phase 4	https://www.gsk-studyregister.com/en/trial-details/?id=AK1A4002			N	N	Y	Y	Y	Y	Y	An analysis-ready dataset is not available for this study. An annotated case report form is not available for this study. A blank case report form will be provided. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Sep-2019
20092	GSK	A Multicenter, Double-Blind, Placebo-Controlled Comparison of the Effects on Sexual Functioning of Wellbutrin (Bupropion HCI) Sustained Release and Sertraline in Outpatients with Moderate to Severe Recurrent Major Depression	bupropion	WELL AK1A4001	Depressive Disorder	Phase 4	https://www.gsk-studyregister.com/en/trial-details/?id=AK1A4001			N	N	Y	Y	Y	Y	Y	An analysis-ready dataset is not available for this study. An annotated case report form is not available for this study. A blank case report form will be provided. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Sep-2019
20093	GSK	A Multicenter, Double-Blind, Placebo-Controlled Comparison of the Safety and Efficacy and Effects on Sexual Functioning of Wellbutrin (Bupropion HCl) Sustained Release (SR) and Fluoxetine in Outpatients with Moderate to Severe Recurrent Major Depression	bupropion	WELL AK1A4007	Depressive Disorder, Major	Phase 4	https://www.gsk-studyregister.com/en/trial-details/?id=AK1A4007			N	N	Y	Y	Y	Y	Y	An analysis-ready dataset is not available for this study. An annotated and a blank case report form are not available for this study. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Sep-2019
20094	GSK	A multicenter dose-response evaluation of the safety and efficacy of bupropion HCI sustained-release versus placebo in depressed outpatients	bupropion	WELL 205	Depressive Disorder, Major	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=WELL 205			N	N	Y	Y	Y	Y	Y	An analysis-ready dataset is not available for this study. An annotated case report form is not available for this study. A blank case report form will be provided. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Sep-2019
20095	GSK	A Multicenter, Double-Blind, Placebo-Controlled Comparison of the Safety and Efficacy and Effects on Sexual Functioning of Wellbutrin (Bupropion HCl) Sustained Release (SR) and Fluoxetine in Outpatients with Moderate to Severe Recurrent Major Depression	bupropion	WELL AK1A4006	Depressive Disorder, Major	Phase 4	https://www.gsk-studyregister.com/en/trial-details/?id=AK1A4006			N	Y	Y	Y	Y	Y	Y	An analysis-ready dataset is not available for this study. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Sep-2019
20099	GSK	Efficacy and safety of alitretinoin in the treatment of severe chronic hand eczema refractory to topical therapy	alitretinoin	ATN117183	Eczema	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=117183	http://clinicaltrials.gov/show/NCT00817063		Y	Y	Y	Y	Y	Y	Y	This study is available in CDISC format.	1-Oct-2019
20100	GSK	Study 205050: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Investigate the Efficacy and Safety of Mepolizumab Administered Subcutaneously in Subjects with Moderate to Severe Atopic Dermatitis	mepolizumab	205050	Dermatitis, Atopic	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=205050	http://clinicaltrials.gov/show/NCT03055195		Y	Y	Y	Y	Y	Y	Y	This study is available in CDISC format.	1-Oct-2019
20101	GSK	A phase I open-label, dose escalation study to investigate the safety, pharmacokinetics, pharmacodynamics and clinical activity of GSK2816126 in subjects with relapsed/refractory diffuse large B cell lymphoma, transformed follicular lymphoma, other Non-Hodgkin’s lymphomas, solid tumors and multiple myeloma	GSK2816126	EZH117208	Neoplasms	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=117208	http://clinicaltrials.gov/show/NCT02082977	https://www.clinicaltrialsregister.eu/ctr-search/search?query=/2013-001585-42	Y	Y	Y	Y	Y	Y	Y		1-Oct-2019
20102	GSK	A Multi-centre, Randomised, Double-blind, Parallel Active-controlled Study Evaluating the Efficacy, Safety and Tolerability of Bupropion Hydrochloride Extended-release (bupropion XL 300mg once daily), Escitalopram oxalate (escitalopram, 10mg-20mg once daily) in Subjects with Major Depressive Disorder	bupropion	LOC114589	Depressive Disorder, Major	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=114589	http://clinicaltrials.gov/show/NCT02191397		Y	Y	Y	Y	Y	Y	Y	This study is available in CDISC format.	1-Oct-2019
20103	GSK	A Phase 3b, Controlled, Open-Label, Multi-Center Study to Evaluate Safety and Immunogenicity of a Single Dose of GlaxoSmithKline’s Meningococcal ACWY Conjugate Vaccine (Menveo), Administered to Healthy Individuals 15 through 55 years of age, approximately 4-6 years after primary ACWY vaccination	GSK3536820A	205352	Infections, Meningococcal	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=205352	http://clinicaltrials.gov/show/NCT02986854	https://www.clinicaltrialsregister.eu/ctr-search/search?query=/2016-003186-25	Y	Y	Y	Y	Y	Y	Y		1-Oct-2019
20104	GSK	Efficacy of GSK Biologicals’ candidate tuberculosis (TB) vaccine GSK 692342 against TB disease, in adults living in a TB endemic region	SB692342	115616	Tuberculosis	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=115616	http://clinicaltrials.gov/show/NCT01755598		Y	Y	Y	Y	Y	Y	Y	There is a Publicaton Steering Committee for this study.	1-Oct-2019
20114	Novartis	A two-part placebo-controlled study to evaluate the safety, tolerability, and preliminary efficacy of BVS857 in patients with spinal and bulbar muscular atrophy (SBMA)	BVS857	CBVS857X2202	Muscle atrophy	Phase 2	https://www.novctrd.com/ctrdweb/trialresult/trialresults/pdf?trialResultId=16190	https://www.clinicaltrials.gov/ct2/show/NCT2024932?term=CBVS857X2202&rank=1	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002608-15	Y	Y	Y	Y	Y	Y	Y		1-Nov-2019
20171	Novartis	A Single Arm, Phase II, Open-Label Study to Determine the Efficacy of 100mg Twice Daily Oral Dosing of Midostaurin Administered to Patients with Aggressive Systemic Mastocytosis or Mast Cell Leukemia with or without an Associated Hematological Clonal Non-Mast Cell Lineage Disease	midostaurin	CPKC412D2201	Mastocytosis	Phase 2	https://www.novctrd.com/ctrdweb/trialresult/trialresults/pdf?trialResultId=17203	https://www.clinicaltrials.gov/ct2/show/NCT782067?term=CPKC412d2201&rank=1	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000280-42	Y	Y	Y	Y	Y	Y	Y		1-Nov-2019
20173	GSK	An open-label, randomised, single-dose, two-period cross-over study to evaluate bioequivalence of SKF101804 Cefixime 200 mg/5 mL suspension versus Cefixime 200 mg/5 mL suspension reference product in healthy adult participants under fasting conditions	cefixime	205731	Infections, Bacterial	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=205731	http://clinicaltrials.gov/show/NCT03408392		N	Y	Y	Y	Y	Y	N	An analysis-ready dataset and a reporting and analysis plan are not available for this study.	1-Nov-2019
20174	GSK	A 29-day, randomized, double-blinded, placebo-controlled, parallel-group, multi-center study to evaluate the efficacy, safety and pharmacokinetics of three-times weekly dosing of GSK1278863 in hemodialysis-dependent subjects with anemia associated with chronic kidney disease who are switched from a stable dose of an erythropoiesis-stimulating agent	daprodustat	204836	Anaemia	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=204836	http://clinicaltrials.gov/show/NCT02689206	https://www.clinicaltrialsregister.eu/ctr-search/search?query=/2015-004790-32	Y	Y	Y	Y	Y	Y	Y	This study is available in CDISC format.	1-Nov-2019
20175	GSK	An eight-week double-blind study comparing the effects of 20 mg of paroxetine to 150 mg of Wellbutrin SR in patients with Major Depressive Disorder	bupropion; paroxetine	WELL AK140016	Depressive Disorder, Major	Phase 4	https://www.gsk-studyregister.com/en/trial-details/?id=AK140016			N	N	N	Y	Y	Y	Y	An analysis-ready dataset and an annotated and a blank case report form are not available for this study. A clinical study report is not available for this study because there is no evidence in the archives that a document was authored. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Nov-2019
20187	Novartis	A phase II, multicenter, single-arm study of oral LDK378 in crizotinib naive adult patients with ALK-activated non-small cell lung cancer	ceritinib	CLDK378A2203	Non-small cell lung carcinoma (NSCLC)	Phase 2	https://www.novctrd.com/ctrdweb/trialresult/trialresults/pdf?trialResultId=17324	https://www.clinicaltrials.gov/ct2/show/NCT1685138?term=CLDK378A2203&rank=1	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003474-36	Y	Y	Y	Y	Y	Y	Y		1-Dec-2019
20188	Novartis	An open-label, phase II (Proof of Concept) trial of PKC412 monotherapy in patients with acute myeloid leukemia (AML) and patients with high risk myelodysplastic syndrome (MDS).	midostaurin	CPKC412A2104E1	Myelodysplastic syndrome (MDS)	Phase 2	https://www.novctrd.com/ctrdweb/trialresult/trialresults/pdf?trialResultId=8663	https://www.clinicaltrials.gov/ct2/show/NCT45942?term=CPKC412A2104&rank=1		Y	Y	Y	Y	Y	Y	Y		1-Dec-2019
20189	Astellas	A randomized, double-blind, factorial, parallel-group, active and placebo-controlled, multicenter dose-ranging study to evaluate the efficacy, safety and tolerability of six dose combinations of Solifenacin Succinate and Mirabegron compared to Mirabegron and Solifenacin Succinate monotherapies in the treatment of overactive bladder	mirabegron	178-CL-100	Urinary Bladder, Overactive	Phase 2	https://www.clinicaltrials.astellas.com/study/?pid=178-CL-100	https://clinicaltrials.gov/ct2/show/NCT01340027	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-020601-32	Y	Y	Y	Y	Y	Y	Y		1-Jan-2020
20259	Astellas	A randomized, double-blind, parallel-group, active-controlled, multicenter study to evaluate the long-term safety and efficacy of combination of Solifenacin Succinate with Mirabegron compared to Solifenacin Succinate and Mirabegron monotherapy in patients with overactive bladder	mirabegron	178-CL-102	Urinary Bladder, Overactive	Phase 3	https://www.clinicaltrials.astellas.com/study/?pid=178-CL-102	https://clinicaltrials.gov/ct2/show/NCT02045862	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-005736-29	Y	Y	Y	Y	Y	Y	Y		1-Jan-2020
20260	Astellas	A Phase II, Open-Label, Multi-Center Study to Compare the Pharmacokinetics of Tacrolimus in Stable Pediatric Allograft Recipients Converted from a Prograf® Based Immunosuppressive Regimen to a Tacrolimus Prolonged Release, Advagraf® Based Immunosuppressive Regimen, Including a Long-Term Follow-Up	tacrolimus extended-release	PMR-EC-1206	Prevention of rejection after organ transplant	Phase 2	https://www.clinicaltrials.astellas.com/study/?pid=PMR-EC-1206	https://clinicaltrials.gov/ct2/show/NCT01294020	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-020925-42	Y	Y	Y	Y	Y	Y	Y		1-Jan-2020
20261	Astellas	A Phase 2a, Randomized, Double-blind, Placebo- and Naproxen-controlled, Parallel-group Study to Assess the Analgesic Efficacy of ASP7962 in Patients with Pain Due to Osteoarthritis of the Knee	ASP7962	7962-CL-0022	Osteoarthritis	Phase 2	https://www.clinicaltrials.astellas.com/study/?pid=7962-CL-0022	https://clinicaltrials.gov/ct2/show/NCT02611466	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004996-22	Y	Y	Y	Y	Y	Y	Y		1-Jan-2020
20262	Astellas	An Open-Label, Randomized Phase 3 Efficacy Study of ASP8273 vs. Erlotinib or Gefitinib in First-line Treatment of Patients with Stage IIIB/IV Non-small Cell Lung Cancer Tumors with EGFR Activating Mutations	naquotinib mesilate	8273-CL-0302	Non-small cell lung cancer	Phase 3	https://www.clinicaltrials.astellas.com/study/?pid=8273-CL-0302	https://clinicaltrials.gov/ct2/show/NCT02588261	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-002894-39	Y	Y	Y	Y	Y	Y	Y		1-Jan-2020
20264	Novartis	A 52-week, multicenter, randomized, double-blind study of subcutaneous secukinumab to demonstrate efficacy as assessed by Psoriasis Area and Severity Index at 16 weeks of treatment compared to ustekinumab and to assess long-term safety, tolerability and efficacy in subjects with moderate to severe plaque psoriasis (CLEAR)	secukinumab	CAIN457A2317	Psoriasis	Phase 3	https://www.novctrd.com/ctrdweb/trialresult/trialresults/pdf?trialResultId=16409	https://www.clinicaltrials.gov/ct2/show/NCT2074982?term=CAIN457A2317&rank=1	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003434-32	Y	Y	Y	Y	Y	Y	Y		1-Jan-2020
20265	Novartis	A 52-week, randomized, double-blind study of secukinumab (300 mg) compared to ustekinumab in subjects with moderate to severe plaque psoriasis	secukinumab	CAIN457A2326	Psoriasis	Phase 3	https://www.novctrd.com/ctrdweb/trialresult/trialresults/pdf?trialResultId=17439	https://www.clinicaltrials.gov/ct2/show/NCT2826603?term=CAIN457A2326&rank=1	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-002898-37	Y	Y	Y	Y	Y	Y	Y		1-Jan-2020
20266	Novartis	A randomized, double-blind, placebo-controlled, multicenter study to demonstrate the efficacy at 16 weeks of secukinumab 150 and 300 mg s.c. and to assess safety, tolerability and long-term efficacy up to 132 weeks in subjects with moderate to severe palmoplantar psoriasis	secukinumab	CAIN457A2312	Psoriasis, Palmoplantar	Phase 3	https://www.novctrd.com/ctrdweb/trialresult/trialresults/pdf?trialResultId=16828	https://www.clinicaltrials.gov/ct2/show/NCT1806597?term=CAIN457A2312&rank=1	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-005412-25	Y	Y	Y	Y	Y	Y	Y		1-Jan-2020
20267	Novartis	A randomized, double-blind, placebo-controlled, multicenter, study to demonstrate the efficacy at 16 weeks of secukinumab 150 and 300 mg s.c. and to assess safety, tolerability and long-term efficacy up to 132 weeks in subjects with moderate to severe nail psoriasis	secukinumab	CAIN457A2313	Psoriasis, nail	Phase 3	https://www.novctrd.com/ctrdweb/trialresult/trialresults/pdf?trialResultId=16951	https://www.clinicaltrials.gov/ct2/show/NCT1807520?term=CAIN457A2313&rank=1	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-005413-40	Y	Y	Y	Y	Y	Y	Y		1-Jan-2020
20269	Astellas	A phase IIIb randomized study of intermittent versus continuous androgen deprivation therapy using ELIGARD 22.5 mg 3-month depot in patients with relapsing or locally advanced prostate cancer who are responsive to such therapy	leuprorelin acetate	EGD-EC-003	Prostate Cancer	Phase 3	https://www.clinicaltrials.astellas.com/study/?pid=EGD-EC-003	https://clinicaltrials.gov/ct2/show/NCT00378690		Y	N	Y	Y	Y	Y	N		1-Jan-2020
20270	Astellas	An Open-Label, Long-Term Extension, Multi-center, Sequential Dose Titration Study to Assess Safety and Efficacy of Solifenacin Succinate Suspension in Pediatric Subjects with Overactive Bladder (OAB)	solifenacin succinate	905-CL-077	Urinary Bladder, Overactive	Phase 3	https://www.clinicaltrials.astellas.com/study/?pid=905-CL-077	https://clinicaltrials.gov/ct2/show/NCT01655069	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002047-10	Y	Y	Y	Y	Y	Y	Y		1-Jan-2020
20271	Astellas	A randomized, double-blind, parallel-group, placebo- and active- controlled, multicenter study to evaluate the efficacy, safety and tolerability of combinations of Solifenacin Succinate and Mirabegron compared to Solifenacin Succinate and Mirabegron monotherapy in the treatment of overactive bladder	mirabegron	178-CL-101	Urinary Bladder, Overactive	Phase 3	https://www.clinicaltrials.astellas.com/study/?pid=178-CL-101	https://clinicaltrials.gov/ct2/show/NCT01972841	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-005735-91	Y	Y	Y	Y	Y	Y	Y		1-Jan-2020
20272	Astellas	A Phase 4, Double-Blind, Randomized, Placebo-Controlled, Parallel Group, Multi-Center, Study to Evaluate the Efficacy, Safety, and Tolerability of Mirabegron in Older Adult Subjects with Overactive Bladder (OAB)	mirabegron	178-MA-1005	Urinary Bladder, Overactive	Phase 4	https://www.clinicaltrials.astellas.com/study/?pid=178-MA-1005	https://clinicaltrials.gov/ct2/show/NCT02216214		Y	Y	Y	Y	Y	Y	Y		1-Jan-2020
20273	ViiV	An evaluation of bone mineral density in HIV-1-infected adult subjects switching from a tenofovir-containing antiretroviral therapy regimen to a dolutegravir plus rilpivirine regimen	dolutegravir	202094	Infection, Human Immunodeficiency Virus	Phase 3	http://www.viiv-clinicalstudyregister.com/study/202094	http://clinicaltrials.gov/show/NCT02478632		Y	Y	Y	Y	Y	Y	Y	This is a sub-study of 201636 and 201637. This study is available in CDISC format.	1-Jan-2020
20274	GSK	A Phase 1, Randomized, Observer-Blind, Dosage-Escalation Study to Evaluate the Safety and Immunogenicity of an Aluminium Hydroxide/LHD153R Adjuvanted Meningococcal C-CRM197 Conjugate Vaccine Compared to Aluminium Hydroxide Adjuvanted Meningococcal C-CRM197 Conjugate Vaccine in Healthy Adults (18-45 years of age).	GSK3536834A	205496	Infections, Meningococcal	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=205496	http://clinicaltrials.gov/show/NCT02639351	https://www.clinicaltrialsregister.eu/ctr-search/search?query=/2014-002430-31	Y	N	Y	Y	Y	Y	Y	An annotated case report form is not available for this study. A blank case report form will be provided.	1-Jan-2020
20275	GSK	Immunogenicity and safety study of GSK Biologicals’ dTpa vaccine, Boostrix™ (263855) in pregnant women	Combined Reduced Antigen Content Diphtheria, Tetanus, Acellular Pertussis Vaccine	116945	Diphtheria; Tetanus; Acellular pertussis	Phase 4	https://www.gsk-studyregister.com/en/trial-details/?id=116945	http://clinicaltrials.gov/show/NCT02377349	https://www.clinicaltrialsregister.eu/ctr-search/search?query=/2014-001119-38	Y	Y	Y	Y	Y	Y	Y	Follow-on studies 201330 and 201334 were conducted.	1-Jan-2020
20276	GSK	Immunogenicity and safety study of GSK Biologicals’ combined diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated polio-virus and Haemophilus influenzae type b vaccine (Infanrix hexa™) (217744) in healthy infants born to mothers vaccinated with Boostrix™ during pregnancy or immediately post-delivery	SB217744	201330	Diphtheria; Tetanus; Acellular pertussis; Hepatitis B; Poliomyelitis; Haemophilus influenzae type b	Phase 4	https://www.gsk-studyregister.com/en/trial-details/?id=201330	http://clinicaltrials.gov/show/NCT02422264	https://www.clinicaltrialsregister.eu/ctr-search/search?query=/2014-001117-41	Y	Y	Y	Y	Y	Y	Y	This is a follow-up study to 116945.	1-Jan-2020
20277	GSK	A 24-week treatment, multi-center, randomized, double-blind, double-dummy, parallel group study to compare Umeclidinium/Vilanterol, Umeclidinium, and Salmeterol in subjects with chronic obstructive pulmonary disease (COPD)	umeclidinium bromide/vilanterol	201749	Pulmonary Disease, Chronic Obstructive	Phase 4	https://www.gsk-studyregister.com/en/trial-details/?id=201749	http://clinicaltrials.gov/show/NCT03034915	https://www.clinicaltrialsregister.eu/ctr-search/search?query=/2016-002513-22	Y	Y	Y	Y	Y	Y	Y	There is a Publication Steering Committee for this study. This study is available in CDISC format.	1-Jan-2020
20278	GSK	An open-label study in healthy male subjects, to determine the excretion balance and pharmacokinetics of [14C]-GSK2269557, administered as a single intravenous microtracer (concomitant with an inhaled non-radiolabelled dose) and a single oral dose	nemiralisib	206764	Pulmonary Disease, Chronic Obstructive	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=206764	http://clinicaltrials.gov/show/NCT03315559	https://www.clinicaltrialsregister.eu/ctr-search/search?query=/2017-002347-16	Y	N	Y	Y	Y	Y	Y	An annotated case report form is not available for this study. A blank case report form will be provided. This study is available in CDISC format.	1-Jan-2020
20279	GSK	A Multicentre, Open-Label, Long-Term, Safety and Tolerability Study of Retigabine Immediate Release (IR) in Adults with Partial-Onset Seizures (Extension of Study RGB113905)	retigabine, ezogabine	RTG113413	Epilepsy	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=113413	http://clinicaltrials.gov/show/NCT01336621	https://www.clinicaltrialsregister.eu/ctr-search/search?query=/2010-022777-34	Y	Y	Y	Y	Y	Y	Y	This is a follow-up study to RGB113905.	1-Jan-2020
20280	GSK	A Multicentre, Open-label, Long-term, Safety, Tolerability, and Efficacy Study of Retigabine Immediate-release (IR) in Asian Adults with Partial Onset Seizures (Extension of Study RTG114855)	retigabine, ezogabine	RTG114873	Epilepsy	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=114873	http://clinicaltrials.gov/show/NCT01777139		Y	N	Y	Y	Y	Y	Y	This is a follow-up study to RTG114855. An annotated case report form is not available for this study. A blank case report form will be provided. This study is available in CDISC format.	1-Jan-2020
20281	GSK	A Phase 2a, Multicenter, Randomized, Adaptive, Open-label, Dose ranging study to evaluate the antiviral effect, safety, tolerability and pharmacokinetics of Cobicistat-boosted GSK2838232 monotherapy over 10 days in HIV-1 infected treatment-naive adults	GSK2838232	200911	Infection, Human Immunodeficiency Virus	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=200911	http://clinicaltrials.gov/show/NCT03045861		Y	N	Y	Y	Y	Y	Y	An annotated case report form is not available for this study. A blank case report form will be provided. This study is available in CDISC format.	1-Jan-2020
20286	Astellas	A Multicentre, Open-label, Pharmacokinetic Study of Modigraf® (Tacrolimus Granules) in de Novo Paediatric Allograft Recipients	tacrolimus	F506-CL-0403	Prevention of rejection after organ transplant	Phase 4	https://www.clinicaltrials.astellas.com/study/?pid=F506-CL-0403	https://clinicaltrials.gov/ct2/show/NCT01371331	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-012258-19	Y	Y	Y	Y	Y	Y	Y		1-Feb-2020
20287	Astellas	Dose Escalation Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics of ASP2215 in Patients With Relapsed or Refractory Acute Myeloid Leukemia	gilteritinib fumarate	2215-CL-0101	Acute myeloid leukemia	Phase 1	https://www.clinicaltrials.astellas.com/study/?pid=2215-CL-0101	https://clinicaltrials.gov/ct2/show/NCT02014558		Y	Y	Y	Y	Y	Y	Y		1-Feb-2020
20288	Astellas	A PHASE 3, DOUBLE-BLIND, RANDOMIZED, MULTI-CENTER, PLACEBO-CONTROLLED SEQUENTIAL DOSE TITRATION STUDY TO ASSESS EFFICACY, SAFETY AND POPULATION PHARMACOKINETICS OF SOLIFENACIN SUCCINATE SUSPENSION IN PEDIATRIC SUBJECTS FROM 5 TO LESS THAN 18 YEARS OF AGE WITH OVERACTIVE BLADDER (OAB)	solifenacin succinate	905-CL-076	Urinary Bladder, Overactive	Phase 3	https://www.clinicaltrials.astellas.com/study/?pid=905-CL-076	https://clinicaltrials.gov/ct2/show/NCT01565707	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002066-20	Y	Y	Y	Y	Y	Y	Y		1-Feb-2020
20289	Astellas	A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of OSI-906 in Patients with Locally Advanced or Metastatic Adrenocortical Carcinoma	linsitinib	OSI-906-301	Adrenocortical carcinoma	Phase 3	https://www.clinicaltrials.astellas.com/study/?pid=OSI-906-301	https://clinicaltrials.gov/ct2/show/NCT00924989	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-012820-97	Y	Y	Y	Y	Y	Y	Y		1-Feb-2020
20290	Astellas	A Randomized, Double-blind, Placebo-controlled, Phase 2 Study to Assess the Efficacy, Safety, and Dose-Response Relationship of ASP1707 in Subjects with Endometriosis Associated Pelvic Pain for 12 Weeks, Followed by a 12-Week Double-blind Extension without Placebo Control, Including a 24-Week Open-Label Leuprorelin Acetate Treatment Group for Bone Mineral Density Assessment	ASP1707	1707-CL-0011	Endometriosis	Phase 2	https://www.clinicaltrials.astellas.com/study/?pid=1707-CL-0011	https://clinicaltrials.gov/ct2/show/NCT01767090	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002791-14	Y	Y	Y	Y	Y	Y	Y		1-Feb-2020
20291	Astellas	A Phase 2, Double-Masked, Randomized, Active Controlled Study to Evaluate the Efficacy and Safety of ASP8232 in Reducing Central Retinal Thickness in Subjects with Diabetic Macular Edema	ASP8232	8232-CL-3001	Diabetic macular edema	Phase 2	https://www.clinicaltrials.astellas.com/study/?pid=8232-CL-3001	https://clinicaltrials.gov/ct2/show/NCT02302079		Y	Y	Y	Y	Y	Y	Y		1-Feb-2020
20294	Astellas	A Phase 2 Open-label, Noncomparative, Multicenter Extension Study to Evaluate the Long-term Safety and Efficacy of ASP015K in Subjects Previously Enrolled in a Phase 2 ASP015K Rheumatoid Arthritis Study	peficitinib hydrobromide	015K-CL-RA25	Rheumatoid Arthritis	Phase 2	https://www.clinicaltrials.astellas.com/study/?pid=015K-CL-RA25	https://clinicaltrials.gov/ct2/show/NCT01711814	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-006021-23	Y	Y	Y	Y	Y	Y	Y		1-Feb-2020
20295	Novartis	β-SPECIFIC 4 Patients: Study of Pediatric EffiCacy and Safety wIth FIrst-line Use of Canakinumab An Open-label Canakinumab (ACZ885) Dose Reduction or Dose Interval Prolongation Efficacy and Safety Study in Patients With Systemic Juvenile Idiopathic Arthritis (SJIA)	canakinumab	CACZ885G2306	Systemic Juvenile Idiopathic Arthritis (SJIA)	Phase 3	https://www.novctrd.com/ctrdweb/trialresult/trialresults/pdf?trialResultId=17206	https://www.clinicaltrials.gov/ct2/show/NCT02296424?term=CACZ885G2306&draw=2&rank=2	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004867-29	Y	Y	Y	Y	Y	Y	Y		1-Feb-2020
20296	Novartis	A Phase II, Double-blind, Randomized, Multi-center, Adaptive Dose-ranging, Placebo-controlled, Parallel-group Study Evaluating Safety, Tolerability and Efficacy on MRI Lesion Parameters and Determining the Dose Response Curve of BAF312 Given Orally Once Daily in Patients With Relapsing-remitting Multiple Sclerosis	siponimod	CBAF312A2201	Relapsing-remitting Multiple Sclerosis	Phase 2	https://www.novctrd.com/ctrdweb/trialresult/trialresults/pdf?trialResultId=6043	https://www.clinicaltrials.gov/ct2/show/NCT879658?term=CBAF312A2201	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-008719-25	Y	Y	Y	Y	Y	Y	Y		1-Feb-2020
20297	Novartis	"Evaluation of Triclabendazole (CGP 23030) in the treatment of chronic human infection with Fasciola hepatica (liver fluke) in Iran."	triclabendazole	CEGA230B2201	Fasciolasis	Phase 2				Y	N	Y	N	N	N	N		1-Feb-2020
20298	Novartis	"Evaluation of Triclabendazole (CGP 23030) in the treatment of chronic human infection with Fasciola hepatica (liver fluke) in Chile."	triclabendazole	CEGA230B2202	Fasciolasis	Phase 2				N	N	Y	N	N	N	N		1-Feb-2020
20299	Novartis	"Evaluation of Triclabendazole (CGP 23030) in the treatment of chronic human infection with Fasciola hepatica (liver fluke) in Cuba."	triclabendazole	CEGA230B2203	Fasciolasis	Phase 2				N	N	Y	N	N	N	N		1-Feb-2020
20300	Novartis	"Evaluation of Triclabendazole (CGP 23030) in the treatment of chronic human infection with Fasciola hepatica (liver fluke) in Bolivia."	triclabendazole	CEGA230B2207	Fasciolasis	Phase 2				N	N	Y	N	N	N	N		1-Feb-2020
20301	Novartis	"Dose finding trial with postprandial triclabendazole in Bolivian children infected with Fasciola hepatica (liver fluke)."	triclabendazole	CEGA230B2208	Fasciolasis	Phase 2				N	N	Y	N	N	N	N		1-Feb-2020
20302	Novartis	"Combined clinicopharmacokinetic trial of triclabendazole in Peruvian patients  infected with Fasciola hepatica (liver fluke)."	triclabendazole	CEGA230B2212	Fasciolasis	Phase 2				N	N	Y	N	N	N	N		1-Feb-2020
20303	GSK	Effects of Dopaminergic Agonist Treatment on Spinal Cord Excitability in Restless Legs Syndrome	ropinirole	999910/188	Restless Legs Syndrome	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=999910/188			N	N	Y	Y	Y	Y	Y	An analysis-ready dataset is not available for this study. An annotated case report form is not available for this study. A blank case report form will be provided. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Jun-2014
20304	GSK	A single dose study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of GSK1550188 in Chinese subjects with Systemic Lupus Erythematosus (SLE)	belimumab	200909	Systemic Lupus Erythematosus	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=200909	http://clinicaltrials.gov/show/NCT02880852		Y	Y	Y	Y	Y	Y	Y	This study is available in CDISC format.	1-Feb-2020
20305	GSK	A single centre, open-label, parallel-group, single oral dose study to evaluate the pharmacokinetics, safety and tolerability of Pyrimethamine in healthy Japanese and Caucasian male subjects	pyrimethamine	204678	Toxoplasmosis	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=204678	http://clinicaltrials.gov/show/NCT03258762		Y	Y	Y	Y	Y	Y	Y	This study is available in CDISC format.	1-Feb-2020
20306	GSK	Randomized, open label, 2-way crossover, single dose bioequivalence study of Paroxetine IR tablets manufactured in GSKT and Mississauga sites in healthy Chinese participants under fasting and fed conditions	paroxetine	207652	Anxiety Disorders	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=207652	http://clinicaltrials.gov/show/NCT03329573		Y	N	Y	Y	Y	Y	Y	An annotated case report form is not available for this study. A blank case report form will be provided. This study is available in CDISC format.	1-Feb-2020
20307	GSK	BEL114333, a Multicenter, Continuation Study of Belimumab in subjects with Systemic Lupus Erythematosus (SLE) who Completed the Phase III study BEL113750 in Northeast Asia or completed the open-label extension of HGS1006-C1115 in Japan	belimumab	BEL114333	Systemic Lupus Erythematosus	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=114333	http://clinicaltrials.gov/show/NCT01597622		Y	N	Y	Y	Y	Y	Y	This is a follow-up study to BEL113750 and HGS1006-C1115. An annotated case report form is not available for this study. A blank case report form will be provided. This study is available in CDISC format.	1-Feb-2020
20308	Astellas	A Phase 2 Study Determining Safety and Tolerability of Enzalutamide (formerly MDV3100) in Combination with Abiraterone Acetate in Bone Metastatic Castration-Resistant Prostate Cancer Patients	enzalutamide	9785-CL-0011	Prostate cancer	Phase 2	https://www.clinicaltrials.astellas.com/study/?pid=9785-CL-0011	https://clinicaltrials.gov/ct2/show/NCT01650194		Y	Y	Y	Y	Y	Y	Y		1-Feb-2020
20309	Astellas	A Randomized, Double-Blind, Multi-Centre Study to Evaluate the Efficacy and Safety of Adding Mirabegron to Solifenacin in Incontinent OAB Subjects who have Received Solifenacin for 4 Weeks and Warrant Additional Relief for their OAB Symptoms	solifenacin succinate	905-EC-012	Urinary Bladder, Overactive	Phase 3	https://www.clinicaltrials.astellas.com/study/?pid=905-EC-012	https://clinicaltrials.gov/ct2/show/NCT01908829	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-005401-41	Y	Y	Y	Y	Y	Y	Y		1-Feb-2020
20310	Astellas	A Phase 2, Double-Blind, Randomized, Placebo Controlled Study to Evaluate the Efficacy and Safety of ASP8232 as Add-On Therapy to Angiotensin Converting Enzyme inhibitor (ACEi) or Angiotensin Receptor Blocker (ARB) in Reducing Albuminuriain Patients with Type 2 Diabetes and Chronic Kidney Disease	ASP8232	8232-CL-0004	Diabetic kidney disease	Phase 2	https://www.clinicaltrials.astellas.com/study/?pid=8232-CL-0004	https://clinicaltrials.gov/ct2/show/NCT02358096	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-002349-23	Y	Y	Y	Y	Y	Y	Y		1-Feb-2020
20311	Astellas	An open-label, phase 1 dose escalation study of oral ASP8273 in subjects with non-small-cell lung cancer (NSCLC) who have epidermal growth factor receptor (EGFR) mutations	naquotinib mesilate	8273-CL-0102	Non-small cell lung cancer	Phase 1	https://www.clinicaltrials.astellas.com/study/?pid=8273-CL-0102	https://clinicaltrials.gov/ct2/show/NCT02113813		Y	Y	Y	Y	Y	Y	Y		1-Feb-2020
20312	Astellas	A Phase 4, Double-blind, Randomized, Placebo-controlled, Multicenter Study to Evaluate the Efficacy, Safety and Tolerability of Mirabegron in Men with Overactive Bladder (OAB) Symptoms While Taking the Alpha Blocker Tamsulosin Hydrochloride for Lower Urinary Tract Symptoms (LUTS) due to Benign Prostatic Hyperplasia (BPH)	mirabegron	178-MA-1008	Urinary Bladder, Overactive	Phase 4	https://www.clinicaltrials.astellas.com/study/?pid=178-MA-1008	https://clinicaltrials.gov/ct2/show/NCT02757768	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-004036-36	Y	Y	Y	Y	Y	Y	Y		1-Feb-2020
20313	Astellas	Phase II Study of ASP0456 - A Double-blind, Placebo-controlled, Parallel-group, Comparative Study in Patients With Chronic Constipation (Not Including Constipation Due to Organic Diseases)	linaclotide	0456-CL-1021	Chronic constipation	Phase 2	https://www.clinicaltrials.astellas.com/study/?pid=0456-CL-1021	https://clinicaltrials.gov/ct2/show/NCT02425722		Y	N	Y	Y	N	Y	N	Synoptic CSR available	1-Feb-2020
20314	Astellas	Phase 3 Study of ASP0456 - A Double-blind, Placebo-controlled, Parallel-group, Comparative Study and an Open-label, Uncontrolled, Long-term Dosing Study in Patients with Chronic Constipation (Not Including Constipation Due to Organic Diseases) -	linaclotide	0456-CL-1031	Chronic constipation	Phase 3	https://www.clinicaltrials.astellas.com/study/?pid=0456-CL-1031	https://clinicaltrials.gov/ct2/show/NCT02809105		Y	N	Y	Y	N	Y	N	Synoptic CSR available	1-Feb-2020
20316	Novartis	Letrozole in the Treatment of Severe and Recurrent Endometriosis	letrozole	CFEM345ADE04	Endometriosis	Phase 2		https://clinicaltrials.gov/ct2/show/study/NCT00240942		N	N	Y	N	N	N	N		1-Mar-2020
20317	Novartis	An Extension Study to the CBAF312A2201 study to evaluate long-term safety, tolerability and efficacy of BAF312 given orally once daily in patients with relapsing- remitting multiple sclerosis	siponimod	CBAF312A2201E1	Relapsing Remitting Multiple Sclerosis	Phase 2	https://www.novctrd.com/ctrdweb/trialresult/trialresults/pdf?trialResultId=16747	https://www.clinicaltrials.gov/ct2/show/NCT1185821?term=CBAF312A2201E1&rank=1	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-014392-51	Y	Y	Y	Y	Y	Y	Y		1-Mar-2020
20318	Novartis	A Phase I/II Study to Assess the Safety and Efficacy of Pazopanib and MK 3475 in Patients With Advanced Renal Cell Carcinoma	pazopanib	CPZP034A2101	Renal cell carcinoma	Phase 1/2	https://www.novctrd.com/ctrdweb/trialresult/trialresults/pdf?trialResultId=17626	https://www.clinicaltrials.gov/ct2/show/NCT02014636	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003785-14	Y	Y	Y	Y	Y	Y	Y		1-Mar-2020
20319	Novartis	A Randomized, Open-label, Multi-center Phase II Study to Compare Bevacizumab Plus RAD001 Versus Interferon Alfa-2a Plus Bevacizumab for the First-line Treatment of Patients With Metastatic Clear Cell Carcinoma of the Kidney	pazopanib	CRAD001L2201	Renal cell carcinoma	Phase 2	https://www.novctrd.com/ctrdweb/trialresult/trialresults/pdf?trialResultId=11483	https://www.clinicaltrials.gov/ct2/show/NCT719264?term=CRAD001L2201&rank=1	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000077-38	Y	Y	Y	Y	Y	Y	Y		1-Mar-2020
20320	Astellas	A phase 2, open-label, single-arm, efficacy and safety study of MDV3100 in patients with hormone-naïve prostate cancer	enzalutamide	9785-CL-0321	Prostate cancer	Phase 2	https://www.clinicaltrials.astellas.com/study/?pid=9785-CL-0321	https://clinicaltrials.gov/ct2/show/NCT01302041	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-021287-16	Y	Y	Y	Y	Y	Y	Y		1-Mar-2020
20321	Astellas	A Phase 3, Open-Label, Baseline-controlled, Multicenter, Sequential Dose Titration Study to Assess the Long-Term Efficacy and Safety, and the Pharmacokinetics of Solifenacin Succinate Suspension in Patients from 5 to Less than 18 years of Age with Neurogenic Detrusor Overactivity (NDO)	solifenacin succinate	905-CL-047	Neurogenic detrusor overactivity	Phase 3	https://www.clinicaltrials.astellas.com/study/?pid=905-CL-047	https://clinicaltrials.gov/ct2/show/NCT01565694	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000330-11	Y	Y	Y	Y	Y	Y	Y		1-Mar-2020
20322	Astellas	A Phase 1 Dose Escalation Study of Intermittent Oral OSI-906 Dosing in Patients with Advanced Solid Tumors	linsitinib	OSI-906-102	Solid tumors	Phase 1	https://www.clinicaltrials.astellas.com/study/?pid=OSI-906-102	https://clinicaltrials.gov/ct2/show/NCT00514306	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005938-20	Y	Y	Y	Y	Y	Y	Y		1-Mar-2020
20323	Astellas	A Phase 1 Dose Escalation Study of Continuous Oral OSI-906 Dosing in Patients with Advanced Solid Tumors	linsitinib	OSI-906-101	Solid tumors	Phase 1	https://www.clinicaltrials.astellas.com/study/?pid=OSI-906-101	https://clinicaltrials.gov/ct2/show/NCT00514007	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005937-39	Y	Y	Y	Y	Y	Y	Y		1-Mar-2020
20324	Astellas	A Phase 3, Double-blind, Randomized Study to Assess the Efficacy and Safety of Ipragliflozin in Combination with Metformin Compared to Metformin Plus Placebo in Subjects in Russia with Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Metformin	ipragliflozin	1941-CL-9001	Diabetes Mellitus, Type 2	Phase 3	https://www.clinicaltrials.astellas.com/study/?pid=1941-CL-9001	https://clinicaltrials.gov/ct2/show/NCT02794792		Y	Y	Y	Y	Y	Y	Y		1-Mar-2020
20325	Astellas	A phase 2, randomized, double-blind, placebo-controlled, parallel group, adaptive, combined proof of concept and dose-finding study to investigate efficacy, safety, pharmacodynamics and pharmacokinetics of ASP3652 in the treatment of female subjects with Bladder Pain Syndrome / Interstitial Cystitis	ASP3652	3652-CL-0018	Bladder Pain	Phase 2	https://www.clinicaltrials.astellas.com/study/?pid=3652-CL-0018	https://clinicaltrials.gov/ct2/show/NCT01613586	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004555-39	Y	Y	Y	Y	Y	Y	Y		1-Mar-2020
20326	Astellas	A Phase 2a, Randomized, Double-Blind, Placebo-Controlled, Sequential Group, Multiple-Dose Escalation Study to Evaluate the Efficacy and Safety of ASP015K in Subjects with Moderate to Severe Plaque Psoriasis	peficitinib hydrobromide	015K-CL-PS01	Psoriasis	Phase 2	https://www.clinicaltrials.astellas.com/study/?pid=015K-CL-PS01	https://clinicaltrials.gov/ct2/show/NCT01096862		Y	Y	Y	Y	Y	Y	Y		1-Mar-2020
20327	Astellas	A Phase I Dose-escalation Study of OSI-906 and Erlotinib (Tarceva®) in Patients With Advanced Solid Tumors	linsitinib	OSI-906-103	Solid tumors	Phase 1	https://www.clinicaltrials.astellas.com/study/?pid=OSI-906-103	https://clinicaltrials.gov/ct2/show/NCT00739453	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001743-20	Y	Y	Y	Y	Y	Y	Y		1-Mar-2020
20328	Astellas	A Phase 1/2 Study Evaluating Intermittent and Continuous OSI-906 and Weekly Paclitaxel in Patients with Recurrent Epithelial Ovarian Cancer (and Other Solid Tumors)	linsitinib	OSI-906-202	Ovarian cancer	Phase 2	https://www.clinicaltrials.astellas.com/study/?pid=OSI-906-202	https://clinicaltrials.gov/ct2/show/NCT00889382	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-010319-34	Y	Y	Y	Y	Y	Y	Y		1-Mar-2020
20329	GSK	A randomized, double-blind, placebo-controlled, parallel group study of once-daily inhaled Fluticasone Furoate Inhalation Powder for six weeks on the hypothalamic-pituitary-adrenocortical axis of children aged 5-11 years with asthma	fluticasone furoate	HZA107118	Asthma	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=107118	http://clinicaltrials.gov/show/NCT02483975		Y	Y	Y	Y	Y	Y	Y	This study is available in CDISC format.	1-Mar-2020
20330	GSK	A single centre, open label, one sequence, cross-over study to evaluate the effect of itraconazole on the pharmacokinetics of single inhaled doses of nemiralisib in healthy subjects	nemiralisib	206874	Pulmonary Disease, Chronic Obstructive	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=206874	http://clinicaltrials.gov/show/NCT03398421		Y	N	Y	Y	Y	Y	Y	An annotated case report form is not available for this study. A blank case report form will be provided. This study is available in CDISC format.	1-Mar-2020
20331	GSK	Long-term immunogenicity of the HIV gp120-NefTat/AS01B vaccine (GSK SB732461)	SB732461	201606	Infection, Human Immunodeficiency Virus	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=201606	http://clinicaltrials.gov/show/NCT03368053		Y	Y	Y	Y	Y	Y	Y	This is a long term immunogenicity follow-up study to 732461/002. This study is available in CDISC format.	1-Mar-2020
20332	GSK	Immunogenicity and safety of GSK Biologicals’ combined diphtheria-tetanus-acellular pertussis-inactivated poliovirus and Haemophilus influenzae type b (DTPa-IPV/Hib) conjugate vaccine	SB213503	116194	Diphtheria; Tetanus; Pertussis; Hepatitis B; Haemophilus influenzae type b	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=116194	http://clinicaltrials.gov/show/NCT02858440	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-005577-43	Y	Y	Y	Y	Y	Y	Y		1-Mar-2020
20333	GSK	A phase I-II double-blind ,randomized study to compare the safety and immunogenicity of GSK Biologicals' candidate HIV vaccine gp120NefTat(20µg) adjuvanted to AS02A, AS02V or AS01B administered intramuscalarly to healthy HIV seronegative volunteers.	SB732461	732461/002	Infection, Human Immunodeficiency Virus	Phase 1				Y	N	Y	Y	Y	Y	Y	A long term immunogenicity follow-up study 201606 was conducted. An annotated case report form is not available for this study. A blank case report form will be provided. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies. There is no GSK Study Register entry for this study.	1-Mar-2020
20343	GSK	A phase III study (a placebo controlled, randomized, double-blind comparative study and an open-label, uncontrolled study) to evaluate the efficacy and safety of GSK1358820 in patients with post-stroke upper limb spasticity	OnabotulinumtoxinA	207660	Spasticity, Post-Stroke	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=207660	http://clinicaltrials.gov/show/NCT03261167		Y	Y	Y	Y	Y	Y	Y		1-Apr-2020
20344	GSK	A single centre, single dose, open-label, randomized, 2-part, 2-way crossover study to determine the bioequivalence of levocetirizine oral disintegrating tablet given with water and without water compared to levocetirizine immediate release tablet in healthy Japanese male subjects	levocetirizine	204706	Rhinitis	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=204706	http://clinicaltrials.gov/show/NCT03555890		Y	Y	Y	Y	Y	Y	Y		1-Apr-2020
20345	GSK	Prospective, observational, multicentre, community-physician based surveillance to estimate the incidence, complications, economic burden and impact on quality of life of herpes zoster in adults >=50 years of age in Germany	Herpes Zoster subunit (HZ/su) vaccine	BEP113206	Herpes Zoster	N/A				Y	Y	Y	Y	Y	Y	Y	There is no GSK Study Register entry for this study.	1-Apr-2020
20346	GSK	Population based surveillance to estimate the burden of herpes zoster and post-herpetic neuralgia in Italy	Herpes Zoster subunit (HZ/su) vaccine	BEP116208	Herpes Zoster	N/A	https://www.gsk-studyregister.com/en/trial-details/?id=116208	http://clinicaltrials.gov/show/NCT01772160		Y	N	Y	Y	Y	Y	Y	An annotated case report form and a blank case report form are not available for this study.	1-Apr-2020
20347	GSK	Physician-practice based cohort study to estimate the burden of herpes zoster and postherpetic neuralgia in Japan	Herpes Zoster subunit (HZ/su) vaccine	200089	Herpes Zoster	N/A	https://www.gsk-studyregister.com/en/trial-details/?id=200089	http://clinicaltrials.gov/show/NCT01873365		Y	Y	Y	Y	Y	Y	Y		1-Apr-2020
20348	GSK	Safety and immunogenicity study of GSK Biologicals’ investigational recombinant chimpanzee adenovirus Type 3-vectored Ebola Zaire vaccine (GSK3390107A) in children in Africa	GSK3390107A	202090	Virus Diseases	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=202090	http://clinicaltrials.gov/show/NCT02548078	https://www.clinicaltrialsregister.eu/ctr-search/search?query=/2014-004714-28	Y	Y	Y	Y	Y	Y	Y		1-Apr-2020
20349	GSK	Safety and immunogenicity study of GSK Biologicals’ investigational recombinant chimpanzee adenovirus Type 3-vectored Ebola Zaire vaccine (GSK3390107A) in adults in Africa	GSK3390107A	202091	Virus Diseases	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=202091	http://clinicaltrials.gov/show/NCT02485301		Y	Y	Y	Y	Y	Y	Y		1-Apr-2020
20350	GSK	A Phase II, Randomized, Comparative, Observer-Blind, Multi-Center Study evaluating the Safety and Immunogenicity of the Liquid Formulation of Group B Streptococcus Trivalent Vaccine and of the Lyophilized Formulation of Group B Streptococcus Trivalent Vaccine in Healthy Non-Pregnant Women aged 18 to 40 Years	GSK3536855A	205220	Infections, Streptococcal	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=205220	http://clinicaltrials.gov/show/NCT02270944	https://www.clinicaltrialsregister.eu/ctr-search/search?query=/2013-003111-22	Y	Y	Y	Y	Y	Y	Y		1-Apr-2020
20355	Novartis	A Multi-center, Randomized, 12-week Treatment, Doubleblind Study to Assess the Efficacy and Safety of QMF149 (150/80 Microgram) Compared With MF Twisthaler® (200 Microgram) in Adult and Adolescent Patients With Asthma	Indacaterol acetate/Mometasone furoate	CQVM149B2303	Asthma	Phase 3	https://www.novctrd.com/ctrdweb/trialresult/trialresults/pdf?trialResultId=17395	https://www.clinicaltrials.gov/ct2/show/NCT02892344?term=CQVM149B2303&draw=2&rank=1	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000472-22	Y	Y	Y	Y	Y	Y	Y		1-May-2020
20356	Novartis	A multi-center, randomized, 52 week treatment, double-blind, triple-dummy, parallel-group study to assess the efficacy and safety of QMF149 compared with mometasone furoate in patients with asthma.	Indacaterol acetate/Mometasone furoate	CQVM149B2301	Asthma	Phase 3	https://www.novctrd.com/ctrdweb/trialresult/trialresults/pdf?trialResultId=17554	https://www.clinicaltrials.gov/ct2/show/NCT02554786?term=CQVM149B2301&draw=2&rank=1		Y	Y	Y	Y	Y	Y	Y		1-May-2020
20357	Novartis	A 26 week, randomized, active-controlled safety study of double-blind formoterol fumarate in free combination with an inhaled corticosteroid versus an inhaled corticosteroid in adolescent and adult patients with persistent asthma.	formoterol fumarate	CFOR258D2416	Asthma	Phase 3	https://www.novctrd.com/ctrdweb/trialresult/trialresults/pdf?trialResultId=15408	https://www.clinicaltrials.gov/ct2/show/NCT1845025?term=CFOR258D2416&rank=1	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-004854-27	Y	Y	Y	Y	Y	Y	Y		1-May-2020
20359	Astellas	A Phase 4, Double-blind, Randomized, Placebo-controlled Multicenter Study to Evaluate the Efficacy and Safety of Mirabegron in Japanese and Korean Male Patients with Overactive Bladder under Treatment with the α-Blocker Tamsulosin for Benign Prostatic Hyperplasia	mirabegron	178-MA-3016	Urinary Bladder, Overactive	Phase 4	https://www.clinicaltrials.astellas.com/study/?pid=178-MA-3016	https://clinicaltrials.gov/ct2/show/NCT02656173		Y	Y	Y	Y	Y	Y	Y		1-May-2020
20360	Astellas	A Phase III, Double-Blind, Randomized Study to Evaluate the Safety and Efficacy of BAL8557 Versus a Caspofungin Followed by Voriconazole Regimen in the Treatment of Candidemia and Other Invasive Candida Infections	isavuconazonium sulfate	9766-CL-0105	Invasive fungal infection	Phase 3	https://www.clinicaltrials.astellas.com/study/?pid=9766-CL-0105	https://clinicaltrials.gov/ct2/show/NCT00413218	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003951-18	Y	Y	Y	Y	Y	Y	Y		1-May-2020
20361	ViiV	A Phase I Study to Evaluate the Pharmacokinetics and Safety of GSK1265744 in Subjects with Hepatic Impairment and Healthy Matched Control Subjects	cabotegravir	201479	Infection, Human Immunodeficiency Virus	Phase 1	https://www.viiv-studyregister.com/en/study/?id=201479	http://clinicaltrials.gov/show/NCT02354950		Y	Y	Y	Y	Y	Y	Y	The data for this study is available in CDISC format.	1-May-2020
20362	ViiV	A Phase I, Open-Label, Parallel-Group Study to Evaluate the Pharmacokinetics and Safety of GSK1265744 in Subjects with Severe Renal Impairment and Healthy Matched Control Subjects	cabotegravir	201480	Infection, Human Immunodeficiency Virus	Phase 1	https://www.viiv-studyregister.com/en/study/?id=201480	http://clinicaltrials.gov/show/NCT02354937		Y	Y	Y	Y	Y	Y	Y	The data for this study is available in CDISC format.	1-May-2020
20363	ViiV	Phase I, single-center, open label, fixed-sequence cross-over study to evaluate the effect of rifabutin on the pharmacokinetics of oral cabotegravir in healthy subjects	cabotegravir	205712	Infection, Human Immunodeficiency Virus	Phase 1	https://www.viiv-studyregister.com/en/study/?id=205712	http://clinicaltrials.gov/show/NCT03149848	https://www.clinicaltrialsregister.eu/ctr-search/search?query=/2017-000103-25	Y	Y	Y	Y	Y	Y	Y	The data for this study is available in CDISC format.	1-May-2020
20364	ViiV	A Phase III, Randomized, Multicenter, Parallel-group, Open-Label Study Evaluating the Efficacy, Safety, and Tolerability of Long-Acting Intramuscular Cabotegravir and Rilpivirine for Maintenance of Virologic Suppression Following Switch from an Integrase Inhibitor Single Tablet Regimen in HIV-1 Infected Antiretroviral Therapy Naive Adult Participants	cabotegravir; rilpivirine	201584	Infection, Human Immunodeficiency Virus	Phase 3	https://www.viiv-studyregister.com/en/study/?id=201584	http://clinicaltrials.gov/show/NCT02938520	https://www.clinicaltrialsregister.eu/ctr-search/search?query=/2016-001646-25	Y	Y	Y	Y	Y	Y	Y	A sister study 201585 was conducted. This study is still ongoing, however data related to the publication(s) is available. The data for this study is available in CDISC format.	1-May-2020
20365	GSK	A randomized, examiner blind, crossover, in situ erosion study to investigate the efficacy of an experimental dentifrice in remineralization of previously softened enamel compared to a placebo dentifrice	potassium nitrate/sodium fluoride	208166	Tooth Erosion	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=208166	http://clinicaltrials.gov/show/NCT03296072		Y	Y	Y	Y	Y	Y	Y	The raw data are included within the analysis-ready data for this study and are not provided separately.	1-May-2020
20366	GSK	Study 110933: Albiglutide versus Placebo in insulin-treated Subjects with new-onset type 1 diabetes mellitus	albiglutide	GLP110933	Diabetes Mellitus, Type 1	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=110933	http://clinicaltrials.gov/show/NCT02284009	https://www.clinicaltrialsregister.eu/ctr-search/search?query=/2014-001825-33	Y	Y	Y	Y	Y	Y	Y	The data for this study is available in CDISC format.	1-May-2020
20367	GSK	A 24 Week Randomised, Double blind and Placebo controlled Study to Evaluate the Efficacy and Safety of 62.5 mcg Umeclidinium Inhalation Powder Delivered Once daily via a Novel Dry Powder Inhaler in Subjects with Chronic Obstructive Pulmonary Disease	umeclidinium bromide	AC4117410	Pulmonary Disease, Chronic Obstructive	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=117410	http://clinicaltrials.gov/show/NCT02184611		Y	Y	Y	Y	Y	Y	Y		1-May-2020
20368	GSK	A Phase IIa Single-Center, Open-Label Study Evaluating the Pharmacokinetics of Repeat Oral Doses of Gepotidacin (GSK2140944) in Adult Female Participants With Uncomplicated Urinary Tract Infection (Acute Cystitis)	gepotidacin	206899	Infections, Bacterial	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=206899	http://clinicaltrials.gov/show/NCT03568942		Y	Y	Y	Y	Y	Y	Y	The data for this study is available in CDISC format.	1-May-2020
20369	GSK	A single centre, single dose, open-label, randomised, 2-way crossover study in healthy Japanese male subjects to evaluate the bioequivalence of daprodustat tablets (2 mg tablet vs. 4 mg tablet) (Part 1) and the food effect on the pharmacokinetics of daprodustat (Part 2)	daprodustat	207727	Anaemia	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=207727	http://clinicaltrials.gov/show/NCT03493386		Y	Y	Y	Y	Y	Y	Y	The data for this study is available in CDISC format.	1-May-2020
20371	GSK	A double-blind (sponsor unblind), randomized, placebo-controlled, single and repeat escalating dose study to investigate the safety, tolerability, and pharmacokinetics of CCI15106 capsules for inhalation in healthy subjects and patients with moderate chronic obstructive pulmonary disease (COPD)	ribavirin	202031	Pulmonary Disease, Chronic Obstructive	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=202031	http://clinicaltrials.gov/show/NCT03243760	https://www.clinicaltrialsregister.eu/ctr-search/search?query=/2015-003960-35	Y	N	Y	Y	Y	Y	Y	An annotated case report form is not available for this study. A blank case report form will be provided. The data for this study is available in CDISC format.	1-May-2020
20372	GSK	A randomized, open-label, cross-over, placebo inhaler study to evaluate the correct use of ELLIPTA™ dry powder inhaler (DPI) compared to DISKUS™ DPI used in combination with HandiHaler DPI in participants with Chronic Obstructive Pulmonary Disease (COPD)	fluticasone furoate/vilanterol/umeclidinium bromide	206901	Pulmonary Disease, Chronic Obstructive	Phase 4	https://www.gsk-studyregister.com/en/trial-details/?id=206901	http://clinicaltrials.gov/show/NCT03227445		Y	Y	Y	Y	Y	Y	Y		1-May-2020
20373	GSK	A double-blind (sponsor unblind), randomized, placebo-controlled, single and repeat escalating dose study to investigate the safety, tolerability, and pharmacokinetics of CCI15106 inhalation powder in healthy participants and participants with moderate chronic obstructive pulmonary disease (COPD) including evaluation of environmental and healthy by-stander exposure levels during dosing	ribavirin	205822	Pulmonary Disease, Chronic Obstructive	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=205822	http://clinicaltrials.gov/show/NCT03235726	https://www.clinicaltrialsregister.eu/ctr-search/search?query=/2017-001070-42	Y	N	Y	Y	Y	Y	Y	An annotated case report form is not available for this study. A blank case report form will be provided. The data for this study is available in CDISC format.	1-May-2020
20374	GSK	A multicentre, randomised, double-blind (sponsor-unblinded), placebo-controlled, repeat dose study to investigate the safety and tolerability, pharmacokinetics, pharmacodynamics, and efficacy of GSK2982772 in subjects with active plaque-type psoriasis	GSK2982772	203167	Psoriasis	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=203167	http://clinicaltrials.gov/show/NCT02776033		Y	Y	Y	Y	Y	Y	Y		1-May-2020
20375	GSK	A multicenter, open-label, long-term, safety, tolerability and efficacy study of retigabine in adult epilepsy patients with partial-onset seizures (Extension of study VRX-RET-E22-301)	retigabine	VRX-RET-E22-303	Epilepsy	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=VRX-RET-E22-303	http://clinicaltrials.gov/show/NCT00310375		N	N	Y	Y	Y	Y	Y	An annotated case report form is not available for this study. A blank case report form will be provided. This is a follow-up study to VRX-RET-E22-301.	1-May-2020
20377	Astellas	Safety and Efficacy of Mirabegron as Add-on Therapy in Patients with Overactive Bladder Treated with Solifenacin: A Postmarketing Open-label Study in Japan	mirabegron	178-CL-110	Urinary Bladder, Overactive	Phase 4	https://www.clinicaltrials.astellas.com/study/?pid=178-CL-110	https://clinicaltrials.gov/ct2/show/NCT01745094		Y	Y	Y	Y	Y	Y	Y	Non-annotated CRF avaiable	1-Jun-2020
20378	Astellas	Postmarketing Study of Mirabegron in Japan: Long-term Add-on Therapy with Antimuscarinics in Patients with Overactive Bladder Treated with Mirabegron	mirabegron	178-CL-112	Urinary Bladder, Overactive	Phase 4	https://www.clinicaltrials.astellas.com/study/?pid=178-CL-112	https://clinicaltrials.gov/ct2/show/NCT02294396		Y	Y	Y	Y	Y	Y	Y	Non-annotated CRF avaiable	1-Jun-2020
20379	Novartis	A multi-national open-label phase II study of the JAK inhibitor INC424 in patients with primary myelofibrosis, post-polycythemia vera myelofibrosis or post-essential thrombocythemia myelofibrosis	ruxolitinib	CINC424A2202	Post-polycythemia vera myelofibrosis (PPV-MF)	Phase 2	https://www.novctrd.com/ctrdweb/trialresult/trialresults/pdf?trialResultId=17208	https://www.clinicaltrials.gov/ct2/show/NCT1392443?term=CINC424A2202&rank=1		Y	Y	Y	Y	Y	Y	Y		1-Jun-2020
20380	Novartis	A double-blind, placebo-controlled, randomized dose ranging trial to determine the safety and efficacy of three dose levels of EMA401 in reducing 24-hour average pain intensity score in patients with post-herpetic neuralgia	olodanrigan	CEMA401A2201	Postherpetic neuralgia (PHN)	Phase 2	https://www.novctrd.com/ctrdweb/trialresult/trialresults/pdf?trialResultId=17628	https://www.clinicaltrials.gov/ct2/show/NCT03094195?term=CEMA401A2201&rank=1	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000280-16	Y	Y	Y	Y	Y	Y	Y		1-Jun-2020
20381	Novartis	A double-blind, placebo-controlled, randomized trial to determine the safety and efficacy of EMA401 in reducing 24-hour average pain intensity score in patients with painful diabetic neuropathy (EMPADINE)	olodanrigan	CEMA401A2202	Diabetic Neuropathic Pain	Phase 2	https://www.novctrd.com/ctrdweb/trialresult/trialresults/pdf?trialResultId=17613	https://www.clinicaltrials.gov/ct2/show/NCT03297294?term=CEMA401A2202&rank=1	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000281-39	Y	Y	Y	Y	Y	Y	Y		1-Jun-2020
20382	ViiV	A Phase III, randomized, multicenter, parallel-group, non-inferiority, open-label study evaluating the efficacy, safety, and tolerability of switching to long-acting cabotegravir plus long-acting rilpivirine from current INI- NNRTI-, or PI-based antiretroviral regimen in HIV-1-infected adults who are virologically suppressed	cabotegravir; rilpivirine	201585	Infection, Human Immunodeficiency Virus	Phase 3	https://www.viiv-studyregister.com/en/study/?id=201585	http://clinicaltrials.gov/show/NCT02951052	https://www.clinicaltrialsregister.eu/ctr-search/search?query=/2016-001647-39	Y	Y	Y	Y	Y	Y	Y	A sister study 201584 was conducted. This study is still ongoing, however data related to the publication(s) is available. The data for this study is available in CDISC format.	1-Jun-2020
20383	GSK	201546, A repeat-dose study of batefenterol/FF (GSK961081/GW685698) compared with placebo in the treatment of COPD	batefenterol; fluticasone furoate	201546	Pulmonary Disease, Chronic Obstructive	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=201546	http://clinicaltrials.gov/show/NCT02573870		Y	Y	Y	Y	Y	Y	Y	The data for this study is available in CDISC format.	1-Jun-2020
20384	GSK	A Randomized, Open-label Study to Evaluate the Immunogenicity of Anthrax Vaccine Adsorbed Alone or Concomitantly with Raxibacumab (GSK3068483)	raxibacumab	201436	Infections, Bacterial	Phase 4	https://www.gsk-studyregister.com/en/trial-details/?id=201436	http://clinicaltrials.gov/show/NCT02339155		Y	Y	Y	Y	Y	Y	Y	The data for this study is available in CDISC format.	1-Jun-2020
20385	GSK	A Phase I, Open-Label, Single-Dose, Multi-Part Study to Assess the Pharmacokinetics of Gepotidacin (GSK2140944) in Male and Female Adult Subjects with Varying Degrees of Renal Impairment and in Matched Control Subjects with Normal Renal Function	gepotidacin	BTZ116849	Infections, Bacterial	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=116849	http://clinicaltrials.gov/show/NCT02729038		Y	Y	Y	Y	Y	Y	Y	The data for this study is available in CDISC format.	1-Jun-2020
20386	GSK	An escalating dose, randomized, placebo-controlled, incomplete-block, 2-period cross-over study to assess the dose response for topical efficacy via airway responsiveness to adenosine-5'-monophosphate (AMP) challenge and the dose response for systemic activity via 24h plasma cortisol suppression and thereby the relative therapeutic index for fluticasone furoate (FF), fluticasone propionate (FP) and budesonide (BUD) in asthmatic subjects	fluticasone furoate; fluticasone propionate	203162	Asthma	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=203162	http://clinicaltrials.gov/show/NCT02991859	https://www.clinicaltrialsregister.eu/ctr-search/search?query=/2016-003002-14	Y	Y	Y	Y	Y	Y	Y	The data for this study is available in CDISC format.	1-Jun-2020
20387	GSK	Randomized, Double-blind, Multicenter, Phase III Study Comparing the Efficacy and Safety of Retosiban Versus Placebo for Women in Spontaneous Preterm Labor	retosiban	200719	Obstetric Labour, Premature	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=200719	http://clinicaltrials.gov/show/NCT02377466	https://www.clinicaltrialsregister.eu/ctr-search/search?query=/2014-003326-41	Y	Y	Y	Y	Y	Y	Y	The data for this study is available in CDISC format.	1-Jun-2020
20388	GSK	A randomized, double-blind, Sponsor open, placebo-controlled, 52 week study evaluating the effect of danirixin (GSK1325756) on lung function and health related quality of life in participants with mild to moderate Chronic Obstructive Pulmonary Disease (COPD)	danirixin	205864	Pulmonary Disease, Chronic Obstructive	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=205864	http://clinicaltrials.gov/show/NCT03170232		Y	Y	Y	Y	Y	Y	Y		1-Jun-2020
20389	GSK	Randomized, Double-blind, Multicenter, Phase III Study Comparing the Efficacy and Safety of Retosiban Versus Atosiban Therapy for Women in Spontaneous Preterm Labor	retosiban	200721	Obstetric Labour, Premature	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=200721	http://clinicaltrials.gov/show/NCT02292771	https://www.clinicaltrialsregister.eu/ctr-search/search?query=/2014-001826-13	Y	Y	Y	Y	Y	Y	Y	The data for this study is available in CDISC format.	1-Jun-2020
20390	GSK	An Exploratory Study to Measure the Effect of Two Dietary Fibers on Satiety and Glycemic Parameters	Oligofructose; Pectin	W7781293	Nutritional supplement	N/A	https://www.gsk-studyregister.com/en/trial-details/?id=W7781293			Y	Y	Y	Y	Y	Y	Y	The raw data are included within the analysis-ready data for this study and are not provided separately. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Jun-2020
20391	GSK	Safety and immunogenicity of Cervarix™ in human immunodeficiency virus infected females	Human Papillomavirus Types 16 and 18 Vaccine	109823 (HPV-019 PRI)	Infections, Papillomavirus	Phase 4	https://www.gsk-studyregister.com/en/trial-details/?id=109823	http://clinicaltrials.gov/show/NCT01031069	https://www.clinicaltrialsregister.eu/ctr-search/search?query=/2013-003429-28	Y	Y	Y	Y	Y	Y	Y		1-Jun-2020
20392	GSK	Immunogenicity and safety study of two formulations of GlaxoSmithKline (GSK) Biologicals’ human rotavirus (HRV) vaccine (444563), in healthy infants starting at age 6-12 weeks	Rotavirus Vaccine	115461 (Rota-081)	Infections, Rotavirus	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=115461	http://clinicaltrials.gov/show/NCT02914184	https://www.clinicaltrialsregister.eu/ctr-search/search?query=/2016-000598-19	Y	Y	Y	Y	Y	Y	Y		1-Jun-2020
20400	Astellas	A Multi-center, Single Arm Study of Enzalutamide in Patients with Progressive Metastatic Castration-Resistant Prostate Cancer Previously Treated With Abiraterone Acetate	enzalutamide	9785-CL-0410	Prostate cancer	Phase 4	https://www.clinicaltrials.astellas.com/study/?pid=9785-CL-0410	https://clinicaltrials.gov/ct2/show/NCT02116582	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002271-17	Y	Y	Y	Y	Y	Y	Y		1-Jul-2020
20565	Astellas	Post-marketing Clinical Study of Ipragliflozin; Multicenter, Open-label Study to Assess the Efficacy of Ipragliflozin Add-on in Reducing Insulin Dose in Patients With Type 2 Diabetes Mellitus Receiving Insulin Therapy	ipragliflozin	1941-MA-3054	Diabetes Mellitus, Type 2	Phase 4	https://www.clinicaltrials.astellas.com/study/?pid=1941-MA-3054	https://clinicaltrials.gov/ct2/show/NCT02847091		Y	N	Y	Y	Y	Y	Y		1-Jul-2020
20566	Astellas	Postmarketing Clinical Study of Ipragliflozin - Long-term Study in Combination With GLP-1 Receptor Agonists in Patients With Type 2 Diabetes Mellitus	ipragliflozin	1941-CL-0132	Diabetes Mellitus, Type 2	Phase 4	https://www.clinicaltrials.astellas.com/study/?pid=1941-CL-0132	https://clinicaltrials.gov/ct2/show/NCT02291874		Y	Y	Y	Y	Y	Y	Y	CRF without annotations available	1-Jul-2020
20567	Astellas	Phase III Study of ASP1941 Double-blind, Parallel-group Study in Combination With Insulin in Patients With Type 1 Diabetes Mellitus	ipragliflozin	1941-CL-6002	Diabetes Mellitus, Type 1	Phase 3	https://www.clinicaltrials.astellas.com/study/?pid=1941-CL-6002	https://clinicaltrials.gov/ct2/show/NCT02897219		Y	Y	Y	Y	Y	Y	Y		1-Jul-2020
20568	Astellas	Phase 2b Study of ASP015K – A Double-Blind, Placebo-Controlled, Dose-Finding Study in Moderate to Severe Rheumatoid Arthritis Patients –	peficitinib hydrobromide	015K-CL-RAJ1	Rheumatoid Arthritis	Phase 2	https://www.clinicaltrials.astellas.com/study/?pid=015K-CL-RAJ1	https://clinicaltrials.gov/ct2/show/NCT01649999		Y	Y	Y	Y	N	Y	Y		1-Jul-2020
20569	Astellas	Phase 3 Study of ASP015K - A Randomized, Double-blind, Placebo-controlled Confirmatory Study of the Safety and Efficacy of ASP015K in Patients With Rheumatoid Arthritis Who Had an Inadequate Response to DMARDs -	peficitinib hydrobromide	015K-CL-RAJ3	Rheumatoid Arthritis	Phase 3	https://www.clinicaltrials.astellas.com/study/?pid=015K-CL-RAJ3	https://clinicaltrials.gov/ct2/show/NCT02308163		Y	Y	Y	Y	Y	Y	Y		1-Jul-2020
20570	Astellas	Phase 3 Study of ASP015K - A Randomized, Double-blind, Placebo-controlled Confirmatory Study of the Efficacy and Safety of ASP015K in Patients With Rheumatoid Arthritis Who Had an Inadequate Response to MTX -	peficitinib hydrobromide	015K-CL-RAJ4	Rheumatoid Arthritis	Phase 3	https://www.clinicaltrials.astellas.com/study/?pid=015K-CL-RAJ4	https://clinicaltrials.gov/ct2/show/NCT02305849		Y	Y	Y	Y	N	Y	Y		1-Jul-2020
20571	Astellas	A Phase 3, Multicenter, Investigator-blind, Randomized, Parallel Group Study to Investigate the Safety and Efficacy of Fidaxomicin Oral Suspension or Tablets Taken q12h, and Vancomycin Oral Liquid or Capsules Taken q6h, for 10 Days in Pediatric Subjects with Clostridium difficile-associated Diarrhea (The SUNSHINE Study)	fidaxomicin	2819-CL-0202	Clostridium difficile infection	Phase 3	https://www.clinicaltrials.astellas.com/study/?pid=2819-CL-0202	https://clinicaltrials.gov/ct2/show/NCT02218372	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-000508-40	Y	Y	Y	Y	Y	Y	Y		1-Jul-2020
20572	Astellas	A randomized, placebo-controlled, double-blind, parallel group phase 2a study of ASP1707 in postmenopausal female patients with rheumatoid arthritis (RA) taking methotrexate (MTX)	ASP1707	1707-CL-3001	Rheumatoid Arthritis	Phase 2	https://www.clinicaltrials.astellas.com/study/?pid=1707-CL-3001	https://clinicaltrials.gov/ct2/show/NCT02884635		Y	Y	Y	Y	Y	Y	Y	CRF without annotations available	1-Jul-2020
20573	Novartis	A Phase III, Randomized, Double-blinded Study Comparing the Combination of the BRAF Inhibitor, Dabrafenib and the MEK Inhibitor, Trametinib to Dabrafenib and Placebo as First-line Therapy in Subjects With Unresectable (Stage IIIC) or Metastatic (Stage IV) BRAF V600E/K Mutation-positive Cutaneous Melanoma	dabrafenib	CDRB436B2301	Melanoma	Phase 3	https://www.novctrd.com/ctrdweb/trialresult/trialresults/pdf?trialResultId=17627	https://clinicaltrials.gov/ct2/show/NCT01584648	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-006087-49	Y	Y	Y	Y	Y	Y	Y		1-Jul-2020
20574	Novartis	A Phase III, Randomised, Open-label Study Comparing the Combination of the BRAF Inhibitor, Dabrafenib and the MEK Inhibitor, Trametinib to the BRAF Inhibitor Vemurafenib in Subjects With Unresectable (Stage IIIc) or Metastatic (Stage IV) BRAF V600E/K Mutation Positive Cutaneous Melanoma	dabrafenib	CDRB436B2302	Melanoma	Phase 3	https://www.novctrd.com/ctrdweb/trialresult/trialresults/pdf?trialResultId=17634	https://www.clinicaltrials.gov/ct2/show/NCT01597908?term=CDRB436B2302&draw=2&rank=1	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-006088-23	Y	Y	Y	Y	Y	Y	Y		1-Jul-2020
20575	Novartis	A multi-center, randomized, double-blind, placebo-controlled, parallel group study to assess the safety, tolerability, pharmacokinetics and preliminary efficacy of CFZ533 in patients with primary Sjoegren's syndrome	CFZ533	CCFZ533X2203	Sjoegren's syndrome	Phase 2	https://www.novctrd.com/ctrdweb/trialresult/trialresults/pdf?trialResultId=17462	https://www.clinicaltrials.gov/ct2/show/NCT2291029?term=CCFZ533X2203&rank=1	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004808-19	Y	Y	Y	Y	Y	Y	Y		1-Jul-2020
20576	Novartis	A single dose, double-blind, placebo-controlled, parallel study to assess the pharmacodynamics, pharmacokinetics and safety and tolerability of VAY736 in patients with primary Sjoegren's syndrome	lanalumab	CVAY736X2201	Sjoegren's syndrome	Phase 2	https://www.novctrd.com/ctrdweb/trialresult/trialresults/pdf?trialResultId=17323	https://www.clinicaltrials.gov/ct2/show/NCT2149420?term=CVAY736X2201&rank=1	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-000250-22	Y	Y	Y	Y	Y	Y	Y		1-Jul-2020
20588	GSK	A Placebo Controlled, Double-blind, Multi-centre, Single Dose, Parallel Group, Randomised Clinical Trial of GSK2862277 in Patients undergoing Oesophagectomy Surgery	GSK2862277	TFR116341	Lung Injury, Acute and Respiratory Distress Syndrome, Adult	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=116341	http://clinicaltrials.gov/show/NCT02221037	https://www.clinicaltrialsregister.eu/ctr-search/search?query=/2014-000643-33	Y	Y	Y	Y	Y	Y	Y		1-Jul-2020
20589	GSK	A Two Part Study to Assess i) the Relative Bioavailability and Food Effect of a Novel Tablet Formulation of Boosted-GSK2838232 Compared to Capsule and ii) the Safety and Pharmacokinetics of Repeated Once-Daily Doses of Non-boosted GSK2838232	GSK2838232	205820	Infection, Human Immunodeficiency Virus	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=205820	http://clinicaltrials.gov/show/NCT03234036		Y	N	Y	Y	Y	Y	Y	An annotated case report form is not available for this study.  A blank case report form will be provided. This study is available in CDISC format.	1-Jul-2020
20591	GSK	An open-label, low interventional clinical study investigating error rates (critical and overall) prior to any retraining in correct use of the ELLIPTA dry powder inhaler (DPI) compared to other DPIs including; DISKUS, Turbuhaler, HandiHaler and Breezhaler as a monotherapy or in combination, in adult patients with Chronic Obstructive Pulmonary Disease (COPD)	fluticasone furoate/vilanterol/umeclidinium bromide	204981	Pulmonary Disease, Chronic Obstructive	Phase 4	https://www.gsk-studyregister.com/en/trial-details/?id=204981	http://clinicaltrials.gov/show/NCT03114969		Y	Y	Y	Y	Y	Y	Y	Raw data are included within the analysis-ready data for this study and are not provided separately.	1-Jul-2020
20592	GSK	A Phase IIb, 24 week, randomized, double-blind, 3 arm parallel group study, comparing the efficacy, safety and tolerability of two doses of umeclidinium bromide administered once-daily via a dry powder inhaler, versus placebo, in participants with asthma	fluticasone furoate/vilanterol/umeclidinium bromide	205832	Asthma	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=205832	http://clinicaltrials.gov/show/NCT03012061	https://www.clinicaltrialsregister.eu/ctr-search/search?query=/2016-002843-40	Y	Y	Y	Y	Y	Y	Y	This study is available in CDISC format.	1-Jul-2020
20593	GSK	Randomised, Double-Blind (Sponsor Open), Placebo-Controlled, Multicentre, Dose Ranging Study to Evaluate the Efficacy and Safety of Danirixin Tablets Administered Twice Daily Compared With Placebo for 24 Weeks in Adult Participants With Chronic Obstructive Pulmonary Disease (COPD)	danirixin	205724	Pulmonary Disease, Chronic Obstructive	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=205724	http://clinicaltrials.gov/show/NCT03034967	https://www.clinicaltrialsregister.eu/ctr-search/search?query=/2016-003675-21	Y	Y	Y	Y	Y	Y	Y	This study is available in CDISC format.	1-Jul-2020
20594	GSK	A Phase IV, 12-week, randomised, double-blind, triple dummy study to compare single inhaler triple therapy, fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) with multiple inhaler therapy (budesonide/formoterol plus tiotropium) based on lung function and symptoms in participants with chronic obstructive pulmonary disease	fluticasone furoate/vilanterol/umeclidinium bromide	207608	Pulmonary Disease, Chronic Obstructive	Phase 4	https://www.gsk-studyregister.com/en/trial-details/?id=207608	http://clinicaltrials.gov/show/NCT03478683	https://www.clinicaltrialsregister.eu/ctr-search/search?query=/2017-001149-28	Y	N	Y	Y	Y	Y	Y	An annotated case report form is not available for this study.  A blank case report form will be provided. This study is available in CDISC format.	1-Jul-2020
20595	GSK	A Phase IV, 12-week, randomised, double-blind, triple dummy study to compare single inhaler triple therapy, fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) with multiple inhaler therapy (budesonide/formoterol plus tiotropium) based on lung function and symptoms in participants with chronic obstructive pulmonary disease	fluticasone furoate/vilanterol/umeclidinium bromid	207609	Pulmonary Disease, Chronic Obstructive	Phase 4	https://www.gsk-studyregister.com/en/trial-details/?id=207609	http://clinicaltrials.gov/show/NCT03478696	https://www.clinicaltrialsregister.eu/ctr-search/search?query=/2017-001150-33	Y	N	Y	Y	Y	Y	Y	An annotated case report form is not available for this study.  A blank case report form will be provided. This study is available in CDISC format.	1-Jul-2020
20596	GSK	Study to evaluate the impact of reactogenicity on Quality of Life (QoL), after administration of GSK Biologicals’ candidate Herpes Zoster subunit (HZ/su) vaccine (GSK1437173A) in adults ≥ 50 years of age	Herpes Zoster subunit (HZ/su) vaccine	204928	Herpes Zoster	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=204928	http://clinicaltrials.gov/show/NCT02979639		Y	Y	Y	Y	Y	Y	Y		1-Jul-2020
20601	Novartis	A multi-center, randomized, double-blind, placebo-controlled clinical trial of deferasirox in patients with myelodysplastic syndromes (low/int-1 risk) and transfusional iron overload	deferasirox	CICL670A2302	Myelodysplastic syndrome (MDS)	Phase 2	https://www.novctrd.com/ctrdweb/trialresult/trialresults/pdf?trialResultId=17377	https://www.clinicaltrials.gov/ct2/show/NCT940602?term=CICL670A2302&rank=1	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-012418-38	Y	Y	Y	Y	Y	Y	Y		1-Aug-2020
20602	Novartis	A phase IIIb, multi-center, open-label study of RAD001 in combination with EXemestane in post-menopausal women with EStrogen receptor positive, human epidermal growth factor receptor 2 negative locally advanced or metastatic breast cancer	everolimus	CRAD001JIC06	Breast cancer	Phase 3	https://www.novctrd.com/ctrdweb/trialresult/trialresults/pdf?trialResultId=17560	https://www.clinicaltrials.gov/ct2/show/NCT03176238?term=CRAD001JIC06&rank=1		Y	Y	Y	Y	Y	Y	Y		1-Aug-2020
20603	Novartis	A Phase II Study of Lapatinib for Brain Metastases in Subjects with ErbB2-Positive Breast Cancer Following Trastuzumab-based Systemic Therapy and Cranial Radiotherapy	lapatinib	EGF105084 (CLAP016A2202)	Breast cancer	Phase 2	https://www.novctrd.com/ctrdweb/trialresult/trialresults/pdf?trialResultId=17400	https://www.clinicaltrials.gov/ct2/show/NCT00263588?term=CLAP016A2202&draw=2&rank=1		Y	Y	Y	Y	Y	Y	Y		1-Aug-2020
20604	Novartis	A Phase IIIB open-label, randomized, multicenter study to evaluate the use of zoledronic acid in the prevention of cancer treatment-related bone loss in post-menopausal women with ER+ and/or PgR+ breast cancer receiving letrozole as adjuvant therapy.	letrozole	CFEM345D2405	Breast cancer	Phase 3	https://www.novctrd.com/ctrdweb/trialresult/trialresults/pdf?trialResultId=4424	https://www.clinicaltrials.gov/ct2/show/NCT171340?term=CFEM345D2405&rank=1		Y	Y	Y	Y	Y	Y	Y		1-Aug-2020
20605	Novartis	An open-label, randomized, multicenter study to evaluate the use of zoledronic acid in the prevention of cancer treatment related bone loss in post-menopausal women with ER+ and/or PgR+ breast cancer receiving Letrozole as adjuvant therapy	letrozole	CFEM345D2406	Breast cancer	Phase 3	https://www.novctrd.com/ctrdweb/trialresult/trialresults/pdf?trialResultId=4923	https://www.clinicaltrials.gov/ct2/show/NCT171314?term=CFEM345D2406&rank=1	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001369-17	Y	Y	Y	Y	Y	Y	Y		1-Aug-2020
20606	Novartis	A randomized study of the JAK inhibitor INC424 tablets compared to best available therapy in subjects with primary myelofibrosis (PMF), post-polycythemia vera-myelofibrosis (PPV-MF) or post-essential thrombocythemia myelofibrosis (PET-MF)	ruxolitinib	CINC424A2352	Myelofibrosis	Phase 3	https://www.novctrd.com/ctrdweb/trialresult/trialresults/pdf?trialResultId=4843	https://www.clinicaltrials.gov/ct2/show/NCT934544?term=CINC424A2352&rank=1	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-009858-24	Y	Y	Y	Y	Y	Y	Y		1-Aug-2020
20607	Novartis	Extending molecular responses with Nilotinib in newly diagnosed chronic myeloid leukemia (CML) patients in chronic phase	nilotinib	CAMN107E2401	Chronic myeloid leukemia (CML)	Phase 3	https://www.novctrd.com/ctrdweb/trialresult/trialresults/pdf?trialResultId=14265	https://www.clinicaltrials.gov/ct2/show/NCT1254188?term=CAMN107E2401&rank=1		Y	Y	Y	Y	Y	Y	Y		1-Aug-2020
20608	Novartis	ENESTChina: A phase III multi-center, open-label, randomized study of nilotinib versus imatinib in Chinese adult patients with newly diagnosed Philadelphia chromosome positive (Ph+) chronic myelogenous leukemia in chronic phase (CML-CP)	nilotinib	CAMN107ECN02	Chronic myeloid leukemia (CML)	Phase 3	https://www.novctrd.com/ctrdweb/trialresult/trialresults/pdf?trialResultId=14123	https://www.clinicaltrials.gov/ct2/show/NCT1275196?term=CAMN107ECN02		Y	Y	Y	Y	Y	Y	Y		1-Aug-2020
20609	Novartis	A phase III multi-center, open-label, randomized study of imatinib versus nilotinib in adult patients with newly diagnosed Philadelphia chromosome positive (Ph positive) chronic myelogenous leukemia in chronic phase (CML-CP).	nilotinib	CAMN107A2303	Chronic myeloid leukemia (CML)	Phase 3	https://www.novctrd.com/ctrdweb/trialresult/trialresults/pdf?trialResultId=8504	https://www.clinicaltrials.gov/ct2/show/NCT471497?term=CAMN107A2303&rank=1	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000208-34	Y	Y	Y	Y	Y	Y	Y		1-Aug-2020
20610	Novartis	phase IA/II multicenter, dose-escalation study of oral AMN107 on a continuous daily dosing schedule in adult patients with Gleevec® (imatinib)-resistant/intolerant CML in chronic or accelerated phase or blast crisis, relapsed/refractory Ph+ ALL, and other hematologic malignancies.	nilotinib	CAMN107A2101	Chronic myeloid leukemia (CML)	Phase 1/2	https://www.novctrd.com/ctrdweb/trialresult/trialresults/pdf?trialResultId=9963	https://www.clinicaltrials.gov/ct2/show/NCT109707?term=CAMN107A2101&rank=1	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001483-51	Y	Y	Y	Y	Y	Y	Y		1-Aug-2020
20611	Novartis	An expanded access protocol of imatinib mesylate in patients with chronic myeloid leukemia who are hematologically or cytogenetically resistant or refractory to, or intolerant of interferon-alpha	imatinib mesilate	CSTI5710113	Chronic myeloid leukemia (CML)	Phase 2	https://www.novctrd.com/ctrdweb/trialresult/trialresults/pdf?trialResultId=1653	https://www.clinicaltrials.gov/ct2/show/NCT00006053?term=CSTI5710113&lead=novartis&draw=2&rank=1		Y	Y	Y	Y	Y	Y	Y		1-Aug-2020
20620	Novartis	A phase II randomized, double-blind placebo controlled, study of letrozole with or without BYL719 or buparlisib, for the neoadjuvant treatment of postmenopausal women with hormone receptor-positive HER2-negative breast cancer	alpelisib	CBYL719A2201	Breast cancer	Phase 2	https://www.novctrd.com/ctrdweb/trialresult/trialresults/pdf?trialResultId=17179	https://www.clinicaltrials.gov/ct2/show/NCT1923168?term=CBYL719A2201&rank=1	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001862-41	Y	Y	Y	Y	Y	Y	Y		1-Sep-2020
20621	Novartis	A 12-week, multicenter, randomized, double-blind, placebo-controlled study to assess the efficacy and safety of QAW039 when added to standard-of-care asthma therapy in patients with uncontrolled asthma	fevipiprant	CQAW039A2316	Uncontrolled asthma	Phase 3	https://www.novctrd.com/ctrdweb/trialresult/trialresults/pdf?trialResultId=17579	https://www.clinicaltrials.gov/ct2/show/NCT03215758?term=CQAW039A2316&rank=1	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001273-16	Y	Y	Y	Y	Y	Y	Y		1-Sep-2020
20622	Novartis	A randomized, double-blind, placebo-controlled study of secukinumab to demonstrate the efficacy at 24 weeks and to assess the safety, tolerability and long term efficacy up to 2 years in patients with active rheumatoid arthritis who have an inadequate response to anti-TNF¿ agents (CAIN457F2302) and a three year extension study to evaluate the long term efficacy, safety and tolerability of secukinumab in patients with active rheumatoid arthritis (CAIN457F2302E1)	secukinumab	CAIN457F2302/E1	Rheumatoid arthritis	Phase 3	https://www.novctrd.com/ctrdweb/trialresult/trialresults/pdf?trialResultId=14947	https://www.clinicaltrials.gov/ct2/show/NCT1377012?term=CAIN457F2302%2FCAIN457F2302E1&rank=1		Y	Y	Y	Y	Y	Y	Y		1-Sep-2020
20719	GSK	Efficacy, immunogenicity and safety study of GSK Biologicals’ candidate malaria vaccine (SB257049) evaluating various dose schedules in a sporozoite challenge model in healthy malaria-naïve adults	RTS,S Vaccine	205081	Malaria	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=205081	http://clinicaltrials.gov/show/NCT03162614		Y	Y	Y	Y	Y	Y	Y		1-Sep-2020
20720	GSK	Persistence of immune response to GSK Biologicals’ HPV vaccine in healthy Chinese female subjects from the HPV-058 study	Human Papillomavirus Types 16 and 18 Vaccine	207347	Cervical Intraepithelial Neoplasia	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=207347	http://clinicaltrials.gov/show/NCT03355820	https://www.clinicaltrialsregister.eu/ctr-search/search?query=/2017-000255-50	Y	Y	Y	Y	Y	Y	Y	This is follow-up study to 112022. There is a Publication Steering Committee for this study.	1-Sep-2020
20721	GSK	Evaluation of immunogenicity, safety and reactogenicity of GSK Biologicals’ dTpa booster vaccine (263855) (Boostrix) administered as a booster dose in healthy Russian subjects	Combined Reduced Antigen Content Diphtheria, Tetanus, Acellular Pertussis Vaccine	201532	Diphtheria; Tetanus; Acellular pertussis	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=201532	http://clinicaltrials.gov/show/NCT03311659	https://www.clinicaltrialsregister.eu/ctr-search/search?query=/2015-003405-42	Y	Y	Y	Y	Y	Y	Y		1-Sep-2020
20722	GSK	Study 200977: Albiglutide + Insulin Glargine Versus Insulin Lispro + Insulin Glargine in the treatment of Subjects With Type 2 Diabetes Mellitus: The Switch Study	albiglutide	200977	Diabetes Mellitus, Type 2	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=200977	http://clinicaltrials.gov/show/NCT02229227	https://www.clinicaltrialsregister.eu/ctr-search/search?query=/2014-001821-34	Y	N	Y	Y	Y	Y	Y	An annotated case report form is not available for this study. A blank case report form will be provided. This study is available in CDISC format.	1-Sep-2020
20724	GSK	A single center, two part, randomized, open label cross-over study to evaluate the effect of itraconazole and rifampicin on the pharmacokinetics of GSK525762 in healthy female subjects of non child bearing potential	molibresib	204946	Neoplasms	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=204946	http://clinicaltrials.gov/show/NCT02706535		Y	Y	Y	Y	Y	Y	Y	This study is available in CDISC format.	1-Sep-2020
20725	GSK	A 2-part randomized, double-blind (sponsor-unblinded), placebo-controlled, ascending dose and parallel group study of TLR4 agonist (GSK1795091) administered to healthy subjects	GSK1795091	204685	Neoplasms	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=204685	http://clinicaltrials.gov/show/NCT02798978	https://www.clinicaltrialsregister.eu/ctr-search/search?query=/2016-000759-28	Y	Y	Y	Y	Y	Y	Y	This study is available in CDISC format.	1-Sep-2020
20726	GSK	A single-centre, randomized, double-blind (sponsor open), placebo-controlled study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of GSK2983559, in single (in both fed and fasted states) and repeat oral doses in healthy participants	GSK2983559	205021	Inflammatory Bowel Diseases	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=205021	http://clinicaltrials.gov/show/NCT03358407	https://www.clinicaltrialsregister.eu/ctr-search/search?query=/2017-002664-40	Y	N	Y	Y	Y	Y	Y	An annotated case report form is not available for this study. A blank case report form will be provided.	1-Sep-2020
20727	Astellas	An Exploratory Study to Compare the Efficacy and Safety of Micafungin as a Pre-emptive Treatment of Invasive Candidiasis Versus Placebo in High Risk Surgical Subjects with Intra-abdominal Infections - A Multicentre, Randomized, Double-blind Study	micafungin	9463-EC-0002	Mycoses	Phase 2	https://www.clinicaltrials.astellas.com/study/?pid=9463-EC-0002	https://clinicaltrials.gov/ct2/show/NCT01122368	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-006409-18	Y	Y	Y	Y	Y	Y	Y		1-Aug-2017
20728	Astellas	An Open Study of ASP8273 in Patients With Non-Small-Cell Lung Cancer (NSCLC) Who Have Epidermal Growth Factor Receptor (EGFR) Mutations	naquotinib mesilate	8273-CL-0101	Non-small cell lung cancer	Phase 2	https://www.clinicaltrials.astellas.com/study/?pid=8273-CL-0101	https://clinicaltrials.gov/ct2/show/NCT02192697		Y	Y	Y	Y	Y	Y	Y	CRF without annotations available	1-Sep-2020
20729	Astellas	An Open-label Phase 1 Study of Oral ASP5878 at Single and Multiple Doses in Patients with Solid Tumors	ASP5878	5878-CL-0101	Solid tumors	Phase 1	https://www.clinicaltrials.astellas.com/study/?pid=5878-CL-0101	https://clinicaltrials.gov/ct2/show/NCT02038673		Y	Y	Y	Y	Y	Y	Y	CRF without annotations available	1-Sep-2020
20730	Astellas	A Phase 3, Multicenter, Double-Blind, Randomized, Parallel-group, Placebo-Controlled Study to Assess the Efficacy and Safety of ASP1941 in Subjects With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Metformin and Sitagliptin	ipragliflozin	1941-CL-2009	Diabetes Mellitus, Type 2	Phase 3	https://www.clinicaltrials.astellas.com/study/?pid=1941-CL-2009	https://clinicaltrials.gov/ct2/show/NCT02452632		N	Y	Y	N	Y	Y	Y		1-Sep-2020
20731	Astellas	A Randomized, Double-Blind, Placebo-Control, Multicenter Clinical Trial evaluating the Efficacy and Safety of Tacrolimus Capsules in the Treatment of Myasthenia Gravis Patients with Inadequate Response to Glucocorticoid Therapy	tacrolimus	F506-CL-0611	Myasthenia gravis	Phase 3	https://www.clinicaltrials.astellas.com/study/?pid=F506-CL-0611	https://clinicaltrials.gov/ct2/show/NCT01325571		Y	N	Y	Y	Y	Y	Y		1-Sep-2020
20736	Novartis	Assessment of Real-Life Care - Describing European Heart Failure Management	sacubitril/valsartan	CLCZ696B3401	Heart Failure	Phase 4				Y	Y	Y	Y	Y	Y	Y		1-Oct-2020
20737	GSK	A 52-week, Phase III, double-blind, active-controlled, parallel-group, multi-center study to evaluate efficacy and safety of daprodustat compared to darbepoetin alfa in Japanese hemodialysis-dependent subjects with anemia associated with chronic kidney disease who are currently ESA users	daprodustat	201754	Anaemia	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=201754	http://clinicaltrials.gov/show/NCT02969655	https://www.clinicaltrialsregister.eu/ctr-search/search?query=/	Y	Y	Y	Y	Y	Y	Y	This study is available in CDISC format.	1-Oct-2020
20738	GSK	A phase III study to evaluate the efficacy and safety of GSK1358820 (botulinum toxin type A) in patients with overactive bladder	OnabotulinumtoxinA	204947	Urinary Bladder, Overactive	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=204947	http://clinicaltrials.gov/show/NCT02820844	https://www.clinicaltrialsregister.eu/ctr-search/search?query=/	Y	Y	Y	Y	Y	Y	Y		1-Oct-2020
20739	GSK	A Randomized, 8 Week Clinical Study to Evaluate the Efficacy of an Experimental Stannous Fluoride Dentifrice in the Relief of Dentinal Hypersensitivity	GSK3730661	208153	Dentin Sensitivity	N/A	https://www.gsk-studyregister.com/en/trial-details/?id=208153	http://clinicaltrials.gov/show/NCT03310268	https://www.clinicaltrialsregister.eu/ctr-search/search?query=/	Y	Y	Y	Y	Y	Y	Y	The raw data are included within the analysis-ready data for this study and are not provided separately.	1-Oct-2020
20740	GSK	A Clinical Study to Assess the Local Cutaneous and Ocular Tolerance of a Developmental Cosmetic Facial Serum Formulation in Healthy Females with Sensitive Skin	GI150835/GI237410/GSK3744919/glycerol	209442	Skin Care	N/A	https://www.gsk-studyregister.com/en/trial-details/?id=209442	http://clinicaltrials.gov/show/NCT03640832	https://www.clinicaltrialsregister.eu/ctr-search/search?query=/	Y	Y	Y	Y	Y	Y	Y	The raw data are included within the analysis-ready data for this study and are not provided separately.	1-Oct-2020
20741	Novartis	A Prospective Evaluation of Natriuretic Peptide Based Referral of CHF Patients in Primary Care	sacubitril/valsartan	CLCZ696B3402	Heart Failure	Phase 4	https://www.novctrd.com/ctrdweb/trialresult/trialresults/pdf?trialResultId=17381	https://www.clinicaltrials.gov/ct2/show/NCT02807857?term=CLCZ696B3402&draw=2&rank=1	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000473-20	Y	Y	Y	Y	Y	Y	Y		1-Nov-2020
20742	GSK	Implementation of a screening tool for subjects with benign prostatic enlargement/obstruction to identify men >=50 years presenting in General Practice with other co-morbidities who should be assessed for BPH	dutasteride/tamsulosin	FDC116114	Prostatic Hyperplasia	Phase 4	https://www.gsk-studyregister.com/en/trial-details/?id=116114	http://clinicaltrials.gov/show/NCT02757963		Y	Y	Y	Y	Y	Y	Y		1-Nov-2020
20743	GSK	A Randomized, Doubled-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Once-Daily, Intranasal Administration of Fluticasone Furoate Nasal Spray 55 mcg and 110 mcg for 4 Weeks in Chinese Pediatric Subjects Ages 2 to 12 Years with Allergic Rhinitis	fluticasone furoate	201492	Rhinitis, Allergic, Perennial and Seasonal	Phase 4	https://www.gsk-studyregister.com/en/trial-details/?id=201492	http://clinicaltrials.gov/show/NCT02424539		Y	Y	Y	Y	Y	Y	Y		1-Nov-2020
20744	GSK	A Phase IIb, Double-Blind, Placebo-Controlled, Dose-Adaptive, Study of the Efficacy and Safety of GSK3196165 in Combination with Methotrexate Therapy, in Subjects with Active Moderate-Severe Rheumatoid Arthritis Despite Treatment with Methotrexate	otilimab	201755	Arthritis, Rheumatoid	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=201755	http://clinicaltrials.gov/show/NCT02504671	https://www.clinicaltrialsregister.eu/ctr-search/search?query=/2014-003453-34	Y	Y	Y	Y	Y	Y	Y	This study is available in CDISC format.	1-Nov-2020
20745	GSK	A Phase IIa, Double-Blind, Mechanistic Study of GSK3196165 in Combination with Methotrexate Therapy in Subjects with Active Rheumatoid Arthritis Despite Treatment with DMARDs	otilimab	205180	Arthritis, Rheumatoid	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=205180	http://clinicaltrials.gov/show/NCT02799472	https://www.clinicaltrialsregister.eu/ctr-search/search?query=/2015-004386-91	Y	N	Y	Y	Y	Y	Y	An annotated case report form is not available for this study. A blank case report form will be provided. This study is available in CDISC format.	1-Nov-2020
20746	GSK	A multi-centre Phase IIa double-blind, placebo-controlled study to investigate the efficacy and safety of GSK3196165 in subjects with inflammatory hand osteoarthritis	otilimab	204851	Osteoarthritis	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=204851	http://clinicaltrials.gov/show/NCT02683785	https://www.clinicaltrialsregister.eu/ctr-search/search?query=/2015-003089-96	Y	Y	Y	Y	Y	Y	Y	This study is available in CDISC format.	1-Nov-2020
20747	GSK	A Multicenter, Placebo-Controlled, Parallel-Design, Dose-Response Evaluation of the Safety and Efficacy of Lamotrigine as Add-On Therapy in Epileptic Outpatients with Partial Seizures	lamotrigine	P42-05	Epilepsy	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=P42-05			N	Y	Y	Y	Y	Y	N	An analysis-ready dataset is not available for this study. A reporting and analysis plan is not available for this study. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Nov-2020
20748	GSK	A Multicenter, Double-Blind, Placebo-Controlled, Add-On, Crossover Study of Lamotrigine in Epileptic Outpatients with Partial Seizures	lamotrigine	P42-06	Epilepsy	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=P42-06			N	N	Y	Y	Y	Y	N	An analysis-ready dataset is not available for this study. An annotated case report form is not available for this study. A blank case report form will be provided. A reporting and analysis plan is not available for this study. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Nov-2020
20749	GSK	A Multicenter, Placebo-Controlled Parallel-Design, Phase III Evaluation of the Safety of Lamotrigine (LAMICTAL) as Add-On Therapy in Outpatients with Partial Seizures	lamotrigine	P42-16	Epilepsy	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=P42-16			N	Y	Y	Y	Y	Y	N	An analysis-ready dataset is not available for this study. A reporting and analysis plan is not available for this study. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory req	1-Nov-2020
20750	GSK	Immunogenicity, reactogenicity and safety study of Pediarix®, Hiberix® and Prevenar 13® co-administered with two different formulations of GSK Biologicals’ HRV vaccine (444563) in healthy infants 6-12 weeks of age	Rotavirus Vaccine	201663	Infections, Rotavirus	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=201663	http://clinicaltrials.gov/show/NCT03207750	https://www.clinicaltrialsregister.eu/ctr-search/search?query=/2016-003210-27	Y	Y	Y	Y	Y	Y	Y		1-Nov-2020
20751	GSK	A Phase II, Multicenter, Randomized, Observer-Blind, Controlled Study to Evaluate Safety and Immunogenicity of a Trivalent Group B Streptococcus Vaccine in Healthy Pregnant Women	Trivalent Group B streptococcus Vaccine	205235	Streptococcus agalactiae	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=205235	http://clinicaltrials.gov/show/NCT02046148		N	Y	Y	Y	Y	Y	Y	An analysis-ready dataset is not available for this study.	1-Nov-2020
20752	Novartis	A randomized, double-blind, double-dummy, 4-week treatment, parallel-group study to evaluate the efficacy and safety of two doses of mometasone furoate delivered via Concept1 or Twisthaler® in adult and adolescent patients with persistent asthma	indacaterol/mometasone furoate	CQMF149E2201	Asthma	Phase 2	https://www.novctrd.com/ctrdweb/trialresult/trialresults/pdf?trialResultId=12184	https://www.clinicaltrials.gov/ct2/show/NCT1555151?term=CQMF149E2201&rank=1	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005100-14	Y	Y	Y	Y	Y	Y	Y		1-Dec-2020
20755	Astellas	Phase 2a Study of ASP5094 - A Phase 2a, Randomized, Placebo-controlled, Double-blind, Parallel-group Study to Evaluate the Efficacy and Safety of ASP5094 in Patients With Rheumatoid Arthritis on Methotrexate -	ASP5094	5094-CL-0201	Rheumatoid Arthritis	Phase 2	https://www.clinicaltrials.astellas.com/study/?pid=5094-CL-0201	https://clinicaltrials.gov/ct2/show/NCT03257852		Y	Y	Y	Y	Y	Y	Y	CRF without annotations available	1-Jan-2021
20756	Astellas	A multi-center, randomized, open-label, pilot and exploratory study investigating safety and efficacy in OPTIMIZEd dosing of Advagraf® kidney transplantation in Asia.	tacrolimus extended-release	506-MA-1001	Prevention of rejection after organ transplant	Phase 4	https://www.clinicaltrials.astellas.com/study/?pid=506-MA-1001	https://clinicaltrials.gov/ct2/show/NCT02161237		Y	Y	Y	Y	Y	Y	Y		1-Jan-2021
20757	Astellas	An open-label, prospective interventional study of the tolerability and efficacy of oral Harnalidge® OCAS® (Tamsulosin) 0.4 mg in patients who are unsatisfied with the treatment of Tamsulosin 0.2 mg	tamsulosin HCl	HAURO-1201-TW	Lower Urinary Tract Symptoms / Benign Prostatic Hyperplasia	Phase 4	https://www.clinicaltrials.astellas.com/study/?pid=HAURO-1201-TW	https://clinicaltrials.gov/ct2/show/NCT02180789		N	Y	Y	N	Y	Y	Y		1-Jan-2021
20758	Novartis	Phase 3, Open-Label, Single-Arm, Single-Dose Gene Replacement Therapy Clinical Trial for Patients With Spinal Muscular Atrophy Type 1 With One or Two SMN2 Copies Delivering AVXS-101 by Intravenous Infusion	Onasemnogene Abeparvovec-xioi	COAV101A12302 (AAVXS-101-CL-303)	SMA - Spinal Muscular Atrophy	Phase 3	https://www.novctrd.com/ctrdweb/trialresult/trialresults/pdf?trialResultId=17657	https://www.clinicaltrials.gov/ct2/show/NCT03306277?term=AVXS101CL303&rank=1	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-000095-39	Y	Y	Y	Y	Y	Y	Y		1-Jan-2021
20760	Novartis	A 16-week Treatment, Multicenter, Randomized, Double Blind, Placebo-controlled, Parallel-group Study to Assess the Effect of Omalizumab on the Expression of FcεRI Receptors of Blood Basophils and Dendritic Cells in Patients With Severe Persistent Non-atopic Asthma, Uncontrolled Despite Optimal Therapy	omalizumab	CIGE025AFR05	Asthma	Phase 3	https://www.novctrd.com/ctrdweb/trialresult/trialresults/pdf?trialResultId=5323	https://www.clinicaltrials.gov/ct2/show/NCT01007149?term=NCT01007149&draw=2&rank=1	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-010937-38	Y	Y	Y	Y	Y	Y	Y		1-Jan-2021
20761	Novartis	A 24-week, Phase III randomized, double-blind, placebo-controlled, parallelgroup, multicenter study of Xolair® (omalizumab) in patients with moderate to severe persistent allergic asthma who remain not adequately controlled despite GINA (2009) Step 4 therapy	omalizumab	CIGE025A2313	Persistent Asthma	Phase 3	https://www.novctrd.com/	https://www.clinicaltrials.gov/ct2/show/NCT1202903?term=CIGE025A2313&rank=1		Y	Y	Y	Y	Y	Y	Y		1-Jan-2021
20762	GSK	A randomised, double-blind, placebo-controlled, parallel group, 8-week treatment study to investigate the safety, pharmacodynamics, and effect of the TLR7 agonist, GSK2245035, on the allergen-induced asthmatic response in subjects with mild allergic asthma	GSK2245035	205540	Asthma	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=205540	http://clinicaltrials.gov/show/NCT02833974	https://www.clinicaltrialsregister.eu/ctr-search/search?query=/2015-005645-31	Y	Y	Y	Y	Y	Y	Y		1-Jan-2021
20763	GSK	A randomised, double blind (sponsor unblinded), placebo-controlled, single ascending dose study to investigate the safety, tolerability, pharmacokinetics, and pharmacodynamics of a IV dose of GSK2831781 in healthy volunteers and patients with plaque psoriasis	GSK2831781	200630	Psoriasis	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=200630	http://clinicaltrials.gov/show/NCT02195349	https://www.clinicaltrialsregister.eu/ctr-search/search?query=/2014-000312-33	Y	Y	Y	Y	Y	Y	Y		1-Jan-2021
20764	GSK	Randomized double blind (sponsor unblind) study evaluating the effect of 14 days of treatment with danirixin (GSK1325756) on neutrophil extracellular traps (NETs) formation in participants with stable chronic obstructive pulmonary disease (COPD)	danirixin	207551	Pulmonary Disease, Chronic Obstructive	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=207551	http://clinicaltrials.gov/show/NCT03250689	https://www.clinicaltrialsregister.eu/ctr-search/search?query=/2017-001069-25	Y	Y	Y	Y	Y	Y	Y		1-Jan-2021
20765	GSK	An open-label study to evaluate correct use and ease of use of the ELLIPTA Dry Powder Inhaler (DPI) in pediatric patients currently receiving inhaled therapy for treatment of their asthma	fluticasone furoate/vilanterol	206924	Asthma	Phase 4	https://www.gsk-studyregister.com/en/trial-details/?id=206924	http://clinicaltrials.gov/show/NCT03478657		Y	Y	Y	Y	Y	Y	Y	This study is available in CDISC format.	1-Jan-2021
20766	GSK	A Randomized, Double-Blind, Placebo-Controlled 52-Week Study to Assess Adverse Events of Special Interest in Adults with Active, Autoantibody-Positive Systemic Lupus Erythematosus Receiving Belimumab	belimumab	BEL115467	Systemic Lupus Erythematosus	Phase 4	https://www.gsk-studyregister.com/en/trial-details/?id=115467	http://clinicaltrials.gov/show/NCT01705977	https://www.clinicaltrialsregister.eu/ctr-search/search?query=/2011-005667-25	Y	Y	Y	Y	Y	Y	Y	This study is available in CDISC format.	1-Jan-2021
20767	GSK	A Phase III, randomized, double-blind, active controlled, parallel group study, comparing the efficacy, safety and tolerability of the fixed dose combination FF/UMEC/VI with the fixed dose dual combination of FF/VI, administered once-daily via a dry powder inhaler in subjects with inadequately controlled asthma	fluticasone furoate/vilanterol/umeclidinium bromide	205715	Asthma	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=205715	http://clinicaltrials.gov/show/NCT02924688	https://www.clinicaltrialsregister.eu/ctr-search/search?query=/2016-001304-37	Y	Y	Y	Y	Y	Y	Y	This study can only be requested for research into the original disease or medicine studied due to restrictions in the patient informed consent. This study is available in CDISC format.	1-Jan-2021
20768	GSK	A randomised, placebo-controlled, double-blind (sponsor open), segmental LPS challenge study to investigate the pharmacodynamics of GSK2798745 in healthy participants	GSK2798745	207464	Healthy Volunteers	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=207464	http://clinicaltrials.gov/show/NCT03511105	https://www.clinicaltrialsregister.eu/ctr-search/search?query=/2017-002388-16	Y	N	Y	Y	Y	Y	Y	An annotated case report form is not available for this study. A blank case report form will be provided.	1-Jan-2021
20769	GSK	Two-dose primary vaccination with either GSK Biologicals' 10-valent pneumococcal vaccine (Synflorix™) or Pfizer’s Prevenar 13™ or both vaccines followed by a booster dose of Synflorix™	10-valent pneumococcal polysaccharide and non-typeable Haemophilus influenzae protein D conjugate vaccine	115992	Infections, Streptococcal	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=115992	http://clinicaltrials.gov/show/NCT01641133	https://www.clinicaltrialsregister.eu/ctr-search/search?query=/2013-003479-36	Y	Y	Y	Y	Y	Y	Y		1-Jan-2021
20770	GSK	Safety and immunogenicity study of GSK Biologicals’ pneumococcal vaccine 2830930A when administered as a single dose in healthy toddlers aged 12-23 months	12-valent pneumococcal polysaccharide and non-typeable Haemophilus influenzae protein D conjugate vaccine	115373	Infections, Streptococcal	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=115373	http://clinicaltrials.gov/show/NCT01485406	https://www.clinicaltrialsregister.eu/ctr-search/search?query=/2011-002225-22	Y	Y	Y	Y	Y	Y	Y		1-Jan-2021
20771	GSK	Long term hepatitis A virus (HAV) antibody persistence in children vaccinated with 1 dose and those vaccinated with 2 doses of Havrix in Panama	Hepatitis A Vaccine, Inactivated	201630	Hepatitis A	N/A	https://www.gsk-studyregister.com/en/trial-details/?id=201630	http://clinicaltrials.gov/show/NCT02712359		Y	Y	Y	Y	Y	Y	Y		1-Jan-2021
20772	GSK	Cross-vaccination study of GSK Biologicals’ Lyophilized formulation of the Herpes Zoster subunit (HZ/su) vaccine (GSK 1437173A) in subjects who previously received placebo in ZOSTER-006 (NCT01165177) and ZOSTER-022 (NCT01165229) studies	Herpes Zoster subunit (HZ/su) vaccine	204486	Herpes Zoster	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=204486	http://clinicaltrials.gov/show/NCT02690207	https://www.clinicaltrialsregister.eu/ctr-search/search?query=/2015-000965-30	Y	Y	Y	Y	Y	Y	Y	This is a nested study of 110390/113077.	1-Jan-2021
20773	Eisai	An Open-label Extension Study to Evaluate the Safety and Tolerability of Perampanel (E2007) Administered as an Adjunctive Therapy in Epilepsy Subjects	perampanel	E2007-J000-341	Epilepsy	Phase 3	not available	https://www.clinicaltrials.gov/ct2/show/NCT02427607	https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-004945-10/results	N	Y	Y	Y	Y	Y	N	No restrictions.	1-Feb-2021
20774	Eisai	A Placebo-Controlled, Double-Blind Comparative Study of E2080 in Lennox-Gastaut Syndrome Patients	rufinamide	E2080-J081-304	Lennox-Gastaut Syndrome	Phase 3	not available	https://www.clinicaltrials.gov/ct2/show/NCT01146951	https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-004952-30/results	N	N	Y	Y	Y	Y	N	No restrictions.	1-Feb-2021
20775	Eisai	A Long Term Extension Study of E2080 in Lennox-Gastaut Patients	rufinamide	E2080-J081-305	Lennox-Gastaut Syndrome	Phase 3	not available	https://www.clinicaltrials.gov/ct2/show/NCT01151540	https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-004953-34/results	N	N	Y	Y	Y	Y	Y	No restrictions.	1-Feb-2021
20776	Eisai	Phase II Clinical Study of E7389 for Locally Advanced or Metastatic Breast Cancer	eribulin mesilate	E7389-J081-221	Breast Cancer	Phase 2	not available	not available	not available	N	Y	Y	Y	Y	Y	N	NCT record obsolete.  Reporting done in conjuction with study E7389-J081-224 (NCT00965523).	1-Feb-2021
20777	Eisai	Phase II Extension Study of E7389 for Locally Advanced or Metastatic Breast Cancer	eribulin mesilate	E7389-J081-224	Breast Cancer	Phase 2	not available	https://www.clinicaltrials.gov/ct2/show/NCT00965523	not available	N	Y	Y	Y	Y	Y	N	No restrictions.	1-Feb-2021
20778	Eisai	A Phase III Open Label, Randomized Two-Parallel-Arm Multicenter Study of E7389 Versus Capecitabine in Patients With Locally Advanced or Metastatic Breast Cancer Previously Treated With Anthracyclines and Taxanes	eribulin mesilate	E7389-G000-301	Breast Cancer	Phase 3	not available	https://www.clinicaltrials.gov/ct2/show/NCT00337103	https://www.clinicaltrialsregister.eu/ctr-search/trial/2005-004009-26/results	Y	Y	Y	Y	Y	Y	Y	No restrictions.	1-Feb-2021
20779	Eisai	The "EMBRACE" Trial: Eisai Metastatic Breast Cancer Study Assessing Physician's Choice Versus E7389. A Phase III Open-Label, Randomized, Parallel, Two-arm, Multi-center Study of E7389 Versus "Treatment of Physician's Choice" in Patients With Locally Recurrent, Metastatic Breast Cancer, Previously Treated With At Least Two and a Maximum of Five Prior Chemotherapy Regimens, Including an Anthracycline and a Taxane	eribulin mesilate	E7389-G000-305	Breast Cancer	Phase 3	not available	https://www.clinicaltrials.gov/ct2/show/NCT00388726	https://www.clinicaltrialsregister.eu/ctr-search/trial/2006-001949-34/results	Y	Y	Y	Y	Y	Y	Y	No restrictions.	1-Feb-2021
20780	Eisai	An Open-label Randomized Parallel Two-arm Multicenter Study of Eribulin Versus Vinorelbine in Female Subjects With Locally Recurrent or Metastatic Breast Cancer, Previously Treated With At Least Two and a Maximum of Five Prior Chemotherapy Regimens, Including an Anthracycline and a Taxane	eribulin mesilate	E7389-C086-304	Breast Cancer	Phase 3	not available	https://www.clinicaltrials.gov/ct2/show/NCT02225470	not available	N	N	Y	Y	Y	N	N	Sharing of clinical data is restricted.	1-Feb-2021
20781	Eisai	A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of Eribulin Mesylate Administered Biweekly (Q2W) for Subjects With Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Metastatic Breast Cancer	eribulin mesilate	E7389-M001-216	HER2-Negative Metastatic Breast Cancer	Phase 2	not available	https://www.clinicaltrials.gov/ct2/show/NCT02481050	not available	Y	Y	Y	Y	Y	Y	Y	No restrictions.	1-Feb-2021
20782	Eisai	The Efficacy, Tolerability and Safety of Donepezil (Aricept) in Parkinson's Disease Patients With Dementia	donepezil	E2020-E044-316	Dementia With Parkinson’s Disease	Phase 3	not available	https://www.clinicaltrials.gov/ct2/show/NCT00165815	not available	Y	Y	Y	Y	Y	Y	N	No restrictions.	1-Feb-2021
20783	Eisai	Double-blind Study of E2020 in Patients With Dementia With Lewy Bodies - Phase II	donepezil	E2020-J081-431	Dementia with Lewy bodies	Phase 2	not available	https://www.clinicaltrials.gov/ct2/show/record/NCT00543855	not available	N	N	Y	Y	Y	Y	N	No restrictions.	1-Feb-2021
20784	Eisai	A Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled Study of E2020 in Patients With Dementia With Lewy Bodies (DLB), Followed by a Long-term Extension Phase	donepezil	E2020-J081-341	Dementia with Lewy bodies	Phase 3	not available	https://www.clinicaltrials.gov/ct2/show/NCT01278407	not available	N	N	Y	Y	Y	Y	N	No restrictions.	1-Feb-2021
20785	Eisai	A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Explore the Safety And Tolerability of Doses of E2007 up to a Maximum of 12 mg In Patients With Refractory Partial Seizures	perampanel	E2007-G000-208	Refractory Partial Seizures	Phase 2	not available	https://www.clinicaltrials.gov/ct2/show/NCT00416195	https://www.clinicaltrialsregister.eu/ctr-search/trial/2006-003702-26/results	N	N	Y	Y	Y	Y	N	No restrictions.	1-Feb-2021
20788	Eisai	An Open-Label, Single-Arm Multicenter Phase 1b/2 Study to Evaluate the Efficacy and Safety of Eribulin Mesylate in Combination With Pembrolizumab in Subjects With Metastatic Triple-Negative Breast Cancer (mTNBC) (ENHANCE-1)	eribulin mesilate	E7389-M001-218	Metastatic Triple-Negative Breast Cancer	Phase 2	not available	https://www.clinicaltrials.gov/ct2/show/NCT02513472	not available	Y	Y	Y	Y	Y	Y	Y	No restrictions.	1-Feb-2021
20789	GSK	A double-blind (sponsor unblinded) study to investigate safety, tolerability, pharmacokinetics, pharmacodynamics and clinical effect of repeat dosing of GSK2646264 in cutaneous lupus erythematosus patients	GSK2646264	204860	Lupus Erythematosus, Cutaneous	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=204860	http://clinicaltrials.gov/show/NCT02927457	https://www.clinicaltrialsregister.eu/ctr-search/search?query=/2016-000277-20	Y	Y	Y	Y	Y	Y	Y		1-Feb-2021
20790	GSK	An open label, randomised, parallel group clinical study to evaluate the effect of the Connected Inhaler System (CIS) on adherence to Relvar/Breo ELLIPTA therapy, in asthmatic subjects with poor control	fluticasone furoate/vilanterol	207040	Asthma	Phase 4	https://www.gsk-studyregister.com/en/trial-details/?id=207040	http://clinicaltrials.gov/show/NCT03380429	https://www.clinicaltrialsregister.eu/ctr-search/search?query=/2017-002266-45	Y	N	Y	Y	Y	Y	Y	An annotated case report form is not available for this study. A blank case report form will be provided. This study is available in CDISC format.	1-Feb-2021
20791	GSK	A Phase I, Open-Label, Single-Dose, Two-Part Study to Assess the Pharmacokinetics of Gepotidacin (GSK2140944) in Male and Female Adult Participants with Varying Degrees of Hepatic Impairment and in Matched Control Participants with Normal Hepatic Function	gepotidacin	BTZ117352	Infections, Bacterial	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=117352	http://clinicaltrials.gov/show/NCT03562117		Y	Y	Y	Y	Y	Y	Y	This study is available in CDISC format.	1-Feb-2021
20792	GSK	Assessment of the efficacy and tolerability of paroxetine by double blind comparison with amitriptyline in depressed patients	paroxetine	PAR MDSA/29060/III/86/03 (019)	Depressive Disorder, Major	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=29060/03/019			Y	N	Y	Y	N	N	N	The data from this study is provided in combined datasets containing data from other paroxetine studies. A raw dataset is not available for this study. An annotated and a blank case report form are not available for this study. A reporting and analysis plan is not available for this study. A protocol is not available for this study because there is no evidence in the archives that a document was authored. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Feb-2021
20793	GSK	An Interim Report to Assess the Efficacy and Tolerability of Paroxetine by Double-Blind Comparison with Amitriptyline in Patients Referred to a Psychiatric Clinic	paroxetine	MDUK/29060/III/85/028A (PAR 184)	Depressive Disorder	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=29060/028/184			Y	N	Y	Y	N	N	N	The data from this study is provided in combined datasets containing data from other paroxetine studies. A raw dataset is not available for this study. An annotated and a blank case report form are not available for this study. A reporting and analysis plan is not available for this study. A protocol is not available for this study because there is no evidence in the archives that a document was authored. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Feb-2021
20794	GSK	A Double Blind Study to Compare the Efficacy and Tolerability of Paroxetine and Amitriptyline in a Multi-Centre General Practice Study in Depressed Patients	paroxetine	PAR MDUK 032	Depressive Disorder	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=29060/032			Y	N	Y	Y	N	N	N	The data from this study is provided in combined datasets containing data from other paroxetine studies. A raw dataset is not available for this study. An annotated and a blank case report form are not available for this study. A reporting and analysis plan is not available for this study. A protocol is not available for this study because there is no evidence in the archives that a document was authored. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Feb-2021
20795	GSK	An Interim Report of a Study to Assess the Effectiveness and Tolerance of Paroxetine in Depressed Patients by Double-Blind Comparison with Amitriptyline (A follow-up final report was not prepared and is not expected for this study).	paroxetine	MDUK/29060/III/85/043	Depressive Disorder	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=29060/043			Y	N	Y	Y	N	N	N	The data from this study is provided in combined datasets containing data from other paroxetine studies. A raw dataset is not available for this study. An annotated and a blank case report form are not available for this study. A reporting and analysis plan is not available for this study. A protocol is not available for this study because there is no evidence in the archives that a document was authored. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Feb-2021
20796	GSK	A Multi-Centre General Practice Study to Compare the Effectiveness and Tolerability of Paroxetine in Elderly Depressed Patients by Double Blind Comparison with Amitriptyline	paroxetine	PAR – MDUK/29060/III/87/049 Hutchinson	Depressive Disorder	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=29060/049			Y	N	Y	Y	N	N	N	The data from this study is provided in combined datasets containing data from other paroxetine studies. A raw dataset is not available for this study. An annotated and a blank case report form are not available for this study. A reporting and analysis plan is not available for this study. A protocol is not available for this study because there is no evidence in the archives that a document was authored. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Feb-2021
20797	GSK	Study comparing the effects of oral Paroxetine and Amitriptyline in adult patients with depression	paroxetine	29060/074	Depressive Disorder	Phase 3				Y	N	Y	Y	N	N	N	The data from this study is provided in combined datasets containing data from other paroxetine studies. A raw dataset is not available for this study.  An annotated and a blank case report form are not available for this study. A reporting and analysis plan is not available for this study. A protocol is not available for this study because there is no evidence in the archives that a document was authored. There is no GSK Study Register entry for this study. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Feb-2021
20798	GSK	Study comparing the effects of oral Paroxetine and Amitriptyline in adult patients with depression	paroxetine	PN-MDHU-29060-III-1 (29060/077)	Depressive Disorder	Phase 3				Y	N	Y	Y	N	N	N	The data from this study is provided in combined datasets containing data from other paroxetine studies. A raw dataset is not available for this study.  An annotated and a blank case report form are not available for this study. A reporting and analysis plan is not available for this study. A protocol is not available for this study because there is no evidence in the archives that a document was authored. There is no GSK Study Register entry for this study. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Feb-2021
20799	GSK	Paroxetine in the treatment of depression – a randomised comparison with amitriptyline.	paroxetine	6121 RAD/Paroxetine/C/4 (PAR 260)	Depressive Disorder	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=29060/260			Y	N	Y	Y	N	N	N	The data from this study is provided in combined datasets containing data from other paroxetine studies. A raw dataset is not available for this study. An annotated and a blank case report form are not available for this study. A reporting and analysis plan is not available for this study. A protocol is not available for this study because there is no evidence in the archives that a document was authored. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Feb-2021
20800	GSK	A multi-centre study to assess the effectiveness and tolerance of paroxetine by double-blind comparison with amitriptyline	paroxetine	PAR 029060.292	Depressive Disorder, Major	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=29060/292			Y	N	Y	Y	N	N	N	The data from this study is provided in combined datasets containing data from other paroxetine studies. A raw dataset is not available for this study. An annotated and a blank case report form are not available for this study. A reporting and analysis plan is not available for this study. A protocol is not available for this study because there is no evidence in the archives that a document was authored. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Feb-2021
20801	GSK	Early Clinical Evaluation of a New Antidepressant: A Double-Blind Parallel Study Comparing Paroxetine 30mg Daily with Amitriptyline 150mg Daily	paroxetine	PAR 29060.318 (HP/82/64A)	Depressive Disorder	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=29060/318			Y	N	Y	Y	N	N	N	The data from this study is provided in combined datasets containing data from other paroxetine studies. A raw dataset is not available for this study. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Feb-2021
20804	GSK	A double-blind, short-term comparison of paroxetine and amitriptyline with a 12-month, rater-blind maintenance phase comparing paroxetine, amitriptyline and lithium in the prevention of depressive relapse in patients with major depression, recurrent.	paroxetine	BRL-29060/109	Depressive Disorder	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=29060/109			Y	N	Y	Y	N	N	N	The data from this study is provided in combined datasets containing data from other paroxetine studies. A raw dataset is not available for this study. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.	1-Mar-2021
20805	GSK	A 52-week, Phase III, open-label, multi-center study to evaluate efficacy and safety of GSK1278863 in Japanese non-dialysis and peritoneal dialysis subjects with anemia associated with chronic kidney disease	daprodustat	201753	Anaemia	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=201753	http://clinicaltrials.gov/show/NCT02791763		Y	Y	Y	Y	Y	Y	Y	This study is available in CDISC format.	1-Mar-2021
20806	GSK	An open-label, randomized, single-dose, two-period cross-over study to evaluate bioequivalence of GSK3542503 hydrochlorothiazide + amiloride hydrochloride 50 mg: 5 mg fixed dose combination tablets versus reference product in healthy adult participants under fasting conditions	GSK3542503	205694	Hypertension	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=205694	http://clinicaltrials.gov/show/NCT03031496		Y	N	Y	Y	Y	Y	Y	An annotated case report form is not available for this study. A blank case report form will be provided.	1-Mar-2021
20807	GSK	Immunogenicity and safety study of a booster dose of GSK Biologicals’ Infanrix hexa™ (217744) in healthy infants born to mothers vaccinated with Boostrix™ during pregnancy or immediately post-delivery	SB217744	201334	Diphtheria; Tetanus; Pertussis; Hepatitis B; Poliomyelitis; Haemophilus influenzae type b	Phase 4	https://www.gsk-studyregister.com/en/trial-details/?id=201334	http://clinicaltrials.gov/show/NCT02853929	https://www.clinicaltrialsregister.eu/ctr-search/search?query=/2014-001120-30	Y	Y	Y	Y	Y	Y	Y	This is a follow-up study to 116945 and 201330.	1-Mar-2021
20808	GSK	A Two Part, Randomized, Open-label, Cross over Study in Healthy Elderly Participants to Evaluate the Relative Bioavailability of Hydrobromide Salt Tablet Formulations of Danirixin in the Fed and Fasted States, and to Evaluate the Effect of Food and Gastric Acid Secretion Suppression on Danirixin Pharmacokinetics Following Administration of Hydrobromide Salt Tablets	danirixin	207573	Pulmonary Disease, Chronic Obstructive	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=207573	http://clinicaltrials.gov/show/NCT03457727		Y	Y	Y	Y	Y	Y	Y	This study is available in CDISC format.	1-Mar-2021
20811	Novartis	A phase II study to determine the efficacy and safety of STI571 in patients with chronic myeloid leukemia who are refractory to or intolerant of interferon-alpha (Extension 1: 2002-2004 and Extension 2: 2004-2013).	imatinib mesilate	CSTI571 0110	Philadelphia chromosome positive acute lymphoblastic leukemia (PH+ ALL)	Phase 2	https://www.novctrd.com/ctrdweb/trialresult/trialresults/pdf?trialResultId=12844	https://www.clinicaltrials.gov/ct2/show/NCT00171223?term=CSTI571+0110&lead=novartis&draw=2&rank=1		Y	Y	Y	Y	Y	Y	Y		1-Mar-2021
20812	Novartis	A phase II study to determine the efficacy and safety of STI571 in patients with chronic myeloid leukemia who are refractory to or intolerant of interferon-alpha (Extension 1: 2002-2004 and Extension 2: 2004-2013).	imatinib mesilate	CSTI571 0110E1	Philadelphia chromosome positive acute lymphoblastic leukemia (PH+ ALL)	Phase 2	https://www.novctrd.com/ctrdweb/trialresult/trialresults/pdf?trialResultId=12844			Y	Y	Y	Y	Y	Y	Y		1-Mar-2021
20813	Novartis	A phase II study to determine the safety and anti-leukemic effects of STI571 in adult patients with Philadelphia chromosome positive leukemia including acute lymphoblastic leukemia, acute myeloid leukemia, lymphoid blast crisis chronic myeloid leukemia and accelerated phase chronic myeloid leukemia extended for a total of 11 years (Extension 1: 2002-2004 and Extension 2: 2004-2013)	imatinib mesilate	CSTI571 0109	Chronic myeloid leukemia (CML)	Phase 2	https://www.novctrd.com/ctrdweb/trialresult/trialresults/pdf?trialResultId=12064	https://www.clinicaltrials.gov/ct2/show/NCT171249		Y	Y	Y	Y	Y	Y	Y		1-Mar-2021
20814	Novartis	A phase II study to determine the safety and anti-leukemic effects of STI571 in adult patients with Philadelphia chromosome positive leukemia including acute lymphoblastic leukemia, acute myeloid leukemia, lymphoid blast crisis chronic myeloid leukemia and accelerated phase chronic myeloid leukemia extended for a total of 11 years (Extension 1: 2002-2004 and Extension 2: 2004-2013)	imatinib mesilate	CSTI571 0109E1	Chronic myeloid leukemia (CML)	Phase 2	https://www.novctrd.com/ctrdweb/trialresult/trialresults/pdf?trialResultId=12064	https://www.clinicaltrials.gov/ct2/show/NCT171249		Y	Y	Y	Y	Y	Y	Y		1-Mar-2021
20815	Novartis	A phase II open-label study to determine the safety and anti-leukemic effects of STI571 in patients with Philadelphia chromosome-positive chronic myeloid leukemia in myeloid blast crisis extended for in total of 11 years (Extension 1: 2002-2004 and Extension 2: 2004- 2013)	imatinib mesilate	CSTI571 0102	Chronic myeloid leukemia (CML)	Phase 2	https://www.novctrd.com/ctrdweb/trialresult/trialresults/pdf?trialResultId=11563	https://www.clinicaltrials.gov/ct2/show/NCT171158		Y	Y	Y	Y	Y	Y	Y		1-Mar-2021
20816	Novartis	A phase II open-label study to determine the safety and anti-leukemic effects of STI571 in patients with Philadelphia chromosome-positive chronic myeloid leukemia in myeloid blast crisis extended for in total of 11 years (Extension 1: 2002-2004 and Extension 2: 2004- 2013)	imatinib mesilate	CSTI571 0102E1	Chronic myeloid leukemia (CML)	Phase 2	https://www.novctrd.com/ctrdweb/trialresult/trialresults/pdf?trialResultId=11563	https://www.clinicaltrials.gov/ct2/show/NCT171158		Y	Y	Y	Y	Y	Y	Y		1-Mar-2021
20817	Novartis	A phase III study of imatinib versus interferon-¿ (IFN-¿) combined with cytarabine (Ara-C) in patients with newly diagnosed previously untreated Philadelphia chromosome positive (Ph+) chronic myelogenous leukemia in chronic phase (CML-CP).	imatinib mesilate	CSTI5710106	Chronic myeloid leukemia (CML)	Phase 3	https://www.novctrd.com/ctrdweb/trialresult/trialresults/pdf?trialResultId=8244	https://www.clinicaltrials.gov/ct2/show/NCT00333840?term=CSTI571A0106&rank=1		Y	Y	Y	Y	Y	Y	Y		1-Mar-2021
20818	Novartis	A randomized Phase III, double-blind, placebo-controlled, multi-center study to evaluate the efficacy and safety of everolimus (RAD001) in adult patients with advanced hepatocellular carcinoma after failure of sorafenib treatment¿ the EVOLVE-1 Study	everolimus	CRAD001O2301	Hepatocellular carcinoma (HCC)	Phase 3	https://www.novctrd.com/ctrdweb/trialresult/trialresults/pdf?trialResultId=12664	https://www.clinicaltrials.gov/ct2/show/NCT1035229?term=CRAD001O2301&rank=1	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-010196-25	Y	Y	Y	Y	Y	Y	Y		1-Mar-2021
20819	Novartis	BRF117277: A Phase II, Open-Label, Multicentre Study of Dabrafenib plus Trametinib in Subjects with BRAF Mutation-Positive Melanoma that has Metastasized to the Brain	dabrafenib/trametinib	CDRB436B2204 (BRF117277	Melanoma	Phase 2	https://www.novctrd.com/ctrdweb/trialresult/trialresults/pdf?trialResultId=17326	https://clinicaltrials.gov/ct2/show/NCT02039947?term=BRF117277&draw=2&rank=1	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003452-21	Y	Y	Y	Y	Y	Y	Y		1-Mar-2021
20820	Novartis	An Open-Label, Dose-Escalation, Phase Ib/II Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of the BRAF Inhibitor GSK2118436 in Combination with the MEK Inhibitor GSK1120212 in Subjects with BRAF Mutant Metastatic Melanoma	dabrafenib/trametinib	CDRB436B2201 (BRF11320)	Metastatic melanoma	Phase 2	https://www.novctrd.com/ctrdweb/trialresult/trialresults/pdf?trialResultId=17378			Y	Y	Y	Y	Y	Y	Y		1-Mar-2021
20821	Novartis	Placebo-controlled prospective randomized study on the antiproliferative efficacy of octreotide in patients with metastasized neuroendocrine tumors of the midgut (PROMID).	octreotide	CSMS995ADE05	Neuroendocrine Tumors (NET)	Phase 3	https://www.novctrd.com/ctrdweb/trialresult/trialresults/pdf?trialResultId=10003	https://www.clinicaltrials.gov/ct2/show/NCT171873?term=CSMS995ADE05&rank=1		Y	Y	Y	Y	Y	Y	Y		1-Mar-2021
20822	Novartis	Phase 3, Open Label, Single Arm, Single Dose Gene Replacement Therapy Clinical Trial for Patients with Spinal Muscular Atrophy Type 1 with One or Two SMN2 Copies Delivering AVXS-101 by Intravenous Infusion	onasemnogene abeparvovec xioi	COAV101A12301 (AAVXS-101-CL-302)	SMA - Spinal Muscular Atrophy	Phase 3	https://www.novctrd.com/ctrdweb/trialresult/trialresults/pdf?trialResultId=17805	https://www.clinicaltrials.gov/ct2/show/NCT03461289?term=AVXS101CL302&rank=1	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000266-29	Y	Y	Y	Y	Y	Y	Y		1-Apr-2021
20826	ViiV	A Double-Blind (Sponsor Unblinded), Randomized, Placebo-Controlled, Single and Repeated Dose Escalation Study to Investigate the Safety, Tolerability and Pharmacokinetics of GSK3640254 in Healthy Participants	GSK3640254	207187	Infection, Human Immunodeficiency Virus	Phase 1	https://www.viiv-studyregister.com/en/study/?id=207187	http://clinicaltrials.gov/show/NCT03231943	https://www.clinicaltrialsregister.eu/ctr-search/search?query=/2017-001367-21	Y	Y	Y	Y	Y	Y	Y	This study is available in CDISC format.	1-Apr-2021
20827	GSK	A multicenter, randomized, double-blind (sponsor-unblinded), placebo-controlled study to investigate the safety and tolerability, pharmacokinetics, pharmacodynamics, and efficacy of GSK2982772 in subjects with moderate to severe rheumatoid arthritis	GSK2982772	203168	Arthritis, Rheumatoid	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=203168	http://clinicaltrials.gov/show/NCT02858492	https://www.clinicaltrialsregister.eu/ctr-search/search?query=/2016-000912-13	Y	Y	Y	Y	Y	Y	Y	The raw data are included within the analysis-ready data for this study and are not provided separately	1-Apr-2021
20828	GSK	A Clinical Study to Investigate the Effects of Two Developmental Cosmetic Moisturizing Cream Formulations on the Barrier Function of Human Skin on the Face and Legs	Developmental Cosmetic Moisturizing Creams	209638	Skin Care	N/A	https://www.gsk-studyregister.com/en/trial-details/?id=209638	http://clinicaltrials.gov/show/NCT03804710		Y	Y	Y	Y	Y	Y	Y	The raw data are included within the analysis-ready data for this study and are not provided separately	1-Apr-2021
20829	Novartis	An open-label, multicenter phase II study to compare the efficacy and safety of RAD001 as first-line followed by second-line sunitinib versus sunitinib as first-line followed by second-line RAD001 in the treatment of patients with metastatic renal cell carcinoma.	everolimus	CRAD001L2202	Renal cell carcinoma (RCC)	Phase 2	https://www.novctrd.com/ctrdweb/trialresult/trialresults/pdf?trialResultId=14929	https://www.clinicaltrials.gov/ct2/show/NCT903175?term=CRAD001L2202&rank=1	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-011056-21	Y	Y	Y	Y	Y	Y	Y		1-Dec-2020
20830	Novartis	Safety and Efficacy Study of ESBA1008 Versus LUCENTIS for the Treatment of Exudative Age-Related Macular Degeneration	brolucizumab	C-10-083	Wet age related macular degeneration (AMD)	Phase 2	https://www.novctrd.com/ctrdweb/trialresult/trialresults/pdf?trialResultId=17631	https://www.clinicaltrials.gov/ct2/show/NCT01304693?term=C+10+083&rank=1	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000536-28	Y	Y	Y	Y	Y	Y	Y		1-May-2021
20831	Novartis	Efficacy and Safety Study of ESBA1008 Versus EYLEA	brolucizumab	C-12-006	Wet age related macular degeneration (AMD)	Phase 2	https://www.novctrd.com/ctrdweb/trialresult/trialresults/pdf?trialResultId=17620	https://www.clinicaltrials.gov/ct2/show/NCT01796964?term=c-12-006&draw=2&rank=1		Y	Y	Y	Y	Y	Y	Y		1-May-2021
20832	Novartis	A Prospective, Two-Staged, Single-Masked Study to Evaluate the Effect of ESBA1008 Applied by Microvolume Injection or Infusion in Subjects With Exudative Age-Related Macular Degeneration	brolucizumab	C-13-001	Wet age related macular degeneration (AMD)	Phase 2	https://www.novctrd.com/ctrdweb/trialresult/trialresults/pdf?trialResultId=17621	https://www.clinicaltrials.gov/ct2/show/NCT01849692?term=c+13+001		Y	Y	Y	Y	Y	Y	Y		1-May-2021
20833	Novartis	A Randomized, Double Masked, Three Dose Safety and Pharmacokinetic Study of RTH258 Following Intravitreal (IVT) Injection in Subjects With Neovascular Age-Related Macular Degeneration	brolucizumab	RTH258-E003	Neovascular Age-Related Macular Degeneration	Phase 2	https://www.novctrd.com/ctrdweb/trialresult/trialresults/pdf?trialResultId=16628	https://www.clinicaltrials.gov/ct2/show/NCT02507388?term=RTH258E003&rank=1		Y	Y	Y	Y	Y	Y	Y		1-May-2021
20834	Novartis	A two-year, randomized, double-masked, multicenter, three-arm study comparing the efficacy and safety of RTH258 versus aflibercept in subjects with neovascular age-related macular degeneration	brolucizumab	CRTH258A2301	Neovascular Age-Related Macular Degeneration	Phase 3	https://www.novctrd.com/ctrdweb/trialresult/trialresults/pdf?trialResultId=17623	https://www.clinicaltrials.gov/ct2/show/NCT02307682?term=CRTH258A2301&draw=2&rank=2		Y	Y	Y	Y	Y	Y	Y		1-May-2021
20835	Novartis	A 24-week, double-masked, multicenter, two-arm extension study to collect safety and efficacy data on brolucizumab 6 mg drug product intended for commercialization in subjects with neovascular age-related macular degeneration who have completed the CRTH258A2301 study	brolucizumab	CRTH258A2301E1	Neovascular Age-Related Macular Degeneration	Phase 3	https://www.novctrd.com/ctrdweb/trialresult/trialresults/pdf?trialResultId=17632			Y	Y	Y	Y	Y	Y	Y		1-May-2021
20836	Novartis	A Two-year, Randomized, Double-masked, Multicenter, Two-arm Study Comparing the Efficacy and Safety of RTH258 6 mg Versus Aflibercept in Subjects With Neovascular Age-related Macular Degeneration	brolucizumab	RTH258-C002	Neovascular Age-Related Macular Degeneration	Phase 3	https://www.novctrd.com/ctrdweb/trialresult/trialresults/pdf?trialResultId=17360	https://www.clinicaltrials.gov/ct2/show/NCT02434328?term=RTH258C002	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004886-26	Y	Y	Y	Y	Y	Y	Y		1-May-2021
20837	Novartis	A Phase II Multicenter, Randomized, Placebo-Controlled, Double-Blind, 12-Month Study to Assess Safety and Efficacy of SelG1 With or Without Hydroxyurea Therapy in Sickle Cell Disease Patients with Sickle Cell-Related Pain Crises, (SUSTAIN)	crizanlizumab	CSEG101A2201	Sickle cell disease	Phase 2	https://www.novctrd.com/ctrdweb/trialresult/trialresults/pdf?trialResultId=17571	https://www.clinicaltrials.gov/ct2/show/NCT01895361		Y	Y	Y	Y	Y	Y	Y		1-May-2021
20838	Novartis	A 52-week, multicenter, randomized, double-blind, placebo-controlled study to assess the efficacy and safety of QAW039 when added to existing asthma therapy in patients with uncontrolled severe asthma.	fevipiprant	CQAW039A2307	asthma	Phase 3	https://www.novctrd.com/ctrdweb/trialresult/trialresults/pdf?trialResultId=17650	https://www.clinicaltrials.gov/ct2/show/NCT02555683?term=CQAW039A2307&rank=1	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-002553-35	Y	Y	Y	Y	Y	Y	Y		1-May-2021
20839	Novartis	A 52-week, multicenter, randomized, double-blind, placebo-controlled study to assess the efficacy and safety of QAW039 when added to existing asthma therapy in patients with uncontrolled severe Asthma.	fevipiprant	CQAW039A2314	asthma	Phase 3	https://www.novctrd.com/ctrdweb/trialresult/trialresults/pdf?trialResultId=17580	https://www.clinicaltrials.gov/ct2/show/NCT02563067?term=CQAW039A2314&rank=1	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-003172-67	Y	Y	Y	Y	Y	Y	Y		1-May-2021
20843	GSK	The effectiveness of Asthma Control Test guided treatment compared with usual care in China adult asthma patients	fluticasone propionate/salmeterol	201097	Asthma	Phase 4	https://www.gsk-studyregister.com/en/trial-details/?id=201097	http://clinicaltrials.gov/show/NCT02868281		Y	N	Y	Y	Y	Y	Y	An annotated case report form and a blank case report form are not available for this study.	1-May-2021
20844	GSK	The Clinical Effectiveness of Fluticasone Furoate/Umeclidinium Bromide/Vilanterol in a Single Inhaler (TRELEGY™ ELLIPTA™) when Compared with Non-ELLIPTA Multiple Inhaler Triple Therapies in COPD Patients within a Usual Care Setting	fluticasone furoate/vilanterol/umeclidinium bromide	206854	Pulmonary Disease, Chronic Obstructive	Phase 4	https://www.gsk-studyregister.com/en/trial-details/?id=206854	http://clinicaltrials.gov/show/NCT03467425	https://www.clinicaltrialsregister.eu/ctr-search/search?query=/2017-004369-29	Y	Y	Y	Y	Y	Y	Y		1-May-2021
20845	GSK	A randomised, double-blind, parallel group PhIII study to assess the clinical efficacy and safety of 100 mg SC Mepolizumab as an add on to maintenance treatment in adults with severe bilateral nasal polyps - SYNAPSE (StudY in NAsal Polyps patients to assess the Safety and Efficacy of mepolizumab)	mepolizumab	205687	Polyps, Nasal	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=205687	http://clinicaltrials.gov/show/NCT03085797	https://www.clinicaltrialsregister.eu/ctr-search/search?query=/2016-004255-70	Y	Y	Y	Y	Y	Y	Y	This study is available in CDISC format.	1-May-2021
20846	GSK	A two-part healthy volunteer study to investigate both the interaction of GSK2586184 with rosuvastatin and simvastatin and to compare the pharmacokinetics of two different formulations of GSK2586184.	solcitinib	117171	Systemic Lupus Erythematosus	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=117171	http://clinicaltrials.gov/show/NCT01953835		Y	Y	Y	Y	Y	Y	Y	This study is available in CDISC format.	1-May-2021
20849	GSK	A phase III study to evaluate the efficacy and safety of GSK1358820 (botulinum toxin type A) in patients with urinary incontinence due to neurogenic detrusor overactivity	OnabotulinumtoxinA	204948	Urinary Bladder, Overactive	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=204948	http://clinicaltrials.gov/show/NCT02849418		Y	Y	Y	Y	Y	Y	Y		1-Jun-2021
20850	GSK	A Phase IIb, Randomized (Stratified), Double-Blind (Sponsor Open), Parallel-Group, Placebo-Controlled, Dose-Finding Study of Nemiralisib (GSK2269557) Added to Standard of Care (SoC) Versus SoC Alone in Participants Diagnosed with an Acute Moderate or Severe Exacerbation of Chronic Obstructive Pulmonary Disease (COPD)	nemiralisib	200879	Pulmonary Disease, Chronic Obstructive	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=200879	http://clinicaltrials.gov/show/NCT03345407	https://www.clinicaltrialsregister.eu/ctr-search/search?query=/2017-001074-42	Y	Y	Y	Y	Y	Y	Y	This study is available in CDISC format.	1-Jun-2021
20851	GSK	A Phase IV, 12 week, randomised, double-blind, double-dummy study to compare single inhaler triple therapy, fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI), with tiotropium monotherapy based on lung function and symptoms in participants with chronic obstructive pulmonary disease	fluticasone furoate/vilanterol/umeclidinium bromide	207626	Pulmonary Disease, Chronic Obstructive	Phase 4	https://www.gsk-studyregister.com/en/trial-details/?id=207626	http://clinicaltrials.gov/show/NCT03474081	https://www.clinicaltrialsregister.eu/ctr-search/search?query=/2017-001190-16	Y	N	Y	Y	Y	Y	Y	:	1-Jun-2021
20852	GSK	A Randomized, Double-Blind, Placebo-Controlled Multicenter Phase II Study to Evaluate the Safety and Efficacy and Dose Response of 28 Days of Once-Daily Dosing of the Oral Motilin Receptor Agonist GSK962040, in Type I and II Diabetic Male and Female Subjects with Gastroparesis	camicinal	114479	Gastroparesis	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=114479	http://clinicaltrials.gov/show/NCT01262898	https://www.clinicaltrialsregister.eu/ctr-search/search?query=/2010-023186-21	Y	Y	Y	Y	Y	Y	Y		1-Jun-2021
20853	Astellas	Open-label Extension Study in Rheumatoid Arthritis Patients Who Have Completed Phase 2b Study or Phase 3 Study of ASP015K	peficitinib hydrobromide	015K-CL-RAJ2	Rheumatoid Arthritis	Phase 3	https://www.clinicaltrials.astellas.com/study/?pid=015K-CL-RAJ2	https://clinicaltrials.gov/ct2/show/NCT01638013		Y	Y	Y	Y	Y	Y	Y		1-Jul-2021
20854	Astellas	An Open-label, Baseline-controlled, Multicenter, Phase 3 Dose titration Study Followed by a Fixed-dose Observation Period to Evaluate Efficacy, Safety and Pharmacokinetics of Mirabegron in Children and Adolescents From 3 to Less Than 18 Years of Age with Neurogenic Detrusor Overactivity (NDO) on Clean Intermittent Catheterization (CIC)	mirabegron	178-CL-206A	Neurogenic detrusor overactivity	Phase 3	https://www.clinicaltrials.astellas.com/study/?pid=178-CL-206A	https://clinicaltrials.gov/ct2/show/NCT02751931	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-002876-25	Y	Y	Y	Y	Y	Y	Y		1-Jul-2021
20855	Novartis	A three-arm, randomized, open label, Phase II study of everolimus in combination with exemestane versus everolimus alone versus capecitabine in the treatment of postmenopausal women with estrogen receptor positive, locally advanced, recurrent, or metastatic breast cancer after recurrence or progression on prior letrozole or anastrozole	everolimus	CRAD001Y2201	Breast Cancer	Phase 2	https://www.novctrd.com/ctrdweb/trialresult/trialresults/pdf?trialResultId=17393	https://www.clinicaltrials.gov/ct2/show/NCT1783444?term=CRAD001Y2201&rank=1	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003757-28	Y	Y	Y	Y	Y	Y	Y		1-Jun-2021
20856	Novartis	An open label, stratified, single-arm phase II study of RAD001 in patients with advanced pancre-atic neuroendocrine tumor (NET) after failure of cytotoxic chemotherapy.	everolimus	CRAD001C2239	Pancreatic neuroendocrine tumor (PNET)	Phase 2	https://www.novctrd.com/ctrdweb/trialresult/trialresults/pdf?trialResultId=4563	https://www.clinicaltrials.gov/ct2/show/NCT363051?term=CRAD001C2239&rank=1	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001247-64	Y	Y	Y	Y	Y	Y	Y		1-Jun-2021
20857	Novartis	A randomized, double-blind, placebo-controlled, multicenter phase III study in patients with advanced carcinoid tumor receiving Sandostatin LAR® Depot and RAD001 10 mg/d or San-dostatin LAR® Depot and placebo	everolimus	CRAD001C2325	Carcinoid tumor	Phase 3	https://www.novctrd.com/ctrdweb/trialresult/trialresults/pdf?trialResultId=4723	https://www.clinicaltrials.gov/ct2/show/NCT412061?term=CRAD001C2325&rank=1	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004507-18	Y	Y	Y	Y	Y	Y	Y		1-Jun-2021
20858	Novartis	A randomized double-blind phase III study of everolimus 10 mg/d plus best supportive care (BSC) versus placebo plus best supportive care in the treatment of patients with advanced pancreatic neuro-endocrine tumor (NET)	everolimus	CRAD001C2324	Pancreatic neuroendocrine tumor (PNET)	Phase 3	https://www.novctrd.com/ctrdweb/trialresult/trialresults/pdf?trialResultId=4703	https://www.clinicaltrials.gov/ct2/show/NCT510068?term=CRAD001C2324&rank=1	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006819-75	Y	Y	Y	Y	Y	Y	Y		1-Jun-2021
20859	GSK	A randomised, double-blind (sponsor unblinded), placebo-controlled, parallel-group, multicentre study to evaluate the efficacy and safety of GSK2269557 administered in addition to standard of care in adult subjects diagnosed with an acute exacerbation of Chronic Obstructive Pulmonary Disease	nemiralisib	116678	Pulmonary Disease, Chronic Obstructive	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=116678	https://www.clinicaltrials.gov/ct2/show/NCT02294734	https://www.clinicaltrialsregister.eu/ctr-search/search?query=/2014-001972-70	Y	Y	Y	Y	Y	Y	Y	The raw data are included within the analysis-ready data for this study and are not provided separately	1-Jul-2021
20860	GSK	A randomised double blind (sponsor unblinded), single and repeat ascending dose First Time in Human study in healthy subjects, cold urticaria and chronic spontaneous urticaria subjects to investigate safety, tolerability, pharmacodynamics and pharmacokinetics of topically applied GSK2646264	GSK2646264	200196	Urticaria	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=200196	https://www.clinicaltrials.gov/ct2/show/NCT02424799	https://www.clinicaltrialsregister.eu/ctr-search/search?query=/2014-001015-39	Y	Y	Y	Y	Y	Y	Y		1-Jul-2021
20861	GSK	A randomised, double-blind, placebo-controlled study to evaluate the safety, efficacy and changes in induced sputum and blood biomarkers following daily repeat doses of inhaled GSK2269557 for 12 weeks in adult subjects diagnosed with an acute exacerbation of Chronic Obstructive Pulmonary Disease (COPD).	nemiralisib	201928	Pulmonary Disease, Chronic Obstructive	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=201928	https://www.clinicaltrials.gov/ct2/show/NCT02522299	https://www.clinicaltrialsregister.eu/ctr-search/search?query=/2015-003696-30	Y	Y	Y	Y	Y	Y	Y	The raw data are included within the analysis-ready data for this study and are not provided separately	1-Jul-2021
20862	GSK	A Phase 3/4, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, 52-Week Study to Evaluate the Efficacy and Safety of Belimumab (HGS1006) in Adult Subjects of Black Race with Systemic Lupus Erythematosus (SLE)	belimumab	115471	Systemic Lupus Erythematosus	Phase 4	https://www.gsk-studyregister.com/en/trial-details/?id=115471	https://www.clinicaltrials.gov/ct2/show/NCT01632241	https://www.clinicaltrialsregister.eu/ctr-search/search?query=/2011-005672-42	Y	Y	Y	Y	Y	Y	Y	This study is available in CDISC format.	1-Jul-2021
20863	GSK	A three part, non-randomised, open label study designed to assess the pharmacokinetics of GSK2982772 following administration of minitab modified release formulations in a capsule relative to an immediate release reference tablet formulation (Part A), the pharmacokinetics of escalating, repeat doses of a selected minitab modified release prototype (Part B), and the pharmacokinetics of GSK2982772 following administration of modified release tablet formulations in the fed and fasted state (Part C) in healthy participants	GSK2982772	205017	Autoimmune Diseases	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=205017	https://www.clinicaltrials.gov/ct2/show/NCT03266172	https://www.clinicaltrialsregister.eu/ctr-search/search?query=/2017-000652-25	Y	Y	Y	Y	Y	Y	Y		1-Jul-2021
20864	GSK	A Phase I/II randomized observer-blind placebo controlled study to evaluate the safety, reactogenicity and immunogenicity of different dose levels of GSK Biologicals’ investigational unadjuvanted RSV Maternal vaccine (GSK3888550A) compared to placebo when administered to healthy non-pregnant women aged 18-45 years	GSK3888550A	208068	Respiratory Syncytial Virus Infections	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=208068	http://clinicaltrials.gov/show/NCT03674177	https://www.clinicaltrialsregister.eu/ctr-search/search?query=/2018-001340-62	Y	Y	Y	Y	Y	Y	Y	This study is available in CDISC format.	1-Jul-2021
20865	GSK	A randomized, single-blind, efficacy study to evaluate oral health and quality of life associated with use of a denture adhesive	carbomer and carmellose sodium gel	209510	Denture Retention	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=209510	http://clinicaltrials.gov/show/NCT03807700		Y	Y	Y	Y	Y	Y	Y		1-Jul-2021
20866	GSK	A Photo-irritation and Photo-sensitisation study in Healthy Subjects for Three Developmental Cosmetic Facial Products	glycerol and niacinamide face cream, serum and lotion	212378	Skin Care	N/A	https://www.gsk-studyregister.com/en/trial-details/?id=212378	http://clinicaltrials.gov/show/NCT04006795		Y	Y	Y	Y	Y	Y	Y		1-Jul-2021
20867	GSK	A Phase I, First Time in Human, Open-Label, Dose Escalation Study to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics of Anti-Her3 Monoclonal Antibody GSK2849330 in Subjects with Advanced Her3-Positive Solid Tumors	GSK2849330	117158	Cancer|Neoplasms	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=117158	http://clinicaltrials.gov/show/NCT01966445	https://www.clinicaltrialsregister.eu/ctr-search/search?query=/2013-001699-39	Y	Y	Y	Y	Y	Y	Y		1-Aug-2021
20868	GSK	A multi-center, randomized, double-blind, placebo controlled, parallel group study to compare cessation versus continuation of long-term mepolizumab treatment in patients with severe eosinophilic asthma (201810)	mepolizumab	201810	Asthma	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=201810	http://clinicaltrials.gov/show/NCT02555371	https://www.clinicaltrialsregister.eu/ctr-search/search?query=/2015-002361-32	Y	Y	Y	Y	Y	Y	Y	This is a long-term safety study linked with MEA115666 and 201312. This study is available in CDISC format.	1-Aug-2021
20869	GSK	An observer-blind, dose ranging safety and immunogenicity study of GSK Biologicals’ GSK1557484A vaccine in children 6 to less than 36 months of age	GSK1557484A	116938	Influenza	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=116938	http://clinicaltrials.gov/show/NCT02719743	https://www.clinicaltrialsregister.eu/ctr-search/search?query=/2015-003458-42	Y	Y	Y	Y	Y	Y	Y		1-Aug-2021
20870	GSK	A Phase III, 52-week, Open-label Study to Evaluate Long-term Safety of Fixed Dose Combination Therapy Fluticasone Furoate/Umeclidinium Bromide/Vilanterol Trifenatate in Japanese Patients with Asthma	fluticasone furoate/vilanterol/umeclidinium bromide	207236	Asthma	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=207236	http://clinicaltrials.gov/show/NCT03184987		Y	Y	Y	Y	Y	Y	Y	This study is available in CDISC format.	1-Aug-2021
20877	Novartis	A randomized, double-blind, active control, multicenter study to evaluate the efficacy at week 52 of secukinumab monotherapy compared with adalimumab monotherapy in patients with active psoriatic arthritis	secukinumab	CAIN457F2366	Psoriatic arthritis	Phase 3	https://www.novctrd.com/ctrdweb/trialresult/trialresults/pdf?trialResultId=17780	https://www.clinicaltrials.gov/ct2/show/NCT02745080?term=CAIN457F2366&rank=1		Y	Y	Y	Y	Y	Y	Y		1-Aug-2021
20878	Novartis	A Phase II Study of the BRAF Inhibitor Dabrafenib as a Single Agent and in Combination With the MEK Inhibitor Trametinib in Subjects With BRAF V600E Mutation Positive Metastatic (Stage IV) Non-small Cell Lung Cancer	Dabrafenib	CDRB436E2201	Cancer	Phase 2		https://www.clinicaltrials.gov/ct2/show/NCT01336634?term=cdrb436e2201&draw=2&rank=1	https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-001161-41/results	Y	Y	Y	Y	Y	Y	Y		1-Sep-2021
20880	Novartis	A Phase III Randomized, Open-label Study Comparing GSK1120212 to Chemotherapy in Subjects With Advanced or Metastatic BRAF V600E/K Mutation-positive Melanoma	GSK1120212	CTMT212A2301 (GSK-114267)	Melanoma	Phase 3		https://www.clinicaltrials.gov/ct2/show/NCT01245062?term=114267&draw=2&rank=1		Y	Y	Y	Y	Y	Y	Y		1-Sep-2021
20882	Novartis	A randomized, double-blind, placebo-controlled, parallel-group, multicenter study to demonstrate the efficacy of subcutaneous secukinumab 300 mg as assessed by the Psoriasis Scalp Severity Index (PSSI) at 12 weeks of treatment, compared to placebo, and to assess safety and tolerability up to 24 weeks in adult subjects with moderate to severe scalp psoriasis	secukinumab	CAIN457AUS01	Moderate to severe scalp psoriasis	Phase 3	https://www.novctrd.com/ctrdweb/trialresult/trialresults/pdf?trialResultId=15507	https://www.clinicaltrials.gov/ct2/show/NCT2267135?term=CAIN457AUS01&rank=1		Y	Y	Y	Y	Y	Y	Y		1-Oct-2021
20883	Novartis	A multi-center, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of 24 weeks treatment with vildagliptin in type 2 diabetes mellitus patients  70 years (drug-naïve or inadequately controlled on oral agents)	vildagliptin	CLAF237A23150	Type 2 Diabetes	Phase 3	https://www.novctrd.com/	https://www.clinicaltrials.gov/ct2/show/NCT1257451?term=CLAF237A23150&rank=1	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022658-18	Y	Y	Y	Y	Y	Y	Y		1-Oct-2021
20884	Novartis	A 24-week, multi-center, double-blind, randomized, placebo-controlled, parallel-group study to assess the efficacy and safety of vildagliptin 50mg bid as an add-on therapy to insulin, with or without metformin, in patients with type 2 diabetes mellitus	vildagliptin	CLAF237A23135	Type 2 Diabetes	Phase 3	https://www.novctrd.com/	https://www.clinicaltrials.gov/ct2/show/NCT1224366?term=CLAF237A23135&rank=1	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-020684-20	Y	Y	Y	Y	Y	Y	Y		1-Oct-2021
20885	Novartis	A multi-center, randomized, double-blind, placebo-controlled clinical trial to evaluate the effect of 52 weeks treatment with vildagliptin on left ventricular function in patients with type 2 diabetes and congestive heart failure	vildagliptin	CLAF237A23118	Type 2 Diabetes	Phase 4	https://www.novctrd.com/	https://www.clinicaltrials.gov/ct2/show/NCT894868?term=CLAF237A23118&rank=1	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-005012-41	Y	Y	Y	Y	Y	Y	Y		1-Oct-2021
20886	Novartis	A multi-center, randomized, double-blind study to evaluate the efficacy and long-term safety of vildagliptin modified release (MR) as add-on therapy to metformin in patients with type 2 diabetes	vildagliptin	CLAF237B2224	Type 2 Diabetes	Phase 2/3	https://www.novctrd.com/	https://www.clinicaltrials.gov/ct2/show/NCT860288?term=CLAF237B2224&rank=1	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-004722-16	Y	Y	Y	Y	Y	Y	Y		1-Oct-2021
20887	Novartis	A 28 week extension to a 24 week multi-center, randomized, double-blind clinical trial to evaluate the safety and tolerability of vildagliptin (50mg qd) versus placebo in patients with type 2 diabetes and moderate or severe renal insufficiency	vildagliptin	CLAF237A23137E1	Type 2 Diabetes	Phase 3	https://www.novctrd.com/	https://www.clinicaltrials.gov/ct2/show/NCT765830?term=CLAF237A23137E1&rank=1	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001243-18	Y	Y	Y	Y	Y	Y	Y		1-Oct-2021
20888	Novartis	A multi-center, randomized, double-blind, clinical trial to evaluate the safety and tolerability of 24 weeks treatment with vildagliptin (50 mg qd) versus placebo in patients with type 2 diabetes and moderate or severe renal insufficiency	vildagliptin	CLAF237A23137	Type 2 Diabetes	Phase 3	https://www.novctrd.com/	https://www.clinicaltrials.gov/ct2/show/NCT646542?term=CLAF237A23137&rank=1	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003723-21	Y	Y	Y	Y	Y	Y	Y		1-Oct-2021
20889	Novartis	A Multi-center, Randomized, Double-Blind, Active Controlled Study to Compare the Effect of 24 Weeks Treatment with Vildagliptin 100 mg qd or Metformin 1500 mg daily in Elderly Drug Naïve Patients with Type 2 Diabetes	vildagliptin	CLAF237A2398	Type 2 Diabetes	Phase 3	https://www.novctrd.com/ctrdweb/trialresult/trialresults/pdf?trialResultId=2652	https://www.clinicaltrials.gov/ct2/show/NCT383578?term=CLAF237A2398&rank=1	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002466-19	Y	Y	Y	Y	Y	Y	Y		1-Oct-2021
20891	Novartis	A multicenter, randomized, double-blind, active controlled study to compare the long-term effect of treatment with LAF237 50 mg bid to glimepiride up to 6 mg daily as add-on therapy in patients with type 2 diabetes inadequately controlled with metformin monotherapy	vildagliptin	CLAF237A2308	Type 2 Diabetes	Phase 3	https://www.novctrd.com/ctrdweb/trialresult/trialresults/pdf?trialResultId=2649	https://www.clinicaltrials.gov/ct2/show/NCT106340?term=CLAF237A2308&rank=1	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-004559-21	Y	Y	Y	Y	Y	Y	Y		1-Oct-2021
20892	Novartis	A multicenter, double-blind, randomized, active controlled study to compare the effect of long term treatment with LAF237 50 mg bid to gliclazide up to 320 mg daily in drug naïve patients with type 2 diabetes	vildagliptin	CLAF237A2310	Type 2 Diabetes	Phase 3	https://www.novctrd.com/	https://www.clinicaltrials.gov/ct2/show/NCT102388?term=CLAF237A2310&rank=1	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000540-24	Y	Y	Y	Y	Y	Y	Y		1-Oct-2021
20893	Novartis	A multicenter, double-blind, randomized, parallel-group study to compare the effect of 24 weeks treatment with LAF237 (50 mg qd or bid) to placebo as add-on therapy to glimepiride in patients with type 2 diabetes inadequately controlled with sulfonylurea monotherapy	vildagliptin	CLAF237A2305	Type 2 Diabetes	Phase 3	https://www.novctrd.com/ctrdweb/trialresult/trialresults/pdf?trialResultId=2274	https://www.clinicaltrials.gov/ct2/show/NCT99944?term=CLAF237A2305&rank=1	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001546-32	Y	Y	Y	Y	Y	Y	Y		1-Oct-2021
20894	Novartis	A multicenter, randomized, double-blind, active controlled study to compare the effect of 24 weeks treatment with LAF237 50 mg bid to rosiglitazone 8 mg qd in drug-naive patients with type 2 diabetes	vildagliptin	CLAF237A2327	Type 2 Diabetes	Phase 3	https://www.novctrd.com/ctrdweb/trialresult/trialresults/pdf?trialResultId=2282	https://www.clinicaltrials.gov/ct2/show/NCT99918?term=CLAF237A2327&rank=1	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-005045-35	Y	Y	Y	Y	Y	Y	Y		1-Oct-2021
20895	Novartis	A multicenter, randomized, double-blind, active controlled study to compare the effect of 52 weeks treatment with LAF237 50 mg bid to metformin up to 1000 mg bid in drug naïve patients with type 2 diabetes.	vildagliptin	CLAF237A2309	Type 2 Diabetes	Phase 3	https://www.novctrd.com/ctrdweb/trialresult/trialresults/pdf?trialResultId=2275	https://www.clinicaltrials.gov/ct2/show/NCT99866?term=CLAF237A2309&rank=1	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000376-14	Y	Y	Y	Y	Y	Y	Y		1-Oct-2021
20896	Novartis	A Multicenter, Double-Blind, Randomized, Active Controlled Study to Compare the Effect of 52 Weeks Treatment with LAF237 50 mg bid to Gliclazide up to 320 mg Daily as Add-On Therapy in Patients with Type 2 Diabetes Inadequately Controlled with Metformin Monotherapy	vildagliptin	CLAF237A2338	Type 2 Diabetes	Phase 3	https://www.novctrd.com/ctrdweb/trialresult/trialresults/pdf?trialResultId=2851	https://www.clinicaltrials.gov/ct2/show/NCT102466?term=CLAF237A2338&rank=1	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000542-20	Y	Y	Y	Y	Y	Y	Y		1-Oct-2021
20897	GSK	Randomized, Double-blind, Placebo Controlled Dose Escalation Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Doses (Intravenous bolus) and constant intravenous infusion over 7 Days of GSK3335065 in Healthy Adult Subjects	GSK3335065	201570	Pancreatitis, Acute Necrotizing	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=201570	http://clinicaltrials.gov/show/NCT03245619	https://www.clinicaltrialsregister.eu/ctr-search/search?query=/2016-001303-22	Y	N	Y	Y	Y	Y	Y	An annotated case report form is not available for this study. A blank case report form will be provided.	1-Sep-2021
20898	GSK	A randomised double-blind (sponsor open), placebo controlled, single ascending dose, First Time in Human study in participants with mild to moderate asthma to assess safety, tolerability, immunogenicity, pharmacokinetics and pharmacodynamics of GSK3511294 administered subcutaneously	GSK3511294	205722	Asthma	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=205722	http://clinicaltrials.gov/show/NCT03287310	https://www.clinicaltrialsregister.eu/ctr-search/search?query=/2016-004256-30	Y	Y	Y	Y	Y	Y	Y		1-Sep-2021
20900	GSK	An Open-Label, Non-Randomized, Multicenter Study to Determine the Pharmacokinetics and Safety of Niraparib Following a Single Oral Dose in Patients with Advanced Solid Tumors and Either Normal Hepatic Function or Moderate Hepatic Impairment	GSK3985771	213354	Ovarian Neoplasms|Neoplasms|Solid Tumor|Hepatic Impairment	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=213354	http://clinicaltrials.gov/show/NCT03359850		Y	Y	Y	Y	Y	Y	Y	Data in CDISC Format	1-Sep-2021
20901	GSK	Immunogenicity and safety study of two different formulations of GlaxoSmithKline (GSK) Biologicals’ oral live attenuated human rotavirus (HRV) vaccine, Rotarix in healthy infants	SB444563	116566	Infections, Rotavirus	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=116566	http://clinicaltrials.gov/show/NCT02141204	https://www.clinicaltrialsregister.eu/ctr-search/search?query=/2012-001875-35	Y	Y	Y	Y	Y	Y	Y	Data in CDISC Format	1-Sep-2021
20902	GSK	A Phase I, Open-label, Dose-finding Study of GSK2636771 Administered in Combination with Enzalutamide (Xtandi^TM ) in Male Subjects with Metastatic Castration-Resistant Prostate Cancer (mCRPC)	GSK2636771	200331	Neoplasms	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=200331	http://clinicaltrials.gov/show/NCT02215096	https://www.clinicaltrialsregister.eu/ctr-search/search?query=/2013-005111-27	Y	Y	Y	Y	Y	Y	Y		1-Sep-2021
20903	GSK	Follow-Up Study to Assess Long-Term Safety and Outcomes in Infants and Children Born to Mothers Participating in Retosiban Treatment Studies	retosiban	200722	Obstetric Labour, Premature	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=200722	http://clinicaltrials.gov/show/NCT02292784	https://www.clinicaltrialsregister.eu/ctr-search/search?query=/2014-000499-24	Y	Y	Y	Y	Y	Y	Y	Data in CDISC Format	1-Sep-2021
20904	GSK	A placebo-controlled, double-blind (sponsor open), randomized, crossover study to assess the efficacy, safety, and tolerability of GSK2798745 in participants with chronic cough	GSK2798745	207702	Cough	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=207702	http://clinicaltrials.gov/show/NCT03372603	https://www.clinicaltrialsregister.eu/ctr-search/search?query=/2017-002265-21	Y	Y	Y	Y	Y	Y	Y		1-Sep-2021
20906	GSK	A multicentre, randomised, double-blind (sponsor-unblinded), placebo-controlled study with open label extension to investigate the safety and tolerability, pharmacokinetics, pharmacodynamics, and efficacy of GSK2982772 in subjects with active ulcerative colitis.	GSK2982772	202152	Colitis, Ulcerative	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=202152	http://clinicaltrials.gov/show/NCT02903966	https://www.clinicaltrialsregister.eu/ctr-search/search?query=/2016-001833-29	Y	Y	Y	N	Y	Y	Y		1-Oct-2021
20907	GSK	A phase IIb randomized, placebo controlled, single centre observer blind, human-challenge study to evaluate the efficacy, safety and immunogenicity of  2 vaccinations with GVGH Shigella sonnei vaccine (1790GAHB) administered by intramuscular route in  healthy non-immune adult population.	GSK3536852A	205626	Dysentery, Bacillary	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=205626	http://clinicaltrials.gov/show/NCT03527173		Y	Y	Y	Y	Y	Y	Y	Data in CDISC Format	1-Oct-2021
20908	GSK	A Phase IIa, open-label, non-randomized, controlled, mono-center study to evaluate the efficacy, immunogenicity and safety of a fractional (Fx) booster dose of GlaxoSmithKline Biologicals’ malaria candidate vaccine RTS,S/AS01E when given to healthy adults subjects previously receiving various primary dose schedules in a sporozoite challenge model.	SB257049	209003	Malaria	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=209003	http://clinicaltrials.gov/show/NCT03824236		Y	Y	Y	Y	Y	Y	Y		1-Oct-2021
20909	GSK	An open-label, randomized, parallel group, single dose study to investigate the PK and safety of belimumab 200 mg intravenous and 200 mg subcutaneous via auto-injector in Chinese healthy participants.	belimumab	209629	Systemic Lupus Erythematosus	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=209629	http://clinicaltrials.gov/show/NCT04136145		Y	Y	Y	N	Y	Y	Y	Data in CDISC Format	1-Oct-2021
20910	GSK	A Phase 2b, Open-Label, Multi-Center Study Assessing the Immunological Persistence of Antibodies at Approximately 2 years After the last Meningococcal Vaccination in Study V102_15 and the Response to a Booster dose of GSK MenABCWY or Meningococcal Serogroup B Vaccines, in Healthy Adolescents	GSK3536819A	205613	Infections, Meningococcal	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=205613	http://clinicaltrials.gov/show/NCT02946385	https://www.clinicaltrialsregister.eu/ctr-search/search?query=/2016-002230-69	Y	Y	Y	Y	Y	Y	Y		1-Oct-2021
20911	GSK	A Phase 2b, Randomized, Controlled, Observer-Blind, Multi-Center Study Assessing the Immunogenicity and Safety of GSK Meningococcal ABCWY Vaccine Administered at Different Schedules Compared to GSK Meningococcal group B vaccine, in Healthy Adolescents	GSK3536819A;GSK3536829A	205215	Infections, Meningococcal	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=205215	http://clinicaltrials.gov/show/NCT02212457	https://www.clinicaltrialsregister.eu/ctr-search/search?query=/2013-002451-15	Y	Y	Y	Y	Y	Y	Y		1-Oct-2021
20912	GSK	A phase 2b, randomized, controlled, observer-blind, multi-center study to evaluate safety and immunogenicity of different formulations of GSK Biologicals’ Meningococcal ACWY conjugate vaccine (GSK3536820A and Menveo) administered to healthy adolescents and young adults 10 to 40 years of age)	GSK3536820A	207467	Meningitis, Meningococcal	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=207467	http://clinicaltrials.gov/show/NCT03433482	https://www.clinicaltrialsregister.eu/ctr-search/search?query=/2017-003456-23	Y	Y	Y	Y	Y	Y	Y		1-Oct-2021
20919	GSK	A Phase I; Multi-Center; Open-Label (Parts 1 and 2); Randomized, Double-Blind, Placebo-Controlled (Part 3); Single-Dose; 3-Part Study to Evaluate the Relative Bioavailability of Three Formulations in Healthy Subjects, Food Effect on Tablet Formulation in Healthy Subjects, and Pharmacokinetics of Gepotidacin (GSK2140944) in Japanese Subjects in Fasted and Fed States	gepotidacin	117351	Infections, Bacterial	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=117351	http://clinicaltrials.gov/show/NCT02853435		Y	Y	Y	Y	Y	Y	Y	Data in CDISC Format	1-Nov-2021
20920	GSK	A Phase I, Double-Blind, Two-Part, Sequential Study to Evaluate the Pharmacokinetics of Gepotidacin Tablets in Healthy Adult and Adolescent Participants	gepotidacin	209611	Infections, Bacterial	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=209611	http://clinicaltrials.gov/show/NCT04079790		Y	N	Y	Y	Y	Y	Y	Data in CDISC Format; An annotated case report form is not available for this study. A blank case report form will be provided;	1-Nov-2021
20921	GSK	A Phase 2, Double-Blinded, Randomized, Placebo-Controlled, Dose-Escalation Study to Examine the Safety, Tolerability, Pharmacokinetics and Antiviral Activity of ISIS 505358 in Treatment-Naïve Patients with Chronic HBV Infection	GSK3228836	205695	Hepatitis B	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=205695	http://clinicaltrials.gov/show/NCT02981602		Y	N	Y	N	Y	Y	Y	Data in CDISC Format; An annotated case report form is not available for this study. A blank case report form will be provided;	1-Nov-2021
20922	GSK	Immunogenicity, reactogenicity and safety of two formulations of GSK Biologicals’ Meningococcal ACWY conjugate vaccine (GSK3536820A and Menveo) in healthy adults 18 to 40 years of age	GSK3536820A	205343	Infections, Meningococcal	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=205343	http://clinicaltrials.gov/show/NCT03652610	https://www.clinicaltrialsregister.eu/ctr-search/search?query=/2017-003692-61	Y	Y	Y	Y	Y	Y	Y	Data in CDISC Format	1-Nov-2021
20923	GSK	A long-term follow-up study of the investigational GSK Biologicals’ GSK3277511A vaccine in adults	GSK3277511A	204913	Respiratory Disorders	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=204913	http://clinicaltrials.gov/show/NCT03201211	https://www.clinicaltrialsregister.eu/ctr-search/search?query=/2016-004248-13	Y	Y	Y	Y	Y	Y	Y	Data in CDISC Format	1-Nov-2021
20924	GSK	Immunogenicity and Safety of Meningococcal MenABCWY Vaccine, and of rMenB+OMV NZ and MenACWY Administered Concomitantly in the Same Arm or in 2 Different Arms, or Alone	GSK3536819A	208205	Meningitis, Meningococcal	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=208205	http://clinicaltrials.gov/show/NCT03587207	https://www.clinicaltrialsregister.eu/ctr-search/search?query=/2017-005128-12	Y	N	Y	Y	Y	Y	Y	Data in CDISC Format; An annotated case report form is not available for this study. A blank case report form will be provided;	1-Nov-2021
20925	Grunenthal	Open-label evaluation of the population pharmacokinetic profile, safety,  tolerability, and efficacy of intravenous tapentadol solution for injection for the  treatment of post-surgical pain in children aged from birth to less than  2 years, including preterm neonates.	Tapentadol	KF5503-73	Moderate to severe acute post-operative pain	Phase 2	https://www.grunenthal.com/en/research-and-development/clinical-trials/data-clinical-trials	NA	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-002259-24	Y	N	Y	N	N	N	N		1-Dec-2021
20926	Grunenthal	Open-label investigation of the pharmacokinetic profile, safety, tolerability, and efficacy of multiple administrations of tapentadol oral solution used for treatment of acute pain in children aged 2 years to less than 7 years.	Tapentadol	KF5503-75	Moderate to severe acute pain	Phase 2	https://www.grunenthal.com/en/research-and-development/clinical-trials/data-clinical-trials	NA	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-000205-77	Y	N	Y	N	N	N	N		1-Dec-2021
20927	Novartis	A Multi-centre 3-year Follow-up Study to Assess the Viral Activity in Patients Who Failed to Achieve Sustained Virologic Response in Novartis-sponsored Alisporivir-studies for Chronic Hepatitis C Patients	alisporivir	CDEB025A2313	Hepatitis C, Chronic	Phase 3	https://www.novctrd.com/ctrdweb/trialresult/trialresults/pdf?trialResultId=13785	https://www.clinicaltrials.gov/ct2/show/NCT2465203?term=CDEB025A2313&rank=1	https://www.clinicaltrialsregister.eu/ctr-search/search?query=CDEB025A2313	Y	Y	Y	Y	Y	Y	Y		1-Dec-2021
20929	Astellas	ASP3550 Phase II Study - A Maintenance-Dose-Finding Study of Three-Month Depot in Patients with Prostate Cancer -	degarelix acetate	3550-CL-0009	Prostate Cancer	Phase 2	https://www.clinicaltrials.astellas.com/study/?pid=3550-CL-0009	https://clinicaltrials.gov/ct2/show/NCT01261572		Y	Y	Y	N	Y	Y	Y	Analysis plan is described into clinical study report. Formats available for datasets without specifications.	1-Dec-2021
20930	Astellas	Phase III Study of ASP3550 – An Open-label, Goserelin Acetate-controlled, Parallel Group Study in Patients with Prostate Cancer –	degarelix acetate	3550-CL-0010	Prostate Cancer	Phase 3	https://www.clinicaltrials.astellas.com/study/?pid=3550-CL-0010	https://clinicaltrials.gov/ct2/show/NCT01964170		Y	Y	Y	Y	Y	Y	Y	Synoptic CSR available.	1-Dec-2021
20940	Novartis	A Study of CAD106 and CNP520 Versus Placebo in Participants at Risk for the Onset of Clinical Symptoms of Alzheimer's Disease (GS1)	CAD106	CAPI015A2201J	Alzheimers Disease	Phase 2/3	https://www.novctrd.com/ctrdweb/trialresult/trialresults/pdf?trialResultId=17821	https://www.clinicaltrials.gov/ct2/show/NCT02565511?term=CAPI015A2201J&draw=2&rank=1	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-002715-15	Y	Y	Y	Y	Y	Y	Y		1-Jan-2022
20941	Novartis	A Study of CNP520 Versus Placebo in Participants at Risk for the Onset of Clinical Symptoms of Alzheimer's Disease (GS2)	CNP520	CCNP520A2202J	Alzheimers Disease	Phase 2/3	https://www.novctrd.com/ctrdweb/trialresult/trialresults/pdf?trialResultId=17811	https://www.clinicaltrials.gov/ct2/show/NCT03131453?term=CCNP520A2202J&draw=2&rank=1	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-002715-15	Y	Y	Y	Y	Y	Y	Y		1-Jan-2022
20942	Astellas	Postmarketing clinical study on enzalutamide —a randomized phase 4 study comparing enzalutamide versus flutamide in castration-resistant prostate cancer patients who have failed combined androgen blockade therapy with bicalutamide plus androgen deprivation therapy—	enzalutamide	9785-MA-3051	Prostate Cancer	Phase 4	https://www.clinicaltrials.astellas.com/study/?pid=9785-MA-3051	https://clinicaltrials.gov/ct2/show/NCT02918968		Y	Y	Y	Y	Y	Y	Y		1-Jan-2022
20943	GSK	A Phase I/II Open-Label, Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of GSK525762 in Subjects with NUT Midline Carcinoma (NMC) and other cancers	molibresib	BET115521	Carcinoma, Midline	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=115521	http://clinicaltrials.gov/show/NCT01587703	https://www.clinicaltrialsregister.eu/ctr-search/search?query=/2014-004982-25	Y	N	Y	Y	Y	Y	Y	Data in CDISC Format; An annotated case report form is not available for this study. A blank case report form will be provided;	1-Feb-2022
20944	GSK	An Open Label, Non-comparative, Multicenter Study to Assess the Pharmacokinetics, Safety and Efficacy of Tafenoquine (SB-252263, WR238605) in the Treatment of Pediatric Subjects with Plasmodium vivax Malaria	tafenoquine	TAF113577	Malaria, Vivax	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=113577	http://clinicaltrials.gov/show/NCT02563496		Y	N	Y	Y	Y	Y	Y	Data in CDISC Format; An annotated case report form is not available for this study. A blank case report form will be provided;	1-Feb-2022
20945	GSK	A multi-centre, one-arm prospective study to evaluate efficacy and safety of switching from Entecavir (ETV) to Tenofovir Disoproxil Fumarate (TDF) in Japanese chronic hepatitis B HBeAg-positive and HBV-DNA undetectable subjects	tenofovir disoproxil fumarate	205883	Hepatitis B, Chronic	Phase 4	https://www.gsk-studyregister.com/en/trial-details/?id=205883	http://clinicaltrials.gov/show/NCT03258710		Y	N	Y	N	Y	Y	Y	An annotated case report form is not available for this study. A blank case report form will be provided.	1-Feb-2022
20946	GSK	An observer-blind study to evaluate the efficacy, safety, reactogenicity and immunogenicity of the GSK Biologicals’ investigational vaccine GSK3277511A when administered to COPD patients	GSK3277511A	207489	Respiratory Disorders	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=207489	http://clinicaltrials.gov/show/NCT03281876	https://www.clinicaltrialsregister.eu/ctr-search/search?query=/2017-000880-34	Y	N	Y	Y	Y	Y	Y	Data in CDISC Format; An annotated case report form is not available for this study. A blank case report form will be provided;	1-Feb-2022
20947	GSK	Phase 2, Multi-Arm Study of Niraparib Administered Alone and in Combination with PD-1 Inhibitor in Patients with Non-Small Cell Lung Cancer	GSK3985771	213352	Neoplasms|Lung Neoplasms	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=213352	http://clinicaltrials.gov/show/NCT03308942		N	N	Y	N	Y	N	Y	An annotated case report form is not available for this study. A blank case report form will be provided.	1-Feb-2022
20988	GSK	A randomised, double-blind (sponsor open), placebo-controlled, three part study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of single (in both fed and fasted states) or repeat doses of GSK3358699 in healthy male participants	GR61229;GSK3358699;GSK562554;sargramostim	207546	Arthritis, Rheumatoid	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=207546	http://clinicaltrials.gov/show/NCT03426995	https://www.clinicaltrialsregister.eu/ctr-search/search?query=/2017-003997-15	Y	N	Y	Y	Y	Y	Y	An annotated case report form is not available for this study. A blank case report form will be provided.	1-Feb-2022
20990	GSK	A two part, non-randomised, open label study designed to assess the pharmacokinetic profile of modified release prototype coated tablet formulations of GSK2982772 relative to an immediate release reference tablet formulation at a fixed strength (Part A) and the pharmacokinetic profile of alternative tablet strengths of the selected modified release prototype coated tablet formulation (Part B, optional) in healthy participants	GSK2982772	209261	Autoimmune Diseases	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=209261	http://clinicaltrials.gov/show/NCT03649412	https://www.clinicaltrialsregister.eu/ctr-search/search?query=/2018-002370-48	Y	N	Y	Y	Y	Y	Y	An annotated case report form is not available for this study. A blank case report form will be provided.	1-Feb-2022
20991	GSK	An open label, randomized, balanced, three treatment, three period, three sequence, single dose, crossover study to evaluate the bioequivalence of test Griseofulvin tablets, 500 mg versus reference Griseofulvin tablets, 500 mg as well as dose proportionality of test Griseofulvin tablets, 250 mg and 500 mg, in healthy, adult participants under fed conditions	griseofulvin	212504	Antifungal Agents	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=212504	http://clinicaltrials.gov/show/NCT04318535		N	Y	Y	Y	Y	Y	Y	Data in CDISC Format; An annotated case report form is not available for this study. A blank case report form will be provided;	1-Feb-2022
20993	ViiV	A Phase 3b multi-center, open label, single arm, 52-week study, evaluating the feasibility, efficacy and safety of rapid Test and Treat intervention in newly diagnosed HIV-1 infected adults using a fixed dose combination of dolutegravir plus lamivudine (DOVATO) as a first line regimen	dolutegravir/lamivudine	212355	HIV Infections	Phase 3	https://www.viiv-studyregister.com/en/study/?id=212355	http://clinicaltrials.gov/show/NCT03945981		Y	Y	Y	Y	Y	Y	Y	Data in CDISC Format	1-Sep-2021
20994	ViiV	An Open-Label Two-way Interaction Clinical Trial to Evaluate the Pharmacokinetic Interactions Between GSK3640254 and Dolutegravir in Healthy Subjects	GSK3640254	209712	HIV Infections	Phase 1	https://www.viiv-studyregister.com/en/study/?id=209712	http://clinicaltrials.gov/show/NCT03816696		Y	N	Y	Y	Y	Y	Y	Data in CDISC Format; An annotated case report form is not available for this study. A blank case report form will be provided;	1-Nov-2021
20995	ViiV	An Open-Label One-way Interaction Clinical Trial to Evaluate the Pharmacokinetic Interactions Between GSK3640254 and Tenofovir Alafenamide/Emtricitabine in Healthy Subjects	GSK3640254	208134	HIV Infections	Phase 1	https://www.viiv-studyregister.com/en/study/?id=208134	http://clinicaltrials.gov/show/NCT03836729		Y	N	Y	Y	Y	Y	Y	Data in CDISC Format; An annotated case report form is not available for this study. A blank case report form will be provided;	1-Nov-2021
20996	ViiV	The Effect of Coadministration of GSK3640254 on the Pharmacokinetics of a Combined Oral Contraceptive Containing Ethinyl Estradiol and Levonorgestrel in Healthy Female Subjects	GSK3640254	208135	HIV Infections	Phase 1	https://www.viiv-studyregister.com/en/study/?id=208135	http://clinicaltrials.gov/show/NCT03984825		Y	N	Y	Y	Y	Y	Y	Data in CDISC Format; An annotated case report form is not available for this study. A blank case report form will be provided;	1-Feb-2022
21004	Novartis	Study to Demonstrate the Efficacy (Including Inhibition of Structural Damage), Safety and Tolerability up to 2 Years of Secukinumab in Active Psoriatic Arthritis (FUTURE5)	secukinumab	CAIN457F2342	Psoriatic Arthritis	Phase 3	https://www.clinicaltrials.gov/ct2/show/NCT02404350?term=CAIN457F2342&draw=2&rank=1	https://www.novctrd.com/ctrdweb/trialresult/trialresults/pdf?trialResultId=17160	https://www.clinicaltrialsregister.eu/ctr-search/search?query=CAIN457F2342	Y	Y	Y	Y	Y	Y	Y		1-Apr-2022
21005	ViiV	An Open-label, Randomized, Single dose, Crossover, Pivotal Bioequivalence Study of Fixed-dose Combination Tablets of Dolutegravir and Lamivudine versus Dolutegravir and Lamivudine single entities and Food Effect Assessment in Healthy Volunteers	dolutegravir/lamivudine	204994	HIV Infections	Phase 1	https://www.viiv-studyregister.com/en/study/?id=204994	http://clinicaltrials.gov/show/NCT03078556		Y	Y	Y	Y	Y	Y	Y	This study is available in CDISC format;	1-Apr-2022
21006	ViiV	A 2-Part, Phase I, Single Dose, Crossover Relative Bioavailability Study of Both TIVICAY 10 mg Conventional Tablets and 5 mg Dispersible Tablets Compared to Conventional TIVICAY Tablets in Healthy Adult Subjects	dolutegravir	205893	HIV Infections	Phase 1	https://www.viiv-studyregister.com/en/study/?id=205893	http://clinicaltrials.gov/show/NCT03095638		Y	Y	Y	Y	Y	Y	Y	This study is available in CDISC format;	1-Apr-2022
21007	ViiV	A Phase I, relative oral bioavailability study of different fixed dose combinations of dolutegravir and lamivudine in healthy subjects	dolutegravir/lamivudine	204993	HIV Infections	Phase 1	https://www.viiv-studyregister.com/en/study/?id=204993	http://clinicaltrials.gov/show/NCT02738931		Y	Y	Y	Y	Y	Y	Y	This study is available in CDISC format;	1-Apr-2022
21008	ViiV	A 2-Part, Phase I, Single-Dose, 3-Period Crossover Relative Bioavailability Study of a Pediatric TRIUMEQ Dispersible Tablet and Pediatric Dolutegravir and Lamivudine (DTG/3TC) Fixed Dose Combination Dispersible Tablet Formulations as Compared With Adult Tablets in Healthy Volunteers	dolutegravir/abacavir/lamivudine	205894	HIV Infections	Phase 1	https://www.viiv-studyregister.com/en/study/?id=205894	http://clinicaltrials.gov/show/NCT03441984		Y	Y	Y	Y	Y	Y	Y	This study is available in CDISC format;	1-Apr-2022
21009	GSK	An Open-label, Non-randomized, 52-Week Study to Evaluate Treatment Holidays and Rebound Phenomenon After Treatment With Belimumab 10 mg/kg in Systemic Lupus Erythematosus Subjects	belimumab	116027	Systemic Lupus Erythematosus	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=116027	http://clinicaltrials.gov/show/NCT02119156		Y	Y	Y	Y	Y	Y	Y	This study is available in CDISC format;	1-Apr-2022
21011	GSK	Safety study of 2 formulations of GSK’s HRV vaccine (444563), in healthy infants starting at age 6-12 weeks	SB444563	208236	Infections, Rotavirus	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=208236	http://clinicaltrials.gov/show/NCT03954743	https://www.clinicaltrialsregister.eu/ctr-search/search?query=/2018-001986-18	Y	Y	Y	Y	Y	Y	Y	This study is available in CDISC format;	1-Apr-2022
21012	GSK	Phase I, observer-blind, safety, reactogenicity and immunogenicity study of GSK’s respiratory syncytial virus (RSV) vaccine GSK3844766A in Japanese subjects aged 60-80 years	GSK3844766A	209699	Respiratory Syncytial Virus Infections	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=209699	http://clinicaltrials.gov/show/NCT04090658		Y	Y	Y	Y	Y	Y	Y	This study is available in CDISC format;	1-Apr-2022
21018	Novartis	Secukinumab in Tumor Necrosis Factor (TNF) - Inadequate Response (IR) Psoriasis Participants. (SIGNATURE)	secukinumab	CAIN457AGB01	Psoriasis	Phase 3	https://www.novctrd.com/ctrdweb/trialresult/trialresults/pdf?trialResultId=16967	https://www.clinicaltrials.gov/ct2/show/NCT01961609?term=CAIN457AGB01&draw=2&rank=1	https://www.clinicaltrialsregister.eu/ctr-search/trial/2013-001855-11/results	N	N	N	N	N	N	N		1-May-2022
21019	Novartis	Multiple-loading Dose Regimen Study in Patients With Chronic Plaque-type Psoriasis	secukinumab	CAIN457A2212	Chronic Plaque Psoriasis	Phase 2	https://www.novctrd.com/ctrdweb/trialresult/trialresults/pdf?trialResultId=5686	https://www.clinicaltrials.gov/ct2/show/NCT00805480?term=CAIN457A2212&draw=2&rank=1		N	N	N	N	N	N	N		1-May-2022
21020	Novartis	Evaluation of Cardiovascular Risk Markers in Psoriasis Patients Treated With Secukinumab (CARIMA)	secukinumab	CAIN457ADE02	Psoriasis	Phase 3	https://www.novctrd.com/ctrdweb/trialresult/trialresults/pdf?trialResultId=16207	https://www.clinicaltrials.gov/ct2/show/NCT02559622?term=CAIN457ADE02&draw=2&rank=1	EudraCT Number 2013-002266-40 - Clinical trial results - EU Clinical Trials Register	N	N	N	N	N	N	N		1-May-2022
21021	Novartis	Study to Evaluate the Effect of Secukinumab Compared to Placebo on Aortic Vascular Inflammation in Subjects With Moderate to Severe Plaque Psoriasis (VIP-S)	secukinumab	CAIN457AUS02	Chronic Plaque Psoriasis	Phase 4	https://www.novctrd.com/ctrdweb/trialresult/trialresults/pdf?trialResultId=17337	https://www.clinicaltrials.gov/ct2/show/NCT02690701?term=CAIN457AUS02&draw=2&rank=1		N	N	N	N	N	N	N		1-May-2022
21022	Novartis	Study of Secukinumab With 2 mL Pre-filled Syringes (ALLURE)	secukinumab	CAIN457A2323	Psoriasis	Phase 3	https://www.novctrd.com/ctrdweb/trialresult/trialresults/pdf?trialResultId=17438	https://www.clinicaltrials.gov/ct2/show/NCT02748863?term=CAIN457A2323&draw=2&rank=1	https://www.clinicaltrialsregister.eu/ctr-search/trial/2015-005170-38/results	N	N	N	N	N	N	N		1-May-2022
21023	Novartis	Study of Efficacy and Safety of Secukinumab in Subjects With Moderate to Severe Chronic Plaque-type Psoriasis	secukinumab	CAIN457A2318	Plaque Psoriasis	Phase 3	https://www.novctrd.com/ctrdweb/trialresult/trialresults/pdf?trialResultId=17567	https://www.clinicaltrials.gov/ct2/show/NCT03066609?term=CAIN457A2318&draw=2&rank=1	https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-000524-25/results	N	N	N	N	N	N	N		1-May-2022
21024	Novartis	Study to Explore the Effect of Secukinumab, Compared to Placebo, on Fat Tissue and Skin in Plaque Psoriasis Patients (ObePso-S)	secukinumab	CAIN457AUS07	Plaque Psoriasis	Phase 4	https://www.novctrd.com/ctrdweb/trialresult/trialresults/pdf?trialResultId=17605	https://www.clinicaltrials.gov/ct2/show/NCT03055494?term=CAIN457AUS07&draw=2&rank=1		N	N	N	N	N	N	N		1-May-2022
21025	Novartis	Efficacy and Safety of 2 Secukinumab Regimens in 90kg or More Weight Group With Moderate/Severe Chronic Plaque Psoriasis	secukinumab	CAIN457A2324	Moderate to Severe Chronic Plaque-type Psoriasis	Phase 3	https://www.novctrd.com/ctrdweb/trialresult/trialresults/pdf?trialResultId=17825	https://www.clinicaltrials.gov/ct2/show/NCT03504852?term=CAIN457A2324&draw=2&rank=1	https://www.clinicaltrialsregister.eu/ctr-search/trial/2015-004620-60/results	N	N	N	N	N	N	N		1-May-2022
21026	Novartis	Study of Efficacy and Safety of Secukinumab 2 mL Auto-injector (300 mg) in Subjects With Moderate to Severe Plaque Psoriasis (MATURE)	secukinumab	CAIN457A2325	Plaque Psoriasis	Phase 3	https://www.novctrd.com/ctrdweb/trialresult/trialresults/pdf?trialResultId=17850	https://www.clinicaltrials.gov/ct2/show/NCT03589885?term=CAIN457A2325&draw=2&rank=1	https://www.clinicaltrialsregister.eu/ctr-search/trial/2018-000518-39/results	N	N	N	N	N	N	N		1-May-2022
21027	Novartis	Study of Secukinumab Compared to Fumaderm® in Adults With Moderate to Severe Psoriasis. (PRIME)	secukinumab	CAIN457ADE06	Psoriasis	Phase 3	https://www.novctrd.com/ctrdweb/trialresult/trialresults/pdf?trialResultId=16347	https://www.clinicaltrials.gov/ct2/show/NCT02474082?term=CAIN457ADE06&draw=2&rank=1	https://www.clinicaltrialsregister.eu/ctr-search/trial/2014-005258-20/results	N	N	N	N	N	N	N		1-May-2022
21028	Novartis	Pazopanib Versus Sunitinib in the Treatment of Locally Advanced and/or Metastatic Renal Cell Carcinoma (COMPARZ)	Pazopanib	CPZP034A2301	Carcinoma, Renal Cell	Phase 3	https://www.novctrd.com/ctrdweb/trialresult/trialresults/pdf?trialResultId=17919	https://www.clinicaltrials.gov/ct2/show/NCT00720941?term=CPZP034A2301&draw=2&rank=1	https://www.clinicaltrialsregister.eu/ctr-search/trial/2008-002102-19/results	N	N	N	N	N	N	N		1-Jul-2022
21029	GSK	Phase III randomized, open controlled, multicenter study to evaluate the immunogenicity and safety of the RTS,S/AS01E candidate malaria vaccine, when administered as primary vaccination at 6, 7.5 and 9 months of age with or without co-administration of measles and rubella and yellow fever vaccines to children living in sub-Saharan Africa	SB257049	200596	Malaria	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=200596	http://clinicaltrials.gov/show/NCT02699099		Y	Y	Y	Y	Y	Y	Y	This study is available in CDISC format;	1-Jun-2022
21030	GSK	A Phase I/II, randomized, controlled, observer-blind, multi-center study to assess the reactogenicity, safety and immunogenicity of three GlaxoSmithKline (GSK) Biologicals’ investigational supra-seasonal universal influenza vaccines (SUIVs) (unadjuvanted or adjuvanted with AS03 or AS01) administered as a 1 or 2-dose priming schedule followed by a booster dose 12 months post-primary vaccination in 18 to 39 year-old healthy subjects.	GSK3816302A	207543	Influenza, Human	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=207543	http://clinicaltrials.gov/show/NCT03275389	https://www.clinicaltrialsregister.eu/ctr-search/search?query=/2017-001584-20	Y	Y	Y	Y	Y	Y	Y	This study is available in CDISC format;	1-Jun-2022
21031	GSK	A phase I open-label, dose escalation study to investigate the safety, pharmacokinetics, pharmacodynamics and clinical activity of GSK2879552 given orally in subjects with relapsed/refractory acute myeloid leukemia	GSK2879552	200200	Leukaemia, Myelocytic, Acute	Phase 1	https://www.gsk-studyregister.com/en/trial-details/?id=200200	http://clinicaltrials.gov/show/NCT02177812		Y	Y	Y	Y	Y	Y	Y		1-Jun-2022
21032	Astellas	A Study to Evaluate the Efficacy and Safety of a Vaccine, ASP0113, in Cytomegalovirus (CMV)-Seronegative Kidney Transplant Recipients Receiving an Organ from a CMV-Seropositive Donor	ASP0113	0113-CL-2001	Transplantation, Kidney	Phase 2	https://www.clinicaltrials.astellas.com/study/?pid=0113-CL-2001	https://clinicaltrials.gov/ct2/show/NCT01974206	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-000464-29	Y	Y	Y	Y	Y	Y	Y		1-Jun-2022
21033	Teva	A Multicenter Assessment of LBR-101 in High Frequency Episodic Migraine	Fremanezumab	LBR-101-022	Episodic Migraine Headache	Phase 2	Not available	https://clinicaltrials.gov/ct2/show/NCT02025556		Y	N	N	Y	Y	Y	Y		1-Jul-2022
21034	Teva	Efficacy and Safety of 2 Dose Regimens of TEV-48125 Versus Placebo for the Preventive Treatment of Episodic Migraine	Fremanezumab	TV48125-CNS-30050	Migraine	Phase 3	Not available	https://ClinicalTrials.gov/show/NCT02629861	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-004598-34	Y	N	N	Y	Y	Y	Y		1-Jul-2022
21035	Teva	Efficacy and Safety of Subcutaneous Administration of Fremanezumab (TEV-48125) for the Preventive Treatment of Migraine	Fremanezumab	TV48125-CNS-30051	Migraine	Phase 3	Not available	https://ClinicalTrials.gov/show/NCT02638103	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-004550-18	Y	N	N	Y	Y	Y	Y		1-Jul-2022
21036	Teva	A Study to Test the Effectiveness and Safety of a New Higher 40mg Dose of Copaxone® Compared to Copaxone® 20mg, the Currently Approved Dose	Glatiramer Acetate	9006	Relapse-Remitting Multiple Sclerosis	Phase 2	Not available	https://clinicaltrials.gov/ct2/show/NCT00202982		Y	N	N	Y	Y	Y	Y		1-Jul-2022
21037	Teva	Clinical Trial Comparing Treatment of Relapsing-Remitting Multiple Sclerosis (RR-MS) With Two Doses of Glatiramer Acetate (GA)	Glatiramer Acetate	GA/9016	Relapsing Remitting Multiple Sclerosis	Phase 3	Not available	https://www.clinicaltrials.gov/ct2/show/NCT00337779?term=NCT00337779&draw=2&rank=1		Y	N	N	Y	Y	Y	Y		1-Jul-2022
21038	Teva	Safety and Tolerability of Glatiramer Acetate (GLACIER)	Glatiramer Acetate	GA-MS-303	Relapsing-Remitting Multiple Sclerosis	Phase 3	Not available	https://www.clinicaltrials.gov/ct2/show/NCT01874145?term=NCT01874145&draw=2&rank=1		Y	N	N	Y	Y	Y	Y		1-Jul-2022
21039	Teva	A Study in Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS) to Assess the Efficacy, Safety and Tolerability of Glatiramer Acetate (GA) Injection 40 mg Administered Three Times a Week Compared to Placebo (GALA)	Glatiramer Acetate	MS-GA-301	Relapsing Remitting Multiple Sclerosis	Phase 3	Not available	https://www.clinicaltrials.gov/ct2/show/NCT01067521?term=NCT01067521&draw=2&rank=1	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-018084-27	Y	N	N	Y	Y	Y	Y		1-Jul-2022
21040	Teva	Study to Assess Medication Satisfaction in Patients With Relapsing Remitting Multiple Sclerosis Treated With Copaxone® (CONFIDENCE)	Glatiramer Acetate	TV44400-CNS-40083	Multiple Sclerosis	Phase 4	Not available	https://www.clinicaltrials.gov/ct2/show/NCT02499900?term=NCT02499900&draw=2&rank=1	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000922-12	Y	N	N	Y	Y	Y	Y		1-Jul-2022
21041	Teva	Study to Evaluate the Efficacy and Safety of Reslizumab Treatment in Patients With Moderate to Severe Asthma	Reslizumab	C38072/3084	Eosinophilic Asthma	Phase 3	Not available	https://clinicaltrials.gov/ct2/show/NCT01508936		Y	N	N	Y	Y	Y	Y		1-Jul-2022
21042	Novartis	Study of Efficacy and Safety of Secukinumab in Patients With Non-radiographic Axial Spondyloarthritis (PREVENT)	secukinumab	CAIN457H2315	Non-radiographic Spondyloarthritis	Phase 3	https://www.novctrd.com/ctrdweb/trialresult/trialresults/pdf?trialResultId=17673	https://www.clinicaltrials.gov/ct2/show/NCT02696031?term=CAIN457H2315&draw=2&rank=1	https://www.clinicaltrialsregister.eu/ctr-search/trial/2015-001106-33/results	N	N	N	N	N	N	N		1-Jul-2022
21043	Novartis	SKIPPAIN - Speed of Onset of SecuKinumab-Induced Relief From Pain in Patients With AxIal SpoNdyloarthritis (SKIPPAIN)	secukinumab	CAIN457H3301	Spondyloarthritis	Phase 3	https://www.novctrd.com/ctrdweb/trialresult/trialresults/pdf?trialResultId=17563	https://www.clinicaltrials.gov/ct2/show/NCT03136861?term=CAIN457H3301&draw=2&rank=1	https://www.clinicaltrialsregister.eu/ctr-search/trial/2017-000401-21/results	N	N	N	N	N	N	N		1-Jul-2022
21044	Novartis	A Phase 1 Study of an Investigational Drug, ALN-PCSSC, in Subjects With Elevated Low Density Lipoprotein Cholesterol (LDL-C)	inclisiran	CKJX839A12101 / ALN-PCSSC-001	Hypercholesterolemia	Phase 1		https://www.clinicaltrials.gov/ct2/show/NCT02314442?term=ALN-PCSSC-001&draw=2&rank=1		N	N	N	N	N	N	N		1-Jul-2022
21045	Novartis	Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events) (CANTOS)	canakinumab	CACZ885M2301	Atherosclerosis	Phase 3	https://www.novctrd.com/ctrdweb/trialresult/trialresults/pdf?trialResultId=17575	https://www.clinicaltrials.gov/ct2/show/NCT01327846?term=CACZ885M2301&draw=2&rank=2	https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-022970-14/results	N	N	N	N	N	N	N		1-Jan-2023
21047	Novartis	An Open-label Extension Study to Evaluate the Safety and Tolerability of Licarbazepine 750-2000 mg/d in the Treatment of Manic Episodes of Bipolar I Disorder	licarbazepine	CLIC477D2302E1	Bipolar I Disorder	Phase 3	https://www.novctrd.com/ctrdweb/trialresult/trialresults/pdf?trialResultId=2549	https://www.clinicaltrials.gov/ct2/show/NCT00238485?term=CLIC477D2302E1&draw=2&rank=1	https://www.clinicaltrialsregister.eu/ctr-search/trial/2004-000686-35/results	N	N	N	N	N	N	N		1-Jul-2022
21048	Novartis	Study of Licarbazepine in the Treatment of Manic Episodes of Bipolar Disorder	licarbazepine	CLIC477D2302	Bipolar Disorder	Phase 3	https://www.novctrd.com/ctrdweb/trialresult/trialresults/pdf?trialResultId=2471	https://www.clinicaltrials.gov/ct2/show/NCT00107939?term=CLIC477D2302&draw=2&rank=2	https://www.clinicaltrialsregister.eu/ctr-search/trial/2004-000113-18/results	N	N	N	N	N	N	N		1-Jul-2022
21053	Novartis	A Phase III Randomized, Open-label Study Comparing GSK2118436 to Dacarbazine (DTIC) in Previously Untreated Subjects With BRAF Mutation Positive Advanced (Stage III) or Metastatic (Stage IV) Melanoma	dabrafenib	BRF113683 / CDRB436A2301	Melanoma	Phase 3	https://www.gsk-clinicalstudyregister.com/study/113683?search=study&search_terms=BRF113683	https://www.clinicaltrials.gov/ct2/show/NCT01227889?term=BRF113683&rank=1	https://www.clinicaltrialsregister.eu/ctr-search/search?query=BRF113683	Y	Y	Y	Y	Y	Y	Y		1-Aug-2018
21055	GSK	A Double-Blind, Placebo-Controlled Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Ascending Dose and Multiple Doses of GSK3389404 in Chronic Hepatitis B Subjects	GSK3389404	205670	Hepatitis B	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=205670	http://clinicaltrials.gov/show/NCT03020745		Y	N	Y	Y	Y	Y	Y	This study is available in CDISC format; An annotated case report form is not available for this study. A blank case report form will be provided;	1-Aug-2022
21056	ViiV	An Open Label, Phase 1 Study to Evaluate the PK, Safety, Tolerability and Acceptability of Long Acting Injections of the HIV Integrase Inhibitor, Cabotegravir (CAB; GSK1265744) in HIV Uninfected Chinese Men	cabotegravir	206898	HIV Infections	Phase 1	https://www.viiv-studyregister.com/en/study/?id=206898	http://clinicaltrials.gov/show/NCT03422172		Y	N	Y	Y	Y	Y	Y	Data in CDISC Format; An annotated case report form is not available for this study. A blank case report form will be provided;	1-Aug-2022
21057	Novartis	Evaluation of the Efficacy and Safety of QVA149 (110/50 μg o.d.) vs Tiotropium (18 µg o.d.) + Salmeterol/Fluticasone Propionate FDC (50/500 µg b.i.d.) in Patients With Moderate to Severe COPD	indacaterol maleate/glycopyrronium bromide	CQVA149A2316	Chronic Obstructive Pulmonary Disease (COPD)	Phase 4	https://www.novctrd.com/ctrdweb/trialresult/trialresults/pdf?trialResultId=17180	https://www.clinicaltrials.gov/ct2/show/NCT02603393?term=CQVA149A2316&draw=2&rank=1	https://www.clinicaltrialsregister.eu/ctr-search/trial/2015-000114-22/results	N	N	N	N	N	N	N		1-Sep-2022
21058	Novartis	Comparison of Indacaterol 150 mcg Once Daily (o.d.) With Salmeterol/Fluticasone Propionate 50 mcg/500 mcg Twice Daily (b.i.d.) (INSTEAD)	indacaterol	CQAB149B2401	Chronic Obstructive Pulmonary Disease (COPD)	Phase 4	https://www.novctrd.com/ctrdweb/trialresult/trialresults/pdf?trialResultId=13550	https://www.clinicaltrials.gov/ct2/show/NCT01555138?term=CQAB149B2401&draw=2&rank=1	https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-003732-31/results	N	N	N	N	N	N	N		1-Sep-2022
21059	Novartis	Lapatinib Plus Capecitabine Versus Trastuzumab Plus Capecitabine in ErbB2 (HER2) Positive Metastatic Breast Cancer	lapatinib plus capecitabine	EGF 111438 / CLAP016A2305	Metastases, Brain	Phase 3	https://www.novctrd.com/ctrdweb/trialresult/trialresults/pdf?trialResultId=17404	https://www.clinicaltrials.gov/ct2/show/NCT00820222?term=111438&draw=2&rank=1	https://www.clinicaltrialsregister.eu/ctr-search/trial/2008-000673-38/results	N	N	N	N	N	N	N		1-Sep-2022
21063	Novartis	A Randomized, Double-blind, Placebo-controlled Phase III Study to Evaluate the Efficacy and Safety of Pazopanib as Adjuvant Therapy for Subjects With Localized or Locally Advanced RCC Following Nephrectomy	papzopanib	113387/CPZP034D2301	Renal cell carcinoma	Phase 3	https://www.novctrd.com/ctrdweb/trialresult/trialresults/pdf?trialResultId=17645	https://www.clinicaltrials.gov/ct2/show/study/NCT01235962?term=NCT01235962&draw=2&rank=1	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-020965-26	Y	Y	Y	Y	Y	Y	Y		1-May-2020
21064	Novartis	RAINBOW Study: RAnibizumab Compared With Laser Therapy for the Treatment of INfants BOrn Prematurely With Retinopathy of Prematurity (RAINBOW)	ranibizumab	CRFB002H2301	Retinopathy of Prematurity	Phase 3	https://www.novctrd.com/ctrdweb/trialresult/trialresults/pdf?trialResultId=17138	https://www.clinicaltrials.gov/ct2/show/NCT02375971?term=CRFB002H2301&draw=2&rank=2	https://www.clinicaltrialsregister.eu/ctr-search/trial/2014-003041-10/results	N	N	N	N	N	N	N		1-Oct-2022
21065	Novartis	Efficacy and Safety of LCZ696 Compared to Valsartan, on Morbidity and Mortality in Heart Failure Patients With Preserved Ejection Fraction (PARAGON-HF)	sacubitril/valsartan	CLCZ696D2301	Heart Failure With Preserved Ejection Fraction	Phase 3	Microsoft Word - Clinical_Trials_Results_Word_Form-CLCZ696D2301_02Jun2020.doc (novctrd.com)	https://www.clinicaltrials.gov/ct2/show/NCT01920711?term=CLCZ696D2301&draw=2&rank=2	https://www.clinicaltrialsregister.eu/ctr-search/trial/2013-001747-31/results	N	N	N	N	N	N	N		1-Oct-2022
21066	ViiV	A Phase 3b, randomised, open-label study of the antiviral activity and safety of dolutegravir compared to lopinavir/ritonavir both administered with dual nucleoside reverse transcriptase inhibitor therapy in HIV-1 infected adult subjects with treatment failure on first line therapy	dolutegravir	200304	HIV Infections	Phase 3	https://www.viiv-studyregister.com/en/study/?id=200304	http://clinicaltrials.gov/show/NCT02227238	https://www.clinicaltrialsregister.eu/ctr-search/search?query=/2014-001057-17	Y	Y	Y	Y	Y	Y	Y	Data in CDISC Format;	1-Oct-2022
21067	GSK	Safety and protective effect study of GSK Biologicals’ Human Papillomavirus (Types 16, 18) Vaccine, Adsorbed (GSK580299) in healthy female subjects from the HPV-039 study.	Human Papillomavirus Types 16 and 18 Vaccine	205779	Cervical Intraepithelial Neoplasia	Phase 4	https://www.gsk-studyregister.com/en/trial-details/?id=205779	http://clinicaltrials.gov/show/NCT03629886		Y	Y	Y	Y	Y	Y	Y	This study is available in CDISC format;	1-Oct-2022
21068	Novartis	16 Week Efficacy and 5 Year Long Term Efficacy, Safety and Tolerability of Secukinumab in Patients With Active Ankylosing Spondylitis (MEASURE2)	secukinumab	CAIN457F2310	Anklyosing Spondylitis	Phase 3	https://www.novctrd.com/ctrdweb/trialresult/trialresults/pdf?trialResultId=17535	https://www.clinicaltrials.gov/ct2/show/NCT01649375?term=CAIN457F2310&draw=2&rank=1	https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-000046-35/results	N	N	N	N	N	N	N		1-Nov-2022
21069	Novartis	16-week Efficacy and 3-year Safety, Tolerability and Efficacy of Secukinumab in Active Ankylosing Spondylitis Patients (MEASURE 3)	secukinumab	CAIN457F2314	Spondylitis, Ankylosing	Phase 3	https://www.novctrd.com/ctrdweb/trialresult/trialresults/pdf?trialResultId=17263	https://www.clinicaltrials.gov/ct2/show/NCT02008916?term=CAIN457F2314&draw=2&rank=1	https://www.clinicaltrialsregister.eu/ctr-search/trial/2013-001090-24/results	N	N	N	N	N	N	N		1-Nov-2022
21070	Novartis	Secukinumab Safety and Efficacy in Juvenile Psoriatic Arthritis (JPsA) and Enthesitis-related Arthritis (ERA)	secukinumab	CAIN457F2304	Juvenile Psoriatic Arthritis, Enthesitis-related Arthritis	Phase 3	https://www.novctrd.com/ctrdweb/trialresult/trialresults/pdf?trialResultId=17822	https://www.clinicaltrials.gov/ct2/show/NCT03031782?term=CAIN457F2304&draw=2&rank=1	https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-003761-26/results	N	N	N	N	N	N	N		1-Nov-2022
21071	ViiV	A qualitative hybrid III implementation study to identify and evaluate strategies for successful implementation of the cabotegravir + rilpivirine long-acting injectable regimen in the US	cabotegravir	209493	HIV Infections	Phase 3	https://www.viiv-studyregister.com/en/study/?id=209493	http://clinicaltrials.gov/show/NCT04001803		Y	N	Y	Y	Y	Y	Y	Data in CDISC Format; An annotated case report form is not available for this study. A blank case report form will be provided;	1-Dec-2022
21072	ViiV	A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability and Pharmacokinetics of GSK3732394 in Healthy Participants	GSK3732394	207863	HIV Infections	PHASE I	https://www.viiv-studyregister.com/en/study/?id=207863	https://clinicaltrials.gov/ct2/show/NCT03984812		Y	Y	Y	Y	Y	Y	Y	Data in CDISC Format;	1-Dec-2022
21073	ViiV	A Phase III, randomized, multicenter, parallel-group, non-inferiority study evaluating the efficacy, safety, and tolerability of switching to dolutegravir plus lamivudine in HIV-1-infected adults who are virologically suppressed	dolutegravir/lamivudine	204862	HIV Infections	PHASE IIIA	https://www.viiv-studyregister.com/en/study/?id=204862	https://clinicaltrials.gov/ct2/show/NCT03446573	https://www.clinicaltrialsregister.eu/ctr-search/search?query=/2015-004401-17	Y	Y	Y	Y	Y	Y	Y	Data in CDISC Format;	1-Dec-2022
21074	GSK	A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Belimumab plus Standard of Care versus Placebo plus Standard of Care in Adult Subjects with Active Lupus Nephritis	belimumab	114054	Lupus Nephritis	Phase 3	https://www.gsk-studyregister.com/en/trial-details/?id=114054	https://clinicaltrials.gov/ct2/show/NCT01639339		Y	Y	Y	Y	Y	Y	Y	This study is available in CDISC format;	1-Dec-2022
21075	GSK	A randomized, double-blind, parallel group, multicenter, stratified study evaluating the efficacy and safety of repeat doses of GSK3772847 compared with placebo in participants with moderately severe asthma	melrilimab	207597	Asthma	Phase 2	https://www.gsk-studyregister.com/en/trial-details/?id=207597	https://clinicaltrials.gov/ct2/show/NCT03207243	https://www.clinicaltrialsregister.eu/ctr-search/search?query=/2017-001072-34	Y	Y	Y	Y	Y	Y	Y	This study is available in CDISC format;	1-Dec-2022
21084	Novartis	A 12 Week Randomized Open Label Parallel Group Multicenter Study to Evaluate Bioequivalence of 20 mg Subcutaneous Ofatumumab Injected by Pre-filled Syringe or Autoinjector in Adult RMS Patients	ofatumumab	COMB157G2102	Multiple Sclerosis	Phase 2	https://www.novctrd.com/ctrdweb/trialresult/trialresults/pdf?trialResultId=17710	https://www.clinicaltrials.gov/ct2/show/NCT03560739?term=COMB157G2102&draw=2&rank=1	Clinical Trials register - Search for COMB157G2102	N	N	N	N	N	N	N		1-Feb-2023
21085	Novartis	Efficacy and Safety of Ofatumumab Compared to Teriflunomide in Patients With Relapsing Multiple Sclerosis (ASCLEPIOS I)	ofatumumab	COMB157G2301	Relapsing Multiple Sclerosis	Phase 3	Microsoft Word - COMB157G2301_NovCTR_20Jul2021_Final_for_Approval 1 (novctrd.com)	https://www.clinicaltrials.gov/ct2/show/NCT02792218?term=COMB157G2301&draw=2&rank=1	Clinical Trials register - Search for COMB157G2301	N	N	N	N	N	N	N		1-Feb-2023
21086	Novartis	Efficacy and Safety of Ofatumumab Compared to Teriflunomide in Patients With Relapsing Multiple Sclerosis. (ASCLEPIOS II)	ofatumumab	COMB157G2302	Relapsing Multiple Sclerosis	Phase 3	Microsoft Word - COMB157G2302_NovCTR_Final_21_Oct_2021 final version (novctrd.com)	https://www.clinicaltrials.gov/ct2/show/NCT02792231?term=COMB157G2302&draw=2&rank=1	https://www.clinicaltrialsregister.eu/ctr-search/search?query=COMB157G2302	N	N	N	N	N	N	N		1-Feb-2023
21087	Novartis	Safety and Efficacy of Ruxolitinib Versus Best Available Therapy in Patients With Corticosteroid-refractory Acute Graft vs. Host Disease After Allogeneic Stem Cell Transplantation (REACH2)	ruxolitinib	CINC424C2301	Corticosteroid Refractory Acute Graft vs Host Disease	Phase 3	Microsoft Word - CTR_CINC424C2301_Final_22Oct2021 (003).docx (novctrd.com)	https://www.clinicaltrials.gov/ct2/show/NCT02913261?term=CINC424C2301&draw=2&rank=1		N	N	N	N	N	N	N		1-Feb-2023
21088	Novartis	Study of Efficacy and Safety of CTL019 in Pediatric ALL Patients (ENSIGN)	tisagenlecleucel	CCTL019B2205J	"B-cell Acute Lymphoblastic Leukemia, Relapsed B-cell Acute Lymphoblastic Leukemia, Refractory B-cell Acute Lymphoblastic Leukemia"	Phase 2	https://www.novctrd.com/ctrdweb/trialresult/trialresults/pdf?trialResultId=16690	https://www.clinicaltrials.gov/ct2/show/NCT02228096?term=CCTL019B2205J&draw=2&rank=1	EudraCT Number 2015-003736-13 - Clinical trial results - EU Clinical Trials Register	N	N	N	N	N	N	N		1-Jan-2023
21090	Astellas	Astagraf XL® to Understand the Impact of Immunosuppression on De Novo DSA Development and Chronic Immune Activation in Kidney Transplantation	tacrolimus extended-release	NCT02723591 EudraCT 2018-003867-79	Prevention of rejection after organ transplant	Phase 4	https://www.clinicaltrials.astellas.com/study/IDTX-MA-3004/	https://clinicaltrials.gov/ct2/show/NCT02723591	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003867-79	Y	Y	Y	Y	Y	Y	Y		1-Feb-2023
21100	Novartis	16-week Efficacy and 2-year Safety, Tolerability and Efficacy of Secukinumab in Participants With Active Ankylosing Spondylitis (MEASURE4)	secukinumab	CAIN457F2320	Anklyosing Spondylitis	Phase 3	https://www.novctrd.com/ctrdweb/trialresult/trialresults/pdf?trialResultId=17259	https://www.clinicaltrials.gov/ct2/show/NCT02159053?term=CAIN457F2320&draw=2&rank=1	https://www.clinicaltrialsregister.eu/ctr-search/trial/2013-005575-41/results	N	N	N	N	N	N	N		1-Mar-2023
21103	Novartis	A 24-Week Efficacy, Safety and Tolerability of Rivastigmine Patch Study in Patients With Probable Alzheimer's Disease	rivastigmine	CENA713D2344	Alzheimer's Disease	Phase 3	https://www.novctrd.com/ctrdweb/trialresult/trialresults/pdf?trialResultId=11845	https://www.clinicaltrials.gov/ct2/show/NCT01399125?term=CENA713D2344&draw=2&rank=1		N	N	N	N	N	N	N		1-Apr-2023
21104	Ono	A multicenter, randomized, open-label, docetaxel- or paclitaxel-controlled study to evaluate the efficacy and safety of ONO-4538 in patients with esophageal cancer refractory or intolerant to combination therapy with fluoropyrimidine and platinum-based drugs.	Nivolumab	ONO-4538-24/CA209473	Esophageal cancer	Phase 3	Not available	https://clinicaltrials.gov/show/NCT02569242	https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-003339-36	Y	Y	Y	Y	Y	N	Y	Sharing of clinical data is restricted for the following countries/area: Japan, Korea, Taiwan, Italia, Germany and the UK.	1-Apr-2023